SCIENTIFIC REPORT





CONTENTS

LE.	ITER FROM THE SCIENTIFIC DIRECTOR	5
1.	INTRODUCTION	9
2.	GOVERNING AND ADVISORY BODIES	13
3.	ORGANIZATIONAL STRUCTURE	17
	3.1. SCIENTIFIC AREAS	19
	3.2. HUMAN RESOURCES	28
4.	SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA	33
	4.1. SCIENTIFIC PRODUCTION. BIBLIOMETRIC INDICATORS	34
	4.2. CLINICAL PRACTICE GUIDELINES	41
	4.3. RESEARCH PROJECTS	50
	4.4. HUMAN RESOURCES	55
	4.5. RICORS, RETICS, INTERNATIONAL NETWORKS, AND ISCIII AND CIBER PLATFORMS	62
	4.6. CLINICAL TRIALS	67
	4.7. INNOVATION AND TRANSFER.	70
	4.8. CLINICAL PRACTICE GUIDELINES IMPLEMENTED IN HEALTHCARE CENTERS	78
5.	RESEARCH AREAS AND GROUPS	81
	5.1. PRIORITY SCIENTIFIC AREAS	82
	5.2. RESEARCH GROUPS	102
6.	FUNDING	241
7.	EDUCATION	249
8.	COMMUNICATIONS	259
9.	COMMON RESEARCH SUPPORT SERVICES (ECAI)	263
PU	BLICACIONES	291
EX	TERNAL ASSOCIATED GROUPS	491



LETTER FROM THE SCIENTIFIC DIRECTOR



6 LETTER FROM THE SCIENTIFIC DIRECTOR 2023 SCIENTIFIC REPORT 7

LETTER FROM THE SCIENTIFIC DIRECTOR



As in previous years, it is an honor for me to present the results of IBIMA Plataforma BIONAND's scientific activity in 2023. This has been a very special year. We have surpassed 1,348 professionals, including researchers (1,156), support technicians (166), and managers (26), who belong to the institute. This reinforces our center's position as one of the most important on the national and international level thanks to the continuous expansion not only of human capital, but also of the quality of the professionals that form part of IBIMA Plataforma BIONAND.

Thus, we have strengthened our role as a multidisciplinary biomedical research institute, reinforcing our nature as a healthcare center in order to directly translate our scientific advances to improving the quality of patient care. In addition, the IBIMA Plataforma BIONAND's Plan has completed its five-year period, with five editions, which has become one of the institute's most appealing initiatives. The plan is a clear commitment to improving the quality and dissemination of scientific production, transfer of results, and visibility of research groups' work.

The data from 2023 demonstrate the institute's scientific excellence, as can be seen in the research groups' scientific production indicators. There were 863 publications (750 original articles and 113 review articles) and a cumulative impact factor of 5,060 points.

In addition, the institute has obtained a total of €30 million in funds raised for health research as a

result of the strategic activities carried out during the past fiscal year. This is an increase of €6 million compared to 2022.

In regard to research projects, 316 projects funded in regional, national, and international competitive calls have been conducted at IBIMA Plataforma BIONAND during 2023. In addition, competitive funding has been obtained for 53 new research projects.

One of the most significant milestones in 2023 in the international scope was the positioning of our institute thanks to the award of a European Research Council (ERC) Starting Grant, with a budget of more than €1.4 million for a project related to the prevention and prediction of myocardial infarction. In addition, the institute made a commitment to attracting international talent through the award of a Marie Skłodowska-Curie Action in the allergy area, three projects funded within the framework of the EU4Health program, and another three projects funded within the Horizon Europe health cluster in collaboration with the European Clinical Research Infrastructure Network (ECRIN).

Also notable was the participation of eight research groups from the institute in RICORS networks and in 21 international networks, as well as in seven CIBER and four platforms of the Carlos III Institute of Health. Another aspect in which there has been a notable increase is clinical trials. The institute's participation in 261 new trials represents a 24% increase compared to 2022.

In addition, charitable sports activities have been held that entailed the direct participation of citizens, such as the 1st Charity Race against Obesity or the 1st HRUM/IBIMA Plataforma BIONAND 7-a-side Soccer Tournament, which raised around €30,000 for promoting biomedical research. This is in line with our drive to transfer the results of our research to the public and make them direct participants in our institute's day-to-day work, opening our center to visits from students from different specialties, professional groups, biotechnology companies, and patient associations so that they can learn first-hand about the work we carry out in the different spaces dedicated to research.

We are very proud of all this work because we truly feel that we are doing our part in the training of future professionals and new generations who must advance in their scientific careers and who we hope will be part of our institute in the coming decades.

In short, our institute has grown thanks to the work of each and every one of those who form part of IBIMA Plataforma BIONAND. We continue to set new goals and objectives for the coming years to maintain our status as a health research institute of excellence with a groundbreaking, innovative nature that will allow us to continue to grow and consolidate our position as a national and international point of reference.

Francisco Tinahones Madueño Scientific Director of IBIMA Plataforma BIONAND





The following report summarizes the scientific activity carried out by the Biomedical Research Institute of Málaga and Nanomedicine Platform, IBIMA Plataforma BIONAND, in 2023.

The institute's mission is to develop and promote a multidisciplinary scientific space for R&D&i of excellence in the field of biomedicine and nanomedicine aimed at industrial transfer and translation into clinical practice in Málaga. The institute is centered around the Regional and Virgen de la Victoria University Hospitals of Málaga together with primary care centers and University of Málaga biotechnology groups.

It is the institute's intention to **integrate** the talent, structures, and centers dedicated to biomedical research in order to promote scientific and technological **innovation**, **inspire** a vocation for research in new professionals, attract talent, and provide training.

The vision of IBIMA Plataforma BIONAND as a biomedical research institute is to be a proactive and innovative organization, a national and European point of reference that aims to offer the best possible research at all times. This vision means the institute is:

- Focused on the organization and structuring of the research system, with knowledge applied to health being the center of the system.
- Attentive to the reality that surrounds the institute in order to take advantage of the possibilities for development arising from opportunities that surround it and successfully face threats by joining European knowledge and development networks.
- Actively aware of achieving sustainability of a system characterized by quality, efficiency, and effectiveness.
- Willing to continuously incorporate innovation (social, organizational, and technological) as an element of efficiency and for good results from the organization.
- Integrated among all the agents involved in the health and research systems but with its own identity that is in consonance with the rest of the agents.

The IBIMA Plataforma BIONAND has been accredited as a Health Research Institute by the Carlos III Institute of Health since January 15, 2015 and was reaccredited on January 15, 2020 according to Royal Decree 279/2016, of June 24. The legal ownership of the institute belongs to the Foundation for Health and Biomedicine Research in Málaga (FIMABIS).

GOVERNING AND ADVISORY BODIES



14 GOVERNING AND ADVISORY BODIES

ibima Plataforma BIONAND 2023 SCIENTIFIC REPORT 15

The governing bodies of the IBIMA Plataforma BIONAND institute are the Board of Directors and the Delegated Commission, as collegiate bodies, and the Scientific Directorate, Vice-Scientific Directorate, and Management as individual bodies. The advisory bodies of the institute are the External Scientific Committee, the Internal Scientific Committee, and the Senate.

In addition, various committees have been organized to ensure compliance with the plans and policies approved by the Board of Directors: **Training and Postgraduate Commission, Innovation Commission, Quality Commission, and Infrastructure Commission.**

The IBIMA Plataforma BIONAND **Board of Directors** is the institute's highest governing body. Its nature and role are defined by the Collaboration Agreement signed on December 30, 2021 among the Regional Ministry of Health and Consumer Affairs; the Regional Ministry of Economic Transformation, Industry, Knowledge, and Universities; the University of Málaga; the Andalusian Health Service; and FIMABIS, the Andalusian public foundation for the conduct of biomedical research in Málaga. The Board of Directors comprises the following members:

- Two representatives from the Regional Ministry of Health and Consumer Affairs of the Regional Government of Andalusia.
- Two representatives from the Regional Ministry of Economic Transformation, Industry, Knowledge, and Universities of the Regional Government of Andalusia, one of which will belong to the Andalusian Health Service.
- Two representatives from the University of Málaga.

The Scientific Directorate, the Vice-Scientific Directorate, and the Management of the IBIMA Plataforma BIONAND as well as a representative of the Andalusian Public Foundation for Progress and Health, as the central research support and management entity of the Regional Ministry of Health and Consumer Affairs, will be non-voting members in order to coordinate with the general and sectoral strategies for research, development, and innovation.

The **Delegated Commission** is an entity aimed at providing the institute with greater agility in decision-making in the periods between Board of Directors meetings. It was created by virtue of a resolution of the Board of Directors dated 11/24/2014. It comprises the following members:

- A representative of the Regional Ministry of Health and Consumer Affairs of the Regional Government of Andalusia or, if applicable, the regional ministry with authority in health matters appointed by the person in charge from the regional ministry.
- A representative of the Regional Ministry of Universities, Research, and Innovation of the Regional Government of Andalusia or, if applicable, the regional ministry with authority in research matters appointed by the person in charge from the regional ministry.
- A representative of the University of Málaga appointed by the Dean.

The Scientific Directorate, the Vice-Scientific Directorate, and the Management of the IBIMA Plataforma BIONAND as well as a representative of the Andalusian Public Foundation for Progress and Health will be non-voting members.

The **External Scientific Committee** is an advisory body for the institute that oversees its scientific quality and advises the Scientific Directorate and the Board of Directors with independent judgment and autonomy for decision-making. It is formed of highly qualified professionals with recognized experience in the field of research.

The External Scientific Committee was proposed and approved at the institute's first Board of Directors meeting in July 2012 and was updated in 2022. Current members include:

- Carlos Diéguez González. Full Professor of Physiology. University of Santiago de Compostela. Chair.
- Mariano Esteban Rodríguez. Department of Molecular and Cellular Biology. National Centre for Biotechnology (CSIC).
- Rafael Bañares Cañizares. Chief of the Gastroenterology Department. Gregorio Marañón University General Hospital. Madrid. Former Scientific Director of Gregorio Marañón Health Research Institute (2011–2015).
- Pablo Lapunzina Badía. Coordinator of the Institute of Medical and Molecular Genetics (INGEMM) of the La Paz University Hospital Research Institute (IdiPaz) and Scientific Director of CIBER-ER.
- Eva Carmona Porquera. Researcher at the Mayo Clinic. Rochester, Minnesota, USA.
- María Vallet Regí. Full Professor of Inorganic Chemistry and Director of the Department of Inorganic and Bioinorganic Chemistry, School of Pharmacy, Complutense University of Madrid.
- Pilar Marco Colás. Institute for Advanced Chemistry of Catalonia (IQAC, CSIC, Barcelona).
- Jesús Jiménez Barbero. CISC Institute of Organic Chemistry and Scientific Director of the Center for Cooperative Research in Biosciences (CIC bioGUNE, Bilbao, Spain).
- Laura Lechuga Gómez. Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, and CIBER-BBN.
- Lina Badimon. Cardiovascular Research Center CSIC-ICCC, Santa Creu i Sant Pau Hospital, (CIC, Barcelona).

The Internal Scientific Committee is an advisory body to the Scientific Directorate on all scientific and organizational matters at the institute. Its decisions are non-binding. It is constituted at the proposal of the Scientific Directorate and is ratified by the Board of Directors. It includes the following members:


- Scientific Directorate of IBIMA Plataforma BIONAND.
- Scientific Vice-Directorate of IBIMA Plataforma BIONAND.
- Management of IBIMA Plataforma BIONAND.
- A representative of the Virgen de la Victoria University Hospital Management and a representative of the Regional University Hospital of Málaga Management.
- A representative of the University of Malaga.
- A representative from primary care.
- The coordinators of the IBIMA Plataforma BIONAND scientific areas.
- A representative of the Training and Postgraduate Commission.
- A representative of the Quality Commission.
- A representative of the postdoctoral researchers and a representative of the predoctoral researchers.
- A representative of the technical staff of the research support units.
- The Management of the Oncology Research Centre of Málaga, CIMO.



ORGANIZATIONAL STRUCTURE



The IBIMA Plataforma BIONAND institute is divided into 2 research programs and 8 scientific areas, 6 priority areas, and 2 multidisciplinary areas, and the Oncology Research Centre of Málaga (CIMO). The organization chart is as follows:



3.1. SCIENTIFIC AREAS

Preclinical and Clinical Research Program:

Area 1. Cardiovascular Diseases, Obesity, and Diabetes. Environmental Determinants and Lifestyle.

Coordinator. Manuel F. Jiménez Navarro

Deputy Coordinator. Mora Murri

Area 2. Molecular and Translational Cancer Biology

Coordinator. Melissa García Caballero

Deputy Coordinator. Elisa Matas Rico

Area 3. Neurosciences, Chronicity, Aging, and Health in Vulnerable Populations.

Coordinator. Antonia Serrano Criado

Deputy Coordinator. Patricia Moreno Peral

Area 4. Autoimmune Diseases, Infectious Diseases, Inflammation, and Allergies.

Coordinator. María José Torres Jaén

Deputy Coordinator. Antonio Fernández Nebro

Nanomedicine Research Program:

Area 7. Nanodiagnostics.

Coordinator. María Luisa García Martín

Area 8. Nanosystems and Advanced Therapies.

Coordinator. Elena González Muñoz

and two multidisciplinary areas:

Area 5. Rare: Rare diseases.

Coordinator. Miguel Angel Medina Torres

Deputy Coordinator. Raquel Yahyaoui Macias

Area 6. Tech: Health Technology and Innovation Area.

Coordinator. Ezequiel Pérez-Inestrosa

Deputy Coordinator. José F. Aldana Montes

There were 71 active research groups in 2023—46 of which were consolidated, 15 emerging, and ten associated — from the various institutions that make up IBIMA Plataforma BIONAND. In addition, there were seven external associated groups under the priority areas. The IBIMA Tech area and the IBIMA Rare area are multidisciplinary; these groups can also participate in other areas as well as in the multidisciplinary areas in order to promote collaboration.

The distribution of the groups by areas and categories is as follows:



Figure 1: Consolidated, emerging, and associated groups by scientific areas

The list of each research area and group with their Lead Researchers (LR) and Co-Lead Researchers (Co-LR) are as follows:

Area 1. Cardiovascular Diseases, Obesity, and Diabetes. Environmental Determinants and Lifestyle.

Consolidated groups:

Code	LR/Co-LR	Group Name
A-01	LR Gabriel Olveira Fuster Gabriel. Co-LR Javier Bermúdez Silva	ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY
A-02	LR Francisco Tinahones Madueño. Co-LR Manuel Macias González. Co-LR Isabel Moreno Indias	OBESITY, DIABETES, AND THEIR COMORBIDITIES: PREVENTION AND TREATMENT.
A-03	LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas, Co-LR Francisco Javier Pavón Morón	CARDIOVASCULAR RESEARCH FOR HEALTH
A-06	LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal	DIABETES, OBESITY, AND OTHER VASCULAR RISK FACTORS. SYSTEMIC AUTOIMMUNE DISEASES.

Code	LR/Co-LR	Group Name
A-07	LR José Antonio González Correa. Co-LR José Pedro de la Cruz Cortés	TRANSLATIONAL RESEARCH ON CARDIOVASCULAR DISEASE
A-09	LR Pedro Valdivielso Felices. Co-LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares.	RESEARCH ON ARTERIOSCLEROSIS, CARDIOVASCULAR PREVENTION, METABOLISM, AND NEUROLOGICAL DISEASES.
A-10	LR Julia Warnberg. Co-LR Napoleón Pérez Farinós	EPIDEMIOLOGY, PHYSICAL ACTIVITY, ACCELEROMETRY, and NUTRITION (EpiPHAAN).
A-17	LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero	ANIMAL MODELS IN CARDIOVASCULAR RESEARCH.
A-19	LR Isabel Leiva Gea, Co-LR David Moreno Pérez, Co-LR Juan Pedro López-Siguero	MULTIDISCIPLINARY PEDIATRIC RESEARCH GROUP
A-21	LR José Luis Guerrero Orriach. Co-LR José Cruz Mañas	RESEARCH ON ORGAN PROTECTION IN THE PERIOPERATIVE PERIOD OF HEART SURGERY
A-23	LR. Mario Gutiérrez Bedmar. Co-LR Rosa López Gigosos	PREVENTIVE MEDICINE AND PUBLIC HEALTH

Emerging groups:

Code	LR/Co-LR	Group Name
AE-11	LR. Verónica López Jiménez. Co-LR Juana Alonso Titos.	NEPHROLOGY AND RENAL TRANSPLANTATION

Associated groups:

Code	LR/Co-LR	Group Name
AA-04	LR María Antonia Estecha Foncea	INTENSIVE CARE MEDICINE
AA-15	LR Cristobal Urbano Carrillo	HEART AND VASCULAR DISEASE
AA-20	LR Cipriano Viñas. Co-LR Antonio Jesús Núñez Montenegro	RESEARCH GROUP ON CARE IN MÁLAGA (INVESCUIDA)
AA-22	LR Eduardo Sánchez Guerrero	BIOPSYCHOSOCIAL INTERVENTION IN COMPLEX HEALTH SYSTEM PROCESSES

External associated groups:

Code	LR/Co-LR	Group Name
AA-24	LR: Miguel Ángel García Ordóñez. Co-LR: Jesus Olmedo Llanes	VASCULAR RISK AND CHRONIC DISEASES
AA-25	Néstor Oliva Damaso	NEFROCONSULTOR

Area 2. Molecular and Translational Biology of Cancer

Consolidated groups

Code	LR/Co-LR	Group Name
B-03	LR Antonio Jiménez Velasco	HEMATOLOGY AND HEMATOTHERAPY
B-04	LR Miguel Ángel Medina Torres	MOLECULAR BASES OF BIOLOGICAL SYSTEMS (SIBIUMA)
B-07	LR Javier Márquez Gómez. Co-LR José Manuel Matés Sánchez.	CANCEROMICS
B-10	LR María Victoria de Gálvez Aranda. Co-LR Enrique Herrera Acosta	SKIN CANCER
B-11	LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico	TRANSLATIONAL RESEARCH ON GENITOURINARY TUMORS GROUP

Emerging groups:

Code	LR/Co-LR	Group Name
BE-15	LR Luis Vicioso. Co-LR Isabel Hierro. Co-LR Rafael E. Carvia Ponsaillé	PATHOLOGICAL ANATOMY
BE-17	LR Jaime Gómez-Millán Barrachina. Co-LR María Jesús García Anaya	CLINICAL, MOLECULAR, AND TECHNOLOGICAL RESEARCH ON RADIATION ONCOLOGY
BE-18	LR Melissa García Caballero	VASCULAR BIOLOGY, TUMOR MICROENVIRONMENT & TARGET DISCOVERY
BE-19	LR Miguel José Ruiz Gómez	RADIOBIOLOGY

Associated groups:

Code	LR/Co-LR	Group Name
BA-1	LR Adolfo Romero Ruiz	QUALITY AND SAFETY IN LABORATORY AND HEMATOLOGY CARE
BA-20	LR. Ismael Herruzo Cabrera	ONCOLOGY AND BENIGN PATHOLOGY

External associated groups:

Code	LR/Co-LR	Group Name
BA-14	LR Maximino Redondo Bautista	TRANSLATIONAL RESEARCH GROUP IN CANCER AND OTHER PREVALENT CHRONIC DISEASES

Area 3. Neurosciences, Chronicity, Aging, and Health in vulnerable populations

Consolidated groups:

Code	LR/Co-LR	Group Name
C-01	LR Pedro Serrano Castro, Co-LR Guillermo Estivill, Co-LR Laura Leyva	NEUROIMMUNOLOGY AND NEUROINFLAMMATION
C-02	LR Juan Ángel Bellón Saameño. Co-LR Patricia Moreno Peral	MENTAL HEALTH, SERVICES, AND PRIMARY CARE (SAMSERAP).
C-03	LR Fermín Mayoral Cleries, Co-LR: Jose Guzman Parra	BASIC, CLINICAL, AND EPIDEMIOLOGICAL RESEARCH ON MENTAL HEALTH GROUP
C-05	LR Antonio J. Jiménez Lara	DEGENERATION AND REGENERATION OF THE CENTRAL NERVOUS SYSTEM
C-06	LR Fernando Rodríguez de Fonseca. Co-LR: Antonia María Serrano Criado. Co-LR: Juan Suárez Pérez	NEUROPSYCHOPHARMACOLOGY
C-07	LR José Ángel Narváez Bueno	BASIC AND APPLIED ASPECTS OF NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES
C-08	LR Francisca Leiva Fernández. Co-LR: Antonio García Ruiz	MAEPAP. MULTIMORBIDITY, ADHERENCE, ECONOMIC EVALUATION, AND PALLIATIVE CARE IN PRIMARY CARE
C-09	LR Antonia Gutiérrez Pérez	NEUROPATHOLOGY OF ALZHEIMER'S DISEASE (NEUROAD)
C-11	LR María Carmen Ramírez Maestre	VULNERABILITY AND RESILIENCE TO CHRONIC PAIN: IMPLICATIONS FOR PSYCHOLOGICAL INTERVENTION
C-12	LR Guadalupe Dávila Arias	COGNITIVE NEUROSCIENCE: APHASIA AND RELATED DISORDERS (UNCA)
C-13	LR José Miguel Morales Asencio	CHRONICITY, DEPENDENCY, CARE, AND HEALTH SERVICES
C-16	LR Ernesto González Mesa. Co-LR Jesús Salvador Jiménez López	MATERNAL-FETAL MEDICINE, EPIGENETICS, WOMEN'S HEALTH CONDITIONS, AND REPRODUCTIVE HEALTH RESEARCH GROUP

Emerging groups:

Code	LR/Co-LR	Group Name
CE-17.	LR. Carmen Ortiz García. Co-LR Ángela García de la Torre. Co-LR Begoña Mora Ordoñez	TECHNOLOGY AND INNOVATION IN EMERGENCY DEPARTMENTS AND HOSPITALIZATION
CE-18.	LR. Stella Martín de las Heras	FORENSIC MEDICINE, TOXICOLOGY, AND FORENSIC ODONTOLOGY

24 ORGANIZATIONAL STRUCTURE 25

Associated groups:

Code	LR/Co-LR	Group Name
CA-10.	LR Francisco J. López Gutiérrez	CAUSAL COGNITION GROUP

External associated groups:

Code	LR/Co-LR	Group Name
CA-14.	LR José Javier García Alegría	CHRONIC DISEASES AND AGING
CA-15.	LR Rafael Gómez García . Co-LR Pilar Barnestein Fonseca	PALLIATIVE CARE
CA-19.	LR. Antonia Fernandez Luque, Co-LR Fernando Zubeldia Santoyo	DigCompSalud. Digital competence for lifelong learning

Area 4. Autoimmune diseases, infectious diseases, inflammation, and allergies.

Consolidated groups:

Code	LR/Co-LR	Group Name
D-01.	LR Jesús Santos González. Co-LR Rosario Palacios Muñoz	CLINICAL RESEARCH GROUP ON HIV INFECTION, ENDOVASCULAR INFECTION, AND BACTEREMIA
D-03.	LR Antonio Fernández Nebro. Co-LR Natalia Mena Vázquez	INFLAMMATORY AND AUTOIMMUNE DISEASES
D-04	LR Mª José Torres Jaén, Co-LR: Lina Mayorga Mayorga	ALLERGIC DISEASES TO DRUGS AND ALLERGENS
D-05	LR Raúl J. Andrade Bellido, Co-LR Eduardo Garcia Fuentes, Co-LR Mercedes Robles Díaz	HEPATOGASTROENTEROLOGY, PHARMACOLOGY, AND TRANSLATIONAL CLINICAL THERAPEUTICS

Emerging groups:

Code	LR/Co-LR	Group Name
DE-02	LR José María Reguera	GROUP FOR THE STUDY OF INFECTIOUS DISEASES
DE-07	LR Manuel Enrique Herrera Gutierrez. Co-LR Emilio Curiel Balsera	INFLAMMATION IN CRITICALLY ILL PATIENTS
DE-08	LR Miguel Jiménez Pérez. Co-LR Julio Santoyo Santoyo	HEPATOGASTROENTEROLOGY, ENDOSCOPY, AND GASTROINTESTINAL SURGERY
DE-09	LR Juan José Borrego García. Co-LR José Manuel Jiménez Guardeño	IMMUNE RESPONSE TO VIRAL INFECTIONS.
DE-10	LR Rafael Luque Aranda. Co-LR Carmen Alba Linero	OPHTHALMOLOGY

Associated groups:

Code	LR/Co-LR	Group Name
DA-06	LR Rosa García Portales	IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMID)

Area 5. IBIMA RARE. Multidisciplinary.

Code	LR/Co-LR	Group Name
A-01	LR Gabriel Olveira Fuster Gabriel. Co-LR Javier Bermúdez Silva	ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY
A-03	LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas, Co-LR Francisco Javier Pavón Morón	CARDIOVASCULAR RESEARCH FOR HEALTH
A-06	LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal	DIABETES, OBESITY, AND OTHER VASCULAR RISK FACTORS. SYSTEMIC AUTOIMMUNE DISEASES.
A-09	LR Pedro Valdivielso Felices. Co-LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares.	RESEARCH ON ARTERIOSCLEROSIS, CARDIOVASCULAR PREVENTION, METABOLISM, AND NEUROLOGICAL DISEASES.
A-17	LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero	ANIMAL MODELS IN CARDIOVASCULAR RESEARCH.
A-19	LR Isabel Leiva Gea, Co-LR David Moreno Pérez, Co-LR Juan Pedro López-Siguero	MULTIDISCIPLINARY PEDIATRIC RESEARCH GROUP
AA-22	LR Eduardo Sánchez Guerrero	BIOPSYCHOSOCIAL INTERVENTION IN COMPLEX HEALTH SYSTEM PROCESSES
B-04	LR Miguel Ángel Medina Torres	MOLECULAR BASES OF BIOLOGICAL SYSTEMS (SIBIUMA)
B-11	LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico	TRANSLATIONAL RESEARCH ON GENITOURINARY TUMORS GROUP
C-01	LR Pedro Serrano Castro, Co-LR Guillermo Estivill, Co-LR Laura Leyva	NEUROIMMUNOLOGY AND NEUROINFLAMMATION
C-03	LR Fermín Mayoral Cleries, Co-LR: Jose Guzman Parra	BASIC, CLINICAL, AND EPIDEMIOLOGICAL RESEARCH ON MENTAL HEALTH GROUP
C-06	LR Fernando Rodríguez de Fonseca. Co-LR: Antonia María Serrano Criado. Co-LR: Juan Suárez Pérez	NEUROPSYCHOPHARMACOLOGY
C-07	LR José Ángel Narváez Bueno	BASIC AND APPLIED ASPECTS OF NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES
FA-07	LR Antonio Leiva Gea	RESEARCH ON ORTHOPEDIC SURGERY AND TRAUMATOLOGY
H-02	LR Iván Durán Jiménez. Co-LR Fabiana Csukasi	Laboratory of Skeletal Biomedicine/Laboratorio de Biomedicina del esqueleto

26 ORGANIZATIONAL STRUCTURE

Area 6. IBIMA Tech: Health Technology and Innovation Area

Consolidated groups:

Code	LR/Co-LR	Group Name
F-02	LR José Ignacio Peláez Sánchez. Co-LR Ezequiel López Rubio	COMPUTATIONAL INTELLIGENCE AND IMAGE ANALYSIS
F-03	LR Iñigo Molina Fernández	COMMUNICATIONS ENGINEERING
F-04	LR Javier González Jiménez. Co-LR Francisco Ángel Moreno Dueñas	MAPIR (MACHINE PERCEPTION AND INTELLIGENT ROBOTICS GROUP)
F-05	LR. Víctor Fernando Muñoz Martínez	MEDICAL ROBOTICS
F-09	LR Fernando Vidal Verdú.	ELECTRONICS FOR INSTRUMENTATION AND SYSTEMS.
F-10	LR Ezequiel Pérez Inestrosa. Co-LR Francisco Nájera Albendín	BIOMIMETIC DENDRIMERS AND PHOTONIC LABORATORY
F-14	LR Antonio Ignacio Cuesta Vargas	CLINIMETRICS IN PHYSICAL THERAPY
F-15	LR José F. Aldana Montes	DATA AND KNOWLEDGE MANAGEMENT, INTEGRATION, AND ANALYSIS (KHAOS)

Emerging groups:

Code	LR/Co-LR	Group Name
FE-17	LR Raquel Cantero Téllez. Co-LR Javier García Orza	HandResearchTeam
FE-18	LR Lorena Aguilar Cano. Co-LR: Francisco Luna Cabrera	REHABILITATION, INNOVATION, AND QUALITY OF LIFE

Associated groups:

Code	LR/Co-LR	Group Name
FA-07	LR Antonio Leiva Gea	RESEARCH ON ORTHOPEDIC SURGERY AND TRAUMATOLOGY
FA-08	LR Alfonso Gago Calderón	ОТОТЕСН

External associated groups:

Code	LR/Co-LR	Group Name
FA-16	LR Enrique Guerado Parra	INNOVATIVE THERAPIES AND NEW TECHNOLOGIES IN THE MUSCULOSKELETAL SYSTEM

Area 7. Nanodiagnostics

Consolidated groups:

Code	LR/Co-LR	Group Name
G-01.	LR María Luisa García Martín	BIOMEDICAL MAGNETIC RESONANCE LABORATORY (BMRL)

Area 8. Nanosystems and advanced therapies

Consolidated groups:

Code	LR/Co-LR	Group Name
H-02	LR Iván Durán Jiménez. Co-LR Fabiana Csukasi	LABORATORY OF SKELETAL BIOMEDICINE/ LABORATORIO DE BIOMEDICINA DEL SKELETO
H-03	LR Jose María Pérez Pomares	DEVELOPMENT AND CARDIOVASCULAR DISEASE

Emerging groups:

Code	LR/Co-LR	Group Name
HE-01	LR Elena González Muñoz	CELL REPROGRAMMING (iPSCs) AND DISEASE CELL MODELS FOR BIOMEDICAL APPLICATIONS

Oncology Research Centre of Málaga (CIMO)

Consolidated groups:

Code	LR/Co-LR	Group Name
CIMO-01	LR Emilio Alba Conejo	CLINICAL AND TRANSLATIONAL RESEARCH ON CANCER
CIMO-02	LR Antonio Rueda Domínguez. Co-LR. Isabel Barragan Mallofret	TRANSLATIONAL RESEARCH ON CANCER IMMUNOTHERAPY.
CIMO-03	LR José Manuel Jerez Aragonés	COMPUTATIONAL INTELLIGENCE IN BIOMEDICINE

The **objectives of the scientific areas** and their research groups are explained in the 2023-2027 strategic plan and in the cooperative scientific plan with the general objective of fostering synergies between the institute's research groups by promoting inter-institutional, inter-area, and intra-area collaboration.

The IBIMA Plataforma BIONAND areas have proposed the following specific objectives:

- Increase scientific production and the conduct of projects resulting from collaboration among the institute's groups.
- Promote collaborative translational research with results close to the market.
- Comply with new Open Science strategies and policies.

The extent to which the annual objectives have been met is measured every six months and submitted to the Board of Directors. The following sections of this report describe the results achieved in 2023.

3.2. HUMAN RESOURCES

In 2023, the IBIMA staff consisted of a total of 1,348 professionals, including researchers (1,156), support technicians (166), and managers (26).

DISTRIBUTION OF PERSONNEL BY GENDER




Figure 2: Number of professionals by category and gender in 2023




Figure 3: Percentage of professionals by category in 2023

In 2023, IBIMA Plataforma BIONAND implemented the actions planned according to its Human Resources Strategy for Researchers (HRS4R). The strategy was launched 2017 after obtaining the "HR Excellence in Research" recognition awarded by the European Commission.



IBIMA's HRS4R action plan is aligned with the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers with the aim of improving the working and employment conditions of researchers with open, transparent, and merit-based recruitment and hiring practices.

e distribution of IBIMA Plataforma BIONAND personnel by gender and

The distribution of IBIMA Plataforma BIONAND personnel by gender and category and according to the European classification of research profiles R1 – R4 (https://euraxess.ec.europa.eu/europe/career-development/training-research-profiles-descriptors) is as follows:




Figure 4: IBIMA Plataforma BIONAND personnel in 2023 by category (Euraxess) and gender

Of the 1,156 researchers who formed part of the Institute in 2023, 229 were R1 researchers, 625 were R2 researchers, 186 were R3 researchers, and 116 were R4 researchers, according to the European classification of research profiles. In addition, 47% (542) were men and 53% (614) were women.




Figure 5: IBIMA Plataforma BIONAND researchers according to the European classification of researchers

INVESTIGATORS ACCORDING TO EURAXESS CATEGORY AND GENDER




Figure 6: IBIMA Plataforma BIONAND Researchers according to European classification of researchers and gender

Research group leaders (LR or Co-LR by gender):

In addition, 59% of researchers have clinical practice activity (figure 8).




Figure 7: Percentage of Group Leaders (LR/Co-LR) by gender

Figure 8: Distribution of researchers according to clinical practice activity

The institute's management personnel are organized into **Research Support Units (RSU)**, whose functions include supporting the institute's scientific objectives through its managing entity FIMABIS:

- Advisory service for fundraising and establishing collaborations.
- Fund management service for R&I activities.
- International project advisory service.
- Clinical trials management service.
- Methodological and statistical support service.
- Advisory and management service for the protection, transfer, and dissemination of results.
- Communication to society and event coordination.
- Management of health research centers and institutes linked to the Andalusian Public Healthcare System.

SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA



4.1. SCIENTIFIC PRODUCTION. BIBLIOMETRIC INDICATORS.

In order to visualize the overall scientific production of IBIMA Plataforma BIONAND over the last five years, the following graph shows the number of publications broken down by type of document.

CHANGES IN SCIENTIFIC PRODUCTION (JCR) AND DISTRIBUTION BY DOCUMENT TYPE





Figure 9: Changes in the number of publications by document type in the last five years

The percentage that corresponds to each document type in 2023 is shown in the following figure:

PUBLICATIONS - DOCUMENT TYPE



To calculate the bibliometric indicators published in this report, only **original research articles and review articles** published in journals with an impact factor that are indexed in the **2022** edition of the **Journal Citation Report** (JCR), the most recent edition available at the time of writing this report, have been considered. **All other types of documents, including editorial material, letters, meeting abstracts, erratum, and articles in press (in press, early access) have been excluded.**

Doc. type	No.	IF	Mean IF	% Q1	% D1	% Led
Articles	750	4,540	6.1	46%	19%	44%
Reviews	113	520	4.6	38%	18%	60%
TOTAL	863	5,060	5.9	45%	19%	46%

The scientific production in 2023 was 863 publications: 750 original articles and 113 reviews. The following figure shows changes in the number of publications in the last five years.

NUMBER OF ORIGINAL AND REVIEW ARTICLES



Figure 11: Changes in the total number of original and review articles in the last five years

On the other hand, regarding the position of publications in the JCR subject category in which they are indexed, Figure 12 shows the percentage of publications in first quartile (Q1) and first decile (D1) journals in the last five years.

ORIGINAL AND REVIEW ARTICLES IN Q1 AND D1




Figure 12: Change in the percentage of first quartile (Q1) and first decile (D1) publications

ORIGINAL AND REVIEW ARTICLES PER QUARTILE (JCR)




Figure 13: Percentage of publications by quartiles

It is notable that 77% of the scientific production in 2023 was published in first (Q1) and second quartile (Q2) journals.

Leadership

Forty-six percent of scientific production was led by IBIMA Plataforma BIONAND researchers who contributed as first, last, or corresponding author, as shown in the following figure:

PUBLICATIONS WITH FIRST AUTHORSHIP (FIRST, LAST, OR CORRESPONDING AUTHOR) BY IBIMA PLATAFORMA BIONAND INVESTIGATORS




Figure 14: Change in the percentage of publications led in the last five years

Impact Factor

When calculating the impact factor (IF), only **original research articles and review articles** were considered. Collaborative publications among different groups and/or areas of the institute were only counted once for the overall calculation.

The institute's cumulative impact factor in 2023 was 5,060 points. Changes in the cumulative and mean impact factor is shown in the following figure:

CUMULATIVE AND MEAN IMPACT FACTOR




Figure 15: Changes in cumulative and mean impact factor.

Collaborations

Figure 16 shows the percentage of publications by IBIMA Plataforma BIONAND researchers published in collaboration with other researchers from national institutions outside of Andalusia (national collaborations) and institutions of other nationalities (international collaborations).

NATIONAL AND INTERNATIONAL COLLABORATIONS




Figure 16: Change in the percentage of scientific production according to national and international collaboration.

On the other hand, the percentage of publications from intra-institute collaborations among groups from different scientific areas and/or institutions that make up the IBIMA Plataforma BIONAND is shown in the following figure.

PUBLICATIONS IN COLLABORATION AMONG AREAS AND/OR IBIMA PLATAFORMA BIONAND INSTITUTIONS

Publications in collaboration among areas and/or ibima plataforma bionand institutions




Figure 17: Changes in the number of publications produced in collaboration among groups from different areas and/or institutions that make up the IBIMA Plataforma BIONAND.

Journals with IF >20 in which works were published in 2023

GROUP	Source Title	IF	D1
CIMO-01 / CIMO-02	NEW ENGLAND JOURNAL OF MEDICINE	158.5	D1
D-05	NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY	65.1	D1
DE-09	NATURE	64.8	D1
CIMO-02	LANCET ONCOLOGY	51.1	D1
CIMO-01/CIMO-02	ANNALS OF ONCOLOGY	50.5	D1
A-01	LANCET DIABETES & ENDOCRINOLOGY	44.5	D1
A-03	EUROPEAN HEART JOURNAL	39.3	D1
CIMO-01	SIGNAL TRANSDUCTION AND TARGETED THERAPY	39.3	D1
H-03	CIRCULATION	37.8	D1
A-02	IMMUNITY	32.4	D1
D-05	GASTROENTEROLOGY	29.4	D1
F-10	ADVANCED MATERIALS	29.4	D1

GROUP	Source Title	IF	D1
CIMO-02	JAMA ONCOLOGY	28.4	D1
D-05 (2) / DE-08	JOURNAL OF HEPATOLOGY	25.7	D1
CIMO-01	EUROPEAN UROLOGY	23.4	D1
A-23 / C-12	LANCET REGIONAL HEALTH-EUROPE	20.9	D1
CIMO-02 (2)	JOURNAL OF THORACIC ONCOLOGY	20.4	D1

4.2. CLINICAL PRACTICE GUIDELINES

In 2023, 49 clinical practice guidelines were published in journals indexed in the JCR:

Group	Authors	Article Title	Source Title
A-02	Reyes-García, R; Moreno-Pérez, O; Bellido, V; Botana- López, M; Rodríguez-Hervada, AD; Fernández-García, D; Fernández-García, JC; Gargallo-Fernández, M; González-Clemente, JM; Jódar-Gimeno, E; Casares, MLDL; López-Fernández, J; Martínez, A; Mezquita- Raya, P; Rozas-Moreno, P; Tejera-Pérez, C; Martín, JS	Comprehensive approach to people with type 2 diabetes. Diabetes Knowledge Area of the Spanish Society of Endocrinology and Nutrition	ENDOCRINO- LOGIA DIABETES Y NUTRICION
A-02	Garcia-Almeida, JM; Garcia-Garcia, C; Ballesteros- Pomar, MD; Olveira, G; Lopez-Gomez, JJ; Bellido, V; Lesmes, IB; Burgos, R; Sanz-Paris, A; Matia-Martin, P; Romero, FB; Breton, JO; Murillo, AZ; Bellido, D	Expert Consensus on Morphofunctional Assessment in Disease- Related Malnutrition. Grade Review and Delphi Study	NUTRIENTS
A-02	Ampudia-Blasco, Francisco Javier; Ugarte-Abasolo, Estibaliz; Chico, Ana; Garcia-Aleman, Jorge; Galan- Barroso, Manuel	Spanish Consensus on the Use of Intermittently Scanned Continuous Glucose Monitoring in the Management of Patients With Insulin Therapy: The MONITOR Project.	Journal of diabetes science and technology
A-02	Rebollo-Pérez, MI; Ojeda, LF; García-Luna, PP; Rocamora, JAI; Olveira, G; Remigio, JRL; Irigoyen, CA; Continente, AC; Martín, CC; Soto, MLF; Almeida, JMG; López, ML; Morell, CL; Pérez, LML; Martínez, TMD; Pereira-Cunill, JL; Vilchez-López, FJ; Rabat-Restrepo, JM	Standards for the Use of Enteral Nutrition in Patients with Diabetes or Stress Hyperglycaemia: Expert Consensus	NUTRIENTS
A-02	Bellido, Virginia; Aguilera, Eva; Cardona-Hernandez, Roque; Diaz-Soto, Gonzalo; Gonzalez Perez de Villar, Noemi; Picon-Cesar, Maria J; Ampudia-Blasco, Francisco Javier	Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes.	Journal of diabetes science and technology

Group	Authors	Article Title	Source Title
A-03	Escobar, Carlos; Freire, Ramon Bover; Marimon, Xavier Garcia-Moll; Gonzalez-Juanatey, Carlos; Morillas, Miren; Munoz, Alfonso Valle; Doblas, Juan Jose Gomez	A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study	CARDIOVAS- CULAR DIAGNOSIS AND THERAPY
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Pinero, MR; Marcos, JFV; Lopez, MAB; Lopez, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratala, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?	CIRUGIA CAR- DIOVASCULAR
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Piñero, MR; Marcos, JFV; Pérez, AP; López, MAB; López, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratalá, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?	REVISTA CLINICA ESPANOLA
A-03	Velilla, Teresa Arrobas; Guijarro, Carlos; Ruiz, Raquel Campuzano; Pinero, Manuel Rodriguez; Francisco Valderrama Marcos, Jose; Lopez, Antonio M Botana; Lopez, Ana Morais; Antonio Garcia Donaire, Jose; Obaya, Juan Carlos; Guerra, Luis Castilla; Carratala, Vicente Pallares; Cabello, Isabel Egocheaga; Lazo, Mercedes Salgueira; Rodrigo, Maria Mar Castellanos; Maria Mostaza Prieto, Jose; Doblas, Juan Jose Gomez; Soto, Antonio Buno	Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?	NEFROLOGIA
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Piñero, MR; Marcos, JFV; Pérez, AP; López, MAB; López, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratalá, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?	CLINICA E IN- VESTIGACION EN ARTERIO- SCLEROSIS
A-03	Arrobas Velilla, Teresa; Guijarro, Carlos; Campuzano Ruiz, Raquel; Rodriguez Pinero, Manuel; Valderrama Marcos, Jose Francisco; Botana Lopez, Antonio M; Morais Lopez, Ana; Garcia Donaire, Jose Antonio; Obaya, Juan Carlos; Castilla Guerra, Luis; Pallares Carratala, Vicente; Egocheaga Cabello, Isabel; Salgueira Lazo, Mercedes; Castellanos Rodrigo, Maria Mar; Mostaza Prieto, Jose Maria; Gomez Doblas, Juan Jose; Buno Soto, Antonio	Consensus document for lipid profile testing and reporting in Spanish clinical laboratories.	ENDOCRINO- LOGIA DIABETES Y NUTRICION
A-03	Arrobas Velilla, Teresa; Guijarro, Carlos; Campuzano Ruiz, Raquel; Rodriguez Pinero, Manuel; Valderrama Marcos, Jose Francisco; Perez Perez, Antonio; Botana Lopez, Manuel Antonio; Morais Lopez, Ana; Garcia Donaire, Jose Antonio; Carlos Obaya, Juan; Castilla Guerra, Luis; Pallares Carratala, Vicente; Egocheaga Cabello, Isabel; Salgueira Lazo, Mercedes; Castellanos Rodrigo, Maria Mar; Mostaza Prieto, Jose Maria; Gomez Doblas, Juan Jose; Buno Soto, Antonio	Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: What parameters should a basic lipid profile include?	REVISTA CLINICA ESPANOLA

Group	Authors	Article Title	Source Title
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Piñero, MR; Marcos, JF; Pérez, AP; López, AMB; López, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratalá, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?	ADVANCES IN LABORATORY MEDICINE- AVANCES EN MEDICINA DE LABORATORIO
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Piñero, MR; Marcos, JFV; Pérez, AP; López, MAB; López, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratalá, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for the determination and reporting of the lipid profile in Spanish clinical laboratories: What parameters should a basic lipid profile include?	ADVANCES IN LABORATORY MEDICINE- AVANCES EN MEDICINA DE LABORATORIO
A-03	Escobar, Carlos; Barrios, Vivencio; Cequier, Angel; Cosin-Sales, Juan; Seijas, Jose; Doblas, Juan Jose Gomez; Arrarte, Vicente; Tunon, Jose; Banach, Maciej	Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome.	JOURNAL OF CLINICAL LIPIDOLOGY
A-03	Pedro-Botet, J; Barrios, V; Sánchez-Margalet, V; Tamargo, J; Arrieta, F; Gámez, JM; Gimeno-Orna, JA; Escobar, C; Gómez-Doblas, JJ; Pérez, A	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Espanola de Cardiologia [Spanish Society of Cardiology] and the Sociedad Espanola de Diabetes [Spanish Diabetes Society]	ENDOCRINO- LOGIA DIABETES Y NUTRICION
A-06	Martínez, PP; Gómez-Huelgas, R; Escribano, PPC; Arévalo-Lorido, JC; Pérez-Soto, MI; Gómez, CJ	Approach to obesity in the elderly population: a consensus report from the Diabetes, Obesity and Nutrition Working Group of Spanish Society of Internal Medicine	REVISTA CLINICA ESPANOLA
A-09	Cardo, ALG; Casas, JAV; Garzón, JRG; Hospital, JLT; López, RM; Macías, JMF; Fernández, AR	18F-DCFPyL PET/CT guidelines	REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
A-19	Rivero Calle, Irene; Del Rosal Rabes, Teresa; Garrote Llanos, Elisa; Nunez Cuadros, Esmeralda; Navarro Gomez, Maria Luisa; Ramos Amador, Jose Tomas; Calvo, Cristina; Alvarez Garcia, Francisco	Consensus document of the Spanish Society of Paediatric Infectious Diseases and the Advisory Committee on Vaccines of the Spanish Association of Pediatrics for vaccination of immunosuppressed individuals.	ANALES DE PEDIATRIA

44 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA

10 Indian Plataforma BIONAND 2023 SCIENTIFIC REPORT 45

Group	Authors	Article Title	Source Title
A-19	Constanti, VA; Garau, AD; Marrodán, BR; Pinto, EV; Gómez, MR; Soto, LG; Borges, AH; Rodríguez, AM	Do not do recommendations in different paediatric care settings	ANALES DE PEDIATRIA
A-19	Garulo, DC; Nunez-Cuadros, E; Lovillo, M; Calzada- Hernandez, J; Martin, S; Silveira, L; Cruz, MJ; Tagarro, A; Rueda, RM; Lopez, A; Aritziturri, M; Calvo, C	Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis	EUROPEAN JOURNAL OF PEDIATRICS
A-19	Martín-Masot, R; Díaz-Martín, JJ; Santamaría- Orleans, A; Navas-López, VM	Spanish Pediatricians' Positions Regarding Prevention, Diagnosis, Nutritional Management, and Challenges in Cow's Milk Protein Allergy	NUTRIENTS
A-23	López-Medrano, F; Alfayate, S; Carratala, J; Chamorro-Camazón, J; Cordero, E; Cruz-Cañete, M; Fernández-Pradai, M; García-Cenoz, M; Marcos, MA; Melón, S; Moreno-Millán, N; Onieva-García, MA; de Lejarazuo, RO; Pérez-Martín, JJ; Rodríguez-García, J; Schwarz-Chavarrir, G; Tagarro-García, A; van Esso- Arbolave, D; Viasus, D; Pumarola, T	Executive summary-Diagnosis, treatment and prophylaxis of influenza virus infection -Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)	ANALES DE PEDIATRIA
A-23	López-Medrano, F; Alfayate, S; Carratalà, J; Chamorro-Camazón, J; Cordero, E; Cruz-Cañete, M; Fernández-Prada, M; García-Cenoz, M; Marcos, MA; Melón, S; Moreno-Millán, N; Onieva-García, MA; de Lejarazu, RO; Pérez-Martín, JJ; Rodríguez-García, J; Schwarz-Chavarri, G; Tagarro-García, A; van Esso- Arbolave, D; Viasus, D; Pumarola, T	Executive summary Diagnosis, treatment and prophylaxis of influenza virus infectionConsensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)	ATENCION PRIMARIA

Group	Authors	Article Title	Source Title
A-23	López-Medrano, F; Alfayate, S; Carratalà, J; Chamorro-Camazón, J; Cordero, E; Cruz-Cañete, M; Fernández-Prada, M; García-Cenoz, M; Marcos, MA; Melón, S; Moreno-Millán, N; Onieva-García, MA; de Lejarazu, RO; Pérez-Martín, JJ; Rodríguez-García, J; Schwarz-Chavarri, G; Tagarro-García, A; van Esso- Arbolave, D; Viasus, D; Pumarola, T	Executive summary. Diagnosis, treatment and prophylaxis of influenza virus infection. Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)	ENFERME- DADES INFECCIOSAS Y MICROBIO- LOGIA CLINICA
AA-04	Ripolles-Melchor, J.; Colomina, M. J.; Aldecoa, C.; Alonso-Cabello, J.; Alonso-Inigo, J. M.; Aya, H.; Basora, M.; Clau-Terre, F.; del Cojo-Peces, E.; Cota-Delgado, F.; Ferrandis-Comes, R.; Galan-Menendez, P.; Garcia-Lopez, D.; Garruti, I.; Lopez, I. J.; Jover-Pinillos, J. L.; Llau-Pitarch, J. V.; Lorente, J. V.; Mesquida, J.; Mojarro, I.; Monge-Garcia, M. I.; Montesinos-Fadrique, S. C.; Munoz-Rodes, J. L.; de Nadal, M.; Ramasco, F.; Tome-Roca, J. L.; Perez, A.; Una-Orejon, R.; Yanes, G.; Zorrilla-Vaca, A.; Escarraman, D.; Garcia-Fernandez, J.	Research priorities in perioperative fluid therapy and hemodynamic monitoring: A Delphi Consensus Survey from the Fluid Therapy and Hemodynamic Monitoring Subcommittee of the Hemostasis, Transfusion Medicine and Fluid Therapy Section (SHTF) of the Spanish Society of Anesthesiology and Critical Care (SEDAR)	REVISTA ESPANOLA DE ANESTESIOLO- GIA Y REANIMACION
AE-11	Lopez, Veronica; Mazuecos, Auxiliadora; Villanego, Florentino; Lopez-Oliva, Maria; Alonso, Angel; Beneyto, Isabel; Crespo, Marta; Diaz-Corte, Carmen; Franco, Antonio; Gonzalez-Roncero, Francisco; Guirado, Luis; Jimenez, Carlos; Juega, Javier; Llorente, Santiago; Paul, Javier; Rodriguez-Benot, Alberto; Ruiz, Juan Carlos; Sanchez-Fructuoso, Ana; Torregrosa, Vicente; Zarraga, Sofia; Rodrigo, Emilio; Hernandez, Domingo	Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients.	NEFROLOGIA
B-03	Chumbita, M; Puerta-Alcalde, P; Yáñez, L; Cuesta, MA; Chinea, A; Español-Morales, I; Fernandez-Abellán, P; Gudiol, C; González-Sierra, P; Rojas, R; Sánchez-Pina, JM; Vadillo, IS; Sánchez, M; Varela, R; Vázquez, L; Guerreiro, M; Monzo, P; Lopera, C; Aiello, TF; Peyrony, O; Soriano, A; Garcia-Vidal, C	High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations	MICROBIOLO- GY SPECTRUM

Group	Authors	Article Title	Source Title
B-03	Mingot-Castellano, Maria Eva; Canaro Hirnyk, Mariana; Sanchez-Gonzalez, Blanca; Alvarez-Roman, Maria Teresa; Barez-Garcia, Abelardo; Bernardo- Gutierrez, Angel; Bernat-Pablo, Silvia; Bolanos- Calderon, Estefania; Butta-Coll, Nora; Caballero- Navarro, Gonzalo; Caparros-Miranda, Isabel Socorro; Entrena-Urena, Laura; Fernandez-Fuertes, Luis Fernando; Garcia-Frade, Luis Javier; Gomez del Castillo, Maria del Carmen; Gonzalez-Lopez, Tomas Jose; Grande-Garcia, Carlos; Guinea de Castro, Jose Maria; Jarque-Ramos, Isidro; Jimenez-Barcenas, Reyes; Lopez-Ansoar, Elsa; Martinez-Carballeira, Daniel; Martinez-Robles, Violeta; Monteagudo- Montesinos, Emilio; Paramo-Fernandez, Jose Antonio; Perera-alvarez, Maria del Mar; Soto-Ortega, Inmaculada; Valcarcel-Ferreiras, David; Pascual- Izquierdo, Cristina	Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)	JOURNAL OF CLINICAL MEDICINE
B-10	Galvan-Casas, C; Ortiz-Alvarez, J; Martinez-Garcia, E; Corbacho-Monne, M	Recommendations from the spanish academy of dermatology and venereology (aedv) for the management of sexual transmitted parasitosis, scabies, and pediculosis pubis.	ACTAS DERMO-SIFIL- IOGRAFICAS
B-11	Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; James, ND; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, CJ; Tombal, B; Antonarakis, ES; Aparicio, AM; Armstrong, AJ; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, RG; Bulbul, M; Caffo, O; Castellano, D; Castro, E; Cheng, HH; Chi, KN; Chowdhury, S; Clarke, CS; Clarke, N; Daugaard, G; De Santis, M; Duran, I; Eeles, R; Efstathiou, E; Efstathiou, J; Ekeke, ON; Evans, CP; Fanti, S; Feng, FY; Fonteyne, V; Fossati, N; Frydenberg, M; George, D; Gleave, M; Gravis, G; Halabi, S; Heinrich, D; Herrmann, K; Higano, C; Hofman, MS; Horvath, LG; Hussain, M; Jereczek-Fossa, BA; Jones, R; Kanesvaran, R; Kellokumpu-Lehtinen, PL; Khauli, RB; Klotz, L; Kramer, G; Leibowitz, R; Logothetis, C; Mahal, B; Maluf, F; Mateo, J; Matheson, D; Mehra, N; Merseburger, A; Morgans, AK; Morris, MJ; Mrabti, H; Mukherji, D; Murphy, DG; Murthy, V; Nguyen, PL; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Pezaro, CJ; Poon, DMC; Pritchard, CC; Rabah, DM; Rathkopf, D; Reiter, RE; Rubin, MA; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Sharifi, N; Skoneczna, I; Soule, H; Spratt, DE; Srinivas, S; Sternberg, CN; Steuber, T; Suzuki, H; Sydes, MR; Taplin, ME; Tilki, D; Turkeri, L; Turco, F; Uemura, H; Uemura, H; Urun, Y; Vale, CL; van Oort, I; Vapiwala, N; Walz, J; Yamoah, K; Ye, DW; Yu, EY; Zapatero, A; Zilli, T; Omlin, A	Management of patients with advanced prostate cancer-metastatic and/ or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022	EUROPEAN JOURNAL OF CANCER

Group	Authors	Article Title	Source Title
B-11	Alvarez Alvarez, Rosa; Manzano, Aranzazu; Agra Pujol, Carolina; Artigas Raventos, Vicente; Correa, Raquel; Cruz Jurado, Josefina; Fernandez, Juan Angel; Garcia del Muro, Xavier; Gonzalez, Jose Antonio; Hindi, Nadia; Lozano Lominchar, Pablo; Martinez- Trufero, Javier; Mendez, Ramiro; Munoz, Mercedes; Munoz Casares, Cristobal; Orbis Castellanos, Francisco; Orellana Fernandez, Ruth; Paniagua Gonzalez, Miguel; Redondo, Andres; Valverde Morales, Claudia; Asencio, Jose Manuel	Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)	CANCERS
C-06	Fraguas, D; Gallego, DA; Arques-Egea, S; Gómez- Revuelta, M; Sánchez-Lafuente, CG; Huerta, DH; Arias, DN; Plasencia-García, BO; Torres, CP; Romero- Guillena, SL; Cucurul, ER; Alamo, C	Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice	INTERNATION- AL JOURNAL OF PSYCHIA- TRY IN CLINI- CAL PRACTICE
C-12	Frisoni, GB; Altomare, D; Ribaldi, F; Villain, N; Brayne, C; Mukadam, N; Abramowicz, M; Barkhof, F; Berthier, M; Bieler-Aeschlimann, M; Blennow, K; Guevara, AB; Carrera, E; Chételat, G; Csajka, C; Demonet, JF; Dodich, A; Garibotto, V; Georges, J; Hurst, S; Jessen, F; Kivipelto, M; Llewellyn, DJ; McWhirter, L; Milne, R; Minguillón, C; Miniussi, C; LuisMolinuevo, J; Nilsson, PM; Noyce, A; Ranson, JM; Grau-Rivera, O; Schott, JM; Solomon, A; Stephen, R; van der Flier, W; van Duijn, C; Vellas, B; Visser, LNC; Cummings, JL; Scheltens, P; Ritchie, C; Dubois, B	Dementia prevention in memory clinics: recommendations from the European task force for brain health services	LANCET REGIONAL HEALTH- EUROPE
CE-17	Pascual-Izquierdo, Cristina; Pinera Salmeron, Pascual; Temboury Ruiz, Francisco; Valcarcel Ferreiras, David; Jimenez Hernandez, Sonia; Salinas Argente, Ramon; del Arco Galan, Carmen; de la Rubia Comos, Javier	Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments - an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES)	EMERGENCIAS
CIMO- 01	Castelo-Branco, L; Pellat, A; Martins-Branco, D; Valachis, A; Derksen, J W G; Suijkerbuijk, K P M; Dafni, U; Dellaporta, T; Vogel, A; Prelaj, A; Groenwold, R H H; Martins, H; Stahel, R; Bliss, J; Kather, J; Ribelles, N; Perrone, F; Hall, P S; Dienstmann, R; Booth, C M; Pentheroudakis, G; Delaloge, S; Koopman, M	ESMO Guidance for Reporting Oncology real- World evidence (GROW).	ANNALS OF ONCOLOGY

48 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA

10 Indian Plataforma BIONAND 2023 SCIENTIFIC REPORT 49

Group	Authors	Article Title	Source Title
CIMO- 01	GillTssen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; James, ND; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, C; Tombal, B; Antonarakis, ES; Aparicio, AM; Armstrong, AJ; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, RG; Bulbul, M; Caffo, O; Castellano, D; Castro, E; Cheng, HH; Chi, KN; Chowdhury, S; Clarke, CS; Clarke, N; Daugaard, G; De, MR; Duran, I; Eeles, R; Efstathiou, E; Efstathiou, J; Ekeke, ON; Evans, CP; Fanti, S; Feng, FY; Fonteyne, V; Fossati, N; Frydenberg, M; Daniel, V; Gleave, M; Gravis, G; Halabi, S; Heinrich, D; Herrmann, K; Higano, C; Hofmanfff, MS; Horvath, LG; Hussain, M; Jereczek-Fossakkk, BA; Jonesmmm, R; Kanesvaran, R; Kellokumpu-Lehtinen, PL; Khauli, RB; Klotz, L; Kramer, G; Leibowitz, R; Logothetisp, CJ; Mahal, BA; Maluf, F; Mateo, J; Matheson, D; Mehra, N; Merseburger, A; Morgans, AK; Morris, MJ; Mrabti, H; Mukherji, D; Murphy, DG; Murthy, V; Nguyen, PL; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Pezaro, C; Poon, DMC; Pritchard, CC; Rabah, DM; Rathkopf, D; Reiter, RE; Rubin, MA; Ryan, CJ; Saad, F; Sade, JP; Sartor, OA; Scher, HI; Sharifi, N; Skoneczna, I; Soule, H; Spratt, DE; Srinivas, S; Sternberg, CN; Steuber, T; Suzuki, H; Sydes, MR; Taplin, ME; Tilki, D; Turkeri, L; Turco, F; Uemura, H; Uemura, H; Urun, Y; Vale, CL; van Oort, I; Vapiwala, N; Walz, J; Yamoah, K; Ye, DW; Yu, EY; Zapatero, A; Zilli, T; Omlin, A	Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022	EUROPEAN UROLOGY
CIMO- 01	Garcia-Saenz, JA; Blancas, I; Echavarria, I; Hinojo, C; Margeli, M; Moreno, F; Pernas, S; Cajal, TRY; Ribelles, N; Bellet, M	SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)	CLINICAL & TRANSLATION- AL ONCOLOGY
CIMO- 01	Serrano, Cesar; Alvarez, Rosa; Carrasco, Juan Antonio; Marquina, Gloria; Martinez-Garcia, Jeronimo; Martinez-Marin, Virginia; Sala, Maria angeles; Sebio, Ana; Sevilla, Isabel; Martin-Broto, Javier	SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)	CLINICAL & TRANSLATION- AL ONCOLOGY
CIMO- 01	Perez-Fidalgo, JA; Ortega, E; Ponce, J; Redondo, A; Sevilla, I; Valverde, C; Verdum, JI; de Alava, E; Lopez, MG; Marquina, G; Sebio, A	Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
CIMO- 02	Guma, J; Palazon-Carrion, N; Rueda-Dominguez, A; Sequero, S; Calvo, V; Garcia-Arroyo, R; Gomez- Codina, J; Llanos, M; Martinez-Banaclocha, N; Provencio, M	SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)	CLINICAL & TRANSLATION- AL ONCOLOGY
D-03	Narváez, J; Aburto, M; Seoane-Mato, D; Bonilla, G; Acosta, O; Candelas, G; Cano-Jiménez, E; Castellví, I; González-Ruiz, JM; Corominas, H; López-Muñiz, B; Martín-López, M; Robles-Pérez, A; Mena-Vázquez, N; Rodríguez-Portal, JA; Ortiz, AM; Sabater-Abad, C; Castrejón, I; dos Santos, R; Garrote-Corral, S; Maese, J; Silva-Fernández, L; Castañeda, S; Valenzuela, C	Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology	REUMATOLO- GIA CLINICA

Group	Authors	Article Title	Source Title
D-03	Cano Garcia, Laura; Dominguez Quesada, Carmen; Rodriguez Vargas, Ana Isabel; Trujillo Martin, Elisa; Martin Martin, Jose Maria	Nursing Recommendations in the Management of Systemic Lupus Erythematosus: A Delphi Consensus.	HISPANIC HEALTH CARE INTERNATION- AL
D-04	Pano-Pardo, JR; Moreno, RE; Cobo, SS; Cubero, SJL; Perianez, PL; del Pozo, LJL; Retamar-Gentil, P; Rodriguez, OA; Torres, JMJ; Vidal-Cortes, P; Colas, SC	Management of Patients with Suspected or Confirmed Antibiotic Allergy: Executive Summary of Guidelines from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC)	JOURNAL OF INVESTIGA- TIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY
D-04	Ingen-Housz-Oro, S; Schmidt, V; Ameri, MM; Abe, R; Brassard, A; Mostaghimi, A; Paller, AS; Romano, A; Didona, B; Kaffenberger, BH; Ben Said, B; Thong, BYH; Ramsay, B; Brezinova, E; Milpied, B; Mortz, CG; Chu, CY; Sotozono, C; Gueudry, J; Fortune, DG; Dridi, SM; Tartar, D; Do-Pham, G; Gabison, E; Phillips, EJ; Lewis, F; Salavastru, C; Horvath, B; Dart, J; Setterfield, J; Newman, J; Schulz, JT; Delcampe, A; Brockow, K; Seminario-Vidal, L; Joerg, L; Watson, MP; Gontalo, M; Lucas, M; Torres, M; Noe, MH; Hama, N; Shear, NH; O'Reilly, P; Wolkenstein, P; Romanelli, P; Dodiuk-Gad, RP; Micheletti, RG; Tiplica, GS; Sheridan, R; Rauz, S; Ahmad, S; Chua, SL; Flynn, TH; Pichler, W; Le, ST; Maverakis, E; Walsh, S; French, LE; Brueggen, MC	Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus	ORPHANET JOURNAL OF RARE DISEASES
D-04	Paño-Pardo, JR; Rodilla, EM; Sacristan, SC; Saldaña, JLC; Párraga, LP; León, JLD; Genti, PR; Oviedo, AR; Jaén, MJT; Vidal-Cortes, P; Sanz, CC	Management of patients with suspected or confirmed antibiotic allergy. Executive summary of guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC)	ENFERME- DADES INFEC- CIOSAS Y MI- CROBIOLOGIA CLINICA

Group	Authors	Article Title	Source Title
D-05	Monte-Boquet, Emilio; Florez, Angeles; Martinez, Guillermo Jose Alcain; Sellas, Agusti	Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain	REUMATOLO- GIA CLINICA
F-14	Nijs, J; Lahousse, A; Fernandez-de-las-Penas, C; Madeleine, P; Fontaine, C; Nishigami, T; Desmedt, C; Vanhoeij, M; Mostaqim, K; Cuesta-Vargas, AI; Kapreli, E; Bilika, P; Polli, A; Leysen, L; Elma, O; Roose, E; Rheel, E; Yilmaz, ST; De Baets, L; Huyamans, E; Turk, A; Saracoglu, I	Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria	BRITISH JOURNAL OF ANAESTHESIA
FE-17	Moreels, T; Cruyt, E; De Baets, S; Andries, L; Arts-Tielemans, M; Rodriguez-Bailon, M; Bergström, A; Boete, K; Bormans, I; Costa, U; Declercq, H; Dekelver, S; Dekyvere, V; Delooz, E; Engels, C; Helderweirt, S; Jarrey, M; Lenaerts, A; Leyman, A; Lim, KH; Meynen, L; Satink, T; Schoenmakers, F; Senn, D; Slembrouck, L; Van Meensel, E; Vangenechten, D; Van Paepeghem, B; De Vriendt, P; van de Velde, D	Self-Management Analysis in Chronic Conditions (SMACC) checklist: an international consensusbased tool to develop, compare and evaluate self-management support programmes	BMJ OPEN

4.3. RESEARCH PROJECTS

In 2023, 316 research projects funded in regional, national, and international competitive calls were conducted at IBIMA Plataforma BIONAND. Of these, 197 were projects managed directly by FIMABIS as the institute's managing entity.



Figure 18: Active competitive research projects in 2023

CHANGES IN ACTIVE PROJECTS




Figure 19: Changes in active competitive research projects at IBIMA 2019–2023

Fifty-three new competitive projects have been awarded to IBIMA Plataforma BIONAND research groups, of which **43** are **managed** by FIMABIS as the institute's managing entity, with a success rate of 23% (43 awarded/188 applied for).

COMPETITIVE PROJECTS AWARDED AND APPLIED FOR



Figure 20: Competitive research projects applied for and awarded in 2023

52 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA

ibima Plataforma BIONAND 2023 SCIENTIFIC REPORT 53

The following table shows the success rates in the main national and regional competitive calls for research projects:

Scope	Nature of the Call	Funding Entity	Call Name	TOTAL APPLIED FOR	TOTAL AWARDED
		SPANISH	AECC 2024 STRATEGIC PROJECTS	1	
		ASSOCIATION AGAINST CANCER	AECC 2024 GENERAL PROJECTS	2	
		BEER AND HEALTH INFORMATION CENTER	MANUEL DE OYA RESEARCH GRANTS. BEER, HEALTH, AND NUTRITION 2023	1	1
		SPANISH RARE DISEASES FEDERATION	CALL FOR FEDER FOUNDATION RESEARCH GRANTS 2023	1	
		LA MARATO DE TV3 FOUNDATION	CALL FOR RESEARCH PROJECTS 2023	1	
		BBVA FOUNDATION	LEONARDO GRANTS TO RESEARCHERS AND CULTURAL CREATORS 2023	2	
	PRIVATE	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION FOUNDATION	CLINICAL AND TRANSLATIONAL RESEARCH GRANTS IN ENDOCRINOLOGY AND NUTRITION 2023	2	2
NATIONAL		SPANISH FOUNDATION OF HEMATOLOGY AND HEMOTHERAPY	FEHH GRANTS FOR CLINICAL RESEARCH 2023	1	
		EUGENIO RODRIGUEZ PASCUAL FOUNDATION	BIOMEDICAL RESEARCH GRANTS 2023	3	
		LA CAIXA FOUNDATION	HEALTH RESEARCH CALL FOR PROPOSALS 2023	3	
		MAPFRE FOUNDATION	IGNACIO HERNANDO DE LARRAMENDI RESEARCH GRANTS 2023	1	
		MUTUA MADRILEÑA FOUNDATION	GRANTS FOR HEALTH RESEARCH PROJECTS 2023	2	
		SPANISH SOCIETY OF CARDIOLOGY	GRANT FOR BASIC OR TRANSLATIONAL RESEARCH PROJECTS IN CARDIOVASCULAR HEALTH 2023	1	1
		SPANISH SOCIETY OF OBESITY SURGERY	RESEARCH GRANTS 2023	1	1
		SPANISH DIABETES SOCIETY	SED GRANTS FOR RESEARCH PROJECTS LED BY YOUNG RESEARCHERS 2023	2	

Scope	Nature of the Call	Funding Entity	Call Name	TOTAL APPLIED FOR	TOTAL AWARDED
		SPANISH SOCIETY	RESEARCH PROJECT GRANTS FOR EMERGING GROUPS 2023	1	
	PRIVATE	OF MEDICAL ONCOLOGY	GRANTS FOR PROJECTS ON NEW TECHNOLOGIES FOR THE STUDY AND CARE OF LONG-TERM CANCER SURVIVORS 2023	1	
	Total PRI\	/ATE		26	5
			GRANTS FOR PUBLIC-PRIVATE PARTNERSHIP PROJECTS 2022	2	2
		STATE RESEARCH AGENCY	AEI-CDTI TRANSMISSIONS INITIATIVE 2023	2	
			R&D&I PROJECTS - KNOWLEDGE GENERATION 2022	5	2
		Total STATE RESEARCH	H AGENCY	9	4
	PUBLIC	CARLOS III INSTITUTE OF HEALTH	STRATEGIC ACTION IN HEALTH- CALL FOR INDEPENDENT CLINICAL RESEARCH PROJECTS 2023	2	1
			STRATEGIC ACTION IN HEALTH -GRANTS FOR PRECISION PERSONALIZED MEDICINE RESEARCH PROJECTS 2022	2	2
NATIONAL			STRATEGIC ACTION IN HEALTH- "FORTALECE" PROGRAM AIMED AT HEALTH RESEARCH INSTITUTES (IIS) 2023	1	1
			STRATEGIC ACTION IN HEALTH -HEALTH TECHNOLOGY DEVELOPMENT PROJECTS 2023	2	1
			STRATEGIC ACTION IN HEALTH- HEALTH R&D&I PROJECTS 2023	44	14
		Total CARLOS III INSTIT	TUTE OF HEALTH	51	19
		MINISTRY OF CONSUMER AFFAIRS	GRANTS FOR THE DEVELOPMENT OF RESEARCH ACTIVITIES RELATED TO GAMBLING DISORDERS 2023	1	1
		Total MINISTRY OF COI	NSUMER AFFAIRS	1	1
		MINISTRY OF HEALTH	GRANTS FOR ADDICTION RESEARCH PROJECTS 2023	2	
		Total MINISTRY OF HEA	ALTH	2	
		INNOVATION IN MEDICAL AND HEALTH TECHNOLOGIES NETWORK	INNOVATION SUPPORT PROGRAM- ITEMAS ISCIII 2023	2	
		Total INNOVATION IN M TECHNOLOGIES NETW		2	
	Total PUB	LIC		65	24
Total NATIO	NAL			91	29

54 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA

10 ima Plataforma BIONAND 2023 SCIENTIFIC REPORT 55

Scope	Nature of the Call	Funding Entity	Call Name	TOTAL APPLIED FOR	TOTAL AWARDED
		ANDALUSIA- EXTREMADURA ASSOCIATION OF ANESTHESIOLOGY, RESUSCITATION, AND PAIN THERAPEUTICS	GUADALQUIVIR GRANT 2023	1	1
		Total ANDALUSIA- EXTREMADURA ASSOCIATION OF ANESTHESIOLOGY, RESUSCITATION, AND PAIN THERAPEUTICS		1	1
		ANDALUSIAN SOCIETY OF MEDICAL ONCOLOGY	SAOM DR. RUIZ BORREGO GRANTS FOR BREAST CANCER RESEARCH PROJECTS 2022	1	1
	PRIVATE		SAOM DR. MORENO NOGUEIRA GRANTS FOR TRANSLATIONAL RESEARCH PROJECTS 2023	1	1
		Total ANDALUSIAN SOCIETY OF MEDICAL ONCOLOGY		2	2
REGIONAL		ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	SPAO GRANTS FOR RESEARCH IN PEDIATRICS 2023	1	1
		Total ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA		1	1
	Total PRI\	/ATE		4	4
	PUBLIC	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	METAnetwork GRANTS FOR SCIENTIFIC RESEARCH ON METABOLISM-RELATED DISEASES 2022	2	
		ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	CALL FOR RESEARCH AND INNOVATION PROJECTS IN THE FIELD OF PRIMARY CARE, COUNTY HOSPITALS, AND HIGH- COMPLEXITY HOSPITAL CENTERS OF ANDALUCIA (CHARES) 2023	11	
	Total ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.			13	
	Total PUB	LIC		13	
	Total REGIONAL			17	4
Total				108	33

4.4. HUMAN RESOURCES

In 2023, IBIMA Plataforma BIONAND had 189 active human resources grants funded in competitive calls.



Figure 21: Human resources grants active in 2023

The research personnel funded entirely or in part through competitive calls and research networks are as follows:

ENTITY	CALL/NETWORK	No. OF PERSONNEL FINANCED
	i-PFIS	6
	JR	8
	MSI	8
	MSII	8
ISCIII	PFIS	14
	RH	15
	SB	11
	T. MANAGEMENT	2
	MSCA INDIVIDUAL ACTIONS	1
Total ISCIII		73
AFCC	POSTDOCTORAL 2019	1
AECC	JUNIOR CLINICIAN 2021 and 2022	2
Total AECC		3

ENTITY	CALL/NETWORK	No. OF PERSONNEL FINANCED
	TECHNICAL SUPPORT PERSONNEL	4
STATE RESEARCH AGENCY	PREDOCTORAL CONTRACTS FOR THE TRAINING OF DOCTORS 2021	1
	RAMÓN Y CAJAL CONTRACTS	1
Total STATE RESEARCH AC	GENCY	6
EUROPEAN COMMISSION	MARIE SKLODOWSKA-CURIE	1
Total EUROPEAN COMMIS	SION	1
Regional Ministry of Health and Consumer Affairs	Incorporation of Postdoctoral Researchers to Groups in the Health and Research Centers of the Andalusian Public Health System	12
Total Regional Ministry of H	Health and Consumer Affairs	12
	PAIDI-GRANTS FOR THE HIRING OF DOCTORAL RESEARCH PERSONNEL BY UNIVERSITIES AND PUBLIC RESEARCH ENTITIES	5
REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	HIRING OF YOUNG PEOPLE BY NON-UNIVERSITY PUBLIC AGENTS OF THE ANDALUSIAN KNOWLEDGE SYSTEM 2021	30
	HIRING OF PREDOCTORAL RESEARCH PERSONNEL IN TRAINING BY THE AGENTS OF THE ANDALUSIAN KNOWLEDGE SYSTEM 2021	2
Total REGIONAL MINISTRY	OF UNIVERSITIES, RESEARCH, AND INNOVATION	37
ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH	PROMOTION OF THE INTERNATIONALIZATION OF R&I IN THE ANDALUSIAN PUBLIC HEALTHCARE SYSTEM: REINFORCEMENT OF SUPPORT STRUCTURES 2021	1
Total FPS		1
	Action B. Clinical Researcher	3
	Renewal Action B Long-term reinforcement	5
SAS	Action C. Nicolás Monardes	9
	Renewal of action C (Nicolás Monardes program)	6
	Renewal of technicians linked to Shared Research Support Structures (ECAIs)	6
Total SAS		29
PT20/00101	RNBB BIOBANKS	7
PT20/00127	Support for Independent Clinical Research and Clinical Trials Platform	3
RD21/0002/0008	Inflammatory Diseases Network	2
RD21/0009/0003	Research Network on Primary Care for Addictions	1

ENTITY	CALL/NETWORK	No. OF PERSONNEL FINANCED
RD21/0016/0012	Research Network on Preventive Activities and Health Promotion in Primary Care	2
RD21/0002/0037	Chronic Disease and Transplant Network	1
RD21/0005/0012	Inflammatory Diseases Network	1
RD21/0016/0015	Research Network on Chronicity, Primary Care, and Health Promotion	2
RIC-0539-2018	NETWORK OF CLINICAL TRIALS ON METABOLISM: DIABETES, OBESITY, AND DYSLIPIDEMIA	3
RIC-0111-2019	ANDALUSIAN NETWORK FOR CLINICAL AND TRANSLATIONAL RESEARCH ON NEUROLOGY (NEURO-RECA)	3

What's more, IBIMA Plataforma BIONAND has been granted 69 new resources out of a total of 155 applied for, which represents a success rate of 45%.

HR GRANTS APPLIED FOR AND AWARDED IN 2023




Figure 22: Human resources grants applied for and awarded in 2023

The following table reflects the competitive HR grants awarded in national and regional calls in 2023 according to funding entity and grant type:

Scope	Nature of the Call	Name of the Funding Entity	Call Name	TOTAL APPLIED FOR	TOTAL AWARDED
			AECC PREDOCTORAL GRANTS 2023	2	2
		SPANISH ASSOCIATION AGAINST CANCER	JUNIOR CLINICIAN IN THE AECC FIELD 2023	1	1
			AECC RESEARCHER 2024	4	
			AECC POSTDOCTORAL 2024	4	
		Total SPANISH ASSOCIATION	N AGAINST CANCER	11	3
		CRIS FOUNDATION FOR	CRIS PROGRAM OF EXCELLENCE 2023	1	
		RESEARCH TO BEAT CANCER	CRIS POST-DOC TALENT PROGRAM 2023	1	
		Total CRIS FOUNDATION FOR	RESEARCH TO BEAT CANCER	2	
	PRIVATE	SPANISH FOUNDATION FOR THE STUDY OF THE LIVER	RESEARCH INTENSIFICATION GRANTS 2023	1	1
		Total SPANISH FOUNDATION I	FOR THE STUDY OF THE LIVER	1	1
NATIONAL		E LA CAIXA FOUNDATION	POSTDOCTORAL JUNIOR LEADER-INCOMING 2023	3	
			POSTDOCTORAL JUNIOR LEADER-RETAINING 2023	2	
		Total LA CAIXA FOUNDATION	1	5	
		RAMÓN ARECES FOUNDATION	GRANTS FOR THE COMPLETION OF DOCTORAL THESES IN LIFE AND MATERIALS SCIENCES 2023	4	
		Total RAMÓN ARECES FOUN	DATION	4	
		TATIANA PÉREZ DE GUZMÁN EL BUENO FOUNDATION	CALL FOR PREDOCTORAL FELLOWSHIPS IN NEUROSCIENCE 2023	2	
		Total TATIANA PÉREZ DE GUZMÁN EL BUENO FOUNDATION		2	
		SPANISH SOCIETY OF RHEUMATOLOGY	CALL FOR GRANTS FOR THE INTENSIFICATION OF RESEARCH ACTIVITY 2022- 2023	1	1
		Total SPANISH SOCIETY OF F	RHEUMATOLOGY	1	1
Total PRIVAT	ГЕ			26	5

Scope	Nature of the Call	Name of the Funding Entity	Call Name	TOTAL APPLIED FOR	TOTAL AWARDED
			JUAN DE LA CIERVA GRANTS 2022	8	
			GRANTS FOR PREDOCTORAL CONTRACTS FOR THE TRAINING OF DOCTORS 2022	2	2
		STATE RESEARCH AGENCY	GRANTS TO PROMOTE RESEARCH CONSOLIDATION 2023	14	3
			GRANTS FOR TECHNICAL SUPPORT PERSONNEL (PTA) 2022	2	2
			GRANTS FOR PUBLIC-PRIVATE PARTNERSHIP PROJECTS 2022	1	1
			ATRAE PROGRAM 2023	2	
		Total STATE RESEARCH AGE	NCY	29	8
	PUBLIC	PUBLIC CARLOS III INSTITUTE OF HEALTH	STRATEGIC ACTION IN HEALTH-CONTRACTS FOR BIOINFORMATICS TECHNICIANS TO SUPPORT RESEARCH AT HEALTH RESEARCH INSTITUTES (IIS) 2023	2	
NATIONAL			STRATEGIC ACTION IN HEALTH-i-PFIS CONTRACTS: DOCTORAL CANDIDATES HEALTH RESEARCH INSTITUTES (IIS)-BUSINESSES IN HEALTH SCIENCES AND TECHNOLOGY 2023	1	1
			STRATEGIC ACTION IN HEALTH-i-PFIS CONTRACTS: DOCTORAL CANDIDATES HEALTH RESEARCH INSTITUTES (IIS)-BUSINESSES IN HEALTH SCIENCES AND TECHNOLOGY 2023 (WITH SS)	2	
			STRATEGIC ACTION IN HEALTH -JUAN RODÉS CONTRACTS 2023	5	3
			STRATEGIC ACTION IN HEALTH -MIGUEL SERVET CONTRACTS 2023	5	1
			STRATEGIC ACTION IN HEALTH-CONTRACTS FOR THE INTENSIFICATION OF RESEARCH ACTIVITY IN THE NATIONAL HEALTH SYSTEM (SNS) 2023	3	2

60 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA

Scope	Nature of the Call	Name of the Funding Entity	Call Name	TOTAL APPLIED FOR	TOTAL AWARDED
		CARLOS III INSTITUTE OF HEALTH	STRATEGIC HEALTH ACTION-PFIS CONTRACTS: PREDOCTORAL CONTRACTS FOR HEALTH RESEARCH TRAINING 2023	4	2
	PUBLIC		STRATEGIC HEALTH ACTION-PFIS CONTRACTS: PREDOCTORAL CONTRACTS FOR HEALTH RESEARCH TRAINING 2023 (WITH SS)	6	2
NATIONAL			STRATEGIC ACTION IN HEALTH -RÍO HORTEGA CONTRACTS 2023	14	8
			STRATEGIC HEALTH ACTION-SARA BORRELL CONTRACTS 2023	10	5
		Total CARLOS III INSTITUTE OF HEALTH		52	24
		MINISTRY OF UNIVERSITIES	PREDOCTORAL CONTRACTS FOR UNIVERSITY PROFESSOR TRAINING (FPU) 2022	2	2
		Total MINISTRY OF UNIVERSI	ITIES	2	2
Total PUBLIC			83	34	
Total NATIO	Total NATIONAL			109	42

ibima Plataforma BIONAND 2023 SCIENTIFIC REPORT 61

Scope	Nature of the Call	Name of the Funding Entity	Call Name	TOTAL APPLIED FOR	TOTAL AWARDED
PUBLIC	ANDALUSIAN HEALTH SERVICE		ACTION A. ANNUAL REINFORCEMENT OF RESEARCH ACTIVITY IN THE CLINICAL UNITS OF THE ANDALUSIAN HEALTH SERVICE 2023	17	16
		ACTION B. INCORPORATION OF CLINICAL RESEARCH PROFESSIONALS INTO ANDALUSIAN HEALTH SERVICE CLINICAL UNITS 2023	3		
			ACTION C RENEWAL (NICOLÁS MONARDES PROGRAM) 2023-PHASE 1	2	2
			ACTION B RENEWAL- RESEARCH CLINICIANS	2	2
			ACTION B RENEWAL - LONG- TERM REINFORCEMENT 2013	2	2
		RENEWAL OF TECHNICIANS LINKED TO SHARED RESEARCH SUPPORT STRUCTURES (ECAIs) 2023	2	2	
		LINK OF TECHNICIANS TO SHARED RESEARCH SUPPORT STRUCTURES 2022.	1	1	
		Total ANDALUSIAN HEALTH	SERVICE	29	25
Total PUBLIC					25
Total				138	67

4.5. RICORS, RETICS, INTERNATIONAL NETWORKS, AND ISCIII AND CIBER PLATFORMS

RICORS:

AREA	NETWORK NAME	IBIMA PARTICIPATION	IBIMA LR	GROUP(S)
	RESEARCH NETWORK ON PRIMARY CARE FOR ADDICTIONS (RIAPAd) RD21/0009/0003	RESEARCH GROUP	Fernando Rodríguez de Fonseca	C-06
PRIMARY CARE.	RESEARCH NETWORK ON PRIMARY CARE FOR ADDICTIONS (RICAPPS) RD21/0009/0003	RESEARCH GROUP	Juan Ángel Bellón Saameño	C-02
CHRONICITY, AND HEALTH PROMOTION	NETWORK FOR RESEARCH ON PRIMARY CARE FOR ADDICTIONS (RICAPPS)	RESEARCH GROUP MEMBER	Juan Daniel Prados	C-08
	PRIMARY CARE INTERVENTIONS TO PREVENT MATERNAL AND CHILD CHRONIC DISEASES OF PERINATAL AND DEVELOPMENTAL ORIGIN	ASSOCIATED CLINICAL GROUP	Ernesto González Mesa	C-16
	INFLAMMATORY DISEASES RD21/0002/0008	RESEARCH GROUP	María José Torres Jaén	D-04
INFLAMMATION AND IMMUNOPATHOLOGY OF ORGANS AND SYSTEMS	INFLAMMATORY DISEASES RD21-0002-0037	RESEARCH GROUP	Antonio Fernández Nebro	D-03
	RICORS2040 (KIDNEY DISEASE) RD21-0005-0012	RESEARCH GROUP	-	AE-11
CEREBRAL VASCULAR DISEASES	RICORS-ICTUS	ASSOCIATED CLINICAL GROUP	Carlos de la Cruz Cosme	A-09
ADVANCED THERAPIES	RICORS TERAV	RESEARCH GROUP MEMBER	Antonio Rodriguez Acosta	ECAI-06

INTERNATIONAL NETWORKS

Group Code	Title	Subtype	Name of the Funding Entity	LR Name
A-01	CA17117 (EVBRES) -Towards an International Network for Evidence- based Research in Clinical Health Research	NETWORK	EUROPEAN COMMISSION	JOSÉ CARLOS FERNÁNDEZ GARCÍA
A-02	ML4Microbiome - Statistical and machine learning techniques in human microbiome studies	NETWORK	EUROPEAN COMMISSION	ISABEL MORENO INDIAS
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	NETWORK	EUROPEAN COMMISSION	ISABEL MORENO INDIAS/PATRICIA RUIZ LIMON/CAROLINA GUTIÉRREZ REPISO
A-02	CA18124 (ESMN) - European Sexual Medicine Network	NETWORK	EUROPEAN COMMISSION	MORA MURRI PIERRI
A-03	IRENE-Implementation Research Network in Stroke Care Quality - IRENE	NETWORK	EUROPEAN COMMISSION	MANUEL FRANCISCO JIMÉNEZ NAVARRO
A-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	NETWORK	EUROPEAN COMMISSION	JORGE RODRIGUEZ CAPITAN
A-03	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-03	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-03	CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure	NETWORK	EUROPEAN COMMISSION	MARIA JOSE SANCHEZ QUINTERO
A-06	CA18216 (VascAgeNet) - Network for Research in Vascular Ageing	NETWORK	EUROPEAN COMMISSION	MARÍA ROSA BERNAL LÓPEZ
A-06	CA21147 (ENOTTA) - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases	NETWORK	EUROPEAN COMMISSION	MARIA DEL MAR AYALA GUTIÉRREZ
A-19	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	NETWORK	EUROPEAN COMMISSION	ISABEL LEIVA GEA
A-19	CA19115 (HyperChildNET) - Network for blood pressure research in children and adolescents	NETWORK	EUROPEAN COMMISSION	VERONICA MARTINEZ RIVERA
A-19	CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	NETWORK	EUROPEAN COMMISSION	PILAR SÁNCHEZ YAÑEZ

64 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA

10 Image Plataforma BIONAND 2023 SCIENTIFIC REPORT 65

Group Code	Title	Subtype	Name of the Funding Entity	LR Name
A-19	CA21168 (JIR-CliPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	NETWORK	EUROPEAN COMMISSION	ROCIO GALINDO ZAVALA
A-21	CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care	NETWORK	EUROPEAN COMMISSION	AIDA RAIGÓN PONFERRADA
AA-20	CA19133 (FOSTREN) - Fostering and strengthening approaches to reducing coercion in European mental health services	NETWORK	EUROPEAN COMMISSION	DANIEL MORENO SANJUÁN
AA-20	CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims	NETWORK	EUROPEAN COMMISSION	DANIEL MORENO SANJUÁN
AA-22	CA18205 - WORCK Worlds of Related Coercions in Work	NETWORK	EUROPEAN COMMISSION	FRANCISCO JAVIER ALCALDE DE HOYOS
AA-24	CA20104 (PhysAgeNet) - Network on evidence-based physical activity in old age	NETWORK	EUROPEAN COMMISSION	JESUS OLMEDO LLANES
C-01	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	NETWORK	EUROPEAN COMMISSION	BEATRIZ GARCIA DIAZ
C-02	CA18138 (Riseup-PPD-Research Innovation and Sustainable Pan- European Network in Peripartum Depression Disorder)	NETWORK	EUROPEAN COMMISSION	SONIA CONEJO CERÓN/PATRICIA MORENO PERAL
C-03	CA17130 (PSYNET) - Enhancing Psychiatric Genetic Counselling, Testing, and Training in Europe	NETWORK	EUROPEAN COMMISSION	FERMIN MAYORAL CLERIES
C-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	NETWORK	EUROPEAN COMMISSION	ANA BELEN PABA DOTES
C-06	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	NETWORK	EUROPEAN COMMISSION	ADRIANA CASTRO ZAVALA
C-06	CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development	NETWORK	EUROPEAN COMMISSION	ANTONIA SERRANO CRIADO
C-08	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	NETWORK	EUROPEAN COMMISSION	FRANCISCA LEIVA FERNÁNDEZ/ PILAR BARNESTEIN FONSECA

Group Code	Title	Subtype	Name of the Funding Entity	LR Name
C-13	CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims	NETWORK	EUROPEAN COMMISSION	JOSÉ CARLOS CANCA SÁNCHEZ
C-13	CA19137 (PARQ): Sudden cardiac arrest prediction and resuscitation network: Improving the quality of care	NETWORK	EUROPEAN COMMISSION	EVA TIMONET ANDREU
C-16	CA18211 (DEVOTION) - Perinatal Mental Health and Birth-Related Trauma: Maximising best practice and optimal outcomes	NETWORK	EUROPEAN COMMISSION	ERNESTO GONZÁLEZ MESA
CE-18	CA22106 (MDVI): Migrant Disaster Victim Identification	NETWORK	EUROPEAN COMMISSION	LETICIA OLGA RUBIO LAMIA
D-04	CA17136 (INDAIRPOLLET) - Indoor Air Pollution Network	NETWORK	EUROPEAN COMMISSION	CARMEN RONDÓN SEGOVIA
D-04	CA18226 (ADOPT)-New approaches for the detection of pathogens and aeroallergens	NETWORK	EUROPEAN COMMISSION	IBON EGUILUZ GRACIA
D-04	CA18227 (COMFA) - The Core Outcome Measures for Food Allergy	NETWORK	EUROPEAN COMMISSION	CRISTOBALINA MAYORGA MAYORGA
D-05	CA17112 -PRO-EURO-DILI NET -PROSPECTIVE EUROPEAN DRUG- INDUCED LIVER INJURY NETWORK	NETWORK	EUROPEAN COMMISSION	RAÚL J. ANDRADE BELLIDO
D-05	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	NETWORK	EUROPEAN COMMISSION	CARLOS LOPEZ GOMEZ
F-14	CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research	NETWORK	EUROPEAN COMMISSION	RAQUEL CANTERO TELLEZ
H-03	CA17129 (CardioRNA): Catalysing transcriptomics research in cardiovascular disease	NETWORK	EUROPEAN COMMISSION	ADRIÁN RUIZ VILLALBA

PRO-EURO-DILI NETWORK - PROSPECTIVE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK >coordinator Raúl J. Andrade

National ECRIN Hub-European Clinical Research Infrastructure Network > coordinator Maribel Lucena

PARTICIPATION IN ISCIII PLATFORMS

Title	Subtype	Name of the Funding Entity	LR Name
PT23/00082 IBIMA BIONAND Platform Innovation Unit. Promotion of technological valorization, knowledge transfer, and consolidation of the industrial network.	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FERNANDO RODRÍGUEZ DE FONSECA
PT23/00049 Biobank and Biomodels Platform, cornerstone of Precision Medicine: expansion, virtualization, and internationalization of the service. Generation of organoids	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FRANCISCO JOSÉ TINAHONES
CERT22-00034. Networked State Consortium for the Development of Medicines for Advanced Therapies (CERTERA)	PLATFORM	CARLOS III INSTITUTE OF HEALTH	FRANCISCO JOSÉ TINAHONES
PT23/00137 Clinical Research and Clinical Trials Unit, UICEC IBIMA Plataforma BIONAND. ISCIII Clinical Research Platform: Consolidation of its international projection, comprehensive management, collaboration, and transfer.	PLATFORM	CARLOS III INSTITUTE OF HEALTH	MARIA ISABEL LUCENA GONZÁLEZ

PARTICIPATION OF IBIMA PLATAFORMA BIONAND GROUPS IN CIBER

Code Group	Title	Subtype	Name of the Funding Entity	LR Name
A-01	CIBERDEM CB07/08/0019 Diabetes and Associated Metabolic Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	GEMMA ROJO MARTÍNEZ
A-02	CIBEROBN CB06/03/0018 Physiopathology of Obesity and Nutrition	CIBER	CARLOS III INSTITUTE OF HEALTH	FRANCISCO TINAHONES
A-03	CIBERCV CB16/11/00360 Cardiovascular Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	MANUEL FRANCISCO JIMÉNEZ NAVARRO
CIMO- 01	CIBERONC CB16/12/00481 Cancer	CIBER	CARLOS III INSTITUTE OF HEALTH	EMILIO ALBA CONEJO
B-04	CIBERER CB06/07/0046 Rare Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	MIGUEL ÁNGEL MEDINA TORRES
C-09	CIBERNED Neurodegenerative Diseases CB06/05/1116	CIBER	CARLOS III INSTITUTE OF HEALTH	ANTONIA GUTIÉRREZ PÉREZ
D-05	CIBEREHD CB07/04/2008 Liver and Gastrointestinal Diseases	CIBER	CARLOS III INSTITUTE OF HEALTH	RAÚL ANDRADE

4.6. CLINICAL TRIALS

In 2023, 1199 clinical studies were conducted at IBIMA and 261 new studies were signed:

ACTIVE CLINICAL STUDIES 2023 = 1199




Figure 23: Active Clinical Studies (Clinical Trials and Observational Studies) in 2023

CLINICAL STUDIES SIGNED IN 2023 = 261




Figure 24: New Clinical Studies (Clinical Trials and Observational Studies) signed in 2023

Of the 1,199 clinical studies conducted in 2023, 849 were trials. Of the 261 new studies signed, 194 were new trials. The following graphs show these active and new clinical trials according to their phase:




Figure 25: Active clinical trials in 2023

Figure 26: New clinical trials signed in 2023

Changes in the clinical trials and studies conducted at the institute during the last five years is as follows:





Figure 27: Changes in Active Clinical Trials and Observational Studies from 2019–2023

Changes in early phase (phases I and II) clinical trials conducted at the institute in the last five years is shown below:



60

2021

2022

2023

Figure 28: Changes in active early-phase clinical trials 2019–2023

2020

44

2019

100

The following figure shows changes in revenue for clinical trials conducted in the last five years:

REVENUE FROM CLINICAL TRIALS




Figure 29: Changes in clinical trial revenue 2019–2023

4.7. INNOVATION AND TRANSFER

Protection

This section summarizes the results of national and international patents and utility models applied for from 2019 to 2023 by researchers at the institute as well as the list of patents applied for in 2023 and granted from 2019 to 2023.

INDICATOR	2019	2020	2021	2022	2023
National patents and utility models	16	15	12	16	15
PCT, international extensions ¹	8	19	20	14	9

¹PCT: Requests for international extension through the Patent Cooperation Treaty procedure. International extensions of patent applications.

PRIORITY PATENT APPLICATIONS/UTILITY MODELS, INDUSTRIAL DESIGNS, AND INTELLECTUAL PROPERTY REGISTRATIONS						
TITLE	REFERENCE	APPLICATION DATE	IBIMA GROUP			
METHOD FOR THE DIAGNOSIS OF ENDOMETRIAL CANCER, AND ITS DEGREE OF SEVERITY AND THE DIAGNOSIS AND PROGNOSIS OF THE DEVELOPMENT OF METASTASES	P202330347	05/03/2023	CIMO-01			
CNR1 AND GPR55 AS EARLY BIOMARKERS OF TYPE 1 DIABETES	P202330380	05/17/2023	A-01			
A METHOD FOR THE EARLY DETECTION OF VOMITING BEHAVIOR IN PATIENTS WITH EATING DISORDERS	EP23382499.4	05/26/2023	A-02			
BIOMARKERS AND DIAGNOSTIC METHOD FOR MONOGENIC DIABETES IN YOUNG ADULT CARRIERS OF DELETERIOUS HNF1A ALLELES	P202330668	07/31/2023	A-01 GENOMICS ECAI			
NANOSYSTEM CONDUCTION SYSTEM TO ADIPOSE TISSUE THROUGH THE CREATION OF A NEGATIVELY CHARGED FIELD	P202330831	10/04/2023	A-01			
AFEBIO: ADVANCED FUNCTIONAL ENRICHMENT AND BIOMEDICAL INTEGRATED OMICS	RPISC2312046289638	12/04/2023	BIOINFORMATICS ECAI			

PRIORITY PATENT APPLICATIONS/UTILITY MODELS, INDUSTRIAL DESIGNS, AND INTELLECTUAL PROPERTY REGISTRATIONS						
TITLE	REFERENCE	APPLICATION DATE	IBIMA GROUP			
METHOD FOR PREDICTING LONG- TERM WEIGHT LOSS AFTER BARIATRIC SURGERY	P202331011	12/04/2023	A-02/D-05			
KLRB1 AS A PROGNOSTIC BIOMARKER IN COVID-19 PATIENTS	P202331044	12/15/2023	BA-14 CIMO-02 BIOBANK ECAI			
MURINE EXTRACELLULAR MATRIX AND ITS USE IN CELL CULTURES	P202330170	02/27/2023	H-03			
5-FLUOROURACIL AS AN ANTIVIRAL AGENT AGAINST VIRUSES OF THE CORONAVIRIDAE FAMILY	P202330781	09/20/2023	A-09			
FLUORESCENT COMPOUNDS BASED ON SYMMETRICAL (BIS)STYRYLINDOLIUMS WITH TWO-PHOTON ABSORPTION PROPERTIES, PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS, AND PROCEDURE AND USE AS MITOCHONDRIAL IDENTIFIERS	P202330836	10/06/2023	F-10			
CLAY FILTERING AND RECOVERY SYSTEM	U202331751	09/30/2023	F-05			
COMPOUNDS WITH ANTIMICROBIAL ACTIVITY OBTAINED FROM MINERAL DUST	U202331752	09/30/2023	F-05			
COMPOUNDS WITH ANTIMICROBIAL ACTIVITY OBTAINED FROM CELLULOSE WASTES	U2023353	09/30/23	F-05			
HIGHLY DIRECTIONAL PLANAR OPTICAL DIFFRACTIVE DEVICE	P202330971	11/23/2023	F-03			
SURFACE GRATING COUPLER SUITABLE FOR PHOTONIC DEVICES, ASSOCIATED METHOD, AND ASSEMBLY WITH SURFACE GRATING COUPLER	P202330970	11/23/2023	F-03			

72 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA 2023 SCIENTIFIC REPORT 73

INTERNATIONAL PATENT APPLICATIONS (PCT)			
TITLE	REFERENCE	APPLICATION DATE	IBIMA GROUP
USE OF SIFNAR2 IN THE TREATMENT OF SARS-COV-2 INFECTION	PCT/ES2023/070210	03/30/2023	C-01
CIRCRNA PROFILING FOR PREDICTING IMMUNOTHERAPY RESPONSE IN PATIENTS WITH CANCER	PCT/ES2023/070341	05/26/2023	CIMO-02 CIMO-01
DEVICE, SYSTEM, AND ACTIVATION PROCEDURE FOR INTRAOPERATIVE DISINFECTION OF BONE PROSTHESES THROUGH THE BIOELECTRIC EFFECT	PCT/ES2023/070371	06/02/2023	FA-16
MESOPOROUS SILICA NANOPARTICLES AND THEIR USE IN IMMUNOGLOBULIN UPTAKE	PCT/ES2023/070450	07/22/2023	D-04
COMPOSITIONS OR COMBINED PREPARATIONS OF ESSENTIAL OILS AND L-CARNITINE	PCT/EP2023/078645	10/16/2023	A-03
SEQUENCING PANEL FOR LIQUID BIOPSY FOR BREAST CANCER PATIENTS	PCT/ES2023/070633	10/27/2023	CIMO-01
INTEGRATED PHOTONIC BIOSENSOR WITH LAYER DISCRIMINATION CAPABILITY AND COHERENT READOUT SYSTEM: DEVICE, ASSEMBLY, AND METHODS ASSOCIATED WITH IT	PCT/ES2023/070688	11/16/2023	F-03
PATIENT WALKING DEVICE	PCT/ES2023/070681	11/14/2023	AA-22

INTERNATIONAL EXTENSIONS			
TITLE	APPLICATION No.	APPLICATION DATE	IBIMA
HIGH-POWER LED-BASED ILLUMINATION DEVICE WITH AUTOMATED SPECTRAL AND IRRADIANCE CONTROL FOR USE IN DERMATOLOGICAL DISEASES THAT REQUIRE PHOTODYNAMIC THERAPY TREATMENT. APPLICATIONS AND RELATED METHODS.	US	11/14/2023	B-10 FA-08
HIGH-POWER LED-BASED ILLUMINATION DEVICE WITH AUTOMATED SPECTRAL AND IRRADIANCE CONTROL FOR USE IN DERMATOLOGICAL DISEASES THAT REQUIRE PHOTODYNAMIC THERAPY TREATMENT. APPLICATIONS AND RELATED METHODS.	EP 22 806 895.3	12/14/2023	B-10 FA-08

PATENT APPLICATIONS GRANTED 2019–2023		
TITLE	APPLICATION No.	IBIMA GROUP
PARKINSON'S DISEASE AND RELATED NEURODEGENERATIVE AND/OR MOTOR DISORDERS.	P202130377	C-07 C-01 A-01
GENE EXPRESSION SIGNATURE AS A PROGNOSTIC MARKER OF RELAPSE IN PATIENTS WITH STAGE I NONSEMINOMATOUS TESTICULAR GERM CELL TUMORS	P202030506	CIMO-01
INTEGRATED MODE CONVERTER AND MULTIPLEXER	SG11202002241S	F-03
INTEGRATED OPTICAL FILTER BASED ON RESONATORS COUPLED BY STRONG BRAGG GRATINGS WITH HIGH LATERAL CONFINEMENT	P201931104	F-03
SUB-WAVELENGTH PERIODIC WAVEGUIDE GRATING, MODAL ADAPTER, POWER DIVIDER, AND POLARIZATION DIVIDER THAT MAKE USE OF SAID WAVEGUIDE	P202030367	F-03
SINGLE-BEAM SIDE DEFLECTOR, MULTIPLEXER/ DEMULTIPLEXER, AND OPTICAL ANTENNA FEEDING DEVICE THAT INCORPORATES THE DEFLECTOR, AND METHODS THAT USE THEM	P202031204	F-03
WALKING AID HANDLE EQUIPPED WITH GALVANIC SKIN RESPONSE (GSR) AND TEMPERATURE SENSORS	U202032693	F-09
WALKING AID HANDLE EQUIPPED WITH PULSE OXIMETER	U202032695	F-09
DEVICE FOR THE INSTILLATION OF GASES INTO A BODY CAVITY	U202031502	F-05
AORTIC OPENING GUIDE DEVICE FOR SUTURELESS PROSTHESIS IMPLANTATION	U202031652	F-05
HYBRID DEVICE FOR DRUG ASPIRATION AND ADMINISTRATION	U201931558	C-01
NEW PYRAZOLONE-TYPE COMPOUNDS FOR THE DIAGNOSIS OF ALLERGY TO BETA-LACTAM ANTIBIOTICS	P201731240	D-04 F-10
FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS	US 15/529.433	C-06
ROBUST, RAPIDLY MANUFACTURED ARTIFICIAL RESPIRATOR	U202030613	F-05
AUXILIARY ARTIFICIAL HEART VALVE ROTATION ARM AND ARTIFICIAL HEART VALVE ROTATION WRENCH	U201932110	F-05
FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS	MX/a/2017/006747	C-06
COMPOSITION USEFUL IN THE DETECTION OF ALLERGY TO CLAVULANIC ACID	P201631133	D-04 F-10
MICROARN SIGNATURE AS AN INDICATOR OF RISK OF EARLY RECURRENCE IN PATIENTS WITH BREAST CANCER	EP 15760852.2	CIMO-01
MICROARN SIGNATURE AS AN INDICATOR OF RISK OF EARLY RECURRENCE IN PATIENTS WITH BREAST CANCER	US 15/125.714	CIMO-01

FLEXIBLE CANNULA INSERTION DEVICE FLEXIBLE CANNULA INSERTION DEVICE COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ALCOHOL USE DISORDERS PROCEDURE TO OBTAIN THE RECOMBINANT IFNAR PROTEIN AND ITS USE AS ANTIVIRAL PEPTIDE DERIVED FROM THE PRU P3 ALLERGEN FROM PRUNUS PERSICA FOR THE TREATMENT OF ALLERGY CONNECTOR FOR THE OXYGENATOR OF AN EXTRACORPOREAL CIRCULATION MACHINE LED-BASED ILLUMINATION DEVICE WITH AUTOMATED DOSE CONTROL FOR THE PHOTODIAGNOSIS OF LIGHT EXPOSURE-RELATED SKIN DISEASES, RELATED APPLICATIONS, AND METHODS A-03 A-03 A-04 D-04 P201531862 C-01 D-04 P201531341 D-04 P201530993 A-03
COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ALCOHOL USE DISORDERS PROCEDURE TO OBTAIN THE RECOMBINANT IFNAR PROTEIN AND ITS USE AS ANTIVIRAL PEPTIDE DERIVED FROM THE PRU P3 ALLERGEN FROM PRUNUS PERSICA FOR THE TREATMENT OF ALLERGY CONNECTOR FOR THE OXYGENATOR OF AN EXTRACORPOREAL CIRCULATION MACHINE LED-BASED ILLUMINATION DEVICE WITH AUTOMATED DOSE CONTROL FOR THE PHOTODIAGNOSIS OF LIGHT EXPOSURE-RELATED SKIN DISEASES, RELATED APPLICATIONS, AND
ALCOHOL USE DISORDERS PROCEDURE TO OBTAIN THE RECOMBINANT IFNAR PROTEIN AND ITS USE AS ANTIVIRAL PEPTIDE DERIVED FROM THE PRU P3 ALLERGEN FROM PRUNUS PERSICA FOR THE TREATMENT OF ALLERGY CONNECTOR FOR THE OXYGENATOR OF AN EXTRACORPOREAL CIRCULATION MACHINE LED-BASED ILLUMINATION DEVICE WITH AUTOMATED DOSE CONTROL FOR THE PHOTODIAGNOSIS OF LIGHT EXPOSURE- RELATED SKIN DISEASES, RELATED APPLICATIONS, AND P201531862 C-01 P201531862 D-04 D-04 D-04 D-05 D-07 D-07 D-08 D-09 D-0
AND ITS USE AS ANTIVIRAL PEPTIDE DERIVED FROM THE PRU P3 ALLERGEN FROM PRUNUS PERSICA FOR THE TREATMENT OF ALLERGY CONNECTOR FOR THE OXYGENATOR OF AN EXTRACORPOREAL CIRCULATION MACHINE LED-BASED ILLUMINATION DEVICE WITH AUTOMATED DOSE CONTROL FOR THE PHOTODIAGNOSIS OF LIGHT EXPOSURE- RELATED SKIN DISEASES, RELATED APPLICATIONS, AND P201531862 C-01 D-04 P201531862 P201531862 P201531862 P201531862 P201531862 P201531862 D-04 P201531862 D-04 P201531862 D-04
PERSICA FOR THE TREATMENT OF ALLERGY CONNECTOR FOR THE OXYGENATOR OF AN EXTRACORPOREAL CIRCULATION MACHINE LED-BASED ILLUMINATION DEVICE WITH AUTOMATED DOSE CONTROL FOR THE PHOTODIAGNOSIS OF LIGHT EXPOSURE- RELATED SKIN DISEASES, RELATED APPLICATIONS, AND P201531341 D-04 L201530993 A-03 B-10 / A-09
CIRCULATION MACHINE LED-BASED ILLUMINATION DEVICE WITH AUTOMATED DOSE CONTROL FOR THE PHOTODIAGNOSIS OF LIGHT EXPOSURE- RELATED SKIN DISEASES, RELATED APPLICATIONS, AND P201500655 B-10 / A-09
CONTROL FOR THE PHOTODIAGNOSIS OF LIGHT EXPOSURE- RELATED SKIN DISEASES, RELATED APPLICATIONS, AND P201500655 B-10 / A-09
RECOMBINANT PROTEIN AND USES IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS EP 13856322.6 C-01 / D-04
RECOMBINANT PROTEIN AND USES IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS US 14/443.814 C-01 / D-04
FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS P201431739 C-06
USE OF ANTIOXIDANTS FOR THE TREATMENT OF COGNITIVE AND BEHAVIOURAL DISORDERS IN INDIVIDUALS WITH FRAGILE X SYNDROME EP11848650.5 C-03
INTEGRATED MODE CONVERTER AND MULTIPLEXER P201731166 F-03
COMBINATION COMPRISING GALANIN AND [LEU31, PRO34] NPY; USES AND METHODS C-07 C-01
MULTI-FUNCTIONAL ELECTRONIC EDUCATIONAL DEVICE FOR VARIOUS BRANCHES OF ENGINEERING P201600861 F-04
SCREENING METHOD FOR THE IDENTIFICATION OF GALANIN RECEPTOR TYPE 2 AGONISTS (GALR2) AND/OR NEUROPEPTIDE Y1 RECEPTOR AGONISTS (NPYY1R) CAPABLE OF PROMOTING THE INTERACTION BETWEEN GALR2/NPYY1R HETERORECEPTORS C-07 C-01
PHARMACEUTICAL COMPOSITION THAT COMPRISES SELECTIVE P201730214 C-07
SEROTONIN REUPTAKE INHIBITORS AND GALANIN C-01
INTEGRATED MODE CONVERTER AND MULTIPLEXER P201731166
GAL(1-15) AND ANALOGS THEREOF FOR USE IN THE PREVENTION AND/OR TREATMENT OF ALCOHOL-RELATED P201731170 C-01

PATENT APPLICATIONS GRANTED 2019–2023		
TITLE	APPLICATION No.	IBIMA GROUP
WAVEGUIDE, METHOD OF MANUFACTURING SAID WAVEGUIDE, AND POLARIZATION SPLITTER THAT MAKES USE OF SAID WAVEGUIDE	P201830653	F-03
DEVICE FOR THE PROCESSING OF SAMPLES USEFUL IN STUDIES RELATED TO THE MASTICATION PROCESS	U201930687	F-02
ATTACHABLE FUNNEL, DEVICE, AND SYSTEM FOR EFFICIENT WATER RECOVERY AND MANAGEMENT	U201931579	F-02

Collaboration with industry

Below is a summary of the indicators of collaboration between the IBIMA Plataforma BIONAND and industry. It includes active licenses, collaborations managed by FIMABIS, and technology companies founded based on a technology developed at IBIMA Plataforma BIONAND from 2019–2023.

INDICATOR	2019	2020	2021	2022	2023
Active Licenses ¹	5	7	11	13	17
Collaborations ²	8	16	16	17	19
SPIN-OFFS/START-UPS CREATED AND ACTIVE	1	1	2	3	3

⁽¹⁾ The number of licensing agreements, not the number of licensed patent families, is counted; a single license may contain several families.

(2) Contracts/agreements for conducting collaborative R&D&I projects

LICENSED/TRANSFERRED PATENT FAMILIES		
TITLE	APPLICATION No.	GROUP
PPAR-ALPHA AGONISTS, DUAL AGONISTS, AND COMBINATIONS FOR THE TREATMENT OF ALCOHOL USE DISORDER	PCT/ES2019/070565 -P201830824 - P201830825	C-06
RECOMBINANT PROTEIN AND ITS USES IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS	ES2470816- US10393758- EP2930183	C-01
METHOD FOR PREDICTING OR FORECASTING THE RESPONSE TO THE TREATMENT OF MULTIPLE SCLEROSIS WITH BETA INTERFERON	PCT/ES2019/070660 -P201830953 -US17281520- EP19869444.0	C-01

76 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA 2023 SCIENTIFIC REPORT 77

LICENSED/TRANSFERRED PATENT FAMILIES		
TITLE	APPLICATION No.	GROUP
COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ALCOHOL USE DISORDERS	P201630447 -PCT/ ES2017/070225 - EP160933084	C-06
USE OF ANTIOXIDANTS FOR THE TREATMENT OF COGNITIVE AND BEHAVIOURAL DISORDERS IN INDIVIDUALS WITH FRAGILE X SYNDROME	PCT/ES2011/070875 -US 14/977,413 - EP11848650.5	C-03
EXTERNAL FIXATOR FOR PELVIC FRACTURES AND TENSIONER FOR OPENING THE FIXATOR	PCT/ES2013/000051- EP 13755839.1	FA-07
1,2,4-OXADIAZOLE DERIVATIVES	P201030093 - PCTES2011/070042	C-06
CLAVULANIC ACID COMPOSITION AND ITS DIAGNOSTIC USE IN ALLERGOLOGY	P200930781	D-04
FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS	PCT/ES2015/070848	C-06
INTEGRATED MODE CONVERTER AND MULTIPLEXER	PCT/EP2018/075753 US17837774	F-03
INTEGRATED POLARIZATION DIVIDER	P201830129 PCT/ ES2019/070031	F-03
WAVEGUIDE, METHOD OF MANUFACTURING SAID WAVEGUIDE, AND POLARIZATION SPLITTER THAT MAKES USE OF SAID WAVEGUIDE	P201830653 PCT/ ES2019/070452 EP19759632.3	F-03
BRICKED SUB-WAVELENGTH PERIODIC WAVEGUIDE, MODAL ADAPTER, POWER DIVIDER AND POLARISATION SPLITTER THAT USE SAID WAVEGUIDE	PCT/ES2021/070279 US17922350	F-03
MULTIMODE INTERFERENCE COUPLER AND METHOD FOR THE STRUCTURAL CONFIGURATION THEREOF	PCT/EP2009/061149 EP09782346.2 US13060341	F-03
MULTIVALENT HAPTEN CARRIER COMPLEXES WITH DENDRIMERS AS CARRIER PROTEIN EMULATORS	P200302737	F-10
INTEGRATED MODE CONVERTER AND MULTIPLEXER	P201731166, PCT/ EP2018/075753	F-03
INTEGRATED PHOTONIC BIOSENSOR WITH LAYER DISCRIMINATION CAPABILITY AND COHERENT READOUT SYSTEM: DEVICE, ASSEMBLY, AND METHODS ASSOCIATED WITH IT	P202230993 PCT/ES2023/070688	F-03
SURFACE GRATING COUPLER SUITABLE FOR PHOTONIC DEVICES, ASSOCIATED METHOD, AND ASSEMBLY WITH SURFACE GRATING COUPLER	P202330970	F-03

SPIN-OFFS/START-UPS CREATED AND ACTIVE			
GALEA Therapeutics	Research and development of drugs for the treatment of fatty liver disease and related diseases focuses on the disease's origin related to obesity and/or alcohol intake.		
ALA Diagnostics	Development and marketing of in vitro diagnostic kits for highly prevalent diseases and/or unresolved medical needs.		
Bioherent	Diagnosis of drug allergies through a system based on a photonic biosensor.		

INNOVATIONS GENERATED IN 2023

Early detection and treatment of children with X-linked adrenoleukodystrophy.

IBIMA Plataforma BIONAND Group: **ENDOCRINOLOGY AND NUTRITION, DIABETES, AND OBESITY (A-01)** Incorporation within the framework of the Eastern Andalusia neonatal screening program (newborns in the provinces of Málaga, Granada, Almería, and Jaén) of neonatal screening for X-linked adrenoleukodystrophy disease with the aim of promoting improved care for these patients.

AFEBIO: Advanced Functional Enrichment and Biomedical Integrated Omics.

IBIMA Plataforma BIONAND Group: Bioinformatics ECAI

Application that allows multi-omic integration of data, allowing for a more complete and accurate view of biological processes. The tool has been developed in R Shiny and is designed to be used by users with little computer knowledge. It allows for the integration and visualization of genomic, transcriptomic, proteomic, and metabolomic data, among others, together with various statistical tools to analyze and explore the integrated data.

ACTIVE IDEAS

At the end of 2023, the Innovation and Technology Transfer Unit of IBIMA Plataforma BIONAND had 116 active ideas at different levels of development. Some 42% of these ideas are in the transfer phase, that is, they have a result that is potentially transferable to clinical practice either directly through their implementation or through agreements with third parties that complete the development until they are marketed. Around 5% of the ideas are in the development phase, which means that there is an innovation or technological development project aimed at achieving a new or improved product, process, service, or organizational model, although it must be taken into account that part of the ideas being transferred also continue to be developed to facilitate their transfer to society. Approximately 10% are being analyzed to guide their development, searching for funding, or being analyzed for their patentability. Finally, 13% of the ideas are in the fundraising phase, which are awaiting the necessary information to evaluate if the idea is viable and move on to its analysis. In addition to the above, almost 30% of the ideas generated at IBIMA Plataforma BIONAND are on the market, implemented in the health system, transferred to third parties for their use, or made available to the research community or society for their use (such as bioinformatics analysis tools or tools to help patients or their families).

78 SCIENTIFIC ACTIVITY AND PRODUCTION. OVERALL DATA 2023 SCIENTIFIC REPORT 79



Figure 30: Active ideas

4.8. CLINICAL PRACTICE GUIDELINES IMPLEMENTED IN HEALTHCARE CENTERS

- "Expert Consensus on Morphofunctional Assessment in Disease-Related Malnutrition. Grade Review and Delphi Study," NUTRIENTS. Garcia-Almeida, JM; Garcia-Garcia, C; Ballesteros-Pomar, MD; Olveira, G; Lopez-Gomez, JJ; Bellido, V; Lesmes, IB; Burgos, R; Sanz-Paris, A; Matia-Martin, P; Romero, FB; Breton, JO; Murillo, AZ; Bellido, D.
- "Standards for the Use of Enteral Nutrition in Patients with Diabetes or Stress Hyperglycaemia: Expert Consensus," NUTRIENTS. Rebollo-Pérez, MI; Ojeda, LF; García-Luna, PP; Rocamora, JAI; Olveira, G; Remigio, JRL; Irigoyen, CA; Continente, AC; Martín, CC; Soto, MLF; Almeida, JMG; López, ML; Morell, CL; Pérez, LML; Martínez, TMD; Pereira-Cunill, JL; Vilchez-López, FJ; Rabat-Restrepo, JM.
- "Approach to obesity in the elderly population: a consensus report from the Diabetes, Obesity and Nutrition Working Group of Spanish Society of Internal Medicine," REVISTA CLINICA ESPAÑOLA. Martínez, PP; Gómez-Huelgas, R; Escribano, PPC; Arévalo-Lorido, JC; Pérez-Soto, MI; Gómez, CJ.
- "Consensus document of the Spanish Society of Paediatric Infectious Diseases and the Advisory Committee on Vaccines of the Spanish Association of Pediatrics for vaccination of immunosuppressed individuals," ANALES DE PEDIATRIA. Rivero Calle, Irene; Del Rosal Rabes, Teresa; Garrote Llanos, Elisa; Nunez Cuadros, Esmeralda; Navarro Gomez, Maria Luisa; Ramos Amador, Jose Tomas; Calvo, Cristina; Alvarez Garcia, Francisco.
- "Executive summary: Guidelines for the diagnosis and treatment of septic arthritis in adults and children, developed by the GEIO (SEIMC), SEIP and SECOT," ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. Benito, Natividad; Martinez-Pastor, Juan Carlos; Lora-Tamayo, Jaime; Ariza, Javier; Baeza, Jose; Belzunegui-Otano, Joaquin; Cobo, Javier; Del-Toro, Maria-Dolores; Fontecha, Cesar G; Font-Vizcarra, Lluis; Horcajada, Juan P; Morata, Laura; Murillo, Oscar; Nolla, Joan M; Nunez-Cuadros, Esmeralda; Pigrau, Carlos; Portillo, Maria Eugenia; Rodriguez-Pardo, Dolors; Sobrino-Diaz, Beatriz; Saavedra-Lozano, Jesus.

- "Executive summary Diagnosis, treatment and prophylaxis of influenza virus infection Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)," ANALES DE PEDIATRIA. López-Medrano, F; Alfayate, S; Carratala, J; Chamorro-Camazón, J; Cordero, E; Cruz-Cañete, M; Fernández-Pradai, M; García-Cenoz, M; Marcos, MA; Melón, S; Moreno-Millán, N; Onieva-García, MA; de Lejarazuo, RO; Pérez-Martín, JJ; Rodríguez-García, J; Schwarz-Chavarrir, G; Tagarro-García, A; van Esso-Arbolave, D; Viasus, D; Pumarola, T.
- "Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients," NEFROLOGIA. Lopez, Veronica; Mazuecos, Auxiliadora; Villanego, Florentino; Lopez-Oliva, Maria; Alonso, Angel; Beneyto, Isabel; Crespo, Marta; Diaz-Corte, Carmen; Franco, Antonio; Gonzalez-Roncero, Francisco; Guirado, Luis; Jimenez, Carlos; Juega, Javier; Llorente, Santiago; Paul, Javier; Rodriguez-Benot, Alberto; Ruiz, Juan Carlos; Sanchez-Fructuoso, Ana; Torregrosa, Vicente; Zarraga, Sofia; Rodrigo, Emilio; Hernandez, Domingo.
- "Nursing Recommendations in the Management of Systemic Lupus Erythematosus: A Delphi Consensus," HISPANIC HEALTH CARE INTERNATIONAL. Cano Garcia, Laura; Dominguez Quesada, Carmen; Rodriguez Vargas, Ana Isabel; Trujillo Martin, Elisa; Martin Martin, Jose Maria.
- "Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?" NEFROLOGIA, CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, ADVANCES IN LABORATORY MEDICINE-AVANCES IN LABORATORY MEDICINE, REVISTA CLINICA ESPAÑOLA, ADVANCES IN LABORATORY MEDICINE-AVANCES IN LABORATORY MEDICINE. Velilla, Teresa Arrobas; Guijarro, Carlos; Ruiz, Raquel Campuzano; Pinero, Manuel Rodriguez; Francisco Valderrama Marcos, Jose; Lopez, Antonio M Botana; Lopez, Ana Morais; Antonio Garcia Donaire, Jose; Obaya, Juan Carlos; Guerra, Luis Castilla; Carratala, Vicente Pallares; Cabello, Isabel Egocheaga; Lazo, Mercedes Salgueira; Rodrigo, Maria Mar Castellanos; Maria Mostaza Prieto, Jose; Doblas, Juan Jose Gomez; Soto, Antonio Buno.
- "Consensus document for lipid profile testing and reporting in Spanish clinical laboratories," ENDOCRINOLOGIA DIABETES Y NUTRICION. Arrobas Velilla, Teresa; Guijarro, Carlos; Campuzano Ruiz, Raquel; Rodriguez Pinero, Manuel; Valderrama Marcos, Jose Francisco; Botana Lopez, Antonio M; Morais Lopez, Ana; Garcia Donaire, Jose Antonio; Obaya, Juan Carlos; Castilla Guerra, Luis; Pallares Carratala, Vicente; Egocheaga Cabello, Isabel; Salgueira Lazo, Mercedes; Castellanos Rodrigo, Maria Mar; Mostaza Prieto, Jose Maria; Gomez Doblas, Juan Jose; Buno Soto, Antonio.
- "Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome," JOURNAL OF CLINICAL LIPIDOLOGY. Escobar, Carlos; Barrios, Vivencio; Cequier, Angel; Cosin-Sales, Juan; Seijas, Jose; Doblas, Juan Jose Gomez; Arrarte, Vicente; Tunon, Jose; Banach, Maciej.
- "Research priorities in perioperative fluid therapy and hemodynamic monitoring: A Delphi Consensus Survey from the Fluid Therapy and Hemodynamic Monitoring Subcommittee of the Hemostasis, Transfusion Medicine and Fluid Therapy Section (SHTF) of the Spanish Society of Anesthesiology and Critical Care (SEDAR)," REVISTA ESPAÑOLA DE ANESTESIOLOGIA Y REANIMACION. Ripolles-Melchor, J.; Colomina, M. J.; Aldecoa, C.; Alonso-Cabello, J.; Alonso-Inigo, J. M.; Aya, H.; Basora, M.; Clau-Terre, F.; del Cojo-Peces, E.; Cota-Delgado, F.; Ferrandis-Comes, R.; Galan-Menendez, P.; Garcia-Lopez, D.; Garruti, I.; Lopez, I. J.; Jover-Pinillos, J. L.; Llau-Pitarch, J. V.; Lorente, J. V.; Mesquida, J.; Mojarro, I.; Monge-Garcia, M. I.; Montesinos-Fadrique, S. C.; Munoz-Rodes, J. L.; de Nadal, M.; Ramasco, F.; Tome-Roca, J. L.; Perez, A.; Una-Orejon, R.; Yanes, G.; Zorrilla-Vaca, A.; Escarraman, D.; Garcia-Fernandez, J.
- "Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain," REUMATOLOGIA CLINICA. Mo.nte-Boquet, Emilio; Florez, Angeles; Martinez, Guillermo Jose Alcain; Sellas, Agusti



RESEARCH AREAS AND GROUPS



5.1. PRIORITY SCIENTIFIC AREAS

Scientific Production

This section shows data on the scientific production of each of IBIMA Plataforma BIONAND's priority research areas. Collaborative publications among different groups in the same area have only been considered once for the calculation. Area 5 (IBIMA Rare is multidisciplinary and publications are not included since they are already included in the rest of the areas):




Figure 31: Cumulative and average impact factor by research areas




Figure 32: Percentage of publications in each area (original articles and reviews) compared to the institute as a whole




Figure 33: Number of publications in each area (original articles and reviews) and number of publications led by area.




Figure 34: Percentage of publications ranked Q1 and D1 in their category (JCR) by area

Active Projects




Figure 35: Active competitive research projects at the regional, national, and international level by scientific area

The percentage of competitive research projects in 2023 conducted by each research area is as follows:

Research Area	Total active research projects	% of total research projects
Area 1	78	25%
Area 2	20	6%
Area 3	91	29%
Area 4	61	20%
IBIMA Tech Area	32	10%
Area 8	13	4%
CIMO	20	6%

The IBIMA Rare area is a multidisciplinary area of the IBIMA Plataforma BIONAND formed by groups that also belong to other areas. The area is not included in this last figure and table so as not to distort the total number of active projects.

Clinical Trials

The clinical trials conducted in each scientific area of the IBIMA Plataforma BIONAND during the past year are as follows:





Figure 36: Distribution of active clinical trials by research areas

Area 1. Cardiovascular Diseases, Obesity, And Diabetes. Environmental Determinants And Lifestyle.

Coordinator: Manuel Jiménez Navarro. Assistant Coordinator: Mora Murri

Scientific Production






Figure 37: Number of publications, number of publications led, and Impact Factor from Area 1

Figure 38: Percentage of publications in Q1 and D1 from Area 1

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-02	Gomez-Perez, AM; Ruiz- Limon, P; Salas-Salvado, J; Vioque, J; Corella, D; Fito, M; Vidal, J; Atzeni, A; Torres- Collado, L; Alvarez-Sala, A; Martinez, MA; Goday, A; Benaiges, D; Garcia-Gavilan, J; Lopez, MRB; Moreno- Indias, I; Tinahones, FJ	Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis	GUT MICROBES	12.2	D1	2023
A-02	Boughanem, H; Ruiz-Limon, P; Pilo, J; Lisbona-Montanez, JM; Tinahones, FJ; Indias, IM; Macias-Gonzalez, M	Linking serum vitamin D levels with gut microbiota after 1-year lifestyle intervention with Mediterranean diet in patients with obesity and metabolic syndrome: a nested cross-sectional and prospective study	GUT MICROBES	12.2	D1	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Year
A-09	Garcia-Casares, N; Gonzalez-Gonzalez, G; de la Cruz-Cosme, C; Garzon- Maldonado, FJ; de Rojas- Leal, C; Ariza, MJ; Narvaez, M; Barbancho, MA; Garcia- Arnes, JA; Tinahones, FJ	Effects of GLP-1 receptor agonists on neurological complications of diabetes	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	2023
A-03	Sánchez-Quintero MJ, Delgado J, Martín Chaves L, Medina-Vera D, Murri M, Becerra-Muñoz VM, Estévez M, Crespo-Leiro MG, Paz López G, González-Jiménez A, A G Ranea J, Queipo- Ortuño MI, Plaza-Andrades I, Rodríguez-Capitán J, Pavón- Morón FJ, Jiménez-Navarro MF.	Multi-Omics Approach Reveals Prebiotic and Potential Antioxidant Effects of Essential Oils from the Mediterranean Diet on Cardiometabolic Disorder Using Humanized Gnotobiotic Mice.	ANTIOXI- DANTS	7	D1	2023
AA-22	Pinero-Pinto, E; Romero- Galisteo, RP; Jimenez- Rejano, JJ; Escobio-Prieto, I; Pena-Salinas, M; Luque- Moreno, C; Palomo-Carrion, R	A pilot randomised controlled trial on the effectiveness of infant massage on the acceptance, commitment and awareness of influence in parents of babies with Down syndrome	JOURNAL OF INTELLECTU- AL DISABILITY RESEARCH	3.6	D1	2023






Area 2. Molecular And Translational Biology Of Cancer

Coordinator: Melissa García Caballero. Assistant Coordinator: Elisa Matas Rico

Scientific Production






Figure 39: No. publications, nopublications led, and Impact Factor from Area 2

Figure 40: Percentage of publications in Q1 and D1 from Area 2

Selection of the five most relevant publications in the area in 2023:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-04	Marrero, AD; Ortega-Vidal, J; Salido, S; Castilla, L; Vidal, I; Quesada, AR; Altarejos, J; Martinez-Poveda, B; Medina, MA	Anti-angiogenic effects of oleacein and oleocanthal: New bioactivities of compounds from Extra Virgin Olive Oil	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	2023
B-04	Vidal, I; Torres-Vargas, JA; Sanchez, JM; Trigal, M; Garcia-Caballero, M; Medina, MA; Quesada, AR	Danthron, an Anthraquinone Isolated from a Marine Fungus, Is a New Inhibitor of Angiogenesis Exhibiting Interesting Antitumor and Antioxidant Properties	ANTIOXI- DANTS	7	D1	2023
B-04	Marrero, AD; Castilla, L; Bernal, M; Manrique, I; Posligua-Garcia, JD; Moya- Utrera, F; Porras-Alcala, C; Espartero, JL; Sarabia, F; Quesada, AR; Medina, MA; Martinez-Poveda, B	Inhibition of Endothelial Inflammatory Response by HT-C6, a Hydroxytyrosol Alkyl Ether Derivative	ANTIOXI- DANTS	7	D1	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Year
B-04	Carrillo, P; Bernal, M; Tellez- Quijona, C; Marrero, AD; Vidal, I; Castilla, L; Caro, C; Dominguez, A; Garcia- Martin, ML; Quesada, AR; Medina, MA; Martinez- Poveda, B	The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	2023
BE-19	Gonzalez-Vidal, A; Mercado- Saenz, S; Burgos-Molina, AM; Alamilla-Presuel, JC; Alcaraz, M; Sendra-Portero, F; Ruiz-Gomez, MJ	Molecular Mechanisms of Resistance to Ionizing Radiation in S. cerevisiae and Its Relationship with Aging, Oxidative Stress, and Antioxidant Activity	ANTIOXI- DANTS	7	D1	2023






trials

Area 3. Neurosciences, Chronicity, Aging, And Health In Vulnerable Populations.

Coordinator: Antonia Serrano Criado, Deputy Coordinator: Patricia Moreno Peral.

Scientific Production






Figure 41: No. publications, no. publications led, and Impact Factor from Area 3

Figure 42: Percentage of publications in Q1 and D1 from Area 3

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-01	Serrano-Castro, Pedro J; Rodriguez-Uranga, Juan J; Cabezudo-Garcia, Pablo; Garcia-Martin, Guillermina; Romero-Godoy, Jorge; Estivill-Torrus, Guillermo; Ciano-Petersen, Nicolas Lundahl; Oliver, Begona; Ortega-Pinazo, Jesus; Lopez-Moreno, Yolanda; Aguilar-Castillo, Maria J; Gutierrez-Cardo, Antonio L; Ramirez-Garcia, Teresa; Sanchez-Godoy, Lorenzo; Carreno, Mar	Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies.	Neurology(R) neuroim- munology & neuroinflam- mation	8.8	D1	2023
C-03	Goodman-Casanova, JM; Guzman-Parra, J; Duran- Jimenez, FJ; Garcia-Gallardo, M; Cuesta-Lozano, D; Mayoral-Cleries, F	Effectiveness of museum- based participatory arts in mental health recovery	INTERNA- TIONAL JOURNAL OF MENTAL HEALTH NURSING	5.6	D1	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Year
C-07	Diaz-Sanchez, E; Lopez-Salas, A; Mirchandani-Duque, M; Alvarez-Contino, JE; Sanchez-Perez, JA; Fuxe, K; Borroto-Escuela, DO; Garcia-Casares, N; Narvaez, M	Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	2023
C-11	Reyes-Pérez, A; López- Martínez, AE; Esteve, R; Ramírez-Maestre, C	Spanish Validation of the COMM Scale to Assess the Misuse of Prescription Opioids in Patients with Chronic Noncancer Pain	INTERNA- TIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION	8	D1	2023
C-12	Lopez-Barroso, D; Paredes- Pacheco, J; Torres-Prioris, M; Davila, G; Berthier, ML	Brain structural and functional correlates of the heterogenous progression of mixed transcortical aphasia	BRAIN STRUCTURE & FUNCTION	3.1	D1	2023








Clinical trials

Area 4. Autoimmune Diseases, Infectious Diseases, Inflammation, And Allergies.

Coordinator: María José Torres Jaén, Deputy Coordinator: Antonio Fernández Nebro

Scientific Production






Figure 43: No. publications, no. publications led, and Impact Factor from Area 4

Figure 44: Percentage of publications in Q1 and D1 from Area 4

Selection of the five most relevant publications in the area in 2023:

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-05	Andrade, RJ; Aithal, GP; de Boer, YS; Liberal, R; Gerbes, A; Regev, A; Beretta-Piccoli, BT; Schramm, C; Kleiner, DE; De Martin, E; Kullak-Ublick, GA; Stirnimann, G; Devarbhavi, H; Vierling, JM; Manns, MP; Sebode, M; Londoño, MC; Avigan, M; Robles-Diaz, M; García-Cortes, M; Atallah, E; Heneghan, M; Chalasani, N; Trivedi, PJ; Hayashi, PH; Taubert, R; Fontana, RJ; Weber, S; Oo, YH; Zen, Y; Licata, A; Lucena, MI; Mieli-Vergani, G; Vergani, D; Björnsson, ES	Nomenclature, diagnosis and management of drug- induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report	JOURNAL OF HEPATOLOGY	25.7	D1	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Year
D-04	Paris, JL; Gaspar, R; Coelho, F; De Beule, PAA; Silva, BFB	Stability Criterion for the Assembly of Core-Shell Lipid-Polymer-Nucleic Acid Nanoparticles	ACS NANO	17.1	D1	2023
D-04	Cho, SH; Nanda, A; Keswani, A; Adinoff, A; Baroody, FM; Bernstein, JA; Gherasim, A; Han, JK; Koepke, JW; Ledford, DK; Pepper, AN; Rondon, C; Schiffman, A; Wagenmann, M; Campo, P	Nasal allergen challenge (NAC): Practical aspects and applications from an EU/US perspective-a Work Group Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee	JOURNAL OF ALLERGY AND CLINICAL IM- MUNOLOGY	14.2	D1	2023
D-05	Fontana, RJ; Bjornsson, ES; Reddy, R; Andrade, RJ	The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury	CLINICAL GASTROEN- TEROLOGY AND HEPA- TOLOGY	12.6	D1	2023
D-03	Mena-Vazquez, N; Rojas-Gimenez, M; Romero-Barco, CM; Gandia-Martinez, M; Perez-Gomez, N; Godoy-Navarrete, FJ; Manrique-Arija, S; Garcia-Studer, A; Calvo-Gutierrez, J; Varela, CF; Morales-Garrido, P; Perez, PC; Mourino-Rodriguez, C; Anon-Onate, I; Espildora, F; Aguilar-Hurtado, MC; Redondo, R; Conde, AH; de los Rios, RAD; Cesar, EC; Velloso-Feijoo, ML; Fernandez-Nebro, A	Analysis of comorbidity in rheumatoid arthritis-associated interstitial lung disease: a nested case-cohort study	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	2023



Active research projects




Clinical trials

Area 6 Ibima Tech: Health Technology And Innovation.

Coordinator: Ezequiel Pérez-Inestrosa. Assistant coordinator: José Aldana Montes

Scientific Production






Figure 45: Number of publications, number of publications led, and Impact Factor from the IBIMA Tech Area

Figure 46: Percentage of publications in Q1 and D1 from the IBIMA Tech Area

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-04	Garcia-Salguero, M; Gonzalez-Jimenez, J	Fast certifiable relative pose estimation with gravity prior*	ARTIFICIAL INTELLIGENCE	14.4	D1	2023
F-05	Costoya, C; Muñoz, V; Tocino, A; Viruel, A	Automorphism groups of Cayley evolution algebras	REVISTA DE LA REAL ACADEMIA DE CIENCIAS EXACTAS FISICAS Y NATURALES SERIE A-MATEMATICAS	2.9	D1	2023
F-10	Dominguez-Alfaro, A; Pais, VF; Guzman- Rios, DB; Collado, D; Najera, F; Perez- Inestrosa, E; Pischel, U	Energy-transfer sensitization of BODIPY fluorescence in a dyad with a two-photon absorbing antenna chromophore	DYES AND PIGMENTS	4.5	D1	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Year
F-15	Rodríguez-Revello, J; Barba-González, C; Rybinski, M; Navas- Delgado, I	KNIT: Ontology reusability through knowledge graph exploration	EXPERT SYSTEMS WITH APPLICATIONS	8.5	D1	2023
F-15	Burgueño, AM; Aldana-Martín, JF; Vázquez-Pendón, M; Barba-González, C; Gómez, YJ; Millán, VG; Navas-Delgado, I	Scalable approach for high-resolution land cover: a case study in the Mediterranean Basin	JOURNAL OF BIG DATA	8.1	D1	2023



Active research projects




Clinical trials

Area 7. Nanodiagnostics.

Coordinator: María Luisa García Martín

Scientific Production






Figure 47: Number of publications, number of publications led, and Impact Factor from Area 7.

Figure 48: Percentage of publications in Q1 and D1 from Area 7.

Group	Authors	Article Title	Source Title	IF	Q/D	Year
G-01	Ortiz-Rivero E., Orozco- Barrera S., Chatterjee H., González-Gómez C.D., Caro C., García-Martín ML., González P.H., Rica R.A., Gámez F.	Light-to-Heat Conversion of Optically Trapped Hot Brownian Particles	ACS NANO	17.1	D1	2023
G-01	Paez-Muñoz, JM; Gámez, F; Fernández-Afonso, Y; Gallardo, R; Leal, MP; Gutiérrez, L; de la Fuente, JM; Caro, C; Garcia-Martín, ML	Optimization of iron oxide nanoparticles for MRI-guided magnetic hyperthermia tumor therapy: reassessing the role of shape in their magnetocaloric effect	JOURNAL OF MATERIALS CHEMISTRY B	7	Q1	2023


Group	Authors	Article Title	Source Title	IF	Q/D	Year
G-01	Ocaña, MC; Bernal, M; Yang, CD; Caro, C; Domínguez, A; Vu, HS; Cárdenas, C; García- Martín, ML; Deberardinis, RJ; Quesada, AR; Martínez- Poveda, B; Medina, MA	New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo	COMMUNICA- TIONS BIOLOGY	5.9	Q1	2023
G-01	Pomary, PK; Eichau, S; Amigo, N; Barrios, L; Matesanz, F; Garcia- Valdecasas, M; Hrom, I; Sanchez, MIG; Garcia- Martin, ML	Multifaceted Analysis of Cerebrospinal Fluid and Serum from Progressive Multiple Sclerosis Patients: Potential Role of Vitamin C and Metal Ion Imbalance in the Divergence of Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis	JOURNAL OF PROTEOME RESEARCH	4.4	Q1	2023
G-01	Avasthi, A; Caro, C; Garcia- Martin, ML; Leal, MP	Deciphering the parameters to produce highly reproducible and scalable iron oxide nanoparticles	REACTION CHEMISTRY & ENGINEERING	3.9	Q2	2023



Area 8. Nanosystems And Advanced Therapies

Coordinator: Elena González Muñoz

Scientific Production






Figure 49: No. publications, no. publications led, and Impact Factor from Area 8

Figure 50: Percentage of publications in Q1 and D1 from Area 8

Group	Authors	Article Title	Source Title	IF	Q/D	Year
H-03	Palmquist-Gomes, P; Ruiz- Villalba, A; Guadix, JA; Romero, JP; Bessieres, B; MacGrogan, D; Conejo, L; Ortiz, A; Picazo, B; Houyel, L; Gomez-Cabrero, D; Meilhac, SM; de la Pompa, JL; Perez- Pomares, JM	Origin of congenital coronary arterio- ventricular fistulae from anomalous epicardial and myocardial development	EXPERIMENTAL AND MOLECU- LAR MEDICINE	12.8	D1	2023
H-02	Nualart, F; Cifuentes, M; Ramirez, E; Martínez, F; Barahona, MJ; Ferrada, L; Saldivia, N; Bongarzone, ER; Thorens, B; Salazar, K	Hyperglycemia increases SCO-spondin and Wnt5a secretion into the cerebrospinal fluid to regulate ependymal cell beating and glucose sensing	PLOS BIOLOGY	9.8	D1	2023


Group	Authors	Article Title	Source Title	IF	Q/D	Year
H-02	Csukasi, F; Bosakova, M; Barta, T; Martin, JH; Arcedo, J; Barad, M; Rico-Llanos, GA; Zieba, J; Becerra, J; Krejci, P; Duran, I; Krakow, D	Skeletal diseases caused by mutations in PTH1R show aberrant differentiation of skeletal progenitors due to dysregulation of DEPTOR	FRONTIERS IN CELL AND DE- VELOPMENTAL BIOLOGY	5.5	Q1	2023
HE-01	Ducic, T; Sanchez-Mata, A; Castillo-Sanchez, J; Algarra, M; Gonzalez-Munoz, E	Monitoring oocyte-based human pluripotency acquisition using synchrotron-based FTIR microspectroscopy reveals specific biomolecular trajectories	SPECTROCHIM- ICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY	4.4	Q1	2023
H-03	Sugahara, F; Pascual-Anaya, J	High-quality total RNA extraction from early-stage lamprey embryos	BIOTECHNIQUES	2.7	Q3	2023



CIMO. Oncology Research Centre Of Málaga

Director: Emilio Alba Conejo.

Scientific Production






Figure 51: No. publications, no. publications led, and Impact Factor from CIMO

Figure 52: Percentage of Q1 and D1 publications from CIMO

Selection of the five most relevant publications from CIMO in 2023

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CIMO- 01	Pascual, Javier; Gil-Gil, Miguel; Proszek, Paula; Zielinski, Christoph; Reay, Alistair; Ruiz-Borrego, Manuel; Cutts, Rosalind; Ciruelos Gil, Eva M; Feber, Andrew; Munoz-Mateu, Montserrat; Swift, Claire; Bermejo, Begona; Herranz, Jesus; Margeli Vila, Mireia; Anton, Antonio; Kahan, Zsuzsanna; Csoszi, Tibor; Liu, Yuan; Fernandez-Garcia, Daniel; Garcia-Murillas, Isaac; Hubank, Michael; Turner, Nicholas C; Martin, Miguel	Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.	Clinical cancer research: an official journal of the American Association for Cancer Research	11.5	D1	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Year
CIMO- 01	Laborda-Illanes, A; Sanchez- Alcoholado, L; Castellano- Castillo, D; Boutriq, S; Plaza-Andrades, I; Aranega- Martin, L; Peralta-Linero, J; Alba, E; Gonzalez-Gonzalez, A; Queipo-Ortuno, MI	Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	2023
CIMO- 01	Javier, GC; Alberto, I; Azucena, GNE; Ivan, V; Debora, M; David, P; Laura, A; Andrea, MS; Esther, S; Oleguer, C; Paula, B; Laura, M; Nuria, V; Miquel, N; Patricia, G; Barbara, A; Neus, B; Tamara, S; Manel, J; Aleix, P; Francesco, S	Determinants of activity and efficacy of anti-PD1/ PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker- based study	CANCER IMMUNOLOGY IMMUNO- THERAPY	5.8	Q1	2023
CIMO- 02	Oliver, J; Onieva, JL; Garrido- Barros, M; Cobo-Dols, M; Martinez-Galvez, B; Garcia- Pelicano, AI; Dubbelman, J; Benitez, JC; Martin, JZ; Cantero, A; Perez-Ruiz, E; Rueda-Dominguez, A; Barragan, I	Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade	CANCERS	5.2	Q2	2023
CIMO- 03	López-García, G; Jerez, JM; Ribelles, N; Alba, E; Veredas, FJ	Explainable clinical coding with in-domain adapted transformers	JOURNAL OF BIOMEDICAL INFORMATICS	4.5	Q2	2023





trials

5.2. RESEARCH GROUPS

Area 1. Cardiovascular Diseases, Obesity, And Diabetes. Environmental Determinants And Lifestyle

Consolidated Groups

A-01. Endocrinology And Nutrition, Diabetes, And Obesity LR Gabriel Olveira Fuster Gabriel. Co-LR Javier Bermúdez Silva

Priority line of research: Obesity, diabetes, and clinical nutrition.

Other lines:

- 1. Obesity and translational diabetes: adipose tissue and beta cell metabolism:
- Pathophysiology of the pancreatic islet in type 2 diabetes.
- Prevention of type 2 diabetes and the inflammatory processes that underlie and precede so-called "beta cell failure"
- Role of angiogenesis in the regulation of adipose tissue expansion in relation to obesity and type 2 diabetes.
- Role of angiogenic microRNAs in the regulation of white, brown, and beige adipose tissue functionality.
- Role of microbiota in obesity and type 2 diabetes.
- Study of the cause-effect relationship between obesity and mental illnesses.
- Thymic adipose tissue as a source of angiogenesis for blood vessel neogeneration in older adult subjects with ischemic heart disease.
- 2. New approaches in clinical-experimental research on diabetes and metabolism and clinical nutrition applied to chronic diseases:
- Type 1 diabetes, new technology, biomarkers, and the psychosocial approach.
- Clinical nutrition and dietetics applied to artificial nutrition.
- Surgical morbid obesity: clinical experimental models.
- Hypogonadism and glomerulopathy associated with obesity.
- Clinical nutrition in chronic diseases (cystic fibrosis and bronchiectasis, cancer, and neurological diseases).
- New methods for the assessment of nutritional status and their prognostic value.
- 3. Epidemiology and risk factors for diabetes and related metabolic diseases
- Epidemiology of diabetes mellitus, obesity, and related metabolic diseases in Spain and Andalusia (prevalence and incidence).
- Study of new prognostic environmental markers (environmental pollution) for hydrocarbon metabolism abnormalities.
- Study of predictive biomarkers of diabetes and metabolic diseases (e.g. mRNA, genetic, epigenetic, and biochemical biomarkers).
- Epidemiology of thyroid diseases in Spain and iodine deficiency disorders.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-01	Ruiz-Garcia, I; Ortiz-Flores, R; Badia, R; Garcia-Borrego, A; Garcia-Fernandez, M; Lara, E; Martin-Montanez, E; Garcia-Serrano, S; Valdes, S; Gonzalo, M; Tapia-Guerrero, SMJ; Fernandez-Garcia, JC; Sanchez-Garcia, A; Munoz-Cobos, F; Calderon-Cid, M; El-Bekay, R; Covas, MI; Rojo-Martinez, G; Olveira, G; Romero-Zerbo, SY; Bermudez-Silva, FJ	Rich oleocanthal and oleacein extra virgin olive oil and inflammatory and antioxidant status in people with obesity and prediabetes. The APRIL study: A randomised, controlled crossover study	CLINICAL NUTRITION	6.3	Q1	Article
A-01	Garcia-Luna, PP; Restrepo, JRM; Munoz-Ayllon, M; Gil, MD; Remon, P; Sanchez- Torralvo, FJ; Pachon, J; Garcia-Gonzalez, JJ; Garcia- Manrique, T; Salvador-Bofill, J; Vicente, D; Olveira, G	Evaluation of Nutritional Interventions in the Care Plan for Cancer Patients: The NOA Project	NUTRIENTS	5.9	Q1	Article
A-01	Sanchez-Torralvo, FJ; Perez- del-Rio, V; Garcia-Olivares, M; Porras, N; Abuin- Fernandez, J; Bravo-Bardaji, MF; Garcia-de-Quevedo, D; Olveira, G	Global Subjective Assessment and Mini Nutritional Assessment Short Form Better Predict Mortality Than GLIM Malnutrition Criteria in Elderly Patients with Hip Fracture	NUTRIENTS	5.9	Q1	Article
A-01	Gentile, AM; Lhamyani, S; Mesa, MM; Pavón-Morón, FJ; Pearson, JR; Salas, J; Clemente-Postigo, M; Costillas, LP; Fuster, GO; Rizky, RE	A Network Comprised of miR-15b and miR-29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
A-01	Gentile, Adriana- Mariel; Lhamyani, Said; Mengual-Mesa, Maria; Garcia-Fuentes, Eduardo; Bermudez-Silva, Francisco- Javier; Rojo-Martinez, Gemma; Clemente-Postigo, Mercedes; Rodriguez- Canete, Alberto; Olveira, Gabriel; El Bekay, Rajaa	MiR-221-3p/222-3p Cluster Expression in Human Adipose Tissue Is Related to Obesity and Type 2 Diabetes.	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article

104 RESEARCH AREAS AND GROUPS

Scientific production and research activity:

Articles	% Art. Led.	% Q 1	% D1	IF
40	30%	65%	15%	249



Networks and Ciber:

CA17117 (EVBRES) -Towards an International Network for Evidence-based Research in Clinical Health Research (European Commission).

CIBERDEM CB07/08/0019 Diabetes and Associated Metabolic Diseases (ISCIII)

Competitive HR contracts funded in 2023:

1 Sara Borrell Contract (ISCIII).

1 contract for the annual reinforcement of research activity in the clinical units of the Andalusian Health Service (SAS).

1 Renewal of Action B (long-term reinforcement) of the SAS.

A-02. Obesity, Diabetes, And Their Comorbidities: **Prevention And Treatment.**

LR Francisco Tinahones Madueño. Co-LR Manuel Macias González. Co-LR Isabel Moreno Indias

Priority line of research: Study of metabolic diseases: diabetes and obesity.

Other lines:

- Gut microbiota, insulin resistance, and obesity.
- Role of adipobiology in metabolic diseases.
- Metabolic effect of bariatric surgery.
- Environmental factors in the genesis of obesity and diabetes.
- Novel cellular and molecular mechanisms of inflammation in metabolic diseases: obesity, diabetes, and
- Genetic and epigenetic factors in the prevention, progression, and treatment of diabetes.
- PREDIMED-Plus study.
- Dietetic-therapeutic approach to obesity: role of ketosis, intermittent fasting, physical exercise, and chronobiology.
- Mitochondrial fitness in metabolic diseases.
- Endocrine-metabolic complications of obesity: NAFLD.
- Hyperlipoproteinemia, insulin resistance, and atherosclerotic disease.
- Analysis of biomarkers of response to a weight loss intervention.
- Immunity of metabolic diseases.
- Role of gestation and breastfeeding in the onset of metabolic diseases.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-02	Gomez-Perez, AM; Ruiz- Limon, P; Salas-Salvado, J; Vioque, J; Corella, D; Fito, M; Vidal, J; Atzeni, A; Torres- Collado, L; Alvarez-Sala, A; Martinez, MA; Goday, A; Benaiges, D; Garcia-Gavilan, J; Lopez, MRB; Moreno- Indias, I; Tinahones, FJ	Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis	GUT MICROBES	12.2	D1	Article
A-02	Boughanem, H; Ruiz-Limon, P; Pilo, J; Lisbona-Montanez, JM; Tinahones, FJ; Indias, IM; Macias-Gonzalez, M	Linking serum vitamin D levels with gut microbiota after 1-year lifestyle intervention with Mediterranean diet in patients with obesity and metabolic syndrome: a nested cross-sectional and prospective study	GUT MICROBES	12.2	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-02	del Saz-Lara, A; Boughanem, H; de las Hazas, MCL; Crespo, C; Saz-Lara, A; Visioli, F; Macias-Gonzalez, M; Davalos, A	Hydroxytyrosol decreases EDNRA expression through epigenetic modification in colorectal cancer cells	PHARMACO- LOGICAL RESEARCH	9.3	D1	Article
A-02	Reina-Perez, I; Artacho- Cordo, F; Mustieles, V; Castellano-Castillo, D; Cardona, F; Jimenez-Diaz, I; Lopez-Medina, JA; Alcaide, J; Ocana-Wilhelmi, L; Iribarne- Duran, LM; Arrebola, JP; Olea, N; Tinahones, FJ; Fernandez, MF	Cross-sectional associations of persistent organic pollutants measured in adipose tissue and metabolic syndrome in clinically diagnosed middle- aged adults	ENVIRON- MENTAL RESEARCH	8.3	D1	Article
A-02	Bellido, D; García-García, C; Talluri, A; Lukaski, HC; García-Almeida, JM	Future lines of research on phase angle: Strengths and limitations	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	Article

Scientific production and research activity:

Articles	%Art. Leader.	% Q 1	% D1	IF
88	43%	64%	30%	540



Networks and Ciber:

CA20128 (PIMENTO): Promoting Innovation of fermented foods (European Commission)

CA18124 (ESMN) - European Sexual Medicine Network

CA18131 (ML4Microbiome) - Statistical and machine learning techniques in human microbiome studies CIBEROBN CB06/03/0018 Physiopathology of Obesity and Nutrition (ISCIII)

Competitive HR contracts funded in 2023:

- 1 PFIS Contract (ISCIII)
- 1 Río Hortega Contract (ISCIII)
- 1 Sara Borrell Contract (ISCIII)
- 2 Miguel Servet Contracts (ISCIII)

1 contract for the annual reinforcement of research activity in the clinical units of the SAS.

1 renewal of the Nicolás Monardes Contract of the SAS.

A-03. Cardiovascular Research For Health LR Manuel Jiménez Navarro. Co-LR Juan José Gómez Doblas, Co-LR Francisco Javier Pavón Morón

Lines of research:

- Ischemic heart disease: New preventive, diagnostic, and therapeutic approaches.
- Biomarkers and risk factors for cardiovascular disease.
- Valvular and aortic diseases: Molecular and genetic bases.
- Pulmonary hypertension and rare diseases.
- Cardiometabolic diseases: sexual dimorphism and lifestyles.
- Clinical and translational research on arrhythmias, cardiomyopathies, and heart failure.
- New information and communication technology in cardiovascular research.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-03	Sánchez-Quintero MJ, Delgado J, Martín Chaves L, Medina-Vera D, Murri M, Becerra-Muñoz VM, Estévez M, Crespo-Leiro MG, Paz López G, González-Jiménez A, A G Ranea J, Queipo- Ortuño MI, Plaza-Andrades I, Rodríguez-Capitán J, Pavón- Morón FJ, Jiménez-Navarro MF.	Multi-Omics Approach Reveals Prebiotic and Potential Antioxidant Effects of Essential Oils from the Mediterranean Diet on Cardiometabolic Disorder Using Humanized Gnotobiotic Mice.	ANTIOXI- DANTS	7	D1	Article
A-03	Osca, Joaquin; Francisco- Pascual, Jaume; Martinez- Basterra, Javier; Martinez, Juan Gabriel; Reis, Hipolito; Oliveira, Mario; Campos, Bieito; Balaguer, Javier; Rubio, Jeronimo; Pavon-Jimenez, Ricardo; Hernandez, Julio; Ormaetxe, Jose Miguel; Zamorano, Jose Luis; Santamaria, Pilar; Alzueta, Javier	Response rate in cardiac resynchronization therapy patients implanted with a left ventricular quadripolar lead and the MultiPoint _{TM} pacing feature early activated. QUARTO III	EUROPEAN JOURNAL OF CLINICAL IN- VESTIGATION	5.5	Q1	Article
A-03	Lozano, Ignacio Fernandez; Asensi, Joaquin Osca; Rodriguez, Javier Alzueta	Spanish implantable cardioverter-defibrillator registry. 19th official report of Heart Rhythm Association of the Spanish Society of Cardiology (2022)	REVISTA ESPANOLA DE CARDIOLOGIA	5.9	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-03	Cerezo, IM; Pérez-Gómez, O; Bautista, R; Seoane, P; Esteban, MA; Balebona, MC; Moriñigo, MA; Tapia- Paniagua, ST	SpPdp11 Administration in Diet Modified the Transcriptomic Response and Its Microbiota Associated in Mechanically Induced Wound Sparus aurata Skin	ANIMALS	3	D1	Article
A-03	Medina-Vera, D; Zambrana- Infantes, EN; López- Gambero, AJ; Verheul- Campos, J; Santín, LJ; Baixeras, E; Suarez, J; Pavon, FJ; Rosell-Valle, C; Fonseca, FRD	Transcending the amyloid- beta dominance paradigm in Alzheimer's disease: An exploration of behavioural, metabolic, and gut microbiota phenotypes in 5xFAD mice	NEUROBIOLO- GY OF DISEASE	6.1	Q1	Article

Scientific production and research activity:

Articles	% Art. Led.	% Q1	% D1	IF
84	24%	40%	14%	434



Networks and Ciber:

IRENE-Implementation Research Network in Stroke Care Quality (European Commission).

CA19101 (DE-PASS) - Determinants of Physical Activities in Settings (European Commission).

CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (European Commission).

CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities.

CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure.

CIBERCV CB16/11/00360 Cardiovascular Diseases (ISCIII).

Competitive HR contracts funded in 2023:

1 ERC GRANT 2023 (Juan Rodés Contract-ISCIII).

- 1 PFIS Contract (ISCIII).
- 1 Río Hortega Contract (ISCIII).

1 contract for the intensification of research activity in the National Health Service (SNS) (ISCIII).

1 contract for the annual reinforcement of the research activity in Andalusian Health Service (SAS) clinical units.

A-06. Diabetes, Obesity, And Other Vascular Risk Factors. Systemic Autoimmune Diseases.

LR Ricardo Gómez Huelgas. Co-LR. Rosa Bernal López

Priority line of research: Diabetes, obesity, and other cardiovascular risk factors.

Other lines:

- Systemic autoimmune diseases.
- Chronic diseases. Diseases in older adults.
- Thromboembolic disease.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-06	Lopez-Sampalo, A; Cobos- Palacios, L; Vilches-Perez, A; Sanz-Canovas, J; Vargas- Candela, A; Mancebo- Sevilla, JJ; Hernandez- Negrin, H; Gomez-Huelgas, R; Bernal-Lopez, MR	COVID-19 in Older Patients: Assessment of Post- COVID-19 Sarcopenia	BIOMEDI- CINES	4.7	Q1	Article
A-06	Carrasco-Fernández, L; García-Sillero, M; Jurado- Castro, JM; Borroto-Escuela, DO; García-Romero, J; Benítez-Porres, J	Influence of limb dominance on body and jump asymmetries in elite female handball	SCIENTIFIC REPORTS	4.6	Q2	Article
A-06	Perez-Belmonte, Luis M; Osuna-Sanchez, Julio; Ricci, Michele; Millan-Gomez, Mercedes; Lopez-Carmona, Maria D; Barbancho, Miguel A; Bernal-Lopez, Maria R; Jansen-Chaparro, Sergio; Lara, Jose P; Gomez- Huelgas, Ricardo	Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older study.	PANMINERVA MEDICA	4.3	Q2	Article
A-06	Bailón, MM; Villalba, NL; Onrubia, JG; Rivas, MR; Rodriguez, MVN; Pérez, MDP; Pedroche, CD; Aizpuru, EMF; Garcia, MVV; Garcia, GMG; Fontán, PMP; Artero, A; Hernandez, EM; Pedrajas, JNA; Galvan, VG; Monge, DM; Giménez, LL; Gómez, M; Cilleros, CM; Ruiz, NP; Sevilla, JE; Méndez, RG; Ramos-Rincón, JM; Huelgas, RG	Prognostic Factors Associated with Acute Heart Failure in Patients Admitted for COVID-19: Analysis of the SEMI- COVID-19 Registry	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-06	Ramos-Rincon, JM; Lopez-Sampalo, A; Cobos-Palacios, L; Ricci, M; Rubio-Rivas, M; Diaz-Simon, R; Martin-Escalante, MD; Castaneda-Perez, S; Fernandez-Madera-Martinez, R; Beato-Perez, JL; Garcia-Garcia, GM; Garcia-Andreu, MD; Arnalich-Fernandez, F; Molinos-Castro, S; Vargas-Nunez, JA; Artero, A; Freire-Castro, SJ; Fernandez-Gomez, J; Cubo-Romano, P; Hernandez-Milian, A; Ines-Revuelta, SM; Boixeda, R; Fernandez-Pedregal, E; Gomez-Huelgas, R	Nosocomial COVID-19: A Nationwide Spanish Study	GERONTOL- OGY	3.5	Q3	Article

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
30	40%	30%	20%	156



Networks:

CA18216 (VascAgeNet) - Network for Research in Vascular Ageing (European Commission).

CA21147 (ENOTTA) - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases.

Competitive HR contracts funded in 2023:

1 PFIS Contract (ISCIII)

1 contract for the annual reinforcement of research activity in the clinical units of the SAS.

A-07. Translational Research On Cardiovascular Disease LR José Antonio González Correa. Co-LR José Pedro de la Cruz Cortés

Priority line of research: Translational research on the effect of olive oil polyphenols on vascular inflammation and micro-and macroagiopathic complications in patients with type 2 diabetes.

Other lines of research:

- Evaluation of biomarkers and risk factors related to the progression of diabetic retinopathy.
- Evaluation of the level of response to antiplatelet therapy with acetylsalicylic acid in patients with type 2 diabetes in primary care.
- Characterization of functional fractions of olives, formulation of new products, and analysis of their effects.
- Intensification of pharmacovigilance activities through an organizational change and training intervention in a primary care clinical management unit (UGC).

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-07	Repiso-Guardeno, Angela; Moreno-Morales, Noelia; Labajos-Manzanares, Maria Teresa; Rodriguez-Martinez, Maria Carmen; Armenta- Peinado, Juan Antonio	Does Tension Headache Have a Central or Peripheral Origin? Current State of Affairs	CURRENT PAIN AND HEADACHE REPORTS	3.7	Q2	Review
A-07	Baeza-Barragán, MR; Manzanares, MTL; Amaya- Alvarez, MC; Vega, FM; Ruiz, JR; Martín-Valero, R	Effectiveness of a 5-Week Virtual Reality Telerehabilitation Program for Children With Duchenne and Becker Muscular Dystrophy: Prospective Quasi-Experimental Study	JMIR SERIOUS GAMES	4	Q2	Article
A-07	Lopez-Villodres, JA; Escamilla, A; Mercado- Saenz, S; Alba-Tercedor, C; Rodriguez-Perez, LM; Arranz-Salas, I; Sanchez- Varo, R; Bermudez, D	Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice	BIOMEDI- CINES	4.7	Q1	Review
A-07	Rodriguez-Perez, MD; Santiago-Corral, L; Ortega- Hombrados, L; Verdugo, C; Arrebola, MM; Martin- Aurioles, E; Fernandez-Prior, MA; Bermudez-Oria, A; De La Cruz, JP; Gonzalez- Correa, JA	The Effect of the Extra Virgin Olive Oil Minor Phenolic Compound 3',4'-Dihydroxyphenylglycol in Experimental Diabetic Kidney Disease	NUTRIENTS	5.9	Q1	Article

Scientific production and research activity:

Articles	% Art. Led	% Q 1	IF
4	75%	50%	18.3



Active projects

A-09. Research On Arteriosclerosis, Cardiovascular Prevention, Metabolism, And Neurological Diseases.

LR Pedro Valdivielso Felices. Co-LR Miguel Ángel Sánchez Chaparro. Co-LR. Natalia García Casares

Priority line of research: Diseases of plasma lipoprotein metabolism.

Other lines:

- Rare diseases. PXE, Turner, and familial chylomicronemia syndromes.
- Epidemiology, stratification, and prevention of cardiovascular risk.
- Use of PET/CT imaging, 3T MRI, and ultrasound in the evaluation of atherosclerotic disease.
- Cognitive impairment, Alzheimer's disease, and vascular risk.
- Neurological diseases and vascular risk.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-09	Garcia-Casares, N; Gonzalez-Gonzalez, G; de la Cruz-Cosme, C; Garzon- Maldonado, FJ; de Rojas- Leal, C; Ariza, MJ; Narvaez, M; Barbancho, MA; Garcia- Arnes, JA; Tinahones, FJ	Effects of GLP-1 receptor agonists on neurological complications of diabetes	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	Q1	Article
A-09	Cosin-Sales, J; Ruiz, RC; Diaz, JLD; Cervantes, CE; Olmo, MRF; Gomez-Doblas, JJ; Mostaza, JM; Pedro-Botet, J; Gili, NP; Valdivielso, P	Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain	ATHERO- SCLEROSIS	5.3	Q2	Article
A-09	Casas, BM; Linares, JLC; Aranda, IB; Villodres, JR; Bohorquez, VM; Jimenez, AG; Corral, MAR; Bosch, R; Chaparro, MAS; Fernandez, MG; Valdivielso, P	Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo- Controlled Crossover Trial	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
A-09	Rioja, J; Ariza, MJ; Benitez- Toledo, MJ; Espildora- Hernandez, J; Coca-Prieto, I; Arrobas-Velilla, T; Camacho, A; Olivecrona, G; Sanchez- Chaparro, MA; Valdivielso, P	Role of lipoprotein lipase activity measurement in the diagnosis of familial chylomicronemia syndrome	JOURNAL OF CLINICAL LIP- IDOLOGY	4.4	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-09	Santos-Ortega, Alvaro; Alba-Linero, Carmen; Urbinati, Facundo; Rochade-Lossada, Carlos; Orti, Rafael; Reyes-Bueno, Jose Antonio; Garzon-Maldonado, Francisco Javier; Serrano, Vicente; de Rojas-Leal, Carmen; de la Cruz-Cosme, Carlos; Espana-Contreras, Manuela; Rodriguez-Calvode-Mora, Marina; Garcia-Casares, Natalia	Structural and Functional Retinal Changes in Patients with Mild Cognitive Impairment with and without Diabetes.	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
23	65%	30%	17%	94



Networks:

RICORS-ICTUS, Cerebral Vascular Diseases (ISCIII)

A-10. Epidemiology, Physical Activity, Accelerometry, And Nutrition (Epiphaan).

LR Julia Wärnberg. Co-LR Napoleón Pérez Farinós

Priority line:

Prevention of cardiovascular disease through Mediterranean diet, physical activity, and behavioral therapy (PREDIMED-Plus).

Other lines:

- Objective measurement of physical activity and sleep through accelerometry.
- Health promotion, healthy lifestyle habits. Nutritional epidemiology.
- Childhood obesity and its determinants.
- Epidemiology and prevention of non-communicable diseases.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-10	Gutierrez-Albaladejo, Natalia; Lopez-de-Andres, Ana; Cuadrado-Corrales, Natividad; Albaladejo- Vicente, Romana; Villanueva-Orbaiz, Rosa; Carricondo, Francisco; Romero-Gomez, Barbara; Jimenez-Garcia, Rodrigo; Perez-Farinos, Napoleon	Asthma Is Associated with Back Pain and Migraine- Results of Population-Based Case-Control Study.	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article
A-10	Llamas-Saez, C; Saez- Vaquero, T; Jimenez-Garcia, R; Lopez-de-Andres, A; Carabantes-Alarcon, D; Zamorano-Leon, JJ; Cuadrado-Corrales, N; Perez-Farinos, N; Warnberg, J	Cross Sectional and Case- Control Study to Assess Time Trend, Gender Differences and Factors Associated with Physical Activity among Adults with Diabetes: Analysis of the European Health Interview Surveys for Spain (2014&2020)	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article
A-10	Ruiz-Perez, M; Moragues, A; Segui-Pons, JM; Muncunill, J; Goyanes, AP; Fernandez, AC	Geographical Distribution and Social Justice of the COVID-19 Pandemic: The Case of Palma (Balearic Islands)	GEOHEALTH	4.8	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-10	Llamas-Saez, Carlos; Saez-Vaquero, Teresa; Jimenez-Garcia, Rodrigo; Lopez-de-Andres, Ana; Carabantes-Alarcon, David; Zamorano-Leon, Jose J; Cuadrado-Corrales, Natividad; Omana-Palanco, Ricardo; de Miguel Diez, Javier; Perez-Farinos, Napoleon	Physical activity among adults with chronic obstructive pulmonary disease in Spain (2014-2020): Temporal trends, sex differences, and associated factors.	Respiratory medicine	4.3	Q2	Article
A-10	Jimenez-Cebrian, AM; Lopez-Lopez, L; Losa- Iglesias, ME; Becerro-de- Bengoa-Vallejo, R; Romero- Morales, C; Lopez-Lopez, D; Montiel-Luque, A; Navarro- Flores, E; de Labra, C	The implications of the foot health status in Parkinson patients: A case-control study	INTERNA- TIONAL WOUND JOURNAL	3.1	Q1	Article

Scientific production and research activity:

Articles	% Art. Led	% Q 1	% D1	IF
44	25%	43%	16%	207



Active projects

A-17. Animal Models In Cardiovascular Research. LR Borja Fernández Corujo. Co-LR Ana Carmen Durán Boyero

Priority line of research: Etiology and pathophysiology of bicuspid aortic valve disease and congenital coronary artery anomalies.

Other lines:

- Animal models of atherosclerosis
- Vascular growth: angiogenesis and arteriogenesis.
- Embryonic development of the cardiovascular system.
- Comparative anatomy and evolution of the cardiovascular system.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. type
A-17	Sánchez-Quintero, MJ; Delgado, J; Chaves, LM; Medina-Vera, D; Murri, M; Becerra-Muñoz, VM; Estévez, M; Crespo-Leiro, MG; López, GP; González-Jiménez, A; Ranea, JAG; Queipo-Ortuño, MI; Plaza-Andrades, I; Rodríguez-Capitán, J; Pavón- Morón, FJ; Jiménez-Navarro, MF	Multi-Omics Approach Reveals Prebiotic and Potential Antioxidant Effects of Essential Oils from the Mediterranean Diet on Cardiometabolic Disorder Using Humanized Gnotobiotic Mice.	ANTIOXI- DANTS	7	D1	Article
A-17	Flores-Lopez, M; Garcia- Marchena, N; Pavon-Moron, FJ; Requena-Ocana, N; Sanchez-Marin, L; Martin- Chaves, L; Garcia-Medina, M; Pedraza, C; Castilla-Ortega, E; Ruiz, JJ; de Fonseca, FR; Araos, P; Serrano, A	Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders	TRANSLA- TIONAL PSYCHIATRY	6.8	Q1	Article

Scientific production and research activity:

Articles	% Q1	% D1	IF
2	100%	50%	13.8



A-19. Multidisciplinary Pediatric Research Group LR Isabel Leiva Gea, Co-LR David Moreno Pérez, Co-LR Juan Pedro López

Priority line of research: Microbiota in patients who have undergone an appendectomy, microbiota after ketogenic diet in refractory epilepsy, microbiota in immunodeficiencies, microbiota in critical patients.

Other lines:

- Diabetes and technology.
- Epidemiology in diabetes.
- Growth.
- Obesity.
- Autoimmunity and inflammatory bowel disease.
- Neonatal cystic fibrosis screening.
- Bronchiolitis. Risk factors in the Bayesian model.
- Teleassistance in complex chronic patients.
- Antibiotic resistance.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-19	Siguero, JPL; Ramon-Krauel, M; López, GP; Fernández, MVB; Balut, CA; Fernández- Aranda, F	Attitudes, Behaviors, and Barriers among Adolescents Living with Obesity, Caregivers, and Healthcare Professionals in Spain: ACTION Teens Survey Study	NUTRIENTS	5.9	Q1	Article
A-19	Martín-Masot, R; Herrador- López, M; Navas-López, VM	Dietary Habit Modifications in Paediatric Patients after One Year of Treatment with the Crohn's Disease Exclusion Diet	NUTRIENTS	5.9	Q1	Article
A-19	Martín-Masot, R; Díaz- Martín, JJ; Santamaría- Orleans, A; Navas-López, VM	Spanish Pediatricians' Positions Regarding Prevention, Diagnosis, Nutritional Management, and Challenges in Cow's Milk Protein Allergy	NUTRIENTS	5.9	Q1	Article
A-19	Martín-Masot, R; Jiménez- Muñoz, M; Herrador-López, M; Flor-Alemany, M; Navas- López, VM; Nestares, T	The Importance of an Early Evaluation after Establishing a Gluten-Free Diet in Children with Celiac Disease	NUTRIENTS	5.9	Q1	Article
A-19	Martín-Masot, R; Herrador- López, M; Navas-López, V; Carmona, FD; Nestares, T; Bossini-Castillo, L	Celiac Disease Is a Risk Factor for Mature T and NK Cell Lymphoma: A Mendelian Randomization Study	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article

Scientific production and research activity:

Articles	% Art. Led	% Q 1	% D1	IF
40	48%	55%	13%	180



Networks:

CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence (European Commission).

CA19115 (HyperChildNET) - Network for blood pressure research in children and adolescents (European Commission).

CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections.

CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections.

RICORS PRIMARY CARE INTERVENTIONS TO PREVENT MATERNAL AND CHILD CHRONIC DISEASES OF PERINATAL AND DEVELOPMENTAL ORIGIN, Primary Care, Chronicity, and Health Promotion (ISCIII).

A-21. Research On Organ Protection In The Perioperative Period Of Heart Surgery

LR José Luis Guerrero Orriach. Co-LR José Cruz Mañas

Priority line of research: Cardioprotection with halogenated compounds.

Other lines:

- Organ protection in heart surgery.
- Anesthesia and cancer.
- Opioid-free anesthesia.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-21	Guerrero-Orriach, JL; Carmona-Luque, MD; Raigón-Ponferrada, A	Beneficial Effects of Halogenated Anesthetics in Cardiomyocytes: The Role of Mitochondria	ANTIOXI- DANTS	7	Q1	Review
A-21	Garcia-Anaya, MJ; Segado-Guillot, S; Cabrera-Rodriguez, J; Toledo-Serrano, MD; Medina-Carmona, JA; Gomez-Millan, J	Dose and volume de- escalation of radiotherapy in head and neck cancer	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	6.2	Q1	Review
A-21	Ponferrada, AR; Ruiz, JCM; Molina, SR; Garcia, VR; Orriach, JLG	The Role of Anesthetic Drugs and Statins in Prostate Cancer Recurrence: Starting at the Actual Knowledge and Walking through a New Paradigm	CANCERS	5.2	Q2	Review
A-21	Villaescusa-Catalan, JM; Rodriguez-Capitan, J; Sanz- Sanchez, CI; Sanchez-Espin, G; Guerrero-Orriach, JL; Moron, FJP; Fernandez- Romero, L; Melero-Tejedor, JM; Such-Martinez, M; Porras-Martin, C; Jimenez- Navarro, M	The Prognostic Value of Previous Coronary Stent Implantation in Patients Undergoing Myocardial Revascularization Surgery	CURRENT VASCULAR PHARMACOL- OGY	4.5	Q2	Article
A-21	Carmona-Luque, MD; Gonzalez-Alvarez, L; Orriach, JLG	Identification of miRNAs as Biomarkers of Cardiac Protection in Non-Genetically Modified Primary Human Cardiomyocytes Exposed to Halogenated Hypnotics in an In Vitro Model of Transfection and Ischemia/ Reperfusion: A New Model in Translational Anesthesia	LIFE-BASEL	3.2	Q2	Article

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
7	100%	29%	14%	34



Networks:

CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care.

Competitive HR contracts funded in 2023:

1 contract for the annual reinforcement of the research activity in the SAS clinical units

A-23. Preventive Medicine And Public Health LR. Mario Gutiérrez Bedmar. Co-LR Rosa López Gigosos

Priority line of research: Preventive medicine and public health.

Other lines:

- Epidemiology and prevention of chronic diseases
- Vaccines
- International health
- Emerging diseases
- Nosocomial infection
- Pollution and environmental health
- Occupational health
- Immunosenescence

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-23	Muñoz-Bravo, C; Olmedo, P; Gil, F; Ruiz-Canela, M; Martínez-González, MA; Martínez, MA; Babio, N; Fitó, M; del Val, JL; Corella, D; Sorlí, J; Ros, E; Fiol, M; Estruch, R; Santos-Lozano, JM; Arós, F; Serra-Majem, L; Pintó, X; Gómez-Gracia, E; Gutiérrez-Bedmar, M	Association between serum copper levels and risk of cardiovascular disease: A nested case-control study in the PREDIMED trial	NUTRITION METABOLISM AND CARDIO- VASCULAR DISEASES	3.9	Q2	Article
A-23	López-Gigosos, R; Vegas- Romero, M; Mariscal, A; Mariscal-López, E; Fang, J; Gutiérrez-Bedmar, M	Excess mortality in 22 European countries in 2020 and 2021: relationship with socioeconomic indicators	PERSPEC- TIVES IN PUBLIC HEALTH	5.8	Q1	Article
A-23	Santa-Barbara, RA; Rivera, FG; Lamb, M; Da-Silva, RV; Bedmar, MG	New technologies for the classification of proximal humeral fractures: Comparison between Virtual Reality and 3D printed models-a randomised controlled trial	VIRTUAL REALITY	4.2	Q1	Article
A-23	Crow, EM; Lopez-Gigosos, R; Mariscal-Lopez, E; Agredano-Sanchez, M; Garcia-Casares, N; Mariscal, A; Gutierrez-Bedmar, M	Psychosocial interventions reduce cortisol in breast cancer patients: systematic review and meta-analysis	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Review

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
A-23	Munoz-Bravo, C; Soler- Iborte, E; Lozano-Lorca, M; Kouiti, M; Torres, CGP; Barrios-Rodriguez, R; Jimenez-Moleon, JJ	Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis	FRONTIERS IN CARDIOVAS- CULAR MEDICINE	3.6	Q2	Review

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
31	13%	58%	29%	190



124 RESEARCH AREAS AND GROUPS

Emerging Groups

AE-11. Nephrology And Renal Transplantation LR Verónica López Jiménez. Co-LR Juana Alonso Titos. Co-LR.

Priority line of research: Strategies to reduce the main complications after renal transplantation (cardiovascular, metabolic, and infectious complications) and the evaluation of risk factors and transplant outcomes.

Other lines:

- Cardiovascular disease and LVH in renal patients.
- Post-transplant diabetes and chronic graft dysfunction.
- Immunosuppressive strategies.
- Survival analysis and predictive models of mortality in renal patients.
- Renal senescence and Klotho expression.
- Evaluation, management, and analysis of risk factors for infectious complications in solid organs after transplantation.
- Analysis of new biomarkers of renal function, mainly chemokines in urine.
- Analysis of lymphocyte subpopulations involved in cellular rejection by means of fine-needle aspiration (FNA) biopsy and flow cytometry.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
AE-11	Vazquez-Sanchez, T; Sanchez- Nino, MD; Ruiz-Esteban, P; Lopez, V; Leon, M; Caballero, A; Ruiz-Escalera, JF; Ortiz, A; Torres, A; Rodriguez, M; Hernandez, D	Time-Dependent Changes of Klotho and FGF-23 Levels after Kidney Transplantation: Role of Cold Ischemia Time, Renal Function and Graft Inflammation	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article
AE-11	Hernández, D; Caballero, A	Kidney transplant in the next decade: Strategies, challenges and vision of the future	NEFROLOGIA	2.6	Q3	Review

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
AE-11	Lopez, Veronica; Mazuecos, Auxiliadora; Villanego, Florentino; Lopez-Oliva, Maria; Alonso, Angel; Beneyto, Isabel; Crespo, Marta; Diaz-Corte, Carmen; Franco, Antonio; Gonzalez- Roncero, Francisco; Guirado, Luis; Jimenez, Carlos; Juega, Javier; Llorente, Santiago; Paul, Javier; Rodriguez- Benot, Alberto; Ruiz, Juan Carlos; Sanchez-Fructuoso, Ana; Torregrosa, Vicente; Zarraga, Sofia; Rodrigo, Emilio; Hernandez, Domingo	Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients.	NEFROLOGIA	2.6	Q3	Review
AE-11	Armas-Padron, AM; Sicilia- Sosvilla, M; Ruiz-Esteban, P; Torres, A; Hernandez, D	Association between Cardiovascular Health, C-Reactive Protein, and Comorbidities in Spanish Urban-Dwelling Overweight/ Obese Hypertensive Patients	JOURNAL OF CARDIOVAS- CULAR DE- VELOPMENT AND DISEASE	2.4	Q3	Article
AE-11	Vazquez-Sanchez, Teresa; Lopez, Veronica; Schuldt, Ruben; Bouarich, Oumayma; Arrebola, Alba; Antunez, Paula; Ruiz, Elia; Ortega, Laura; Hernandez, Domingo	Importance of Frailty in Kidney Transplant Recipients.	Transplanta- tion proceedings	0.9	Q4	Article

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
19	53%	21%	5%	70



Active projects



trials

Networks:

RICORS2040 (KIDNEY DISEASE), Inflammation and Immunopathology of Organs and Systems (ISCIII).

Associated Groups

AA-04. Intensive Care Medicine LR María Antonia Estecha Foncea

Lines of research:

- Care circuits and mortality.
- Biotechnology in critically ill patients with multiple organ dysfunction syndrome.
- Critical patient safety.
- Organ and tissue donation.
- Professional and user participation.
- Care circuits and mortality.
- Biotechnology in critically ill patients with multiple organ dysfunction syndrome.
- Critical patient safety.
- Organ and tissue donation.
- Professional and user participation.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
AA-04	Sanchez-Garcia, AM; Martinez- Lopez, P; Gomez-Gonzalez, AM; Rodriguez-Capitan, J; Jimenez- Lopez, RJ; Almeida, JMG; Avanesi- Molina, E; Zamboschi, N; Rueda- Molina, C; Doncel-Abada, V; Molina-Ramos, AI; Cabrera-Cesar, E; Ben-Abdellatif, I; Gordillo- Resina, M; Perez-Mesa, E; Nieto- Gonzalez, M; Nuevo-Ortega, P; Reina-Artacho, C; Fernandez, PLS; Jimenez-Navarro, MF; Estecha- Foncea, MA	Multidisciplinary approach of the sequelae one month after hospital discharge in patients with severe bilateral COVID-19 pneumonia, are there differences depending on the respiratory therapy used during admission to intensive care?	MEDICINA INTENSIVA	3	Q3	Article
AA-04	Simón-Frapolli, VJ; Vegas- Aguilar, IM; Fernández-Jiménez, R; Cornejo-Pareja, IM; Sanchez- García, AM; Martínez-López, P; Nuevo-Ortega, P; Reina- Artacho, C; Estecha-Foncea, MA; Gómez-González, AM; González- Jiménez, MB; Avanesi-Molina, E; Tinahones-Madueño, FJ; García- Almeida, JM	Phase angle and rectus femoris cross-sectional area as predictors of severe malnutrition and their relationship with complications in outpatients with post- critical SARS-CoV2 disease	FRONTIERS IN NUTRITION	5	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
AA-04	Sanchez-Garcia, AM; Martinez- Lopez, P; Gomez-Gonzalez, AM; Rodriguez-Capitan, J; Pavon- Moron, FJ; Jimenez-Lopez, RJ; Garcia-Almeida, JM; Avanesi- Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abad, V; Molina-Ramos, AI; Cabrera- Cesar, E; Ben-Abdellatif, I; Gordillo-Resina, M; Perez-Mesa, E; Nieto-Gonzalez, M; Nuevo- Ortega, P; Reina-Artacho, C; Sanchez-Fernandez, PL; Jimenez- Navarro, MF; Estecha-Foncea, MA	Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia	INTERNA- TIONAL JOURNAL OF MEDICAL SCIENCES	3.6	Q2	Article
AA-04	Ripolles-Melchor, J.; Colomina, M. J.; Aldecoa, C.; Alonso-Cabello, J.; Alonso-Inigo, J. M.; Aya, H.; Basora, M.; Clau-Terre, F.; del Cojo-Peces, E.; Cota-Delgado, F.; Ferrandis-Comes, R.; Galan-Menendez, P.; Garcia-Lopez, D.; Garruti, I.; Lopez, I. J.; Jover-Pinillos, J. L.; Llau-Pitarch, J. V.; Lorente, J. V.; Mesquida, J.; Mojarro, I.; Monge-Garcia, M. I.; Montesinos-Fadrique, S. C.; Munoz-Rodes, J. L.; de Nadal, M.; Ramasco, F.; Tome-Roca, J. L.; Perez, A.; Una-Orejon, R.; Yanes, G.; Zorrilla-Vaca, A.; Escarraman, D.; Garcia-Fernandez, J.	Research priorities in perioperative fluid therapy and hemodynamic monitoring: A Delphi Consensus Survey from the Fluid Therapy and Hemodynamic Monitoring Subcommittee of the Hemostasis, Transfusion Medicine and Fluid Therapy Section (SHTF) of the Spanish Society of Anesthesiology and Critical Care (SEDAR)	REVISTA ESPANOLA DE ANESTESIO- LOGIA Y REANIMACION	1.3	0	Article

Scientific production and research activity:

Articles	% Art. Led	% Q 1	% D1	IF
4	50%	0%		13



AA-15. Heart And Vascular Disease LR Cristobal Urbano Carrillo

Lines of research:

- Cardiovascular epidemiology.
- Heart failure.
- Cardiac interventionism.
- Congenital heart diseases.
- Pre-transplant evaluation of solid organs.
- Heart and kidney failure.
- Systems of processes and organizational methods.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
AA-15	Ballesteros, G; Conejo, L; Zabala, JI	A complex rhythm for a complex congenital heart disease	JOURNAL OF ELECTROCAR- DIOLOGY	1.3	Q4	Article
AA-15	Núñez, FR; Pardeiro, CA; Albert, Bl; Alvarez-Fuente, M; Barreiro, VB; Tejerizo, FB; Betrián-Blasco, P; Sánchez, FC; López, JME; González, LF; Linde, DH; Moreno, MR; Cebada, FS; Sanz-Ruiz, R; Argüelles, JIZ	Dosimetric parameters in congenital cardiac catheterizations in Spain: the GTH-SECPCC Radcong-21 multicenter registry	REC-INTER- VENTIONAL CARDIOLOGY	1.4		Article
AA-15	Ballesteros Tejerizo, F; Coserría Sánchez, F; Freixa, X; Amat-Santos, I; Balbacid D, E; Betrián Blasco, P; Blanco Mata, R; Carrasco, JI; del Cerro Marín, MJ; Flores Fernández, M; Gómez Jaume, A; Insa Albert, B; Navalón Pérez, MJ; Ojeda Pineda, S; Rueda Núñez, F; Sánchez Gila, J; Sanz- Ruiz, R; Zabala Argüelles, JI	Spanish cardiac catheterization in congenital heart diseases registry. Second official report from the ACI-SEC and the GTH- SECPCC (2021)	REC-INTER- VENTIONAL CARDIOLOGY	1.4		Article
AA-15	Rodríguez, DJS; Ciézar, AJP; Román, DG; Carrillo, CAU	The dog, valves' best friend: infective endocarditis due to Capnocytophaga canimorsus-a case report	EUROPEAN HEART JOUR- NAL-CASE REPORTS	1		Article

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
12	33%	33%	17%	49



130 RESEARCH AREAS AND GROUPS 101 Plataforma BIONAND 2023 SCIENTIFIC REPORT 131

AA-20. Research Group On Care In Málaga (Invescuida) LR Cipriano Viñas. Co-LR Antonio Jesús Núñez Montenegro

Priority line of research: Attention to chronicity.

Other lines:

- Care of patients with chronic wounds.
- Complications associated with the use of vascular devices: phlebitis, bacteremia, thrombosis, etc. An innovation project funded in 2018 that began to be implemented in 2019.
- Clinical practice guidelines for pressure ulcers in pediatrics and neonatology.
- Care of ostomies.
- Validation of the "ESCENDE" Tool (Developmentally Sensitive Neonatal Nursing Care Scale) to determine the level of care intensity in a neonatal intensive care unit.
- Prevention of infections in neonatal intensive care units.
- Psychological intervention in palliative care patients.

Research activity

Networks:

CA19133 (FOSTREN) - Fostering and strengthening approaches to reducing coercion in European mental health services (European Commission).

CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims (European Commission).

AA-22. Biopsychosocial Intervention In Complex Processes In Health Systems

LR Eduardo Sánchez Guerrero

Priority line of research: Syndemic constructs for the bio-psycho-social model (MBPS)

Other lines:

- Semiotics, topography, functionality, and nosology (BPS System).
- ICD-11 and ICF ontologies and Dual MBPS Diagnosis.
- MBPS modulation systems.
- Capabilities and potentialities. Determinants of health.
- Cultural and bioactive physiological configurators MBPS.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
AA-22	Pinero-Pinto, E; Romero- Galisteo, RP; Jimenez- Rejano, JJ; Escobio-Prieto, I; Pena-Salinas, M; Luque- Moreno, C; Palomo-Carrion, R	A pilot randomised controlled trial on the effectiveness of infant massage on the acceptance, commitment and awareness of influence in parents of babies with Down syndrome	JOURNAL OF INTELLECTU- AL DISABILITY RESEARCH	3.6	D1	Article
AA-22	Heredia-Callejon, A; Garcia- Perez, P; Armenta-Peinado, JA; Infantes-Rosales, MA; Rodriguez-Martinez, MC	Influence of the Therapeutic Alliance on the Rehabilitation of Stroke: A Systematic Review of Qualitative Studies	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Review
AA-22	Seoane-Martín, ME; Rodríguez-Martínez, MC	Potential Role of Occupational Therapist Intervention in Elementary School for Children with Additional Support Needs: A Systematic Review	CHIDREN- BASEL	2.4	Q2	Review
AA-22	Romero-Galisteo, RP; Valverde-Martinez, MA; Fernandez-Medina, IM; Cortes-Rodriguez, AE; Garcia-Lopez, H; Nunez- Nagy, S	Sexuality in People with Disabilities: A Qualitative Study of Physiotherapists' Perceptions	SEXUALITY RESEARCH AND SOCIAL POLICY	2.6	Q2	Article
AA-22	Romero-Galisteo, RP; Pinero-Pinto, E; Palomo- Carrión, R; Luque-Moreno, C; Molina-Torres, G; González- Sánchez, M	Translation, cross-cultural adaptation and validation of the Rett syndrome motor evaluation scale (RESMES): Spanish version	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY	3.1	Q2	Article

132 RESEARCH AREAS AND GROUPS

Articles % Art. Led % Q1 % D1 IF 16 31% 13% 6% 48



Patents applied for

Networks:

CA18205 - WORCK Worlds of Related Coercions in Work (European Commission)

External Associated Groups

AA-24. Vascular Risk And Chronic Diseases LR: Miguel Ángel García Ordóñez. Co-LR: Jesus Olmedo Llanes

Lines of research:

- Vascular risk factors and cardiovascular disease.
- Type 2 diabetes mellitus.
- Hypertension.
- Dyslipidemia.
- Complex chronic diseases.
- Chronicity and frailty.
- Pluripathological patients.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
AA-24	Sánchez-Yáñez, E; Huertas-Fernández, MJ; Robustillo-Cortes, MD; Ramos-Guerrero, R; Fernández-Espínola, S; Diaz- Acedo, R; Montero-Martin, V; Morillo-Verdugo, R	Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project	REVISTA ESPANOLA DE QUIMIOTER- APIA	1.9	Q4	Article

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
1				1.9



Networks:

CA20104 (PhysAgeNet) - Network on evidence-based physical activity in old age.

Competitive HR contracts funded in 2023:

1 contract for the annual reinforcement of research activity in the clinical units of the SAS.

134 RESEARCH AREAS AND GROUPS

AA-25. Nefroconsultor LR. Consent for publication not granted

Lines of research

- Referral to the nephrology department from non-specialized care.
- Glomerular diseases, renal tubular dysfunction.

Featured publications:

Gı	roup	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
AA	A-25	Visiedo, L; Pérez, R; Rivas- Ruiz, F; Payan, JJ; Rey, L; Tortajada, B; Abilés, J	Hypovitaminosis D and its relationship with nutritional status and quality of life in patients undergoing haemodialysis.	NUTRICION HOSPITALARIA	1.2	Q4	Article

Articles	% Art. Led	% Q 1	% D1	IF
1				1.2

Area 2. Molecular and Translational Biology of Cancer

Consolidated Groups

B-03. Hematology And Hematotherapy LR Antonio Jiménez Velasco

Priority line of research:

Study of genetic/genomic profiles with an influence on the diagnosis, treatment, and survival of adult and pediatric patients with hematologic neoplasms. Individualized treatment and quality of life.

Other lines:

- 1. Transplantation of hematopoietic stem cells in adult and pediatric patients:
- Home-based hematopoietic stem cell transplantation and quality of life.
- Study of variables involved in graft-versus-host disease.
- Study of chimerism in allogeneic hematopoietic stem cell transplantation using new technologies (real-time PCR and digital PCR), prognostic implications, and prediction of relapse.
- 2. CAR-T (Chimeric Antigen Receptor-T) cell therapy: efficacy and quality of life studies.
- 3. Study of rare hematologic-based diseases: diagnosis and individualized treatment.
- 4. Hemostasis and Thrombosis: Clinical and laboratory approach to new therapies for patients with hemophilia. Digital tools for the management and analysis of information in hemophilia. Immune thrombocytopenia. Thrombophilic states of genetic and acquired origin. Thrombosis in oncohematology.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
B-03	Mingot-Castellano, Maria Eva; Canaro Hirnyk, Mariana; Sanchez-Gonzalez, Blanca; Alvarez-Roman, Maria Teresa; Barez-Garcia, Abelardo; Bernardo-Gutierrez, Angel; Bernat-Pablo, Silvia; Bolanos-Calderon, Estefania; Butta-Coll, Nora; Caballero-Navarro, Gonzalo; Caparros-Miranda, Isabel Socorro; Entrena-Urena, Laura; Fernandez-Fuertes, Luis Fernando; Garcia-Frade, Luis Javier; Gomez del Castillo, Maria del Carmen; Gonzalez-Lopez, Tomas Jose; Grande-Garcia, Carlos; Guinea de Castro, Jose Maria; Jarque-Ramos, Isidro; Jimenez-Barcenas, Reyes; Lopez-Ansoar, Elsa; Martinez-Carballeira, Daniel; Martinez-Robles, Violeta; Monteagudo-Montesinos, Emilio; Paramo-Fernandez, Jose Antonio; Perera-alvarez, Maria del Mar; Soto-Ortega, Inmaculada; Valcarcel-Ferreiras, David; Pascual-Izquierdo, Cristina	Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Review

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
B-03	Chumbita, M; Puerta-Alcalde, P; Yáñez, L; Cuesta, MA; Chinea, A; Español- Morales, I; Fernandez-Abellán, P; Gudiol, C; González-Sierra, P; Rojas, R; Sánchez-Pina, JM; Vadillo, IS; Sánchez, M; Varela, R; Vázquez, L; Guerreiro, M; Monzo, P; Lopera, C; Aiello, TF; Peyrony, O; Soriano, A; Garcia-Vidal, C	High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations	MICROBIOL- OGY SPEC- TRUM	3.7	Q2	Article
B-03	Hernández, D; Caballero, A	Kidney transplant in the next decade: Strategies, challenges and vision of the future	NEFROLO- GIA	2.6	Q3	Review
B-03	Lopez-Jaime, FJ; Benitez, O; Jordan, BLD; Montano, A; Coll, J; Paris, LQ; Solano, MDGD	Expert opinion paper on the treatment of hemophilia a with emicizumab	HEMATOL- OGY	1.9	Q4	Article
B-03	Lopez-Jaime, FJ; Fernandez-Bello, I; Calavia-Aranda, E; Reina-Monso, B; Montano, A	Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX-FP): A case report	CLINICAL CASE REPORTS	0.7		Article

Scientific production and research activity:

Articles	% Art. Led	% Q1	% D1	IF
21	29%	38%	14%	104



B-04. Molecular Bases Of Biological Systems (Sibiuma) LR Miguel Ángel Medina Torres

Lines of research:

- Angiogenesis and tumor microenvironment: Identification and characterization of angiogenesis modulators. Metabolism in the tumor microenvironment.
- Metabolism of biogenic amines and polyamines in health and disease.
- Bioinformatics and networks: Interactome, disease network, and drug modeling with predictive methods.
- Bioinformatics workflows for automation of genomic analysis. Analysis of transposon expression in cancer
- Application of lines 1-4 to rare diseases.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
B-04	Marrero, AD; Ortega-Vidal, J; Salido, S; Castilla, L; Vidal, I; Quesada, AR; Altarejos, J; Martinez-Poveda, B; Medina, MA	Anti-angiogenic effects of oleacein and oleocanthal: New bioactivities of compounds from Extra Virgin Olive Oil	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	Article
B-04	Vidal, I; Torres-Vargas, JA; Sanchez, JM; Trigal, M; Garcia-Caballero, M; Medina, MA; Quesada, AR	Danthron, an Anthraquinone Isolated from a Marine Fungus, Is a New Inhibitor of Angiogenesis Exhibiting Interesting Antitumor and Antioxidant Properties	ANTIOXI- DANTS	7	D1	Article
B-04	Marrero, AD; Castilla, L; Bernal, M; Manrique, I; Posligua-Garcia, JD; Moya- Utrera, F; Porras-Alcala, C; Espartero, JL; Sarabia, F; Quesada, AR; Medina, MA; Martinez-Poveda, B	Inhibition of Endothelial Inflammatory Response by HT-C6, a Hydroxytyrosol Alkyl Ether Derivative	ANTIOXI- DANTS	7	D1	Article
B-04	Allali-Boumara, I; Marrero, AD; Quesada, AR; Martinez- Poveda, B; Medina, MA	Pyroptosis Modulators: New Insights of Gasdermins in Health and Disease	ANTIOXI- DANTS	7	D1	Review
B-04	Carrillo, P; Bernal, M; Tellez- Quijona, C; Marrero, AD; Vidal, I; Castilla, L; Caro, C; Dominguez, A; Garcia- Martin, ML; Quesada, AR; Medina, MA; Martinez- Poveda, B	The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	Article

138 RESEARCH AREAS AND GROUPS

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
22	50%	73%	41%	117



Ciber:

CIBERER CB06/07/0046 Rare Diseases (ISCIII)

B-07. Canceromics LR Javier Márquez Gómez

Priority line of research: Functional genomics and cancer proteomics.

Other lines of research:

- Cellular and molecular bases of glutamate synthesis in brain.
- New antitumor strategies and therapies based on glutaminase isoenzymes.
- Transgenic animal models with amino acid metabolism deficits.
- Heterologous expression of recombinant human proteins with therapeutic and biotechnological value.

ibima Plataforma BIONAND 2023 SCIENTIFIC REPORT 139

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
B-07	Cisneros, E; Martinez-Padilla, A; Cardenas, C; Marquez, J; de Mues, AO; Roza, C	Identification of Potential Visceral Pain Biomarkers in Colon Exudates from Mice with Experimental Colitis: An Exploratory In Vitro Study	JOURNAL OF PAIN	4	Q2	Article
B-07	De los Santos-Jimenez, J; Rosales, T; Ko, B; Campos- Sandoval, JA; Alonso, FJ; Marquez, J; DeBerardinis, RJ; Mates, JM	Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines	CANCERS	5.2	Q2	Article
B-07	Infantes-Lopez, MI; Nieto- Quero, A; Chaves-Pena, P; Zambrana-Infantes, E; Cifuentes, M; Marquez, J; Pedraza, C; Perez-Martin, M	New insights into hypothalamic neurogenesis disruption after acute and intense stress: implications for microglia and inflammation	FRONTIERS IN NEURO- SCIENCE	4.3	Q2	Article
B-07	Nieto-Quero, A; Infantes-López, MI; Zambrana-Infantes, E; Chaves-Peña, P; Gavito, AL; Munoz-Martin, J; Tabbai, S; Márquez, J; de Fonseca, FR; García-Fernández, MI; Santín, LJ; Pedraza, C; Pérez-Martin, M	Unveiling the Secrets of the Stressed Hippocampus: Exploring Proteomic Changes and Neurobiology of Posttraumatic Stress Disorder	CELLS	6	Q2	Article

Scientific production and research activity

Articles	% Art. Led	IF	
4	25%	19.5	



140 RESEARCH AREAS AND GROUPS 101 REPORT 141

B-10. Skin Cancer

LR María Victoria de Gálvez Aranda. Co-LR Enrique Herrera Acosta

Priority line of research: Research on the processes involved in the development of skin cancer and other diseases that arise from overexposure to solar radiation and research on prevention through the development of photoprotection tools.

Other lines:

- Studies of the mechanisms involved in the development of skin cancer with a specific search for new prognostic factors as well as a therapeutic approach.
- Research on the effects of biologic therapy on psoriasis and other dermatoses.
- Analysis of the etiopathogenesis of photodermatosis for a comprehensive approach to prevention and treatment measures.
- Research on the mechanisms involved in the generation of photoaging hyperpigmentation and a comprehensive approach to photoprotection strategies to prevent them.
- Measurement of ultraviolet, visible, and IR solar and artificial radiation in order to generate algorithms for solar and artificial exposure that are safe and for preventive purposes.
- Non-intrusive technology-based research on the analysis of sun damage to the skin and topical photoprotection tools.
- Research on new topical photoprotectors based on natural substances.
- Development of solar and artificial radiation measurement tools based on specific sensors and development of new technology for photodiagnosis and phototherapy.
- Development of communication strategies for sun damage prevention.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
B-10	Martín, MD; Aguilar, S; Aguilera-Arjona, J; Rivas- Ruiz, F; Rodríguez-Martínez, A; de Castro-Maqueda, G; Cambil-Martín, J; de Galvez-Aranda, V; Blázquez- Sánchez, N	Risk assessment of occupational skin cancer among outdoor workers in southern Spain: local pilot study	OCCUPATION- AL AND ENVI- RONMENTAL MEDICINE	4.9	Q1	Article
B-10	Ruiz-Villaverde, R; Herrera- Acosta, E; de Casas, AR; Villegas-Romero, IM; Moreno-Suárez, FG; Vílchez- Márquez, F; Galán-Gutiérrez, M; Vázquez-Bayo, MC; Cases-Mérida, S; Almazán- Fernández, FM	Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article
B-10	de Galvez, Maria Victoria; Castillo-Munoz, Rosa Maria; Lopez-Navarro, Norberto; Lopez-Jimenez, Patricio; Navarrete-de Galvez, Enrique; Bosch-Garcia, Ricardo; Herrera-Acosta, Enrique; Aguilera, Jose	Summer and spring elbow rashes is a variant of polymorphous light eruption: confirmation by photoprovocation and histopathology in a series of five cases.	FRONTIERS IN MEDICINE	3.9	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
B-10	Salman Monte, Tarek Carlos; Mateo, Patricia Fanlo; Izquierdo, Maria Galindo; Cervera, Ricard; Lopez, Norberto; Pallares, Lucio; Angel Torres, Maria Jose; Ortega, Silvia Perez	An online survey of the Spanish Lupus Patient Association (FELUPUS): patient perceptions and experiences	CLINICAL RHEUMATOL- OGY	3.4	Q3	Article
B-10	Aguilera, J; Navarrete-de Galvez, E; Sanchez-Roldan, C; Herrera-Ceballos, E; de Galvez, MV	Sun-protective Properties of Technical Sportswear Fabrics 100% Polyester: The Influence of Moisture and Sweat on Protection against Different Biological Effects of Ultraviolet (UV) Radiation	PHOTOCHEM- ISTRY AND PHOTOBIOL- OGY	3.3	Q2	Article
B-10	Galvan-Casas, C; Ortiz- Alvarez, J; Martinez-Garcia, E; Corbacho-Monne, M	Recommendations from the spanish academy of dermatology and venereology (aedv) for the management of sexual transmitted parasitosis, scabies, and pediculosis pubis.	ACTAS DERMO-SIFIL- IOGRAFICAS	3.2	0	Article

Scientific production and research activity:

Articles	% Art. Led	% Q1	IF
9	22%	11%	30



Active projects



Clinical trials



Patents applied for

B-11. Translational Research On Genitourinary Tumors Group LR Bernardo Herrera Imbroda. Co-LR Elisa Matas Rico

Priority line of research: Genetic and molecular epidemiology of genitourinary cancer.

Other lines of research:

- Development of new antineoplastic molecules in genitourinary tumors.
- Oncogenesis and taxonomy of genitourinary tumors.
- Prognostic and predictive biomarkers in genitourinary cancer.
- Advanced therapies in urologic oncology.
- Lysophosphatidic acid and autotaxin-mediated signaling in genitourinary tumors.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
B-11	Pook, D; Geynisman, DM; Carles, J; de Braud, F; Joshua, AM; Pérez- Gracia, JL; Pérez, CL; Shin, SJ; Fang, BN; Barve, M; Maruzzo, M; Bracarda, S; Kim, M; Kerloeguen, Y; Gallo, JD; Maund, SL; Harris, A; Huang, KC; Poon, V; Sutaria, DS; Gurney, H	A Phase Ib, Open- label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer	CLINICAL CANCER RESEARCH	11.5	D1	Article
B-11	Pollock, Y; Smith, MR; Saad, F; Chowdhury, S; Oudard, S; Hadaschik, B; Olmos, D; Lee, JY; Uemura, H; Bhaumik, A; Londhe, A; Rooney, B; Brookman-May, SD; De Porre, P; Mundle, SD; Small, EJ	Clinical characteristics associated with falls in patients with non- metastatic castration- resistant prostate cancer treated with apalutamide	PROSTATE CANCER AND PROSTATIC DISEASES	4.8	Q1	Article
B-11	Lozano, R; Castro, E; -Campos, FL; Thorne, H; Ramirez-Backhaus, M; Aragon, IM; Cendon-Florez, Y; Gutierrez-Pecharroman, A; Salles, DC; Romero-Laorden, N; Lorente, D; Gonzalez-Peramato, P; Calatrava, A; Alonso, C; Anido, U; Arevalo-Lobera, S; Balmana, J; Chirivella, I; Juan-Fita, MJ; Llort, G; Cajal, TRY; Almagro, E; Alameda, D; Lopez-Casas, PP; Herrera, B; Mateo, J; Pritchard, CC; Antonarakis, ES; Lotan, TL; Rubio- Briones, J; Sandhu, S; Olmos, D	Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers	EUROPEAN JOURNAL OF CANCER	8.4	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
B-11	Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; James, ND; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, CJ; Tombal, B; Antonarakis, ES; Aparicio, AM; Armstrong, AJ; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, RG; Bulbul, M; Caffo, O; Castellano, D; Castro, E; Cheng, HH; Chi, KN; Chowdhury, S; Clarke, CS; Clarke, N; Daugaard, G; De Santis, M; Duran, I; Eeles, R; Efstathiou, E; Efstathiou, J; Ekeke, ON; Evans, CP; Fanti, S; FenWg, FY; Fonteyne, V; Fossati, N; Frydenberg, M; George, D; Gleave, M; Gravis, G; Halabi, S; Heinrich, D; Herrmann, K; Higano, C; Hofman, MS; Horvath, LG; Hussain, M; Jereczek-Fossa, BA; Jones, R; Kanesvaran, R; Kellokumpu- Lehtinen, PL; Khauli, RB; Klotz, L; Kramer, G; Leibowitz, R; Logothetis, C; Mahal, B; Maluf, F; Mateo, J; Matheson, D; Mehra, N; Merseburger, A; Morgans, AK; Morris, MJ; Mrabti, H; Mukherji, D; Murphy, DG; Murthy, V; Nguyen, PL; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Pezaro, CJ; Poon, DMC; Pritchard, CC; Rabah, DM; Rathkopf, D; Reiter, RE; Rubin, MA; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Sharifi, N; Skoneczna, I; Soule, H; Spratt, DE; Srinivas, S; Sternberg, CN; Steuber, T; Suzuki, H; Sydes, MR; Taplin, ME; Tilki, D; Turkeri, L; Turco, F; Uemura, H; Uemura, H; Urun, Y; Vale, CL; van Oort, I; Vapiwala, N; Walz, J; Yamoah, K; Ye, DW; Yu, EY; Zapatero, A; Zilli, T; Omlin, A	Management of patients with advanced prostate cancer-metastatic and/or castration- resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022	EUROPEAN JOURNAL OF CANCER	8.4	Q1	Article
B-11	Matsubara, N; de Bono, J; Olmos, D; Procopio, G; Kawakami, S; Urun, Y; van Alphen, R; Flechon, A; Carducci, MA; Choi, YD; Hotte, SJ; Korbenfeld, E; Kramer, G; Agarwal, N; Chi, KN; Dearden, S; Gresty, C; Kang, JY; Poehlein, C; Harrington, EA; Hussain, M	Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA	CLINICAL CANCER RESEARCH	11.5	D1	Article

ibima Plataforma BIONAND 2023 SCIENTIFIC REPORT 145

Scientific production and research activity

Articles	% Q 1	% D1	IF
8	63%	25%	56



Competitive HR contracts funded in 2023:

1 junior clinician from the Spanish Association Against Cancer (AECC) 1 grant from the State Research Agency for hiring for public-private projects.

Emerging Groups

BE-15. Pathological Anatomy LR Luis Vicioso. Co-LR Isabel Hierro. Co-LR Rafael E. Carvia Ponsaillé

Priority line of research: Anatomic pathological factors of prognostic value or that are decisive for the therapeutic approach in oncology.

Other lines:

Anatomic pathological studies of autoimmune, infectious, or inflammatory diseases with prognostic or therapeutic value.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BE-15	Pilo, J; García-Flores, LA; Clemente-Postigo, M; Arranz- Salas, I; Alcaide, J; Ramos- Fernandez, M; Lozano, J; Boughanem, H; Kompella, P; Macías-González, M	8-Oxoguanine DNA Glycosylase 1 Upregulation as a Risk Factor for Obesity and Colorectal Cancer	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
BE-15	Jimenez-Rodriguez, B; Alba- Bernal, A; Lopez-Lopez, E; Quiros-Ortega, ME; Carbajosa, G; Garrido-Aranda, A; Alvarez, M; Godoy-Ortiz, A; Queipo-Ortuno, MI; Vicioso, L; Diaz-Cordoba, G; Roldan- Diaz, MD; Velasco-Suelto, J; Hernando, C; Bermejo, B; Julve-Parreno, A; Lluch, A; Pascual, J; Comino-Mendez, I; Alba, E	Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
BE-15	Kullmann, F; Strissel, PL; Strick, R; Stoehr, R; Eckstein, M; Bertz, S; Wullich, B; Sikic, D; Wach, S; Taubert, H; Olbert, P; Heers, H; Lara, MF; Macias, ML; Matas- Rico, E; Lozano, MJ; Prieto, D; Hierro, I; van Doeveren, T; Bieche, I; Masliah-Planchon, J; Beaurepere, R; Boormans, JL; Allory, Y; Herrera-Imbroda, B; Hartmann, A; Weyerer, V	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort	JOURNAL OF CLINICAL PA- THOLOGY	3.4	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BE-15	de Vera, MTD; Cuadra, JDP; Pinos, DD; Martin, IH	Pleural empyema secondary to perforated diverticulosis due to biliary neoplasia infiltration	BMJ CASE REPORTS	0.9		Article
BE-15	Robles-Mezcua, A; Ruíz- Salas, A; Medina-Palomo, C; Robles-Mezcua, M; Díaz- Expósito, A; Ortega-Jiménez, MV; Gimeno-Blanes, JR; Jiménez-Navarro, MF; García-Pinilla, JM	The Novel Variant NP_00454563.2 (p.Glu259Glyfs*77) in Gene PKP2 Associated with Arrhythmogenic Cardiomyopathy in 8 Families from Malaga, Spain	GENES	3.5	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	IF
6	17%	50%	23.7

BE-17. Clinical, Molecular, And Technological Research On Radiation Oncology

LR Jaime Gómez-Millán Barrachina. Co-LR María Jesús García Anaya

Priority line of research: Prognostic and predictive factors of response to ionizing radiation in upper aerodigestive tract and gynecologic tumors.

Other lines:

- New techniques in cancer treatment with radiotherapy. Etiopathogenesis of mucositis.
- Immunologic factors associated with response in SBRT.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BE-17	Cerezo, MV; Soria-Reyes, LM; Pajares, B; Gomez- Millan, J; Blanca, MJ	Development and psychometric properties of the Stressors in Breast Cancer Scale	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article
BE-17	García-Anaya, MJ; Segado-Guillot, S; Cabrera-Rodríguez, J; Toledo-Serrano, MD; Medina-Carmona, JA; Gómez-Millán, J	Dose and volume de- escalation of radiotherapy in head and neck cancer	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	6.2	Q1	Review
BE-17	Forne, AF; Anaya, MJG; Guillot, SJS; Andrade, IP; Fernandez, LD; Ocon, MJL; Perez, YL; Queipo-Ortuno, MI; Gomez-Millan, J	Influence of the microbiome on radiotherapy-induced oral mucositis and its management: A comprehensive review	ORAL ONCOLOGY	4.8	D1	Review

Articles	% Art. Led	% Q 1	% D1	IF
3	67%	100%	33%	14.8



BE-18. Vascular Biology, Tumor Microenvironment & Target **Discovery**

LR Melissa García Caballero

Priority line of research: Study of the tumor microenvironment, characterization of endothelial reprogramming, identification of new therapeutic targets, and development of new drugs.

Other lines: Study of diseases that depend on deregulated lymph/angiogenesis.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BE-18	Vidal, I; Torres-Vargas, JA; Sanchez, JM; Trigal, M; Garcia-Caballero, M; Medina, MA; Quesada, AR	Danthron, an Anthraquinone Isolated from a Marine Fungus, Is a New Inhibitor of Angiogenesis Exhibiting Interesting Antitumor and Antioxidant Properties	ANTIOXI- DANTS	7	D1	Article
BE-18	Viudez-Pareja, C; Kreft, E; Garcia-Caballero, M	Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment	FRONTIERS IN MEDICINE	7.3	Q1	Review
BE-18	Montenegro-Navarro N., García-Báez C., García- Caballero M.	Molecular and metabolic orchestration of the lymphatic vasculature in physiology and pathology	NATURE COMMUNICA- TIONS	16.6	D1	Review

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
3	67%	100%	67%	31



projects

Competitive HR contracts funded in 2023:

1 pre-doctoral contract from the Spanish Association Against Cancer

BE-19. Radiobiology LR Miguel José Ruiz Gómez

Lines of research:

- Molecular markers of antineoplastic drug resistance, radiation, and cellular aging.
- Effect of electromagnetic fields. Evaluation of cell damage and mechanisms of repair and resistance.
- Molecular radiobiology.
- Study of chronological and replicative cellular aging and its relationship with the effects and molecular mechanisms of resistance to drugs and physical agents.
- Biological and environmental dosimetry.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BE-19	López-Díaz, B; Mercado- Sáenz, S; Burgos-Molina, AM; González-Vidal, A; Sendra-Portero, F; Ruiz- Gómez, MJ	Genomic DNA damage induced by co-exposure to DNA damaging agents and pulsed magnetic field	INTERNA- TIONAL JOURNAL OF RADIATION BIOLOGY	2.6	Q1	Article
BE-19	Gonzalez-Vidal, A; Mercado- Saenz, S; Burgos-Molina, AM; Alamilla-Presuel, JC; Alcaraz, M; Sendra-Portero, F; Ruiz-Gomez, MJ	Molecular Mechanisms of Resistance to Ionizing Radiation in S. cerevisiae and Its Relationship with Aging, Oxidative Stress, and Antioxidant Activity	ANTIOXI- DANTS	7	D1	Article
BE-19	Mercado-Sáenz, S; González-Vidal, A; Burgos- Molina, AM; López-Díaz, B; Sendra-Portero, F; Ruiz- Gómez, MJ	Pulsed magnetic field increases the effect of ultraviolet C radiation and thermal shock in aged yeasts	INTERNA- TIONAL MI- CROBIOLOGY	3.1	Q3	Article
BE-19	Francisco Sendra-Portero, Miguel Souto, Minerva Becker, Vicky Goh	Undergraduate radiology education in Europe in 2022: a survey from the European Society of Radiology (ESR)	INSIGHTS INTO IMAGING	4.7	Q1	Article
BE-19	Adarve Castro A, D. Domínguez Pinosa, V. Soria Utrillac, J.A. O'Farrell del Campob, F. Sendra Portero y M.J. Ruiz-Gómez	Update in imaging tests used for the localization of parathyroid pathology	RADIOLOGÍA	1.3	Q4	Review

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
10	90%	40%	10%	32.5



Active projects

Associated Groups

BA-16. Quality And Safety In Laboratory And Hematology Care LR Adolfo Romero Ruiz

Lines of research:

- Clinical safety.
- Pre-blood test.
- Hematology.
- Clinical analysis.
- Care.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BA-16	Vallejo-Feria, R; Gómez- Salgado, J; Ruiz, AR; Romero-Serrano, R; Cruz- Salgado, O; Guillén-Gestoso, C; García-Iglesias, JJ	Impact of COVID-19 on stress, anxiety and depression in people with Obsessive-Compulsive Disorder: a systematic review	REVISTA ES- PANOLA DE SALUD PUBLI- CA	1.1	Q4	Article
BA-16	Gomez-Ramirez, Susana; Brilli, Elisa; Tarantino, Germano; Girelli, Domenico; Munoz, Manuel	Sucrosomial Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency.	PHARMACEU- TICALS	4.6	Q2	Review

Articles	% Art. Led	% Q1	% D1	IF
2	50%			5.7

LR Ismael Herruzo Cabrera

BA-20. Oncology And Benign Pathology

Lines of research:

- Priority line: Prostate tumors, head and neck tumors, brain tumors, breast tumors, pediatric and adolescent tumors, hyperthermia treatment.
- Other lines: Benign diseases (skin tumors). Rheumatologic diseases. Degenerative diseases (Alzheimer's disease).

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BA-20	Galve-Calvo, E; Alonso- Babarro, A; Martínez-García, M; Pi-Figueras, M; Villalba, G; Alonso, S; Contreras, J	Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients	ADVANCES IN THERAPY	3.8	Q2	Review
BA-20	Muscaritoli, M; Bar-Sela, G; Battisti, NML; Belev, B; Contreras-Martínez, J; Cortesi, E; de Brito-Ashurst, I; Prado, CM; Ravasco, P; Yalcin, S	Oncology-Led Early Identification of Nutritional Risk: A Pragmatic, Evidence- Based Protocol (PRONTO)	CANCERS	5.2	Q2	Article
BA-20	Sosa-Fajardo, P; Blanco- Suarez, JM; Pineda- Munguía, A; Rubí-Olea, L; Peleteiro-Higuero, P; Gajate, P; Zafra-Martín, J; Siva, S; Bossi, A; López-Campos, F; Couñago, F	Stereotactic body radiation therapy for kidney cancer. Where do we stand?	INTERNA- TIONAL JOURNAL OF UROLOGY	2.6	Q3	Review

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D 1	IF
3	33%			11.6



External Associated Groups

BA-14. Translational Research Group On Cancer And Other Prevalent Chronic Diseases LR Maximino Redondo Bautista

Lines of research:

- Evaluation of health services in oncologic diseases.
- Study of inhibitor of apoptosis proteins in cancer.
- Study of biomarkers of immunoediting and response to immunotherapy in cancer and health outcomes attributable to said immunotherapy.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BA-14	Téllez, T; Martin-García, D; Redondo, M; García-Aranda, M	Clusterin Expression in Colorectal Carcinomas	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Review
BA-14	Miret, C; Orive, M; Sala, M; García-Gutiérrez, S; Sarasqueta, C; Legarreta, MJ; Redondo, M; Rivero, A; Castells, X; Quintana, JM; Garin, O; Ferrer, M	Reference values of EORTC QLQ-C30, EORTC QLQ- BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after	QUALITY OF LIFE RE- SEARCH	3.5	Q2	Article
BA-14	Orive, Miren; Barrio, Irantzu; Lazaro, Santiago; Gonzalez, Nerea; Bare, Marisa; de Larrea, Nerea Fernandez; Redondo, Maximino; Cortajarena, Sarai; Bilbao, Amaia; Aguirre, Urko; Sarasqueta, Cristina; Quintana, Jose M	Five-year follow-up mortality prognostic index for colorectal patients.	International journal of colorectal disease	2.8	Q2	Article
BA-14	Garcia-Gutierrez, S; Villanueva, A; Lafuente, I; Rodriguez, I; Lozano- Bahamonde, A; Murga, N; Orus, J; Camacho, ER; Quintana, JM; Quiros, R	Factors related to early readmissions after acute heart failure: a nested casecontrol study	BMC CARDIO- VASCULAR DISORDERS	2.1	Q3	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
BA-14	Quintana, JM; Anton- Ladislao, A; Lázaro, S; Gonzalez, N; Bare, M; de Larrea, NF; Redondo, M; Escobar, A; Sarasqueta, C; Garcia-Gutierrez, S; Aguirre, U; Briones, E	Quality Indicators and Outcomes in a Prospective Cohort of Colorectal Cancer Patients	JOURNAL OF GASTROIN- TESTINAL CANCER	1.6		Article

Scientific production and research activity:

Articles	% Art. Led	% Q 1	% D1	IF
8	38%	13%		27.9



MyWAVE - European network for advancing electromagnetic hyperthermic medical technologies (European

Research Network on Chronicity, Primary Care, and Health Promotion (RICAPPS), RD21-0016-0015.

Area 3. Neurosciences, Chronicity, Aging, and Health in Vulnerable **Populations**

Consolidated Groups

C-01. Neuroimmunology And Neuroinflammation Co-LR Pedro Serrano Castro, Co-LR Guillermo Estivill, Co-LR Laura Leyva

Priority lines of research:

- 1Neuroimmunology of multiple sclerosis.
- Neuroinflammatory basis of epilepsy.

Other lines:

- 1Advanced therapies in neurological diseases.
- Neuromodulation techniques of brain circuits.
- Psychopharmacology applied in experimental models of diseases with a neuroinflammatory component:
- Personalized medicine in neurology and new therapeutic perspectives.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-01	Serrano-Castro, Pedro J; Rodriguez-Uranga, Juan J; Cabezudo-Garcia, Pablo; Garcia- Martin, Guillermina; Romero- Godoy, Jorge; Estivill-Torrus, Guillermo; Ciano-Petersen, Nicolas Lundahl; Oliver, Begona; Ortega-Pinazo, Jesus; Lopez- Moreno, Yolanda; Aguilar-Castillo, Maria J; Gutierrez-Cardo, Antonio L; Ramirez-Garcia, Teresa; Sanchez-Godoy, Lorenzo; Carreno, Mar	Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune- Associated Epilepsy With Anti-Gad65 Antibodies.	Neurology(R) neuroim- munology & neuroinflam- mation	8.8	D1	Article
C-01	Ciano-Petersen, Nicolas Lundahl; Robert, Melisse; Muniz-Castrillo, Sergio; Wucher, Valentin; Klich, Amna; Vogrig, Alberto; Villagran Garcia, Macarena; Farina, Antonio; Goncalves, David; Picard, Geraldine; Rogemond, Veronique; Joubert, Bastien; Oliver-Martos, Begona; Serrano-Castro, Pedro J; Maucort-Boulch, Delphine; Honnorat, Jerome	Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis.	Neurology(R) neuroim- munology & neuroinflam- mation	8.8	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-01	Ciano-Petersen, NL; Aliaga- Gaspar, P; Hurtado-Guerrero, I; Reyes, V; Rodriguez-Bada, JL; Rodriguez-Traver, E; Brichette- Mieg, I; Fernandez, LL; Serrano- Castro, P; Alonso, A; Oliver- Martos, B	Natalizumab- immunogenicity evaluation in patients with infusion related events or disease exacerbations	FRONTIERS IN IMMUNOLOGY	7.3	Q1	Article
C-01	Nieto-Quero, A; Infantes-López, MI; Zambrana-Infantes, E; Chaves-Peña, P; Gavito, AL; Munoz-Martin, J; Tabbai, S; Márquez, J; de Fonseca, FR; García-Fernández, MI; Santín, LJ; Pedraza, C; Pérez-Martin, M	Unveiling the Secrets of the Stressed Hippocampus: Exploring Proteomic Changes and Neurobiology of Posttraumatic Stress Disorder	CELLS	6	Q2	Article
C-01	Manas-Padilla, MC; Melgar- Locatelli, S; Vicente, L; Gil-Rodriguez, S; Rivera, P; Rodriguez-Perez, C; Castilla- Ortega, E	Temozolomide treatment inhibits spontaneous motivation for exploring a complex object in mice: A potential role of adult hippocampal neurogenesis in curiosity	JOURNAL OF COMPARA- TIVE NEUROL- OGY	2.5	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
31	48%	32%	6%	120



Networks:

CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (European Commission).

Competitive HR contracts funded in 2023:

1 contract for the annual reinforcement of the research activity in SAS clinical units 1 contract for renewal of long-term reinforcements (SAS)

C-02. Mental Health, Services, And Primary Care (SAMSERAP). LR Juan Ángel Bellón Saameño. Co-LR Patricia Moreno Peral

Lines of research:


- Develop and validate risk algorithms to predict the onset of common mental illnesses.
- Design, develop, and evaluate innovative programs for the prevention of common mental illnesses.
- Generate evidence on the effectiveness, cost-effectiveness, and acceptance of prevention programs for common mental illnesses.
- Evaluate the implementation of programs for the prevention of common mental illnesses.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-02	Gomez-Gomez, I; Motrico, E; Moreno-Peral, P; Casajuana- Closas, M; Lopez-Jimenez, T; Zabaleta-del-Olmo, E; Claveria, A; LLobera, J; Marti-Lluch, R; Ramos, R; Maderuelo-Fernandez, JA; Vicens, C; Dominguez- Garcia, M; Bartolome- Moreno, C; Recio-Rodriguez, JI; Bellon, JA	A multiple health behaviour change intervention to prevent depression: A randomized controlled trial	GENERAL HOSPITAL PSYCHIATRY	7	Q1	Article
C-02	Moreno-Peral P., Rodríguez- Morejón A., Bellón J.A., García-Huércano C., Martínez-Vispo C., Campos-Paino H., Galán S., Reyes-Martín S., Sánchez Aguadero N., Rangel- Henriques M., Motrico E., Conejo-Cerón S.	Effectiveness of a universal personalized intervention for the prevention of anxiety disorders: Protocol of a randomized controlled trial (the prevANS project)	Internet Interventions	4.3	Q1	Article
C-02	Motrico, E; Bina, R; Kassianos, AP; Le, HN; Mateus, V; Oztekin, D; Rodriguez-Munoz, MF; Moreno-Peral, P; Conejo- Ceron, S	Effectiveness of interventions to prevent perinatal depression: An umbrella review of systematic reviews and meta-analysis	GENERAL HOSPITAL PSYCHIATRY	7	Q1	Review
C-02	Campos-Paino, H; Moreno- Peral, P; Gomez-Gomez, I; Conejo-Ceron, S; Galan, S; Reyes-Martin, S; Bellon, JA	Effectiveness of social support-based interventions in preventing depression in people without clinical depression: A systematic review and meta-analysis of randomized controlled trials	INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY	7.5	Q1	Review

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-02	Nieto-Quero, A; Infantes- López, MI; Zambrana- Infantes, E; Chaves-Peña, P; Gavito, AL; Munoz-Martin, J; Tabbai, S; Márquez, J; de Fonseca, FR; García- Fernández, MI; Santín, LJ; Pedraza, C; Pérez-Martin, M	Unveiling the Secrets of the Stressed Hippocampus: Exploring Proteomic Changes and Neurobiology of Posttraumatic Stress Disorder	CELLS	6	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
10	70%	60%	10%	53



Networks:

CA18138 (Riseup-PPD) - Research Innovation and Sustainable Pan-European Network in Peripartum Depression Disorder (European Commission) RICAPPS, Research Network on Primary Care for Addictions (ISCIII)

Competitive HR contracts funded in 2023:

1 Sara Borrell Contract (ISCIII)

1 pre-doctoral contract for university professor training from the Ministry of Universities.

C-03. Basic, Clinical, And Epidemiological Research On Mental **Health Group**

LR Fermín Mayoral Cleries, Co-LR: Jose Guzman Parra

Priority line of research: Genetic psychiatry: analysis of genetic variables associated with the expression of the bipolar I and II phenotype in a cohort of families with high aggregation.

Other lines of research:

- Biomarkers and new therapeutic targets in general developmental disorders.
- Evaluation and use of new technology for healthy aging.
- Epidemiology and evaluation of mental health outcomes.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-03	Goodman-Casanova, JM; Guzman-Parra, J; Duran- Jimenez, FJ; Garcia-Gallardo, M; Cuesta-Lozano, D; Mayoral-Cleries, F	Effectiveness of museum- based participatory arts in mental health recovery	INTERNA- TIONAL JOUR- NAL OF MEN- TAL HEALTH NURSING	5.6	D1	Article
C-03	Ramos-Martin, J; Perez- Berlanga, JM; Oliver, J; Moreno-Kustner, B	Non-lethal suicidal behavior in university students of Spain during COVID-19	FRONTIERS IN PSYCHIATRY	4.7	Q2	Article
C-03	Ramos-Martin, J; Sanchez- Lafuente, CG; Martinez- Garcia, AI; Castillo-Jimenez, P; Guzman-Parra, J; Moreno- Kustner, B	Suicidal behavior in persons attended in out-of-hospital emergency services in Spain	FRONTIERS IN PSYCHIATRY	4.7	Q2	Article
C-03	Goodman-Casanova, JM; Cuesta-Lozano, D; Alupoaei, C; Bello, EMG; Herrera- Imbroda, J; Mayoral-Cleries, F; Guzman-Parra, J	Psychometric validation of the 15-item Questionnaire about the Process of Recovery in Spain (QPR-15- SP)	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article
C-03	Herrera-Imbroda, J; Guzman-Parra, J; Bordallo- Aragon, A; Moreno-Kustner, B; Mayoral-Cleries, F	Risk of psychiatric readmission in the homeless population: A 10-year follow- up study	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
22	50%	55%	14%	107



Networks:

CA17130 (PSYNET) - Enhancing Psychiatric Genetic Counselling, Testing, and Training in Europe (European Commission).

CA19101 (DE-PASS) - Determinants of Physical Activities in Settings (European Commission).

Competitive HR contracts funded in 2023:

1 Sara Borrell Contract (ISCIII).

1 Juan Rodés Contract (ISCIII).

1 contract for the annual reinforcement of research activity in clinical units of the SAS.

C-05. Degeneration And Regeneration Of The Central Nervous System

LR Antonio J. Jiménez Lara

Lines of research:

- Experimental studies on possible stem cell therapies in the treatment of fetal-neonatal hydrocephalus.
- Long-term conditioning of microglia.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-05	Garcia-Bonilla, M; Ojeda- Perez, B; Shumilov, K; Rodriguez-Perez, LM; Dominguez-Pinos, D; Vitorica, J; Jimenez, S; Ramirez-Lorca, R; Echevarria, M; Cardenas- Garcia, C; Iglesias, T; Gutierrez, A; McAllister, JP; Limbrick, DD; Paez- Gonzalez, P; Jimenez, AJ	Generation of Periventricular Reactive Astrocytes Overexpressing Aquaporin 4 Is Stimulated by Mesenchymal Stem Cell Therapy	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
C-05	López-Villodres, JA; Escamilla, A; Mercado- Sáenz, S; Alba-Tercedor, C; Rodriguez-Perez, LM; Arranz-Salas, I; Sanchez- Varo, R; Bermúdez, D	Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice	BIOMEDI- CINES	4.7	Q1	Review
C-05	Armas-Melián, K; Ros, B; Gómez-Barreno, L; Iglesias, S; Arráez, MA	Neuroendoscopic septostomy in unilateral and bilateral ventricular hydrocephalus	CHILDS NER- VOUS SYSTEM	1.4	Q3	Article
C-05	Portero, FS; Pinos, DD; Bayarri, MS	The current situation of Radiology training in medical studies in Spain	RADIOLOGIA	1.3		Article
C-05	Paez-Gonzalez, P; Lopez- de-San-Sebastian, J; Ceron-Funez, R; Jimenez, AJ; Rodriguez-Perez, LM	Therapeutic strategies to recover ependymal barrier after inflammatory damage: relevance for recovering neurogenesis during development	FRONTIERS IN NEUROSCI- ENCE	4.3	Q2	Review

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
6	33%	33%		18.2



Active projects

C-06. Neuropsychopharmacology LR Fernando Rodríguez de Fonseca. Co-LR: Antonia María Serrano Criado. Co-LR: Juan Suárez Pérez

Priority line of research: Study of the biological basis of the behavior and pathophysiology of highly prevalent degenerative diseases. These include addiction disorders (drug abuse), eating disorders (obesity, diabetes, dyslipidemia), Alzheimer's disease, as well as anxiety and depression syndromes throughout their course and in disease models (psychiatric comorbidity).

Other lines:

- Alcoholic and non-alcoholic steatohepatitis.
- Neuropsychopharmacology of neurodegenerative diseases (ischemia, Parkinson's disease).
- Metabolic programming during development and growth (obesity, diabetes).
- Development of new therapeutic chemical entities or new indications for existing drugs.
- Pharmacological evaluation of food for special medical purposes (FSMPs).

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-06	Flores-Lopez, M; Garcia- Marchena, N; Pavon-Moron, FJ; Requena-Ocana, N; Sanchez-Marin, L; Martin- Chaves, L; Garcia-Medina, M; Pedraza, C; Castilla- Ortega, E; Ruiz, JJ; de Fonseca, FR; Araos, P; Serrano, A	Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders	TRANSLA- TIONAL PSY- CHIATRY	6.8	Q1	Article
C-06	Medina-Vera, D; Zambrana- Infantes, EN; López- Gambero, AJ; Verheul- Campos, J; Santín, LJ; Baixeras, E; Suarez, J; Pavon, FJ; Rosell-Valle, C; Fonseca, FRD	Transcending the amyloid- beta dominance paradigm in Alzheimer's disease: An exploration of behavioural, metabolic, and gut microbiota phenotypes in 5xFAD mice	NEUROBIOL- OGY OF DIS- EASE	6.1	Q1	Article
C-06	Tovar, Ruben; de Ceglia, Marialuisa; Ubaldi, Massimo; Rodriguez-Pozo, Miguel; Soverchia, Laura; Cifani, Carlo; Rojo, Gema; Gavito, Ana; Hernandez-Folgado, Laura; Jagerovic, Nadine; Ciccocioppo, Roberto; Baixeras, Elena; Rodriguez de Fonseca, Fernando; Decara, Juan	Administration of Linoleoylethanolamide Reduced Weight Gain, Dyslipidemia, and Inflammation Associated with High-Fat-Diet-Induced Obesity.	NUTRIENTS	5.9	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-06	Herrera-Imbroda, Jesus; Flores-Lopez, Maria; Requena-Ocana, Nerea; Araos, Pedro; Garcia- Marchena, Nuria; Ropero, Jessica; Bordallo, Antonio; Suarez, Juan; Pavon-Moron, Francisco J; Serrano, Antonia; Mayoral, Fermin; Rodriguez de Fonseca, Fernando	Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients.	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
C-06	Herrera-Imbroda, J; Flores- Lopez, M; Requena-Ocana, N; Araos, P; Ropero, J; Garcia-Marchena, N; Bordallo, A; Suarez, J; Pavon-Moron, FJ; Serrano, A; Mayoral, F; de Fonseca, FR	Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
35	46%	69%	11%	178



Networks:

RIAPAd, Research Network on Primary Care for Addictions, RD21/0009/0003 (ISCIII).

CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infant development.

CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development.

Competitive HR contracts funded in 2023:

1 Río Hortega contract (ISCIII)

1 tenewal of the Nicolás Monardes Program.

C-07. Basic And Applied Aspects Of Neuropsychiatric And Neurodegenerative Diseases LR José Ángel Narváez Bueno

Priority line of research:

Basic biomedical aspects of neurotransmission and regeneration in the central nervous system to aspects applied to clinical care and treatment with approaches to neuropsychiatric and neurodegenerative diseases from different approximations but which converge on the study of basic mechanisms that will allow for the development of new diagnostic and therapeutic tools for the treatment of these diseases.

Other lines:

- Study the role of neuropeptides of the central nervous system (CNS) in key areas for the mediation of behavioral functions associated with anxiety, depression, and fear.
- Analyze the functional interaction of the opioid and dopaminergic systems during opioid dependence in areas related to the learning and consolidation of addictive behavioral habits.
- Delve deeper into the molecular and cellular bases involved (such as oxidative stress) in the genesis of neurodegenerative processes such as aging and Parkinson's disease and study the neuroprotective effects of IGF-II.
- Early diagnosis, monitoring, and intervention in neurodegenerative and neuropsychiatric diseases and through autonomic and cognitive assessment techniques. Basic and applied aspects.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-07	Chao-Ecija, A; Dawid-Milner, M S	BaroWavelet: An R-based tool for dynamic baroreflex evaluation through wavelet analysis techniques.	COMPUTER METHODS AND PRO- GRAMS IN BIOMEDICINE	6.1	Q1	Article
C-07	Diaz-Sanchez, E; Lopez- Salas, A; Mirchandani- Duque, M; Alvarez-Contino, JE; Sanchez-Perez, JA; Fuxe, K; Borroto-Escuela, DO; Garcia-Casares, N; Narvaez, M	Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	Article
C-07	Vazquez-Gonzalez, Noemi; Leiva-Fernandez, Jose; Cotta-Luque, Victor M; Leiva-Fernandez, Francisca; Rius-Diaz, Francisca; Martos-Crespo, Francisco; Martin-Montanez, Elisa; Barnestein-Fonseca, Pilar	Effectiveness of an educational intervention about inhalation technique in healthcare professionals in primary care: a cluster randomized trial.	FRONTIERS IN PHARMACOL- OGY	5.6	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-07	Alvarez-Contino, JE; Diaz- Sanchez, E; Mirchandani- Duque, M; Sanchez-Perez, JA; Barbancho, MA; Lopez- Salas, A; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narvaez, M	GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions	JOURNAL OF CELLULAR PHYSIOLOGY	5.6	Q1	Article
C-07	Gonzalez-Garcia, M; Carrillo-Franco, L; Peinado- Aragones, CA; Diaz-Casares, A; Gago, B; Lopez-Gonzalez, MV; Dawid-Milner, MS	Impact of the glutamatergic neurotransmission within the A5 region on the cardiorespiratory response evoked from the midbrain dlPAG	PFLUGERS ARCHIV-EU- ROPEAN JOURNAL OF PHYSIOLOGY	4.5	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
28	43%	46%	18%	160



Active projects

C-08. Maepap. Multimorbidity, Adherence, Economic Evaluation, And Palliative Care In Primary Care

LR Francisca Leiva Fernández, Co-LR: Antonio García Ruiz

Priority line of research: Research on clinical, educational, and economic aspects of multimorbidity, polymedication and treatment adherence in primary care.

Other lines:

- * Identification of health professionals' educational needs on multimorbidity and polymedication.
- Evaluation of training interventions on multimorbidity, polymedication, and treatment adherence for health professionals.
- Creation and validation of a questionnaire to assess the beliefs of patients with COPD on inhalation therapy.
- Validation of the mental model of disease in patients with COPD in our setting.
- Research on health outcomes (treatment adherence, quality of life, pulmonary function) in patients with COPD.
- Evaluation of the effectiveness of educational interventions in patients with COPD to improve inhaler technique and treatment adherence.
- Educational impact of a journal club on the acquisition of evidence-based medicine and nursing skills.
- Evaluation and improvement of teaching quality in specialized health training.
- Financial assessment of health technology (including drugs).
- Drug management: from efficacy to efficiency to effectiveness.
- Development of the IDC-Pal tool: Diagnostic Instrument of Complexity in Palliative Care (PC), in a comanagement model.
- Development of a multidisciplinary care plan for the last days of life.
- Validation and cultural adaptation of the "Conversation guide for serious illness."
- Research on volunteering in palliative care.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-08	Vazquez-Gonzalez, Noemi; Leiva-Fernandez, Jose; Cotta-Luque, Victor M; Leiva-Fernandez, Francisca; Rius-Diaz, Francisca; Martos-Crespo, Francisco; Martin-Montanez, Elisa; Barnestein-Fonseca, Pilar	Effectiveness of an educational intervention about inhalation technique in healthcare professionals in primary care: a cluster randomized trial.	FRONTIERS IN PHARMACOL- OGY	5.6	Q1	Article
C-08	Martín-Cazorla, F; Ramos- Medina, V; Rubio-Lamia, L; Santos-Amaya, I; Jódar- Sánchez, F	How much does a forensic autopsy cost in Spain?	FORENSIC SCIENCE MEDICINE AND PATHOL- OGY	1.8	Q2	Article
C-08	Barnestein-Fonseca, P; Vibora-Martín, E; Ruiz- Torreras, I; Chapinal-Bascón, H; Martín-Roselló, ML; Gómez-García, R	ITV-Pal programme: protocol of evaluation of the implementation of tech- volunteer programme in palliative care services	BMJ OPEN	2.9	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-08	Munoz, JLG; Soler, NGA; Ruiz, AJG	Study Protocol on Social Return on Investment (SROI) Project of the Surgical Waiting List Management System	HEALTHCARE	2.8	Q2	Article
C-08	Barnestein-Fonseca, P; Cotta-Luque, V; Aguiar- Leiva, V; Leiva-Fernandez, J; Martos-Crespo, F; Leiva- Fernandez, F	The importance of reminders and patient preferences to improve inhaler technique in older adults with COPD	FRONTIERS IN PHARMACOL- OGY	5.6	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	IF
11	82%	27%	36



Networks:

CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence (European Commission).

RICAPPS, Research Network on Primary Care for Addictions (ISCIII).

C-09. Neuropathology Of Alzheimer's Disease (Neuroad) LR Antonia Gutiérrez Pérez

Priority line of research: Neuroinflammation and glial response in Alzheimer's disease.

Other lines:

- Decipher new pathogenic mechanisms involved in Alzheimer's disease that will allow for greater translational success to symptoms in humans. Impact of risk factors. Identification of biomarkers and therapeutic targets.
- Develop new animal models of Alzheimer's disease that better recapitulate human disease. Preclinical studies in in vivo models of new therapeutic strategies and evaluation of drugs.
- Development of in vitro models of Alzheimer's disease using patient-derived iPSCs. Studies of pathogenic mechanisms and evaluation of new drugs in human cellular platforms.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-09	Quan, L; Moreno-Gonzalez, I; Xie, ZG; Gamez, N; Ve- gas-Gomez, L; Song, QY; Gu, JH; Lin, WH; Gomez-Gutier- rez, R; Wu, TF	A near-infrared probe for detecting and interposing amyloid beta oligomeriza- tion in early Alzheimer's disease	ALZHEIMERS & DEMENTIA	14	D1	Article
C-09	Garcia-Bonilla, M; Ojeda-Perez, B; Shumilov, K; Rodriguez-Perez, LM; Dominguez-Pinos, D; Vitorica, J; Jimenez, S; Ramirez-Lorca, R; Echevarria, M; Cardenas-Garcia, C; Iglesias, T; Gutierrez, A; McAllister, JP; Limbrick, DD; Paez-Gonzalez, P; Jimenez, AJ	Generation of Periventricular Reactive Astrocytes Overexpressing Aquaporin 4 Is Stimulated by Mesenchymal Stem Cell Therapy	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
C-09	Lopez-Villodres, JA; Esca- milla, A; Mercado-Saenz, S; Alba-Tercedor, C; Ro- driguez-Perez, LM; Ar- ranz-Salas, I; Sanchez-Varo, R; Bermudez, D	Microbiome Alterations and Alzheimer's Disease: Mod- eling Strategies with Trans- genic Mice	BIOMEDI- CINES	4.7	Q1	Review
C-09	Munoz-Castro, C; Mejias-Ortega, M; Sanchez-Mejias, E; Navarro, V; Trujillo-Estrada, L; Jimenez, S; Garcia-Leon, JA; Fernandez-Valenzuela, JJ; Sanchez-Mico, MV; Rome- ro-Molina, C; Moreno-Gon- zalez, I; Baglietto-Vargas, D; Vizuete, M; Gutierrez, A; Vitorica, J	Monocyte-derived cells invade brain parenchyma and amyloid plaques in human Alzheimer's disease hippocampus	ACTA NEURO- PATHOLOGI- CA COMMUNI- CATIONS	7.1	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-09	Gomez-Gutierrez, R; Ghosh, U; Yau, WM; Gamez, N; Do, K; Kramm, C; Shirani, H; Vegas-Gomez, L; Schulz, J; Moreno-Gonzalez, I; Gutier- rez, A; Nilsson, KPR; Tycko, R; Soto, C; Morales, R	Two structurally defined A & beta; polymorphs pro- mote different pathological changes in susceptible mice	EMBO RE- PORTS	7.7	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D 1	IF
8	13%	63%	13%	51.8



Active projects

Ciber:

CIBERNED Neurodegenerative Diseases CB06/05/1116 (ISCIII)

C-11. Vulnerability And Resilience To Chronic Pain: Implications For Psychological Intervention LR María Carmen Ramírez Maestre

Priority line of research: Coping styles and strategies and vulnerability to pain: individual differences and implications for psychological intervention.

Other lines:

- Variables psicosociales de vulnerabilidad y protección implicadas en el proceso de cronificación del dolor
 / The role of psychosocial variables of vulnerability and protection in pain chronification.
- Patrones de actividad y gestión de metas/ Patterns of activity and goal management strategies.
- Variables predictoras del abuso de opioides y medicación coadyuvante en los pacientes con dolor crónico no oncológico: desarrollo de una escala de detección y clasificación de riesgo / Predictive variables of opioid and coadjuvant drug abuse in patients with chronic non-oncologic pain: Development of an instrument to assess and classify risk of abuse.
- Trastorno de estrés postraumático y dolor crónico como entidades comórbidas: análisis de factores transdiagnósticos / Post-traumatic stress disorder and chronic pain as comorbid entities: Analysis of transdiagnostic factors.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. type
C-11	López-Martínez, AE; Sainero-Tirado, G; Esteve, R; Reyes-Pérez, A; Ruiz- Párraga, GT; de la Vega, R; Serrano-Ibáñez, ER; Ramírez-Maestre, C	Does Pain Catastrophizing and Distress Intolerance Mediate the Relationship Between PTSD and Prescribed Opioid Misuse in People With Chronic Noncancer Pain?	PSYCHOLOG- ICAL TRAU- MA-THEORY RESEARCH PRACTICE AND POLICY	6.3	D1	Article
C-11	Lopez-Martinez, AE; Serrano-Ibanez, ER; Solis-Serrano, L; Ramirez- Maestre, C; Esteve, R	Empathy among health science undergraduates toward the diagnosis of chronic pain: An experimental study	NURSE EDU- CATION TO- DAY	3.9	D1	Article
C-11	de la Vega, R; Serrano- Ibáñez, ER; Ruiz-Párraga, GT; Palermo, TM; Wicksell, R; Fernández-Jiménez, E; Oliva, S; Roldán, S; Monfort, L; Peláez, MJ; Carmona, ML; Ramírez-Maestre, C; López- Martínez, AE; Miró, J; Esteve, R	Protocol for a multi-phase, multi-center, real-world, hybrid effectiveness- implementation study of a digital intervention for pediatric chronic pain co- designed with patients (Digital SPA)	DIGITAL HEALTH	3.9	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. type
C-11	Reyes-Pérez, A; López- Martínez, AE; Esteve, R; Ramírez-Maestre, C	Spanish Validation of the COMM Scale to Assess the Misuse of Prescription Opioids in Patients with Chronic Noncancer Pain	INTERNA- TIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION	8	D1	Article
C-11	Serrano-Ibáñez, ER; de la Vega-castelo, AM; Varela, C; Montero-Matellanes, MM; Gómez-Pulido, A	The Current Mental Health of Healthcare Workers 3 Years After the Start of the Pandemic: The Relationship Between Coping Strategies and Indices of Mental Health	SAGE OPEN	2	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
9	89%	56%	33%	33.9







Clinical trials

C-12. Cognitive Neuroscience: Aphasia And Related Disorders (UNCA)

LR Guadalupe Dávila Arias

Priority line of research: Post-stroke aphasia.

Other lines:

- Validation of diagnostic tests in aphasia and related cognitive and behavioral disorders.
- Design of therapeutic strategies for speech and language disorders.
- Language learning in healthy subjects and individuals with aphasia.
- Echo, imitation, contagion, and repetition and their importance in normal and pathological language.

Featured publications:

	•					
Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-12	Lopez-Barroso, D; Paredes- Pacheco, J; Torres-Prioris, M; Davila, G; Berthier, ML	Brain structural and functional correlates of the heterogenous progression of mixed transcortical aphasia	BRAIN STRUCTURE & FUNCTION	3.1	D1	Article
C-12	Berthier, ML; Edelkraut, L; Lopez-Gonzalez, FJ; Lopez-Barroso, D; Mohr, B; Pulvermuller, F; Starkstein, SE; Jorge, RE; Torres-Prioris, MJ; Davila, G	Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study	BRAIN AND LANGUAGE	2.5	Q1	Article
C-12	Berthier, ML; Davila, G	Pharmacotherapy for post- stroke aphasia: what are the options?	EXPERT OPINION ON PHARMACO- THERAPY	3.2	Q3	Article
C-12	Davila, G; Torres-Prioris, MJ; Lopez-Barroso, D; Berthier, ML	Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System	CNS DRUGS	6	Q1	Review
C-12	Moreno-Torres, I; Lozano, A; Bermúdez, R; Pino, J; Méndez, MDG; Nava, E	Unmasking Nasality to Assess Hypernasality	APPLIED SCIENC- ES-BASEL	2.7	Q2	Article

Articles	% Art. Led	% Q1	% D1	IF
6	83%	67%	33%	38.4





C-13. Chronicity, Dependency, Care, And Health Services LR José Miguel Morales Asencio

Priority line of research: Multidisciplinary models of care and interventions in individuals with chronic diseases and multimorbidity as well as individuals in situations of dependency.

Other lines:

- Health inequalities in the caregivers of individuals with multimorbidity and dependence.
- Clinical safety in individuals with chronic disease, multimorbidity, and dependence.
- Improving the effectiveness of health care for individuals with chronic diseases and their caregivers (methods and instruments for evidence-based healthcare, design and implementation of clinical practice guidelines).

The spectrum ranges from interventions and models of care for people with chronic pain or type II diabetes mellitus, prevention of adverse events in this population, development and analysis of services for individuals with multimorbidity (case management, transitional care, etc.), or the health impact of the role of family caregiver in the medium-and long-term, among other examples.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-13	Reinoso-Cobo, Andres; Ortega-Avila, Ana-Belen; Pineda-Galan, Consolacion; Alabau-Dasi, Raquel; Exposito-Ruiz, Manuela; Banwell, George; Ramos- Petersen, Laura; Gijon- Nogueron, Gabriel	Follow-up of health-related quality of life and pain in a cohort of patients with rheumatoid arthritis before and after COVID-19	FOOT AND ANKLE SUR- GERY	2.5	Q2	Article
C-13	Martinez-Rico, M; Ortega- Avila, AB; Pineda-Galan, C; Gijon-Nogueron, G; Rios, MP; Alabua-Dasi, R; Marchena- Rodriguez, A	Effect of Spatiotemporal Parameters on the Gait of Children Aged from 6 to 12 Years in Podiatric Tests: A Cross Sectional Study	HEALTHCARE	2.8	Q2	Article
C-13	Ortega-Avila, AB; Gijon- Nogueron, G; Cervera-Garvi, P; Guerra-Marmolejo, C; Chicharro-Luna, E; Reinoso-Cobo, A; Marchena- Rodriguez, A	Transcultural adaptation and validation of the Spanish version of the Global Pain Scale	JOURNAL OF ORTHO- PAEDIC RE- SEARCH	2.8	Q2	Article
C-13	Figueredo, MCS; Morilla- Herrera, JC; Uttumchandani, SK; Perez, ED; Giraldos, MS; del Val, MAN; Martin, MJH; Borrego, ABG; Irazusta, MG; Gonzalez, MG; Morales- Asencio, JM	Longitudinal assessment of the eating pattern of people with dementia and its association with problems for feeding and malnutrition: a prospective follow-up study protocol	BMJ OPEN	2.9	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-13	Prieto-Molina, A; Aranda- Gallardo, M; Moya-Suárez, AB; Rivas-Ruiz, F; Peláez- Cherino, J; Canca-Sánchez, JC	Patient transfers from emergency departments to other in-hospital areas: a failure mode and effects analysis	EMERGEN- CIAS	5.5	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
29	34%	21%	3%	81



Networks:

CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims (European Commission).

CA19137 (PARQ): Sudden cardiac arrest prediction and resuscitation network: Improving the quality of care (European Commission).

Competitive HR contracts funded in 2023:

4 contracts for the annual reinforcement of research activity in clinical units of the SAS.

C-16. Maternal-Fetal Medicine, Epigenetics, Women's Health Conditions, And Reproductive Health Research Group LR Ernesto González Mesa. Co-LR Jesús Salvador Jiménez López

Priority line of research: Research in the field of reproductive health.

Other lines:

- Perinatal exposure and psychoevolutionary development.
- Prematurity, prognostic markers of fetal neurodevelopment, mood disorders in the perinatal period, multiple pregnancy, and reproductive pathology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
C-16	Gonzalez-Mesa, E; Rengel- Diaz, C; Riklikiene, O; Thomson, G; Cazorla- Granados, O; Abreu, W; Morgado-Neves, D; Isbir, GG; Jonsdottir, SS; Karlsdottir, SI; Lalor, J	Assessment of the attitude towards childbirth in health sciences students-development and validation of the questionnaire Cave-St	CURRENT PSYCHOLOGY	2.8	Q2	Article
C-16	Díaz-Mohedo, E; Aguirre, IO; García, EM; Infantes- Rosales, MA; Hita- Contreras, F	Functional Exercise Versus Specific Pelvic Floor Exercise: Observational Pilot Study in Female University Students	HEALTHCARE	2.8	Q2	Article
C-16	Díaz-Mohedo, E; González- Roldán, G; Muñoz-Gámez, I; Padilla-Romero, V; Castro- Martín, E; Cabrera-Martos, I; Sánchez-García, C	Implicit Motor Imagery for Chronic Pelvic Pain: A Cross- Sectional Case-Control Study	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article
C-16	Banos Candenas, Laura; Abehsera Davo, Daniel; Castano Frias, Lucia; Gonzalez Mesa, Ernesto	Retrospective Study of First Trimester Metrorrhagia: Pregnancy Follow-Up and Relationship with the Appearance of Gestational Complications.	Medicina (Kaunas, Lith- uania)	2.6	Q2	Article
C-16	Medrano-Sánchez, EM; Pérez-Carricondo, A; Beteta- Romero, P; Díaz-Mohedo, E	Spanish Cross-Cultural Adaptation of the Australian Pelvic Floor Questionnaire	JOURNAL OF PERSONAL- IZED MEDI- CINE	3.4	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D 1	IF
13	46%	15%		43

ibima Plataforma BIONAND 2023 SCIENTIFIC REPORT 177



Networks:

CA18211 (DEVOTION) - Perinatal Mental Health and Birth-Related Trauma: Maximising best practice and optimal outcomes (European Commission).

RICORS PRIMARY CARE INTERVENTIONS TO PREVENT MATERNAL AND CHILD CHRONIC DISEASES OF PERINATAL AND DEVELOPMENTAL ORIGIN (ISCIII).

Emerging Groups

CE-17. Technology And Innovation In Emergency Departments And Hospitalization

LR. Carmen Ortiz García. Co-LR Ángela García de la Torre. Co-LR Begoña Mora Ordoñez

Priority line of research:

Safety and well-being in emergency department and hospitalization patient care.

Other lines:

- Development of shared healthcare scenarios and technical and organizational innovation.
- Detection of vital and social risk or prevention of health problems and their sequelae.
- Participation in the third-sector health system or associations of expatients/users.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CE-17	Maroto-Garcia, J; Martinez-Escribano, A; Delgado-Gil, V; Manez, M; Mugueta, C; Varo, N; de la Torre, AG; Ruiz-Galdon, M	Biochemical biomarkers for multiple sclerosis	CLINICA CHIMICA ACTA	5	Q1	Article
CE-17	Pascual-Izquierdo, Cristina; Pinera Salmeron, Pascual; Temboury Ruiz, Francisco; Valcarcel Ferreiras, David; Jimenez Hernandez, Sonia; Salinas Argente, Ramon; del Arco Galan, Carmen; de la Rubia Comos, Javier	Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments-an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES)	EMERGEN- CIAS	5.5	Q1	Review

Scientific production and research activity

Articles	% Art. Led.	% Q 1	% D1	IF
2	50%	100%	0%	10.5



CE-18. Forensic Medicine, Toxicology, And Forensic Odontology LR. Stella Martín de las Heras

Priority line of research: Gender violence, forensic odontology, mineralized samples subjected to thermal stress, forensic toxicology.

Other lines:

* Forensic genetics, medical ethics, training and education in medicine and health sciences

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CE-18	Zapata-Calvente, AL; Martin-de-las-Heras, S; Cavanillas, AB; Andreasen, K; Rasch, V; Khan, KS	E-health psychological intervention in pregnant women exposed to intimate partner violence (eIPV): A protocol for a pilot randomised controlled trial	PLOS ONE	3.7	Q2	Article
CE-18	Martín-Cazorla, F; Ramos- Medina, V; Rubio-Lamia, L; Santos-Amaya, I; Jódar- Sánchez, F	How much does a forensic autopsy cost in Spain?	FORENSIC SCIENCE MEDICINE AND PATHOL- OGY	1.8	Q2	Article
CE-18	Rubio, L; Suarez, J; Martin- de-las-Heras, S; Zapico, SC	Partners in Postmortem Interval Estimation: X-ray Diffraction and Fourier Transform Spectroscopy	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
CE-18	Andreasen, K; Zapata- Calvente, AL; Martin-de-las- Heras, S; Bueno-Cavanillas, A; Schei, B; Dokkedahl, S; de León, SD; Lopez, RF; Oviedo- Gutiérrez, A; Ankerstjerne, LBS; Megias, JL; Khan, KS; Rasch, V; Linde, DS	Video Consultations and Safety App Targeting Pregnant Women Exposed to Intimate Partner Violence in Denmark and Spain: Nested Cohort Intervention Study (STOP Study)	JMIR FOR- MATIVE RE- SEARCH	2.2	Q3	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
4	50%	25%		13.3

Networks:

CA22106 (MDVI): Migrant Disaster Victim Identification (European Commission).

Associated Groups

CA-10. Causal Cognition Group LR Francisco J. López Gutiérrez

Lines of research:

- Associative learning mechanisms.
- Learning systems involved in the acquisition and extinction of conditioned fear.
- Cerebral bases of the reinforcement learning system.
- Individual differences in reinforcement learning as a marker of vulnerability to anxiety disorders.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CA-10	Cobos, PL; Valle, TM; Quintero, MJ; Lopez, FJ	Individual Differences in Vulnerability Factors for Anxiety Disorders: A Study on the Acquisition, Extinction, and Renewal of Avoidance, and the Concomitant Dynamics of Relief	COLLABRA- PSYCHOLOGY	2.5	Q2	Article
CA-10	Luna, R; Vadillo, MA; Luque, D	Model-free decision making resists improved instructions and is enhanced by stimulus-response associations	CORTEX	3.6	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
2	100%	50%		6.1



External Associated Groups

CA-14. Chronic Diseases And Aging LR José Javier García Alegría

Lines of research:

- Chronic cardiovascular diseases.
- Quality and evaluation of healthcare outcomes in chronic diseases and aging.
- Infectious diseases.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CA-14 EXT	De la Torre-Lima, Javier; Oteo, Jose Antonio; Pinilla, Javier; Mansilla, Rosa; Zamora, Carmen; Ayala Vargas, Victoria; Morillo- Verdugo, Ramon; Moreno, Santiago; Fuster-Ruiz de Apodaca, Maria Jose; Perez- Molina, Jose A; Colom, Joan	Study on the approach to HIV: health management and the healthcare process in Spain.	ENFERME- DADES INFEC- CIOSAS Y MI- CROBIOLOGIA CLINICA	2.5	Q4	Article
CA-14 EXT	Ramos-Rincon, JM; Lopez-Sampalo, A; Cobos-Palacios, L; Ricci, M; Rubio-Rivas, M; Diaz-Simon, R; Martin-Escalante, MD; Castaneda-Perez, S; Fernandez-Madera-Martinez, R; Beato-Perez, JL; Garcia-Garcia, GM; Garcia-Andreu, MD; Arnalich-Fernandez, F; Molinos-Castro, S; Vargas-Nunez, JA; Artero, A; Freire-Castro, SJ; Fernandez-Gomez, J; Cubo-Romano, P; Hernandez-Milian, A; Ines-Revuelta, SM; Boixeda, R; Fernandez-Pedregal, E; Gomez-Huelgas, R	Nosocomial COVID-19: A Nationwide Spanish Study	GERONTOL- OGY	3.5	Q3	Article
CA-14 EXT	Baron, DR; Sanchez, NB; Ruiz, FR; Martinez, AR; Arjona, JA; Maqueda, GD; Araujo, IG; Aranda, MVD; Martinez, AR; Martin, MD	Occupational Sun Exposure Among Physical Education Teachers in Primary and Secondary Schools in Andalusia, Spain	JOURNAL OF CANCER EDU- CATION	1.6	Q3	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CA-14 EXT	Visiedo, Lucia; Perez Abud, Rocio; Rivas-Ruiz, Francisco; Payan, Juan Jesus; Rey, Laura; Tortajada, Begona; Abiles, Jimena	Hypovitaminosis D and its relationship with nutritional status and quality of life in patients undergoing haemodialysis.	NUTRICION HOSPITALAR- IA	1.2	Q4	Article
CA-14 EXT	Diez-Manglano, J; Carretero- Gomez, J; Chimeno-Vinas, M M; Martin-Escalante, M D; Recio-Iglesias, J; Manzano- Espinosa, L; Zapatero- Gaviria, A; Del Prado, N; Elola, J	RECALMIN IV. Evolution in the activity of internal medicine units of the National Health System (2008-2021).	REVISTA CLINICA ES- PANOLA	2.9	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
5				11.7







Clinical trials

CA-15. Palliative Care LR María Luisa Martín Roselló

Lines of research: Clinical, educational, and economic aspects of palliative care.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CA-15 EXT	Barnestein-Fonseca, P; Vibora-Martín, E; Ruiz- Torreras, I; Chapinal-Bascón, H; Martín-Roselló, ML; Gómez-García, R	ITV-Pal programme: protocol of evaluation of the implementation of tech- volunteer programme in palliative care services	BMJ OPEN	2.9	Q2	Article
CA-15 EXT	Barnestein-Fonseca, P; Cotta-Luque, V; Aguiar- Leiva, V; Leiva-Fernández, J; Martos-Crespo, F; Leiva- Fernández, F	The importance of reminders and patient preferences to improve inhaler technique in older adults with COPD	FRONTIERS IN PHARMACOL- OGY	5.6	Q1	Article
CA-15 EXT	Vázquez-González, N; Leiva- Fernández, J; Cotta-Luque, VM; Leiva-Fernández, F; Rius-Díaz, F; Martos-Crespo, F; Martín-Montañez, E; Barnestein-Fonseca, P	Effectiveness of an educational intervention about inhalation technique in healthcare professionals in primary care: a cluster randomized trial.	FRONTIERS IN PHARMACOL- OGY	5.6	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
3	100%	67%		14.1

Networks:

CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence (European Commission).

CA-19. Digcompsalud. Digital Competence For Lifelong Learning LR Antonia Fernandez Luque, Co-LR Fernando Zubeldia Santoyo

Lines of research:

- Artificial intelligence in the study of older adults.
- Dependence and frailty.
- Improvements in health care.

Other lines:

Digital competence, open science, educational technology, digital transformation, curriculum design, lifelong learning, virtual library, school for patients, health technology, open education, digital health.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CA-19	Domínguez-Rodríguez, A; Hernández-Vaquero, D; Suero-Méndez, C; Burillo-Putze, G; Gil, V; Calvo-Rodríguez, R; Piñera- Salmerón, P; Llorens, P; Martín-Sánchez, FJ; Abreu- González, P; Formica, F; Miró, O	Effects of midazolam vs morphine in patients with acute pulmonary edema with left ventricular systolic dysfunction: a secondary analysis of data from the MIMO trial	EMERGEN- CIAS	5.5	Q1	Article
CA-19	Montero-Pérez, FJ; Requena, AMC; del Castillo, JG; Jacob, J; García-Lamberechts, EJ; Salmerón, PP; Alquezar-Arbé, A; Aguiló, S; Alonso, CF; Burillo-Putze, G; Caro, MC; Salado, AID; Mojarro, EM; Eiroa-Hernández, P; Parra-Esquivel, P; Perez, JJL; Grinspan, MR; Quispe, IGO; Tejera, MG; Lázaro, LS; Fernández, BE; Fuentes, L; Méndez, CS; Toro-Gallardo, MDV; Chaib, FB; Ramírez, PP; Miró, O	Impact of the COVID-19 pandemic on demand for emergency department care for older patients: the EDEN- 7 COVID cohort study	EMERGEN- CIAS	5.5	Q1	Article
CA-19	Suero, C; Martín, A; Coll-Vinent, B; González- Torrecilla, E; Ormaetxe, J; Alvarez, M; del Arco, C; Cancio, M; Varona, M; Sánchez, S; Sánchez, J; Fernández-Lozano, I; Arribas, F; Martín-Méndez, M; Peinado, R	Long-term prognosis and emergency management for patients with an implantable cardioverter defibrillator: the EMERGE-ICD study	EMERGEN- CIAS	5.5	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CA-19	Alquézar-Arbé, A; Osorio, GI; Jacob, J; García-Lamberechts, EJ; Salmerón, PP; Llorens, P; Burillo-Putze, G; Requena, AC; Gil, A; Fernández, C; Aguiló, S; Jiménez, S; Blázquez, BE; Mesinoi, DR; Mojarroj, EM; Vaswani-Bulchandk, A; Rodríguez-Cabreral, M; Martínez, PA; Gioya, GD; González, FXA; Tejera, MG; García, MB; Fernández, BE; Llopis, F; Méndez, CS; del Castillo, JG; SIESTA Network	Influence of type of household on prognosis at one year in patients ≥65 years attending hospital emergency departments in Spain. The EDEN-6 study	MATURITAS	4.9	Q1	Article
CA-19	Domínguez-Rodríguez, A; Hernandez-Vaquero, D; Suero-Mendez, C; Burillo-Putze, G; Gil, V; Calvo-Rodriguez, R; Piñera- Salmeron, P; Llorens, P; Martín-Sánchez, FJ; Abreu- Gonzalez, P; Miró, O	Midazolam versus morphine in acute cardiogenic pulmonary edema patients with and without atrial fibrillation: findings from the MIMO trial	EUROPEAN JOURNAL OF EMERGENCY MEDICINE	4.4	Q1	Article

Articles	% Art. Led	% Q 1	% D1	IF
10	10%	60%		45.1



Active projects



Clinical trials

Area 4. Autoimmune Diseases, Infectious Diseases, Inflammation, And Allergies.

Consolidated Groups

D-01. Clinical Research Group On Hiv Infection, Endovascular Infection, And Bacteremia

LR Jesús Santos González. Co-LR Rosario Moreno Palacios

Priority line of research: HIV infection

Other lines of research:

- HIV/HCV infection.
- Other sexually transmitted infections.
- Endovascular infections and bacteremia.
- Osteoarticular infections.
- International health and imported infections.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
D-01	Palacios, R; Gómez-Ayerbe, C; Casado, JL; Tejerina, F; Montes, ML; Castaño, M; Ocampo, A; Rial, D; Ribera, E; Galindo, MJ; Hidalgo, C; Fariñas, C; Montero, M; Payeras, T; Fanjul, F; de la Torre, J; Santos, J	Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119	HIV MEDICINE	3	Q3	Article
D-01	Lopez-Lopez, Pedro; Frias, Mario; Perez-Jimenez, Ana Belen; Freyre-Carrillo, Carolina A.; Pineda, Juan A.; Aguilera, Antonio; Fuentes, Ana; Alados, Juan Carlos; Reina, Gabriel; Ramirez- Arellano, Encarnacion; Viciana, Isabel; Mesquita, Joao; Caballero-Gomez, Javier; Rivero-Juarez, Antonio; Rivero, Antonio	Optimization of the molecular diagnosis of the acute hepatitis E virus infection	MICROBIAL BIOTECHNOL- OGY	5.7	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
D-01	Vizcarra, Pilar; Moreno, Ana; Vivancos, Maria J.; Garcia, Alfonso Muriel; Schacke, Margarita Ramirez; Gonzalez-Garcia, Juan; Curran, Adrian; Palacios, Rosario; Guirao, Antonio Jesus Sanchez; Banuls, Sergio Reus; Guillen, Santiago Moreno; Casado, Jose L.; Spanish HIV Res Network CoRIS	A Risk Assessment Tool for Predicting Fragility Fractures in People with HIV: Derivation and Internal Validation of the FRESIA Model	JOURNAL OF BONE AND MINERAL RESEARCH	6.2	Q1	Article
D-01	Escrihuela-Vidal, F; Berbel, D; Fernandez-Hidalgo, N; Escola-Verge, L; Munoz, P; Olmedo, M; Goenaga, MA; Goikoetxea, J; Farinas, MC; De Alarcon, A; Miro, JM; Ojeda, G; Plata, A; Cuervo, G; Carratala, J; GAMES Investigators	Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci	CLINICAL INFECTIOUS DISEASES	11.8	D1	Article
D-01	Polo, R; García-Albéniz, X; Terán, C; Morales, M; Rial- Crestelo, D; Garcinuño, MA; del Toro, MG; Hita, C; Gómez-Sirvent, JL; Buzón, L; de Santiago, AD; Arellano, JP; Sanz, J; Bachiller, P; Alfaro, EM; Díaz-Brito, V; Masiá, M; Hernández-Torres, A; Guerra, JM; Santos, J; Arazo, P; Muñoz, L; Arribas, JR; de Salazar, PM; Moreno, S; Hernán, MA; Del Amo, J	Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a doubleblind placebo-controlled randomized trial in healthcare workers	CLINICAL MI- CROBIOLOGY AND INFECTION	14.2	D1	Article

Articles	% Art. Led	% Q 1	% D1	IF
9	11%	56%	22%	56.7



D-03. Inflammatory And Autoimmune Diseases LR Antonio Fernández Nebro. Co-LR Natalia Mena Vázquez

Priority line of research: Immunologically mediated inflammatory diseases.

Other lines:

- Microbiota in inflammatory diseases.
- Cardiovascular risk in inflammatory diseases.
- Nursing care in osteoarticular diseases.


Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
D-03	Mena-Vazquez, N; Godoy-Navarrete, FJ; Lisbona-Montanez, JM; Redondo-Rodriguez, R; Manrique-Arija, S; Rioja, J; Mucientes, A; Ruiz-Limon, P; Garcia-Studer, A; Ortiz- Marquez, F; Oliver-Martos, B; Cano-Garcia, L; Fernandez- Nebro, A	Inflammatory Biomarkers in the Diagnosis and Prognosis of Rheumatoid Arthritis- Associated Interstitial Lung Disease	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
D-03	Cano-Garcia, L; Redondo-Rodriguez, R; Manrique-Arija, S; Dominguez-Quesada, C; Vacas, JC; Armenteros-Ortiz, P; Ruiz-Vilchez, D; Martin-Martin, JM; Garcia-Studer, A; Ortiz-Marquez, F; Mena-Vazquez, N; Fernandez-Nebro, A	Prevalence of Malnutrition and Associated Factors in Older Patients with Rheumatoid Arthritis: A Cross-Sectional Study	NUTRIENTS	5.9	Q1	Article
D-03	Cano-Garcia, L; Manrique- Arija, S; Dominguez- Quesada, C; Vacas-Perez, JC; Armenteros-Ortiz, PJ; Ruiz-Vilchez, D; Martfi- Martiin, JM; Redondo- Rodriguez, R; Garcia-Studer, A; Ortiz-Marquez, F; Mena- Vazquez, N; Fernandez- Nebro, A	Sarcopenia and Nutrition in Elderly Rheumatoid Arthritis Patients: A Cross-Sectional Study to Determine Prevalence and Risk Factors	NUTRIENTS	5.9	Q1	Article
D-03	Mena-Vazquez, N; Ruiz- Limon, P; Moreno-Indias, I; Manrique-Arija, S; Lisbona- Montanez, JM; Rioja, J; Mucientes, A; Martin- Nunez, GM; Cano-Garcia, L; Tinahones, FJ; Fernandez- Nebro, A	Adiposity is associated with expansion of the genus Dialister in rheumatoid arthritis patients	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
D-03	Mena-Vazquez, N; Rojas-Gimenez, M; Romero-Barco, CM; Gandia-Martinez, M; Perez-Gomez, N; Godoy-Navarrete, FJ; Manrique-Arija, S; Garcia-Studer, A; Calvo-Gutierrez, J; Varela, CF; Morales-Garrido, P; Perez, PC; Mourino-Rodriguez, C; Anon-Onate, I; Espildora, F; Aguilar-Hurtado, MC; Redondo, R; Conde, AH; de los Rios, RAD; Cesar, EC; Velloso-Feijoo, ML; Fernandez-Nebro, A	Analysis of comorbidity in rheumatoid arthritis-associated interstitial lung disease: a nested casecohort study	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
19	37%	42%	16%	94.6



Networks:

RICORS INFLAMMATORY DISEASES, RD21-0002-0037 (ISCIII)

Competitive HR contracts funded in 2023:

1 PFIS contract (ISCIII).

1 contract for the intensification of research activity in the SNS (ISCIII).

1 contract for intensification of research activity from the Spanish Society of Rheumatology.

1 contract for the annual reinforcement of research activity in clinical units of the SAS.

D-04. Allergic Diseases To Drugs And Allergens LR María José Torres Jaén, Co-LR: Lina Mayorga Mayorga

Priority line of research: Study of allergic reactions.

Other lines:

- Study of the mechanisms involved and improvement in the diagnosis and treatment of allergic reactions to drugs.
- Study of the mechanisms involved and improvement in the diagnosis and treatment of allergic reactions to food
- Study of the mechanisms involved and improvement in the diagnosis and treatment of allergic respiratory diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
D-04	Paris, JL; Monio, C; Perez- Moreno, AM; Jurado- Escobar, R; Bogas, G; Fernandez, TD; Montanez, MI; Mayorga, C; Torres, MJ	Influence of Pore Size in Protein G'-Grafted Mesoporous Silica Nanoparticles as a Serum Pretreatment System for In Vitro Allergy Diagnosis	ADVANCED HEALTHCARE MATERIALS	10	D1	Article
D-04	Céspedes J.A., Fernández- Santamaría R., Ariza A., Bogas G., Doña I., Rondón C., Salas M., Labella M., Frecha C., Mayorga C., Torres M.J., Fernández T.D.	Diagnosis of immediate reactions to amoxicillin: Comparison of basophil activation markers CD63 and CD203c in a prospective study	ALLERGY	12.4	D1	Article
D-04	Dona, I; Guidolin, L; Bogas, G; Olivieri, E; Labella, M; Schiappoli, M; Maria, RSD; Dama, A; Salas, M; Senna, G; Bonadonna, P; Torres, MJ	Resensitization in suspected penicillin allergy	ALLERGY	12.4	D1	Article
D-04	Cho, SH; Nanda, A; Keswani, A; Adinoff, A; Baroody, FM; Bernstein, JA; Gherasim, A; Han, JK; Koepke, JW; Ledford, DK; Pepper, AN; Rondon, C; Schiffman, A; Wagenmann, M; Campo, P	Nasal allergen challenge (NAC): Practical aspects and applications from an EU/US perspective-a Work Group Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	14.2	D1	Article
D-04	Paris, JL; Gaspar, R; Coelho, F; De Beule, PAA; Silva, BFB	Stability Criterion for the Assembly of Core-Shell Lipid-Polymer-Nucleic Acid Nanoparticles	ACS NANO	17.1	D1	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
25	52%	80%	68%	228



Networks:

CA17136 (INDAIRPOLLET) - Indoor Air Pollution Network (European Commission).

CA18226 (ADOPT)- New approaches for the detection of pathogens and aeroallergens (European Commission).

CA18227 (COMFA) - The Core Outcome Measures for Food Allergy (European Commission).

RICORS INFLAMMATORY DISEASES RD21/0002/0008 (ISCIII).

Competitive HR contracts funded in 2023:

- 1 MARIE SKLODOWSKA-CURIE Contract: POSTDOCTORAL FELLOWSHIPS EUROPEAN FELLOWSHIPS 2022 (European Commission).
- 1 pre-doctoral contract for doctoral training (AEI).
- 2 contracts to promote RESEARCH CONSOLIDATION (AEI).
- 1 PFIS contract (ISCIII)
- 3 Río Hortega contracts (ISCIII)
- 1 Juan Rodés contract (ISCIII)
- 1 contract for the annual reinforcement of the research activity in SAS clinical units
- 1 contract for the renewal of clinical-research professionals (SAS)
- 1 contract for renewal of long-term reinforcements (SAS)

D-05. Hepatogastroenterology, Pharmacology, And Translational Clinical Therapeutics

LR Raúl J. Andrade Bellido, Co-LR Maribel Lucena, Co-LR Mercedes Robles Díaz

Lines of research:

- Epidemiological research, causality, and genetic factors and identification of biomarkers in hepatotoxicity.
- Etiopathogenesis and new treatments in inflammatory bowel disease.
- Etiopathogenesis, clinical course, and noninvasive diagnosis in nonalcoholic fatty liver disease.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
D-05	Martín-Reyes F., Bernal M., Rodríguez-Díaz C., Rodríguez-de los Reyes D., Ho-Plagaro A., Rodríguez- Pacheco F., Camacho- Martel L., Camargo-Camero R., Rodríguez-González F.J., Alcain-Martínez G., Martín- Masot R., Navas-López V.M., Villanueva-Paz M., Lucena M.I., García-Fuentes E., López-Gómez C.	Mitochondrial Stress Links Environmental Triggers with Pro-Inflammatory Signaling in Crohn's Disease	ANTIOXI- DANTS	7	D1	Article
D-05	Niu, H; Ma, JY; Medina-Caliz, I; Robles-Diaz, M; Bonilla- Toyos, E; Ghabril, M; Lucena, MI; Alvarez-Alvarez, I; Andrade, RJ	Potential benefit and lack of serious risk from corticosteroids in druginduced liver injury: An international, multicentre, propensity score-matched analysis	ALIMENTARY PHARMACOL- OGY & THER- APEUTICS	7.6	D1	Article
D-05	Martin-Reyes, F; Ho- Plagaro, A; Rodriguez-Diaz, C; Lopez-Gomez, C; Garcia- Serrano, S; de los Reyes, DR; Gonzalo, M; Fernandez- Garcia, JC; Montiel-Casado, C; Fernandez-Aguilar, JL; Fernandez, JR; Garcia- Fuentes, E; Rodriguez- Pacheco, F	Oleic acid regulates the circadian rhythm of adipose tissue in obesity	PHARMACO- LOGICAL RE- SEARCH	9.3	D1	Article
D-05	Fontana, RJ; Bjornsson, ES; Reddy, R; Andrade, RJ	The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury	CLINICAL GASTROEN- TEROLOGY AND HEPA- TOLOGY	12.6	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
D-05	Andrade, RJ; Aithal, GP; de Boer, YS; Liberal, R; Gerbes, A; Regev, A; Beretta-Piccoli, BT; Schramm, C; Kleiner, DE; De Martin, E; Kullak-Ublick, GA; Stirnimann, G; Devarbhavi, H; Vierling, JM; Manns, MP; Sebode, M; Londoño, MC; Avigan, M; Robles-Diaz, M; García-Cortes, M; Atallah, E; Heneghan, M; Chalasani, N; Trivedi, PJ; Hayashi, PH; Taubert, R; Fontana, RJ; Weber, S; Oo, YH; Zen, Y; Licata, A; Lucena, MI; Mieli-Vergani, G; Vergani, D; Björnsson, ES	Nomenclature, diagnosis and management of drug- induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report	JOURNAL OF HEPATOLOGY	25.7	D1	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
30	57%	70%	37%	245







Clinical trials



Patents applied for

Networks and Ciber:

CA17112 - PRO-EURO-DILI NET - PROSPECTIVE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK (European Commission).

CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities.

CIBEREHD CB07/04/2008 Liver and Digestive Diseases (ISCIII).

Competitive HR contracts funded in 2023:

- 1 i-PFIS contract (ISCIII).
- 2 Río Hortega contracts (ISCIII).
- 1 Sara Borrell contract (ISCIII).
- 1 Miguel Servet contract (ISCIII).
- 1 pre-doctoral contract for the training of doctors from the State Research Agency.
- 1 contract for the annual reinforcement of research activity in the clinical units of the SAS.
- 1 intensification grant for researchers of the Spanish Foundation for the Study of the Liver.

Emerging Groups

DE-02. Group For The Study Of Infectious Diseases LR José María Reguera

Priority line of research: HIV infection

Other lines:

- Endovascular infection.
- Multidrug-resistant bacteria.
- Identification of NTM by means of MALDITOF.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DE-02	Benavent, E; Kortajarena, X; Sobrino-Diaz, B; Gasch, O; Rodríguez-Pardo, D; Escudero-Sanchez, R; Bahamonde, A; Rodriguez- Montserrat, D; García-País, MJ; López, MDD; Sorli, L; Nodar, A; Vilchez, HH; Muñez, E; Iribarren, JA; Ariza, J; Murillo, O	Vertebral osteomyelitis after spine instrumentation surgery: risk factors and management	JOURNAL OF HOSPITAL INFECTION	6.9	Q1	Article
DE-02	Hidalgo-Tenorio, C; Sadyrbaeva-Dolgova, S; Enríquez-Gómez, A; Muñoz, P; Plata-Ciezar, A; Miró, JM; Alarcón, A; Martínez- Marcos, FJ; Loeches, B; Escrihuela-Vidal, F; Vinuesa, D; Herrero, C; Boix-Palop, L; Arenas, MD; Vázquez, EG; de las Revillas, FA	EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Grampositive cocci	INTERNA- TIONAL JOUR- NAL OF AN- TIMICROBIAL AGENTS	10.8	D1	Article
DE-02	Escrihuela-Vidal, F; Berbel, D; Fernandez-Hidalgo, N; Escola-Verge, L; Munoz, P; Olmedo, M; Goenaga, MA; Goikoetxea, J; Farinas, MC; De Alarcon, A; Miro, JM; Ojeda, G; Plata, A; Cuervo, G; Carratala, J; GAMES Investigators	Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci	CLINICAL INFECTIOUS DISEASES	11.8	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DE-02	Polo, R; García-Albéniz, X; Terán, C; Morales, M; Rial- Crestelo, D; Garcinuño, MA; del Toro, MG; Hita, C; Gómez-Sirvent, JL; Buzón, L; de Santiago, AD; Arellano, JP; Sanz, J; Bachiller, P; Alfaro, EM; Díaz-Brito, V; Masiá, M; Hernández-Torres, A; Guerra, JM; Santos, J; Arazo, P; Muñoz, L; Arribas, JR; de Salazar, PM; Moreno, S; Hernán, MA; Del Amo, J	Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a doubleblind placebo-controlled randomized trial in healthcare workers	CLINICAL MI- CROBIOLOGY AND INFEC- TION	14.2	D1	Article
DE-02	Perez-Galera, S; Bravo-Ferrer, JM; Paniagua, M; Kostyanev, T; de Kraker, MEA; Feifel, J; Sojo-Dorado, J; Schotsman, J; Canton, R; Daikos, GL; Carevic, B; Dragovac, G; Tan, LK; Raka, L; Hristea, A; Viale, P; Akova, M; Reguera, JM; de Santis, LV; Torre-Cisneros, J; Cano, A; Roilides, E; Radulovic, L; Kirakli, C; Shaw, E; Falagas, ME; Pintado, V; Goossens, H; Bonten, MJ; Gutierrez-Gutierrez, B; Rodriguez-Bano, J	Risk factors for infections caused by carbapenem- resistant Enterobacterales: an international matched case-control-control study (EURECA)	ECLINI- CALMEDICINE	15.1	D1	Article

Articles	% Q 1	% D1	IF
13	54%	31%	88



Active projects



Clinical trials

DE-07. Inflammation In Critically Ill PatientsLR Manuel Enrique Herrera Gutierrez. Co-LR Emilio Curiel Balsera

Priority line of research: Study of the inflammatory response and treatment measures.

Other lines: Inflammatory response in different scenarios: Extracorporeal surgery, acute kidney disease, acute liver disease. Extracorporeal organ support. Ischemic heart disease. Ischemic/hemorrhagic brain disease.

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DE-07	González-Fernández, M; Quilez-Trasobares, N; Barea- Mendoza, JA; Molina-Collado, Z; Arias-Verdu, D; Barrueco- Francioni, J; Seller-Pérez, G; Herrera-Gutiérrez, ME; Riera, JASI	Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient	SCIENTIFIC REPORTS	4.6	Q2	Article
DE-07	Lopez-Delgado, JC; Servia-Goixart, L; Grau-Carmona, T; Bordeje-Laguna, L; Portugal-Rodriguez, E; Lorencio-Cardenas, C; Vera-Artazcoz, P; Macaya-Redin, L; Martinez-Carmona, JF; Corral, JM; Flordelís-Lasierra, JL; Seron-Arbeloa, C; Alcazar-Espin, MD; Navas-Moya, E; Aldunate-Calvo, S; Martino, BN; de Lagran, IM	Factors associated with the need of parenteral nutrition in critically ill patients after the initiation of enteral nutrition therapy	FRONTIERS IN NUTRITION	5	Q2	Article
DE-07	Lopez-Delgado, JC; Grau-Carmona, T; Mor-Marco, E; Bordeje-Laguna, ML; Portugal-Rodriguez, E; Lorencio-Cardenas, C; Vera-Artazcoz, P; Macaya-Redin, L; Llorente-Ruiz, B; Iglesias-Rodriguez, R; Monge-Donaire, D; Martinez-Carmona, JF; Sanchez-Ales, L; Sanchez-Miralles, A; Crespo-Gomez, M; Leon-Cinto, C; Flordelis-Lasierra, JL; Servia-Goixart, L	Parenteral Nutrition: Current Use, Complications, and Nutrition Delivery in Critically Ill Patients	NUTRIENTS	5.9	Q1	Article

Articles	% Art. Led	% Q 1	% D 1	IF
3	33%	33%		15.5



Active projects



Clinical trials

DE-08. Hepatogastroenterology, Endoscopy, And Gastrointestinal Surgery

LR Miguel Jiménez Pérez. Co-LR Julio Santoyo Santoyo

Priority line of research: Liver diseases: viral, metabolic, and toxic. Liver transplantation. Gastrointestinal oncology.

Other lines: Inflammatory bowel disease. Digestive endoscopy.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DE-08	Gonzalez Grande, Rocio; Bravo Aranda, Ana; Santaella Leiva, Inmaculada; Lopez Ortega, Susana; Jimenez Perez, Miguel	Acute liver failure secondary to malignant infiltration: A single center experience.	SEMINARS IN ONCOLOGY	4	Q2	Review
DE-08	Fundora, Y; Hessheimer, AJ; Del Prete, L; Maroni, L; Lanari, J; Barrios, O; Clarysse, M; Gastaca, M; Gómez, MB; Bonadona, A; Janek, J; Boscà, A; Martínez, JMA; Zozaya, G; Garnica, DL; Magistri, P; León, F; Magini, G; Patrono, D; Nicovsky, J; Hakeem, AR; Nadalin, S; McCormack, L; Palacios, P; Zieniewicz, K; Blanco, G; Nuño, J; Saborido, BP; Echeverri, J; Bynon, JS; Martins, PN; López, VL; Dayangac, M; Lodge, JPA; Romagnoli, R; Toso, C; Santoyo, J; Di Benedetto, F; Gómez-Gavara, C; Rotellar, F; Gómez-Bravo, MA; Andújar, RL; Girard, E; Valdivieso, A; Pirenne, J; Lladó, L; Germani, G; Cescon, M; Hashimoto, K; Quintini, C; Cillo, U; Polak, WG; Fondevila, C	Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis	JOURNAL OF HEPATOLOGY	25.7	D1	Article
DE-08	Bazaga, S; García-Alonso, FJ; Tormo, JRA; Moreno, BM; Sanchiz, V; Suria, C; Garcia-Sumalla, A; Gornals, JB; Chavarria, C; Loras, C; García-Fernandez, FJ; Terán, A; Vazquez-Sequeiros, E; Sanz, RP; Pérez-Carazo, L; Súbtil, JC; Pérez-Millan, A; Porta, FU; Bea, VB; de la Serna-Higuera, C; Garcia, IP; Colán-Hernández, J; Huertas, C; Guarner-Argente, C; Perez-Miranda, M	Endoscopic removal of lumenapposing metal stents-risk factors for stent embedment, complex removals, and adverse events: analysis from a multicenter prospective case series	ENDOSCOPY	9.3	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DE-08	Martín-Reyes, F; Ho-Plagaro, A; Rodríguez-Díaz, C; Lopez-Gómez, C; Garcia-Serrano, S; de los Reyes, DR; Gonzalo, M; Fernández-Garcia, JC; Montiel-Casado, C; Fernández-Aguilar, JL; Fernández, JR; García-Fuentes, E; Rodríguez-Pacheco, F	Oleic acid regulates the circadian rhythm of adipose tissue in obesity	PHARMACO- LOGICAL RE- SEARCH	9.3	D1	Article
DE-08	Mela, V; Agüera, Z; Alvarez-Bermudez, MD; Martín-Reyes, F; Granero, R; Sanchez-García, A; Oliva-Olivera, W; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sánchez-Gallegos, P; Martínez-Moreno, JM; Sancho-Marín, R; Fernández-Aranda, F; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	The Relationship between Depressive Symptoms, Quality of Life and miRNAs 8 Years after Bariatric Surgery	NUTRIENTS	5.9	Q1	Article

Articles	% Art. Led	% Q1	% D1	IF
12	58%	33%	25%	66.6



DE-09. Immune Response To Viral Infections. LR Juan José Borrego García. Co-LR José Manuel Jiménez Guardeño

Priority line of research: Study of the immune response to viral infections and the mechanisms of viral immunopathology.

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DE-09	Burnap, SA; Ortega-Prieto, AM; Jimenez-Guardeño, JM; Ali, H; Takov, K; Fish, M; Shankar-Hari, M; Giacca, M; Malim, MH; Mayr, M	Cross-Linking Mass Spectrometry Uncovers Interactions Between High- Density Lipoproteins and the SARS-CoV-2 Spike Glycoprotein	MOLECULAR & CELLULAR PROTEOMICS	7	D1	Article
DE-09	Leiva-Rebollo, R; Gemez- Mata, J; Castro, D; Borrego, JJ; Labella, AM	Immune response of DNA vaccinated-gilthead seabream (Sparus aurata) against LCDV-Sa infection: relevance of the inflammatory process	FRONTIERS IN IMMUNOLOGY	7.3	Q1	Article
DE-09	López-Vázquez, C; Souto, S; Olveira, JG; Riaza, A; González, O; Brea, C; Labella, AM; Castro, D; Bandín, I	Nervous Necrosis Virus (NNV) Booster Vaccination Increases Senegalese Sole Survival and Enhances Immunoprotection	ANIMALS	3	D1	Article
DE-09	Pallett, LJ; Swadling, L; Diniz, M; Maini, AA; Schwabenland, M; Gasull, AD; Davies, J; Kucykowicz, S; Skelton, JK; Thomas, N; Schmidt, NM; Amin, OE; Gill, US; Stegmann, KA; Burton, AR; Stephenson, E; Reynolds, G; Whelan, M; Sanchez, J; de Maeyer, R; Thakker, C; Suveizdyte, K; Uddin, I; Ortega-Prieto, AM; Grant, C; Froghi, F; Fusai, G; Lens, S; Perez-del-Pulgar, S; Al-Akkad, W; Mazza, G; Noursadeghi, M; Akbar, A; Kennedy, PTF; Davidson, BR; Prinz, M; Chain, BM; Haniffa, M; Gilroy, DW; Dorner, M; Bengsch, B; Schurich, A; Maini, MK	Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS	NATURE	64.8	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DE-09	De Tena, PB; Paniagua, STT; Sevilla, JAV; Clavijo, E; Manzanares, EM; Gonzalez- Domenech, CM; Azzaroli, F	Unusual Surge of Acute Hepatitis A Cases in 2016 and 2017 in Malaga, Southern Spain: Characterization and Relationship with Other Concurrent European Outbreaks	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article

Articles	% Art. Led	% Q 1	% D1	IF
7	29%	57%	43%	91



Active projects

DE-10. Ophthalmology. LR Rafael Luque Aranda. Co-LR Carmen Alba Linero

Priority line of research: Autoimmune diseases, infectious diseases and ocular allergies.

Other lines:

- Ocular involvement in neurological diseases.
- Ocular involvement in cardiovascular diseases.

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DE-10	Casas, BM; Linares, JLC; Aranda, IB; Villodres, JR; Bohorquez, VM; Jimenez, AG; Corral, MAR; Bosch, R; Chaparro, MAS; Fernandez, MG; Valdivielso, P	Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo- Controlled Crossover Trial	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
DE-10	Fauquert, JL; Alba-Linero, C; Gherasim, A; Testera- Montes, A; Bentabol-Ramos, G; Maria-Garcia, RSD; Torres, MJ; Eguiluz-Gracia, I; Rondon, C	Organ-specific allergen challenges in airway allergy: Current utilities and future directions	ALLERGY	12.4	D1	Review
DE-10	Carazo-Barrios, L; Cabrera- Maestre, A; Alba-Linero, C; Gutierrez-Bedmar, M; Garzon-Maldonado, FJ; Serrano, V; de la Cruz- cosme, C; Garcia-Casares, N	Retinal Neurodegeneration Measured With Optical Coherence Tomography and Neuroimaging in Alzheimer Disease: A Systematic Review	JOURNAL OF NEURO-OPH- THALMOLOGY	2.9	Q2	Review
DE-10	Santos-Ortega, A; Alba- Linero, C; Urbinati, F; Rocha-de-Lossada, C; Orti, R; Reyes-Bueno, JA; Garzón- Maldonado, FJ; Serrano, V; de Rojas-Leal, C; de la Cruz-Cosme, C; España- Contreras, M; Rodríguez- Calvo-de-Mora, M; García- Casares, N	Structural and Functional Retinal Changes in Patients with Mild Cognitive Impairment with and without Diabetes.	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
4	25%	50%	25%	24.8

Clinical

trials



Associated Groups

DA-06. Immune-Mediated Inflammatory Diseases (IMID) LR Rosa García Portal es

Lines of research:

- Comorbidity, prevalence, and impact of immune-mediated inflammatory diseases.
- Biotherapies and targeted therapies in rheumatoid arthritis, psoriatic arthritis, spondyloarthropathies, and uveitis.
- Pharmacogenetics.

Featured publications

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DA-06	Sanchez-Yanez, Elena; Jose Huertas-Fernandez, Maria; de las Aguas Robustillo-Cortes, Maria; Ramos-Guerrero, Rosa; Fernandez- Espinola, Sergio; Diaz-Acedo, Rocio; Montero-Martin, Violeta; Morillo-Verdugo, Ramon	Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project	REVISTA ESPANOLA DE QUIMIOTER- APIA	1.9	Q4	Article
DA-06	Gomez-Vaquero, Carmen; Hernandez, Jose Luis; Olmos, Jose Manuel; Cerda, Dacia; Calleja, Cristina Hidalgo; Lopez, Juan Antonio Martinez; Arboleya, Luis; Rey, Francisco Javier Aguilar del; Pardo, Silvia Martinez; Vilamajo, Inmaculada Ros; Armangue, Xavier Suris; Grados, Dolors; Audera, Chesus Beltran; Suero-Rosario, Evelyn; Gracia, Inmaculada Gomez; Chamizo, Asuncion Salmoral; Martin-Esteve, Irene; Florez, Helena; Naranjo, Antonio; Castaneda, Santos; Bruno, Soledad Ojeda; Carazo, Sara Garcia; Garcia- Vadillo, Alberto; Vives, Laura Lopez; Martinez-Ferrert, Angels; Panos, Helena Borrell; Acin, Pilar Aguado; Castellanos-Moreira, Raul; Satorra, Pau; Tebe, Cristian; Guanabens, Nuria	High incidence of clinical fragility fractures in postmenopausal women with rheumatoid arthritis. A case-control study	BONE	4.1	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
DA-06	Padilla-Galo, Alicia; Carmona, Isabel Moya; Ausin, Pilar; Fernandez, Luis Carazo; Garcia-Moguel, Ismael; Velasco-Garrido, Jose Luis; Andujar-Espinosa, Ruben; Casas-Maldonado, Francisco; Martinez-Moragon, Eva; Rivera, Carlos Martinez; Solsona, Elisabet Vera; Lopez, Fernando Sanchez-Toril; Alonso, Andrea Trisan; Aparicio, Marina Blanco; Valverde-Monge, Marcela; Azcona, Borja Valencia; Cervera, Marta Palop; Nuevo, Javier; Tena, Jesus Sanchez; Resler, Gustavo; Luzon, Elisa; Naon, Alberto Levy	Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study	RESPIRATORY RESEARCH	5.8	Q1	Article

Articles	% Art. Led	% Q 1	% D1	IF
3	33%	33%		11.8

Area 6. IBIMA Tech: Health Technology and Innovation Area

F-02. Computational Intelligence And Image Analysis LR José Ignacio Peláez Sánchez. Co-LR Ezequiel López Rubio

Lines of research:

- Neurocomputing.
- Digital image analysis.
- Intelligent decision support systems.
- Computational learning.
- Grouping analysis.
- Decision making.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-02	Garcia-Aguilar, I; Garcia- Gonzalez, J; Luque-Baena, RM; Lopez-Rubio, E	Object detection in traffic videos: an optimized approach using superresolution and maximal clique algorithm	NEURAL COMPUTING & APPLICA- TIONS	6	Q2	Article
F-02	Fernandez-Rodriguez, JD; Garcia-Gonzalez, J; Benitez- Rochel, R; Molina-Cabello, MA; Ramos-Jimenez, G; Lopez-Rubio, E	Automated detection of vehicles with anomalous trajectories in traffic surveillance videos	INTEGRATED COMPUT- ER-AIDED ENGINEERING	6.5	Q1	Article
F-02	Fernandez-Rodriguez, JD; Palomo, EJ; Ortiz-De- Lazcano-Lobato, JM; Ramos- Jimenez, G; Lopez-Rubio, E	Dynamic learning rates for continual unsupervised learning	INTEGRATED COMPUT- ER-AIDED ENGINEERING	6.5	Q1	Article
F-02	Garcia-Aguilar, I; Garcia- Gonzalez, J; Luque-Baena, RM; Lopez-Rubio, E; Dominguez, E	Optimized instance segmentation by super-resolution and maximal clique generation	INTEGRATED COMPUT- ER-AIDED ENGINEERING	6.5	Q1	Article
F-02	Teran-Pineda, D; Thurnhofer-Hemsi, K; Dominguez, E	Human Gait Activity Recognition Using Multimodal Sensors	INTERNA- TIONAL JOURNAL OF NEURAL SYS- TEMS	8	Q1	Article

Articles	% Art. Led	% Q 1	% D1	IF
12	100%	33%		60.5



208 RESEARCH AREAS AND GROUPS 100 Plataforma BIONAND 2023 SCIENTIFIC REPORT 209

F-03. Communications Engineering LR Iñigo Molina Fernández

Lines of research:

- R&D in telecommunication networks, systems, and services.
- Signal processing in biomedicine.
- e-Health.
- Biosensors.
- Applications of adaptive optics in ophthalmology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-03	Pérez-Armenta, C; Ortega- Moñux, A; Luque-González, JM; Halir, R; Schmid, J; Cheben, P; Molina- Fernández, I; Wangüemert- Pérez, JG	Polarization insensitive metamaterial engineered multimode interference coupler in a 220 nm silicon- on-insulator platform	OPTICS AND LASER TECHNOLOGY	5	Q1	Article
F-03	Pérez-Armenta, C; Mackay, KK; Hadij-ElHouati, A; Ortega-Moñux, A; Molina- Fernández, I; Wangüemert- Pérez, JG; Schmid, JH; Cheben, P; Ye, WN	Thermally induced sideband generation in silicon- on-insulator cladding modulated Bragg notch filters	OPTICS EXPRESS	3.8	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
2	50%	50%		8.8



Active projects



Patents applied for

F-04. MAPIR (Machine Perception And Intelligent Robotics Group) LR Javier González Jiménez. Co-LR Cipriano Galindo Andrades

Priority line of research: Use of robotic technology to improve the independence of older adults in their homes.

Other lines of research:

- Development and research on robotic telepresence systems that allow for extending independent living and social interaction among older adults. This system is designed so that a family member, caregiver, or healthcare professional can virtually visit the user's home, experiencing an interaction very similar to a conventional in-person visit.
- Development of automatic, safe navigation systems in small settings as well as systems for friendly interaction among older adults with a certain degree of cognitive frailty who live alone in their homes. This interaction seeks to alleviate the feeling of loneliness by contributing to users' independence and well-being.
- Development and research on sensor networks and algorithms for sensing activity in the environment as well as physiological parameters of individuals (patients with chronic diseases, at risk, in rehabilitation, etc.) for the purpose of monitoring and control by public health professionals (doctors, nurses, social workers, etc.).

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-04	Garcia-Salguero, M; Gonzalez-Jimenez, J	Certifiable Solver for Real- Time N-View Triangulation	IEEE ROBOTICS AND AUTOMATION LETTERS	5.2	Q2	Article
F-04	Garcia-Salguero, M; Gonzalez-Jimenez, J	Fast certifiable relative pose estimation with gravity prior*	ARTIFICIAL INTELLI- GENCE	14.4	D1	Article
F-04	Jaenal, A; Moreno, FA; Gonzalez-Jimenez, J	Sequential Monte Carlo localization in topometric appearance maps	INTERNA- TIONAL JOURNAL OF ROBOTICS RESEARCH	9.2	Q1	Article
F-04	Ambrosio-Cestero, G; Ruiz- Sarmiento, JR; Gonzalez- Jimenez, J	The Robot@Home2 dataset: A new release with improved usability tools	SOFTWAREX	3.4	Q2	Article
F-04	Ojeda, P; Monroy, J; Gonzalez-Jimenez, J	VGR Dataset: A CFD-based Gas Dispersion Dataset for Mobile Robotic Olfaction	JOURNAL OF INTELLIGENT & ROBOTIC SYSTEMS	3.3	Q3	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
10	50%	40%	20%	63.5



Active projects

F-05. Medical Robotics LR. Victor Fernando Muñoz Martínez

Priority line: Development of robotic assistants for laparoscopic surgery.

Other lines:

- Design of surgical robots.
- Instrument movement control.
- Automated surgical planning.
- Fault-tolerant control architectures.
- Development of human-machine interfaces.
- Telesurgery.
- Medical devices.
- Digital twins.

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-05	Costoya, C; Muñoz, V; Tocino, A; Viruel, A	Automorphism groups of Cayley evolution algebras	REVISTA DE LA REAL ACADEMIA DE CIENCIAS EXAC- TAS FISICAS Y NATURALES SERIE A-MATEMATICAS	2.9	D1	Article
F-05	Ror, AK; Gupta, R; Jelínek, M; Pandey, SB; Castro-Tirado, AJ; Hu, YD; Malenáková, A; Strobl, J; Thöne, CC; Hudec, R; Karpov, S; Kumar, A; Aryan, A; Oates, SR; Fernández-García, E; del Pulgar, CP; Caballero- García, MD; Castellón, A; Carrasco-García, IM; Pérez- García, ; Terol, AJR; Rendon, F	Prompt Emission and Early Optical Afterglow of Very-high-energy Detected GRB 201015A and GRB 201216C: Onset of the External Forward Shock	ASTROPHYSICAL JOURNAL	4.9	Q1	Article
	Paz-Delgado, GJ; Sánchez- Ibáñez, JR; Domínguez, R; Pérez-Del-Pulgar, CJ; Kirchner, F; García-Cerezo, A	Combined Path and Motion Planning for Workspace Restricted Mobile Manipulators in Planetary Exploration	IEEE ACCESS	3.9	Q2	Article
	Hu, YD; Fernández-García, E; Caballero-García, MD; Pérez-García, I; Carrasco- García, IM; Castellón, A; del Pulgar, CP; Terol, AJR; Castro-Tirado, AJ	The burst observer and optical transient exploring system in the multi-messenger astronomy era	FRONTIERS IN ASTRONOMY AND SPACE SCIENCES	3	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-05	Paz-Delgado, GJ; Pérez- del-Pulgar, CJ; Azkarate, M; Kirchner, F; García-Cerezo, A	Multi-stage warm started optimal motion planning for over-actuated mobile platforms	INTELLIGENT SER- VICE ROBOTICS	2.5	Q4	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
8	25%	25%	13%	24.6



Active projects



Patents applied for

F-09. Electronics For Instrumentation And Systems LR Fernando Vidal Verdú.

Lines of research:

- Research on electronics and instrumentation.
- Bioinformatics/Biomedicine.
- Applications in rehabilitation and assistance systems.
- Use of artificial intelligence techniques in diagnostic systems.
- Identification of correlations between genetic data and diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-09	Gómez-de-Gabriel, JM; Fernández-Madrigal, JA; Rey-Merchán, MD; López-Arquillos, A	A Safety System based on Bluetooth Low Energy (BLE) to prevent the misuse of Personal Protection Equipment (PPE) in construction	SAFETY SCI- ENCE	6.1	Q1	Article
F-09	Lora-Rivera, R; Oballe- Peinado, O; Vidal-Verdu, F	Proposal and Implementation of a Procedure for Compliance Recognition of Objects with Smart Tactile Sensors	SENSORS	3.9	Q2	Article
F-09	Hidalgo-Lopez, JA; Castellanos-Ramos, J	Simplifying Capacitive Sensor Readout Using a New Direct Interface Circuit	IEEE TRANS- ACTIONS ON INSTRUMEN- TATION AND MEASURE- MENT	5.6	Q1	Article
F-09	Lora-Rivera, R; Oballe- Peinado, O; Vidal-Verdu, F	Texture Detection With Feature Extraction on Embedded FPGA	IEEE SEN- SORS JOUR- NAL	4.3	Q1	Article
F-09	Hidalgo-Lopez, JA; Castellanos-Ramos, J	Two proposals to simplify resistive sensor readout based on Resistance-to-Time-to-Digital conversion	MEASURE- MENT	5.6	Q1	Article

Articles	% Art. Led	% Q1	% D1	IF
9	67%	56%		39.2



F-10. Biomimetic Dendrimers And Photonic Laboratory LR Ezequiel Perez-Inestrosa

Priority line of research: Preparation of dendrimeric structures to emulate multivalent bioactive macromolecules and visualize their interactions.

Other lines:

- Synthesis of new suitably functionalized dendrimer and dendron systems.
- Preparation of solid supports (nanoparticles) for their functionalization with dendrimer systems.
- Synthesis of fluorescent markers for dendrimeric systems.
- Design and synthesis of sensors for biomedical information processing.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-10	Chen-Wu, J; Guzman-Rios, DB; Remon, P; Gonzalez- Delgado, JA; Martinez- Martinez, AJ; Najera, F; Arteaga, JF; Pischel, U	Photofunctional Scope of Fluorescent Dithienylethene Conjugates with Aza- Heteroaromatic Cations	ADVANCED MATERIALS	29.4	D1	Article
F-10	Dreos, A; Ge, JY; Najera, F; Tebikachew, BE; Perez- Inestrosa, E; Moth-Poulsen, K; Blennow, K; Zetterberg, H; Hanrieder, J	Investigating New Applications of a Photoswitchable Fluorescent Norbornadiene as a Multifunctional Probe for Delineation of Amyloid Plaque Polymorphism	ACS SEN- SORS	8.9	D1	Article
F-10	Royo, R; Mainik, P; Benitez- Martin, C; Andreu, R; Blasco, E; Najera, F; Villacampa, B	Highly Efficient Photoninitiators Based on 4H-Pyranylidene Derivatives for Two-Photon Laser Printing	ADVANCED MATERIALS TECHNOLO- GIES	6.8	Q1	Article
F-10	Silva, Maria J S A; Zhang, Yiyi; Vinck, Robin; Santos, Fabio M F; Antonio, Joao P M; Gourdon-Grunewaldt, Lisa; Zaouter, Charlotte; Castonguay, Annie; Patten, Shunmoogum A; Cariou, Kevin; Bosca, Francisco; Najera, Francisco; Arteaga, Jesus F; Gasser, Gilles; Pischel, Uwe; Gois, Pedro M P	BASHY Dyes Are Highly Efficient Lipid Droplet- Targeting Photosensitizers that Induce Ferroptosis through Lipid Peroxidation.	BIOCONJU- GATE CHEM- ISTRY	4.7	D1	Article
F-10	Dominguez-Alfaro, A; Pais, VF; Guzman-Rios, DB; Collado, D; Najera, F; Perez- Inestrosa, E; Pischel, U	Energy-transfer sensitization of BODIPY fluorescence in a dyad with a two-photon absorbing antenna chromophore	DYES AND PIGMENTS	4.5	D1	Article

Articles	% Art. Led	% Q1	% D1	IF
8	38%	75%	50%	68.1



Active projects



Patents applied for

216 RESEARCH AREAS AND GROUPS

F-14. Clinimetrics In Physical Therapy LR Antonio Ignacio Cuesta Vargas

Priority line of research: Develop and validate instruments for clinical assessment and diagnosis that incorporate biomechanics, physiology, psychometrics, and clinical signs

Other lines:

- Development, validation, and sensitivity to change of instruments for measuring outcomes in clinical sciences.
- Physiology and biomechanics applied to musculoskeletal (dys)function. Preclinical studies.
- Multimodal health promotion interventions in chronic conditions. Clinical studies.
- Health solutions based on portable information and communication technologies. Telemedicine and mHealth. Translational studies and innovation.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-14	Roldan-Jimenez, C	What are the physiologic effects of Resistance Exercise behind breast cancer-related lymphedema prevention?	MEDICAL HY- POTHESES	4.7	Q2	Article
F-14	Carrasco-Vega, E; Martinez- Moya, M; Barni, L; Guiducci, S; Nacci, F; Gonzalez- Sanchez, M	Questionnaires for the subjective evaluation of patients with fibromyalgia: a systematic review	EUROPEAN JOURNAL OF PHYSICAL AND REHA- BILITATION MEDICINE	4.5	D1	Review
F-14	Roldan-Jimenez, C; Cuadros- Romero, M; Bennett, P; Cuesta-Vargas, AI	Differences in Tridimensional Shoulder Kinematics between Asymptomatic Subjects and Subjects Suffering from Rotator Cuff Tears by Means of Inertial Sensors: A Cross- Sectional Study	SENSORS	3.9	Q2	Article
F-14	Trinidad-Fernandez, M; Bossavit, B; Salgado- Fernandez, J; Abbate-Chica, S; Fernandez-Leiva, AJ; Cuesta-Vargas, AI	Head-Mounted Display for Clinical Evaluation of Neck Movement Validation with Meta Quest 2	SENSORS	3.9	Q2	Article
F-14	Fuentes-Abolafio, IJ; Trinidad-Fernandez, M; Escriche-Escuder, A; Roldan-Jimenez, C; Arjona- Caballero, JM; Bernal-Lopez, MR; Ricci, M; Gomez- Huelgas, R; Perez-Belmonte, LM; Cuesta-Vargas, AI	Kinematic Parameters That Can Discriminate in Levels of Functionality in the Six- Minute Walk Test in Patients with Heart Failure with a Preserved Ejection Fraction	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
30	57%	13%	10%	90



Networks:

CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research.

F-15. Data And Knowledge Management, Integration, And Analysis

LR José F. Aldana Montes

Priority line of research: (Big) data analytics (management, integration, and analysis of data and big data).

Other lines:

(KHAOS)

- Clinical data management.
- Electronic medical records.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
F-15	Rodríguez-Revello, J; Barba- González, C; Rybinski, M; Navas-Delgado, I	KNIT: Ontology reusability through knowledge graph exploration	EXPERT SYSTEMS WITH APPLI- CATIONS	8.5	D1	Article
F-15	Burgueño, AM; Aldana- Martín, JF; Vázquez-Pendón, M; Barba-González, C; Gómez, YJ; Millán, VG; Navas-Delgado, I	Scalable approach for high- resolution land cover: a case study in the Mediterranean Basin	JOURNAL OF BIG DATA	8.1	D1	Article
F-15	Nematzadeh, H; Garcia- Nieto, J; Navas-Delgado, I; Aldana-Montes, JF	Ensemble-based genetic algorithm explainer with automized image segmentation: A case study on melanoma detection dataset	COMPUTERS IN BIOLOGY AND MEDICINE	7.7	D1	Article
F-15	Segura-Ortiz, A; Garcia- Nieto, J; Aldana-Montes, JF; Navas-Delgado, I	GENECI: A novel evolutionary machine learning consensus-based approach for the inference of gene regulatory networks	COMPUTERS IN BIOLOGY AND MEDICINE	7.7	D1	Article
F-15	Cardas, C; Aldana-Martín, JF; Burgueño-Romero, AM; Nebro, AJ; Mateos, JM; Sánchez, JJ	On the performance of SQL scalable systems on Kubernetes: a comparative study	CLUSTER COMPUT- ING-THE JOURNAL OF NETWORKS SOFTWARE TOOLS AND APPLICA- TIONS	4.4	Q1	Article

Articles	% Art. Led	% Q1	% D1	IF
10	100%	50%	40%	50



Active projects

220 RESEARCH AREAS AND GROUPS

EMERGING GROUPS

FE-17. Hand Research TeamLR Raquel Cantero Téllez. Co-LR Javier García Orza

Priority line of research: Use of new technologies and innovative treatments for hand injuries.

Other lines: New treatments in the conservative and post-surgical approach to hand injuries. Wrist and hand proprioception. Thumb conditions. Psychological aspects of hand injuries. Influence of traumatic, neurological, and rheumatic hand injuries on activities of daily living. Biomechanical and anatomical underpinnings of hand conditions. Effectiveness of the use of orthoses for objective and functional improvement of the hand. Study of the hand in musicians.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
FE-17	Salazar-Frías, D; Funes, M; Merchán-Baeza, J; Ricchetti, G; Torralba-Muñoz, J; Rodríguez-Bailón, M	Translation, cross-cultural adaptation and validation of the 10-item Weekly Calendar Planning Activity in Spanish-speaking ABI patients: a multicenter study	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article
FE-17	Estudillo, AJ; Lee, YJ; Alvarez-Montesinos, JA; García-Orza, J	High-frequency transcranial random noise stimulation enhances unfamiliar face matching of high resolution and pixelated faces	BRAIN AND COGNITION	2.5	Q2	Article
FE-17	Garcia-Orza, J; Gutierrez- Cordero, I; Larios, C; Csilinko, A; Alvarez- Montesinos, JA	Length is not all that matters: testing the role of number identity and the ratio of fillers in comparisons of multi-digits with different digit length	PSYCHO- LOGICAL RESEARCH- PSYCHOLO- GISCHE FORSCHUNG	2.3	Q3	Article
FE-17	Capdevila, E; Rodríguez- Bailón, M; Szot, AC; Gálvez- Ruiz, P; Portell, M	Cross-cultural adaptation and validation of the Spanish version of the Client-Centred Rehabilitation Questionnaire (CCRQ)	DISABILITY AND REHA- BILITATION	2.2	Q2	Article
FE-17	Requejo-Herrero, P; Pineda- Galan, C; Medina-Porqueres, I	Anterior cruciate ligament ruptures in Spanish soccer first division: An epidemiological retrospective study	KNEE	1.9	Q3	Article

Articles	% Art. Led	% Q 1	% D1	IF
12	75%	8%		24.9



Active projects

FE-18. Rehabilitation, Innovation, And Quality Of Life LR Irene de Torres García. Co-LR: Francisco Luna Cabrera

Priority line of research: Neurorehabilitation, digital health, and technological innovation.

Other lines:

- Cardiac rehabilitation.
- Respiratory rehabilitation.
- Mobility aids.
- Promotion of physical exercise.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
FE-18	Sanchez-Garcia, AM; Martinez-Lopez, P; Gomez- Gonzalez, AM; Rodriguez- Capitan, J; Jimenez-Lopez, RJ; Almeida, JMG; Avanesi- Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel- Abada, V; Molina-Ramos, AI; Cabrera-Cesar, E; Ben-Abdellatif, I; Gordillo- Resina, M; Perez-Mesa, E; Nieto-Gonzalez, M; Nuevo- Ortega, P; Reina-Artacho, C; Fernandez, PLS; Jimenez- Navarro, MF; Estecha- Foncea, MA	Multidisciplinary approach of the sequelae one month after hospital discharge in patients with severe bilateral COVID-19 pneumonia, are there differences depending on the respiratory therapy used during admission to intensive care?	MEDICINA INTENSIVA	3	Q3	Article
FE-18	Simón-Frapolli, VJ; Vegas- Aguilar, IM; Fernández- Jiménez, R; Cornejo-Pareja, IM; Sanchez-García, AM; Martínez-López, P; Nuevo- Ortega, P; Reina-Artacho, C; Estecha-Foncea, MA; Gómez-González, AM; González-Jiménez, MB; Avanesi-Molina, E; Tinahones-Madueño, FJ; García-Almeida, JM	Phase angle and rectus femoris cross-sectional area as predictors of severe malnutrition and their relationship with complications in outpatients with post-critical SARS- CoV2 disease	FRONTIERS IN NUTRITION	5	Q2	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
FE-18	Sánchez-García, AM; Martínez-López, P; Gómez- González, AM; Rodriguez- Capitán, J; Pavón-Morón, FJ; Jiménez-López, RJ; García- Almeida, JM; Avanesi- Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel- Abad, V; Molina-Ramos, AI; Cabrera-César, E; Ben-Abdellatif, I; Gordillo- Resina, M; Pérez-Mesa, E; Nieto-González, M; Nuevo- Ortega, P; Reina-Artacho, C; Sánchez-Fernández, PL; Jiménez-Navarro, MF; Estecha-Foncea, MA	Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia	NTERNATIONAL JOURNAL OF MEDICAL SCIENCES	3.6	Q2	Article

Articles	% Art. Led	% Q1	% D1	IF
3				11.6



224 RESEARCH AREAS AND GROUPS

Associated Groups

FA-07. Research On Orthopedic Surgery And Traumatology LR Antonio Leiva Gea

Lines of research:

- Chondral injuries, new therapies in orthopedic surgery and traumatology.
- Autologous chondrocyte implantation.
- Osteosynthesis.
- Biomechanical optimization of orthopedic surgery and traumatology procedures.
- Elongation of bone segments in dysplasias.
- Infection in orthopedic surgery and traumatology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
FA-07	Maghnie, M; Semler, O; Guillen-Navarro, E; Selicorni, A; Heath, KE; Haeusler, G; Hagenas, L; Merker, A; Leiva-Gea, A; Gonzalez, VL; Raimann, A; Rehberg, M; Santos-Simarro, F; Ertl, DA; Gregersen, PA; Onesimo, R; Landfeldt, E; Jarrett, J; Quinn, J; Rowell, R; Pimenta, J; Cohen, S; Butt, T; Shediac, R; Mukherjee, S; Mohnike, K	Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study	ORPHANET JOURNAL OF RARE DISEASES	3.7	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
1				3.7



FA-08. Ototech LR Rafael Urquiza de la Rosa

Lines of research:

- Research and development of technological devices for otology. Implantable hearing aids.
- Evaluation of hearing treatment quality.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
FA-08	Moreno-Torres, I; Lozano, A; Bermúdez, R; Pino, J; Méndez, MDG; Nava, E	Unmasking Nasality to Assess Hypernasality	APPLIED SCIENC- ES-BASEL	2.7	Q2	Article

Articles	%Art. Leader.	% Q1	% D 1	IF
1				2.7



226 RESEARCH AREAS AND GROUPS

ibimo Plataforma BIONAND 2023 SCIENTIFIC REPORT 227

External Associated Groups

FA-16. Innovative Therapies And New Technologies In The Musculoskeletal System LR Enrique Guerado Parra

Lines of research:

- Clinical research on orthopedic and traumatological surgery.
- Genomics in diseases of the musculoskeletal system.
- Cellular processes in osteogenesis.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
FA-16	Tamimi, I; García-Meléndez, G; Vieitez-Riestra, I; Palacios-Penedo, S; Garceso, DM; Sanchez, A; Tamimi, F; Guerado, E; Milner, MSD; de Quevedo, DG; Gonzalez-Quevedo, D	The Use of β-Blockers and the Risk of Undergoing a Knee Arthroplasty: A Nested Case-Control Study	JOURNAL OF BONE AND JOINT SURGERY- AMERICAN VOLUME	5.3	D1	Article
FA-16	Tamimi, A; Hassuneh, M; Tamimi, I; Juweid, M; Shibli, D; AlMasri, B; Tamimi, F	Admission criteria and academic performance in medical school	BMC MEDICAL EDUCATION	3.6	Q1	Article
FA-16	Joeris, A; Sprague, S; Blauth, M; Gosch, M; Wattanapanom, P; Jarayabhand, R; Poeze, M; Wong, MK; Kwek, EBK; Hegeman, JH; Perez- Uribarri, C; Guerado, E; Revak, TJ; Zohner, S; Joseph, D; Phillips, MR	Cost-effectiveness analysis of the Geriatric Fracture Center (GFC) concept: a prospective multicentre cohort study	BMJ OPEN	2.9	Q2	Article
FA-16	Gonzalez-Quevedo, D; Fernandez-Arroyabe, N; Moriel-Garceso, D J; Martinez-Malo, F J; Martin- Garcia, F; Arenas-Ros, J; Zambrana-Vico, S; Puerta- Migueles, L; Saez-Casado, M; Sanchez-Garcia, A; Tamimi, I	Reverse total shoulder arthroplasty for proximal humerus fractures: Primary or delayed after failed treatment?	Injury	2.5	Q2	Article

Articles	% Art. Led	% Q1	% D1	IF
4	75%	50%	25%	14.3



Active projects



Patents applied for

Area 7. Nanodiagnostics

G-01. Biomedical Magnetic Resonance Laboratory (BMRL) LR María Luisa García Martín

Lines of research:

- Development of multifunctional magnetic nanomaterials for tumor theranostics.
- Magnetic resonance metabolomics of tissue and biofluid biopsies for the identification of diagnostic, prognostic, and treatment response biomarkers.

Other lines:

- Magnetic nanoparticles as contrast agents for magnetic resonance imaging (MRI).
- Magnetic nanoparticles for magnetic hyperthermia therapy.
- Multifunctional nanomaterials for multimodal imaging and/or tumor therapy.
- Magic angle spinning MRI metabolomics for breast and brain tumor biopsies.
- Biofluid metabolomics using high-resolution MRI in multiple sclerosis and other autoimmune diseases.
- Biofluid metabolomics using high resolution MRI in cancer.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
G-01	Ortiz-Rivero E., Orozco- Barrera S., Chatterjee H., González-Gómez C.D., Caro C., García-Martín ML., González P.H., Rica R.A., Gámez F.	Light-to-Heat Conversion of Optically Trapped Hot Brownian Particles	ACS NANO	17.1	D1	Article
G-01	Paez-Muñoz, JM; Gámez, F; Fernández-Afonso, Y; Gallardo, R; Leal, MP; Gutiérrez, L; de la Fuente, JM; Caro, C; Garcia-Martín, ML	Optimization of iron oxide nanoparticles for MRI-guided magnetic hyperthermia tumor therapy: reassessing the role of shape in their magnetocaloric effect	JOURNAL OF MATERIALS CHEMISTRY B	7	Q1	Article
G-01	Ocaña, MC; Bernal, M; Yang, CD; Caro, C; Domínguez, A; Vu, HS; Cárdenas, C; García- Martín, ML; Deberardinis, RJ; Quesada, AR; Martínez- Poveda, B; Medina, MA	New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo	COMMUNICA- TIONS BIOLOGY	5.9	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
G-01	Pomary, PK; Eichau, S; Amigo, N; Barrios, L; Matesanz, F; Garcia- Valdecasas, M; Hrom, I; Sanchez, MIG; Garcia- Martin, ML	Multifaceted Analysis of Cerebrospinal Fluid and Serum from Progressive Multiple Sclerosis Patients: Potential Role of Vitamin C and Metal Ion Imbalance in the Divergence of Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis	JOURNAL OF PROTEOME RESEARCH	4.4	Q1	Article
G-01	Avasthi, A; Caro, C; Garcia- Martin, ML; Leal, MP	Deciphering the parameters to produce highly reproducible and scalable iron oxide nanoparticles	REACTION CHEMISTRY & ENGINEERING	3.9	Q2	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
11	36%	82%	27%	90



projects

Area 8. Nanosystems And Advanced Therapies

H-02. Skeletal Biomedicine Laboratory LR Iván Durán Jiménez. Co-LR Fabiana Csukasi

Priority line of research: Precision medicine in skeletal diseases.

Other lines:

- Study of disease mechanisms and precision therapies in skeletal dysplasias.
- Study of skeletal stem cell differentiation and metabolism.
- Development of a transcriptomic atlas of the skeleton.
- Gene therapy and gene editing aimed at bone diseases.
- Study of the influence of cellular stress and inflammation on the skeleton.
- Skeletal tissue engineering. Development of biomaterials and organoids.
- Therapies based on mesenchymal stem cell secretomes.
- Use of zebrafish as a model for skeletal diseases.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
H-02	Nualart, F; Cifuentes, M; Ramirez, E; Martínez, F; Barahona, MJ; Ferrada, L; Saldivia, N; Bongarzone, ER; Thorens, B; Salazar, K	Hyperglycemia increases SCO-spondin and Wnt5a secretion into the cerebrospinal fluid to regulate ependymal cell beating and glucose sensing	PLOS BIOLOGY	9.8	D1	Article
H-02	Castro-Varela, P; Rubilar, M; Rodrigues, B; Pacheco, MJ; Caneda-Santiago, CT; Mari-Beffa, M; Figueroa, FL; Abdala-Diaz, R	A sequential recovery extraction and biological activity of water-soluble sulfated polysaccharides from the polar red macroalgae Sarcopeltis skottsbergii	ALGAL RESEARCH- BIOMASS BIOFUELS AND BIO- PRODUCTS	5.1	Q1	Article
H-02	Bergen, DJM; Maurizi, A; Formosa, MM; McDonald, GLK; El-Gazzar, A; Hassan, N; Brandi, ML; Riancho, JA; Rivadeneira, F; Ntzani, E; Duncan, EL; Gregson, CL; Kiel, DP; Zillikens, MC; Sangiorgi, L; Högler, W; Duran, I; Mäkitie, O; Van Hul, W; Hendrickx, G	High Bone Mass Disorders: New Insights From Connecting the Clinic and the Bench	JOURNAL OF BONE AND MINERAL RESEARCH	6.2	Q1	Review

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
H-02	Garcia-Marquez, J; Moreira, BR; Valverde-Guillen, P; Latorre-Redoli, S; Caneda- Santiago, CT; Acien, G; Martinez-Manzanares, E; Mari-Beffa, M; Abdala-Diaz, RT	In Vitro and In Vivo Effects of Ulvan Polysaccharides from Ulva rigida	PHARMACEU- TICALS	4.6	Q2	Article
H-02	Csukasi, F; Bosakova, M; Barta, T; Martin, JH; Arcedo, J; Barad, M; Rico-Llanos, GA; Zieba, J; Becerra, J; Krejci, P; Duran, I; Krakow, D	Skeletal diseases caused by mutations in PTH1R show aberrant differentiation of skeletal progenitors due to dysregulation of DEPTOR	FRONTIERS IN CELL AND DEVELOP- MENTAL BIOLOGY	5.5	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
5	40%	80%	20%	31.2



Networks and Ciber:

RD16/0011/0022 Cell Therapy Network-TerCel (ISCIII)

232 RESEARCH AREAS AND GROUPS ibima Plataforma BIONAND 2023 SCIENTIFIC REPORT 233

H-03. Development And Cardiovascular Disease LR Jose María Pérez Pomares

Priority line of research: Study of the embryonic foundations of cardiovascular disease. Study of the cellular and molecular mechanisms of cardiovascular pathophysiology.

Other lines:

- Embryonic cardiovascular development.
- Cardiovascular repair and regeneration.
- Fibrosis in the context of cardiomyopathies.
- Cardiovascular histopathology.
- Differentiation of cardiovascular progenitor cells.
- Vascular pathology.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc Type
H-03	Siguero-Alvarez, M; Salguero-Jimenez, A; Grego-Bessa, J; de la Barrera, J; MacGrogan, D; Prados, B; Sanchez-Saez, F; Pineiro- Sabaris, R; Felipe-Medina, N; Torroja, C; Gomez, MJ; Sabater-Molina, M; Escriba, R; Richaud-Patin, I; Iglesias- Garcia, O; Sbroggio, M; Callejas, S; O'Regan, DP; McGurk, KA; Dopazo, A; Giovinazzo, G; Ibanez, B; Monserrat, L; Perez- Pomares, JM; Sanchez-Cabo, F; Pendas, AM; Raya, A; Gimeno-Blanes, JR; de la Pompa, JL	A Human Hereditary Cardiomyopathy Shares a Genetic Substrate With Bicuspid Aortic Valve	CIRCULATION	37.8	D1	Article
H-03	Tamura, M; Ishikawa, R; Nakanishi, Y; Pascual- Anaya, J; Fukui, M; Saitou, T; Sugahara, F; Rijli, FM; Kuratani, S; Suzuki, DG; Murakami, Y	Comparative analysis of Hmx expression and the distribution of neuronal somata in the trigeminal ganglion in lamprey and shark: insights into the homology of the trigeminal nerve branches and the evolutionary origin of the vertebrate jaw	ZOOLOGICAL LETTERS	2.7	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc Type
H-03	Coppiello, Giulia; Barlabe, Paula; Moya-Jodar, Marta; Abizanda, Gloria; Pogontke, Cristina; Barreda, Carolina; Iglesias, Elena; Linares, Javier; Arellano-Viera, Estibaliz; Larequi, Eduardo; San Martin-Uriz, Patxi; Carvajal-Vergara, Xonia; Pelacho, Beatriz; Mazo, Manuel Maria; Perez- Pomares, Jose Maria; Ruiz-Villalba, Adrian; Ullate- Agote, Asier; Prosper, Felipe; Aranguren, Xabier L	Generation of heart and vascular system in rodents by blastocyst complementation.	DEVELOP- MENTAL CELL	11.8	D1	Article
H-03	Sugahara, F; Pascual-Anaya, J	High-quality total RNA extraction from early-stage lamprey embryos	BIOTECH- NIQUES	2.7	Q3	Article
H-03	Palmquist-Gomes, P; Ruiz- Villalba, A; Guadix, JA; Romero, JP; Bessieres, B; MacGrogan, D; Conejo, L; Ortiz, A; Picazo, B; Houyel, L; Gomez-Cabrero, D; Meilhac, SM; de la Pompa, JL; Perez- Pomares, JM	Origin of congenital coronary arterio-ventricular fistulae from anomalous epicardial and myocardial development	EXPERIMEN- TAL AND MOLECULAR MEDICINE	12.8	D1	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
6	33%	83%	67%	72.2







Patents applied for

Networks:

CA17129 (CardioRNA): Catalysing transcriptomics research in cardiovascular disease

Emerging Group

HE-01. Cell Reprogramming (IPSCs) And Cell Models Of Disease For Biomedical Applications LR Elena González Muñoz

Priority line of research: Cellular reprogramming (iPSCs) and generation of cellular models of disease for biomedical applications.

Other lines: Regenerative medicine and personalized medicine.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
HE-01	Ducic, T; Sanchez-Mata, A; Castillo-Sanchez, J; Algarra, M; Gonzalez-Munoz, E	Monitoring oocyte-based human pluripotency acquisition using synchrotron-based FTIR microspectroscopy reveals specific biomolecular trajectories	SPECTRO- CHIMICA ACTA PART A-MOLECU- LAR AND BIO- MOLECULAR SPECTROS- COPY	4.4	Q1	Article

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D 1	IF
1	100%	100%	0%	4.4



Oncology Research Centre Of Málaga (CIMO) Director. Emilio Alba Conejo

CIMO-01. Clinical And Translational Research On Cancer LR Emilio Alba Conejo

Lines of research:

- Clinical-translational research on breast, prostate, gynecological, digestive, and germ cell cancers.
- * Translational research on the identification of epigenetic/genetic markers of early stages of cancer.
- Research on the use of new diagnostic techniques (liquid biopsy...) and markers.
- Research on the relationship between microbiota and cancer.
- Research using real world data.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CIMO- 01	Pascual, Javier; Gil-Gil, Miguel; Proszek, Paula; Zielinski, Christoph; Reay, Alistair; Ruiz-Borrego, Manuel; Cutts, Rosalind; Ciruelos Gil, Eva M; Feber, Andrew; Munoz-Mateu, Montserrat; Swift, Claire; Bermejo, Begona; Herranz, Jesus; Margeli Vila, Mireia; Anton, Antonio; Kahan, Zsuzsanna; Csoszi, Tibor; Liu, Yuan; Fernandez-Garcia, Daniel; Garcia-Murillas, Isaac; Hubank, Michael; Turner, Nicholas C; Martin, Miguel	Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.	Clinical cancer research: an official journal of the Ameri- can Associa- tion for Cancer Research	11.5	D1	Article
CIMO- 01	Javier, GC; Alberto, I; Azucena, GNE; Ivan, V; Debora, M; David, P; Laura, A; Andrea, MS; Esther, S; Oleguer, C; Paula, B; Laura, M; Nuria, V; Miquel, N; Patricia, G; Barbara, A; Neus, B; Tamara, S; Manel, J; Aleix, P; Francesco, S	Determinants of activity and efficacy of anti-PD1/ PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker- based study	CANCER IM- MUNOLOGY IMMUNO- THERAPY	5.8	Q1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CIMO- 01	Jimenez-Rodriguez, B; Alba-Bernal, A; Lopez- Lopez, E; Quiros-Ortega, ME; Carbajosa, G; Garrido- Aranda, A; Alvarez, M; Godoy-Ortiz, A; Queipo- Ortuno, MI; Vicioso, L; Diaz- Cordoba, G; Roldan-Diaz, MD; Velasco-Suelto, J; Hernando, C; Bermejo, B; Julve-Parreno, A; Lluch, A; Pascual, J; Comino-Mendez, I; Alba, E	Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis	INTERNA- TIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article
CIMO- 01	Laborda-Illanes, A; Sanchez- Alcoholado, L; Castellano- Castillo, D; Boutriq, S; Plaza-Andrades, I; Aranega- Martin, L; Peralta-Linero, J; Alba, E; Gonzalez-Gonzalez, A; Queipo-Ortuno, MI	Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids	BIOMEDICINE & PHARMA- COTHERAPY	7.5	D1	Article
CIMO- 01	Forne, AF; Anaya, MJG; Guillot, SJS; Andrade, IP; Fernandez, LD; Ocon, MJL; Perez, YL; Queipo-Ortuno, MI; Gomez-Millan, J	Influence of the microbiome on radiotherapy-induced oral mucositis and its management: A comprehensive review	ORAL ONCOL- OGY	4.8	D1	Review

Scientific production and research activity

Articles	% Art. Led	% Q 1	% D1	IF
47	26%	55%	32%	516







Clinical trials

Patents applied for

Ciber:

CIBERONC CB16/12/00481 Cancer (ISCIII)

Competitive HR contracts funded in 2023:

1 pre-doctoral contract from the Spanish Association Against Cancer

CIMO-02. Translational Research On Cancer Immunotherapy LR Antonio Rueda Domínguez. Co-LR. Isabel Barragan Mallofret

Priority line of research: Oncology and hematology.

Other lines of research: Cancer immunotherapy.


Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CIMO- 02	Dols, MC; Zambrano, CB; Cabezón-Gutiérrez, L; Chicas-Sett, R; López- Barajas, MIB; Navalón, FJG; Pérez, JLF; Bermúdez, GS; Torres, PT; Mingorance, ID; Marín, AG; Oriol, AL; Lario, AP; Mauriño, PS; Gómez, OH; Muñoz, DM; González, IH; Sanz-Yagüe, A; López, BS	One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study	BMJ SUPPORTIVE & PALLIATIVE CARE	2.7	Q3	Article
CIMO- 02	Provencio, M; Nadal, E; Gonzalez-Larriba, JL; Martinez-Marti, A; Bernabe, R; Bosch-Barrera, J; Casal- Rubio, J; Calvo, V; Insa, A; Ponce, S; Reguart, N; de Castro, J; Mosquera, J; Cobo, M; Aguilar, A; Vivanco, GL; Camps, C; Lopez-Castro, R; Moran, T; Barneto, I; Rodriguez-Abreu, D; Serna- Blasco, R; Benitez, R; de la Rosa, CA; Palmero, R; Hernando-Trancho, F; Martin-Lopez, J; Cruz- Bermudez, A; Massuti, B; Romero, A	Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE	158.5	D1	Article
CIMO- 02	Chaves, P; Garrido, M; Oliver, J; Perez-Ruiz, E; Barragan, I; Rueda-Dominguez, A	Preclinical models in head and neck squamous cell carcinoma	BRITISH JOURNAL OF CANCER	8.8	Q1	Review
CIMO- 02	Besse, B; Felip, E; Campelo, RG; Cobo, M; Mascaux, C; Madroszyk, A; Cappuzzo, F; Hilgers, W; Romano, G; Denis, F; Viteri, S; Debieuvre, D; Galetta, D; Baldini, E; Razaq, M; Robinet, G; Maio, M; Delmonte, A; Roch, B; Masson, P; Schuette, W; Zer, A; Remon, J; Costantini, D; Vasseur, B; Dziadziuszko, R	Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy:	ANNALS OF ONCOLOGY	50.5	D1	Article

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CIMO- 02	Leal, T; Kotecha, R; Ramlau, R; Zhang, L; Milanowski, J; Cobo, M; Roubec, J; Petruzelka, L; Havel, L; Kalmadi, S; Ward, J; Andric, Z; Berghmans, T; Gerber, DE; Kloecker, G; Panikkar, R; Aerts, J; Delmonte, A; Pless, M; Greil, R; Rolfo, C; Akerley, W; Eaton, M; Iqbal, M; Langer, C	Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non- small-cell lung cancer following progression on or after platinum- based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study	LANCET ONCOLOGY	51.1	D1	Article

Scientific production and research activity

Articles	% Art. Led	% Q1	% D1	IF
34	9%	41%	21%	462





applied for

Competitive HR contracts funded in 2023:

- 1 contract to promote research consolidation from the State Research Agency.
- $1\,pre-doctoral\,contract\,for\,university\,professor\,training\,(FPU)\,from\,the\,Ministry\,of\,Universities.$
- $1\,contract\,for\,the\,annual\,reinforcement\,of\,the\,research\,activity\,in\,SAS\,clinical\,units$

CIMO-03. Computational Intelligence In Biomedicine LR José Manuel Jerez Aragonés

Lines of research:

- Clinical informatics.
- Clinical data mining.
- Clinical bioinformatics.

Featured publications:

Group	Authors	Article Title	Source Title	IF	Q/D	Doc. Type
CIMO- 03	Cervera-Garvi, P; Aguilar- Nunez, D; Paez-Moguer, J; Jerez, JM; Navarro-Ledesma, S	Differences in the Impact of Plantar Fasciopathy on the Spatio-Temporal Gait Parameters between Participants with Bilateral Plantar Fasciopathy and Healthy Subjects: A Cross- Sectional Study	APPLIED SCIENCES- BASEL	2.7	Q2	Article
CIMO- 03	López-García, G; Jerez, JM; Ribelles, N; Alba, E; Veredas, FJ	Explainable clinical coding with in-domain adapted transformers	JOURNAL OF BIOMEDICAL INFORMATICS	4.5	Q2	Article

Articles	% Art. Led	% Q 1	% D1	IF
2	50%			7.2





FUNDING



242 FUNDING

The following graph shows changes in the revenue obtained by IBIMA Plataforma BIONAND over the last five years. This revenue is the sum of competitive and non-competitive grants (donations, agreements, and service provision agreements) obtained by the Institute in addition to the invoicing generated by the clinical studies performed.

CHANGES IN REVENUE OBTAINED (2019-2023)




Figure 53: Changes in revenue obtained (2019–2023)

As can be seen in the graph, the revenue obtained by or awarded to IBIMA has increased or remained steady over the years. This indicates that the institute is a consolidated project with a clear vocation for growth. It generates synergies that translate into sustained growth.

CHANGES IN COMPETITIVE VERSUS NON-COMPETITIVE REVENUE (2019-2023)




Figure 54: Changes in competitive versus non-competitive revenue (2019–2023)

In regard to the competitive and non-competitive revenue obtained, both have increased or remained steady, with similar figures for both revenue types.

On analyzing expenditures, the proportion is the same, though non-competitive revenue spent was slightly lower, as shown in the following table for the 2023 fiscal year:




Figure 55: Revenue spent 2023: Competitive vs non-competitive

ibimo Plataforma BIONAND 2023 SCIENTIFIC REPORT 245

The following table shows revenue spent broken down by the nature of the revenue:

Description of funding body	Budget 2023	Spent 2023	%
Competitive	9,117,183	10,796,487	53%
Competitive Private Grants	217,688	543,461	3%
CSYC	1,345,122	1,596,708	8%
CUII	724,110	832,174	4%
FPS	37,720	56,898	0%
International EUROPEAN	438,811	386,154	2%
ISCIII	4,643,479	5,443,322	27%
MINISTRY OF ECONOMY, TRADE, AND BUSINESS	55,500	747,129	4%
MINISTRY OF EDUCATION AND VOCATIONAL TRAINING	21,880	0	0%
MINISTRY OF HEALTH, SOCIAL SERVICES, AND EQUALITY	66,047	43,078	0%
Other Revenue	36,270	14,751	0%
Other public bodies	554,356	126,969	1%
SAS	976,202	1,005,845	5%
Non-competitive	8,061,436	9,615,920	47%
CSYC	300,000	300,000	1%
CUII	300,000	300,000	1%
Donations/Agreements	1,001,000	1,311,822	6%
Clinical Studies	4,966,870	6,223,835	30%
Provision of Services	953,566	940,263	5%
SAS	120,000	120,000	1%
UMA	420,000	420,000	2%
Total	17,178,619	20,412,408	100%

Eighty-seven percent of the resources are allocated to research and the rest to funding both management and scientific structures:




Figure 56: Revenue spent 2023: Research versus structural

Destination of funding	Budget 2023	Spent 2023	%
Structural	€2,521,788.46	€2,645,455.34	13%
Research	€14,656,830.12	€17,766,952.30	87%
Total	17,178,619	20,412,408	100%

The sources of funding for structural revenues are as follows:

Description of structural revenue	Budget 2023	Spent 2023	%
Competitive Private Grants	15,188	26,828	1%
CSYC	410,247	406,665	15%
CUII	333,369	346,372	13%
Donations/Agreements	91,000	107,900	4%
FPS	4,920	6,661	0%
International EUROPEAN	67,991	70,760	3%
ISCIII	494,692	600,531	23%
MINISTRY OF ECONOMY, TRADE, AND BUSINESS	34,500	47,405	2%
MINISTRY OF HEALTH, SOCIAL SERVICES, AND EQUALITY	9,047	5,876	0%
Other Revenue	36,270	14,751	1%
Other public bodies	0	9,469	0%
Provision of Services	268,566	278,871	11%
SAS	336,000	303,368	11%
UMA	420,000	420,000	16%
Total	2,521,789	2,645,455	100%

The revenue that funds the structural expenses of IBIMA's budget are shown below:

Operating expenses:	BUDGET 2023	12/31/2023	VAR	Funding source	Total
Davagnal Evnanditures	020 625	015 767	77,142	HR grants and cofunding	447,395
Personnel Expenditures	838,625	915,767		Member contributions	468,372
Durchasing	96.018	359.629	359,822	Invoicing for services	174,650
Purchasing	96,016	359,629	359,622	Indirect costs (OH)	184,979
External Services	737.138	746.513	-86,836	Indirect costs (OH)	723,346
Externat Services	737,130	740,515	-00,030	Member contributions	23,167
entral Services Operating Expenses (Structure Cost)	591,123	384,583	-223,120	Member contributions	384,583
BIMA Plataforma BIONAND Plan Grants	258,297	263,878	22,858	Member contributions	263,878
Total Operating Expenses:	2,521,201	2,670,371	123,555		2,670,370

246 FUNDING Plataforma BIONAND 2023 SCIENTIFIC REPORT 247

The expenses of the profit and loss account are shown in the following chart:

EXPENSES AS OF 12-31-2023




Figure 57: Revenue spent 2023

Balance sheet of the managing entity:

ASSET	2023	2022
A) NON-CURRENT ASSETS	17,867,067	17,022,139
I. Intangible assets	1,033,702	915,235
III. Tangible assets	11,033,452	10,311,748
VI. Long-term financial investments	5,799,913	5,795,155
B) CURRENT ASSETS	47,881,475	39,542,129
II. Inventory	34,281	37,303
IV. Users and other debtors of the institute's activity	2,917,108	2,694,528
V. Trade debtors and other accounts receivable	8,387,766	8,085,807
VII. Short-term financial investments	25,927,917	21,956,879
VIII. Short-term accruals	28,228	26,560
IX. Cash and other cash equivalents	10,586,175	6,741,051
TOTAL ASSETS (A+B)	65,748,542	56,564,268

NET EQUITY AND LIABILITIES	2023	2022
A) NET EQUITY	14,254,388	12,853,456
A-1) Equity	1,148,568	792,824
I. Endowment/Social Fund	6,010	6,010
II. Reserves	776,688	651,636
IV. Fiscal year surplus	365,870	135,178
A-3) grants, donations, and bequests received	13,105,820	12,060,632
B) NON-CURRENT LIABILITIES	8,374,823	7,301,662
I. Long-term reserves	440,874	467,920
II. Long-term debts	7,933,949	6,833,742
C) CURRENT LIABILITIES	43,119,331	36,409,149
II. Short-term reserves	0	34,919
III. Short-term debts	22,988,003	19,545,774
VII. Trade creditors and other accounts payables	2,921,490	2,858,145
VIII. Short-term accruals	17,209,838	13,970,311
TOTAL NET EQUITY AND LIABILITIES (A+B+C)	65,748,542	56,564,268



250 EDUCATION

Doctoral Programs of the University of Málaga for the 2022–2023 academic year, regulated by RD 99/2011 dated January 28 and modifications dated June 3, 2016

Biomedicine, Translational Research, and New Technologies in Health

Lines of Research:

- Research on Cardiometabolic and Renal Disease
- Systemic Diseases
- Advances in Skin, Inflammatory, and Oncologic Disease Research
- Molecular Biology of Cancer. Its Importance in Diagnosis and Treatment
- Genomics Applied to Medicine
- Clinical and Experimental Pharmacology, New Therapies and Technologies
- Basic and Applied Neuroscience
- Clinical, Technological, and Experimental Research on Radiobiology, Medical Imaging, Hearing, and Vision.
- Epidemiology and Public Health
- Surgery, Obstetrics, and Gynecology.

Advanced Biotechnology

Lines of Research:

- Bioengineering and tissue regeneration
- Neurogenesis
- Glutamatergic neurotransmission
- Plant-pathogen interaction
- Plant biotechnology
- Improvement and biotechnology of fruit and vegetable species
- Biotechnology of aquatic systems
- Electrophysiology of aquatic plants

Cellular and Molecular Biology

Lines of Research:

- Molecular biology
- Systems biology
- Neurobiology
- Microbiology
- Developmental biology

Health Sciences

Lines of Research:

- Translational research on cardiovascular disease
- Hormone biology, metabolism, and diabetes
- Research on natural products
- Methodology and research tools in the assessment of care and health outcomes

Chemistry and Chemical Technologies. Materials and Nanotechnology

Lines of Research:

- Biochemistry and organic chemistry
- Chemical-physical methods in materials science and technology
- Functional materials
- Materials and processes for sustainability, energy, and the environment
- Chemical engineering and environmental technology

Psychology

Lines of Research:

- Biological foundations of behavior
- Psychology of basic processes
- Methodology of behavioral sciences
- Developmental and educational psychology
- Psychology of social intervention
- Clinical and health psychology
- Physical activity, performance, management, and health

Information Technology

Lines of Research:

- Software Engineering
- Security, Networks, and Embedded Systems
- Bioevolutionary and Bioinspired Algorithms
- Parallel Architectures and Algorithms
- Computational Intelligence
- Intelligent Systems

Master's Degrees at the University of Málaga in the 2022–2023 academic year Health Sciences

- Master's Degree in Health Economics, Healthcare Management, and the Rational Use of Medicines
- Master's Degree in Physical Activity and Sports Research
- Master's Degree in New Research Trends in Health Sciences
- Master's Degree in General Healthcare Psychology
- Master's Degree in International Health

Sciences

- Master's Degree in Cellular and Molecular Biology
- Master's Degree in Advanced Biotechnology

Other University Expert Certificates and Master's Degree in which IBIMA Plataforma BIONAND researchers have participated are the following:

- Interdisciplinary Continuing Education Master's Degree in in Palliative Care.
- Continuing Education Master's Degree in Biomedical Research on Diabetes and Obesity.
- Continuing Education Master's Degree in Biomedical Research: the dialog between clinical findings and molecules.
- Continuing Education Master's Degree in Adult and Pediatric Critical Care Nursing
- University Expert Certificate in Diet Therapy.
- University Expert Certificate in Ethics for Healthcare Professionals.
- University Expert Certificate in Therapeutic Exercise and Functional Rehabilitation in Physical Therapy.
- University Expert Certificate in Podiatric Forefoot Surgery.
- Interdisciplinary University Expert Certificate in Palliative Care.

252 EDUCATION 2023 SCIENTIFIC REPORT 253

DOCTORAL THESES

The following table lists the theses supervised by IBIMA Plataforma BIONAND researchers:

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
A-01	Varela Moreno, Esperanza	EFICACIA Y EFICIENCIA DE UN PROGRAMA DE INTERVENCIÓN PSICOLÓGICA BASADO EN UNA APLICACIÓN WEB PARA EL TRATAMIENTO DE LA DEPRESIÓN EN PACIENTES CON DIABETES MELLITUS TIPO 2: EL RETO DE UNA NUEVA PLATAFORMA TECNOLÓGICA	NO	Anarte Ortiz, María Teresa	-
A-01	Sánchez Torralvo, Francisco José	EFICACIA DE LA INYECCIÓN INTRAGÁSTRICA DE TOXINA BOTULÍNICA A MEDIANTE ENDOSCOPIA EN PACIENTES CON OBESIDAD. (ESTUDIO INTRATOX)	NO	Olveira Fuster, Gabriel	Valdés Hernández, Sergio
A-02	Díaz Perdigones, Cristina María	CAMBIOS EN LA MICROBIOTA INTESTINAL EN PACIENTES CON DIABETES TIPO 2 E INTOLERANCIA A METFORMINA TRAS REINTRODUCCIÓN DE LA MISMA	NO	Tinahones Madueño, Francisco J.	-
A-03	Molina Ramos, Ana Isabel	PROCEDIMIENTOS DE ABLACIÓN PERCUTÁNEA DE VENAS PULMONARES EN FIBRILACIÓN AURICULAR: CRIOABLACIÓN Y RADIOFRECUENCIA	NO	Alzueta Rodriguez, Javier	-
A-03	Romero Trevejo, José Lorenzo	NUEVO MODELO CLÍNICO Y OFTALMOLÓGICO PARA LA PREDICCIÓN DE LA ENFERMEDAD CORONARIA	NO	Jimenez Navarro, Manuel Francisco	-
A-03/ A-17	Soto Navarrete, María Teresa	ETIOFISIOPATOLOGÍA DE LA ENFERMEDAD DE LA VÁLVULA AÓRTICA BICÚSPIDE EN MODELOS ANIMALES	YES	Fernández Corujo, Francisco De Borja	UCH MARTINEZ, MIGUEL
A-06	Cobos Palacios, Lidia	IMPACTO DE LA MODIFICACIÓN DEL ESTILO DE VIDA SOBRE EL PROCESO INFLAMATORIO Y LA RIGIDEZ ARTERIAL EN UNA POBLACIÓN DE EDAD AVANZADA CON OBESIDAD METABÓLICAMENTE SANA	-	Ricardo Gómez Huelgas	María Rosa Bernal López
A-06/ C-07	Osuna Sanchez, Julio	MANEJO DE LA HIPERGLUCEMIA HOSPITALARIA USANDO LINAGLIPTINA EN VARIOS SUBGRUPOS DE PACIENTES CON DIABETES MELLITUS TIPO 2	NO	Pérez Belmonte, Luis Miguel	Lara Muñoz, José Pablo

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
A-06/ F-14	Fuentes Abolafio, Iván José	CARACTERIZACIÓN DE PACIENTES CON INSUFICIENCIA CARDÍACA CON FRACCIÓN DE EYECCIÓN PRESERVADA BASADA EN EL ANÁLISIS ERGOMÉTRICO, BIOMECÁNICO Y ECOGRÁFICO	NO	Gómez Huelgas, Ricardo	CUESTA VARGAS, ANTONIO IGNACIO
A-09	Carazo Barrios, Lina	ESTUDIO DEL NERVIO ÓPTICO MEDIANTE TOMOGRAFÍA DE COHERENCIA ÓPTICA COMO BIOMARCADOR PRECOZ DE DETERIORO COGNITIVO	NO	García Casares, Natalia	-
A-10	Guirre Bustamante, Javiera Paz	LA SALUD BUCAL DEL ADULTO MAYOR CON RIESGO CARDIOVASCULAR. RELACIÓN CON LA CALIDAD DE VIDA Y LA SALUD PÚBLICA	NO	Wärnberg, Julia	BARON LOPEZ, FRANCISCO JAVIER
A-19	Gato Moreno, Mario	EDUCACIÓN NUTRICIONAL PRECOZ EN LA PREVENCIÓN DE LA OBESIDAD INFANTIL	NO	Lopez Siguero, Juan Pedro	LEIVA GEA, ISABEL MARÍA
A-19	De Las Rivas Ramírez, Nieves	ANÁLISIS DE LOS FACTORES DE RIESGO PARA EL DESARROLLO Y LA PROGRESIÓN DE LA RETINOPATÍA DEL PREMATURO EN EL HOSPITAL MATERNO INFANTIL DE MÁLAGA	NO	Sánchez Tamayo, Tomas	-
A-19	Porcel Chacón, Rocío	EVALUACIÓN DEL CONTROL METABÓLICO Y COSTES DIRECTOS EN PACIENTES PEDIÁTRICOS CON DIABETES MELLITUS TIPO 1 TRAS LA IMPLANTACIÓN DE UN SISTEMA DE MONITORIZACIÓN DE GLUCEMIA INTERSTICIAL TIPO FLASH	-	Leopoldo Tapia Ceballos	Isabel Leiva Gea
AA-04	Sanchez Garcia, Ana Maria	VALORACION MULTIDISCIPLINAR DEL SÍNDROME POST CUIDADOS INTENSIVOS EN COVID-19	NO	Martínez López, Pilar	-
B-04	Aguilera Cobos, Lorena	IMPORTANCIA DE LA BIOINFORMÁTICA EN LA IMPLEMENTACIÓN DE LA MEDICINA PERSONALIZADA DE PRECISIÓN EN LOS SISTEMAS SANITARIOS: EL CASO DEL CÁNCER DE PULMÓN	NO	Claros Diaz, Manuel Gonzalo	-
B-04/ BE-18	Torres Vargas, Jose Antonio	BÚSQUEDA Y CARACTERIZACIÓN DE NUEVOS INHIBIDORES DE LA ANGIOGÉNESIS	YES	Rodríguez Quesada, Ana	GARCÍA CABALLERO, MELISSA
B-10	Aguilera Arjona, José	RADIACIÓN SOLAR Y ARTIFICAL EFECTIVA PARA DIFERENTES EFECTOS FOTOBIOLÓGICOS CUTÁNEOS. AVANCES EN ESTRATEGIAS DE DIAGNÓSTICO Y FOTOPROTECCIÓN	NO	Galvez Aranda, M. Victoria De	-

254 EDUCATION 2023 SCIENTIFIC REPORT 255

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
B-10	Garcia Montero, Pablo	CALIDAD DE VIDA RELACIONADA CON LA SALUD EN PACIENTES CON CÁNCER DE PIEL NO MELANOMA EN EL HOSPITAL COSTA DEL SOL: ESTUDIO DE COHORTE PROSPECTIVA	NO	Galvez Aranda, M. Victoria De	-
BE-19	Alamilla Presuel, Juan Carlos	IDENTIFICACIÓN DE NUEVAS PROTEÍNAS RELACIONADAS CON LA RESISTENCIA A RADIACIÓN IONIZANTE Y EL ENVEJECIMIENTO CELULAR EN S. CEREVISIAE	NO	Ruiz Gómez, Miguel José	-
C-01	Cabezudo García, Pablo	EPILEPSIA ASOCIADA A AUTOINMUNIDAD: PREVALENCIA Y CARACTERÍSTICAS EN PACIENTES CON EPILEPSIA FARMACORRESISTENTE DEL LÓBULO TEMPORAL DE ETIOLOGÍA DESCONOCIDA E INICIO NO RECIENTE	NO	Serrano Castro, Pedro Jesus	Estivill Torrús, Guillermo
C-01/ C-07	Rodríguez Losada, Noela	SOPORTES CELULARES BASADOS EN SUSTRATOS DE GRAFENO PARA TERAPIA CELULAR EN ENFERMEDAD DEL PARKINSON	NO	Narvaez Bueno, Jose Angel	ARRÁEZ SANCHEZ, MIGUEL ÁNGEL
C-03	Castillejos Anguiano, M ^a Del Carmen	ATENCIÓN PRIMARIA A PACIENTES CON ESQUIZOFRENIA Y TRASTORNOS AFINES	NO	Moreno Kustner, Berta	-
C-06	Requena Ocaña, Nerea	Factores protectores y biomarcadores de deterioro cognitivo en el trastorno por uso de alcohol. Protective factors and biomarkers of cognitive impairment in alcohol use disorder	YES	Fernando Antonio Rodríguez De Fonseca	-
C-06	Sánchez Marín, Laura	ALCOHOL Y ESTRÉS EN LA ADOLESCENCIA COMO FACTORES DE VULNERABILIDAD EN LOS TRASTORNOS DE ANSIEDAD: PAPEL DEL SISTEMA ENDOCANNABINOIDE	YES	Serrano Criado, Antonia M.	RODRÍGUEZ DE FONSECA, FERNANDO
C-06/ C-01	Mañas Padilla, María Del Carmen	ALTERACIONES CONDUCTUALES Y COGNITIVAS INDUCIDAS POR COCAÍNA: BENEFICIOS DEL ENRIQUECIMIENTO AMBIENTAL	YES	Castilla Ortega, Maria Estela	SANTIN NUÑEZ, LUIS JAVIER
C-07/ A-01	Cabrera García, Pablo	EFECTO DEL FACTOR DE CRECIMIENTO INSULÍNICO TIPO II SOBRE EL DAÑO OXIDATIVO- MITOCONDRIAL Y NEURONAL INDUCIDO POR MPP+ Y CORTICOSTERONA EN NEURONAS DOPAMINÉRGICAS EN CULTIVO	NO	Martín Montañez, Elisa	ROMERO ZERBO, SILVANA YANINA
C-08	Fernández Fernández, Eloísa	EFECTIVIDAD DE LA EVALUACIÓN PREOPERATORIA VIRTUAL CON VIDEOCONFERENCIA EN CIRUGÍAS DE FEMINIZACIÓN FACIAL	NO	Garcia Agua Soler, Nuria	-

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
C-13	Gutiérrez Rodríguez, Laura Del Carmen	GRADIENTES DE COMPETENCIAS EN ENFERMERAS DE PRÁCTICA AVANZADA, ENFERMERAS ESPECIALISTAS Y ENFERMERAS CLÍNICAS GENERALISTAS	NO	Morales Asencio, Jose Miguel	García Mayor, Silvia
CIMO- 03	Moreno Barea, Francisco Javier	DESARROLLO DE TÉCNICAS DE AUMENTO DE DATOS PARA LA APLICACIÓN DE APRENDIZAJE PROFUNDO EN PROBLEMAS DE BIOINFORMÁTICA	YES	Franco, Leonardo	JEREZ ARAGONES, JOSÉ MANUEL
D-04	Fernández Santamaría, Rubén	CELLULAR RECOGNITION OF DRUG ANTIGENIC DETERMINANTS BY ALLERGIC PATIENTS. INCLUSION OF NEW PARAMETERS TO IMPROVE CELLULAR IN VITRO TESTS	YES	Torres Jaén, María José	FERNÁNDEZ DUARTE, TAHIA DIANA
D-04	Labella Álvarez, Marina	CARACTERIZACIÓN DEL FENOTIPO- ENDOTIPO E IDENTIFICACIÓN DE BIOMARCADORES EN LAS REACCIONES DE HIPERSENSIBILIDAD POR QUIMIOTERÁPICOS	NO	Torres Jaén, María José	BOGAS HERRERA, GÁDOR
D-05	Ho Plágaro, Ailec	PAPEL DEL DUODENO EN EL DESARROLLO DE LA OBESIDAD MÓRBIDA Y LA RESISTENCIA A LA INSULINA	NO	García Fuentes, Eduardo	-
D-05	Cueto Sanchez, Alejandro	PAPEL DEL SISTEMA INMUNE Y LA MICROBIOTA INTESTINAL EN EL DAÑO HEPÁTICO INDUCIDO POR FÁRMACOS. BÚSQUEDA DE NUEVOS BIOMARCADORES	NO	Lucena Gonzalez, M Isabel	-
DE-08	Mirón Fernández, Irene	ESTUDIO DE LAS DIFERENCIAS CLÍNICAS E HISTOLÓGICAS Y ANÁLISIS DE LA SUPERVIVENCIA EN CÁNCER DE COLON DERECHO E IZQUIERDO	NO	Mera Velasco, Santiago	-
F-02	Martínez Martínez, Sofía Louise	ENTREPRENEURIAL UNIVERSITY: ENTREPRENEURIAL HUMAN CAPITAL AND NEW SOCIOECONOMIC VALUE	YES	Ayuso Sánchez, Luis Manuel	-
F-03	Ginel Moreno, Pablo	SURFACE-EMITTING ANTENNAS FOR OPTICAL PHASED ARRAYS BASED ON SILICON WAVEGUIDES	NO	Ortega Moñux, Alejandro	-
F-10	Stamenkovic, Vladimir	DEVELOPMENT OF NOVEL NANOBIOSENSORS FOR DIAGNOSTICS OF ADVERSE DRUG REACTIONS	NO	Pérez Inestrosa, Ezequiel	-
F-14	Escriche Escuder, Adrian	ESTUDIO DE LAS CARGAS APLICADAS EN EL TRATAMIENTO DE LAS TENDINOPATÍAS EN FISIOTERAPIA	YES	Cuesta Vargas, Antonio Ignacio	-

256 EDUCATION

GROUP	DOCTORAL CANDIDATE	TITLE	EUROPEAN MENTION	NAME OF DIRECTOR 1	NAME OF DIRECTOR 2
F-14	Fernández Torres, Raúl	INSTRUMENTOS DE EVALUACIÓN EN POBLACIÓN CON ENFERMEDAD DE PIE DIABÉTICO	YES	González Sánchez, Manuel	-
F-14	Pérez Panero, Alberto José	ABORDAJE DEL PIE DIABÉTICO SEGÚN LAS GUÍAS DE PRÁCTICA CLÍNICA Y SU EVALUACIÓN MEDIANTE PATIENT- REPORTED OUTCOME MEASURES (PROMS)	YES	Ruiz Muñoz, María	GONZÁLEZ SÁNCHEZ, MANUEL
F-15	Hurtado Requena, Sandro	INTEGRATION AND ANALYSIS OF BIOMEDICAL DATA FROM MULTIPLE CLINICAL TRIALS	YES	Navas Delgado, Ismael	-
F-15	Para Fernandez, Jesús	APLICACIÓN DE TÉCNICAS DE APRENDIZAJE AUTOMÁTICO Y OPTIMIZACIÓN A PROBLEMAS REALES EN LA INDUSTRIA 4.	NO	Nebro Urbaneja, Antonio Jesus	-

IBIMA Plataforma BIONAND Educational Program

Educational activities organized by IBIMA in 2023:

- Series of meetings of the Clinical Neurosciences Clinical Unit, Neuroimmunology, and Neuroinflammation Group.
- Conference on female scientists and gender equality in the SSPA.
- 9th Transfer Conferences of the Clinimetrics Group.
- Introduction to spectral cytometry.
- Webinar III: Learning from ERC Advanced Grants 2021. The experience of 3 ERC Grantees.
- IX Interdisciplinary Conference on Advances in Rare Diseases IBIMA-Rare.
- I Izasa Scientific Conference.
- BIMA Platform BIONAND X Anniversary Conferences. 'El Corte Inglés' Cultural Space.
- 24th Edition of the Online Course on Good Clinical Practice Standards.
- Leadership, Biomedical Research, and Clinical Context: Difficulties and Opportunities
- Independent Clinical Research Methods.
- Critical Reading for the Uninitiated.
- Workshop on APC management (open access journal publishing and funding the costs)
- Use of different statistical software (R, SPSS, Grapada, etc.).
- Psychodynamic Psychotherapy (PDP) Program 2022–2023 edition.
- Workshop on open research data management.
- GenScript Visit
- Research career + two researchers
- Data Protection
- Bioinformatics (Genomics, Proteomics, and Metabolomics)
- * EATRIS Plus Summer Course on Precision Medicine "Multimodal Biomarkers and Diagnostics"
- APA Standard Workshop
- Workshop on visibility of scientific production
- IX University Extension Course on Animal Experimentation, Welfare, and Protection in Research and Teaching. A, B, C Functions
- II Izasa Scientific Conference
- Basic and advanced aspects of proteomics

- Information day about the Cost program
- Creation of a research project budget
- Good laboratory practices course
- XXII Conferences on Hepatology 2023
- Biobank. General information
- Basic statistics in biomedical research and research methodology.
- I Nursing Research Conferences
- Researchers' skills on communicating science to the public
- Flow Cytometry Unit. Basic and Translational Research Applications
- Informative talk on the new COST actions approved
- Information day on the European Research Council (ERC) to promote the participation of the Andalusian scientific community.

ibima Plataforma BIONAND 2023 SCIENTIFIC REPORT 257

- Residents' Day at the Maternal and Children's Hospital
- Residents' Day at the Virgen de la Victoria University Hospital.
- Talk by Emilio Alba "Straight talk about cancer"
- Gene therapy for rare diseases
- From a research career to the pharmaceutical industry: a round trip?
- Creation and management of databases (November)
- II Primary Care Research Conferences
- Basic Bioinformatics
- Advanced Statistics
- Industrial and intellectual property management (SPTO patents)
- I Endometriosis Conference
- Conference on treatment adherence: the patient's perspective
- Mandatory research training program for specialists in training at the Midwifery Teaching Unit of Málaga province.
- How to carry out a health sciences research project
- Advanced office software
- Access to international consortiums in the scope of Horizon Europe
- How to start a career in biomedical teaching and research at the university



COMMUNICATIONS



260 COMMUNICATIONS

Changes in the number of news items appearing in the press that refer to IBIMA Plataforma BIONAND in the five years (news items also published in the health portals of the Regional Ministry of Health and Consumer Affairs and the Andalusian Health Service; websites of the University of Málaga and the Regional Hospital of Málaga and the Virgen de la Victoria Hospital) and disseminated through their corporate social networks:

CHANGE IN NUMBER OF NEWS ITEMS PARTICIPATED IN




Figure 58: Changes in the number of news items participated in from 2019–2023

PRESS RELEASES:

A total of 98 press releases have been created that were coordinated with both the University of Málaga and with the Regional and Virgen de la Victoria University Hospitals in 2023. There were 83 in 2022 and 77 in 2021.

PRESS HITS:

These 98 releases, together with other information from different journalistic genres, have led to 1,650 hits in both online and in the print media in 2023.

Some of the most significant news items of 2023:

EuropaPress. IBIMA receives a donation from ASAMMA for genetic research related to metastatic breast

EuropaPress. IBIMA and the Regional Hospital of Málaga raise €11,350 for biomedical research in the 7-a-side soccer tournament.

DiarioSUR. Last year, IBIMA raised €30 million for research, 6 million more than in 2022.

EuropaPress. IBIMA obtains a €1.5-million international grant to advance myocardial infarction research. DiarioSUR. A study conducted in Malaga links melatonin to breast cancer tumor reduction.

DiarioSUR. An IBIMA study reveals that 40% of older adults with hip fractures have malnutrition.

La Opinión de Málaga. An algorithm capable of differentiating between two types of hepatitis has been

Infosalus. Extra virgin olive oil may inhibit the angiogenesis that causes cancer metastasis.

In regard to audiovisual news hits, the institute appeared a total of 349 times on television and there were 229 mentions on the radio. In total, there were a total of 578 hits in audiovisual media in 2023. The media's rebroadcasts of their news items in different programs throughout the day or news bulletins as well as other television genres other than news programs, such as interviews with the research community as an extension of the official information disseminated through press releases, are also included. Images that the news media have obtained through news items provided in press conferences are also included.

AUDIENCE:

In regard to the website's audience, 57,333 users accessed the website in 2023. This figure has remained stable compared to the previous year due to the release of the new website during the last quarter of the year. The number of pages viewed by users was 339,000, which was a slight increase in the number of pages viewed. What's more, the average session duration was two minutes and ten seconds, a slight increase compared to 2022. The user profile has the following characteristics:

- These are users who tend to browse the website quite often, visiting several pages within the website in the course of their session (1.8 pages per session).
- More than 75% of the audience is between the ages of 18 and 44 and those aged 25 to 34 are the most common, representing more than 35% of visitors.
- In 2023, the balance between men and women who visit the website remained steady, with a similar percentage as in 2022: practically 50%.
- Spain, the United States of America, and Mexico are the three most common countries of origin of the audience, representing 77.36%, 3.32%, and 1.15% of traffic, respectively.
- **ACQUISITION:** The acquisition of users who enter the website is in line with the channel through which they access it. Based on the data extracted, the following conclusions can be drawn:
- Compared to the 73.8% organic traffic recorded in 2022, there was a 64.41% increase in 2023, while direct traffic grew from 19.1% to 30%. This indicates an increase in brand awareness and a user profile that knows the URL of the website and accesses it directly in the browser.
- Social traffic served as a channel to the website for 1.54% of users, while email experienced a slight increase to over 1.5%.
- The user profile, therefore, is a user who continues to access the website through organic traffic, although there is greater knowledge of the direct link to the website, which is why the greatest increase in acquisition in the last year was through this method. In other words, it is accessed through different search engines. There was a reduction in social network and direct traffic, while email traffic remained practically stable.

Finally, in terms of social networks, the total number of followers is 13,884:

Facebook:	1,678 followers
Twitter:	4,080 followers
LinkedIn:	6,432 followers
Instagram:	1,632 followers
Youtube:	62 followers



ibimo Plataforma BIONAND 2023 SCIENTIFIC REPORT 265

The IBIMA BIONAND Platform spaces dedicated to research total 9,612 m². They are distributed between the Regional University Hospitals (General H. and Civil H.) and the Virgen de la Victoria University Hospital in Málaga and the University of Málaga (UMA), by virtue of agreements signed for the use of spaces and/or shared use, as well as the Malaga TechPark building.

The following is a description of the ECAIs that support the various research groups and are necessary for carrying out the institute's activity.

Shared Research Support Services (ECAI)

- * CLINICAL RESEARCH AND CLINICAL STUDIES (7th floor of the HURM and Phase I Unit at the HUVV.
- METHODOLOGICAL AND STATISTICAL ADVISORY SERVICE
- GENOMICS (node in the Malaga TechPark building, node in the IBIMA laboratory at the HUVV, and node on the 1st floor of the UMA Bioinnovation building at Málaga TechPark)
- PROTEOMICS (SCAI building of the UMA on the Teatinos Campus)
- CELL THERAPY AND GMP ROOMS (7th floor HURM)
- BIOBANK (basement of pavilions 5 and 6 of the Civil H.)
- ANIMAL EXPERIMENTATION (Málaga TechPark building and Animal Experimentation Center at the UMA, Teatinos Campus).
- * BIOINFORMATICS (Malaga TechPark and UMA building, Bioinnovation building in the Málaga TechPark).
- CELL BIOLOGY (CYTOMETRY AND CULTURES) (Málaga TechPark building and laboratories 1, 2, and 3
 in the hospitals)
- NANOIMAGING (Málaga TechPark building).
- HISTOLOGY (Málaga TechPark building).
- CHEMISTRY (Málaga TechPark building).

Common Research Spaces (Laboratories):

- Laboratory 1. Location: Civil Hospital (HRUM), basements of pavillions 2, 5, and 6.
- Laboratory 2. Location: Virgen de la Victoria University Hospital.
- Laboratory 3 or Regenerative Medicine Laboratory (LMR, for its initials in Spanish). Location: Basement of the HRUM Administration Wing.
- Phase I Clinical Trials Unit: Virgen de la Victoria University Hospital.
- Phase II-III Clinical Trials Unit: Virgen de la Victoria University Hospital.
- Laboratories of the Málaga TechPark building.

Common Research Spaces in the laboratories of the School of Medicine (Pharmacology Department), School of Health Sciences (experimental and human movement laboratory), School of Sciences (Laboratory BIO-267 and cellular biology, animal and plant physiology, and Department of Organic Chemistry laboratories), School of Psychology (laboratories in basic physiology, psychobiology, and behavioral sciences methods), all located on the Teatinos Campus of the University of Málaga.

PRIMARY CARE research space: Two offices on the 2nd floor of the Civil Hospital.

CLINICAL STUDIES

We conduct research to contribute to improving citizens' health. Our commitment is shared with industry leaders, who rely on our institute to conduct their clinical trials thanks to the robustness of our healthcare system, the high level of training of our professionals, and our state-of-the-art infrastructure for the optimal performance of clinical research activity.

Independent Clinical Research and Clinical Trials Unit (UICEC)

IBIMA Plataforma BIONAND's Clinical Research and Clinical Trials Unit is a multidisciplinary support structure for the research groups at the research institute — the Regional and Virgen de la Victoria University Hospitals of Málaga and primary care — to conduct clinical research studies.

The IBIMA UICEC forms part of the Spanish Clinical Research Network (SCReN) and is partially funded by the Carlos III Institute of Health (PT23/00137; PT20/00127). On the European level, SCReN forms part of ECRIN, the European Clinical Research Infrastructure Network. SCReN is a national hub and supports and manages international multicenter clinical trials.

Services:

- Methodological and regulatory scientific advising.
- Management and administrative processing.
- Scientific coordination and management of clinical research.
- Scientific management of clinical research.
- Performing studies: Pre-start-up for clinical trials, conduct, finalization, and close-out.
- Monitoring.
- Pharmacovigilance.

Coordinator: Ms. María Isabel Lucena González, Scientific Director of UICEC.

Personnel in 2023: 9 Professionals

Clinical Studies Unit of the Regional University Hospital of Málaga

The aim of the Clinical Studies Unit of the Regional University Hospital of Málaga is to foster and promote observational studies and national and international clinical trials at the center in order to generate knowledge and improve patient health.

The platform's coordinator is the institutional representative of the center before the clinical units, the pharmaceutical industry, and the CRO. Operationally, it is under the institution's managing director.

Services:

- Technical and administrative support to promote and dynamize the management and conduct of clinical trials and commercial observational studies.
- Promote the research activity of the clinical units for both consolidated and emerging units.
- Increase the number of commercial, national, and international clinical trials.
- Resolution of incidents that hinder the conduct of clinical trials.
- Optimize contract management and metrics/timing.

Coordinator: Mr. Francisco Carabantes Ocón

266 COMMON RESEARCH SUPPORT SERVICES (ECAI) 2023 SCIENTIFIC REPORT 267

Clinical Studies Unit of the Virgen de la Victoria University Hospital in Málaga

The aim of the Clinical Studies Unit of the Virgen de la Victoria University Hospital Málaga is to foster and promote national and international observational studies and clinical trials at the center in order to generate knowledge and improve patient health.

The platform's coordinator is the institutional representative of the center for the clinical units, the pharmaceutical industry, and the CRO. Operationally, it is under the institution's managing director.

Services:

- Technical and administrative support to promote and dynamize the management and conduct of clinical trials and commercial observational studies.
- Promote the research activity of the clinical units for both consolidated and emerging units.
- Increase the number of commercial, national, and international clinical trials.
- Resolution of incidents that hinder the conduct of clinical trials.
- Optimize contract management and metrics/timing.
- Manage the infrastructure of the Phase II/III clinical research assistance area.

Phase II/III clinical research care area

Newly created area with more than 600 square meters for phase II and III clinical research with a total of ten consultation rooms, a samples collection room, a day hospital, and sample processing rooms.

Coordinator: Mr. Manuel F. Jiménez Navarro

Phase I Clinical Trials Unit

The Phase I Clinical Research Unit, located in the Virgen de la Victoria University Hospital, can be directly accessed from outside the hospital. It has a user reception area, a consultation room for samples collection, a nursing station, two consultation rooms, a day hospital, and two double rooms.

Coordinator: Mr. Javier García Corbacho.

Main results 2023:

No. of active independent clinical trials	No. of new independent clinical trials	No. of new early phase (I-II) clinical trials	Revenue from clinical trials (€)
316	34	80	8.697.620,90€

Location: This platform is located on the first floor (Phase I Clinical Trials Unit) and on the 2nd floor (Phase II/III Clinical Research Care Area) of the Virgen de la Victoria University Hospital and on the 7th floor of Pavilion A of the Regional University Hospital of Málaga.

METHODOLOGICAL AND STATISTICAL ADVISORY SERVICE

The aim of this research advisory unit for research groups is focused on fulfilling the full potential to generate data that are crucial to detect, solve, and prevent problems related to patients' health. It offers specialized biomathematical support that adds rigor and takes special care in design, implementation, and analysis. It provides scientific support that bridges the gap between clinical and translational research.

Services:

- Methodological and epidemiological advising: Methodological advising and/or review of research protocols, analysis of the grounds for rejecting projects, review of scientific articles.
- Statistical advising: sampling and sample size calculation, descriptive analysis of data, inferential
 analysis (bivariate and multivariate), support in the use of free software for statistical analysis, and review
 of scientific articles.
- Advising to research groups: gathering knowledge about the work conducted in the research groups to support starting lines of research or clinical innovation and identify and promote possible inter-unit, inter-center, and international collaborations. Support for groups' research personnel in the exploitation of their data as well as in the dissemination of their experimental results in national and international forums. Advising for research groups on their research interests in order to define objectives and outline appropriate strategies to achieve them.
- Educational activities: education on research methodology, the use of free software for statistical data analysis, advanced statistics, preparation of a scientific manuscript for publication in peer-reviewed scientific journals, critical reading of scientific literature, and specific educational courses according to researchers' needs.

Coordinator: Rita Pérez González

GENOMICS

Platform that facilitates sequencing services (DNA using the Sanger method, Ultrasequencing, and Pyrosequencing) and SNP genotyping. It also creates genetic reports of monogenic diabetes. It is accredited in good practices according to the ISO 17043 standard coordinated by the European Molecular Genetics Quality Network (EMQN), which it participates in annually.

The Genomics ECAI provides technical and methodological support for research projects for the use of data and statistics. It provides services in two ways:

- Internal service through temporary access for IBIMA Plataforma BIONAND researchers who need its infrastructure to conduct research projects funded by different programs.
- External services to public and private, national and international institutions.

It is organized into two sections:

Genotyping, sequencing, pyrosequencing, and miRNA expression section, which encompasses the largest percentage of the work requested.

Ion GeneStudio S5 System

Biomarkers section, in which diagnostic, prognostic, progress, or treatment response biomarkers are identified. This section provides support to numerous projects. The ECAI is part of EATRIS (European Advanced Translational Research Infrastructure in Medicine).

This ECAI also includes the CIBER-IBIMA Metagenomics Platform, which provides microbiota analysis services to national CIBER researchers as well as to internal and external researchers who request it. The following infrastructure, distributed in different lines, is available to provide the portfolio of services:

Nucleic acid extraction area
Fume extraction hood
Maxwell automated DNA extraction
QIAcube automated DNA extraction
NanoDrop 2000 C nanospectrophotometer
Qubit 4 Fluorometer
Biotek Synergy MX Fluorimeter
Nucleic acid amplification area:
Thermocyclers:
QIAamplifier 96, Qiagen
MyCycler gradient, Bio-Rad
Mastercycler gradient, Eppendorf
Veriti 96-Well Thermal Cycler, Applied Biosystems
Real-time thermal cyclers:
CFX96 Real Time System, Bio-Rad
The LightCycler® 480 Instrument II, Roche Diagnostics
7500 Fast Real-Time PCR System, Thermo Fisher Scientific
Mx3005P qPCR real-time PCR, Agilent Stratagene
QuantStudio 6 Flex Real-Time PCR System
QuantStudio 12 Real-Time PCR System
Nucleic acid amplification area:
Pyrosequencing:
PyroMark Q96 ID, Qiagen
PyroMark Q48 Autoprep, Qiagen
Sanger sequencing:
Avant Genetic Analyzer 3130XL, Applied Biosystems
Next Generation Sequencing (NGS):
Ion Chef System

ibimo Plataforma BIONAND 2023 SCIENTIFIC REPORT 269

Scientific Coordinator: Dr. Isabel Moreno Indias

Personnel in 2023: 2 Technicians

Location: This platform's main headquarters is located at the IBIMA Plataforma BIONAND building in Malaga TechPark. It also has spaces in the basement of Pavilion 5 of the Civil Hospital (Regional University Hospital of Málaga) and in the laboratory on the 1st floor of the Virgen de la Victoria University Hospital.

PROTEOMICS

The main objective of this platform is to provide scientific and technical support and advising in the identification and characterization of proteins and other biomolecules, mainly through mass spectrometry techniques.

Services:

- Sample preparation:
- Protein extraction.
- Desalting and concentration of samples.
- Peptide purification through RP-HPLC.
- Manual and automated enzymatic digestion of proteins in gel and in solution.
- Preparation of histological sections for MALDI-Imaging.
- Sample preparation for MALDI-Imaging of colonies.
- Chromatography:
 - HPLC: High Performance Liquid Chromatography.
 - FPLC: Fast Protein Liquid Chromatography.
- TLC: Thin-layer Chromatography.
- Mass spectometry:
 - Determination of protein molecular masses.
- Identification of proteins in purified samples and complex mixtures.
- Relative protein quantification by: LFQ, TMT, SILAC.
- Study of post-translational modifications.
- Analysis of protein profiles.
- Study of the spatial distribution and relative abundance of analytes in intact samples of animal or plant tissues through MALDI-Imaging.
- Study of bacterial metabolite profiles in microbial colonies and/or biofilms through MALDI-Imaging.
- Immunoassays: simultaneous detection and quantification of different secreted proteins (cytokines, chemokines, growth factors, etc.) by means of immunoassays based on Luminex technology.

Coordinator: Mr. Javier Marquez Gómez

Personnel in 2023: 3 Technicians

Location: This platform is located in the Proteomics Unit, 2nd floor of the SCAI building of the University of Malaga.

CELL CULTURE AND CYTOMETRY

CELL CULTURE

The Cell Culture Unit provides the institute's research groups and other public or private institutions the possibility of culturing and maintaining cells (mainly murine and human), including both primary cultures and established cell lines, offering advising from specialized personnel and the conduct of assays with guaranteed flexibility and adaptation to specific requirements.

Services

GENERAL:

- Maintenance and disinfection of biosafety hoods.
- Maintenance and disinfection of incubators.
- Regular change of water in CO2 incubators.
- Maintenance and disinfection of thermostatic baths.
- Periodic analysis of mycoplasma contamination in incubators.
- Solid waste disposal and treatment and disposal of liquid waste.
- Equipment and facilities for the use of viral vectors in cell culture.
- Daily monitoring of temperature and CO2 in incubators.
- Annual certification of cabins and incubators.

SPECIFIC:

- Advising on the acquisition and maintenance of cell lines.
- Cryopreservation of samples.
- Analysis of mycoplasma contamination.

Scientific Coordinator: Dr. Elena González Muñoz

Personnel in 2023: 1 Technician in charge shared with the Animal Housing Unit.

Main results 2023:

- Addition of 1 new research group and service to 15 research groups in regard to the services offered.
- Education and training on the correct use of the Unit for the personnel of 12 research groups (37 users).
- User management using a calendar in Clustermarket as well as billing of services provided to internal and external entities has been incorporated.

DISSEMINATION:

- 1. 3 visits organized for high school and vocational training students.
- $2. \quad 3 \ visits \ organized \ for \ undergraduate \ biology \ students \ at \ the \ University \ of \ Malaga.$

CYTOMETRY

The main objective of this unit is to provide support for the conduct of research studies carried out by the different groups that form part of the Institute or other research centers through scientific advising, sample analysis, and presentation of results in the field of flow cytometry.

The unit's primary mission is to provide efficient, quality service in order to promote and carry out research.

The catalog of services includes, among others:

- Analysis of cell populations via fluorescence:
 - Identification of cell populations through intracellular or extracellular antigen labeling
 - Cell viability, cell cycle, and apoptosis studies using vital dyes (Annexin-V/Propidium Iodide, TUNEL, mitochondrial membrane potential determination, sub-G0 peak detection, etc.)
 - Studies of oxidative stress using fluorescent probes
 - Determination of cell proliferative index using labeled nucleoside analogs (BrdU)

- Fluorescent protein-guided gene expression studies (GFP, YFP, etc.)
- Quantification of cytokines and other soluble proteins
- Intracellular Ca2+ mobilization studies
- Spectral analysis: Provides the possibility to analyze up to 40 colors
- Cell sorting from single cells collected in tubes or plates

Scientific Coordinator: Dr. Elena González Muñoz

Personnel in 2023: 1 Technician specialized in cytometry and cell separation.

Main results 2023:

- Incorporation of a specialist technician. This has made it possible to bring this technology closer to users who have no previous knowledge and to improve experiment design and results analysis.
- Establishment of the spectral cytometry and cell separation service on new equipment (separation cytometer with spectral technology) as part of the portfolio of services offered by the unit.
- Incorporation of a cytometer analyzer that allows for automatic reading from a plate.
- Ten research groups used the cytometry unit, including both independent users of the analyzer and users of the spectral cytometry and cell separation services offered by the specialist technician.
- Seven users were trained to use the cytometer analyzer correctly and autonomously.
- User management using a calendar in Clustermarket as well as billing of services provided to internal and external entities has been incorporated.
- A cytometry analysis software license has been purchased and access has been granted to five users.

DISSEMINATION:

- 1. Introductory talk on the Cytometry Unit for IBIMA-BIONAND
- 2. Several visits organized for high school and vocational training students, undergraduate biology students (University of Malaga), and representatives of other entities, as well as occasional visits by researchers from other institutions

Location: This platform is located in the IBIMA BIONAND platform building in Malaga TechPark.

CELL THERAPY AND GMP ROOMS

The institute's Cell Production Unit (UPC) has three rooms authorized for the aseptic manufacture of advanced therapy drugs according to GMP (Good Manufacturing Practices) standards. The facilities meet the quality and safety requirements necessary for aseptic drug manufacturing. The facilities meet the quality and safety requirements for the aseptic manufacture of medicines according to the Spanish Agency of Medicines and Medical Devices (AEMPS) guidelines since 2012. It is part of the Andalusian Network for the Design and Translation of Advanced Therapies (RADyTTA), whose objective is to promote the development and application in clinical practice of the results obtained from research in the fields of cell, tissue, gene, and nanomedicine therapy.

In addition, through the RADyTTA, the unit belongs to the RICORS Network of Advanced Therapies (TERAV), which aims to establish the scientific collaborations necessary for the clinical development of safe and effective advanced academic therapies and the coordination of networked technological structures that facilitate the translation of these therapies to the National Health System in order to facilitate their clinical translation and patients' access to them.

This unit is authorized by the Spanish Agency of Medicines and Medical Devices for the manufacture of cell therapy drugs based on expanded adult mesenchymal adipose tissue-derived stem cells (ADSCs) for autologous or allogeneic use as well as the conduct of the corresponding quality controls according to the European Pharmacopoeia (Ph. Eur) for use in clinical trials in diseases that do not have or do not adequately respond to conventional treatments, such as amyotrophic lateral sclerosis (ALS), structural fecal incontinence, or acute cerebral infarction or stroke, and severe SARS-CoV-2 pneumonia.

Plataforma BIONAND 2023 SCIENTIFIC REPORT 273

In addition, it manufactures drugs for compassionate use procedures with prior authorization from the AEMPS for the following diseases:

- Graft-versus-host disease (GVHD)
- Neurological diseases: ALS, multiple sclerosis
- Fecal incontinence
- Severe SARS-CoV-2 pneumonia.
- Pediatric craniosynostosis

It pioneered the First External Quality Program in Advanced Therapies (www.eqa-atmp.com), which aims to standardize and verify the quality of the tests and techniques used in the manufacture of advanced therapy drugs.

The ECAI is currently collaborating with the University of Málaga on the creation of a 3D bioprinting platform for the preclinical evaluation of customized implants manufactured by bioprinting for the surgical correction of critical cranio-maxillofacial defects in pediatric patients.

Services:

- Isolation of adult mesenchymal stem cells derived from adipose tissue, in vitro expansion to obtain the dose assigned according to protocol, and subsequent packaging.
- Quality controls for cell therapy trials.
- Environmental and surface microbiological control of facilities with ISO classification: air volumetrics, settle plates, surfaces using contact plates.
- Grading of thermal equipment: refrigerators, freezers, stoves, etc.
- Microbiological control testing of cellular products (Ph. Eur. 2.6.27), Mycoplasma (Ph. Eur. 2.6.7), endotoxins (Ph. Eur. 2.6.14), characterization of cellular products (Ph. Eur. 2.7.24), cell count and viability (Ph. Eur. 2.7.29), promotion of cell growth in culture and cell population doublings, genetic stability of advanced therapy medicinal products, cell recovery rate after thawing.
- Potency assay by estimating the immunosuppressive capacity of mesenchymal cells.
- Methodological, scientific, and technical advising on cell therapy clinical trials.
- Management, evaluation, and advising on trial documentation.
- Education on an introduction to cell therapy.
- External Quality Assurance Program in Advanced Therapies.

Coordinator: Dr. Antonio Rodríguez Acosta

Personnel in 2023: 3 Technicians

Main results 2023:

- In 2023, 45 batches of ADSC-based drugs were manufactured for compassionate use for patients with GvHD (allogeneic treatment).
- Quality control tests were performed the Grenoble Tissue Center (France) and for the Regional Transfusion Center of Málaga.
- Three batches of drugs were manufactured for a multicenter, randomized, double-blind, Phase IIb clinical trial to evaluate the safety and efficacy of intralesional administration of two doses of expanded allogenic adipose tissue-derived stem cells (ADSCs) conditioned in hyaluronic acid hydrogel as a treatment for patients with fecal incontinence.
- It expanded participation in the External Quality Assurance Program for Advanced Therapy Medicinal Products (www.eqa-atmp.com) to the most prestigious regional tissue and blood bank establishments in the country.
- Since 2012, it has been actively collaborating with the RADyTTA, the Graduate School, and the University
 of Granada to offer a Master's Degree in Manufacturing of Advanced Therapy Medicinal Products.
- Since 2021, it has been collaborating with the International University of Andalusia in the teaching of the Master's Degree in Advanced Biotechnology.

It has become part of the EATRIS European platform and the ISCIII's 3D Printing and Bioprinting HUB platform.

Location: This platform is located in the Cleanroom, 7th floor of Pavilion A of the Regional University Hospital of Málaga.

BIOBANK

One of the institute's research support structures is the Provincial Biobank of Málaga, which in turn belongs to the Andalusian Public Health System Biobank. It is a unique biobank structure in terms of its potential and capacity for obtaining, transforming, preserving, and distributing samples for research purposes. It comprises 26 nodes located in SSPA (Andalusian Public Health Service) health centers. The Provincial Biobank of Málaga comprises 3 nodes: the Regional University Hospital of Málaga, the Virgen de la Victoria University Hospital, and the Costa del Sol Hospital in Marbella. It also has the support of the regional hospitals and the Axarquia, Ronda, and Antequera Hospitals.

It is registered and authorized by the competent authorities with file number B.0001601 dated 09/16/2020 and is under the Regional Government of Andalusia's Regional Ministry of Health and Families. The Costa del Sol Biobank has its own registration, with file number B.0000414, and is under the Costa del Sol State-Owned Company, 12/03/2012.

The Provincial Biobank of Málaga was started 14 years ago. Since its inception, it has worked to become what it is today: a platform of services for provincial researchers, most of whom belong to the Institute, that allows users to carry out their projects with the assurance that the biobank guarantees that the ethical, legal, and technical requirements for biological samples and their associated data are met.

Services:

- Provision of samples and data for research projects.
- Provision of samples and data for clinical trials in collaboration with the Clinical Trials Platform of Málaga.
- Processing of samples.
- Preservation of samples at different temperatures.
- Technical, scientific, ethical, and quality advising on the collection, storage, and management of human samples in biomedical research.
- Files for diagnostic confirmation.
- Real-time web-based remote equipment monitoring.

Work is being done to optimize tasks according to employee's positions, standardize procedures, improve the management of clinical care samples with primary care, improve services for clinical trials, and unify strategic lines.

The manners in which the biobank provides these services are:

- Requests for sample provision: activation of circuits for sample collection, delivery of samples or data, and their custody.
- Requests for custody: use of facilities for sample conservation.
- Requests for processing: processing of samples for researchers.

Scientific Director: Ms. María Luisa Hortas Nieto

Coordinator: Tatiana Díaz Córdoba Personnel in 2023: 7 Technicians


Main results 2023:

Services provided to research projects:

No. of users ANNUAL TOTAL	HRUM	HUVV	HCS
103	63	37	3


1. Sample collection and receipt

NEW DONORS




Note: it should be noted that these data are only counted when we can assign donors, i.e. they have signed the biobank informed consent form.

NEW DONATIONS




NUMBER OF INITIAL SAMPLES REGISTERED



276 COMMON RESEARCH SUPPORT SERVICES (ECAI) 2023 SCIENTIFIC REPORT 277


2. Use, distribution, and tracking of bioresources

NUMBER OF TOTAL SAMPLES DISTRIBUTED




3. Requests

NUMBER OF TOTAL REQUESTS RECEIVED (LOCAL AND FROM THE NETWORK)



NUMBER OF REQUESTS RECEIVED BY TYPE OF REQUEST



Services provided to clinical trials:

Number of first visits attended to	77
No. of active trials (cumulative)	370
No. of requests attended (samples for clinical trials)	658
Mean biobank management time (days)	0.87
Mean actual response time (days)	1.35
Maximum actual response time (days)	5
Number of samples outside hospitals without the Málaga biobank	40
No. of samples from hospitals outside Málaga	3
No. of complete blocks delivered	2167
Express biopsies attended to	84

Resources and infrastructure:

The biobank's resources and infrastructure have increased significantly in the last 3 years, which shows that it is a consolidated unit with a clear vocation for expansion and growth, generating the synergies necessary for the ongoing development of the structure according to demand. In this sense, the institute continues to provide important support to this unit: it covers the costs of equipment maintenance and repair, commits to acquiring the necessary equipment for the structure, and provides its technicians with the necessary tools to advance in their professional careers.

At present, its facilities cover 346 m², of which 230 m² correspond to four cryopreservation rooms. The remainder is divided into four sample reception and registration areas and three processing laboratories.

All of its locations have the necessary equipment for the transformation of the biological sample and their conservation according to the standard operating procedures. The cryopreservation rooms have equipment for preserving samples at -196 °C (11), -80 °C (44), -20 °C, 4 °C (5), and room temperature (5). It features digital temperature monitoring, validation with an external probe, 24/7 alarm management, connection to a power generator, independent air conditioning, CO2 and O2 detection, forced ventilation activation, etc. In addition, there are internal and external maintenance plans for all available equipment as well as a comprehensive emergency plan. The sample processing laboratories are also equipped with IIA biological safety laminar flow cabinets (2), microtome, tissue safe, refrigerated centrifuges (2), and other laboratory equipment.

Invoicing for services:

Invoicing for services provided during the 2023 financial year was done entirely through the Andalusian Public Foundation for Progress and Health and totaled €73,867.50. Málaga represents 51.54% of the total income of the SSPA biobank, a total of €143,329.83.

Publications:

Article: "Measurement of yield and quality of DNA in human buffy coat is extraction method dependent." T. Díaz, J. Ortega-Pinazo, B. Martínez, A. Jiménez, J. M. Gómez-Zumaquero, Z. Caracuel, M. L. Hortas & P. Ferro. Preparative Biochemistry & Biotechnology DOI:10.1080/10826068.2022.2119574. 09/19/2022

Research projects led and collaborations:

- 1. Principal LR Biobank (Francisco Tinahones Madueño). National Platform for Biobanks, Biomodels, and 3D Printing, PT23/00049, ISCIII. Total amount: €287,680. Duration: 3 years.
- 2. Principal LR Biobank (María Luisa Hortas Nieto): Participation in the CJS2017 call with an Innovation project. Funded, file: PIN-0191-2017. Title: "Development of a multiplatform web application that facilitates real-time communication between research sample donors and the Andalusian Public Health System biobank." Total amount: €49,358.26. Completed in the first quarter of 2022.
- Collaborating LR Biobank: Participation in the CJS2017 call with an Innovation project. Granted, file: PIN-0302-2017. Title: Pinnocav Project: Development, Implementation, Piloting, and Evaluation of a Platform for Organizational Innovation and Personalized Medicine for the Optimization of the Care Process and Management of Patients with Bladder Cancer. Completed in the first quarter of 2022.
- 4. Garantía Juvenil POJE 2022 (POEJ-00039-29): Funded. Hiring of 1 Technician in training.

Internalization of the structure:

The Biobank, Organoids, 3D Printing, and Animal Biomodel Platform provides services to IBIMA researchers to conduct their research activity in international and national networks. The international networks that IBIMA participates in are:

- European Biobanking research infrastructure (BBMRI-ERIC) (https://www.bbmri-eric.eu): European research infrastructure for biobanks, which brings together the main actors in the field of biobanks to promote biomedical research. This network offers a variety of services. It includes 20 countries as full members and 5 countries as observers. Spain has been an observer member since November 2021. In Málaga, we work in full alignment with the national and European strategy as part of this network of networks. Málaga stands out in the quality objective, co-leading one of the working groups.
- European Infrastructure for Translational Medicine (EATRIS) (https://eatris.eu): European infrastructure formed by more than 80 cutting-edge translational medicine research institutes. It has four platforms; IBIMA participates in two of them: Advanced Therapies Platform and Biomarkers Platform, providing cutting-edge technologies and synergies to advance the development of innovative therapies, vaccines,

and diagnostics. The platform collaborates by offering collections of samples and associated clinical data to the scientific community and promoting direct international collaborations. A member of the team has been selected for a training program within EATRIS Plus that aims to forge ties and exchange knowledge, the foundation of all collaborative networking.

Educational and Research Activities:

Туре	Number
3.1Education Provided	15
Education Received	20
3.2Communications at conferences	4
3.3Publications	1
3.4Participation in research projects	4
3.4Outreach activities	4

Among the **education provided**, the following are noteworthy:

- Workplace mentoring of a clinical analysis laboratory advanced vocational training student.
- Training of Litoral High School teachers for the dual degree "Specialization Course on Cell Cultures."
- Participation in teaching for the Master's Degree in Biomedical Research on Diabetes and Obesity. 60
 ECTS credits. 2022-2023 school year. Participation in 1 cancer clinical trial.
- Online Clinical Session (Webinar): Biobank of the Andalusian Public Healthcare System in the clinical field. IAVANTE. 06/08/2022 I Ed. 06/27/2023 II Ed.
- Online Course: "Management of samples for research" organized by the SSPA biobank, accredited by the Andalusian Healthcare Quality Agency (ACSA).

Conferences:

Participation in the "I Workshops of the ISCIII Biobanks and Biomodels Platform," October 26-28, with the following communications accepted:

- "BIOBANKS AS KEY SUPPORT UNITS IN HOSPITALS: OUR EXPERIENCE IN THE HIPRA COVID-19 VACCINE CLINICAL TRIAL" Author: Carmen Cañadas Jiménez
- * "BIOBANKS AS KEY SUPPORT UNITS IN HOSPITALS: EXPRESS BIOPSY," Author: Ana Toledo Arrebola
- * "APPROACHING OUR DONORS TO OFFER BETTER SOLUTIONS," Author: Tatiana Díaz Córdoba

Dissemination activities:

Notable among the dissemination activities of the Biobank ECAI to the public was the participation in the XI European Researchers' Night 2023 and the celebration of A Cup of Science as part of Science Week 2023. Furthermore, the ECAI recruited donors from the Andalusian Registry of Donors for Research (REDMI). In addition, the nursing students of the Divino Pastor Institute visited the facilities in an open doors day organized by our ECAI. Lastly, the ECAI participated in the X Conference of the Andalusian Sjögren's Syndrome Association with an information table and recruitment of REDMI donors.

Other notable results:

- Adaptation of the Biobank Information System for clinical trials management.
- Its certification was renewed in 2024 according to the ISO 9001-2015 standard. The unit is certified under the UNE-EN ISO 9001:2015 Standard and participates in the creation of national guidelines for the UNE-EN ISO 20387 accreditation of biobanks, under the coordination of the national platform.

- Notable new services and innovations introduced include the creation and implementation of the Donor Portal, developed thanks to autonomous community funding received for this competitive public innovation project. This portal facilitates real-time citizen participation in biomedical research in an easy and accessible way. Donors can consult the results of the research projects they have participated in, manage their informed consent forms, and consult the availability of samples, among other options. The results of this project have been protected through an intellectual property registration. The project received the IBIMA Plataforma BIONAND 2022 Award for innovations transferred to clinical practice for the results obtained. The Researcher's Portal was also created (Intellectual Property Registry FIMABIS-21008) in coordination with the SSPA biobank, which makes it possible to manage the entirety of an application online. In addition, the ECAI is working to better the website so as to improve user access to the platform.
- User satisfaction was greater than 8.5.

Location: This platform is located in Pavilion 5 in the basement of the Civil Hospital and in the Research Laboratory on the 1st floor of the Virgen de la Victoria University Hospital.

ANIMAL EXPERIMENTATION (UMA)

Maintenance, breeding, and housing of the animals used in different experimental procedures in ongoing research projects.

Services offered:

- Acquisition of animal models.
- Mouse/rat breeding and maintenance, transgenic models.
- Technical support service for performing experimental procedures.
- Advising on regulatory requirements for animal experimentation.
- Facilities:
 - Breeding unit for animals with an SPF biological barrier,
 - Three laboratories for processing samples and preparing reagents.
 - Service for booking and using facilities for animal surgical procedures.
 - Service for booking and using facilities for performing behavioral studies.
- Advising:
 - Service or advising on experimental and behavioral procedures.
 - Service or advising for breeding and reproduction.
 - Advising on animal welfare and standardization of animal models.
- Training:
 - Training on basic experimental techniques.
 - Use of experimental, surgical, and behavioral devices.

Coordinator: Mr. Ricardo González Carrascosa

Personnel in 2023: 5 technicians and 1 administrative assistant.

Location: This platform is located in the University of Málaga Animal Experimentation building.

ANIMAL EXPERIMENTATION (PTA BUILDING)

The animal housing service in the IBIMA Plataforma BIONAND building is a research support service whose objective is to provide housing for experimental animals, facilities, material, equipment, and advising necessary to conduct pre-clinical trials on the technologies and products developed at the center both for research groups and companies. The service has the necessary facilities and equipment to work with rats, mice, and zebrafish.

Rodent housing services:

The rodent housing service was authorized by the Regional Government of Andalusia's Regional Ministry of Agriculture and Fisheries in 2013. It has the capacity to house 170 rats and 2200 mice, with the possibility of expanding this capacity.

Services offered:

- Housing of laboratory rats and mice.
- Centralized supply of animal diets, shavings, sawdust, cages, racks, feeding bottles, etc.
- Provision of special diets for specific physiological or pathological studies.
- Type II special biological waste management service.
- Maintenance and care of animals in special conditions (temperature, light, humidity, sterile environment, etc.) during the conduct of the experiments that require them.
- Technical support service for performing experimental procedures (animal handling, routes of administration, sample collection, etc.).
- Rat and mouse breeding and maintenance service.

Zebrafish housing services:

The zebrafish housing service was authorized by the Regional Ministry of Agriculture and Fisheries in 2014. It has capacity to hold around 2000 zebrafish in 2 racks with 50 tanks each, with the possibility of expanding this capacity in the future.

Services offered:

- Zebrafish housing.
- Advising on zebrafish handling, linecrossing, growth, and development.
- Maintenance of zebrafish WT lines.

The animal housing facility has its own Animal Experimentation Ethics Committee that includes 5 members responsible for evaluating all animal experimentation projects to be carried out in the center. Approval must be requested from the Regional Ministry of Agriculture, Fisheries, Water, and Rural Development.

Scientific Manager: Mr. José María Pérez Pomares

Personnel in 2023: 1 Technician

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

BIOINFORMATICS

The main function of this platform is to provide methodological support and assistance in the field of bioinformatics to biomedical research groups.

Services:

- Database and clinical information collection system design.
- Review and advising on research projects. Improvements in methodology.
- Design of specialized applications and software for biomedical research.
- Management and advising on the REDCap data management platform that is integrated into the Andalusian Public Healthcare System and the University of Málaga.
- Omics analysis: proteomics, genomics, epigenomics, transcriptomics (coding and non-coding RNA, small RNA), microbiota.
- Mediation and advising for research groups for the creation of multidisciplinary projects. Search for potential collaborations.
- Automation of data processing and statistical analysis.
- Conduct of complex statistical analyses and use of machine learning and data mining techniques.
- Multiomics integration studies. (MixOmics)

- Design of data management plans and monitoring of FAIR principles.
- Prioritization of variants based on phenotypic information.
- Phenotypic quality assessment of patient and disease cohorts.
- Analysis for the prioritization of different small RNA species.

Novelties 2023:

- 5 new services have been added to the catalog:
 - Copy number variation (CNV) analysis.
- Genome-Wide Association Studies (GWAs).
- Implementation of techniques for identifying de novo transcripts.
- Expression Quantitative Trait Loci (eQTL) integration studies
- Expression Quantitative Trait Methylation (eQTM) integration studies.
- The registration of a new technology patent has been processed.
- Three specialized training courses were held.
- Two dissemination activities on data management plans were held.

Coordinator: Mr. Andrés González Jiménez


Personnel in 2023: 3 technicians, distributed as follows:

- 1 specialist technical coordinator
- 1 bioinformatics technician. (10 months)
- 1 bioinformatics technician. (9 months)

Main results 2023:

No. of services provided	No. of services in collaboration with other ECAIs	Interprovincial collaborations	Participation in international networks	Groups contacted to offer services	Hours of training provided
67	5	3	4	10	52

DISTRIBUTION OF SERVICES PROVIDED BY SUBJECT AREA



Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

CELL BIOLOGY (CYTOMETRY AND CULTURE)

This research support platform offers cytrometry, cell culture, immunochemistry, and sample processing services as well as the sterilization of instruments and reagents.

It has facilities for use by the different IBIMA research groups as well as for possible external users. There is a reservation system for equipment or services.

Coordinators: Ms. Cristobalina Mayorga, Mr. Manuel Macías, and Mr. Fernando Rodríguez de Fonseca.

Personnel in 2023: 4 technicians

Location: This platform is located in pavilions 5 and 6 of the Civil Hospital, in the Regenerative Medicine laboratory of the Regional University Hospital of Málaga, and in the laboratory on the 1st floor of the Virgen de la Victoria University Hospital.

HISTOLOGY

The main objective of this platform is to provide scientific-technical support and advising for the processing of histological samples in the field of biomedical research.

Services:

- Sample preparation:
- Fixation using cryosubstitution and aldehydes
- Embedding in paraffin, resin, or OCT
- Histochemistry of basic stains
- Immunohistochemistry for antibody tissue labeling
- Histological slices:
 - Using the EXaC hard section method
- Using conventional paraffin microtomy
- Using a cryostat for cryosections
- Image acquisition and processing:
 - Sample analysis advising
 - Automated image acquisition using a slide loader up to 40x in brightfield, darkfield, and polarization.
 - Fluorescence image acquisition.
 - Histomorphometry
 - Brightfield, fluorescence, or polarization image analysis.

Coordinator: Iván Durán

Personnel in 2023: 1 Technician

Main results 2023:

- More than 100 uninvoiced conventional histology jobs were performed.
- Eleven assisted histology projects with data analysis were carried out for a total invoicing of €27,767.88.
- Fifteen dissemination activities were carried out.

284 COMMON RESEARCH SUPPORT SERVICES (ECAI) 2023 SCIENTIFIC REPORT 285

PUBLICATIONS:

Articles:

- García-García, G., Caro, C., Fernández-Álvarez, F., García-Martín, M. L., & Arias, J. L. (2023). Multi-stimuliresponsive chitosan-functionalized magnetite/poly(ε-caprolactone) nanoparticles as theranostic platforms for combined tumor magnetic resonance imaging and chemotherapy. Nanomedicine: nanotechnology, biology, and medicine, 52, 102695. https://doi.org/10.1016/j.nano.2023.102695
- Ocaña, M. C., Bernal, M., Yang, C., Caro, C., Domínguez, A., Vu, H. S., Cárdenas, C., García-Martín, M. L., DeBerardinis, R. J., Quesada, A. R., Martínez-Poveda, B., & Medina, M. Á. (2023). New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo. Communications biology, 6(1), 1084. https://doi.org/10.1038/s42003-023-05443-4
- Carrillo, P., Bernal, M., Téllez-Quijorna, C., Marrero, A. D., Vidal, I., Castilla, L., Caro, C., Domínguez, A., García-Martín, M. L., Quesada, A. R., Medina, M. A., & Martínez-Poveda, B. (2023). The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 158, 114070. https://doi.org/10.1016/j. biopha.2022.114070
- 4. Paez-Muñoz, J. M., Gámez, F., Fernández-Afonso, Y., Gallardo, R., Pernia Leal, M., Gutiérrez, L., de la Fuente, J. M., Caro, C., & García-Martín, M. L. (2023). Optimization of iron oxide nanoparticles for MRI-guided magnetic hyperthermia tumor therapy: reassessing the role of shape in their magnetocaloric effect. Journal of materials chemistry. B, 11(46), 11110–11120. https://doi.org/10.1039/d3tb01821k
- Csukasi F, Bosakova M, Barta T, Martin JH, Arcedo J, Barad M, Rico-Llanos GA, Zieba J, Becerra J, Krejci P, Duran I, Krakow D. Skeletal diseases caused by mutations in *PTH1R* show aberrant differentiation of skeletal progenitors due to dysregulation of DEPTOR. Front Cell Dev Biol. 2023 Jan 16;10:963389. doi: 10.3389/fcell.2022.963389
- 6. P Palmquist-Gomes, A Ruiz-Villalba, J A Guadix J P Romero B Bessiéres, D MacGrogan, L Conejo, A Ortiz, B Picazo, L Houyel, D Gómez-Cabrero S M Meilhac, J L de la Pompa, J M Pérez-Pomares. Origin of congenital coronary arterio-ventricular fistulae from anomalous epicardial and myocardial development. Exp Mol Med. 2023 Jan;55(1):228-239. doi: 10.1038/s12276-022-00913-x. Epub 2023 Jan 18.

DISSEMINATION:

1. First IBIMA Platforma BIONAND research conference.

TEACHING SUPPORT:

1. On-demand personalized histology courses according to research projects.

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

NANOIMAGING UNIT

The Nanoimaging Unit has been designed and optimized to provide highly varied, integrated technological support for biomedical research based on nanotechnology, offering advanced services to internal and external users. This facility is accredited as a Singular Scientific and Technological Infrastructure (ICTS), as a hub of the ICTS NANBIOSIS.

The unit brings together a wide range of state-of-the-art technologies and is divided into four departments, all of which are staffed by technical specialists:

- Preclinical small animal imaging: small animal (preclinical) imaging is a vital tool in biomedical research that allows for studying biological processes and potential drugs in animal models using non-invasive methods. This service offers some of the most relevant preclinical imaging types: magnetic resonance imaging (MRI), in vivo bioluminescence and fluorescence imaging, nuclear imaging (PET/SPECT), and X-ray computed tomography (CT). These techniques are essential for the preclinical evaluation and characterization of new diagnostic and therapeutic agents. The combined use of these technologies and new highly specific imaging probes are the basis of molecular imaging.
- **Nuclear magnetic resonance imaging (NMRI):** this department is equipped with two high-resolution NMR spectrometers: a 400 MHz NMR spectrometer for routine experiments and a spectrometer with a larger magnetic field, 600 MHz, dedicated to high-resolution magic angle NMR spectroscopy (HR-MAS) and conventional spectroscopy of samples that require greater sensitivity. It also has a TD-NMR analyzer for magnetic relaxivity measurements in the clinical field (1.44 T).
- Electron Microscopy: It offers access to conventional transmission electron microscopy (TEM), Cryo-EM and Tomography, and high-resolution environmental scanning electron microscopy (SEM). In addition, the service has an outstanding infrastructure for preparing samples through cryo-immobilization. All equipment has been optimized for biological and nanomedical applications. Although biological and medical applications are the main objective of this service, it can also be used in other scientific and engineering fields, including quality control studies, failure analysis, etc.
- Optical microscopy: This facility houses an excellent range of optical microscopy facilities designed to support high quality biomedical research. The equipment includes conventional, confocal, multiphoton, and super-resolution microscopes as well as advanced processing software, such as IMARIS.

The equipment included in the different services of the unit is listed below:

1. SMALL ANIMAL PRECLINICAL IMAGING SERVICE:

- Bruker MRI 9.4T: Multinuclear imaging and spectroscopy system. Magnetic resonance imaging (MRI) is a very versatile technique that offers excellent morphological, functional, and physiological information. In addition, significant advances made over the past few years in the development of highly sensitive contrast agents using nanotechnology approaches have brought MRI into the field of molecular imaging.
- Bruker Albira SI: Trimodal positron emission tomography, single-photon emission computed tomography, and X-ray computed tomography (PET/SPECT/CT) system. Positron emission tomography (PET) is a non-invasive diagnostic technique that allows for taking images of the animal's body that show the activity and metabolism of the body's organs. Radioactively-labeled substances that are distributed throughout the body are used. Single-photon emission computed tomography (SPECT) uses gamma rays that produce radioactive isotopes. These isotopes are introduced into the animal's body as part of biologically active molecules. The procedure is similar to that of positron emission tomography (PET), but in SPECT, it is the isotope that directly produces the gamma ray, while in PET, the isotope produces a positron which is then annihilated by an electron to produce the two gamma rays. These two gamma rays exit in opposite

286 EXTERNAL ASSOCIATED GRUPS

directions and their simultaneous detection makes it possible to locate the isotope in a more precise manner than in SPECT. However, SPECT is simpler because it can use isotopes that are easier to obtain and have a longer half-life.

Computed tomography (CT) allows for taking high-quality 3D imaging of preclinical animal models based on the reconstruction of 2D X-ray images captured at different angles. Albira uses dedicated beds for mice and rats with built-in anesthetic gas. Different image-capturing modes allow users to balance capture time and image quality. The Albira software package automates the reconstruction process, while the PMOD software that is included allows users to perform advanced analysis and export data to popular formats such as DICOM. It allows for the possibility of combining CT data with fluorescence.

Bruker In-Vivo Xtreme: Multimodal imaging system for rats and mice, BRUKER. The In-Vivo Xtreme is a multimodal optical and X-ray system for small animal imaging designed to combine sensitivity, speed, and flexibility for the widest range of molecular imaging applications. Equipped with a high-performance 58 mm f/1.3 lens and a 4MP back-illuminated CCD camera, the In-Vivo Xtreme is suitable for demanding intravital bioluminescence and fluorescence imaging challenges.

2. MAGNETIC RESONANCE SERVICE:

- Bruker Avance 600 MHz NMR spectrometer: High resolution spectrometer equipped with Prodigy TCI liquid cryoprobe, TXI room temperature probe, and HR-MAS (high-resolution magic angle spinning) probe. In biomedicine, the use of liquid state NMR studies has expanded from classical metabolic studies that use enriched stable isotope tracers to more recent applications in biofluid metabolomics (urine, plasma, CSF).
- Solid-state NMR, HR-MAS, allows for obtaining high-resolution spectra from intact tissue, i.e. without the need for any metabolite extraction procedure. HR-MAS spectroscopy is widely used for metabolomic studies, especially in cancer research, in which the metabolic profile (metabolome) of tumor biopsies can be characterized using only a few milligrams of intact tissue (tissue biopsy). The HR-MAS technique can also be used to characterize the structure and elucidate partially insoluble compounds.
- Bruker Ascend 400 MHz NMR spectrometer: High resolution spectrometer equipped with a BBFO Plus probe optimized for the direct detection of X-nuclei in the ³¹P to ¹⁵N range. Liquid NMR is a fundamental tool in both chemistry and biomedical research. Its applications in chemistry range from the elucidation of small molecule structures to studies of protein-ligand interactions.
- Bruker Minispec (TD-RMN): This piece of equipment allows for measuring magnetic relaxation times, T1 and T2, at clinical fields, 1.44T. Relaxation measurements are fundamental in characterizing the magnetic compounds developed as MRI contrast agents.

3. OPTICAL MICROSCOPY SERVICE:

Zeiss LSM 980 NLO Multiphoton Confocal Microscope: Multiphoton confocal microscope with conventional and resonant scanning. Multiphoton (or two-photon) microscopy takes advantage of the near-simultaneous absorption of two or more photons that act to excite a fluorescent molecule with the combined energy of both photons. In practice, this means that low-energy infrared light can be used to see fluorescent molecules that are normally excited by high-energy blue and ultraviolet light. Using this method, fluorescent molecules can be visualized at much greater depths than with conventional microscopy. Infrared light is also much less damaging to living tissue than UV or blue excitation, making it ideal for viewing model organisms or tissue explants. The Zeiss LSM 980 NLO microscope combines confocal and multiphoton modes in one machine and it can easily switch between different modes.

• Leica HyD SP5 Confocal Microscope: Confocal microscope with conventional and resonant scanning. Confocal laser scanning microscopy is a very popular technique that uses a combination of laser illumination and a mask through a pinhole to ensure that only focal plane fluorescence reaches the detector. This avoids the characteristic blurring typical of conventional fluorescence microscopy and allows images to be captured as detailed optical slices and then used to build 3D models. Confocal microscopy is one of the most versatile techniques available in optical microscopy.

ibimo Plataforma BIONAND 2023 SCIENTIFIC REPORT 287

- Nikon Eclipse TIRF/N-STORM fluorescence microscope: This conventional fluorescent microscope is equipped with incubators for timelapse studies on live samples. Fluorescence microscopy offers a wide range of tools to visualize microscopic events. For many purposes, conventional widefield fluorescence microscopy remains the best choice. The CCD detectors used for conventional microscopy are usually more sensitive than the photomultiplier tubes used in confocal microscopes. As the camera captures the entire field of view simultaneously, it also allows for faster imaging. Examples where conventional microscopy may be more appropriate include visualization of individual molecules, receptors, or small organisms, such as bacteria and yeasts. The TIRF (Total Internal Reflection Fluorescence) technique combines the sensitivity of conventional fluorescence with selective illumination to enhance the contrast of features in close proximity to the coverslip. In addition, this equipment allows for performing superresolution spectroscopy based on STORM (STochastic Optical Reconstruction Microscopy). Historically, the intrinsic diffraction of light has made it difficult to use fluorescence to distinguish structures less than 200 nm away. Super-resolution microscopy refers to techniques that selectively activate fluorescent molecules to map their position up to 10 times more accurately than conventional fluorescent microscopy. The Nikon N-Storm system is capable of locating molecules with a resolution of up to 20 nm.
- Basic Nikon Eclipse Ti fluorescence microscope: Conventional fluorescence microscope with incubators for timelapse studies on live samples.
- Perkin Elmer Operetta HCS (High-Content Screening) equipment: High-content screening (HCS) attempts to bridge the gap between microscopy and cytometry by providing large amounts of statistically useful and phenotypically rich data. High-content screening combines automated microscopy with customizable algorithms capable of detecting and quantifying many different types of phenotypic information in fixed and live cells. The HCS Operetta combines the quality of a spinning disk confocal microscope with Harmony HCS software, which contains many common algorithms such as nuclei and cell detection as well as the ability to detect complex phenotypes automatically using machine learning.

4. ELECTRON MICROSCOPY DEPARTMENT:

- * Thermo Scientific-FEI Tecnai G2 20 Twin Transmission Electron Microscope: In addition to the conventional applications of transmission electron microscopy, this equipment allows for more advanced studies, such as tomography-ET, cryo-ET, cryo-tomography, and EDS (Energy-Dispersive X-ray Spectroscopy)
- Thermo Scientific-FEI Quanta 250 FEG Scanning Electron Microscope: One of the most notable features of this equipment is that it is equipped to perform studies in environmental, ESEM (environmental scanning electron microscopy), wet-STEM (scanning transmission electron microscopy), and EDS (energy dispersive X-ray spectroscopy) mode.

5. SAMPLE PREPARATION ROOMS:

Electron Microscopy Department:

- Vitrobot Mark IV from Thermo Scientific-FEI, for sample preparation in aqueous solution for cryo-ET.
- LEICA EM UC7 Ultramicrotome, with LEICA EM FC7 cryoultramicrotomy module.
- LEICA EM AFS2 low-temperature freeze substitution and sample inclusion equipment with a LEICA EM FSP automatic reagent dispensing system.

288 EXTERNAL ASSOCIATED GRUPS

ibimo Plataforma BIONAND 2023 SCIENTIFIC REPORT 289

- LEICA EM HPM 100 high-pressure freeze fixation equipment
- LEICA EM SCD 500 high-vacuum sample coating and metal coating system
- Glass knife preparation equipment for cryo-ultramicrotomy, LEICA EM KMR3 (slicing) and LEICA EM MP (mounting for collecting slices)
- LEICA DM1000 conventional optical microscope
- LEICA S4 E stereomicroscope with LEICA L2 illumination system
- Laboratory for embedding samples in resin (shared use laboratory)

Nuclear Magnetic Resonance Service:

- Class II biosafety hood
- Cold room (common use area)

Scientific Manager: Dr. María Luisa García Martín

Coordinator: Dr. Mónica Feijóo Cuaresma

Personnel in 2023: 5 technicians

Main results 2023:

- A total of 57 requests were responded to, with total invoicing of €65,000.
- Five training activities were carried out.
- Ten teaching support activities were carried out.
- The unit was cited in 12 scientific articles published in 2023.
- More than 35 users belonging to 25 research groups used the Nanoimaging Unit's services.

Location: This platform is located in the IBIMA Plataforma BIONAND building in Málaga TechPark.

CHEMISTRY

The unit's mission is to provide services to researchers from the IBIMA Plataforma BIONAND and associated laboratories as well as to visitors from other research institutes. It also contributed to conducting research projects and promoting cooperation among groups.

This service offers infrastructure and equipment for the synthesis and physical and chemical characterization of molecules and nanomaterials as well as for the evaluation of their interaction with biological samples. The platform is equipped with:

- Particle Analyzer by Dynamic Light Scattering (DLS) Particle Analyzer Malvern Nano ZS90 ZetaSizer
- NTA, Nanoparticle Tracking Analysis
- Four-glove dry chamber
- Varian UV-Vis Absorption Spectrometer (CARY-100 BIO-MELT)
- PerkinElmer LS-55 Plate Fluorescence Spectrometer
- FT/IR Infrared Spectrometer Jasco PS-4000
- HPLC chromatograph with UV-Vis and refractive index detectors. JASCO LC-2000-PLUS
- FPLC chromatograph with UV-Vis and electrochemical detectors. JASCO UV-2075
- GPC WATERS chromatograph: gel permeation or molecular exclusion chromatograph with photo diode array UV-Vis spectrometry detector, refractive index detector, light scattering detector, and fraction collector.
- MBraun MB-SPS-800 5-solvent drying system
- Lan Technics Polarimeter
- Melting point meter

Scientific Manager: María Isabel Montañez

Location: IBIMA Plataforma BIONAND building in Málaga TechPark.

The IBIMA Plataforma BIONAND center has chemical synthesis laboratories duly equipped with safety cabins, rotary evaporators, safety cabinets, etc. The Chemistry Platform is located at IBIMA Plataforma BIONAND and comprises several facilities/spaces:

- General Chemistry Laboratory (floor 1)
- Chemistry Unit (floor -1).

Operation:

- User self-service (own use).
- You must log in to most equipment with a username/password.
- This requires prior user authorization by the person in charge of the unit (request by email) after confirming that the user has mastered and knows how to operate the equipment to be used.
- Access to the Chemistry Unit room requires authorization to enter with a card.



PUBLICATIONS



Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Pironi, L; Jezerski, D; Sobocki, J; Lal, S; Vanuytsel, T; Theilla, M; Sasdelli, AS; Chambrier, C; Matysiak, K; Aimasso, U; Rasmussen, HH; Jukes, A; Kunecki, M; Seguy, D; Schneider, SM; Daniels, J; Poullenot, F; Mundi, MS; Matras, P; Folwarski, M; Crivelli, A; Wyer, N; Ellegard, L; Santarpia, L; Arvanitakis, M; Spaggiari, C; Lamprecht, G; Guglielmi, FW; Lezo, A; Layec, S; Boluda, ER; Guz-Mark, A; Gandullia, P; Cuerda, C; Osland, E; Spagnuolo, MI; Krznaric, Z; Masconale, L; Chapman, B; Maiz-Jimenez, M; Orlandoni, P; Rocha, MHMD; Virgili-Casas, MN; Doitchinova-Simeonova, M; Czako, L; Van Gossum, A; D'Antiga, L; Ee, LC; Warodomwichit, D; Taus, M; Kolacek, S; Thibault, R; Verlato, G; Serralde-Zuniga, AE; Botella-Carretero, JI; Aguayo, PS; Olveira, G; Chomtho, S; Pisprasert, V; Moisejevs, G; Murillo, AZ; Jauregui, MEP; Diez, MB; Jahit, MS; Densupsoontorn, N; Tamer, A; Brillanti, G; Joly, F	COVID-19 infection in patients on long- term home parenteral nutrition for chronic intestinal failure	CLINICAL NUTRITION ESPEN	3		Article	2023
A-01	la Marca, G; Carling, RS; Moat, SJ; Yahyaoui, R; Ranieri, E; Bonham, JR; Schielen, PCJI	Current State and Innovations in Newborn Screening: Continuing to Do Good and Avoid Harm	INTERNATIONAL JOURNAL OF NEONATAL SCREENING	3.5		Review	2023
A-01	Bouzas, C; Pastor, R; Garcia, S; Monserrat-Mesquida, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Goday, A; Martinez, JA; Alonso-Gomez, AM; Fernandez-Barcelo, O; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majema, L; Riquelme-Gallegop, B; Martin-Sanchez, V; Pinto, X; Delgado-Rodriguez, M; Matia, P; Vidal, J; Cardenas-Salas, JJ; Daimiel, L; Ros, E; Toledo, E; Manzanares, JM; Gonzalez-Monge, I; Munoz, MA; Martinez-Urbistondo, D; Tojal-Sierra, L; Munoz-Bravoaf, C; Miralles-Gisbert, S; Martin, M; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Basterra-Gortari, FJ; Gutierrez-Carrasquilla, L; Guillem-Saiz, P; Satorres, A; Abete, I; Sorto-Sanchez, C; Diez-Espino, J; Babio, N; Fito, M; Tur, JA	Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
A-01	Medas, F; Dobrinja, C; Al-Suhaimi, EA; Altmeier, J; Anajar, S; Arikan, AE; Azaryan, I; Bains, L; Basili, G; Bolukbasi, H; Bononi, M; Borumandi, F; Bozan, MB; Brenta, G; Brunaud, L; Brunner, M; Buemi, A; Canu, GL; Cappellacci, F; Cartwright, B; Fusté, IC; Cavalheiro, B; Cavallaro, G; Chala, A; Chan, SYB; Chaplin, J; Cheema, MS; Chiapponi, C; Chiofalo, MG; Chrysos, E; D'Amore, A; de Cillia, M; De Crea, C; de Manzini, N; de Matos, LL; De Pasquale, L; Del Rio, P; Demarchi, MS; Dhiwakar, M; Donatini, G; Dora, JM; D'Orazi, V; Gamgaram, VKD; Eismontas, V; Kabiri, E; El Malki, HO; Elzahaby, I; Enciu, O; Eskander, A; Feroci, F; Figueroa-Bohorquez, D; Filis, D; François, G; Frías-Fernández, P; Gamboa-Dominguez, A; Genc, V; Giordano, D; Gómez-Pedraza, A; Graceffa, G; Griffin, J; Guerreiro, SC; Gupta, K; Gupta, KK; Gurrado, A; Hajiioannou, J; Hakala, T; Harahap, WA; Hargitai, L; Hartl, D; Hellmann, A; Hlozek, J; Hoang, VT; lacobone, M; Innaro, N; Ioannidis, O; Jang, JHI; Xavier, JC Jr; Jovanovic, M; Kaderli, RM; Kakamad, F; Kaliszewski, K; Karamanliev, M; Katoh, H; Kosec, A; Kovacevic, B; Kowalski, LP; Kralik, R; Yadav, SK; Kumorová, A; Lampridis, S; Lasithiotakis, K; Leclere, JC; Leong, EKF; Leow, MKS; Lim, JY; Lino-Silva, LS; Liu, SYW; Llorach, NP; Lombardi, CP; López-Gómez, J; Lori, E; Quintanilla-Dieck, L; Lucchini, R; Madani, A; Manatakis, D; Markovic, I; Materazzi, G; Mazeh, H; Mercante, G; Meyer-Rochow, GY; Mihaljevic, O; Miller, JA; Minuto, M; Monacelli, M; Mulita, F; Mullineris, B; Muñoz-de-Nova, JL; Girardi, FM; Nader, S; Napadon, T; Nastos, C; Offi, C; Ronen, O; Oragano, L; Orois, A; Pan, YQ; Panagiotidis, E; Panchangam, RB; Papavramidis, T; Parida, PK; Paspala, A; Pérez, OV; Petrovic, S; Raffaelli, M; Ramacciotti, CF; Gimenez, TR; Vázquez, AR; Roh, JL; Rossi, L; Sanabria, A; Santeerapharp, A; Semenov, A; Seneviratne, S; Serdar, A; Sheahan, P; Sheppard, SC; Slotcavage, RL; Smaxwil, C; Kim, SY; Sorrenti, S; Spartalis, E; Sriphrapradang, C; Testini, M; Turk, Y; Tzikos, G; Vabalayte, K; Vargas-Osorio, K; Sebastian,	Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	LANCET DIABETES & ENDOCRINOLOGY	44.5	D1	Article	2023
A-01	Caballano-Infantes, E; Ho-Plagaro, A; Lopez-Gomez, C; Martin-Reyes, F; Rodriguez-Pacheco, F; Taminiau, B; Daube, G; Garrido-Sanchez, L; Alcain-Martinez, G; Andrade, RJ; Garcia-Cortes, M; Lucena, MI; Garcia-Fuentes, E; Rodriguez-Diaz, C	Membrane Vesicles of Toxigenic Clostridioides difficile Affect the Metabolism of Liver HepG2 Cells	ANTIOXIDANTS	7	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Garcia, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubin-Garcia, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Goday, A; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Pinto, X; Gaforio, JJ; Matia, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Guillem-Saiz, P; Valle-Hita, C; Cabanes, R; Abete, I; Goicolea-Guemez, L; Gomez-Gracia, E; Tercero-Macia, C; Colom, A; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Cenoz, JC; Barragan, R; Khoury, N; Castaner, O; Zulet, MA; Vaquero-Luna, J; Bes-Rastrollo, M; de las Heras-delgado, S; Ciurana, R; Martin-Sanchez, V; Tur, JA; Bouzas, C	Metabolic syndrome criteria and severity and carbon dioxide (CO2) emissions in an adult population	GLOBALIZATION AND HEALTH	10.8	D1	Article	2023
A-01	Martin-Reyes, F; Ho-Plagaro, A; Rodriguez-Diaz, C; Lopez-Gomez, C; Garcia-Serrano, S; de los Reyes, DR; Gonzalo, M; Fernandez-Garcia, JC; Montiel-Casado, C; Fernandez-Aguilar, JL; Fernandez, JR; Garcia-Fuentes, E; Rodriguez-Pacheco, F	Oleic acid regulates the circadian rhythm of adipose tissue in obesity	PHARMACOLOGICAL RESEARCH	9.3	D1	Article	2023
A-01	Martinez-García, MA; Méndez, R; Olveira, C; Girón, R; García-Clemente, M; Máiz, L; Sibila, O; Golpe, R; Rodríguez-Hermosa, JL; Barreiro, E; Prados, C; Rodríguez-López, J; Oscullo, G; Labarca, G; de la Rosa, D	The U-Shaped Relationship Between Eosinophil Count and Bronchiectasis Severity The Effect of Inhaled Corticosteroids	CHEST	9.6	D1	Article	2023
A-01	Gentile, AM; Lhamyani, S; Mesa, MM; Pavón-Morón, FJ; Pearson, JR; Salas, J; Clemente-Postigo, M; Costillas, LP; Fuster, GO; Rizky, RE	A Network Comprised of miR-15b and miR- 29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-01	Aguilera-Venegas, G; Roanes-Lozano, E; Rojo-Martinez, G; Galan-Garcia, JL	A proposal of a mixed diagnostic system based on decision trees and probabilistic experts rules	JOURNAL OF COMPUTATIONAL AND APPLIED MATHEMATICS	2.4	Q1	Article	2023
A-01	Tovar, Ruben; de Ceglia, Marialuisa; Ubaldi, Massimo; Rodriguez-Pozo, Miguel; Soverchia, Laura; Cifani, Carlo; Rojo, Gema; Gavito, Ana; Hernandez-Folgado, Laura; Jagerovic, Nadine; Ciccocioppo, Roberto; Baixeras, Elena; Rodriguez de Fonseca, Fernando; Decara, Juan	Administration of Linoleoylethanolamide Reduced Weight Gain, Dyslipidemia, and Inflammation Associated with High-Fat-Diet- Induced Obesity.	NUTRIENTS	5.9	Q1	Article	2023
A-01	Bouzas, C; Pastor, R; Garcia, S; Monserrat-Mesquida, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Schroder, H; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Romero-Secin, A; Pinto, X; Gaforio, JJ; Matia, P; Vidal, J; Zapatero, M; Daimiel, L; Ros, E; Garcia-Arellano, A; Babio, N; Gonzalez-Monje, I; Castaner, O; Abete, I; Tojal-Sierra, L; Benavente-Marin, JC; Signes-Pastor, A; Konieczna, J; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Bes-Rastrollo, M; Mestres, C; Guillem-Saiz, P; Goday, A; Goicolea-Guemez, L; Puig-Aguilo, E; Ruiz-Canela, M; Palau-Galindo, A; Fito, M; Tur, JA	Association of monetary diet cost of foods and diet quality in Spanish older adults	FRONTIERS IN PUBLIC HEALTH	5.2	Q1	Article	2023
A-01	Garcia, S; Bouzas, C; Mateos, D; Pastor, R; Alvarez, L; Rubin, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Goday, A; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Pinto, X; Gaforio, JJ; Matia, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Bes-Rastrollo, M; Guillem-Saiz, P; Nishi, S; Cabanes, R; Abete, I; Goicolea-Guemez, L; Gomez-Gracia, E; Signes-Pastor, AJ; Colom, A; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Vazquez, Z; Sorli, JV; Pascual, M; Castaner, O; Zulet, MA; Vaquero-Luna, J; Basterra-Gortari, FJ; Babio, N; Ciurana, R; Martin-Sanchez, V; Tur, JA	Carbon dioxide (CO2) emissions and adherence to Mediterranean diet in an adult population: the Mediterranean diet index as a pollution level index	ENVIRONMENTAL HEALTH	6	Q1	Article	2023
A-01	Aguilera-Venegas, G; Lopez-Molina, A; Rojo-Martinez, G; Galan-Garcia, JL	Comparing and tuning machine learning algorithms to predict type 2 diabetes mellitus	JOURNAL OF COMPUTATIONAL AND APPLIED MATHEMATICS	2.4	Q1	Article	2023
A-01	Garcia-Luna, PP; Restrepo, JRM; Munoz-Ayllon, M; Gil, MD; Remon, P; Sanchez-Torralvo, FJ; Pachon, J; Garcia-Gonzalez, JJ; Garcia-Manrique, T; Salvador-Bofill, J; Vicente, D; Olveira, G	Evaluation of Nutritional Interventions in the Care Plan for Cancer Patients: The NOA Project	NUTRIENTS	5.9	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Hernández, LC; Moreno, RMG; Cartagena, MNB; Peláez, A; Sole, A; Fernández, AA; Montiel, AF; Olveira, C; Olveira, G; Bonilla, AG; Crespo, BG; Clemente, MG; García, MS; Vázquez, JQ; Castro, EB; González, JR; Marrero, AE; Diab-Cáceres, L; Hernández, CR; de Lucas, EZ; Sanchez, CP; Aparicio, MB; Neyra, AL; Santiago, VS; Paredes, CL; Pecellin, ID; de la Cruz, OA; Gallego, EQ	Experience With Elexacaftor/Tezacaftor/ Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease	ARCHIVOS DE BRONCONEUMOLOGIA	8	Q1	Article	2023
A-01	Garcia-Almeida, JM; Garcia-Garcia, C; Ballesteros-Pomar, MD; Olveira, G; Lopez-Gomez, JJ; Bellido, V; Lesmes, IB; Burgos, R; Sanz-Paris, A; Matia-Martin, P; Romero, FB; Breton, JO; Murillo, AZ; Bellido, D	Expert Consensus on Morphofunctional Assessment in Disease-Related Malnutrition. Grade Review and Delphi Study	NUTRIENTS	5.9	Q1	Article	2023
A-01	Grande, E; Moreno, F; Trigo, J; Capdevila, J; Abiles, J; Sirvent, M; Garrido-Siles, M; Olveira, G; Ocon, J; Soto, MLF	Expert design thinking workshops to analyze users' perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study	SUPPORTIVE CARE IN CANCER	3.1	Q1	Article	2023
A-01	Sanchez-Torralvo, FJ; Perez-del-Rio, V; Garcia-Olivares, M; Porras, N; Abuin-Fernandez, J; Bravo-Bardaji, MF; Garcia-de-Quevedo, D; Olveira, G	Global Subjective Assessment and Mini Nutritional Assessment Short Form Better Predict Mortality Than GLIM Malnutrition Criteria in Elderly Patients with Hip Fracture	NUTRIENTS	5.9	Q1	Article	2023
A-01	Martinez-Montoro, JI; Nunez-Sanchez, MA; Martinez-Sanchez, MA; Balaguer-Roman, A; Fernandez-Ruiz, VE; Ferrer-Gomez, M; Sledzinski, T; Frutos, MD; Fernandez-Garcia, JC; Mika, A; Ramos-Molina, B	Hepatic and serum branched-chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case-control study	OBESITY	6.9	Q1	Article	2023
A-01	de Lucas, MDG; Caballero, I; Fernández-García, JC; Domínguez-Rodríguez, M; Moreno-Moreno, P; Jiménez-Millán, A; Botana-López, M; Avilés, B; Merino-Torres, JF; Soto, A; Tejera, C; Morales, C	Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter realworld study	FRONTIERS IN ENDOCRINOLOGY	5.2	Q1	Article	2023
A-01	Gentile, Adriana-Mariel; Lhamyani, Said; Mengual-Mesa, Maria; Garcia-Fuentes, Eduardo; Bermudez-Silva, Francisco-Javier; Rojo-Martinez, Gemma; Clemente-Postigo, Mercedes; Rodriguez-Canete, Alberto; Olveira, Gabriel; El Bekay, Rajaa	MiR-221-3p/222-3p Cluster Expression in Human Adipose Tissue Is Related to Obesity and Type 2 Diabetes.	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-01	Fernandez-Jimenez, Rocio; Cabrera Cesar, Eva; Sanchez Garcia, Ana; Espildora Hernandez, Francisco; Vegas-Aguilar, Isabel M; Amaya-Campos, Maria Del Mar; Cornejo-Pareja, Isabel; Guirado-Pelaez, Patricia; Simon-Frapolli, Victor; Murri, Mora; Garrido-Sanchez, Lourdes; Martinez Mesa, Alvaro; Pinel-Jimenez, Lorena; Benitez-Cano Gamonoso, Miguel; Dalla-Rovere, Lara; Garcia Olivares, Maria; Velasco-Garrido, Jose Luis; Tinahones-Madueno, Francisco; Garcia-Almeida, Jose Manuel	Rectus Femoris Cross-Sectional Area and Phase Angle asPredictors of 12-Month Mortality in Idiopathic Pulmonary Fibrosis Patients.	NUTRIENTS	5.9	Q1	Article	2023
A-01	Ruiz-Garcia, I; Ortiz-Flores, R; Badia, R; Garcia-Borrego, A; Garcia-Fernandez, M; Lara, E; Martin-Montanez, E; Garcia-Serrano, S; Valdes, S; Gonzalo, M; Tapia-Guerrero, SMJ; Fernandez-Garcia, JC; Sanchez-Garcia, A; Munoz-Cobos, F; Calderon-Cid, M; El-Bekay, R; Covas, MI; Rojo-Martinez, G; Olveira, G; Romero-Zerbo, SY; Bermudez-Silva, FJ	Rich oleocanthal and oleacein extra virgin olive oil and inflammatory and antioxidant status in people with obesity and prediabetes. The APRIL study: A randomised, controlled crossover study	CLINICAL NUTRITION	6.3	Q1	Article	2023
A-01	Rebollo-Pérez, MI; Ojeda, LF; García-Luna, PP; Rocamora, JAI; Olveira, G; Remigio, JRL; Irigoyen, CA; Continente, AC; Martín, CC; Soto, MLF; Almeida, JMG; López, ML; Morell, CL; Pérez, LML; Martínez, TMD; Pereira-Cunill, JL; Vilchez-López, FJ; Rabat-Restrepo, JM	Standards for the Use of Enteral Nutrition in Patients with Diabetes or Stress Hyperglycaemia: Expert Consensus	NUTRIENTS	5.9	Q1	Article	2023
A-01	Guzman-Parra, J; Sanchez-Alvarez, N; Guzik, J; Bergero-Miguel, T; de Diego-Otero, Y; Perez-Costillas, L	The Impact of Stressful Life Events on Suicidal Ideation in Gender Dysphoria: A Moderator Effect of Perceived Social Support	ARCHIVES OF SEXUAL BEHAVIOR	3.8	Q1	Article	2023
A-01	Mela, V; Agüera, Z; Alvarez-Bermudez, MD; Martín-Reyes, F; Granero, R; Sanchez-García, A; Oliva-Olivera, W; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sánchez-Gallegos, P; Martínez-Moreno, JM; Sancho-Marín, R; Fernández-Aranda, F; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	The Relationship between Depressive Symptoms, Quality of Life and miRNAs 8 Years after Bariatric Surgery	NUTRIENTS	5.9	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Martinez-Montoro, Jose Ignacio; Doulatram-Gamgaram, Viyey Kishore; Olveira, Gabriel; Valdes, Sergio; Fernandez-Garcia, Jose Carlos	Management of thyroid dysfunction and thyroid nodules in the ageing patient.	EUROPEAN JOURNAL OF INTERNAL MEDICINE	8	Q1	Review	2023
A-01	Leon-Sanz, M; Linares, F; Gonzalo, M; Tapia, MJ; Maiz-Jimenez, M; Aguado, MR; Lizan, L; Olveira, G	Compliance with a high-protein and energy- dense oral nutritional supplement in patients with disease-related malnutrition: a randomized open-label crossover trial	FRONTIERS IN NUTRITION	5	Q2	Article	2023
A-01	Hevilla, F; Padial, M; Blanca, M; Barril, G; Jimenez-Salcedo, T; Ramirez-Ortiz, M; Nogueira, A; Gentile, A; Garcia-Escobar, E; Romero-Zerbo, SY; Olveira, G	Effect on nutritional status and biomarkers of inflammation and oxidation of an oral nutritional supplement (with or without probiotics) in malnourished hemodialysis patients. A multicenter randomized clinical trial Renacare Trial	FRONTIERS IN NUTRITION	5	Q2	Article	2023
A-01	de Adana, MSR; Dominguez, ME; Morillas, V; Colomo, N; Vallejo-Mora, R; Guerrero, M; Garcia-Escobar, E; Carreira, M; Romero-Zerbo, Y; Linares, F; Gonzalez-Mariscal, I; Bermudez-Silva, FJ; Olveira, G; Rojo-Martinez, G	Efficacy and safety of basal insulin degludec 100 IU/mL versus glargine 300 IU/mL for type 1 diabetes: The single-center INEOX randomized controlled trial	DIABETES RESEARCH AND CLINICAL PRACTICE	5.1	Q2	Article	2023
A-01	Paz-Graniel, I; Fito, M; Ros, E; Buil-Cosiales, P; Corella, D; Babio, N; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Martin-Sanchez, V; Pinto, X; Gaforio, JJ; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Garcia-Gavilan, JF; Toledo, E; Nishi, SK; Sorli, JV; Castaner, O; Garcia-Rios, A; de la Hera, MG; Baron-Lopez, FJ; Ruiz-Canela, M; Morey, M; Casas, R; Garrido-Garrido, EM; Tojal-Sierra, L; Fernandez-Garcia, JC; Vazquez-Ruiz, Z; Fernandez-Carrion, R; Goday, A; Pena-Orihuela, PJ; Compan-Gabucio, L; Schroder, H; Martinez-Gonzalez, MA; Salas-Salvado, J	Impact of COVID-19 pandemic on the PREDIMED-Plus randomized clinical trial: Effects on the interventions, participants follow-up, and adiposity	FRONTIERS IN NUTRITION	5	Q2	Article	2023
A-01	Ozcariz, E; Guardiola, M; Amigo, N; Rojo-Martinez, G; Valdes, S; Rehues, P; Masana, L; Ribalta, J	NMR-based metabolomic profiling identifies inflammation and muscle-related metabolites as predictors of incident type 2 diabetes mellitus beyond glucose: The Di@bet.es study	DIABETES RESEARCH AND CLINICAL PRACTICE	5.1	Q2	Article	2023
A-01	García Almeida J.M., Bellido D., De Luis D., Guzmán Rolo G., Olveira G.	Protocol for a prospective cohort study on the feasibility of application of nutritional ultrasound in the diagnosis and follow-up of patients with nutritional risk at hospital discharge: study on body composition and function (DRECO)	BMJ Open	2.9	Q2	Article	2023
A-01	Ortega-Pinazo, J; Pacheco-Rodríguez, MJ; Serrano-Castro, PJ; Martínez, B; Pinto-Medel, MJ; Gómez-Zumaquero, JM; Lago-Sampedro, A; Garcia-Díaz, B; Estivill-Torrús, G; Gallego, PEF	Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices	MOLECULAR BIOLOGY REPORTS	2.8	Q3	Article	2023
A-01	Diez, JJ; Anda, E; Alcazar, V; Isidro, ML; Familiar, C; Paja, M; Rojas-Marcos, PM; Perez-Corral, B; Navarro, E; Romero-Lluch, AR; Oleaga, A; Pamplona, MJ; Fernandez-Garcia, JC; Megia, A; Manjon-Miguelez, L; Sanchez-Ragnarsson, C; Iglesias, P; Sastre, J	Consumption of health resources in older people with differentiated thyroid carcinoma: a multicenter analysis	ENDOCRINE	3.7	Q3	Article	2023
A-01	Cano-Ibáñez, N; Serra-Majem, L; Martín-Peláez, S; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Lassale, C; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Gómez-Pérez, AM; Lapetra, J; Fernández-Aranda, F; Bueno-Cavanillas, A; Tur, JA; Cubelos, N; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Calderón, C; Daimiel, L; Ros, E; Gea, A; Babio, N; Gimenez-Alba, IM; Zomeño-Fajardo, MD; Abete, I; Sierra, LT; Romero-Galisteo, RP; de la Hera, MG; Martín-Padillo, M; García-Ríos, A; Casas, RM; Fernández-García, JC; Santos-Lozano, JM; Toledo, E; Becerra-Tomas, N; Sorli, J; Schröder, H; Zulet, MA; Sorto-Sánchez, C; Diez-Espino, J; Gómez-Martínez, C; Fitó, M; Sánchez-Villegas, A	Dietary diversity and depression: cross- sectional and longitudinal analyses in Spanish adult population with metabolic syndrome. Findings from PREDIMED-Plus trial	PUBLIC HEALTH NUTRITION	3.2	Q3	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-01	Ortiz, A; Galán, CD; Fernández-García, JC; Cerezo, JG; Ochoa, RI; Núñez, J; Gutiérrez, FP; Navarro-Gonázlez, JF	Documento de consenso sobre el abordaje de la hiperpotasemia	NEFROLOGIA	2.6	Q3	Article	2023
A-01	Reyes-Garcia, R; Moreno-Perez, O; Bellido, V; Botana-Lopez, M; Rodriguez-Hervada, AD; Fernandez-Garcia, D; Fernandez-Garcia, JC; Gargallo-Fernandez, M; Gonzalez-Clemente, JM; Jodar-Gimeno, E; Casares, MLDL; Lopez-Fernandez, J; Martinez, A; Mezquita-Raya, P; Rozas-Moreno, P; Tejera-Perez, C; Martin, JS	Comprehensive approach to people with type 2 diabetes. Diabetes Knowledge Area of the Spanish Society of Endocrinology and Nutrition	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.9	Q4	Article	2023
A-01	Menendez Torre, Edelmiro Luis; Pujante Alarcon, Pedro; Basterra-Gortari, Francisco Javier; Rojo-Martinez, Gemma; Santos Mata, Maria Angeles	Survey of Spanish hospitals on diabetes care resources.	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.9	Q4	Article	2023
A-02	Ampudia-Blasco, Francisco Javier; Ugarte-Abasolo, Estibaliz; Chico, Ana; Garcia-Aleman, Jorge; Galan-Barroso, Manuel	Spanish Consensus on the Use of Intermittently Scanned Continuous Glucose Monitoring in the Management of Patients With Insulin Therapy: The MONITOR Project.	Journal of diabetes science and technology	5		Article	2023
A-02	Jiménez De Nunzio S., Portal-Núñez S., Arias Macías C.M., Bruna Del Cojo M., Adell-Pérez C., Latorre Molina M., Macías-González M., Adell-Pérez A.	Does a Dysbiotic Oral Microbiome Trigger the Risk of Chronic Inflammatory Disease?	Current Treatment Options in Allergy	1.1		Review	2023
A-02	Bellido, Virginia; Aguilera, Eva; Cardona-Hernandez, Roque; Diaz-Soto, Gonzalo; Gonzalez Perez de Villar, Noemi; Picon-Cesar, Maria J; Ampudia-Blasco, Francisco Javier	Expert Recommendations for Using Time- in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient- Centered Glycemic Control in People With Diabetes.	Journal of diabetes science and technology	5		Review	2023
A-02	Mena-Vazquez, N; Ruiz-Limon, P; Moreno-Indias, I; Manrique-Arija, S; Lisbona-Montanez, JM; Rioja, J; Mucientes, A; Martin-Nunez, GM; Cano-Garcia, L; Tinahones, FJ; Fernandez-Nebro, A	Adiposity is associated with expansion of the genus Dialister in rheumatoid arthritis patients	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
A-02	Baenas, I; Miranda-Olivos, R; Granero, R; Sole-Morata, N; Sanchez, I; Pastor, A; del Pino-Gutierrez, A; Codina, E; Tinahones, FJ; Fernandez-Formoso, JA; Vilarrasa, N; Guerrero-Perez, F; Lopez-Urdiales, R; Virgili, N; Soriano-Mas, C; Jimenez-Murcia, S; de la Torre, R; Fernandez-Aranda, F	Association of anandamide and 2-arachidonoylglycerol concentrations with clinical features and body mass index in eating disorders and obesity	EUROPEAN PSYCHIATRY	7.8	D1	Article	2023
A-02	Atzeni, A; Nishi, SK; Babio, N; Belzer, C; Konstanti, P; Vioque, J; Corella, D; Castaner, O; Vidal, J; Moreno-Indias, I; Torres-Collado, L; Asensio, EM; Fito, M; Gomez-Perez, AM; Arias, A; Ruiz-Canela, M; Hu, FB; Tinahones, FJ; Salas-Salvado, J	Carbohydrate quality, fecal microbiota and cardiometabolic health in older adults: a cohort study	GUT MICROBES	12.2	D1	Article	2023
A-02	Fernandez-Valero, Andrea; Pena-Montero, Nerea; Lima-Rubio, Fuensanta; Gutierrez-Repiso, Carolina; Linares-Pineda, Teresa Maria; Picon-Cesar, Maria Jose; Sancho-Marin, Raquel; Tinahones, Francisco J; Morcillo, Sonsoles; Molina-Vega, Maria	Changes in Oxidative Stress and Intestinal Permeability during Pregnancy in Women with Gestational Diabetes Mellitus Treated with Metformin or Insulin and Healthy Controls: A Randomized Controlled Trial.	ANTIOXIDANTS	7	D1	Article	2023
A-02	Bouzas, C; Pastor, R; Garcia, S; Monserrat-Mesquida, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Goday, A; Martinez, JA; Alonso-Gomez, AM; Fernandez-Barcelo, O; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majema, L; Riquelme-Gallegop, B; Martin-Sanchez, V; Pinto, X; Delgado-Rodriguez, M; Matia, P; Vidal, J; Cardenas-Salas, JJ; Daimiel, L; Ros, E; Toledo, E; Manzanares, JM; Gonzalez-Monge, I; Munoz, MA; Martinez-Urbistondo, D; Tojal-Sierra, L; Munoz-Bravoaf, C; Miralles-Gisbert, S; Martin, M; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Basterra-Gortari, FJ; Gutierrez-Carrasquilla, L; Guillem-Saiz, P; Satorres, A; Abete, I; Sorto-Sanchez, C; Diez-Espino, J; Babio, N; Fito, M; Tur, JA	Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
A-02	Reina-Perez, I; Artacho-Cordo, F; Mustieles, V; Castellano-Castillo, D; Cardona, F; Jimenez-Diaz, I; Lopez-Medina, JA; Alcaide, J; Ocana-Wilhelmi, L; Iribarne-Duran, LM; Arrebola, JP; Olea, N; Tinahones, FJ; Fernandez, MF	Cross-sectional associations of persistent organic pollutants measured in adipose tissue and metabolic syndrome in clinically diagnosed middle-aged adults	ENVIRONMENTAL RESEARCH	8.3	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Khoury, N; Martinez, MA; Paz-Graniel, I; Martinez-Gonzalez, MA; Corella, D; Castaner, O; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pinto, X; Gaforio, JJ; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorli, JV; Perez-Vega, KA; Garcia-Rios, A; Bellvert, NG; Gomez-Gracia, E; Zulet, MA; Chaplin, A; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vazquez-Ruiz, Z; Asensio, EM; Goday, A; Pena-Orihuela, PJ; Signes-Pastor, AJ; Garcia-Arellano, A; Fito, M; Babio, N; Salas-Salvado, J	Dietary intake of polychlorinated dibenzo- p-dioxins and furans, adiposity and obesity status	ENVIRONMENTAL RESEARCH	8.3	D1	Article	2023
A-02	Pérez-Burillo, S; Hinojosa-Nogueira, D; Rufián-Henares, JA; Pastoriza, S	Effect of in vitro digestion and fermentation on antioxidant capacity of weight loss foods and Maillard reaction products content	FOOD RESEARCH INTERNATIONAL	8.1	D1	Article	2023
A-02	García-Casares, N; González-González, G; de la Cruz-Cosme, C; Garzón-Maldonado, FJ; de Rojas-Leal, C; Ariza, MJ; Narváez, M; Barbancho, MA; García-Arnés, JA; Tinahones, FJ	Effects of GLP-1 receptor agonists on neurological complications of diabetes	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	Article	2023
A-02	Bellido, D; García-García, C; Talluri, A; Lukaski, HC; García-Almeida, JM	Future lines of research on phase angle: Strengths and limitations	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	Article	2023
A-02	Gomez-Perez, AM; Ruiz-Limon, P; Salas-Salvado, J; Vioque, J; Corella, D; Fito, M; Vidal, J; Atzeni, A; Torres-Collado, L; Alvarez-Sala, A; Martinez, MA; Goday, A; Benaiges, D; Garcia-Gavilan, J; Lopez, MRB; Moreno-Indias, I; Tinahones, FJ	Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis	GUT MICROBES	12.2	D1	Article	2023
A-02	Gonzalez-Rellan, MJ; Parracho, T; Heras, V; Rodriguez, A; Fondevila, MF; Novoa, E; Lima, N; Varela-Rey, M; Senra, A; Chantada-Vazquez, MDP; Ameneiro, C; Bernardo, G; Fernandez-Ramos, D; Lopitz-Otsoa, F; Bilbao, J; Guallar, D; Fidalgo, M; Bravo, S; Dieguez, C; Martinez-Chantar, ML; Millet, O; Mato, JM; Schwaninger, M; Prevot, V; Crespo, J; Frühbeck, G; Iruzubieta, P; Nogueiras, R	Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function	MOLECULAR METABOLISM	8.1	D1	Article	2023
A-02	Ni, JQ; Nishi, SK; Babio, N; Ros, E; Basterra-Gortari, FJ; Corella, D; Castaner, O; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Cano-Ibanez, N; Tur, JA; Fernandez-Garcia, JM; Pinto, X; Delgado-Rodriguez, M; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Fernandez-Aranda, F; Ruiz-Canela, M; Sola, CM; Portoles, O; Sala-Vila, A; Garcia-Rios, A; Compan-Gabucio, LM; Gomez-Gracia, E; Zulet, MA; Chaplin, A; Casas, R; Martinez-Diz, S; Tojal-Sierra, L; Gomez-Perez, AM; Toledo, E; Rios, S; Ortega-Azorin, C; de la Torre, R; Pena-Orihuela, PJ; Garcia-de la Hera, M; Sayon-Orea, C; Malcampo, M; PREDIMED Plus Investigators	Higher versus lower nut consumption and changes in cognitive performance over two years in a population at risk of cognitive decline: a cohort study	AMERICAN JOURNAL OF CLINICAL NUTRITION	7.1	D1	Article	2023
A-02	Paz-Graniel, I; Babio, N; Nishi, SK; Martínez-González, MA; Corella, D; Fitó, M; Martínez, A; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sánchez, VM; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Calderon-Sanchez, C; Daimiel, L; Ros, E; Fernández-Aranda, F; Toledo, E; Valle-Hita, C; Sorli, JV; Lassale, C; Garcia-Rios, A; Oncina-Canovas, A; Barón-Lopez, FJ; Zulet, MA; Rayó, E; Casas, R; Thomas-Carazo, E; Tojal-Sierra, L; Damas-Fuentes, M; Ruiz-Canela, M; de las Heras-delgado, S; Fernandez-Carrión, R; Castañer, O; Peña-Orihuela, PJ; Gonzalez-Palacios, S; Buil-Cosiales, P; Goday, A; Salas-Salvadó, J	How Did the COVID-19 Lockdown Pandemic Affect the Depression Symptomatology in Mediterranean Older Adults with Metabolic Syndrome?	DEPRESSION AND ANXIETY	7.4	D1	Article	2023
A-02	del Saz-Lara, A; Boughanem, H; de las Hazas, MCL; Crespo, C; Saz-Lara, A; Visioli, F; Macias-Gonzalez, M; Davalos, A	Hydroxytyrosol decreases EDNRA expression through epigenetic modification in colorectal cancer cells	PHARMACOLOGICAL RESEARCH	9.3	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Boughanem, H; Ruiz-Limon, P; Pilo, J; Lisbona-Montanez, JM; Tinahones, FJ; Indias, IM; Macias-Gonzalez, M	Linking serum vitamin D levels with gut microbiota after 1-year lifestyle intervention with Mediterranean diet in patients with obesity and metabolic syndrome: a nested cross-sectional and prospective study	GUT MICROBES	12.2	D1	Article	2023
A-02	Caballano-Infantes, E; Ho-Plágaro, A; López-Gómez, C; Martín-Reyes, F; Rodríguez-Pacheco, F; Taminiau, B; Daube, G; Garrido-Sánchez, L; Alcaín-Martínez, G; Andrade, RJ; García-Cortés, M; Lucena, MI; García-Fuentes, E; Rodríguez-Díaz, C	Membrane Vesicles of Toxigenic Clostridioides difficile Affect the Metabolism of Liver HepG2 Cells	ANTIOXIDANTS	7	D1	Article	2023
A-02	Garcia, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubín-García, M; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Goday, A; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Pintó, X; Gaforio, JJ; Matia, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Sayón-Orea, C; Guillem-Saiz, P; Valle-Hita, C; Cabanes, R; Abete, I; Goicolea-Güemez, L; Gómez-Gracia, E; Tercero-Maciá, C; Colom, A; García-Ríos, A; Castro-Barquero, S; Fernández-García, JC; Santos-Lozano, JM; Cenoz, JC; Barragán, R; Khoury, N; Castañer, O; Zulet, MA; Vaquero-Luna, J; Bes-Rastrollo, M; de las Heras-delgado, S; Ciurana, R; Martin-Sánchez, V; Tur, JA; Bouzas, C	Metabolic syndrome criteria and severity and carbon dioxide (CO2) emissions in an adult population	GLOBALIZATION AND HEALTH	10.8	D1	Article	2023
A-02	Sánchez-Quintero, MJ; Delgado, J; Chaves, LM; Medina-Vera, D; Murri, M; Becerra-Muñoz, VM; Estévez, M; Crespo-Leiro, MG; López, GP; González-Jiménez, A; Ranea, JAG; Queipo-Ortuño, MI; Plaza-Andrades, I; Rodríguez-Capitán, J; Pavón-Morón, FJ; Jiménez-Navarro, MF	Multi-Omics Approach Reveals Prebiotic and Potential Antioxidant Effects of Essential Oils from the Mediterranean Diet on Cardiometabolic Disorder Using Humanized Gnotobiotic Mice.	ANTIOXIDANTS	7	D1	Article	2023
A-02	Gatsiou, A; Tual-Chalot, S; Napoli, M; Ortega-Gomez, A; Regen, T; Badolia, R; Cesarini, V; Garcia-Gonzalez, C; Chevre, R; Ciliberti, G; Silvestre-Roig, C; Martini, M; Hoffmann, J; Hamouche, R; Visker, JR; Diakos, N; Wietelmann, A; Silvestris, DA; Georgiopoulos, G; Moshfegh, A; Schneider, A; Chan, W; Guenther, S; Backs, J; Kwak, S; Selzman, CH; Stamatelopoulos, K; Rose-John, S; Trautwein, C; Spyridopoulos, I; Braun, T; Waisman, A; Gallo, A; Drakos, SG; Dimmeler, S; Sperandio, M; Soehnlein, O; Stellos, K	The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation	IMMUNITY	32.4	D1	Article	2023
A-02	García-Conde, U; Navarro-Alarcón, M; Navajas-Porras, B; Hinojosa-Nogueira, D; Delgado-Osorio, A; Pérez-Burillo, S; Pastoriza, S; Navarro-Moreno, M; Rufián-Henares, JA	Total Zn of foods and bioaccesible fractions in the small and large intestine after in vitro digestion and fermentation with fecal material of healthy adults and children: Influence of culinary techniques	FOOD RESEARCH INTERNATIONAL	8.1	D1	Article	2023
A-02	Garcia, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubin-Garcia, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Fito, M; Martinez, JA; Tojal-Sierra, L; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Cano-Ibanez, N; Pinto, X; Delgado-Rodriguez, M; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Buil-Cosiales, P; Martinez-Rodriguez, MA; Coltell, O; Castaner, O; Garcia-Rios, A; Barcelo, C; Gomez-Gracia, E; Zulet, MA; Konieczna, J; Casas, R; Masso-Guijarro, P; Goicolea-Guemez, L; Bernal-Lopez, MR; Bes-Rastrollo, M; Shyam, S; Gonzalez, JI; Zomeno, MD; Pena-Orihuela, PJ; Gonzalez-Palacios, S; Toledo, E; Khoury, N; Perez, KA; Martin-Sanchez, V; Tur, JA; Bouzas, C	Ultra-processed foods consumption as a promoting factor of greenhouse gas emissions, water, energy, and land use: A longitudinal assessment	SCIENCE OF THE TOTAL ENVIRONMENT	9.8	D1	Article	2023
A-02	Hernandez-Alonso, P; Boughanem, H; Canudas, S; Becerra-Tomas, N; de la Puente, MF; Babio, N; Macias-Gonzalez, M; Salas-Salvado, J	Circulating vitamin D levels and colorectal cancer risk: A meta-analysis and systematic review of case-control and prospective cohort studies	CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION	10.2	D1	Review	2023
A-02	Martinez-Montoro, JI; Benitez-Porres, J; Tinahones, FJ; Ortega-Gomez, A; Murri, M	Effects of exercise timing on metabolic health	OBESITY REVIEWS	8.9	D1	Review	2023
A-02	Cornejo-Pareja, I; Vegas-Aguilar, IM; Fernandez-Jimenez, R; Garcia-Garcia, C; Bellido-Guerrero, D; Tinahones, F; Garcia-Almeida, JM	Phase angle and COVID-19: A systematic review with meta-analysis	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Fernandez-Jimenez, R; Martin-Masot, R; Cornejo-Pareja, I; Vegas-Aguilar, IM; Herrador-Lopez, M; Tinahones, FJ; Navas-Lopez, VM; Bellido-Guerrero, D; Garcia-Almeida, JM	Phase angle as a marker of outcome in hospitalized pediatric patients. A systematic review of the evidence (GRADE) with meta-analysis	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	Review	2023
A-02	Pilo, J; Garcia-Flores, LA; Clemente-Postigo, M; Arranz-Salas, I; Alcaide, J; Ramos-Fernandez, M; Lozano, J; Boughanem, H; Kompella, P; Macias-Gonzalez, M	8-Oxoguanine DNA Glycosylase 1 Upregulation as a Risk Factor for Obesity and Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-02	Halvorsen, YD; Lock, JP; Frias, JP; Tinahones, FJ; Dahl, D; Conery, AL; Freeman, MW	A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults	DIABETES OBESITY & METABOLISM	5.8	Q1	Article	2023
A-02	Gentile, AM; Lhamyani, S; Mesa, MM; Pavón-Morón, FJ; Pearson, JR; Salas, J; Clemente-Postigo, M; Costillas, LP; Fuster, GO; Rizky, RE	A Network Comprised of miR-15b and miR- 29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-02	Shyam, S; Garcia-Gavilan, JF; Paz-Graniel, I; Gaforio, JJ; Martinez-Gonzalez, MA; Corella, D; Martinez, JA; Alonso-Gomez, AM; Waernberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sanchez, VM; Pinto, X; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Fernandez-Aranda, F; Nishi, SK; Garcia-Regata, O; Toledo, E; Asensio, EM; Castaner, O; Garcia-Rios, A; Torres-Collado, L; Gomez-Gracia, E; Zulet, MA; Ruiz, NG; Casas, R; Cano-Ibanez, N; Tojal-Sierra, L; Gomez-Perez, AM; Sorli, JV; Cinza-Sanjurjo, S; Martin-Pelaez, S; Pena-Orihuela, PJ; Oncina-Canovas, A; Perez-Araluce, R; Zomeno, MD; Chaplin, A; Delgado-Rodriguez, M; Babio, N; Fito, M; Salas-Salvado, J	Association of adiposity and its changes over time with COVID-19 risk in older adults with overweight/obesity and metabolic syndrome: a longitudinal evaluation in the PREDIMED-Plus cohort	BMC MEDICINE	9.3	Q1	Article	2023
A-02	Bouzas, C; Pastor, R; Garcia, S; Monserrat-Mesquida, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Schroder, H; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Romero-Secin, A; Pinto, X; Gaforio, JJ; Matia, P; Vidal, J; Zapatero, M; Daimiel, L; Ros, E; Garcia-Arellano, A; Babio, N; Gonzalez-Monje, I; Castaner, O; Abete, I; Tojal-Sierra, L; Benavente-Marin, JC; Signes-Pastor, A; Konieczna, J; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Bes-Rastrollo, M; Mestres, C; Guillem-Saiz, P; Goday, A; Goicolea-Guemez, L; Puig-Aguilo, E; Ruiz-Canela, M; Palau-Galindo, A; Fito, M; Tur, JA	Association of monetary diet cost of foods and diet quality in Spanish older adults	FRONTIERS IN PUBLIC HEALTH	5.2	Q1	Article	2023
A-02	Valle-Hita, Cristina; Diaz-Lopez, Andres; Becerra-Tomas, Nerea; Toledo, Estefania; Cornejo-Pareja, Isabel; Abete, Itziar; Sureda, Antoni; Bes-Rastrollo, Maira; Martinez, J Alfredo; Tinahones, Francisco J; Tur, Josep A; Garciduenas-Fimbres, Tany E; Paris-Palleja, Francisco; Goday, Albert; Goni-Ruiz, Nuria; Salas-Salvado, Jordi; Babio, Nancy	Associations between ultra-processed food consumption and kidney function in an older adult population with metabolic syndrome.	CLINICAL NUTRITION	6.3	Q1	Article	2023
A-02	Garcia, S; Bouzas, C; Mateos, D; Pastor, R; Alvarez, L; Rubin, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Goday, A; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Pinto, X; Gaforio, JJ; Matia, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Bes-Rastrollo, M; Guillem-Saiz, P; Nishi, S; Cabanes, R; Abete, I; Goicolea-Guemez, L; Gomez-Gracia, E; Signes-Pastor, AJ; Colom, A; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Vazquez, Z; Sorli, JV; Pascual, M; Castaner, O; Zulet, MA; Vaquero-Luna, J; Basterra-Gortari, FJ; Babio, N; Ciurana, R; Martin-Sanchez, V; Tur, JA	Carbon dioxide (CO2) emissions and adherence to Mediterranean diet in an adult population: the Mediterranean diet index as a pollution level index	ENVIRONMENTAL HEALTH	6	Q1	Article	2023
A-02	Hinojosa-Nogueira, D; Muros, JJ; Navajas-Porras, B; Delgado-Osorio, A; Pérez-Burillo, S; Pastoriza, S; Rufián-Henares, JA	Development of a food composition database of different food contaminants CONT11 and estimation of dietary exposure in children of southern Spain	FOOD AND CHEMICAL TOXICOLOGY	4.3	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Donat-Vargas, C; Mico, V; San-Cristobal, R; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Fitó, M; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Damas-Fuentes, M; Lapetra, J; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Cinza-Sanjurjo, S; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Causso, C; Ros, E; Toledo, E; Manzanares, JM; Ortega-Azorín, C; Castañer, O; Peña-Orihuela, PJ; Zazo, JM; Muñoz Bravo, C; Martinez-Urbistondo, D; Chaplin, A; Casas, R; Cano Ibáñez, N; Tojal-Sierra, L; Gómez-Perez, AM; Pascual Roquet-Jalmar, E; Mestre, C; Barragán, R; Schröder, H; Garcia-Rios, A; Candela García, I; Ruiz-Canela, M; Babio, N; Malcampo, M; Daimiel, L; Martinez, A	Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk	NUTRIENTS	5.9	Q1	Article	2023
A-02	Oliveras-Canellas, N; Moreno-Navarrete, JM; Lorenzo, PM; Garrido-Sanchez, L; Becerril, S; Rangel, O; Latorre, J; Vargas, ED; Pardo, M; Valenti, V; Romero-Cabrera, JL; Oliva-Olivera, W; Silva, C; Dieguez, C; Villarroya, F; Lopez, M; Crujeiras, AB; Seoane, LM; Lopez-Miranda, J; Fruhbeck, G; Tinahones, FJ; Fernandez-Real, JM	Downregulated Adipose Tissue Expression of Browning Genes With Increased Environmental Temperatures	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.8	Q1	Article	2023
A-02	Ruiz-Sanchez, Jorge Gabriel; Paja-Fano, Miguel; Gonzalez Boillos, Marga; Pla Peris, Begona; Pascual-Corrales, Eider; Garcia Cano, Ana Maria; Parra Ramirez, Paola; Martin Rojas-Marcos, Patricia; Vicente Delgado, Almudena; Gomez Hoyos, Emilia; Ferreira, Rui; Garcia Sanz, Inigo; Recasens Sala, Monica; Barahona San Millan, Rebeca; Picon Cesar, Maria Jose; Diaz Guardiola, Patricia; Garcia Gonzalez, Juan Jesus; Perdomo, Carolina M; Manjon Miguelez, Laura; Garcia Centeno, Rogelio; Percovich, Juan Carlos; Rebollo Roman, Angel; Gracia Gimeno, Paola; Robles Lazaro, Cristina; Morales-Ruiz, Manuel; Hanzu, Felicia A; Araujo-Castro, Marta	Effect of Obesity on Clinical Characteristics of Primary Aldosteronism Patients at Diagnosis and Postsurgical Response.	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	5.8	Q1	Article	2023
A-02	Gutierrez-Repiso, Carolina; Cantarero-Cuenca, Antonio; Gonzalez-Jimenez, Andres; Linares-Pineda, Teresa; Pena-Montero, Nerea; Ocana-Wilhelmi, Luis; Tinahones, Francisco J; Morcillo, Sonsoles	Epigenetic Marks as Predictors of Metabolic Response to Bariatric Surgery: Validation from an Epigenome Wide Association Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-02	Linares-Pineda, T; Pena-Montero, N; Fragoso-Bargas, N; Gutierrez-Repiso, C; Lima-Rubio, F; Suarez-Arana, M; Sanchez-Pozo, A; Tinahones, FJ; Molina-Vega, M; Picon-Cesar, MJ; Sommer, C; Morcillo, S	Epigenetic marks associated with gestational diabetes mellitus across two time points during pregnancy	CLINICAL EPIGENETICS	5.7	Q1	Article	2023
A-02	Garcia-Almeida, JM; Garcia-Garcia, C; Ballesteros-Pomar, MD; Olveira, G; Lopez-Gomez, JJ; Bellido, V; Lesmes, IB; Burgos, R; Sanz-Paris, A; Matia-Martin, P; Romero, FB; Breton, JO; Murillo, AZ; Bellido, D	Expert Consensus on Morphofunctional Assessment in Disease-Related Malnutrition. Grade Review and Delphi Study	NUTRIENTS	5.9	Q1	Article	2023
A-02	Bullon-Vela, V; Xu, YF; Razquin, C; Abete, I; Zulet, MA; Martinez-Gonzalez, MA; Buil-Corsiales, P; Vitelli-Storelli, F; Sanchez, VM; Vazquez-Ruiz, Z; Sayon-Orea, C; Dominguez-Fernandez, M; Cid, C; Estruch, R; Lamuela-Raventos, RM; Fito, M; Blanchart, G; Babio, N; Salas-Salvado, J; Tinahones, FJ; Tur, JA; Romaguera, D; Konieczna, J; Pinto, X; Daimiel, L; Rodriguez-Mateos, A; Martinez, JA	Health associations of liver enzymes and inflammatory scores with urinary citrus flavonoid metabolites	FOOD & FUNCTION	6.1	Q1	Article	2023
A-02	Martinez-Montoro, JI; Nunez-Sanchez, MA; Martinez-Sanchez, MA; Balaguer-Roman, A; Fernandez-Ruiz, VE; Ferrer-Gomez, M; Sledzinski, T; Frutos, MD; Fernandez-Garcia, JC; Mika, A; Ramos-Molina, B	Hepatic and serum branched-chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case-control study	OBESITY	6.9	Q1	Article	2023
A-02	Mena-Vazquez, N; Godoy-Navarrete, FJ; Lisbona-Montanez, JM; Redondo-Rodriguez, R; Manrique-Arija, S; Rioja, J; Mucientes, A; Ruiz-Limon, P; Garcia-Studer, A; Ortiz-Marquez, F; Oliver-Martos, B; Cano-Garcia, L; Fernandez-Nebro, A	Inflammatory Biomarkers in the Diagnosis and Prognosis of Rheumatoid Arthritis- Associated Interstitial Lung Disease	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-02	Shyam S., García-Gavilán J.F., Paz-Graniel I., Gaforio J.J., Martínez-González M.Á., Corella D., Martínez J.A., Alonso-Gómez Á.M., Wärnberg J., Vioque J., Romaguera D., López-Miranda J., Estruch R., Tinahones F.J., Lapetra J., Serra-Majem J.L., Bueno-Cavanillas A., Tur J.A., Sánchez V.M., Pintó X., Matía-Martín P., Vidal J., del Mar Alcarria M., Daimiel L., Ros E., Fernandez-Aranda F., Nishi S.K., García-Regata Ó., Araluce R.P., Asensio E.M., Castañer O., Garcia-Rios A., Oncina-Cánovas A., Bouzas C., Zulet M.A., Rayó E., Casas R., Martin-Pelaez S., Tojal-Sierra L., Bernal-López M.R., Carlos S., Sorlí J.V., Goday A., Peña-Orihuela P.J., Pastor-Morel A., Eguaras S., Zomeño M.D., Delgado-Rodríguez M., Babio N., Fitó M., Salas-Salvadó J.	Intensive Weight-Loss Lifestyle Intervention Using Mediterranean Diet and COVID-19 Risk in Older Adults: Secondary Analysis of PREDIMED-Plus Trial	JOURNAL OF NUTRITION HEALTH & AGING	5.8	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Perez-Vega, KA; Castaner, O; Sanllorente, A; Lassale, C; Ros, E; Pinto, X; Estruch, R; Salas-Salvado, J; Corella, D; Alonso-Gomez, AM; Serra-Majem, L; Razquin, C; Fiol, M; Lapetra, J; Gomez-Gracia, E; Tinahones, FJ; Hernaez, A; Fito, M	Mediterranean Diet, Energy Restriction, Physical Activity, and Atherogenicity of Very- Low Density Lipoproteins: Findings from Two Randomized Controlled Trials	MOLECULAR NUTRITION & FOOD RESEARCH	5.2	Q1	Article	2023
A-02	Vijaya, AK; Iesmantaite, M; Mela, V; Baltriukiene, D; Burokas, A	Microglia isolation from aging mice for cell culture: A beginner's guide	FRONTIERS IN CELLULAR NEUROSCIENCE	5.3	Q1	Article	2023
A-02	Gentile, AM; Lhamyani, S; Mengual-Mesa, M; García-Fuentes, E; Bermúdez-Silva, FJ; Rojo-Martinez, G; Clemente-Postigo, M; Rodriguez-Cañete, A; Olveira, G; El Bekay, R	MiR-221-3p/222-3p Cluster Expression in Human Adipose Tissue Is Related to Obesity and Type 2 Diabetes	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-02	Araujo-Castro, M; Fano, MP; Peris, BP; Boillos, MG; Pascual-Corrales, E; Cano, AMG; Ramirez, PP; Rojas-Marcos, PM; Ruiz-Sanchez, JG; Delgado, AV; Hoyos, EG; Ferreira, R; Sanz, IG; Sala, MR; San Millan, RB; Cesar, MJP; Guardiola, PD; Perdomo, CM; Miguelez, LM; Centeno, RG; Percovich, JC; Roman, AR; Gimeno, PG; Lazaro, CR; Morales-Ruiz, M; Gutierrez, MC; Collao, SAF; Meneses, D; Nunez, MAS; Quesada, VE; Ribas, EM; Sanchez, AS; Diaz, CG; Lamas, C; Guerrero-Vazquez, R; Tous, MD; Gotarredona, JS; Alevras, TM; Mateo, EMM; Hanzu, FA	Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION	5.4	Q1	Article	2023
A-02	Fernandez-Jimenez, Rocio; Cabrera Cesar, Eva; Sanchez Garcia, Ana; Espildora Hernandez, Francisco; Vegas-Aguilar, Isabel M; Amaya-Campos, Maria Del Mar; Cornejo-Pareja, Isabel; Guirado-Pelaez, Patricia; Simon-Frapolli, Victor; Murri, Mora; Garrido-Sanchez, Lourdes; Martinez Mesa, Alvaro; Pinel-Jimenez, Lorena; Benitez-Cano Gamonoso, Miguel; Dalla-Rovere, Lara; Garcia Olivares, Maria; Velasco-Garrido, Jose Luis; Tinahones-Madueno, Francisco; Garcia-Almeida, Jose Manuel	Rectus Femoris Cross-Sectional Area and Phase Angle asPredictors of 12-Month Mortality in Idiopathic Pulmonary Fibrosis Patients.	NUTRIENTS	5.9	Q1	Article	2023
A-02	Garcia-Garcia, C; Vegas-Aguilar, IM; Rioja-Vazquez, R; Cornejo-Pareja, I; Tinahones, FJ; Garcia-Almeida, JM	Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial)	NUTRIENTS	5.9	Q1	Article	2023
A-02	Rebollo-Pérez, MI; Ojeda, LF; García-Luna, PP; Rocamora, JAI; Olveira, G; Remigio, JRL; Irigoyen, CA; Continente, AC; Martín, CC; Soto, MLF; Almeida, JMG; López, ML; Morell, CL; Pérez, LML; Martínez, TMD; Pereira-Cunill, JL; Vilchez-López, FJ; Rabat-Restrepo, JM	Standards for the Use of Enteral Nutrition in Patients with Diabetes or Stress Hyperglycaemia: Expert Consensus	NUTRIENTS	5.9	Q1	Article	2023
A-02	Schoch, L; Sutelman, P; Suades, R; Badimon, L; Moreno-Indias, I; Vilahur, G	The gut microbiome dysbiosis is recovered by restoring a normal diet in hypercholesterolemic pigs	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	5.5	Q1	Article	2023
A-02	Mela, V; Agüera, Z; Alvarez-Bermudez, MD; Martín-Reyes, F; Granero, R; Sanchez-García, A; Oliva-Olivera, W; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sánchez-Gallegos, P; Martínez-Moreno, JM; Sancho-Marín, R; Fernández-Aranda, F; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	The Relationship between Depressive Symptoms, Quality of Life and miRNAs 8 Years after Bariatric Surgery	NUTRIENTS	5.9	Q1	Article	2023
A-02	Boughanem, H; Kompella, P; Tinahones, FJ; Macias-Gonzalez, M	An overview of vitamins as epidrugs for colorectal cancer prevention	NUTRITION REVIEWS	6.1	Q1	Review	2023
A-02	Martinez-Montoro, Jose Ignacio; Doulatram-Gamgaram, Viyey Kishore; Olveira, Gabriel; Valdes, Sergio; Fernandez-Garcia, Jose Carlos	Management of thyroid dysfunction and thyroid nodules in the ageing patient.	EUROPEAN JOURNAL OF INTERNAL MEDICINE	8	Q1	Review	2023
A-02	Boughanem, H; Bottcher, Y; Tome-Carneiro, J; de las Hazas, MCL; Davalos, A; Cayir, A; Macias-Gonzalez, M	The emergent role of mitochondrial RNA modifications in metabolic alterations	WILEY INTERDISCIPLINARY REVIEWS-RNA	7.3	Q1	Review	2023
A-02	Mela, V; Gaban, AS; Shatz, PM; Guillot-Sestier, MV; Lynch, MA	Acute Stress, Induced by IFN plus A, and Chronic Stress, Induced by Age, Affect Microglia in a Sex-Specific Manner	MOLECULAR NEUROBIOLOGY	5.1	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	D'Elia, D; Truu, J; Lahti, L; Berland, M; Papoutsoglou, G; Ceci, M; Zomer, A; Lopes, MB; Ibrahimi, E; Gruca, A; Nechyporenko, A; Frohme, M; Klammsteiner, T; Pau, ECD; Marcos-Zambrano, LJ; Hron, K; Pio, G; Simeon, A; Suharoschi, R; Moreno-Indias, I; Temko, A; Nedyalkova, M; Apostol, ES; Truica, CO; Shigdel, R; Telalovic, JH; Bongcam-Rudloff, E; Przymus, P; Jordamovic, NB; Falquet, L; Tarazona, S; Sampri, A; Isola, G; Perez-Serrano, D; Trajkovik, V; Klucar, L; Loncar-Turukalo, T; Havulinna, AS; Jansen, C; Bertelsen, RJ; Claesson, MJ	Advancing microbiome research with machine learning: key findings from the ML4Microbiome COST action	FRONTIERS IN MICROBIOLOGY	5.2	Q2	Article	2023
A-02	Piñar-Gutiérrez, A; Romero-Lluch, AR; Dueñas-Disotuar, S; de Lara-Rodríguez, I; Gálvez-Moreno, MA; Martín-Hernández, T; García-Alemán, J; Martínez-de Pinillos, G; Navarro-González, E	Bone metastases from differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series	EUROPEAN THYROID JOURNAL	4.7	Q2	Article	2023
A-02	Linares-Pineda, TM; Pena-Montero, N; Gutierrez-Repiso, C; Lima-Rubio, F; Sanchez-Pozo, A; Tinahones, FJ; Molina-Vega, M; Picon-Cesar, MJ; Morcillo, S	Epigenome wide association study in peripheral blood of pregnant women identifies potential metabolic pathways related to gestational diabetes	EPIGENETICS	3.7	Q2	Article	2023
A-02	Vegas-Aguilar, IM; Guirado-Pelaez, P; Fernandez-Jimenez, R; Boughanem, H; Tinahones, FJ; Garcia-Almeida, JM	Exploratory Assessment of Nutritional Evaluation Tools as Predictors of Complications and Sarcopenia in Patients with Colorectal Cancer	CANCERS	5.2	Q2	Article	2023
A-02	Linares-Pineda, TM; Gutiérrez-Repiso, C; Peña-Montero, N; Molina-Vega, M; Rubio, FL; Arana, MS; Tinahones, FJ; Picón-César, MJ; Morcillo, S	Higher \(\) cell death in pregnant women, measured by DNA methylation patterns of cell-free DNA, compared to new-onset type 1 and type 2 diabetes subjects: a cross-sectional study	DIABETOLOGY & METABOLIC SYNDROME	4.8	Q2	Article	2023
A-02	Martinez-Montoro, JI; Generoso-Pinar, M; Ocana-Wilhelmi, L; Gutierrez-Repiso, C; Sanchez-Garcia, A; Soler-Humanes, R; Fernandez-Serrano, JL; Sanchez-Gallego, P; Martinez-Moreno, JM; Garcia-Fuentes, E; Tinahones, FJ; Garrido-Sanchez, L	Hypertension and hypercholesterolemia are predictive factors associated with type 2 diabetes persistence after metabolic surgery: A prospective study	DIABETES RESEARCH AND CLINICAL PRACTICE	5.1	Q2	Article	2023
A-02	Paz-Graniel, I; Fito, M; Ros, E; Buil-Cosiales, P; Corella, D; Babio, N; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Martin-Sanchez, V; Pinto, X; Gaforio, JJ; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Garcia-Gavilan, JF; Toledo, E; Nishi, SK; Sorli, JV; Castaner, O; Garcia-Rios, A; de la Hera, MG; Baron-Lopez, FJ; Ruiz-Canela, M; Morey, M; Casas, R; Garrido-Garrido, EM; Tojal-Sierra, L; Fernandez-Garcia, JC; Vazquez-Ruiz, Z; Fernandez-Carrion, R; Goday, A; Pena-Orihuela, PJ; Compan-Gabucio, L; Schroder, H; Martinez-Gonzalez, MA; Salas-Salvado, J	Impact of COVID-19 pandemic on the PREDIMED-Plus randomized clinical trial: Effects on the interventions, participants follow-up, and adiposity	FRONTIERS IN NUTRITION	5	Q2	Article	2023
A-02	González-Palacios, S; Oncina-Cánovas, A; García-de-la-Hera, M; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Schröder, H; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Cano-Ibañez, N; Tur, JA; Martín-Sánchez, V; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquer, C; Daimiel, L; Ros, E; Bes-Rastrollo, M; Atzeni, A; Sorli, J; Zomeño, MD; Peña-Orihuela, PJ; Compañ-Gabucio, LM; Barón-López, FJ; Zulet, MA; Konieczna, J; Casas, RM; Garrido-Garrido, EM; Tojal-Sierra, L; Gomez-Perez, AM; Ruiz-Canela, M; Palau, A; Saiz, C; Pérez-Vega, KA; Garcia-Rios, A; Torres-Collado, L; Basterra-Gortari, J; Garcidueñas-Fimbres, TE; Malcampo, M; Vioque, J	Increased ultra-processed food consumption is associated with worsening of cardiometabolic risk factors in adults with metabolic syndrome: Longitudinal analysis from a randomized trial	ATHEROSCLEROSIS	5.3	Q2	Article	2023
A-02	Lendínez-Jurado, A; López-Siguero, JP; Gómez-Perea, A; Ariza-Jiménez, AB; Becerra-Paz, I; Tapia-Ceballos, L; Cruces-Ponce, C; Jiménez-Hinojosa, JM; Morcillo, S; Leiva-Gea, I	Pediatric Type 1 Diabetes: Is Age at Onset a Determining Factor in Advanced Hybrid Closed-Loop Insulin Therapy?	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Simón-Frapolli, VJ; Vegas-Aguilar, IM; Fernández-Jiménez, R; Cornejo-Pareja, IM; Sanchez-García, AM; Martínez-López, P; Nuevo-Ortega, P; Reina-Artacho, C; Estecha-Foncea, MA; Gómez-González, AM; González-Jiménez, MB; Avanesi-Molina, E; Tinahones-Madueño, FJ; García-Almeida, JM	Phase angle and rectus femoris cross- sectional area as predictors of severe malnutrition and their relationship with complications in outpatients with post- critical SARS-CoV2 disease	FRONTIERS IN NUTRITION	5	Q2	Article	2023
A-02	Toledo, E; Wittenbecher, C; Razquin, C; Ruiz-Canela, M; Clish, CB; Liang, LM; Alonso, A; Hernandez-Alonso, P; Becerra-Tomas, N; Aros-Borau, F; Corella, D; Ros, E; Estruch, R; Garcia-Rodriguez, A; Fito, M; Lapetra, J; Fiol, M; Alonso-Gomez, AM; Serra-Majem, L; Deik, A; Salas-Salvado, J; Hu, FB; Martinez-Gonzalez, MA	Plasma lipidome and risk of atrial fibrillation: results from the PREDIMED trial	JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY	3.4	Q2	Article	2023
A-02	Sánchez-García, AM; Martínez-López, P; Gómez-González, AM; Rodriguez-Capitán, J; Pavón-Morón, FJ; Jiménez-López, RJ; García-Almeida, JM; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abad, V; Molina-Ramos, AI; Cabrera-César, E; Ben-Abdellatif, I; Gordillo-Resina, M; Pérez-Mesa, E; Nieto-González, M; Nuevo-Ortega, P; Reina-Artacho, C; Sánchez-Fernández, PL; Jiménez-Navarro, MF; Estecha-Foncea, MA	Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES	3.6	Q2	Article	2023
A-02	García Almeida J.M., Bellido D., De Luis D., Guzmán Rolo G., Olveira G.	Protocol for a prospective cohort study on the feasibility of application of nutritional ultrasound in the diagnosis and follow-up of patients with nutritional risk at hospital discharge: study on body composition and function (DRECO)	BMJ Open	2.9	Q2	Article	2023
A-02	Silva, AM; Campa, F; Stagi, S; Gobbo, LA; Buffa, R; Toselli, S; Silva, DAS; Goncalves, EM; Langer, RD; Guerra-Junior, G; Machado, DRL; Kondo, E; Sagayama, H; Omi, N; Yamada, Y; Yoshida, T; Fukuda, W; Gonzalez, MC; Orlandi, SP; Koury, JC; Moro, T; Paoli, A; Kruger, S; Schutte, AE; Andreolli, A; Earthman, CP; Fuchs-Tarlovsky, V; Irurtia, A; Castizo-Olier, J; Mascherini, G; Petri, C; Busert, LK; Cortina-Borja, M; Bailey, J; Tausanovitch, Z; Lelijveld, N; Ghazzawi, HA; Amawi, AT; Tinsley, G; Kangas, ST; Salpeteur, C; Vazquez-Vazquez, A; Fewtrell, M; Ceolin, C; Sergi, G; Ward, LC; Heitmann, BL; da Costa, RF; Vicente-Rodriguez, G; Cremasco, MM; Moroni, A; Shepherd, J; Moon, J; Knaan, T; Mueller, MJ; Braun, W; Garcia-Almeida, JM; Palmeira, AL; Santos, I; Larsen, SC; Zhang, XY; Speakman, JR; Plank, LD; Swinburn, BA; Ssensamba, JT; Shiose, K; Cyrino, ES; Bosy-Westphal, A; Heymsfield, SB; Lukaski, H; Sardinha, LB; Wells, JC; Marini, E	The bioelectrical impedance analysis (BIA) international database: aims, scope, and call for data	EUROPEAN JOURNAL OF CLINICAL NUTRITION	4.7	Q2	Article	2023
A-02	Rognoni, T; Fernández-Matarrubia, M; Martinez-González, MA; Salas-Salvadó, J; Corella, D; Castañer, O; Martínez, JA; Alonso-Gómez, AM; Gómez-Gracia, E; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Ibañez, NC; Tur, JA; Pérez, RM; Pintó, X; Delgado-Rodríguez, M; Ramos, MO; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Goñi-Ruiz, N; Babio, N; Sorlí, JV; Schröderj, H; García-Riose, A; Compañ-Gabucio, L; Warnberg, J; Zulet, MA; Chaplin, A; Sacanella, E; Bouzalmate-Hajjaj, A; Tojal-Sierra, L; Damas-Fuentes, M; Vázquez, Z; Gómez-Martínez, C; Saiz, C; Malcampo, M; Ortiz-Morales, AM; Martínez-Avilés, V; García-Gavilan, J; Abete, I; Fitó, M; Toledo, E	Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome	JOURNAL OF ALZHEIMERS DISEASE	4	Q2	Article	2023
A-02	Araujo-Castro, M; Fano, MP; Peris, BP; Boillos, MG; Pascual-Corrales, E; García-Cano, AM; Ramírez, PP; Rojas-Marcos, PM; Ruiz-Sanchez, JG; Vicente, A; Gómez-Hoyos, E; Ferreira, R; Sanz, IG; Recasens, M; San Millan, RB; César, MJP; Guardiola, PD; Perdomo, C; Manjón, L; García-Centeno, R; Percovich, JC; Román, AR; Gimeno, PG; Lázaro, CR; Morales, M; Calatayud, M; Collao, SAF; Meneses, D; Nuñez, MAS; Quesada, VE; Ribas, EM; Sánchez, AS; Diaz, CG; Lamas, C; Guerrero-Vázquez, R; Tous, MD; Serrano, J; Michalopoulou, T; Mateo, EMM; Hanzu, F	Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications on cardiometabolic profile and on surgical outcomes	ENDOCRINE CONNECTIONS	2.9	Q3	Article	2023
A-02	Ortega-Pinazo, J; Pacheco-Rodríguez, MJ; Serrano-Castro, PJ; Martínez, B; Pinto-Medel, MJ; Gómez-Zumaquero, JM; Lago-Sampedro, A; Garcia-Díaz, B; Estivill-Torrús, G; Gallego, PEF	Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices	MOLECULAR BIOLOGY REPORTS	2.8	Q3	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-02	Cano-Ibáñez, N; Serra-Majem, L; Martín-Peláez, S; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Lassale, C; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Gómez-Pérez, AM; Lapetra, J; Fernández-Aranda, F; Bueno-Cavanillas, A; Tur, JA; Cubelos, N; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Calderón, C; Daimiel, L; Ros, E; Gea, A; Babio, N; Gimenez-Alba, IM; Zomeño-Fajardo, MD; Abete, I; Sierra, LT; Romero-Galisteo, RP; de la Hera, MG; Martín-Padillo, M; García-Ríos, A; Casas, RM; Fernández-García, JC; Santos-Lozano, JM; Toledo, E; Becerra-Tomas, N; Sorli, J; Schröder, H; Zulet, MA; Sorto-Sánchez, C; Diez-Espino, J; Gómez-Martínez, C; Fitó, M; Sánchez-Villegas, A	Dietary diversity and depression: cross- sectional and longitudinal analyses in Spanish adult population with metabolic syndrome. Findings from PREDIMED-Plus trial	PUBLIC HEALTH NUTRITION	3.2	Q3	Article	2023
A-02	Ruiz, S; Gil, J; Biagetti, B; Venegas, E; Camara, R; Garcia-Centeno, R; Galvez, MA; Pico, A; Maraver, S; Gonzalez, I; Abellan, P; Trincado, P; Herrera, M; Olvera, P; Xifra, G; Bernabeu, I; Serra-Soler, G; Azriel, S; Garcia, L; Carvalho, D; Jordà, M; Valassi, E; Puig, J; Puig-Domingo, M	Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly	CLINICAL ENDOCRINOLOGY	3.2	Q3	Article	2023
A-02	Diaz, T; Ortega-Pinazo, J; Martinez, B; Jimenez, A; Gomez-Zumaquero, JM; Caracuel, Z; Hortas, ML; Ferro, P	Measurement of yield and quality of DNA in human buffy coat is extraction method dependent	PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY	2.9	Q3	Article	2023
A-02	Sánchez-García, AM; Martínez-López, P; Gómez-González, AM; Rodriguez-Capitán, J; Jiménez-López, RJ; Almeida, JMG; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abada, V; Molina-Ramos, AI; Cabrera-César, E; Ben-Abdellatif, I; Gordillo-Resina, M; Pérez-Mesa, E; Nieto-González, M; Nuevo-Ortega, P; Reina-Artacho, C; Fernández, PLS; Jiménez-Navarro, MF; Estecha-Foncea, MA	Multidisciplinary approach of the sequelae one month after hospital discharge in patients with severe bilateral COVID-19 pneumonia, are there differences depending on the respiratory therapy used during admission to intensive care?	MEDICINA INTENSIVA	3	Q3	Article	2023
A-02	Román, DD; Vallo, FG; Gómez, JC; Gómez, JJL; Santabalbina, FJT; Rolo, GG; Almeida, JMG; Paris, AS	Decreased muscle mass in type-2 diabetes. A hidden comorbidity to consider	NUTRICION HOSPITALARIA	1.2	Q4	Article	2023
A-02	Reyes-García, R; Moreno-Pérez, O; Bellido, V; Botana-López, M; Rodríguez-Hervada, AD; Fernández-García, D; Fernández-García, JC; Gargallo-Fernández, M; González-Clemente, JM; Jódar-Gimeno, E; Casares, MLDL; López-Fernández, J; Martínez, A; Mezquita-Raya, P; Rozas-Moreno, P; Tejera-Pérez, C; Martín, JS	Comprehensive approach to people with type 2 diabetes. Diabetes Knowledge Area of the Spanish Society of Endocrinology and Nutrition	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.9	Q4	Article	2023
A-02	Garcia Almeida, Jose Manuel; Vegas Aguilar, Isabel Maria; Calleja Fernandez, Alicia; Porca Fernandez, Cristina; Casanas Quintana, Tamara; Tejera Perez, Cristina; Tinahones Madueno, Francisco Jose; Bellido Guerrero, Diego	Glycaemic and insulinaemic impact of a diabetes-specific oral nutritional supplement with extra-virgin olive oil in patients with type 2 diabetes mellitus at nutritional risk: a randomized, double-blind, crossover, multicentre clinical trial (DIACARE).	NUTRICION HOSPITALARIA	1.2	Q4	Article	2023
A-02	Madrid-Paredes, A; Leyva-Martínez, S; Avila-Rubio, V; Molina-Soria, JB; Sorribes-Carrera, P; Yeste-Doblas, C; López-Medina, JA; Luna-López, VE; Fernández-Soto, ML	Impact of nutritional and educational support on home enteral nutrition	JOURNAL OF HEALTH POPULATION AND NUTRITION	1.9	Q4	Article	2023
A-02	Vegas Aguilar, Isabel Maria; Porca Fernandez, Cristina; Casanas Quintana, Tamara; Calleja Fernandez, Alicia; Tejera Perez, Cristina; Tinahones Madueno, Francisco Jose; Bellido Guerrero, Diego; Garcia Almeida, Jose Manuel	Organoleptic evaluation of a diabetes- specific oral nutritional supplement with extra virgin olive oil in patients at nutritional risk and type 2 diabetes mellitus: Double- blind, randomized, crossover and multicenter clinical trial (DIACARE)].	NUTRICION HOSPITALARIA	1.2	Q4	Article	2023
A-02	Tinahones Madueno, Francisco Jose	Nutrition and microbiota	NUTRICION HOSPITALARIA	1.2	Q4	Review	2023
A-02	Garcia-Almeida, JM; Garcia-Garcia, C; Vegas-Aguilar, IM; Pomar, MDB; Cornejo-Pareja, IM; Medina, BF; Roman, DADL; Guerrero, DB; Lesmes, IB; Madueno, FJT	Nutritional ultrasound (R): Conceptualisation, technical considerations and standardisation	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.9	Q4	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Pinero, MR; Marcos, JFV; Lopez, MAB; Lopez, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratala, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?	CIRUGIA CARDIOVASCULAR	0.3		Article	2023
A-03	Cruzado-Alvarez, Concepcion; Perez-Cabeza, Alejandro Isidoro; Robles-Mezcua, Ainhoa; Robles-Mezcua, Maria; Garcia-Pinilla, Jose Manuel	Analysis of the activity of the telephone nursing consultation on demand for patients with heart failure	ENFERMERIA CLINICA	0.5		Article	2023
A-03	Rodriguez-Leor, Oriol; Toledano, Beatriz; Lopez-Palop, Ramon; Rivero, Fernando; Brugaletta, Salvatore; Linares, Jose Antonio; Benito, Tomas; Carrillo, Pilar; Puigfel, Marti; Cediel, German; Sadaba, Mario; Vaquerizo, Beatriz; Rondan, Juan; Gomez, Ivan; Alfonso, Fernando; Saez, Roberto; Planas, Ana; Lozano, Fernando; Hernandez, Felipe; Sabate, Manel; Ruiz-Arroyo, Jose Ramoen; Torres, Francisco; Hernandez, Jose Maria de la Torre; Gutierrez, Enrique; Cid-Alvarez, Ana Belen; Diez, Jose Luis; Fernandez, Luis; Moreu, Jose; Ojeda, Soledad; Cerrato, Pablo; Ruiz-Quevedo, Valeriano; Sanchis, Juan; Gomez-Menchero, Antonio; Ocaranza, Raymundo; Mohandes, Mohsen; Hernandez, Jose Maria; Alfageme, Miren Maite; Aguiar, Pablo; Minguez, Jose Ramon Lopez; de Prado, Armando Perez	Changes in the Treatment Strategy Following Intracoronary Pressure Wire in a Contemporaneous Real-Life Cohort of Patients With Intermediate Coronary Stenosis. Results From a Nationwide Registry	CARDIOVASCULAR REVASCULARIZATION MEDICINE	1.7		Article	2023
A-03	Romero-Trevejo, JL; Sanchez-Perez, A; Munoz-Garcia, E; Fernandez-Romero, L; Jimenez-Navarro, MF	Comparison of central corneal thickness measurements obtained by OrbscanIIz((R)) and ultrasound pachymetry: A concordance study in the usual clinical practice	SAUDI JOURNAL OF OPHTHALMOLOGY	0.4		Article	2023
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Piñero, MR; Marcos, JFV; Pérez, AP; López, MAB; López, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratalá, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.6		Article	2023
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Piñero, MR; Marcos, JF; Pérez, AP; López, AMB; López, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratalá, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?	ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO	1		Article	2023
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Piñero, MR; Marcos, JFV; Pérez, AP; López, MAB; López, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratalá, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for the determination and reporting of the lipid profile in Spanish clinical laboratories: What parameters should a basic lipid profile include?	ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO	1		Article	2023
A-03	Pedro-Botet, Juan; Plana, Nuria; Mostaza, Jose Maria; Gomez-Doblas, Juan Jose; Fernandez Olmo, Maria Rosa; Escobar Cervantes, Carlos; Diaz-Diaz, Jose Luis; Campuzano Ruiz, Raquel; Valdivielso, Pedro; Cosin- Sales, Juan	Hypercholesterolaemia control in Spain: The same situation with different regional realities	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.6		Article	2023
A-03	Villaescusa-Catalan, JM; Romero-Molina, S; Al-Houssaini, W; Lavreshin, A; Porras-Martin, C	Left atrial wall dissection after on-pump coronary surgery	CIRUGIA CARDIOVASCULAR	0.3		Article	2023
A-03	Cobo Marcos, Marta; de la Espriella, Rafael; Gayan Ordas, Jara; Zegri, Isabel; Pomares, Antonia; Llacer, Pau; Fort, Aleix; Rodriguez Chavarri, Adriana; Mendez, Ana; Blazquez, Zorba; Caravaca Perez, Pedro; Rubio Gracia, Jorge; Recio-Mayoral, Alejandro; Garcia Pinilla, Jose Manuel; Jose Soler, Maria; Garrido Gonzalez, Ramon; Luis Gorriz, Jose; Gonzalez Rico, Miguel; Castro, Almudena; Nunez, Julio	Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry	CURRENT HEART FAILURE REPORTS	3.5		Article	2023
A-03	Medina-Vera D., Enache D., Tambaro S., Abuhashish E., Rosell-Valle C., Winblad B., Rodríguez De Fonseca F., Bereczki E., Nilsson P.	Translational potential of synaptic alterations in Alzheimer's disease patients and amyloid precursor protein knock-in mice	BRAIN COMMUNICATIONS	4.8		Article	2023
A-03	Teran-Pineda, D; Thurnhofer-Hemsi, K; Dominguez, E	Analysis and Recognition of Human Gait Activity Based on Multimodal Sensors	MATHEMATICS	2.4	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Mesnier, Jules; Ternacle, Julien; Cheema, Asim N.; Campelo-Parada, Francisco; Urena, Marina; Veiga-Fernandez, Gabriela; Nombela-Franco, Luis; Munoz-Garcia, Antonio J.; Vilalta, Victoria; Regueiro, Ander; del Val, David; Asmarats, Lluis; del Trigo, Maria; Serra, Vicenc; Bonnet, Guillaume; Jonveaux, Melchior; Rezaei, Effat; Matta, Anthony; Himbert, Dominique; Hernandez, Jose Maria de la Torre; Tirado-Conte, Gabriela; Fernandez-Nofrerias, Eduard; Vidal, Pablo; Alfonso, Fernando; Gutierrez-Alonso, Lola; Oteo, Juan Francisco; Belahnech, Yassin; Mohammadi, Siamak; Philippon, Francois; Modine, Thomas; Rodes-Cabau, Josep	Cardiac Death After Transcatheter Aortic Valve Replacement With Contemporary Devices	JACC- CARDIOVASCULAR INTERVENTIONS	11.3	D1	Article	2023
A-03	Santos-Gallego, CG; Requena-Ibanez, JA; Picatoste, B; Fardman, B; Ishikawa, K; Mazurek, R; Pieper, M; Sartori, S; Rodriguez-Capitan, J; Fuster, V; Badimon, JJ	Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction	CIRCULATION- CARDIOVASCULAR IMAGING	7.5	D1	Article	2023
A-03	Ojeda, S; González-Manzanares, R; Jiménez-Quevedo, P; Piñón, P; Asmarats, L; Amat-Santos, I; Fernández-Nofrerias, E; del Valle, R; Muñoz-García, E; Ferrer-Gracia, MC; de la Torre, JM; Ruiz-Quevedo, V; Regueiro, A; Sanmiguel, D; García-Blas, S; Elízaga, J; Baz, JA; Romaguera, R; Cruz-Gonzalez, I; Moreu, J; Gheorghe, LL; Salido, L; Moreno, R; Urbano, C; Serra, V; Pan, MN	Coronary Obstruction After Transcatheter Aortic Valve Replacement	JACC- CARDIOVASCULAR INTERVENTIONS	11.3	D1	Article	2023
A-03	Cannie, DE; Syrris, P; Protonotarios, A; Bakalakos, A; Pruny, JF; Ditaranto, R; Martinez-Veira, C; Larranaga-Moreira, JM; Medo, K; Bermudez-Jimenez, FJ; Ben Yaou, R; Leturcq, F; Mezcua, AR; Marini-Bettolo, C; Cabrera, E; Reuter, C; Freire, JL; Rodriguez-Palomares, JF; Mestroni, L; Taylor, MRG; Parikh, VN; Ashley, EA; Barriales-Villa, R; Jimenez-Jaimez, J; Garcia-Pavia, P; Charron, P; Biagini, E; Pinilla, JMG; Bourke, J; Savvatis, K; Wahbi, K; Elliott, PM	Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure	EUROPEAN HEART JOURNAL	39.3	D1	Article	2023
A-03	Pascual-Figal, Domingo; Zamorano, J. Luis; Domingo, Mar; Morillas, Herminio; Nunez, Julio; Cobo Marcos, Marta; Riquelme-Perez, Alejandro; Teis, Albert; Santas, Enrique; Caro-Martinez, Cesar; Manuel Pinilla, Jose; Rodriguez-Palomares, Jose F.; Dobarro, David; Restrepo-Cordoba, M. Alejandra; Gonzalez-Juanatey, J. Ramon; Genis, Antoni Bayes	Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: the DAPA-MODA study	EUROPEAN JOURNAL OF HEART FAILURE	18.2	D1	Article	2023
A-03	Mangner, Norman; Panagides, Vassili; del Val, David; Abdel-Wahab, Mohamed; Crusius, Lisa; Durand, Eric; Ihlemann, Nikolaj; Urena, Marina; Pellegrini, Costanza; Giannini, Francesco; Gasior, Tomasz; Wojakowski, Wojtek; Landt, Martin; Auffret, Vincent; Sinning, Jan-Malte; Cheema, Asim N.; Nombela-Franco, Luis; Chamandi, Chekrallah; Campelo-Parada, Francisco; Munoz-Garcia, Erika; Herrmann, Howard C.; Testa, Luca; Kim, Won-Keun; Eltchaninoff, Helene; Sondergaard, Lars; Himbert, Dominique; Husser, Oliver; Latib, Azeem; Le Breton, Herve; Servoz, Clement; Gervais, Philippe; Cote, Melanie; Thiele, Holger; Holzhey, David; Linke, Axel; Rodes-Cabau, Josep	Incidence, Clinical Characteristics, and Impact of Absent Echocardiographic Signs in Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation	CLINICAL INFECTIOUS DISEASES	11.8	D1	Article	2023
A-03	Avvedimento, Marisa; Campelo-Parada, Francisco; Munoz-Garcia, Erika; Nombela-Franco, Luis; Fischer, Quentin; Donaint, Pierre; Serra, Vicenc; Veiga, Gabriela; Gutierrez, Enrique; Esposito, Giovanni; Vilalta, Victoria; Alperi, Alberto; Regueiro, Ander; Asmarats, Lluis; Ribeiro, Henrique B.; Matta, Anthony; Munoz-Garcia, Antonio; Tirado-Conte, Gabriela; Urena, Marina; Metz, Damien; Rodenas-Alesina, Eduard; Hernandez, Jose Maria de la Torre; Fernandez-Nofrerias, Eduard; Pascual, Isaac; Vidal-Cales, Pablo; Arzamendi, Dabit; Campanha-Borges, Diego Carter; Trinh, Kim Hoang; Cote, Melanie; Faroux, Laurent; Rodes-Cabau, Josep	Late Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention in the Workup Pre-TAVR	JACC- CARDIOVASCULAR INTERVENTIONS	11.3	D1	Article	2023
A-03	Sánchez-Quintero MJ, Delgado J, Martín Chaves L, Medina-Vera D, Murri M, Becerra-Muñoz VM, Estévez M, Crespo-Leiro MG, Paz López G, González-Jiménez A, A G Ranea J, Queipo-Ortuño MI, Plaza-Andrades I, Rodríguez-Capitán J, Pavón-Morón FJ, Jiménez-Navarro MF.	Multi-Omics Approach Reveals Prebiotic and Potential Antioxidant Effects of Essential Oils from the Mediterranean Diet on Cardiometabolic Disorder Using Humanized Gnotobiotic Mice.	ANTIOXIDANTS	7	D1	Article	2023
A-03	Lund, LH; Crespo-Leiro, MG; Laroche, C; Garcia-Pinilla, JM; Bennis, A; Vataman, EB; Polovina, M; Radovanovic, S; Apostolovic, SR; Asanin, M; Gackowski, A; Kaplon-Cieslicka, A; Cabac-Pogorevici, I; Anker, SD; Chioncel, O; Coats, AJS; Filippatos, G; Lainscak, M; Mcdonagh, T; Mebazaa, A; Metra, M; Piepoli, M; Rosano, GM; Ruschitzka, F; Savarese, G; Seferovic, PM; lung, B; Popescu, BA; Maggioni, AP	Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery	EUROPEAN JOURNAL OF HEART FAILURE	18.2	D1	Article	2023
A-03	Regueiro, A; Alperi, A; Vilalta, V; Asmarats, L; Baz, JA; Nombela-Franco, L; Calabuig, A; Muñoz-García, A; Sabaté, M; Moris, C; Picard-Deland, M; Pelletier-Beaumont, E; Rodés-Cabau, J	Safety and Efficacy of TAVR With a Pressure Sensor and Pacing Guidewire SAFE-TAVI Trial	JACC- CARDIOVASCULAR INTERVENTIONS	11.3	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Cerezo, IM; Pérez-Gómez, O; Bautista, R; Seoane, P; Esteban, MA; Balebona, MC; Moriñigo, MA; Tapia-Paniagua, ST	SpPdp11 Administration in Diet Modified the Transcriptomic Response and Its Microbiota Associated in Mechanically Induced Wound Sparus aurata Skin	ANIMALS	3	D1	Article	2023
A-03	Gentile, AM; Lhamyani, S; Mesa, MM; Pavón-Morón, FJ; Pearson, JR; Salas, J; Clemente-Postigo, M; Costillas, LP; Fuster, GO; Rizky, RE	A Network Comprised of miR-15b and miR- 29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-03	Herrera-Imbroda, Jesus; Flores-Lopez, Maria; Requena-Ocana, Nerea; Araos, Pedro; Garcia-Marchena, Nuria; Ropero, Jessica; Bordallo, Antonio; Suarez, Juan; Pavon-Moron, Francisco J; Serrano, Antonia; Mayoral, Fermin; Rodriguez de Fonseca, Fernando	Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients.	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-03	Herrera-Imbroda, J; Flores-Lopez, M; Requena-Ocana, N; Araos, P; Ropero, J; Garcia-Marchena, N; Bordallo, A; Suarez, J; Pavon-Moron, FJ; Serrano, A; Mayoral, F; de Fonseca, FR	Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-03	Minana, Gema; de la Espriella, Rafael; Palau, Patricia; Amiguet, Martina; Seller, Julia; Garcia Pinilla, Jose Manuel; Nunez, Eduardo; Gorriz, Jose Luis; Valle, Alfonso; Sanchis, Juan; Bayes-Genis, Antoni; Nunez, Julio	Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction.	REVISTA ESPANOLA DE CARDIOLOGIA	5.9	Q1	Article	2023
A-03	Teran-Pineda, D; Thurnhofer-Hemsi, K; Dominguez, E	Human Gait Activity Recognition Using Multimodal Sensors	INTERNATIONAL JOURNAL OF NEURAL SYSTEMS	8	Q1	Article	2023
A-03	Li, Chi-Hion Pedro; Estevez-Loureiro, Rodrigo; Freixa, Xavier; Teles, Rui; Molina-Ramos, Ana I.; Pan, Manuel; Nombela-Franco, Luis; Melica, Bruno; Amat-Santos, Ignacio J.; Cruz-Gonzalez, Ignacio; Asmarats, Lluis; Alarcon, Robert; Sanchis, Laura; Fernandez-Peregrina, Estefania; Baz, Jose Antonio; Millan, Xavier; Menduina, Irene; Arzamendi, Dabit	Iberian experience with PASCAL transcatheter edge-to-edge repair for mitral valve regurgitation	REVISTA ESPANOLA DE CARDIOLOGIA	5.9	Q1	Article	2023
A-03	Dotor, L; García-Pinilla, JM; Martín, S; Cea, P	Langmuir and Langmuir-Blodgett technologies as nanoarchitectonic tools for the incorporation of curcumin in membrane systems	NANOSCALE	6.7	Q1	Article	2023
A-03	de Frutos, F; Ochoa, JP; Fernandez, AI; Gallego-Delgado, M; Navarro-Penalver, M; Casas, G; Basurte, MT; Larranaga-Moreira, JM; Mogollon, MV; Robles-Mezcua, A; Garcia-Granja, PE; Climent, V; Palomino-Doza, J; Garcia-Alvarez, A; Brion, M; Brugada, R; Jimenez-Jaimez, J; Bayes-Genis, A; Ripoll-Vera, T; Pena-Pena, ML; Rodriguez-Palomares, JF; Gonzalez-Carrillo, J; Villacorta, E; Espinosa, MA; Garcia-Pavia, P; Mirelis, JG	Late gadolinium enhancement distribution patterns in non-ischaemic dilated cardiomyopathy: genotype-phenotype correlation	EUROPEAN HEART JOURNAL- CARDIOVASCULAR IMAGING	6.2	Q1	Article	2023
A-03	Hernandez-Vaquero, Daniel; Rodriguez-Caulo, Emiliano; Vigil-Escalera, Carlota; Blanco-Herrera, Oscar; Berastegui, Elisabet; Arias-Dachary, Javier; Souaf, Souhayla; Parody, Gertrudis; Laguna, Gregorio; Adsuar, Alejandro; Castella, Manel; Valderrama, Jose F.; Pulitani, Ivana; Canovas, Sergio; Ferreiro, Andrea; Garcia-Valentin, Antonio; Carnero, Manuel; Pareja, Pilar; Corrales, Jose A.; Blazquez, Jose A.; Macias, Diego; Fletcher-Sanfeliu, Delfina; Martinez, Daniel; Martin, Elio; Martin, Miren; Margarit, Juan; Hernandez-Estefania, Rafael; Monguio, Emilio; Otero, Juan; Silva, Jacobo	Life expectancy after surgical aortic valve replacement for low-gradient aortic stenosis with preserved ejection fraction	REVISTA ESPANOLA DE CARDIOLOGIA	5.9	Q1	Article	2023
A-03	Tizon-Marcos, H; Toloba, A; Cachinero, IS; Elosua, R; Sionis, A; Fernandez-Aviles, F; Bueno, H; Carrillo, A; Bayes, A; Sanchez, PL; Roque, M; Mila, L; Elorriaga, A; Vaquero, J; Fernandez-Berges, D; Bosch, D; Alameda, J; Almor, JM; Jimenez-Navarro, M; Martinez, L; Sanchis, J; Sanchez, E; Rubert, C; Ruiz-Valdepenas, L; Rodriguez, M; Lozano, I; Abu-Assi, E; Gonzaalez, VB; Marrugat, J	Long-term outcomes of extended DAPT in a real-life cohort of consecutive STEMI patients	REVISTA ESPANOLA DE CARDIOLOGIA	5.9	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Requena-Ocana, N; Araos, P; Serrano-Castro, PJ; Flores-Lopez, M; Garcia-Marchena, N; Oliver-Martos, B; Ruiz, JJ; Gavito, A; Pavon, FJ; Serrano, A; Mayoral, F; Suarez, J; de Fonseca, FR	Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-03	Requena-Ocaña, N; Flores-López, M; García-Marchena, N; Pavón-Morón, FJ; Pedraza, C; Wallace, A; Castilla-Ortega, E; de Fonseca, FR; Serrano, A; Araos, P	Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-03	Abumayyaleh, Mohammad; Gil, Ivan J. Nunez; Viana-LLamas, Maria C.; Roubin, Sergio Raposeiras; Romero, Rodolfo; Alfonso-Rodriguez, Emilio; Uribarri, Aitor; Feltes, Gisela; Becerra-Munoz, Victor Manuel; Santoro, Francesco; Pepe, Martino; Castro Mejia, Alex Fernando; Signes-Costa, Jaime; Gonzalez, Adelina; Marin, Francisco; Lopez-Pais, Javier; Manzone, Edoardo; Cancela, Olalla Vazquez; Paeres, Carolina Espejo; Masjuan, Alvaro Lopez; Velicki, Lazar; Weiss, Christel; Chipayo, David; Fernandez-Ortiz, Antonio; El-Battrawy, Ibrahim; Akin, Ibrahim	Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry	FRONTIERS IN ENDOCRINOLOGY	5.2	Q1	Article	2023
A-03	Osca, Joaquin; Francisco-Pascual, Jaume; Martinez-Basterra, Javier; Martinez, Juan Gabriel; Reis, Hipolito; Oliveira, Mario; Campos, Bieito; Balaguer, Javier; Rubio, Jeronimo; Pavon-Jimenez, Ricardo; Hernandez, Julio; Ormaetxe, Jose Miguel; Zamorano, Jose Luis; Santamaria, Pilar; Alzueta, Javier	Response rate in cardiac resynchronization therapy patients implanted with a left ventricular quadripolar lead and the MultiPoint TM pacing feature early activated. QUARTO III	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	5.5	Q1	Article	2023
A-03	Lorenzo, M; Minana, G; Palau, P; Amiguet, M; Seller, J; Pinilla, JMG; Dominguez, E; Villar, S; de la Espriella, R; Nunez, E; Gorriz, JL; Valle, A; Bodi, V; Sanchis, J; Bayes-Genis, A; Nunez, J	Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Fraction	JOURNAL OF CARDIAC FAILURE	6	Q1	Article	2023
A-03	Jurado-Roman, Alfonso; Freixa, Xavier; Cid, Belen; Cruz-Gonzalez, Ignacio; Sarnago Cebada, Fernando; Baz, Jose Antonio; Lozano, Inigo; Sabate, Manel; Jimenez, Jesus; Inigo Garcia, Luis Antonio; Subinas Elorriaga, Asier; Berenguer Jofresa, Alberto; Novo Garcia, Enrique; Perez Vizcayno, Maria Jose; Carrillo Suarez, Xavier; Pinar Bermudez, Eduardo; Calvino Santos, Ramon; Alvarez Anton, Salvador; Trillo Nouche, Ramiro; Ruiz Arroyo, Jose Ramon; Fernandez Cisnal, Agustin; Amat-Santos, Ignacio J; Jerez Valero, Miguel; Rama Merchan, Juan Carlos; Vaquerizo, Beatriz; Tejada Ponce, David; Ruiz Nodar, Juan Miguel; Sanchez Perez, Ignacio; Tejedor, Paula; Elizaga, Jaime; Jimenez Cabrera, Francisco Manuel; Bullones Ramirez, Juan Antonio; Sanchez Aquino, Rosa; Portero Perez, Maria Pilar; Roura, Gerard; Mohandes, Mohsen; Saez Moreno, Roberto, Avanzas, Pablo; Caballero, Juan; Torres Bosco, Alfonso Miguel; Merchan Herrera, Antonio; Robles Alonso, Javier; Bosa Ojeda, Francisco; Garcia San Roman, Koldobika; Agudelo, Victor Hugo; Martin Lorenzo, Pedro; Fernandez, Juan Carlos; Perez de Prado, Armando; Ruiz Quevedo, Valeriano; Cruz Gonzalez, Ignacio; Moreu Burgos, Jose; Ruiz Garcia, Juan; Sanchez Burguillos, Francisco Jose; Nunez Pernas, Daniel; Baello Monge, Pascual; Hernando Marrupe, Lorenzo; Franco Pelaez, Juan Antonio; Jurado Roman, Alfonso; Pomar Domingo, Francisco; Fuertes Ferre, Georgina; Pimienta Gonzalez, Raquel; Morales Ponce, Francisco Jose; Sanchez Recalde, Angel; Ojeda Pineda, Soledad; Frutos Garcia, Araceli; Millan Segovia, Raul; Fajardo Molina, Ricardo; Diez Gil, Jose Luis; Guisado Rasco, Agustin; Gomez Menchero, Antonio Enrique; Bosch, Eduard; Oteo Dominguez, Juan Francisco; Gutierrez-Barrios, Alejandro; Cascon Perez, Jose Domingo; Casanova Sandoval, Juan Manuel; Fernandez Portales, Javier; Rivero Crespo, Fernando; Gonzalez Caballero, Eva; Ocaranza Sanchez, Raymundo; Zueco, Javier; Garcia Del Blanco, Bruno; Alonso Briales, Juan Horacio; Sanchez Gila, Joaquin; Vizcaino Arellano, Manuel; Carballo Garrido, Julio; Andraka,	Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022).	Revista espanola de cardiologia (English ed.)	5.9	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Lozano, Ignacio Fernandez; Asensi, Joaquin Osca; Rodriguez, Javier Alzueta	Spanish implantable cardioverter- defibrillator registry. 19th official report of Heart Rhythm Association of the Spanish Society of Cardiology (2022)	REVISTA ESPANOLA DE CARDIOLOGIA	5.9	Q1	Article	2023
A-03	Galeano, P; de Ceglia, M; Mastrogiovanni, M; Campanelli, L; Medina-Vera, D; Campolo, N; Novack, GV; Rosell-Valle, C; Suárez, J; Aicardo, A; Campuzano, K; Castaño, EM; Do Carmo, S; Cuello, AC; Bartesaghi, S; Radi, R; de Fonseca, FR; Morelli, L	The Effect of Fat Intake with Increased Omega-6-to-Omega-3 Polyunsaturated Fatty Acid Ratio in Animal Models of Early and Late Alzheimer's Disease-like Pathogenesis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-03	Tirado-Conte, Gabriela; Rodes-Cabau, Josep; Oteo, Juan F.; Pan, Manuel; Munoz, Erika; Witberg, Guy; Cheema, Asim; Alpieri, Alberto; Lopez, Diego; Amat-Santos, Ignacio; Akodad, Mariama; Ojeda, Soledad; Serra, Vicenc; Garcia-Blas, Sergio; Alfonso, Fernando; De Backer, Ole; Asmarats, Luis; Munoz, Antonio; Hamdan, Ashraf; Toggweiler, Stefan; del Valle, Raquel; Salido, Luisa; Cruz-Gonzalez, Ignacio; Estevez-Loureiro, Rodrigo; Alfaro, Luis Enrique Martin; Gheorghe, Livia; Dabrowski, Maciec; Berenguer, Alberto; Arzamendi, Dabit; Saia, Francesco; Webb, John; Sondergaard, Lars; Nombela-Franco, Luis	Transcatheter aortic valve implantation in patients with extra-small aortic annuli	EUROINTERVENTION	6.2	Q1	Article	2023
A-03	Medina-Vera, D; Zambrana-Infantes, EN; López-Gambero, AJ; Verheul-Campos, J; Santín, LJ; Baixeras, E; Suarez, J; Pavon, FJ; Rosell-Valle, C; Fonseca, FRD	Transcending the amyloid-beta dominance paradigm in Alzheimer's disease: An exploration of behavioural, metabolic, and gut microbiota phenotypes in 5xFAD mice	NEUROBIOLOGY OF DISEASE	6.1	Q1	Article	2023
A-03	Cequier, A; Bueno, H; Macaya, C; Bertomeu, V; Gonzalez-Juanatey, JR; Iniguez, A; Anguita, M; Cruz, I; Calvo, D; Gomez-Doblas, JJ; Hernandez, JMD; del Prado, N; Padial, LR; Perez-Villacastin, J; Bernal, JL; Elola, J; RECALCAR project researchers	Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020	REVISTA ESPANOLA DE CARDIOLOGIA	5.9	Q1	Article	2023
A-03	Sánchez-Quintero M.J., Rodríguez-Díaz C., Rodríguez-González F.J., Fernández-Castañer A., García-Fuentes E., López-Gómez C.	Role of Mitochondria in Inflammatory Bowel Diseases: A Systematic Review	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Review	2023
A-03	Velilla, TA; Guijarro, C; Ruiz, RC; Piñero, MR; Marcos, JFV; Pérez, AP; López, MAB; López, AM; Donaire, JAG; Obaya, JC; Guerra, LC; Carratalá, VP; Cabello, IE; Lazo, MS; Rodrigo, MMC; Prieto, JMM; Doblas, JJG; Soto, AB	Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?	REVISTA CLINICA ESPANOLA	2.9	Q2	Article	2023
A-03	De Luca, Giuseppe; Algowhary, Magdy; Uguz, Berat; Oliveira, Dinaldo C.; Ganyukov, Vladimir; Busljetik, Oliver; Cercek, Miha; Jensen, Lisette Okkels; Loh, Poay Huan; Calmac, Lucian; Ferrer, Gerard Roura i; Quadros, Alexandre; Milewski, Marek; D'Uccio, Fortunato Scotto; von Birgelen, Clemens; Versaci, Francesco; Ten Berg, Jurrien; Casella, Gianni; Lung, Aaron Wong Sung; Kala, Petr; Gil, Jose Luis Diez; Carrillo, Xavier; Dirksen, Maurits; Munoz, Victor Becerra; Lee, Michael Kang-yin; Juzar, Dafsah Arifa; Joaquim, Rodrigo de Joaquim; Paladino, Roberto; Milicic, Davor; Davlouros, Periklis; Bakraceski, Nikola; Zilio, Filippo; Donazzan, Luca; Kraaijeveld, Adriaan; Galasso, Gennaro; Arpad, Lux; Marinucci, Lucia; Guiducci, Vincenzo; Menichelli, Maurizio; Scoccia, Alessandra; Yamac, Aylin Hatice; Mert, Kadir Ugur; Rios, Xacobe Flores; Kovarnik, Tomas; Kidawa, Michal; Moreu, Jose; Flavien, Vincent; Fabris, Enrico; Martinez-Luengas, Inigo Lozano; Boccalatte, Marco; Ojeda, Francisco Bosa; Arellano-Serrano, Carlos; Caiazzo, Gianluca; Cirrincione, Giuseppe; Kao, Hsien-Li; Fores, Juan Sanchis; Vignali, Luigi; Pereira, Helder; Manzo-Silberman, Stephane; Ordonez, Santiago; Arat Ozkan, Alev; Scheller, Bruno; Lehitola, Heidi; Teles, Rui; Mantis, Christos; Antti, Ylitalo; Silveira, Joao Antonio Brum; Zoni, Cesar Rodrigo; Bessonov, Ivan; Uccello, Giuseppe; Kochiadakis, George; Alexopulos, Dimitrios; Uribe, Carlos E.; Kanakakis, John; Faurie, Benjamin; Gabrielli, Gabriele; Barrios, Alejandro Gutierrez; Bachini, Juan Pablo; Rocha, Alex; Tam, Frankie C. C.; Rodriguez, Alfredo; Lukito, Antonia Anna; Saint-Joy, Veauthyelau; Pessah, Gustavo; Tuccillo, Andrea; Ielasi, Alfonso; Cortese, Giuliana; Parodi, Guido; Burgadha, Mohammed Abed; Kedhi, Elvin; Lamelas, Pablo; Suryapranata, Harry; Nardin, Matteo; Verdoia, Monica	Age-Related Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS- STEMI COVID-19 Registry	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Molina-Cabello M.A., Thurnhofer-Hemsi K., Molina-Cabello D., Palomo E.J.	Are learning styles useful? A new software to analyze correlations with grades and a case study in engineering	Computer Applications in Engineering Education	2.9	Q2	Article	2023
A-03	Lopes, LR; Losi, MA; Sheikh, N; Laroche, C; Charron, P; Gimeno, J; Kaski, JP; Maggioni, AP; Tavazzi, L; Arbustini, E; Brito, D; Celutkiene, J; Hagege, A; Linhart, A; Mogensen, J; Garcia-Pinilla, JM; Ripoll-Vera, T; Seggewiss, H; Villacorta, E; Caforio, A; Elliott, PM	Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry	EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES	5.2	Q2	Article	2023
A-03	Mulet, Alba; Nunez-Gil, Ivan J.; Carbonell, Juan Antonio; Soriano, Joan B.; Viana-Llamas, Maria C.; Raposeiras-Roubin, Sergio; Romero, Rodolfo; Alfonso-Rodriguez, Emilio; Uribarri, Aitor; Feltes, Gisela; Becerra-Munoz, Victor M.; Santoro, Francesco; Pepe, Martino; Castro-Mejia, Alex F.; Chipayo, David; Corbi-Pascual, Miguel; Lopez-Pais, Javier; Vedia, Oscar; Manzone, Edoardo; Molina-Romera, German; Espejo-Paeres, Carolina; Lopez-Masjuan, Alvaro; Velicki, Lazar; Fernandez-Ortiz, Antonio; El-Battrawy, Ibrahim; Signes-Costa, Jaime	Clinical Profile and Determinants of Mortality in Patients with Interstitial Lung Disease Admitted for COVID-19	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-03	Arrobas Velilla, Teresa; Guijarro, Carlos; Campuzano Ruiz, Raquel; Rodriguez Pinero, Manuel; Valderrama Marcos, Jose Francisco; Perez Perez, Antonio; Botana Lopez, Manuel Antonio; Morais Lopez, Ana; Garcia Donaire, Jose Antonio; Carlos Obaya, Juan; Castilla Guerra, Luis; Pallares Carratala, Vicente; Egocheaga Cabello, Isabel; Salgueira Lazo, Mercedes; Castellanos Rodrigo, Maria Mar; Mostaza Prieto, Jose Maria; Gomez Doblas, Juan Jose; Buno Soto, Antonio	Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: What parameters should a basic lipid profile include?	REVISTA CLINICA ESPANOLA	2.9	Q2	Article	2023
A-03	Amiguet, M; Palau, P; Dominguez, E; Seller, J; Pinilla, JMG; de la Espriella, R; Minana, G; Valle, A; Sanchis, J; Gorriz, JL; Bayes-Genis, A; Nunez, J	Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
A-03	De Luca, G; Manzo-Silberman, S; Algowhary, M; Uguz, B; Oliveira, DC; Ganyukov, V; Busljetik, O; Cercek, M; Okkels, L; Loh, PH; Calmac, L; Ferrer, GRI; Quadros, A; Milewski, M; di Uccio, FS; von Birgelen, C; Versaci, F; Ten Berg, J; Casella, G; Lung, AWS; Kala, P; Gil, JLD; Carrillo, X; Dirksen, M; Becerra, V; Lee, MKY; Juzar, DA; Joaquim, RD; Paladino, R; Milicic, D; Davlouros, P; Bakraceski, N; Zilio, F; Donazzan, L; Kraaijeveld, A; Galasso, G; Arpad, L; Marinucci, L; Guiducci, V; Menichelli, M; Scoccia, A; Yamac, AH; Mert, K; Rios, XF; Kovarnik, T; Kidawa, M; Moreu, J; Flavien, V; Fabris, E; Martínez-Luengas, IL; Boccalatte, M; Ojeda, FB; Arellano-Serrano, C; Caiazzo, G; Cirrincione, G; Kao, HL; Forés, JS; Vignali, L; Pereira, H; Ordoñez, S; Özkan, AA; Scheller, B; Lehtola, H; Teles, R; Mantis, C; Antti, Y; Silveira, JAB; Zoni, CR; Bessonov, I; Uccello, G; Kochiadakis, G; Alexopulos, D; Uribe, CE; Kanakakis, J; Faurie, B; Gabrielli, G; Barrios, AG; Bachini, JP; Rocha, A; Tam, FCC; Rodriguez, A; Lukito, AA; Saint-Joy, V; Pessah, G; Tuccillo, A; Ielasi, A; Cortese, G; Parodi, G; Bouraghda, MA; Moura, M; Kedhi, E; Lamelas, P; Suryapranata, H; Nardin, M; Verdoia, M	Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-03	Gonzalez-Juanatey, C; Anguita-Sanchez, M; Barrios, V; Nunez-Gil, I; Gomez-Doblas, JJ; Garcia-Moll, X; Lafuente-Gormaz, C; Rollan-Gomez, MJ; Peral-Disdier, V; Martinez-Dolz, L; Rodriguez-Santamarta, M; Vinolas-Prat, X; Soriano-Colome, T; Munoz-Aguilera, R; Plaza, I; Curcio-Ruigomez, A; Orts-Soler, E; Segovia-Cubero, J; Fanjul, V; Marin-Corral, J; Cequier, A; SAVANA Res Grp	Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real- World Setting in Spain	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-03	Cosin-Sales, J; Ruiz, RC; Diaz, JLD; Cervantes, CE; Olmo, MRF; Gomez-Doblas, JJ; Mostaza, JM; Pedro-Botet, J; Gili, NP; Valdivielso, P	Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain	ATHEROSCLEROSIS	5.3	Q2	Article	2023
A-03	Escobar, Carlos; Barrios, Vivencio; Cequier, Angel; Cosin-Sales, Juan; Seijas, Jose; Doblas, Juan Jose Gomez; Arrarte, Vicente; Tunon, Jose; Banach, Maciej	Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome.	JOURNAL OF CLINICAL LIPIDOLOGY	4.4	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Dobarro, D; Donoso-Trenado, V; Sole-Gonzalez, E; Moliner-Abos, C; Garcia-Pinilla, JM; Lopez-Fernandez, S; Ruiz-Bustillo, S; Diez-Lopez, C; Castrodeza, J; Mendez-Fernandez, AB; Vaqueriza-Cubillo, D; Cobo-Marcos, M; Tobar, J; Sagasti-Aboitiz, I; Rodriguez, M; Escolar, V; Abecia, A; Codina, P; Gomez-Otero, I; Pastor, F; Marzoa-Rivas, R; Gonzalez-Babarro, E; de Juan-Baguda, J; Melendo-Viu, M; de Frutos, F; Gonzalez-Costello, J	Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry	ESC HEART FAILURE	3.8	Q2	Article	2023
A-03	Ramos-Maqueda, J; Migueles, JH; Molina-Jimenez, M; Ruiz-Gonzalez, D; Cabrera-Borrego, E; Salas, AR; Soriano-Maldonado, A; Jimenez-Jaimez, J	Lifestyle physical activity and rapid-rate non-sustained ventricular tachycardia in arrhythmogenic cardiomyopathy	HEART	5.7	Q2	Article	2023
A-03	Esteban-Fernández, A; Anguita-Sánchez, M; Bonilla-Palomas, JL; Anguita-Gámez, M; Rosillo, N; del Prado, N; Bernal, JL; Fernández-Pérez, C; Fernández-Rozas, I; Gómez-Doblas, JJ; Pérez-Villacastin, J; Elola, FJ	One-year readmissions for circulatory diseases and in-hospital mortality after an index episode of heart failure in elderly patients. A nationwide data from public hospitals in Spain between 2016 and 2018	CLINICAL RESEARCH IN CARDIOLOGY	5	Q2	Article	2023
A-03	Panagides, V; Cheema, AN; Urena, M; Nombela-Franco, L; Veiga-Fernandez, G; Vilalta, V; Regueiro, A; Del Val, D; Asmarats, L; del Trigo, M; Serra, V; Munoz-Garcia, A; Rezaei, E; Himbert, D; Tirado-Conte, G; Hernandez, JMD; Fernandez-Nofrerias, E; Cepas-Guillén, PL; Alfonso, F; Gutierrez-Alonso, L; Domínguez, JFO; Belanech, Y; Paradis, JM; Mesnier, J; Rodés-Cabau, J	Optimal Degree of Balloon-Expandable Transcatheter Valve Oversizing in Patients With Borderline Aortic Annulus Measurements: Insights From a Multicenter Real-World Experience	CIRCULATION- CARDIOVASCULAR INTERVENTIONS	5.6	Q2	Article	2023
A-03	Nunez-Gil, Ivan J.; Feltes, Gisela; Viana-Llamas, Maria C.; Raposeiras-Roubin, Sergio; Romero, Rodolfo; Alfonso-Rodriguez, Emilio; Uribarri, Aitor; Santoro, Francesco; Becerra-Munoz, Victor; Pepe, Martino; Castro-Mejia, Alex F.; Signes-Costa, Jaime; Gonzalez, Adelina; Marin, Francisco; Lopez-Pais, Javier; Cerrato, Enrico; Vazquez-Cancela, Olalla; Espejo-Paeres, Carolina; Masjuan, Alvaro Lopez; Velicki, Lazar; El-Battrawy, Ibrahim; Ramakrishna, Harish; Fernandez-Ortiz, Antonio; Perez-Villacastin, Julian	Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-03	Sánchez-García, AM; Martínez-López, P; Gómez-González, AM; Rodriguez-Capitán, J; Pavón-Morón, FJ; Jiménez-López, RJ; García-Almeida, JM; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abad, V; Molina-Ramos, AI; Cabrera-César, E; Ben-Abdellatif, I; Gordillo-Resina, M; Pérez-Mesa, E; Nieto-González, M; Nuevo-Ortega, P; Reina-Artacho, C; Sánchez-Fernández, PL; Jiménez-Navarro, MF; Estecha-Foncea, MA	Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES	3.6	Q2	Article	2023
A-03	Maza-Quiroga, R; Thurnhofer-Hemsi, K; López-Rodríguez, D; López-Rubio, E	Regression of the Rician Noise Level in 3D Magnetic Resonance Images from the Distribution of the First Significant Digit	AXIOMS	2	Q2	Article	2023
A-03	Garcia-Guimaraes, Marcos; Sanz-Ruiz, Ricardo; Sabate, Manel; Velazquez-Martin, Maite; Veiga, Gabriela; Ojeda, Soledad; Avanzas, Pablo; Cortes, Carlos; Trillo-Nouche, Ramiro; Perez-Guerrero, Ainhoa; Gutierrez-Barrios, Alejandro; Becerra-Munoz, Victor; Lozano-Ruiz-Poveda, Fernando; de Prado, Armando Perez; del Val, David; Bastante, Teresa; Alfonso, Fernando	Spontaneous coronary artery dissection and ST-segment elevation myocardial infarction: Does clinical presentation matter?	INTERNATIONAL JOURNAL OF CARDIOLOGY	3.5	Q2	Article	2023
A-03	Medina-Vera, D; Zhao, HJ; Bereczki, E; Rosell-Valle, C; Shimozawa, M; Chen, GF; de Fonseca, FR; Nilsson, P; Tambaro, S	The Expression of the Endocannabinoid Receptors CB2 and GPR55 Is Highly Increased during the Progression of Alzheimer's Disease in App(NL-G-F) Knock-In Mice	BIOLOGY-BASEL	4.2	Q2	Article	2023
A-03	Robles-Mezcua, A; Ruiz-Salas, A; Medina-Palomo, C; Robles-Mezcua, M; Diaz-Exposito, A; Ortega-Jimenez, MV; Gimeno-Blanes, JR; Jimenez-Navarro, MF; Garcia-Pinilla, JM	The Novel Variant NP_00454563.2 (p.Glu259Glyfs*77) in Gene PKP2 Associated with Arrhythmogenic Cardiomyopathy in 8 Families from Malaga, Spain	GENES	3.5	Q2	Article	2023
A-03	Villaescusa-Catalan, JM; Rodriguez-Capitan, J; Sanz-Sanchez, CI; Sanchez-Espin, G; Guerrero-Orriach, JL; Moron, FJP; Fernandez-Romero, L; Melero-Tejedor, JM; Such-Martinez, M; Porras-Martin, C; Jimenez-Navarro, M	The Prognostic Value of Previous Coronary Stent Implantation in Patients Undergoing Myocardial Revascularization Surgery	CURRENT VASCULAR PHARMACOLOGY	4.5	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	Sanchez, R; Ripoll-Vera, T; Lopez-Mendoza, M; de Juan-Ribera, J; Gimeno, JR; Hermida, A; Ruz-Zafra, MA; Torregrosa, JV; Mora, A; Garcia-Pinilla, JM; Fortuny, E; Aguinaga-Barrilero, A; Torra, R	The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants	ORPHANET JOURNAL OF RARE DISEASES	3.7	Q2	Article	2023
A-03	Conde, AC; Martín, DM; Ruiz, RC; Olmo, MRF; Ariño, CM; Doblas, JJG; Teruel, JLG; Ramos, PM; Marimon, XGM; Romeo, MJS; Jiménez, DL; Esteban, VA; Rebollar, JCO; Cervantes, CE; Martínez, JJG	Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Review	2023
A-03	Gomez-Moyano, E; Rodriguez-Capitan, J; Roman, DG; Bueno, JAR; Sanchez, AV; Hernandez, FE; Angulo, GEG; Mora, MJM; Thurnhofer-Hemsi, K; Molina-Ramos, AI; Romero-Cuevas, M; Jimenez-Navarro, M; Pavon-Moron, FJ	Postural orthostatic tachycardia syndrome and other related dysautonomic disorders after SARS-CoV-2 infection and after COVID-19 messenger RNA vaccination	FRONTIERS IN NEUROLOGY	3.4	Q2	Review	2023
A-03	Gallego-Zazo, Natalia; Miranda-Alcaraz, Lucia; Cruz-Utrilla, Alejandro; Del Cerro Marin, Maria Jesus; Alvarez-Fuente, Maria; Del Mar Rodriguez Vazquez Del Rey, Maria; Guillen Rodriguez, Inmaculada; Becerra-Munoz, Victor Manuel; Moya-Bonora, Amparo; Ochoa Parra, Nuria; Parra, Alejandro; Pascual, Patricia; Cazalla, Mario; Silvan, Cristina; Arias, Pedro; Valverde, Diana; de Jesus-Perez, Vinicio; Lapunzina, Pablo; Escribano-Subias, Pilar; Tenorio-Castano, Jair	Seven Additional Patients with SOX17 Related Pulmonary Arterial Hypertension and Review of the Literature.	GENES	3.5	Q2	Review	2023
A-03	Escobar, Carlos; Freire, Ramon Bover; Marimon, Xavier Garcia-Moll; Gonzalez-Juanatey, Carlos; Morillas, Miren; Munoz, Alfonso Valle; Doblas, Juan Jose Gomez	A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study	CARDIOVASCULAR DIAGNOSIS AND THERAPY	2.4	Q3	Article	2023
A-03	Rivera-Caravaca, Jose Miguel; Sanchez, Manuel Anguita; Fernandez, Marcelo Sanmartin; Rafols, Carles; Baron-Esquivias, Gonzalo; Ynsaurriaga, Fernando Arribas; Freixa-Pamias, Roman; Goya, Inaki Lekuona; Rodriguez, Jose Manuel Vazquez; Perez-Cabeza, Alejandro I.; Cosin-Sales, Juan; Montilla, Isabel Urena; Blanco, Antonio Alvarez-Vieitez; Marin, Francisco	Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment	AMERICAN JOURNAL OF CARDIOLOGY	2.8	Q3	Article	2023
A-03	Velilla, Teresa Arrobas; Guijarro, Carlos; Ruiz, Raquel Campuzano; Pinero, Manuel Rodriguez; Francisco Valderrama Marcos, Jose; Lopez, Antonio M Botana; Lopez, Ana Morais; Antonio Garcia Donaire, Jose; Obaya, Juan Carlos; Guerra, Luis Castilla; Carratala, Vicente Pallares; Cabello, Isabel Egocheaga; Lazo, Mercedes Salgueira; Rodrigo, Maria Mar Castellanos; Maria Mostaza Prieto, Jose; Doblas, Juan Jose Gomez; Soto, Antonio Buno	Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?	NEFROLOGIA	2.6	Q3	Article	2023
A-03	Sánchez-García, AM; Martínez-López, P; Gómez-González, AM; Rodriguez-Capitán, J; Jiménez-López, RJ; Almeida, JMG; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abada, V; Molina-Ramos, AI; Cabrera-César, E; Ben-Abdellatif, I; Gordillo-Resina, M; Pérez-Mesa, E; Nieto-González, M; Nuevo-Ortega, P; Reina-Artacho, C; Fernández, PLS; Jiménez-Navarro, MF; Estecha-Foncea, MA	Multidisciplinary approach of the sequelae one month after hospital discharge in patients with severe bilateral COVID-19 pneumonia, are there differences depending on the respiratory therapy used during admission to intensive care?	MEDICINA INTENSIVA	3	Q3	Article	2023
A-03	Marin, Francisco; Fernandez, Marcelo Sanmartin; Baron-Esquivias, Gonzalo; Barrios, Vivencio; Lekuona, Inaki; Perez-Cabeza, Alejandro, I; Masjuan, Jaime; del Vigo, Esther Recalde; Rodriguez, Jose Manuel Vazquez; Freixa-Pamias, Roman; Schilling, Vanessa Roldan; Arribas, Fernando; Priu, Carles Rafols; Sanchez, Manuel Anguita	Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban	JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH	2.1	Q3	Article	2023
A-03	Gomez Doblas, Juan Jose; Cepeda-Rodrigo, Jose Maria; Agra Bermejo, Rosa; Blanco Labrador, Elvira; Blasco, Maria Teresa; Carrera Izquierdo, Margarita; Lekuona, Inaki; Recio Mayoral, Alejandro; Rafols, Carles; Manito, Nicolas	Outcomes and factors associated with mortality in patients with atrial fibrillation and heart failure: FARAONIC study.	Clinical cardiology	2.7	Q3	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-03	De Luca, Giuseppe; Algowhary, Magdy; Uguz, Berat; Oliveira, Dinaldo C.; Ganyukov, Vladimir; Zimbakov, Zan; Cercek, Miha; Jensen, Lisette Okkels; Loh, Poay Huan; Calmac, Lucian; Ferrer, Gerard Roura, I; Quadros, Alexandre; Milewski, Marek; Di Uccio, Fortunato Scotto; von Birgelen, Clemens; Versaci, Francesco; Ten Berg, Jurrien; Casella, Gianni; Lung, Aaron Wong Sung; Kala, Petr; Gil, Jose Luis Diez; Carrillo, Xavier; Dirksen, Maurits; Becerra-Munoz, Victor M.; Lee, Michael Kang-Yin; Juzar, Dafsah Arifa; Joaquim, Rodrigo de Moura; De Simone, Ciro; Milicic, Davor; Davlouros, Periklis; Bakraceski, Nikola; Zilio, Filippo; Donazzan, Luca; Kraaijeveld, Adriaan; Galasso, Gennaro; Arpad, Lux; Marinucci, Lucia; Guiducci, Vincenzo; Menichelli, Maurizio; Scoccia, Alessandra; Yamac, Aylin Hatice; Mert, Kadir Ugur; Rios, Xacobe Flores; Kovarnik, Tomas; Kidawa, Michal; Moreu, Jose; Flavien, Vincent; Fabris, Enrico; Martinez-Luengas, Inigo Lozano; Boccalatte, Marco; Ojeda, Francisco Bosa; Arellano-Serrano, Carlos; Caiazzo, Gianluca; Cirrincione, Giuseppe; Kao, Hsien-Li; Fores, Juan Sanchis; Vignali, Luigi; Pereira, Helder; Manzo-Silbermann, Stephane; Ordonez, Santiago; Ozkan, Alev Arat; Scheller, Bruno; Lehtola, Heidi; Teles, Rui; Mantis, Christos; Antti, Ylitalo; Silveira, Joao Antonio Brum; Bessonov, Ivan; Zoni, Rodrigo; Savonitto, Stefano; Kochiadakis, George; Alexopoulos, Dimitrios; Uribe, Carlos E.; Kanakakis, John; Faurie, Benjamin; Gabrielli, Gabriele; Barrios, Alejandro Gutierrez; Bachini, Juan Pablo; Rocha, Alex; Tam, Frankie Chor-Cheung; Rodriguez, Alfredo; Lukito, Antonia Anna; Bellemain-Appaix, Anne; Pessah, Gustavo; Cortese, Giuliana; Parodi, Guido; Burgadha, Mohammed Abed; Kedhi, Elvin; Lamelas, Pablo; Suryapranata, Harry; Nardin, Matteo; Verdoia, Monica	SARS-CoV-2 Positivity, Stent Thrombosis, and 30-day Mortality in STEMI Patients Undergoing Mechanical Reperfusion	ANGIOLOGY	2.8	Q3	Article	2023
A-03	Alvarez-Ortega, Carlos Antonio; Ruiz, Miguel Angel; Solorzano-Guillen, Cesar; Barrera, Alberto; Toquero-Ramos, Jorge; Martinez-Alday, Jesus Daniel; Grande, Carlos; Maria Segura, Jose; Garcia-Alberola, Arcadio; Morina-Vazquez, Pablo; Ferrero-de-Loma-Osorio, Angel; Villuendas, Roger; Cozar, Rocio; Fe Arcocha, Maria; Ibanez, Alicia; Peinado, Rafael	Time to-30°C as a predictor of acute success during cryoablation in patients with atrial fibrillation	CARDIOLOGY JOURNAL	2.9	Q3	Article	2023
A-03	Gonzalez-Juanatey, JR; Comin-Colet, J; Figal, DP; Bayes-Genis, A; Cepeda, JM; Garcia-Pinilla, JM; Garcia-Quintana, A; Manzano, L; Zamorano, JL	Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat	PATIENT PREFERENCE AND ADHERENCE	2.2	Q3	Review	2023
A-03	Esteban-Fernández, A; Anguita-Sánchez, M; Bonilla-Palomas, JL; Anguita-Gámez, M; García, M; Bernal, JL; Del Prado, N; Fernández-Perez, C; Pérez-Villacastin, J; Gómez-Doblas, JJ; Elola, FJ	Characteristics and in-hospital mortality of elderly patients with heart failure in Spanish hospitals	JOURNAL OF GERIATRIC CARDIOLOGY	2.5	Q4	Article	2023
A-03	Arrobas Velilla, Teresa; Guijarro, Carlos; Campuzano Ruiz, Raquel; Rodriguez Pinero, Manuel; Valderrama Marcos, Jose Francisco; Botana Lopez, Antonio M; Morais Lopez, Ana; Garcia Donaire, Jose Antonio; Obaya, Juan Carlos; Castilla Guerra, Luis; Pallares Carratala, Vicente; Egocheaga Cabello, Isabel; Salgueira Lazo, Mercedes; Castellanos Rodrigo, Maria Mar; Mostaza Prieto, Jose Maria; Gomez Doblas, Juan Jose; Buno Soto, Antonio	Consensus document for lipid profile testing and reporting in Spanish clinical laboratories.	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.9	Q4	Article	2023
A-03	Lajnef, R; Ben Abdallah, L; Tapia-Paniagua, S; Turki, Y; Medina, A; Mehri, I; Moriñigo, MA; Hassen, A	Intraspecific characterization of Vibrio alginolyticus isolates recovered from aquaculture systems and marine biotopes in Tunisia by PCR-RFLP, ECP and OMPs profiling	ACTA ADRIATICA	0.9	Q4	Article	2023
A-03	Pedro-Botet, J; Barrios, V; Sánchez-Margalet, V; Tamargo, J; Arrieta, F; Gámez, JM; Gimeno-Orna, JA; Escobar, C; Gómez-Doblas, JJ; Pérez, A	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/ very high cardiovascular risk. Consensus document of the Sociedad Espanola de Cardiologia [Spanish Society of Cardiology] and the Sociedad Espanola de Diabetes [Spanish Diabetes Society]	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.9	Q4	Article	2023
A-06	Huespe, IA; Ferraris, A; Lalueza, A; Valdez, PR; Peroni, ML; Cayetti, LA; Mirofsky, MA; Boietti, B; Gomez-Huelgas, R; Casas-Rojo, JM; Anton-Santos, JM; Nunez-Cortes, JM; Lumbreras, C; Ramos-Rincon, JM; Barrio, NG; Pedrera-Jimenez, M; Martin-Escalante, MD; Ruiz, FR; Onieva-Garcia, MA; Toso, CR; Risk, MR; Klen, R; Pollan, JA; Gomez-Varela, D	COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes. A multicontinental cohort study	JOURNAL OF MEDICAL VIROLOGY	12.7	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-06	Klen, R; Huespe, IA; Gregalio, FA; Blanco, ALL; Jimenez, M; Barrio, NG; Valdez, PR; Mirofsky, MA; Boietti, B; Gomez-Huelgas, R; Casas-Rojo, JM; Anton-Santos, JM; Pollan, JA; Gomez-Varela, D	Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study	ELIFE	7.7	D1	Article	2023
A-06	Khoury, N; Martinez, MA; Paz-Graniel, I; Martinez-Gonzalez, MA; Corella, D; Castaner, O; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pinto, X; Gaforio, JJ; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorli, JV; Perez-Vega, KA; Garcia-Rios, A; Bellvert, NG; Gomez-Gracia, E; Zulet, MA; Chaplin, A; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vazquez-Ruiz, Z; Asensio, EM; Goday, A; Pena-Orihuela, PJ; Signes-Pastor, AJ; Garcia-Arellano, A; Fito, M; Babio, N; Salas-Salvado, J	Dietary intake of polychlorinated dibenzo- p-dioxins and furans, adiposity and obesity status	ENVIRONMENTAL RESEARCH	8.3	D1	Article	2023
A-06	Gomez-Perez, AM; Ruiz-Limon, P; Salas-Salvado, J; Vioque, J; Corella, D; Fito, M; Vidal, J; Atzeni, A; Torres-Collado, L; Alvarez-Sala, A; Martinez, MA; Goday, A; Benaiges, D; Garcia-Gavilan, J; Lopez, MRB; Moreno-Indias, I; Tinahones, FJ	Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis	GUT MICROBES	12.2	D1	Article	2023
A-06	Garcia, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubin-Garcia, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Fito, M; Martinez, JA; Tojal-Sierra, L; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Cano-Ibanez, N; Pinto, X; Delgado-Rodriguez, M; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Buil-Cosiales, P; Martinez-Rodriguez, MA; Coltell, O; Castaner, O; Garcia-Rios, A; Barcelo, C; Gomez-Gracia, E; Zulet, MA; Konieczna, J; Casas, R; Masso-Guijarro, P; Goicolea-Guemez, L; Bernal-Lopez, MR; Bes-Rastrollo, M; Shyam, S; Gonzalez, JI; Zomeno, MD; Pena-Orihuela, PJ; Gonzalez-Palacios, S; Toledo, E; Khoury, N; Perez, KA; Martin-Sanchez, V; Tur, JA; Bouzas, C	Ultra-processed foods consumption as a promoting factor of greenhouse gas emissions, water, energy, and land use: A longitudinal assessment	SCIENCE OF THE TOTAL ENVIRONMENT	9.8	D1	Article	2023
A-06	Martinez-Montoro, JI; Benitez-Porres, J; Tinahones, FJ; Ortega-Gomez, A; Murri, M	Effects of exercise timing on metabolic health	OBESITY REVIEWS	8.9	D1	Review	2023
A-06	Bernabeu-Wittel, M; Para, O; Voicehovska, J; Gómez-Huelgas, R; Václavík, J; Battegay, E; Holecki, M; van Munster, BC	Competences of internal medicine specialists for the management of patients with multimorbidity. EFIM multimorbidity working group position paper	EUROPEAN JOURNAL OF INTERNAL MEDICINE	8	Q1	Article	2023
A-06	Lopez-Sampalo, A; Cobos-Palacios, L; Vilches-Perez, A; Sanz-Canovas, J; Vargas-Candela, A; Mancebo-Sevilla, JJ; Hernandez-Negrin, H; Gomez-Huelgas, R; Bernal-Lopez, MR	COVID-19 in Older Patients: Assessment of Post-COVID-19 Sarcopenia	BIOMEDICINES	4.7	Q1	Article	2023
A-06	Shyam S., García-Gavilán J.F., Paz-Graniel I., Gaforio J.J., Martínez-González M.Á., Corella D., Martínez J.A., Alonso-Gómez Á.M., Wärnberg J., Vioque J., Romaguera D., López-Miranda J., Estruch R., Tinahones F.J., Lapetra J., Serra-Majem J.L., Bueno-Cavanillas A., Tur J.A., Sánchez V.M., Pintó X., Matía-Martín P., Vidal J., del Mar Alcarria M., Daimiel L., Ros E., Fernandez-Aranda F., Nishi S.K., García-Regata Ó., Araluce R.P., Asensio E.M., Castañer O., Garcia-Rios A., Oncina-Cánovas A., Bouzas C., Zulet M.A., Rayó E., Casas R., Martin-Pelaez S., Tojal-Sierra L., Bernal-López M.R., Carlos S., Sorlí J.V., Goday A., Peña-Orihuela P.J., Pastor-Morel A., Eguaras S., Zomeño M.D., Delgado-Rodríguez M., Babio N., Fitó M., Salas-Salvadó J.	Intensive Weight-Loss Lifestyle Intervention Using Mediterranean Diet and COVID-19 Risk in Older Adults: Secondary Analysis of PREDIMED-Plus Trial	JOURNAL OF NUTRITION HEALTH & AGING	5.8	Q1	Article	2023
A-06	García-Sillero, M; Maroto-Izquierdo, S; Galván-García, M; Benitez-Porres, J; Vargas-Molina, S; Jurado-Castro, JM	Acute Effects of Blood Flow Restriction Training on Movement Velocity and Neuromuscular Signal during the Back Squat Exercise	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-06	Martínez, PP; Gómez-Huelgas, R; Escribano, PPC; Arévalo-Lorido, JC; Pérez-Soto, MI; Gómez, CJ	Approach to obesity in the elderly population: a consensus report from the Diabetes, Obesity and Nutrition Working Group of Spanish Society of Internal Medicine	REVISTA CLINICA ESPANOLA	2.9	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-06	Florido-Santiago, M; Perez-Belmonte, LM; Osuna-Sanchez, J; Barbancho, MA; Ricci, M; Millan-Gomez, M; Bernal-Lopez, MR; Gomez-Huelgas, R; Lara, JP	Assessment of long-term cognitive dysfunction in older patients who undergo heart surgery	NEUROLOGIA	3.9	Q2	Article	2023
A-06	Ropero-Luis, G; López-Sampalo, A; Sanz-Cánovas, J; Ruiz-Cantero, A; Gómez-Huelgas, R	Characteristics of hospitalized patients with hypercalcemia in the province of Malaga: A longitudinal, retrospective, multicenter study	REVISTA CLINICA ESPANOLA	2.9	Q2	Article	2023
A-06	Borroto-Escuela, DO; Lopez-Salas, A; Wydra, K; Bartolini, M; Zhou, ZL; Frankowska, M; Suder, A; Benitez-Porres, J; Romero-Fernandez, W; Filip, M; Fuxe, K	Combined treatment with Sigma1R and A2AR agonists fails to inhibit cocaine self-administration despite causing strong antagonistic accumbal A2AR-D2R complex interactions: the potential role of astrocytes	FRONTIERS IN MOLECULAR NEUROSCIENCE	4.8	Q2	Article	2023
A-06	Vargas-Molina, S; Bonilla, DA; Petro, JL; Carbone, L; García-Sillero, M; Jurado-Castro, JM; Schoenfeld, BJ; Benítez-Porres, J	Efficacy of progressive versus severe energy restriction on body composition and strength in concurrent trained women	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY	3	Q2	Article	2023
A-06	de la Calle, GM; Reyne, AG; Lora-Tamayo, J; Miguez, AM; Arnalich-Fernandez, F; Perez, JLB; Nunez, JAV; Martinez, MAC; Rivera, NA; Garcia, EO; Moreno, BS; Castro, SJF; Rhyman, N; Fontan, PMP; Piles, L; Caleya, JFL; Villarejo, MEF; Jimenez-Garcia, N; Boixeda, R; Noya, AG; Gutierrez, AG; Oterino, JAM; Huelgas, RG; Santos, JMA; Bermejo, CL	Impact of days elapsed from the onset of symptoms to hospitalization in COVID-19 inhospital mortality: Time matters	REVISTA CLINICA ESPANOLA	2.9	Q2	Article	2023
A-06	Casas-Rojo, JM; Ventura, PS; Santos, JMA; de Latierro, AO; Arevalo-Lorido, JC; Mauri, M; Rubio-Rivas, M; Gonzalez-Vega, R; Giner-Galvan, V; Perpina, BO; Fonseca-Aizpuru, E; Muino, A; Del Corral-Beamonte, E; Gomez-Huelgas, R; Arnalich-Fernandez, F; Barrio, ML; Sancha-Lloret, A; Lorite, IR; Loureiro-Amigo, J; Pintos-Martinez, S; Garcia-Sardon, E; Montano-Martinez, A; Rojano-Rivero, MG; Ramos-Rincon, JM; Lopez-Escobar, A	Improving prediction of COVID-19 mortality using machine learning in the Spanish SEMI-COVID-19 registry	INTERNAL AND EMERGENCY MEDICINE	4.6	Q2	Article	2023
A-06	Carrasco-Fernández, L; García-Sillero, M; Jurado-Castro, JM; Borroto-Escuela, DO; García-Romero, J; Benítez-Porres, J	Influence of limb dominance on body and jump asymmetries in elite female handball	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
A-06	Fuentes-Abolafio, IJ; Trinidad-Fernandez, M; Escriche-Escuder, A; Roldan-Jimenez, C; Arjona-Caballero, JM; Bernal-Lopez, MR; Ricci, M; Gomez-Huelgas, R; Perez-Belmonte, LM; Cuesta-Vargas, AI	Kinematic Parameters That Can Discriminate in Levels of Functionality in the Six-Minute Walk Test in Patients with Heart Failure with a Preserved Ejection Fraction	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-06	Perez-Belmonte, Luis M; Osuna-Sanchez, Julio; Ricci, Michele; Millan-Gomez, Mercedes; Lopez-Carmona, Maria D; Barbancho, Miguel A; Bernal-Lopez, Maria R; Jansen-Chaparro, Sergio; Lara, Jose P; Gomez-Huelgas, Ricardo	Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older study.	PANMINERVA MEDICA	4.3	Q2	Article	2023
A-06	Casas-Rojo, Jose-Manuel; Anton-Santos, Juan-Miguel; Millan-Nunez-Cortes, Jesus; Gomez-Huelgas, Ricardo; Ramos-Rincon, Jose-Manuel; Rubio-Rivas, Manuel; Corrales-Gonzalez, Miguel-Angel; Fernandez-Madera-Martinez, Maria-Rosa; Beato-Perez, Jose-Luis; Arnalich-Fernandez, Francisco; Gallego-Lezaun, Cristina; Perez-Martinez, Pablo; Molinos-Castro, Sonia; Tung-Chen, Yale; Madrazo, Manuel; Mendez-Bailon, Manuel; Monge-Monge, Daniel; Garcia-Garcia, Gema-Maria; Garcia-Fenoll, Rosa; Gilabert, Noemi; Fuerte-Martinez, Rebeca; Contreras-Sanchez, Marta; Rhyman, Nicolas; Peris-Garcia, Jorge; Lumbreras-Bermejo, Carlos	Mortality reduction in older COVID-19- patients hospitalized in Spain during the second pandemic wave from the SEMI- COVID-19 Registry.	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
A-06	Bailón, MM; Villalba, NL; Onrubia, JG; Rivas, MR; Rodriguez, MVN; Pérez, MDP; Pedroche, CD; Aizpuru, EMF; Garcia, MVV; Garcia, GMG; Fontán, PMP; Artero, A; Hernandez, EM; Pedrajas, JNA; Galvan, VG; Monge, DM; Giménez, LL; Gómez, M; Cilleros, CM; Ruiz, NP; Sevilla, JE; Méndez, RG; Ramos-Rincón, JM; Huelgas, RG	Prognostic Factors Associated with Acute Heart Failure in Patients Admitted for COVID-19: Analysis of the SEMI-COVID-19 Registry	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-06	Gabriel, R; Boukichou-Abdelkader, N; Gilis-Januszewska, A; Makrilakis, K; Gomez-Huelgas, R; Kamenov, Z; Paulweber, B; Satman, I; Djordjevic, P; Alkandari, A; Mitrakou, A; Lalic, N; Egido, J; Mas-Fontao, S; Calvet, JH; Pastor, JC; Lindstrom, J; Lind, M; Acosta, T; Silva, L; Tuomilehto, J	Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-06	Lopez-Sampalo, A; Hernandez-Negrin, H; Bernal-Lopez, M-R; Rubio-Rivas, M; Martin-Escalante, M D; Wikman-Jogersen, P; Garcia-Reyne, A; Fernandez-Madera Martinez, R; Gomez-Antunez, M; Beato-Perez, J L; Torres-Pena, J D; Martin-Oterino, J A; Loureiro-Amigo, J; Vicente de la Sota, J; Gil-Sanchez, R; Lorenzo-Lopez Reboiro, M; Bernal-Roman, B; Fernandez-Sola, J; Amoros-Martinez, F; Vicente-Lopez, N; Valle-Bernard, R; Lopez-Ruiz, A; Ramos-Rincon, J-M; Gomez-Huelgas, R	The impact of frailty on intra-hospital survival in older patients with COVID-19 infection: the importance of early identification. SEMI-COVID National Registry.	REVISTA CLINICA ESPANOLA	2.9	Q2	Article	2023
A-06	Ramos-Rincon, JM; Ventura, PS; Casas-Rojo, JM; Maurl, M; Bermejo, CL; de Latlerro, AO; Rublo-Rivas, M; Merida-Rodrigo, L; Perez-Casado, L; Giner-Galvan, V; Barrientos-Guerrero, M; Gallego-Lezaun, C; Milian, AH; Manzano, L; Blazquez-Encinar, JC; Solis-Marquinez, MN; Garcia, MG; Lobo-Garcia, J; Valente, VAR; Roig-Marti, C; Leon-Tellez, M; Tellerfa-Gomez, P; Gonzalez-Juarez, MJ; Gomez-Huelgas, R; Lopez-Escobar, A	Validation of the RIM Score-COVID in the Spanish SEMI-COVID-19 Registry	INTERNAL AND EMERGENCY MEDICINE	4.6	Q2	Article	2023
A-06	Jurado-Castro, JM; Vargas-Molina, S; Gómez-Urquizá, JL; Benítez-Porres, J	Effectiveness of real-time classroom interactive competition on academic performance: a systematic review and meta-analysis	PEERJ COMPUTER SCIENCE	3.8	Q2	Review	2023
A-06	Gomez, CR; Negrin, HH; Gutierrez, MDA	Eosinophilic granulomatosis with polyangeitis	CLINICAL MEDICINE	3.9	Q2	Review	2023
A-06	Cuesta-Vargas, Antonio Ignacio; Fuentes-Abolafio, Ivan Jose; Garcia-Conejo, Celia; Diaz-Balboa, Estibaliz; Trinidad-Fernandez, Manuel; Gutierrez-Sanchez, Daniel; Escriche-Escuder, Adrian; Cobos-Palacios, Lidia; Lopez-Sampalo, Almudena; Perez-Ruiz, Jose Maria; Roldan-Jimenez, Cristina; Perez-Velasco, Miguel Angel; Mora-Robles, Javier; Lopez-Carmona, M Dolores; Perez-Cruzado, David; Martin-Martin, Jaime; Perez-Belmonte, Luis Miguel	Effectiveness of a cardiac rehabilitation program on biomechanical, imaging, and physiological biomarkers in elderly patients with heart failure with preserved ejection fraction (HFpEF): FUNNEL+study protocol	BMC CARDIOVASCULAR DISORDERS	2.1	Q3	Article	2023
A-06	Ramos-Rincon, JM; Lopez-Sampalo, A; Cobos-Palacios, L; Ricci, M; Rubio-Rivas, M; Diaz-Simon, R; Martin-Escalante, MD; Castaneda-Perez, S; Fernandez-Madera-Martinez, R; Beato-Perez, JL; Garcia-Garcia, GM; Garcia-Andreu, MD; Arnalich-Fernandez, F; Molinos-Castro, S; Vargas-Nunez, JA; Artero, A; Freire-Castro, SJ; Fernandez-Gomez, J; Cubo-Romano, P; Hernandez-Milian, A; Ines-Revuelta, SM; Boixeda, R; Fernandez-Pedregal, E; Gomez-Huelgas, R	Nosocomial COVID-19: A Nationwide Spanish Study	GERONTOLOGY	3.5	Q3	Article	2023
A-06	Sanz-Canovas, J; Ricci, M; Cobos-Palacios, L; Lopez-Sampalo, A; Hernandez-Negrin, H; Vazquez-Marquez, M; Mancebo-Sevilla, JJ; Alvarez-Recio, E; Lopez-Carmona, MD; Perez-Velasco, MA; Perez-Belmonte, LM; Gomez-Huelgas, R; Bernal-Lopez, MR	Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases	REVIEWS IN CARDIOVASCULAR MEDICINE	2.7	Q3	Review	2023
A-07	Rodriguez-Perez, MD; Santiago-Corral, L; Ortega-Hombrados, L; Verdugo, C; Arrebola, MM; Martin-Aurioles, E; Fernandez-Prior, MA; Bermudez-Oria, A; De La Cruz, JP; Gonzalez-Correa, JA	The Effect of the Extra Virgin Olive Oil Minor Phenolic Compound 3',4'-Dihydroxyphenylglycol in Experimental Diabetic Kidney Disease	NUTRIENTS	5.9	Q1	Article	2023
A-07	Lopez-Villodres, JA; Escamilla, A; Mercado-Saenz, S; Alba-Tercedor, C; Rodriguez-Perez, LM; Arranz-Salas, I; Sanchez-Varo, R; Bermudez, D	Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice	BIOMEDICINES	4.7	Q1	Review	2023
A-07	Baeza-Barragán, MR; Manzanares, MTL; Amaya-Alvarez, MC; Vega, FM; Ruiz, JR; Martín-Valero, R	Effectiveness of a 5-Week Virtual Reality Telerehabilitation Program for Children With Duchenne and Becker Muscular Dystrophy: Prospective Quasi-Experimental Study	JMIR SERIOUS GAMES	4	Q2	Article	2023
A-07	Repiso-Guardeno, Angela; Moreno-Morales, Noelia; Labajos-Manzanares, Maria Teresa; Rodriguez- Martinez, Maria Carmen; Armenta-Peinado, Juan Antonio	Does Tension Headache Have a Central or Peripheral Origin? Current State of Affairs	CURRENT PAIN AND HEADACHE REPORTS	3.7	Q2	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-09	Camacho, Ana; Ariza, Maria Jose; Amigo, Nuria; Macias Guillen, Patricia; Sanchez Chaparro, Miguel Angel; Valdivielso, Pedro	A case of hypocholesterolemia under study.	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.6		Article	2023
A-09	Espildora-Hernandez, Javier; Martin-Cortes, Salvador; Benitez-Toledo, Maria Jose; Coca-Prieto, Inmaculada; Sanchez-Chaparro, Miguel Angel; Valdivielso, Pedro	Doctors' perception of red wine consumption and cardiovascular health.	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.6		Article	2023
A-09	Pedro-Botet, J; Plana, N; Mostaza, JM; Gómez-Doblas, JJ; Olmo, MRF; Cervantes, CE; Díaz-Díaz, JL; Ruiz, RC; Valdivielso, P; Cosin-Sales, J	Hypercholesterolaemia control in Spain: The same situation with different regional realities	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.6		Article	2023
A-09	Brotons, C; Moral-Peláez, I; Vicuña, J; Ameixeiras, C; Fernández-Lavandera, C; Sánchez-Chaparro, MA	Update and validation of the lifetime cardiovascular risk in Spain: IBERLIFERISK2	CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS	1.6		Article	2023
A-09	Mena-Vázquez, N; Rojas-Gimenez, M; Romero-Barco, CM; Gandía-Martínez, M; Perez-Gómez, N; Godoy-Navarrete, FJ; Manrique-Arija, S; Garcia-Studer, A; Calvo-Gutiérrez, J; Varela, CF; Morales-Garrido, P; Pérez, PC; Mouriño-Rodriguez, C; Añón-Oñate, I; Espildora, F; Aguilar-Hurtado, MC; Redondo, R; Conde, AH; de los Ríos, RAD; César, EC; Velloso-Feijoo, ML; Fernández-Nebro, A	Analysis of comorbidity in rheumatoid arthritis-associated interstitial lung disease: a nested case-cohort study	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
A-09	Diaz-Sanchez, E; Lopez-Salas, A; Mirchandani-Duque, M; Alvarez-Contino, JE; Sanchez-Perez, JA; Fuxe, K; Borroto-Escuela, DO; Garcia-Casares, N; Narvaez, M	Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
A-09	Garcia-Casares, N; Gonzalez-Gonzalez, G; de la Cruz-Cosme, C; Garzon-Maldonado, FJ; de Rojas-Leal, C; Ariza, MJ; Narvaez, M; Barbancho, MA; Garcia-Arnes, JA; Tinahones, FJ	Effects of GLP-1 receptor agonists on neurological complications of diabetes	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	Article	2023
A-09	Garcia-Garcia, I; Fernandez-Andujar, M; Narvaez, M; Garcia-Casares, N	Assessing adipokines as potential biomarkers of dementia, Alzheimer's disease, and mild cognitive impairment: A systematic review and meta-analysis	OBESITY REVIEWS	8.9	D1	Review	2023
A-09	Alvarez-Contino, JE; Diaz-Sanchez, E; Mirchandani-Duque, M; Sanchez-Perez, JA; Barbancho, MA; Lopez-Salas, A; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narvaez, M	GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions	JOURNAL OF CELLULAR PHYSIOLOGY	5.6	Q1	Article	2023
A-09	Casas, BM; Linares, JLC; Aranda, IB; Villodres, JR; Bohorquez, VM; Jimenez, AG; Corral, MAR; Bosch, R; Chaparro, MAS; Fernandez, MG; Valdivielso, P	Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-09	Crow, EM; Lopez-Gigosos, R; Mariscal-Lopez, E; Agredano-Sanchez, M; Garcia-Casares, N; Mariscal, A; Gutierrez-Bedmar, M	Psychosocial interventions reduce cortisol in breast cancer patients: systematic review and meta-analysis	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Review	2023
A-09	Pinazo-Bandera, JM; Aranda, J; García-García, AM; Alcantara, R; Ortega-Alonso, A; Del Campo-Herrera, E; Clavijo, E; Garcia-Escaño, MD; Ruiz, JJR; Morales-Herrera, M; Valle-López, V; Martin-Alarcón, R; Viciana, I; Jiménez, JB; Fernández-García, F; Toro-Ortiz, JP; Sanchez-Yáñez, E; Alvarez-alvarez, I; Andrade, RJ; Robles-Díaz, M; Garcia-Cortés, M	Hepatitis C virus point-of-care microelimination approach in a vulnerable population in the South of Spain	GASTROENTEROLOGY REPORT	3.6	Q2	Article	2023
A-09	Cosin-Sales, J; Ruiz, RC; Diaz, JLD; Cervantes, CE; Olmo, MRF; Gomez-Doblas, JJ; Mostaza, JM; Pedro-Botet, J; Gili, NP; Valdivielso, P	Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain	ATHEROSCLEROSIS	5.3	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-09	Rioja, J; Ariza, MJ; Benitez-Toledo, MJ; Espildora-Hernandez, J; Coca-Prieto, I; Arrobas-Velilla, T; Camacho, A; Olivecrona, G; Sanchez-Chaparro, MA; Valdivielso, P	Role of lipoprotein lipase activity measurement in the diagnosis of familial chylomicronemia syndrome	JOURNAL OF CLINICAL LIPIDOLOGY	4.4	Q2	Article	2023
A-09	Santos-Ortega, Alvaro; Alba-Linero, Carmen; Urbinati, Facundo; Rocha-de-Lossada, Carlos; Orti, Rafael; Reyes-Bueno, Jose Antonio; Garzon-Maldonado, Francisco Javier; Serrano, Vicente; de Rojas-Leal, Carmen; de la Cruz-Cosme, Carlos; Espana-Contreras, Manuela; Rodriguez-Calvo-de-Mora, Marina; Garcia-Casares, Natalia	Structural and Functional Retinal Changes in Patients with Mild Cognitive Impairment with and without Diabetes.	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-09	Williams, Kate; Tickler, Georgina; Valdivielso, Pedro; Alonso, Jordi; Vera-Llonch, Montserrat; Cubells, Laia; Acaster, Sarah	Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience.	ORPHANET JOURNAL OF RARE DISEASES	3.7	Q2	Article	2023
A-09	Bardon De Tena, Paula; Tapia Paniagua, Silvana Teresa; Vico Sevilla, Jose Alberto; Clavijo, Encarnacion; Martinez Manzanares, Eduardo; Gonzalez-Domenech, Carmen Maria; Azzaroli, Francesco	Unusual Surge of Acute Hepatitis A Cases in 2016 and 2017 in Malaga, Southern Spain: Characterization and Relationship with Other Concurrent European Outbreaks	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-09	Lopez-Pineda, J; Rodriguez-Martinez, MC; Gomez-Rodriguez, R; Garcia-Casares, L; Garcia-Casares, N	Biomechanical Assessments in Woodwind Musicians: A Systematic Review	HEALTHCARE	2.8	Q2	Review	2023
A-09	Sagües-Sesé, E; García-Casares, N; Alvarez-Twose, I	Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review	CLINICAL AND TRANSLATIONAL ALLERGY	4.4	Q2	Review	2023
A-09	Garcia-Arnes, JA; Garcia-Casares, N	Doping and sports endocrinology: Growth hormone, IGF-1, insulin, and erythropoietin	REVISTA CLINICA ESPANOLA	2.9	Q2	Review	2023
A-09	Carazo-Barrios, L; Cabrera-Maestre, A; Alba-Linero, C; Gutierrez-Bedmar, M; Garzon-Maldonado, FJ; Serrano, V; de la Cruz-cosme, C; Garcia-Casares, N	Retinal Neurodegeneration Measured With Optical Coherence Tomography and Neuroimaging in Alzheimer Disease: A Systematic Review	JOURNAL OF NEURO- OPHTHALMOLOGY	2.9	Q2	Review	2023
A-09	Cardo, ALG; Casas, JAV; Garzón, JRG; Hospital, JLT; López, RM; Macías, JMF; Fernández, AR	18F-DCFPyL PET/CT guidelines	REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR	1.2	Q4	Article	2023
A-09	Carazo-Barrios, Lina; Gallardo-Tur, Alejandro; Aguilar-Monge, Alba; Luisa Heras-Gonzalez, M.; Sempere-Fernandez, Jose F.; Hamad-Cueto, Omar; Heras-Perez, Jose A.; de la Cruz-Cosme, Carlos	Impact of COVID-19 lockdown on patients with idiopathic intracranial hypertension in Spain	REVISTA DE NEUROLOGIA	1.2	Q4	Article	2023
A-10	Dimyati, A; Junaidi, J; Wiradihardja, S; Dlis, F; Mahardhika, DB; Dermawan, DF; Quintero, AM; Gil-Espinosa, FJ; Setiawan, E	DOES MOVEMENT GAMES IMPACT ON INCREASING SPORTS PARTICIPATION, FUNDAMENTAL MOVEMENT SKILL AND LIFE SATISFACTION OF STUDENTS DISABILITIES?	REVISTA IBEROAMERICANA DE PSICOLOGIA DEL EJERCICIO Y EL DEPORTE	1		Article	2023
A-10	Alconchel, BR; Miranda-León, M; Gavala-González, J; Fernández-García, JC	GOLF PUTTING IN ADOLESCENTS: RANDOM PRACTICE VERSUS ERROR FREE LEARNING	REVISTA IBEROAMERICANA DE CIENCIAS DE LA ACTIVIDAD FISICA Y EL DEPORTE	0.4		Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-10	Perez, AT; Baro, IR; Gonzalez, JG; Garcia, JCF	Relationship between throwing ability and academic performance at school age	SPORTIS-SCIENTIFIC TECHNICAL JOURNAL OF SCHOOL SPORT PHYSICAL EDUCATION AND PSYCHOMOTRICITY	0.7		Article	2023
A-10	Ridwan, M; Tuasikal, ARS; Marhaendra, FJ; Ristanto, KO; Gazali, N; Monterrosa-Quintero, A; Gil-Espinosa, FJ; Raman, A; Setiawan, E	Technology Readiness and Psychological Correlate with Academic Achievement of Elite Student-Athletes at the College Level?	RETOS-NUEVAS TENDENCIAS EN EDUCACION FISICA DEPORTE Y RECREACION	1.3		Article	2023
A-10	Benavente-Marín, JC; Barón-López, FJ; Barcenilla, BG; Abril, GL; Aguirre, JMR; Gómez, SF; Pérez-Farinós, N; Wärnberg, J	THE PHYSICAL EDUCATION CLASS AS A REFERENCE FOR IDENTIFYING VIGOROUS ACTIVITIES USING ACCELEROMETRY IN 8-AND 9-YEAR-OLD CHILDREN	REVISTA IBEROAMERICANA DE CIENCIAS DE LA ACTIVIDAD FISICA Y EL DEPORTE	0.4		Article	2023
A-10	Rusmanto, R; Tomoliyus, T; Sulastion, A; Gazali, N; Abdullah, KH; Gil-Espinosa, FJ; Setiawan, E	Virtual Reality to Promoting Sports Engagement and Some Technical skills in Junior Football Athletes: A 12-Week Randomized Controlled Trial	RETOS-NUEVAS TENDENCIAS EN EDUCACION FISICA DEPORTE Y RECREACION	1.3		Article	2023
A-10	Bouzas, C; Pastor, R; Garcia, S; Monserrat-Mesquida, M; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Goday, A; Martínez, JA; Alonso-Gómez, AM; Fernández-Barceló, O; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majema, L; Riquelme-Gallegop, B; Martín-Sánchez, V; Pintó, X; Delgado-Rodriguez, M; Matía, P; Vidal, J; Cardenas-Salas, JJ; Daimiel, L; Ros, E; Toledo, E; Manzanares, JM; Gonzalez-Monge, I; Muñoz, MA; Martinez-Urbistondo, D; Tojal-Sierra, L; Muñoz-Bravoaf, C; Miralles-Gisbert, S; Martin, M; García-Ríos, A; Castro-Barquero, S; Fernández-García, JC; Santos-Lozano, JM; Basterra-Gortari, FJ; Gutiérrez-Carrasquilla, L; Guillem-Saiz, P; Satorres, A; Abete, I; Sorto-Sanchez, C; Díez-Espino, J; Babio, N; Fitó, M; Tur, JA	Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
A-10	Khoury, N; Martinez, MA; Paz-Graniel, I; Martinez-Gonzalez, MA; Corella, D; Castaner, O; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pinto, X; Gaforio, JJ; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorli, JV; Perez-Vega, KA; Garcia-Rios, A; Bellvert, NG; Gomez-Gracia, E; Zulet, MA; Chaplin, A; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vazquez-Ruiz, Z; Asensio, EM; Goday, A; Pena-Orihuela, PJ; Signes-Pastor, AJ; Garcia-Arellano, A; Fito, M; Babio, N; Salas-Salvado, J	Dietary intake of polychlorinated dibenzo- p-dioxins and furans, adiposity and obesity status	ENVIRONMENTAL RESEARCH	8.3	D1	Article	2023
A-10	Umbert, AC; Cantallops, RL; Monserrat, MR; Fernandez, AC; Barcelo, JM	From control systems to safety culture in the global foodservice outlet arena: A Balearic Islands perspective.	TRENDS IN FOOD SCIENCE & TECHNOLOGY	15.3	D1	Article	2023
A-10	Ni, JQ; Nishi, SK; Babio, N; Ros, E; Basterra-Gortari, FJ; Corella, D; Castañer, O; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Cano-Ibáñez, N; Tur, JA; Fernández-García, JM; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Fernández-Aranda, F; Ruiz-Canela, M; Solà, CM; Portolés, O; Sala-Vila, A; Garcia-Rios, A; Compañ-Gabucio, LM; Gómez-Gracia, E; Zulet, MA; Chaplin, A; Casas, R; Martínez-Diz, S; Tojal-Sierra, L; Gómez-Pérez, AM; Toledo, E; Rios, S; Ortega-Azorín, C; de la Torre, R; Peña-Orihuela, PJ; Garcia-de la Hera, M; Sayón-Orea, C; Malcampo, M; PREDIMED Plus Investigators	Higher versus lower nut consumption and changes in cognitive performance over two years in a population at risk of cognitive decline: a cohort study	AMERICAN JOURNAL OF CLINICAL NUTRITION	7.1	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-10	Paz-Graniel, I; Babio, N; Nishi, SK; Martinez-Gonzalez, MA; Corella, D; Fito, M; Martinez, A; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sanchez, VM; Pinto, X; Delgado-Rodriguez, M; Matia-Martin, P; Vidal, J; Calderon-Sanchez, C; Daimiel, L; Ros, E; Fernandez-Aranda, F; Toledo, E; Valle-Hita, C; Sorli, JV; Lassale, C; Garcia-Rios, A; Oncina-Canovas, A; Baron-Lopez, FJ; Zulet, MA; Rayo, E; Casas, R; Thomas-Carazo, E; Tojal-Sierra, L; Damas-Fuentes, M; Ruiz-Canela, M; de las Heras-delgado, S; Fernandez-Carrion, R; Castaner, O; Pena-Orihuela, PJ; Gonzalez-Palacios, S; Buil-Cosiales, P; Goday, A; Salas-Salvado, J	How Did the COVID-19 Lockdown Pandemic Affect the Depression Symptomatology in Mediterranean Older Adults with Metabolic Syndrome?	DEPRESSION AND ANXIETY	7.4	D1	Article	2023
A-10	Garcia, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubin-Garcia, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Goday, A; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Pinto, X; Gaforio, JJ; Matia, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Guillem-Saiz, P; Valle-Hita, C; Cabanes, R; Abete, I; Goicolea-Guemez, L; Gomez-Gracia, E; Tercero-Macia, C; Colom, A; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Cenoz, JC; Barragan, R; Khoury, N; Castaner, O; Zulet, MA; Vaquero-Luna, J; Bes-Rastrollo, M; de las Heras-delgado, S; Ciurana, R; Martin-Sanchez, V; Tur, JA; Bouzas, C	Metabolic syndrome criteria and severity and carbon dioxide (CO2) emissions in an adult population	GLOBALIZATION AND HEALTH	10.8	D1	Article	2023
A-10	Garcia, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubin-Garcia, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Fito, M; Martinez, JA; Tojal-Sierra, L; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Cano-Ibanez, N; Pinto, X; Delgado-Rodriguez, M; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Buil-Cosiales, P; Martinez-Rodriguez, MA; Coltell, O; Castaner, O; Garcia-Rios, A; Barcelo, C; Gomez-Gracia, E; Zulet, MA; Konieczna, J; Casas, R; Masso-Guijarro, P; Goicolea-Guemez, L; Bernal-Lopez, MR; Bes-Rastrollo, M; Shyam, S; Gonzalez, JI; Zomeno, MD; Pena-Orihuela, PJ; Gonzalez-Palacios, S; Toledo, E; Khoury, N; Perez, KA; Martin-Sanchez, V; Tur, JA; Bouzas, C	Ultra-processed foods consumption as a promoting factor of greenhouse gas emissions, water, energy, and land use: A longitudinal assessment	SCIENCE OF THE TOTAL ENVIRONMENT	9.8	D1	Article	2023
A-10	Shyam, Sangeetha; Garcia-Gavilan, Jesus Francisco; Paz-Graniel, Indira; Gaforio, Jose J; Martinez-Gonzalez, Miguel Angel; Corella, Dolores; Martinez, J Alfredo; Alonso-Gomez, Angel M; Warnberg, Julia; Vioque, Jesus; Romaguera, Dora; Lopez-Miranda, Jose; Estruch, Ramon; Tinahones, Francisco J; Lapetra, Jose; Serra-Majem, J Luis; Bueno-Cavanillas, Aurora; Tur, Josep A; Sanchez, Vicente Martin; Pinto, Xavier; Matia-Martin, Pilar; Vidal, Josep; Vazquez, Clotilde; Daimiel, Lidia; Ros, Emilio; Fernandez-Aranda, Fernando; Nishi, Stephanie K; Garcia-Regata, Oscar; Toledo, Estefania; Asensio, Eva M; Castaner, Olga; Garcia-Rios, Antonio; Torres-Collado, Laura; Gomez-Gracia, Enrique; Zulet, M Angeles; Ruiz, Nuria Goni; Casas, Rosa; Cano-Ibanez, Naomi; Tojal-Sierra, Lucas; Gomez-Perez, A M; Sorli, Jose V; Cinza-Sanjurjo, Sergio; Martin-Pelaez, Sandra; Pena-Orihuela, Patricia J; Oncina-Canovas, Alejandro; Perez-Araluce, Rafael; Zomeno, Maria Dolores; Chaplin, Alice; Delgado-Rodriguez, Miguel; Babio, Nancy; Fito, Montserrat; Salas-Salvado, Jordi	Association of adiposity and its changes over time with COVID-19 risk in older adults with overweight/obesity and metabolic syndrome: a longitudinal evaluation in the PREDIMED-Plus cohort	BMC MEDICINE	9.3	Q1	Article	2023
A-10	Bouzas, C; Pastor, R; Garcia, S; Monserrat-Mesquida, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Schroder, H; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Romero-Secin, A; Pinto, X; Gaforio, JJ; Matia, P; Vidal, J; Zapatero, M; Daimiel, L; Ros, E; Garcia-Arellano, A; Babio, N; Gonzalez-Monje, I; Castaner, O; Abete, I; Tojal-Sierra, L; Benavente-Marin, JC; Signes-Pastor, A; Konieczna, J; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Bes-Rastrollo, M; Mestres, C; Guillem-Saiz, P; Goday, A; Goicolea-Guemez, L; Puig-Aguilo, E; Ruiz-Canela, M; Palau-Galindo, A; Fito, M; Tur, JA	Association of monetary diet cost of foods and diet quality in Spanish older adults	FRONTIERS IN PUBLIC HEALTH	5.2	Q1	Article	2023
A-10	Garcia, S; Bouzas, C; Mateos, D; Pastor, R; Alvarez, L; Rubin, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Goday, A; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Pinto, X; Gaforio, JJ; Matia, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Bes-Rastrollo, M; Guillem-Saiz, P; Nishi, S; Cabanes, R; Abete, I; Goicolea-Guemez, L; Gomez-Gracia, E; Signes-Pastor, AJ; Colom, A; Garcia-Rios, A; Castro-Barquero, S; Fernandez-Garcia, JC; Santos-Lozano, JM; Vazquez, Z; Sorli, JV; Pascual, M; Castaner, O; Zulet, MA; Vaquero-Luna, J; Basterra-Gortari, FJ; Babio, N; Ciurana, R; Martin-Sanchez, V; Tur, JA	Carbon dioxide (CO2) emissions and adherence to Mediterranean diet in an adult population: the Mediterranean diet index as a pollution level index	ENVIRONMENTAL HEALTH	6	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-10	Donat-Vargas, Carolina; Mico, Victor; San-Cristobal, Rodrigo; Martinez-Gonzalez, Miguel Angel; Salas-Salvado, Jordi; Corella, Dolores; Fito, Montserrat; Alonso-Gomez, Angel Maria; Warnberg, Julia; Vioque, Jesus; Romaguera, Dora; Lopez-Miranda, Jose; Estruch, Ramon; Damas-Fuentes, Miguel; Lapetra, Jose; Serra-Majem, Luis; Bueno-Cavanillas, Aurora; Tur, Josep Antoni; Cinza-Sanjurjo, Sergio; Pinto, Xavier; Delgado-Rodriguez, Miguel; Matia-Martin, Pilar; Vidal, Josep; Causso, Claudia; Ros, Emilio; Toledo, Estefania; Manzanares, Josep Maria; Ortega-Azorin, Carolina; Castaner, Olga; Pena-Orihuela, Patricia Judith; Zazo, Juan Manuel; Munoz Bravo, Carlos; Martinez-Urbistondo, Diego; Chaplin, Alice; Casas, Rosa; Cano Ibanez, Naomi; Tojal-Sierra, Lucas; Gomez-Perez, Ana Maria; Pascual Roquet-Jalmar, Elena; Mestre, Cristina; Barragan, Rocio; Schroder, Helmut; Garcia-Rios, Antonio; Candela Garcia, Inmaculada; Ruiz-Canela, Miguel; Babio, Nancy; Malcampo, Mireia; Daimiel, Lidia; Martinez, Alfredo	Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk	NUTRIENTS	5.9	Q1	Article	2023
A-10	Ruiz-Sanchez, FJ; Martins, MD; Losa-Iglesias, ME; Becerro-de-Bengoa-Vallejo, R; Gomez-Salgado, J; Romero-Morales, C; Jimenez-Cebrian, AM; Lopez-Lopez, D	Impact of Multiple Sclerosis on Foot Health and Quality of Life: A Prospective Case- Control Investigation	INTERNATIONAL JOURNAL OF PUBLIC HEALTH	4.6	Q1	Article	2023
A-10	Homs, C; Berruezo, P; Arcarons, A; Warnberg, J; Oses, M; Gonzalez-Gross, M; Gusi, N; Aznar, S; Marin-Cascales, E; Gonzalez-Valeiro, MA; Serra-Majem, L; Terrados, N; Tur, JA; Segu, M; Fito, M; Benavente-Marin, JC; Labayen, I; Zapico, AG; Sanchez-Gomez, J; Jimenez-Zazo, F; Alcaraz, PE; Sevilla-Sanchez, M; Herrera-Ramos, E; Pulgar-Munoz, S; Bouzas, C; Mila, R; Schroder, H; Gomez, SF	Independent and Joined Association between Socioeconomic Indicators and Pediatric Obesity in Spain: The PASOS Study	NUTRIENTS	5.9	Q1	Article	2023
A-10	Shyam S., García-Gavilán J.F., Paz-Graniel I., Gaforio J.J., Martínez-González M.Á., Corella D., Martínez J.A., Alonso-Gómez Á.M., Wärnberg J., Vioque J., Romaguera D., López-Miranda J., Estruch R., Tinahones F.J., Lapetra J., Serra-Majem J.L., Bueno-Cavanillas A., Tur J.A., Sánchez V.M., Pintó X., Matía-Martín P., Vidal J., del Mar Alcarria M., Daimiel L., Ros E., Fernandez-Aranda F., Nishi S.K., García-Regata Ó., Araluce R.P., Asensio E.M., Castañer O., Garcia-Rios A., Oncina-Cánovas A., Bouzas C., Zulet M.A., Rayó E., Casas R., Martin-Pelaez S., Tojal-Sierra L., Bernal-López M.R., Carlos S., Sorlí J.V., Goday A., Peña-Orihuela P.J., Pastor-Morel A., Eguaras S., Zomeño M.D., Delgado-Rodríguez M., Babio N., Fitó M., Salas-Salvadó J.	Intensive Weight-Loss Lifestyle Intervention Using Mediterranean Diet and COVID-19 Risk in Older Adults: Secondary Analysis of PREDIMED-Plus Trial	JOURNAL OF NUTRITION HEALTH & AGING	5.8	Q1	Article	2023
A-10	Zapico, AG; Aparicio-Ugarriza, R; Quesada-Gonzalez, C; Gomez, SF; Warnberg, J; Medrano, M; Gusi, N; Aznar, S; Marin-Cascales, E; Gonzalez-Valeiro, MA; Serra-Majem, L; Pulgar, S; Tur, JA; Segu, M; Fito, M; Homs, C; Benavente-Marin, JC; Sanchez-Gomez, J; Jimenez-Zazo, F; Alcaraz, PE; Sevilla-Sanchez, M; Herrera-Ramos, E; Bouzas, C; Sistac, C; Schroder, H; Gesteiro, E; Gonzalez-Gross, M	Lifestyle behaviors clusters in a nationwide sample of Spanish children and adolescents: PASOS study	PEDIATRIC RESEARCH	3.6	Q1	Article	2023
A-10	Monserrat-Mesquida, M; Rodenas-Munar, M; Gomez, SF; Warnberg, J; Medrano, M; Gonzalez-Gross, M; Gusi, N; Aznar, S; Marin-Cascales, E; Gonzalez-Valeiro, MA; Serra-Majem, L; Pulgar, S; Segu, M; Fito, M; Segun, G; Benavente-Marin, JC; Labayen, I; Zapico, AG; Sanchez-Gomez, J; Jimenez-Zazo, F; Alcaraz, PE; Sevilla-Sanchez, M; Herrera-Ramos, E; Schroder, H; Tur, JA; Bouzas, C	Parents' Diet Quality and Physical Activity Are Associated with Lifestyle in Spanish Children and Adolescents: The PASOS Study	NUTRIENTS	5.9	Q1	Article	2023
A-10	Rodenas-Munar, Marina; Monserrat-Mesquida, Margalida; Gomez, Santiago F; Warnberg, Julia; Medrano, Maria; Gonzalez-Gross, Marcela; Gusi, Narcis; Aznar, Susana; Marin-Cascales, Elena; Gonzalez-Valeiro, Miguel A; Serra-Majem, Lluis; Pulgar, Susana; Segu, Marta; Fito, Montse; Torres, Silvia; Benavente-Marin, Juan Carlos; Labayen, Idoia; Zapico, Augusto G; Sanchez-Gomez, Jesus; Jimenez-Zazo, Fabio; Alcaraz, Pedro E; Sevilla-Sanchez, Marta; Herrera-Ramos, Estefania; Schroder, Helmut; Bouzas, Cristina; Tur, Josep A	Perceived Quality of Life Is Related to a Healthy Lifestyle and Related Outcomes in Spanish Children and Adolescents: The Physical Activity, Sedentarism, and Obesity in Spanish Study.	NUTRIENTS	5.9	Q1	Article	2023
A-10	Jimenez-Cebrian, AM; Lopez-Lopez, L; Losa-Iglesias, ME; Becerro-de-Bengoa-Vallejo, R; Romero-Morales, C; Lopez-Lopez, D; Montiel-Luque, A; Navarro-Flores, E; de Labra, C	The implications of the foot health status in Parkinson patients: A case-control study	INTERNATIONAL WOUND JOURNAL	3.1	Q1	Article	2023
A-10	Herrera-Ramos, E; Tomaino, L; Sanchez-Villegas, A; Ribas-Barba, L; Gomez, SF; Warnberg, J; Oses, M; Gonzalez-Gross, M; Gusi, N; Aznar, S; Marin-Cascales, E; Gonzalez-Valeiro, MA; Terrados, N; Tur, JA; Segu, M; Fito, M; Homs, C; Benavente-Marin, JC; Labayen, I; Zapico, AG; Sanchez-Gomez, J; Jimenez-Zazo, F; Alcaraz-Ramon, PE; Sevilla-Sanchez, M; Pulgar-Munoz, S; Bouzas, C; Sistac-Sorigue, C; Schroder, H; Serra-Majem, L	Trends in Adherence to the Mediterranean Diet in Spanish Children and Adolescents across Two Decades	NUTRIENTS	5.9	Q1	Article	2023
A-10	Moragues, A; Segui-Pons, JM; Fernandez, AC; Ruiz-Perez, M	Analysis of Road Accessibility by Residents and Tourists to Public Hospitals in Mallorca (Balearic Islands, Spain)	SUSTAINABILITY	3.9	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-10	Gutierrez-Albaladejo, Natalia; Lopez-de-Andres, Ana; Cuadrado-Corrales, Natividad; Albaladejo-Vicente, Romana; Villanueva-Orbaiz, Rosa; Carricondo, Francisco; Romero-Gomez, Barbara; Jimenez-Garcia, Rodrigo; Perez-Farinos, Napoleon	Asthma Is Associated with Back Pain and Migraine-Results of Population-Based Case-Control Study.	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-10	Valero-Cantero, I; Casals, C; Espinar-Toledo, M; Baron-Lopez, FJ; Martinez-Valero, FJ; Vazquez-Sanchez, MA	Cancer Patients' Satisfaction with In-Home Palliative Care and Its Impact on Disease Symptoms	HEALTHCARE	2.8	Q2	Article	2023
A-10	Llamas-Saez, C; Saez-Vaquero, T; Jimenez-Garcia, R; Lopez-de-Andres, A; Carabantes-Alarcon, D; Zamorano-Leon, JJ; Cuadrado-Corrales, N; Perez-Farinos, N; Warnberg, J	Cross Sectional and Case-Control Study to Assess Time Trend, Gender Differences and Factors Associated with Physical Activity among Adults with Diabetes: Analysis of the European Health Interview Surveys for Spain (2014&2020)	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-10	Valero-Cantero, I; Casals, C; Espinar-Toledo, M; Baron-Lopez, FJ; Soler, NGA; Vazquez-Sanchez, MA	Effects of Music on the Quality of Life of Family Caregivers of Terminal Cancer Patients: A Randomised Controlled Trial	HEALTHCARE	2.8	Q2	Article	2023
A-10	Ruiz-Perez, M; Moragues, A; Segui-Pons, JM; Muncunill, J; Goyanes, AP; Fernandez, AC	Geographical Distribution and Social Justice of the COVID-19 Pandemic: The Case of Palma (Balearic Islands)	GEOHEALTH	4.8	Q2	Article	2023
A-10	Paz-Graniel, I; Fito, M; Ros, E; Buil-Cosiales, P; Corella, D; Babio, N; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Martin-Sanchez, V; Pinto, X; Gaforio, JJ; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Garcia-Gavilan, JF; Toledo, E; Nishi, SK; Sorli, JV; Castaner, O; Garcia-Rios, A; de la Hera, MG; Baron-Lopez, FJ; Ruiz-Canela, M; Morey, M; Casas, R; Garrido-Garrido, EM; Tojal-Sierra, L; Fernandez-Garcia, JC; Vazquez-Ruiz, Z; Fernandez-Carrion, R; Goday, A; Pena-Orihuela, PJ; Compan-Gabucio, L; Schroder, H; Martinez-Gonzalez, MA; Salas-Salvado, J	Impact of COVID-19 pandemic on the PREDIMED-Plus randomized clinical trial: Effects on the interventions, participants follow-up, and adiposity	FRONTIERS IN NUTRITION	5	Q2	Article	2023
A-10	Gonzalez-Palacios, S; Oncina-Canovas, A; Garcia-de-la-Hera, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Schroder, H; Martinez, JA; Alonso-Gomez, AM; Warnberg, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Cano-Ibanez, N; Tur, JA; Martin-Sanchez, V; Pinto, X; Delgado-Rodriguez, M; Matia-Martin, P; Vidal, J; Vazquer, C; Daimiel, L; Ros, E; Bes-Rastrollo, M; Atzeni, A; Sorli, JV; Zomeno, MD; Pena-Orihuela, PJ; Compan-Gabucio, LM; Baron-Lopez, FJ; Zulet, MA; Konieczna, J; Casas, RM; Garrido-Garrido, EM; Tojal-Sierra, L; Gomez-Perez, AM; Ruiz-Canela, M; Palau, A; Saiz, C; Perez-Vega, KA; Garcia-Rios, A; Torres-Collado, L; Basterra-Gortari, J; Garciduenas-Fimbres, TE; Malcampo, M; Vioque, J; PREDIMED-PLUS Trial investigators	Increased ultra-processed food consumption is associated with worsening of cardiometabolic risk factors in adults with metabolic syndrome: Longitudinal analysis from a randomized trial	ATHEROSCLEROSIS	5.3	Q2	Article	2023
A-10	Llamas-Saez, Carlos; Saez-Vaquero, Teresa; Jimenez-Garcia, Rodrigo; Lopez-de-Andres, Ana; Carabantes-Alarcon, David; Zamorano-Leon, Jose J; Cuadrado-Corrales, Natividad; Omana-Palanco, Ricardo; de Miguel Diez, Javier; Perez-Farinos, Napoleon	Physical activity among adults with chronic obstructive pulmonary disease in Spain (2014-2020): Temporal trends, sex differences, and associated factors.	RESPIRATORY MEDICINE	4.3	Q2	Article	2023
A-10	Navarro-Flores, E; Losa-Iglesias, ME; Casado-Hernandez, I; Becerro-de-Bengoa-Vallejo, R; Romero-Morales, C; Palomo-Lopez, P; Lopez-Lopez, D; Jimenez-Cebrian, AM	Repeatability and reliability of the footwear assessment tool in Spanish patients: A transcultural adaptation	JOURNAL OF TISSUE VIABILITY	2.5	Q2	Article	2023
A-10	Ahmadnezhad, L; Lopez-Lopez, D; Becerro-de-Bengoa-Vallejo, R; Jimenez-Cebrian, AM; Gomez-Salgado, J; Losa-Iglesias, ME; Andreo-Garcia, MV; Navarro-Flores, E	Translated and adaptation into Persian of the podiatric health questionnaire (PHQ)	JOURNAL OF TISSUE VIABILITY	2.5	Q2	Article	2023
A-10	Ballesteros, BLM; Lopez-de-Andres, A; Jimenez-Garcia, R; Zamorano-Leon, JJ; Carabantes-Alarcon, D; Cuadrado-Corrales, N; Del-Barrio, JL; Perez-Farinos, N; De Miguel-Diez, J	Trends and Outcomes in Lung Transplantation in Patients with and without Idiopathic Pulmonary Fibrosis in Spain during the Period 2016-2020	HEALTHCARE	2.8	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-10	Rognoni, T; Fernández-Matarrubia, M; Martinez-González, MA; Salas-Salvadó, J; Corella, D; Castañer, O; Martínez, JA; Alonso-Gómez, AM; Gómez-Gracia, E; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Ibañez, NC; Tur, JA; Pérez, RM; Pintó, X; Delgado-Rodríguez, M; Ramos, MO; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Goñi-Ruiz, N; Babio, N; Sorlí, JV; Schröderj, H; García-Riose, A; Compañ-Gabucio, L; Warnberg, J; Zulet, MA; Chaplin, A; Sacanella, E; Bouzalmate-Hajjaj, A; Tojal-Sierra, L; Damas-Fuentes, M; Vázquez, Z; Gómez-Martínez, C; Saiz, C; Malcampo, M; Ortiz-Morales, AM; Martínez-Avilés, V; García-Gavilan, J; Abete, I; Fitó, M; Toledo, E	Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome	JOURNAL OF ALZHEIMERS DISEASE	4	Q2	Article	2023
A-10	García-López, FJ; Pastora-Bernal, JM; Moreno-Morales, N; Estebanez-Pérez, MJ; Liñán-González, A; Martín-Valero, R	Virtual reality to improve low-back pain and pelvic pain during pregnancy: a pilot RCT for a multicenter randomized controlled trial	FRONTIERS IN MEDICINE	3.9	Q2	Article	2023
A-10	Repiso-Guardeño, A; Moreno-Morales, N; Labajos-Manzanares, MT; Rodríguez-Martínez, MC; Armenta-Peinado, JA	Does Tension Headache Have a Central or Peripheral Origin? Current State of Affairs	CURRENT PAIN AND HEADACHE REPORTS	3.7	Q2	Review	2023
A-10	Porras-García, E; Calderón, IFE; Gavala-González, J; Fernández-García, JC	Potential neuroprotective effects of fermented foods and beverages in old age: a systematic review	FRONTIERS IN NUTRITION	5	Q2	Review	2023
A-10	Cano-Ibáñez, N; Serra-Majem, L; Martín-Peláez, S; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Lassale, C; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Gómez-Pérez, AM; Lapetra, J; Fernández-Aranda, F; Bueno-Cavanillas, A; Tur, JA; Cubelos, N; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Calderón, C; Daimiel, L; Ros, E; Gea, A; Babio, N; Gimenez-Alba, IM; Zomeño-Fajardo, MD; Abete, I; Sierra, LT; Romero-Galisteo, RP; de la Hera, MG; Martín-Padillo, M; García-Ríos, A; Casas, RM; Fernández-García, JC; Santos-Lozano, JM; Toledo, E; Becerra-Tomas, N; Sorli, J; Schröder, H; Zulet, MA; Sorto-Sánchez, C; Diez-Espino, J; Gómez-Martínez, C; Fitó, M; Sánchez-Villegas, A	Dietary diversity and depression: cross- sectional and longitudinal analyses in Spanish adult population with metabolic syndrome. Findings from PREDIMED-Plus trial	PUBLIC HEALTH NUTRITION	3.2	Q3	Article	2023
A-10	Castro-Méndez, A; Canca-Sánchez, FJ; Pabón-Carrasco, M; Jiménez-Cebrián, AM; Córdoba-Fernández, A	Evaluation of Gait Parameters on Subjects with Hallux Limitus Using an Optogait Sensor System: A Case-Control Study	MEDICINA-LITHUANIA	2.6	Q3	Article	2023
A-10	Bazan, MJA; Mora, CF; Orcal, LEB; Vicente, MP; Perez, LH; Warnberg, J; Rivas, FJP; Farinos, NP	A Questionnaire Survey of Personal and Occupational Variables Associated With SARS-COV-2 Infection in Health Care Personnel of the Spanish Central Military Hospital	MILITARY MEDICINE	1.2	Q4	Article	2023
A-17	Sánchez-Quintero, MJ; Delgado, J; Chaves, LM; Medina-Vera, D; Murri, M; Becerra-Muñoz, VM; Estévez, M; Crespo-Leiro, MG; López, GP; González-Jiménez, A; Ranea, JAG; Queipo-Ortuño, MI; Plaza-Andrades, I; Rodríguez-Capitán, J; Pavón-Morón, FJ; Jiménez-Navarro, MF	Multi-Omics Approach Reveals Prebiotic and Potential Antioxidant Effects of Essential Oils from the Mediterranean Diet on Cardiometabolic Disorder Using Humanized Gnotobiotic Mice.	ANTIOXIDANTS	7	D1	Article	2023
A-17	Flores-Lopez, M; Garcia-Marchena, N; Pavon-Moron, FJ; Requena-Ocana, N; Sanchez-Marin, L; Martin-Chaves, L; Garcia-Medina, M; Pedraza, C; Castilla-Ortega, E; Ruiz, JJ; de Fonseca, FR; Araos, P; Serrano, A	Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders	TRANSLATIONAL PSYCHIATRY	6.8	Q1	Article	2023
A-19	Murias, Sara; Boteanu, Alina; Calvo, Inmaculada; Nunez, Esmeralda; Bravo, Beatriz; Bustabad, Sagrario; Camacho, Marisol; Clemente, Daniel; Grana, Jenaro; de Inocencio, Jaime; Lacruz, Lucia; Mesa-Del-Castillo, Pablo; Nieto-Gonzalez, Juan Carlos; Pinedo, Maria Del Carmen; Quesada, Estefania; Vargas, Carmen; Anton, Jordi	What drives the decision to optimise biological treatment in children and youngsters with juvenile idiopathic arthritis? A discrete-choice experiment.	REUMATOLOGIA CLINICA	1.5		Article	2023
A-19	Reina-Perez, I; Artacho-Cordo, F; Mustieles, V; Castellano-Castillo, D; Cardona, F; Jimenez-Diaz, I; Lopez-Medina, JA; Alcaide, J; Ocana-Wilhelmi, L; Iribarne-Duran, LM; Arrebola, JP; Olea, N; Tinahones, FJ; Fernandez, MF	Cross-sectional associations of persistent organic pollutants measured in adipose tissue and metabolic syndrome in clinically diagnosed middle-aged adults	ENVIRONMENTAL RESEARCH	8.3	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-19	Rodriguez-Molinoa, P; Sola, IM; Lopez, JGD; Baquero-Artigao, F; Diaz-Almirone, M; Moreno-Perez, D; Calvo, C; Escosa-Garcia, L	Duration of antibiotic therapy among paediatricians: A national survey of current clinical practice in Spain	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS	10.8	D1	Article	2023
A-19	Martín-Reyes F., Bernal M., Rodríguez-Díaz C., Rodríguez-de los Reyes D., Ho-Plagaro A., Rodríguez-Pacheco F., Camacho-Martel L., Camargo-Camero R., Rodríguez-González F.J., Alcain-Martínez G., Martín-Masot R., Navas-López V.M., Villanueva-Paz M., Lucena M.I., García-Fuentes E., López-Gómez C.	Mitochondrial Stress Links Environmental Triggers with Pro-Inflammatory Signaling in Crohn's Disease	ANTIOXIDANTS	7	D1	Article	2023
A-19	Zapata-Cobo, P; Salvador-Martín, S; Velasco, M; Palomino, LM; Clemente, S; Segarra, O; Moreno-Alvarez, A; Fernandez-Lorenzo, A; Pérez-Moneo, B; Montraveta, M; Sanchez, C; Tolin, M; Loverdos, I; Fobelo, MJ; Navas-López, VM; Magallares, L; García-Romero, R; Sánchez-Hernández, JG; Rodríguez, A; Bossacoma, F; Balboa, MJ; Salcedo, E; Sanjurjo-Sáez, M; López-Fernández, LA	Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children	PHARMACOLOGICAL RESEARCH	9.3	D1	Article	2023
A-19	Fernandez-Jimenez, R; Martin-Masot, R; Cornejo-Pareja, I; Vegas-Aguilar, IM; Herrador-Lopez, M; Tinahones, FJ; Navas-Lopez, VM; Bellido-Guerrero, D; Garcia-Almeida, JM	Phase angle as a marker of outcome in hospitalized pediatric patients. A systematic review of the evidence (GRADE) with meta- analysis	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	Review	2023
A-19	Salvador-Martin, S; Zapata-Cobo, P; Velasco, M; Palomino, LM; Clemente, S; Segarra, O; Sanchez, C; Tolin, M; Moreno-alvarez, A; Fernandez-Lorenzo, A; Perez-Moneo, B; Loverdos, I; Lopez, VMN; Millan, A; Magallares, L; Torres-Peral, R; Garcia-Romero, R; Pujol-Muncunill, G; Merino-Bohorquez, V; Rodriguez, A; Salcedo, E; Lopez-Cauce, B; Marin-Jimenez, I; Menchen, L; Laserna-Mendieta, E; Lucendo, AJ; Sanjurjo-Saez, M; Lopez-Fernandez, LA	Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-19	Siguero, JPL; Ramon-Krauel, M; López, GP; Fernández, MVB; Balut, CA; Fernández-Aranda, F	Attitudes, Behaviors, and Barriers among Adolescents Living with Obesity, Caregivers, and Healthcare Professionals in Spain: ACTION Teens Survey Study	NUTRIENTS	5.9	Q1	Article	2023
A-19	Martín-Masot, R; Herrador-López, M; Navas-López, V; Carmona, FD; Nestares, T; Bossini-Castillo, L	Celiac Disease Is a Risk Factor for Mature T and NK Cell Lymphoma: A Mendelian Randomization Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-19	Martín-Masot, R; Herrador-López, M; Navas-López, VM	Dietary Habit Modifications in Paediatric Patients after One Year of Treatment with the Crohn's Disease Exclusion Diet	NUTRIENTS	5.9	Q1	Article	2023
A-19	Calzada-Hernández, J; Anton, J; de Carpi, JM; López-Montesinos, B; Calvo, I; Donat, E; Núñez, E; Alonso, JB; Mellado, MJ; Baquero-Artigao, F; Leis, R; Vegas-Alvarez, AM; San Ildefonso, MM; Pinedo-Gago, MD; Eizaguirre, FJ; Tagarro, A; Camacho-Lovillo, M; Pérez-Gorricho, B; Gavilán-Martín, C; Guillén, S; Sevilla-Pérez, B; Peña-Quintana, L; Mesa-Del-Castillo, P; Fortuny, C; Tebruegge, M; Noguera-Julian, A	Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-\(\bar{\Bar}\) inhibitor initiation in children in Spain	EUROPEAN JOURNAL OF PEDIATRICS	3.6	Q1	Article	2023
A-19	Pelaez-Cantero, MJ; Morales-Asencio, JM; Navarro-Mingorance, A; Madrid-Rodriguez, A; Tavera-Tolmo, A; Escobosa-Sanchez, O; Martino-Alba, R	End of life in patients attended by pediatric palliative care teams: what factors influence the place of death and compliance with family preferences?	EUROPEAN JOURNAL OF PEDIATRICS	3.6	Q1	Article	2023
A-19	Slocker-Barrio, M; López-Herce-Cid, J; Bustinza-Arriortúa, A; Fresán-Ruiz, E; Jordán-García, I; de Carlos-Vicente, JC; Morteruel-Arizcuren, E; García-Soler, P; Nieto-Moro, M; Schüffelmann, C; Belda-Hofheinz, S; Herrera-Castillo, LX; Uriona-Tuma, SM; Pinós-Tella, L; Peña-López, Y	Increase in Incidence Rates and Risk Factors for Multidrug Resistant Bacteria in Septic Children: A Nationwide Spanish Cohort Study (2013-2019)	ANTIBIOTICS-BASEL	4.8	Q1	Article	2023
A-19	Plaza-Diaz, J; Ruiz-Ojeda, FJ; Morales, J; Martin-Masot, R; Climent, E; Silva, A; Martinez-Blanch, JF; Enrique, M; Tortajada, M; Ramon, D; Alvarez, B; Chenoll, E; Gil, A	Innova 2020: A Follow-Up Study of the Fecal Microbiota of Infants Using a Novel Infant Formula between 6 Months and 12 Months of Age	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-19	Gutiérrez-Díaz, I; Sanz-Martinez, M; Castro, AM; Rodríguez-Belvís, MV; Carreira, N; Jiménez, S; Mangas, C; Queralt, M; Herrador, M; Martín-Masot, R; Ferrer, P; Navas-López, VM; Espín, B; Leis, R; Díaz, JJ; Delgado, S	Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity	EUROPEAN JOURNAL OF PEDIATRICS	3.6	Q1	Article	2023
A-19	Garulo, DC; Nunez-Cuadros, E; Lovillo, M; Calzada-Hernandez, J; Martin, S; Silveira, L; Cruz, MJ; Tagarro, A; Rueda, RM; Lopez, A; Aritziturri, M; Calvo, C	Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis	EUROPEAN JOURNAL OF PEDIATRICS	3.6	Q1	Article	2023
A-19	Focht, G; Kuint, RC; Greer, MLC; Pratt, L; Castro, DA; Church, PC; Navas-Lopez, VM; Baldassano, RN; Mortensen, JH; Rieder, F; Yerushalmi, B; Ilivitzki, A; Konen, O; Griffiths, AM; Turner, D	Prospective Validation of the Lemann Index in Children: A Report From the Multicentre ImageKids Study	JOURNAL OF CROHNS & COLITIS	8	Q1	Article	2023
A-19	de la Vega, R; Serrano-Ibáñez, ER; Ruiz-Párraga, GT; Palermo, TM; Wicksell, R; Fernández-Jiménez, E; Oliva, S; Roldán, S; Monfort, L; Peláez, MJ; Carmona, ML; Ramírez-Maestre, C; López-Martínez, AE; Miró, J; Esteve, R	Protocol for a multi-phase, multi-center, real-world, hybrid effectiveness-implementation study of a digital intervention for pediatric chronic pain co-designed with patients (Digital SPA)	DIGITAL HEALTH	3.9	Q1	Article	2023
A-19	Martín-Masot, R; Díaz-Martín, JJ; Santamaría-Orleans, A; Navas-López, VM	Spanish Pediatricians' Positions Regarding Prevention, Diagnosis, Nutritional Management, and Challenges in Cow's Milk Protein Allergy	NUTRIENTS	5.9	Q1	Article	2023
A-19	Martín-Masot, R; Jiménez-Muñoz, M; Herrador-López, M; Flor-Alemany, M; Navas-López, VM; Nestares, T	The Importance of an Early Evaluation after Establishing a Gluten-Free Diet in Children with Celiac Disease	NUTRIENTS	5.9	Q1	Article	2023
A-19	Montoro, DV; Camacho, VR; Gonzalez, LA; Alonso, JMC	Thigh ultrasound monitoring identifies muscle atrophy in mechanically ventilated pediatric patients	EUROPEAN JOURNAL OF PEDIATRICS	3.6	Q1	Article	2023
A-19	Herrador-López, M; Martín-Masot, R; Navas-López, VM	Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis	NUTRIENTS	5.9	Q1	Review	2023
A-19	Martín-Masot, R; Jiménez-Muñoz, M; Herrador-López, M; Navas-López, VM; Obis, E; Jové, M; Pamplona, R; Nestares, T	Metabolomic Profiling in Children with Celiac Disease: Beyond the Gluten-Free Diet	NUTRIENTS	5.9	Q1	Review	2023
A-19	de Célix, CR; Martín-de-Carpi, J; Pujol-Muncunill, G; Palomino, LM; Rodríguez-Belvís, MV; Martín-Masot, R; Navas-López, VM; Ricart, E; Casanova, MJ; Rodríguez-Martínez, A; Leo-Carnerero, E; Alcaraz, A; Mañosa, M; Hernández, V; Cobelas, MCC; Sánchez, C; Menchén, L; Mesonero, F; Barreiro-De Acosta, M; Martinón-Torres, N; Sandoval, CT; Váazquez, AR; Corsino, P; Vicente, R; Hernández-Camba, A; Alonso, JRA; Alonso-Abreu, I; Millán, AMC; Reverter, LP; Castro, B; Fernández-Salgado, E; Cuiñas, MMB; Benítez, JM; Madero, L; Clemente, F; Riestra, S; Jiménez-Treviño, S; Boscá-Watts, M; Crehuáa-Gaudiza, E; Moya, MC; Huguet, JM; Largo-Blanco, EM; Vives, LG; Plaza, R; Guerra, I; Barrio, J; Escartín, L; Alfambra, E; Cruz, N; Muñoz, MC; Pino, MGM; Van Domselaar, M; Botella, B; Miquel, DM; Grau, MCR; De La Mano, A; Ber, Y; Iñiguez, MC; Martínez-Pérez, TD; Chaparro, M; Gisbert, JP	Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-19	Guerrero-del-Cueto, F; Ramos-Fernandez, JM; Leiva-Gea, I; Reina-Moreno, E; Ortiz-Ortigosa, A; Carazo-Gallego, B; Cordon-Martinez, AM; Moreno-Perez, D; Nunez-Cuadros, E	Bronchiolitis before and after the SARS- CoV-2 pandemic: Twelve years of experience in a Spanish paediatric hospital	PEDIATRIC PULMONOLOGY	3.1	Q2	Article	2023
A-19	Carcavilla, A; Cambra, A; Santomé, JL; Seidel, V; Cruz, J; Alonso, M; Pozo, J; Valenzuela, I; Guillén-Navarro, E; Santos-Simarro, F; González-Casado, I; Rodríguez, A; Medrano, C; López-Siguero, JP; Ezquieta, B	Genotypic Findings in Noonan and Non- Noonan RASopathies and Patient Eligibility for Growth Hormone Treatment	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-19	Martín-Masot, R; Diaz-Martin, JJ; Santamaría-Orleans, A; Navas-López, VM	Impact of the COVID-19 pandemic on the digitization of routine pediatric practice in Spain: A nationwide survey study	FRONTIERS IN PEDIATRICS	2.6	Q2	Article	2023
A-19	Lendinez-Jurado, A; Gomez-Perea, A; Ariza-Jimenez, AB; Tapia-Ceballos, L; Becerra-Paz, I; Martos-Lirio, MF; Moreno-Jabato, F; Leiva-Gea, I	Impact on glucometric variables and quality of life of the advanced hybrid closed-loop system in pediatric and adolescent type 1 diabetes	JOURNAL OF DIABETES	4.5	Q2	Article	2023
A-19	Lendinez-Jurado, Alfonso; Lopez-Siguero, Juan Pedro; Gomez-Perea, Ana; Ariza-Jimenez, Ana B; Becerra-Paz, Icia; Tapia-Ceballos, Leopoldo; Cruces-Ponce, Carmen; Jimenez-Hinojosa, Jose Manuel; Morcillo, Sonsoles; Leiva-Gea, Isabel	Pediatric Type 1 Diabetes: Is Age at Onset a Determining Factor in Advanced Hybrid Closed-Loop Insulin Therapy?	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-19	Mondejar-Lopez, P; Moreno-Galarraga, L; de Manuel-Gomez, C; Blitz-Castro, E; Bravo-Lopez, M; Gartner, S; Perez-Ruiz, E; Caro-Aguilera, P; Sanz-Santiago, V; Lopez-Neyra, A; Luna-Paredes, C; Garcia-Gonzalez, M; Costa-Colomer, J; Cols-Roig, M; Delgado-Pecellin, I; Castillo-Corullon, S; de Valbuena-Maiz, MR; Garcia-Marcos, PW; Aguilar-Fernandez, AJ; Martin-De Vicente, C; Barajas-Sanchez, MV; Mesa-Medina, O; Bover-Bauza, C; Figuerola-Mulet, J; Garcia-Aviles, B; Rodriguez-Saez, MJ; Garcia-Magan, C; Juarez-Marruecos, P; Gutierrez-Martinez, JR; Cortell-Aznar, I; Gomez-Pastrana, D; Velasco-Gonzalez, MV; Barrio, MI; Sanchez-Solis, M; de la Cruz, OA; Pastor-Vivero, MD	SARS-CoV-2 infection in children with cystic fibrosis: A cross-sectional multicenter study in Spain. New waves, new knowledge	PEDIATRIC PULMONOLOGY	3.1	Q2	Article	2023
A-19	Balaguer, J; Hidalgo, LG; Hladun, R; Vega, CM; Alonso, V	Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma	TARGETED ONCOLOGY	5.4	Q2	Review	2023
A-19	Sáncheza, FV; Sanzb, JAS; Mirasc, EB; Pastorizad, ID; Echevarria, IN; Merillasg, MJA; Madrid, FM; Cantero, MJP; Iniguezj, JPG; Galán, IR	Accompaniment of minors during health care procedures	ANALES DE PEDIATRIA	2.1	Q3	Article	2023
A-19	Pérez-Muñuzuri, A; Boix, H; Sánchez-Redondo, MD; Cernada, M; Espinosa-Fernández, MG; González-Pacheco, N; Martín-Ancel, A; Couce, ML; Luna, MS	Care levels in neonatal units in Spain: An updated vision for a new reality	ANALES DE PEDIATRIA	2.1	Q3	Article	2023
A-19	Rivero Calle, Irene; Del Rosal Rabes, Teresa; Garrote Llanos, Elisa; Nunez Cuadros, Esmeralda; Navarro Gomez, Maria Luisa; Ramos Amador, Jose Tomas; Calvo, Cristina; Alvarez Garcia, Francisco	Consensus document of the Spanish Society of Paediatric Infectious Diseases and the Advisory Committee on Vaccines of the Spanish Association of Pediatrics for vaccination of immunosuppressed individuals.	ANALES DE PEDIATRIA	2.1	Q3	Article	2023
A-19	Constanti, VA; Garau, AD; Marrodán, BR; Pinto, EV; Gómez, MR; Soto, LG; Borges, AH; Rodríguez, AM	Do not do recommendations in different paediatric care settings	ANALES DE PEDIATRIA	2.1	Q3	Article	2023
A-19	Saldaña-García, N; Martínez-Pajares, JD; Chaffanel-Peláez, M; del Mar Serrano-Martín, M; Espinosa-Fernández, MG; Tapia-Moreno, E; Sánchez-Tamayo, T	Prenatal rescue dose of betamethasone in the preterm infant with intrauterine growth restriction	ANALES DE PEDIATRIA	2.1	Q3	Article	2023
A-19	Azor, BR; Martin-Masot, R; Khialani, AD; Fernandez-Martin, JM; Fernandez, CG; Navas-Lopez, VM	Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease	ANALES DE PEDIATRIA	2.1	Q3	Article	2023
A-19	Martos-Lirio, MF; Calvo-Medina, R; Ruiz-Garcia, C; Ramos-Fernandez, JM	Congenital myotonia. Incidence and presentation of a series of cases	REVISTA DE NEUROLOGIA	1.2	Q4	Article	2023
A-19	Goycochea-Valdivia, WA; Aboza-García, M; Moreno-Pérez de Tudelab, R; Carazo-Gallego, B; Roldan-Tormo, E; Ruiz-Sáez, B; Vázquez-Pérez, A; Peromingo-Matute, E; Croche-Santander, B; Obando-Pacheco, P; Obando-Santaella, I	Infective endocarditis in paediatric patients from Andalusia (Spain), 2008-2020	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.5	Q4	Article	2023
A-19	Ortiz-Ortigosa, A; Calvo-Medina, R; Ruiz-García, C; Vera-Medialdea, R; Ramos-Fernández, JM	KIF1A gene-associated neurological disease: the correlation between genotype and phenotype	REVISTA DE NEUROLOGIA	1.2	Q4	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-21	Guerrero-Orriach, JL; Carmona-Luque, MD; Raigón-Ponferrada, A	Beneficial Effects of Halogenated Anesthetics in Cardiomyocytes: The Role of Mitochondria	ANTIOXIDANTS	7	D1	Review	2023
A-21	Garcia-Anaya, MJ; Segado-Guillot, S; Cabrera-Rodriguez, J; Toledo-Serrano, MD; Medina-Carmona, JA; Gomez-Millan, J	Dose and volume de-escalation of radiotherapy in head and neck cancer	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	6.2	Q1	Review	2023
A-21	Carmona-Luque, MD; Gonzalez-Alvarez, L; Orriach, JLG	Identification of miRNAs as Biomarkers of Cardiac Protection in Non-Genetically Modified Primary Human Cardiomyocytes Exposed to Halogenated Hypnotics in an In Vitro Model of Transfection and Ischemia/ Reperfusion: A New Model in Translational Anesthesia	LIFE-BASEL	3.2	Q2	Article	2023
A-21	Villaescusa-Catalan, JM; Rodriguez-Capitan, J; Sanz-Sanchez, CI; Sanchez-Espin, G; Guerrero-Orriach, JL; Moron, FJP; Fernandez-Romero, L; Melero-Tejedor, JM; Such-Martinez, M; Porras-Martin, C; Jimenez-Navarro, M	The Prognostic Value of Previous Coronary Stent Implantation in Patients Undergoing Myocardial Revascularization Surgery	CURRENT VASCULAR PHARMACOLOGY	4.5	Q2	Article	2023
A-21	Ponferrada, AR; Molina, SR; Ruiz, JCM; Josefa, GM; Orriach, JLG	Anesthesia and Cancer: Something More than Avoiding Stress Response	CURRENT GENE THERAPY	3.6	Q2	Review	2023
A-21	Malo-Manso, A; Fontaneda-Heredia, A; Romero-Molina, S; Sepulveda-Haro, E; Escalona-Belmonte, JJ; Guerrero-Orriach, JL	Opioid-Free Anaesthesia Improves Anaesthesia Recovery when Compared with that of Opioid-Based Anaesthesia. Systematic Review and Meta-Analysis of Clinical Trials	CURRENT MEDICINAL CHEMISTRY	4.1	Q2	Review	2023
A-21	Ponferrada, AR; Ruiz, JCM; Molina, SR; Garcia, VR; Orriach, JLG	The Role of Anesthetic Drugs and Statins in Prostate Cancer Recurrence: Starting at the Actual Knowledge and Walking through a New Paradigm	CANCERS	5.2	Q2	Review	2023
A-23	García-Márquez, J; Alvarez-Torres, D; Cerezo, IM; Domínguez-Maqueda, M; Figueroa, FL; Alarcón, FJ; Acién, G; Martínez-Manzanares, E; Abdala-Díaz, RT; Béjar, J; Arijo, S	Combined Dietary Administration of Chlorella fusca and Ethanol-Inactivated Vibrio proteolyticus Modulates Intestinal Microbiota and Gene Expression in Chelon labrosus	ANIMALS	3	D1	Article	2023
A-23	Huespe, IA; Ferraris, A; Lalueza, A; Valdez, PR; Peroni, ML; Cayetti, LA; Mirofsky, MA; Boietti, B; Gómez-Huelgas, R; Casas-Rojo, JM; Antón-Santos, JM; Núñez-Cortés, JM; Lumbreras, C; Ramos-Rincón, JM; Barrio, NG; Pedrera-Jiménez, M; Martin-Escalante, MD; Ruiz, FR; Onieva-García, MA; Toso, CR; Risk, MR; Klén, R; Pollán, JA; Gómez-Varela, D	COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes. A multicontinental cohort study	JOURNAL OF MEDICAL VIROLOGY	12.7	D1	Article	2023
A-23	Khoury, N; Martínez, MA; Paz-Graniel, I; Martínez-González, MA; Corella, D; Castañer, O; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sanjurjo, SC; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Sayon-Orea, C; Sorlí, JV; Pérez-Vega, KA; Garcia-Rios, A; Bellvert, NG; Gómez-Gracia, E; Zulet, MA; Chaplin, A; Casas, R; Salcedo-Bellido, I; Tojal-Sierra, L; Bernal-Lopez, MR; Vázquez-Ruiz, Z; Asensio, EM; Goday, A; Peña-Orihuela, PJ; Signes-Pastor, AJ; Garcia-Arellano, A; Fitó, M; Babio, N; Salas-Salvadó, J	Dietary intake of polychlorinated dibenzo- p-dioxins and furans, adiposity and obesity status	ENVIRONMENTAL RESEARCH	8.3	D1	Article	2023
A-23	Razquin, C; Ruiz-Canela, M; Wernitz, A; Toledo, E; Corella, D; Alonso-Gómez, A; Fitó, M; Gómez-Gracia, E; Estruch, R; Fiol, M; Lapetra, J; Serra-Majem, L; Ros, E; Arós, F; Salas-Salvadó, J; Schulze, MB; Martinez-Gonzalez, MA	Effects of Supplemented Mediterranean Diets on Plasma-Phospholipid Fatty Acid Profiles and Risk of Cardiovascular Disease after 1 Year of Intervention in the PREDIMED Trial	CLINICAL CHEMISTRY	9.3	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-23	Ni, JQ; Nishi, SK; Babio, N; Ros, E; Basterra-Gortari, FJ; Corella, D; Castañer, O; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Cano-Ibáñez, N; Tur, JA; Fernández-García, JM; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Fernández-Aranda, F; Ruiz-Canela, M; Solà, CM; Portolés, O; Sala-Vila, A; Garcia-Rios, A; Compañ-Gabucio, LM; Gómez-Gracia, E; Zulet, MA; Chaplin, A; Casas, R; Martínez-Diz, S; Tojal-Sierra, L; Gómez-Pérez, AM; Toledo, E; Rios, S; Ortega-Azorín, C; de la Torre, R; Peña-Orihuela, PJ; Garcia-de la Hera, M; Sayón-Orea, C; Malcampo, M; PREDIMED Plus Investigators	Higher versus lower nut consumption and changes in cognitive performance over two years in a population at risk of cognitive decline: a cohort study	AMERICAN JOURNAL OF CLINICAL NUTRITION	7.1	D1	Article	2023
A-23	Garcia, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubín-García, M; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Goday, A; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Pintó, X; Gaforio, JJ; Matia, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Sayón-Orea, C; Guillem-Saiz, P; Valle-Hita, C; Cabanes, R; Abete, I; Goicolea-Güemez, L; Gómez-Gracia, E; Tercero-Maciá, C; Colom, A; García-Ríos, A; Castro-Barquero, S; Fernández-García, JC; Santos-Lozano, JM; Cenoz, JC; Barragán, R; Khoury, N; Castañer, O; Zulet, MA; Vaquero-Luna, J; Bes-Rastrollo, M; de las Heras-delgado, S; Ciurana, R; Martin-Sánchez, V; Tur, JA; Bouzas, C	Metabolic syndrome criteria and severity and carbon dioxide (CO2) emissions in an adult population	GLOBALIZATION AND HEALTH	10.8	D1	Article	2023
A-23	Corominas, J; Garriga, C; Prenafeta, A; Moros, A; Cañete, M; Barreiro, A; González-González, L; Madrenas, L; Güell, I; Clotet, B; Izquierdo-Useros, N; Raïch-Regué, D; Gallemí, M; Blanco, J; Pradenas, E; Trinité, B; Prado, JG; Blanch-Lombarte, O; Pérez-Caballero, R; Plana, M; Esteban, I; Pastor-Quiñones, C; Núñez-Costa, X; Abu Taleb, R; McSkimming, P; Soriano, A; Nava, J; Anagua, JO; Ramos, R; Lluch, RM; Comes, AC; Romero, SO; Gomez, XM; Sans-Pola, C; Moltó, J; Benet, S; Bailón, L; Arribas, JR; Borobia, AM; Parada, JQ; Navarro-Pérez, J; Giner, MJF; Lucas, RO; Jiménez, MDV; Compán, SO; Alvarez-Mon, M; Troncoso, D; Arana-Arri, E; Meijide, S; Imaz-Ayo, N; García, PM; Martínez, SD; Fernández, SR; Prat, T; Torroella, E; Ferrer, L	Safety and immunogenicity of the protein- based PHH-IV compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non- inferiority phase IIb trial	LANCET REGIONAL HEALTH-EUROPE	20.9	D1	Article	2023
A-23	García, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubín-García, M; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Fitó, M; Martínez, JA; Tojal-Sierra, L; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Cano-Ibañez, N; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Buil-Cosiales, P; Martínez-Rodríguez, MA; Coltell, O; Castañer, O; Garcia-Rios, A; Barceló, C; Gómez-Gracia, E; Zulet, MA; Konieczna, J; Casas, R; Massó-Guijarro, P; Goicolea-Güemez, L; Bernal-López, MR; Bes-Rastrollo, M; Shyam, S; González, JI; Zomeño, MD; Peña-Orihuela, PJ; González-Palacios, S; Toledo, E; Khoury, N; Perez, KA; Martín-Sánchez, V; Tur, JA; Bouzas, C	Ultra-processed foods consumption as a promoting factor of greenhouse gas emissions, water, energy, and land use: A longitudinal assessment	SCIENCE OF THE TOTAL ENVIRONMENT	9.8	D1	Article	2023
A-23	Martínez-González, MA; Montero, P; Ruiz-Canela, M; Toledo, E; Estruch, R; Gómez-Gracia, E; Li, J; Ros, E; Arós, F; Hernáez, A; Corella, D; Fiol, M; Lapetra, J; Serra-Majem, L; Pintó, X; Cofán, M; Sorli, JV; Babio, N; Marquez-Sandoval, YF; Castañer, O; Salas-Salvadó, J	Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial	CARDIOVASCULAR DIABETOLOGY	9.3	D1	Article	2023
A-23	Shyam, S; Garcia-Gavilan, JF; Paz-Graniel, I; Gaforio, JJ; Martinez-Gonzalez, MA; Corella, D; Martinez, JA; Alonso-Gomez, AM; Waernberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sanchez, VM; Pinto, X; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Fernandez-Aranda, F; Nishi, SK; Garcia-Regata, O; Toledo, E; Asensio, EM; Castaner, O; Garcia-Rios, A; Torres-Collado, L; Gomez-Gracia, E; Zulet, MA; Ruiz, NG; Casas, R; Canolbanez, N; Tojal-Sierra, L; Gomez-Perez, AM; Sorli, JV; Cinza-Sanjurjo, S; Martin-Pelaez, S; Pena-Orihuela, PJ; Oncina-Canovas, A; Perez-Araluce, R; Zomeno, MD; Chaplin, A; Delgado-Rodriguez, M; Babio, N; Fito, M; Salas-Salvado, J	Association of adiposity and its changes over time with COVID-19 risk in older adults with overweight/obesity and metabolic syndrome: a longitudinal evaluation in the PREDIMED-Plus cohort	BMC MEDICINE	9.3	Q1	Article	2023
A-23	García, S; Bouzas, C; Mateos, D; Pastor, R; Alvarez, L; Rubín, M; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Goday, A; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, L; Riquelme-Gallego, B; Pintó, X; Gaforio, JJ; Matía, P; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Bes-Rastrollo, M; Guillem-Saiz, P; Nishi, S; Cabanes, R; Abete, I; Goicolea-Güemez, L; Gómez-Gracia, E; Signes-Pastor, AJ; Colom, A; García-Ríos, A; Castro-Barquero, S; Fernández-García, JC; Santos-Lozano, JM; Vázquez, Z; Sorli, JV; Pascual, M; Castañer, O; Zulet, MA; Vaquero-Luna, J; Basterra-Gortari, FJ; Babio, N; Ciurana, R; Martín-Sánchez, V; Tur, JA	Carbon dioxide (CO2) emissions and adherence to Mediterranean diet in an adult population: the Mediterranean diet index as a pollution level index	ENVIRONMENTAL HEALTH	6	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-23	Razquin, C; Ruiz-Canela, M; Toledo, E; Clish, CB; Guasch-Ferré, M; García-Gavilán, JF; Wittenbecher, C; Alonso-Gómez, A; Fitó, M; Liang, LM; Corella, D; Gómez-Gracia, E; Estruch, R; Fiol, M; Santos-Lozano, JM; Serra-Majem, L; Ros, E; Aros, F; Salas-Salvadó, J; Hu, FB; Martfnez-González, MA	Circulating Amino Acids and Risk of Peripheral Artery Disease in the PREDIMED Trial	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
A-23	Donat-Vargas, C; Mico, V; San-Cristobal, R; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Fitó, M; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Damas-Fuentes, M; Lapetra, J; Serra-Majem, L; Bueno-Cavanillas, A; Tur, JA; Cinza-Sanjurjo, S; Pintó, X; Delgado-Rodríguez, M; Matía-Martín, P; Vidal, J; Causso, C; Ros, E; Toledo, E; Manzanares, JM; Ortega-Azorín, C; Castañer, O; Peña-Orihuela, PJ; Zazo, JM; Muñoz Bravo, C; Martinez-Urbistondo, D; Chaplin, A; Casas, R; Cano Ibáñez, N; Tojal-Sierra, L; Gómez-Perez, AM; Pascual Roquet-Jalmar, E; Mestre, C; Barragán, R; Schröder, H; Garcia-Rios, A; Candela García, I; Ruiz-Canela, M; Babio, N; Malcampo, M; Daimiel, L; Martinez, A	Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk	NUTRIENTS	5.9	Q1	Article	2023
A-23	Pérez-Vega, KA; Castañer, O; Sanllorente, A; Lassale, C; Ros, E; Pintó, X; Estruch, R; Salas-Salvadó, J; Corella, D; Alonso-Gómez, AM; Serra-Majem, L; Razquin, C; Fiol, M; Lapetra, J; Gómez-Gracia, E; Tinahones, FJ; Hernáez, A; Fitó, M	Mediterranean Diet, Energy Restriction, Physical Activity, and Atherogenicity of Very- Low Density Lipoproteins: Findings from Two Randomized Controlled Trials	MOLECULAR NUTRITION & FOOD RESEARCH	5.2	Q1	Article	2023
A-23	Santa-Barbara, RA; Rivera, FG; Lamb, M; Da-Silva, RV; Bedmar, MG	New technologies for the classification of proximal humeral fractures: Comparison between Virtual Reality and 3D printed models-a randomised controlled trial	VIRTUAL REALITY	4.2	Q1	Article	2023
A-23	Ruiz-García, I; Ortíz-Flores, R; Badía, R; García-Borrego, A; García-Fernández, M; Lara, E; Martín-Montañez, E; García-Serrano, S; Valdés, S; Gonzalo, M; Tapia-Guerrero, SMJ; Fernandez-García, JC; Sánchez-García, A; Muñoz-Cobos, F; Calderón-Cid, M; El-Bekay, R; Covas, MI; Rojo-Martínez, G; Olveira, G; Romero-Zerbo, SY; Bermúdez-Silva, FJ	Rich oleocanthal and oleacein extra virgin olive oil and inflammatory and antioxidant status in people with obesity and prediabetes. The APRIL study: A randomised, controlled crossover study	CLINICAL NUTRITION	6.3	Q1	Article	2023
A-23	Torres, CGP; Barrios-Rodríguez, R; Muñoz-Bravo, C; Toledo, E; Dierssen, T; Jiménez-Moleon, JJ	Mediterranean diet and risk of breast cancer: An umbrella review	CLINICAL NUTRITION	6.3	Q1	Review	2023
A-23	Crow, EM; Lopez-Gigosos, R; Mariscal-Lopez, E; Agredano-Sanchez, M; Garcia-Casares, N; Mariscal, A; Gutierrez-Bedmar, M	Psychosocial interventions reduce cortisol in breast cancer patients: systematic review and meta-analysis	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Review	2023
A-23	Díaz-Gutiérrez, J; Martínez-González, MA; Alonso, A; Toledo, E; Salas-Salvadó, J; Sorlí, J; Ros, E; Fitó, M; Estruch, R; Arós, F; Fiol, M; Lapetra, J; Gómez-Gracia, E; Serra-Majem, L; Pintó, X; Portolés, O; Babio, N; Castañer, O; Ruiz-Canela, M	American Heart Association's life simple 7 and the risk of atrial fibrillation in the PREDIMED study cohort	NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES	3.9	Q2	Article	2023
A-23	Muñoz-Bravo, C; Olmedo, P; Gil, F; Ruiz-Canela, M; Martínez-González, MA; Martínez, MA; Babio, N; Fitó, M; del Val, JL; Corella, D; Sorlí, J; Ros, E; Fiol, M; Estruch, R; Santos-Lozano, JM; Arós, F; Serra-Majem, L; Pintó, X; Gómez-Gracia, E; Gutiérrez-Bedmar, M	Association between serum copper levels and risk of cardiovascular disease: A nested case-control study in the PREDIMED trial	NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES	3.9	Q2	Article	2023
A-23	Santos, JL; Ruiz-Canela, M; Razquin, C; Clish, CB; Guasch-Ferré, M; Babio, N; Corella, D; Gómez-Gracia, E; Fiol, M; Estruch, R; Lapetra, J; Fitó, M; Aros, F; Serra-Majem, L; Liang, LM; Martínez, MA; Toledo, E; Salas-Salvadó, J; Hu, FB; Martínez-González, MA	Circulating citric acid cycle metabolites and risk of cardiovascular disease in the PREDIMED study	NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES	3.9	Q2	Article	2023
A-23	García-Márquez, J; Moreira, BR; Valverde-Guillén, P; Latorre-Redoli, S; Caneda-Santiago, CT; Acién, G; Martínez-Manzanares, E; Marí-Beffa, M; Abdala-Díaz, RT	In Vitro and In Vivo Effects of Ulvan Polysaccharides from Ulva rigida	PHARMACEUTICALS	4.6	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-23	Toledo, E; Wittenbecher, C; Razquin, C; Ruiz-Canela, M; Clish, CB; Liang, LM; Alonso, A; Hernandez-Alonso, P; Becerra-Tomas, N; Aros-Borau, F; Corella, D; Ros, E; Estruch, R; Garcia-Rodriguez, A; Fito, M; Lapetra, J; Fiol, M; Alonso-Gomez, AM; Serra-Majem, L; Deik, A; Salas-Salvado, J; Hu, FB; Martinez-Gonzalez, MA	Plasma lipidome and risk of atrial fibrillation: results from the PREDIMED trial	JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY	3.4	Q2	Article	2023
A-23	Rognoni, T; Fernández-Matarrubia, M; Martinez-González, MA; Salas-Salvadó, J; Corella, D; Castañer, O; Martínez, JA; Alonso-Gómez, AM; Gómez-Gracia, E; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Ibañez, NC; Tur, JA; Pérez, RM; Pintó, X; Delgado-Rodríguez, M; Ramos, MO; Vidal, J; Vázquez, C; Daimiel, L; Ros, E; Goñi-Ruiz, N; Babio, N; Sorlí, JV; Schröderj, H; García-Riose, A; Compañ-Gabucio, L; Warnberg, J; Zulet, MA; Chaplin, A; Sacanella, E; Bouzalmate-Hajjaj, A; Tojal-Sierra, L; Damas-Fuentes, M; Vázquez, Z; Gómez-Martínez, C; Saiz, C; Malcampo, M; Ortiz-Morales, AM; Martínez-Avilés, V; García-Gavilan, J; Abete, I; Fitó, M; Toledo, E	Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome	JOURNAL OF ALZHEIMERS DISEASE	4	Q2	Article	2023
A-23	De Tena, PB; Paniagua, STT; Sevilla, JAV; Clavijo, E; Manzanares, EM; Gonzalez-Domenech, CM; Azzaroli, F	Unusual Surge of Acute Hepatitis A Cases in 2016 and 2017 in Malaga, Southern Spain: Characterization and Relationship with Other Concurrent European Outbreaks	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
A-23	Lorenzo-Rebenaque, L; Lopez-Fernandez, S; Marco-Jimenez, F; Montoro-Dasi, L; Marin, C; Vega, S; Martinez-Manzanares, E; Farinas, F	Zoonotic Parasites in Playgrounds in Southern Spain: A One Health Approach	MICROORGANISMS	4.5	Q2	Article	2023
A-23	Carazo-Barrios, L; Cabrera-Maestre, A; Alba-Linero, C; Gutierrez-Bedmar, M; Garzon-Maldonado, FJ; Serrano, V; de la Cruz-cosme, C; Garcia-Casares, N	Retinal Neurodegeneration Measured With Optical Coherence Tomography and Neuroimaging in Alzheimer Disease: A Systematic Review	JOURNAL OF NEURO- OPHTHALMOLOGY	2.9	Q2	Review	2023
A-23	Munoz-Bravo, C; Soler-Iborte, E; Lozano-Lorca, M; Kouiti, M; Torres, CGP; Barrios-Rodriguez, R; Jimenez-Moleon, JJ	Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis	FRONTIERS IN CARDIOVASCULAR MEDICINE	3.6	Q2	Review	2023
A-23	López-Medrano, F; Alfayate, S; Carratala, J; Chamorro-Camazón, J; Cordero, E; Cruz-Cañete, M; Fernández-Pradai, M; García-Cenoz, M; Marcos, MA; Melón, S; Moreno-Millán, N; Onieva-García, MA; de Lejarazuo, RO; Pérez-Martín, JJ; Rodríguez-García, J; Schwarz-Chavarrir, G; Tagarro-García, A; van Esso-Arbolave, D; Viasus, D; Pumarola, T	Executive summary - Diagnosis, treatment and prophylaxis of influenza virus infection - Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)	ANALES DE PEDIATRIA	2.1	Q3	Article	2023
A-23	López-Medrano, F; Alfayate, S; Carratalà, J; Chamorro-Camazón, J; Cordero, E; Cruz-Cañete, M; Fernández-Prada, M; García-Cenoz, M; Marcos, MA; Melón, S; Moreno-Millán, N; Onieva-García, MA; de Lejarazu, RO; Pérez-Martín, JJ; Rodríguez-García, J; Schwarz-Chavarri, G; Tagarro-García, A; van Esso-Arbolave, D; Viasus, D; Pumarola, T	Executive summaryDiagnosis, treatment and prophylaxis of influenza virus infectionConsensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)	ATENCION PRIMARIA	2.5	Q3	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
A-23	López-Medrano, F; Alfayate, S; Carratalà, J; Chamorro-Camazón, J; Cordero, E; Cruz-Cañete, M; Fernández-Prada, M; García-Cenoz, M; Marcos, MA; Melón, S; Moreno-Millán, N; Onieva-García, MA; de Lejarazu, RO; Pérez-Martín, JJ; Rodríguez-García, J; Schwarz-Chavarri, G; Tagarro-García, A; van Esso-Arbolave, D; Viasus, D; Pumarola, T	Executive summary. Diagnosis, treatment and prophylaxis of influenza virus infection. Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS)	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.5	Q4	Article	2023
AA-04	Ripolles-Melchor, J.; Colomina, M. J.; Aldecoa, C.; Alonso-Cabello, J.; Alonso-Inigo, J. M.; Aya, H.; Basora, M.; Clau-Terre, F.; del Cojo-Peces, E.; Cota-Delgado, F.; Ferrandis-Comes, R.; Galan-Menendez, P.; Garcia-Lopez, D.; Garruti, I.; Lopez, I. J.; Jover-Pinillos, J. L.; Llau-Pitarch, J. V.; Lorente, J. V.; Mesquida, J.; Mojarro, I.; Monge-Garcia, M. I.; Montesinos-Fadrique, S. C.; Munoz-Rodes, J. L.; de Nadal, M.; Ramasco, F.; Tome-Roca, J. L.; Perez, A.; Una-Orejon, R.; Yanes, G.; Zorrilla-Vaca, A.; Escarraman, D.; Garcia-Fernandez, J.	Research priorities in perioperative fluid therapy and hemodynamic monitoring: A Delphi Consensus Survey from the Fluid Therapy and Hemodynamic Monitoring Subcommittee of the Hemostasis, Transfusion Medicine and Fluid Therapy Section (SHTF) of the Spanish Society of Anesthesiology and Critical Care (SEDAR)	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION	1.3		Article	2023
AA-04	Simón-Frapolli, VJ; Vegas-Aguilar, IM; Fernández-Jiménez, R; Cornejo-Pareja, IM; Sanchez-García, AM; Martínez-López, P; Nuevo-Ortega, P; Reina-Artacho, C; Estecha-Foncea, MA; Gómez-González, AM; González-Jiménez, MB; Avanesi-Molina, E; Tinahones-Madueño, FJ; García-Almeida, JM	Phase angle and rectus femoris cross- sectional area as predictors of severe malnutrition and their relationship with complications in outpatients with post- critical SARS-CoV2 disease	FRONTIERS IN NUTRITION	5	Q2	Article	2023
AA-04	Sanchez-Garcia, AM; Martinez-Lopez, P; Gomez-Gonzalez, AM; Rodriguez-Capitan, J; Pavon-Moron, FJ; Jimenez-Lopez, RJ; Garcia-Almeida, JM; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abad, V; Molina-Ramos, AI; Cabrera-Cesar, E; Ben-Abdellatif, I; Gordillo-Resina, M; Perez-Mesa, E; Nieto-Gonzalez, M; Nuevo-Ortega, P; Reina-Artacho, C; Sanchez-Fernandez, PL; Jimenez-Navarro, MF; Estecha-Foncea, MA	Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES	3.6	Q2	Article	2023
AA-04	Sanchez-Garcia, AM; Martinez-Lopez, P; Gomez-Gonzalez, AM; Rodriguez-Capitan, J; Jimenez-Lopez, RJ; Almeida, JMG; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abada, V; Molina-Ramos, AI; Cabrera-Cesar, E; Ben-Abdellatif, I; Gordillo-Resina, M; Perez-Mesa, E; Nieto-Gonzalez, M; Nuevo-Ortega, P; Reina-Artacho, C; Fernandez, PLS; Jimenez-Navarro, MF; Estecha-Foncea, MA	Multidisciplinary approach of the sequelae one month after hospital discharge in patients with severe bilateral COVID-19 pneumonia, are there differences depending on the respiratory therapy used during admission to intensive care?	MEDICINA INTENSIVA	3	Q3	Article	2023
AA-15	Núñez, FR; Pardeiro, CA; Albert, BI; Alvarez-Fuente, M; Barreiro, VB; Tejerizo, FB; Betrián-Blasco, P; Sánchez, FC; López, JME; González, LF; Linde, DH; Moreno, MR; Cebada, FS; Sanz-Ruiz, R; Argüelles, JIZ	Dosimetric parameters in congenital cardiac catheterizations in Spain: the GTH-SECPCC Radcong-21 multicenter registry	REC-INTERVENTIONAL CARDIOLOGY	1.4		Article	2023
AA-15	Sarria-García, E; Navarrete-Espinosa, I; Vera-Puente, F; Cano-Nieto, J; Ruiz-Alonso, E; Calleja-Rosas, F	Prognosis of the adult congenital heart disease surgically corrected. Analise of results and risk factors for mortality and readmissions	CIRUGIA CARDIOVASCULAR	0.3		Article	2023
AA-15	Ballesteros Tejerizo, Fernando[16]; Coserría Sánchez, Félix[2]; Freixa, Xavier[4]; Amat-Santos, Ignacio J[12], [15]; Balbacid Domingo, Enrique[18]; Betrián Blasco, Pedro[14]; Blanco Mata, Roberto[17]; Carrasco, José Ignacio[6]; del Cerro Marín, María Jesús[7]; Flores Fernández, Marta[11]; Gómez Jaume, Alfredo[9]; Insa Albert, Beatriz[1]; Navalón Pérez, Miguel José[13]; Ojeda Pineda, Soledad[19]; Rueda Núñez, Fernando[5]; Sánchez Gila, Joaquín[10]; Sanz-Ruiz, Ricardo[12], [8]; Zabala Argüelles, Juan Ignacio[3]	Spanish cardiac catheterization in congenital heart diseases registry. Second official report from the ACI-SEC and the GTH-SECPCC (2021)	REC-INTERVENTIONAL CARDIOLOGY	1.4		Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AA-15	Rodríguez, DJS; Ciézar, AJP; Román, DG; Carrillo, CAU	The dog, valves' best friend: infective endocarditis due to Capnocytophaga canimorsus-a case report	EUROPEAN HEART JOURNAL-CASE REPORTS	1		Article	2023
AA-15	Ojeda, S; González-Manzanares, R; Jiménez-Quevedo, P; Piñón, P; Asmarats, L; Amat-Santos, I; Fernández-Nofrerias, E; del Valle, R; Muñoz-García, E; Ferrer-Gracia, MC; de la Torre, JM; Ruiz-Quevedo, V; Regueiro, A; Sanmiguel, D; García-Blas, S; Elízaga, J; Baz, JA; Romaguera, R; Cruz-Gonzalez, I; Moreu, J; Gheorghe, LL; Salido, L; Moreno, R; Urbano, C; Serra, V; Pan, MN	Coronary Obstruction After Transcatheter Aortic Valve Replacement	JACC- CARDIOVASCULAR INTERVENTIONS	11.3	D1	Article	2023
AA-15	Palmquist-Gomes, P; Ruiz-Villalba, A; Guadix, JA; Romero, JP; Bessieres, B; MacGrogan, D; Conejo, L; Ortiz, A; Picazo, B; Houyel, L; Gomez-Cabrero, D; Meilhac, SM; de la Pompa, JL; Perez-Pomares, JM	Origin of congenital coronary arterioventricular fistulae from anomalous epicardial and myocardial development	EXPERIMENTAL AND MOLECULAR MEDICINE	12.8	D1	Article	2023
AA-15	Gentile, AM; Lhamyani, S; Mesa, MM; Pavón-Morón, FJ; Pearson, JR; Salas, J; Clemente-Postigo, M; Costillas, LP; Fuster, GO; Rizky, RE	A Network Comprised of miR-15b and miR- 29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
AA-15	Jurado-Roman, Alfonso; Freixa, Xavier; Cid, Belen; Cruz-Gonzalez, Ignacio; Sarnago Cebada, Fernando; Baz, Jose Antonio; Lozano, Inigo; Sabate, Manel; Jimenez, Jesus; Inigo Garcia, Luis Antonio; Subinas Elorriaga, Asier; Berenguer Jofresa, Alberto; Novo Garcia, Enrique; Perez Vizcayno, Maria Jose; Carrillo Suarez, Xavier; Pinar Bermudez, Eduardo; Calvino Santos, Ramon; Alvarez Anton, Salvador; Trillo Nouche, Ramiro; Ruiz Arroyo, Jose Ramon; Fernandez Cisnal, Agustin; Amat-Santos, Ignacio J; Jerez Valero, Miguel; Rama Merchan, Juan Carlos; Vaquerizo, Beatriz; Tejada Ponce, David; Ruiz Nodar, Juan Miguel; Sanchez Perez, Ignacio; Tejedor, Paula; Elizaga, Jaime; Jimenez Cabrera, Francisco Manuel; Bullones Ramirez, Juan Antonio; Sanchez Aquino, Rosa; Portero Perez, Maria Pilar; Roura, Gerard; Mohandes, Mohsen; Saez Moreno, Roberto; Avanzas, Pablo; Caballero, Juan; Torres Bosco, Alfonso Miguel; Merchan Herrera, Antonio; Robles Alonso, Javier; Bosa Ojeda, Francisco; Garcia San Roman, Koldobika; Agudelo, Victor Hugo; Martin Lorenzo, Pedro; Fernandez, Juan Carlos; Perez de Prado, Armando; Ruiz Quevedo, Valeriano; Cruz Gonzalez, Ignacio; Moreu Burgos, Jose; Ruiz Garcia, Juan; Sanchez Burguillos, Francisco Jose; Nunez Pernas, Daniel; Baello Monge, Pascual; Hernando Marrupe, Lorenzo; Franco Pelaez, Juan Antonio; Jurado Roman, Alfonso; Pomar Domingo, Francisco; Fuertes Ferre, Georgina; Pimienta Gonzalez, Raquel; Morales Ponce, Francisco Jose; Sanchez Recalde, Angel; Ojeda Pineda, Soledad; Frutos Garcia, Araceli; Millan Segovia, Raul; Fajardo Molina, Ricardo; Diez Gil, Jose Luis; Guisado Rasco, Agustin; Gomez Menchero, Antonio Enrique; Bosch, Eduard; Oteo Dominguez, Juan Francisco; Gutierrez-Barrios, Alejandro; Cascon Perez, Jose Domingo; Casanova Sandoval, Juan Manuel; Fernandez Portales, Javier; Rivero Crespo, Fernando; Gonzalez Caballero, Eva; Ocaranza Sanchez, Raymundo; Zueco, Javier; Garcia Del Blanco, Bruno; Alonso Briales, Juan Horacio; Sanchez Gila, Joaquin; Vizcaino Arellano, Manuel; Carballo Garrido, Julo; Andraka,	Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022).	Revista espanola de cardiologia (English ed.)	5.9	Q1	Article	2023
AA-15	Gomez-Moyano, E; Rodriguez-Capitan, J; Roman, DG; Bueno, JAR; Sanchez, AV; Hernandez, FE; Angulo, GEG; Mora, MJM; Thurnhofer-Hemsi, K; Molina-Ramos, AI; Romero-Cuevas, M; Jimenez-Navarro, M; Pavon-Moron, FJ	Postural orthostatic tachycardia syndrome and other related dysautonomic disorders after SARS-CoV-2 infection and after COVID-19 messenger RNA vaccination	FRONTIERS IN NEUROLOGY	3.4	Q2	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AA-15	Cuesta-Vargas, AI; Fuentes-Abolafio, IJ; García-Conejo, C; Díaz-Balboa, E; Trinidad-Fernández, M; Gutiérrez-Sánchez, D; Escriche-Escuder, A; Cobos-Palacios, L; López-Sampalo, A; Pérez-Ruíz, JM; Roldán-Jiménez, C; Pérez-Velasco, MA; Mora-Robles, J; López-Carmona, MD; Pérez-Cruzado, D; Martín-Martín, J; Pérez-Belmonte, LM	Effectiveness of a cardiac rehabilitation program on biomechanical, imaging, and physiological biomarkers in elderly patients with heart failure with preserved ejection fraction (HFpEF): FUNNEL plus study protocol	BMC CARDIOVASCULAR DISORDERS	2.1	Q3	Article	2023
AA-15	García-Touchard, A; Sabaté, M; Gonzalo, N; Peral, V; Vaquerizo, B; Ruiz-Salmerón, R; del Blanco, BG; Jiménez-Mazuecos, J; Molina, E; Martínez-Romero, P; Hernandez-García, JM; Ruiz-Quevedo, V; Urbano, C; Fernández-Portales, J; Rumoroso, JR; Casanova-Sandoval, J; Pinar, E; Lopez-Pais, J; Oteo, JF; Alfonso, F	Very long-term efficacy and safety of paclitaxel-eluting balloon after a bare-metal stent for the treatment of ST-elevation myocardial infarction: 8-year results of a randomized clinical trial (PEBSI study)	CARDIOVASCULAR DIAGNOSIS AND THERAPY	2.4	Q3	Article	2023
AA-15	Ballesteros, G; Conejo, L; Zabala, JI	A complex rhythm for a complex congenital heart disease	JOURNAL OF ELECTROCARDIOLOGY	1.3	Q4	Article	2023
AA-22	Pinero-Pinto, E; Romero-Galisteo, RP; Jimenez-Rejano, JJ; Escobio-Prieto, I; Pena-Salinas, M; Luque-Moreno, C; Palomo-Carrion, R	A pilot randomised controlled trial on the effectiveness of infant massage on the acceptance, commitment and awareness of influence in parents of babies with Down syndrome	JOURNAL OF INTELLECTUAL DISABILITY RESEARCH	3.6	D1	Article	2023
AA-22	March-Amengual, JM; Cambra-Badii, I; Galán, CP; Busquets-Alibés, E; Aguado, MM; Ramon-Aribau, A; Grande, LF; Cayuela, AC; Sala, NTI; Andrade-Gómez, E; Martínez-Perez, N; Jerez-Roig, J	The impact of the COVID-19 pandemic on enrollment in undergraduate health-related studies in Spain	BMC MEDICAL EDUCATION	3.6	Q1	Article	2023
AA-22	Martinez-Rico, M; Ortega-Avila, AB; Pineda-Galan, C; Gijon-Nogueron, G; Rios, MP; Alabua-Dasi, R; Marchena-Rodriguez, A	Effect of Spatiotemporal Parameters on the Gait of Children Aged from 6 to 12 Years in Podiatric Tests: A Cross Sectional Study	HEALTHCARE	2.8	Q2	Article	2023
AA-22	Reinoso-Cobo, A; Ortega-Avila, AB; Pineda-Galan, C; Alabau-Dasi, R; Exposito-Ruiz, M; Banwell, G; Ramos-Petersen, L; Gijon-Nogueron, G	Follow-up of health-related quality of life and pain in a cohort of patients with rheumatoid arthritis before and after COVID-19	FOOT AND ANKLE SURGERY	2.5	Q2	Article	2023
AA-22	Díaz-Mohedo, E; Aguirre, IO; García, EM; Infantes-Rosales, MA; Hita-Contreras, F	Functional Exercise Versus Specific Pelvic Floor Exercise: Observational Pilot Study in Female University Students	HEALTHCARE	2.8	Q2	Article	2023
AA-22	Romero-Galisteo, RP; Valverde-Martinez, MA; Fernandez-Medina, IM; Cortes-Rodriguez, AE; Garcia- Lopez, H; Nunez-Nagy, S	Sexuality in People with Disabilities: A Qualitative Study of Physiotherapists' Perceptions	SEXUALITY RESEARCH AND SOCIAL POLICY	2.6	Q2	Article	2023
AA-22	Romero-Galisteo, RP; Pinero-Pinto, E; Palomo-Carrión, R; Luque-Moreno, C; Molina-Torres, G; González-Sánchez, M	Translation, cross-cultural adaptation and validation of the Rett syndrome motor evaluation scale (RESMES): Spanish version	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY	3.1	Q2	Article	2023
AA-22	López-Pineda, J; Rodríguez-Martínez, MC; Gómez-Rodríguez, R; García-Casares, L; García-Casares, N	Biomechanical Assessments in Woodwind Musicians: A Systematic Review	HEALTHCARE	2.8	Q2	Review	2023
AA-22	Repiso-Guardeño, A; Moreno-Morales, N; Labajos-Manzanares, MT; Rodríguez-Martínez, MC; Armenta-Peinado, JA	Does Tension Headache Have a Central or Peripheral Origin? Current State of Affairs	CURRENT PAIN AND HEADACHE REPORTS	3.7	Q2	Review	2023
AA-22	Heredia-Callejon, A; Garcia-Perez, P; Armenta-Peinado, JA; Infantes-Rosales, MA; Rodriguez-Martinez, MC	Influence of the Therapeutic Alliance on the Rehabilitation of Stroke: A Systematic Review of Qualitative Studies	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AA-22	Martinez-Calderon, J; Flores-Cortes, M; Morales-Asencio, JM; Pineda-Galán, C; García-Rios, MC; Torrontegui-Duarte, M; Luque-Suarez, A	Is it Possible to Reduce Pain-Related Fear in Individuals with Knee Osteoarthritis? a Systematic Review of Randomised Clinical Trials	PHYSIOTHERAPY THEORY AND PRACTICE	2	Q2	Review	2023
AA-22	Seoane-Martín, ME; Rodríguez-Martínez, MC	Potential Role of Occupational Therapist Intervention in Elementary School for Children with Additional Support Needs: A Systematic Review	CHILDREN-BASEL	2.4	Q2	Review	2023
AA-22	Requejo-Herrero, P; Pineda-Galan, C; Medina-Porqueres, I	Anterior cruciate ligament ruptures in Spanish soccer first division: An epidemiological retrospective study	KNEE	1.9	Q3	Article	2023
AA-22	Cano-Ibáñez, N; Serra-Majem, L; Martín-Peláez, S; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Lassale, C; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Gómez-Pérez, AM; Lapetra, J; Fernández-Aranda, F; Bueno-Cavanillas, A; Tur, JA; Cubelos, N; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Calderón, C; Daimiel, L; Ros, E; Gea, A; Babio, N; Gimenez-Alba, IM; Zomeño-Fajardo, MD; Abete, I; Sierra, LT; Romero-Galisteo, RP; de la Hera, MG; Martín-Padillo, M; García-Ríos, A; Casas, RM; Fernández-García, JC; Santos-Lozano, JM; Toledo, E; Becerra-Tomas, N; Sorli, J; Schröder, H; Zulet, MA; Sorto-Sánchez, C; Diez-Espino, J; Gómez-Martínez, C; Fitó, M; Sánchez-Villegas, A	Dietary diversity and depression: cross- sectional and longitudinal analyses in Spanish adult population with metabolic syndrome. Findings from PREDIMED-Plus trial	PUBLIC HEALTH NUTRITION	3.2	Q3	Article	2023
AA-22	Guerra-Armas, J; Flores-Cortes, M; Pineda-Galan, C; Luque-Suarez, A; La Touche, R	Role of Immersive Virtual Reality in Motor Behaviour Decision-Making in Chronic Pain Patients	BRAIN SCIENCES	3.3	Q3	Review	2023
AA-22	Flores-Cortes, M; Guerra-Armas, J; Pineda-Galan, C; La Touche, R; Luque-Suarez, A	Sensorimotor Uncertainty of Immersive Virtual Reality Environments for People in Pain: Scoping Review.	BRAIN SCIENCES	3.3	Q3	Review	2023
AE-11	Mejia-Chew, C; Carver, PL; Rutjanawech, S; Camargo, LFA; Fernandes, R; Belga, S; Daniels, SA; Mller, NJ; Burkhard, S; Theodoropoulos, NM; Postma, DF; van Duijn, PJ; Farias, MC; Gonzlez-Rico, C; Hand, J; Lowe, A; Bodro, M; Vanino, E; Cruz, AF; Ramos, A; Makek, MJ; Mjahed, RB; Manuel, O; Kamar, N; Calvo-Cano, A; Carrasco, LR; Muoz, P; Rodrguez, S; Prez-Recio, S; Sab, N; Alvarez, RR; Silva, JT; Mularoni, A; Vidal, E; Alonso-Titos, J; del Rosal, T; Classen, AY; Goss, CW; Agarwal, M; Lpez-Medrano, F	Risk Factors for Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients: A Multinational Case- Control Study	CLINICAL INFECTIOUS DISEASES	11.8	D1	Article	2023
AE-11	Sevillano, AM; Caravaca-Fontán, F; Garcia-Galan, LC; Fernandez-Juarez, G; Lopez-Revuelta, K; Guzmán, DA; Martín-Reyes, G; Quintana, LF; Rodas, LM; de la Nieta, MDS; Rabasco, C; Espinosa, M; Diaz-Encarnación, M; San Miguel, L; Barrios, C; Rodriguez, E; Garcia, P; Valera, A; Peña, JK; Shabaka, A; Velo, M; Sierra, M; Gonzalez, F; Fernandez-Reyes, MJ; Heras, M; Delgado, P; Gutierrez, E; Moreno, JA; Praga, M	Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria- Related Acute Kidney Injury in Older Patients With IgA Nephropathy	KIDNEY INTERNATIONAL REPORTS	6	Q1	Article	2023
AE-11	Farina-Hernandez, A; Marrero-Miranda, D; Perez-Carreno, E; De Vera-Gonzalez, A; Gonzalez, A; Acosta-Sorensen, C; Rodriguez-Rodriguez, AE; Collantes, T; Garcia, MD; Rodriguez-Munoz, AI; Rodriguez-Alvarez, C; Rivero, A; Macia, M; Teran, E; Sanchez-Dorta, NV; Perez-Tamajon, L; Alvarez-Gonzalez, A; Gonzalez-Rinne, A; Rodriguez-Hernandez, A; De Bonis-Redondo, E; Rodriguez-Adanero, C; Hernandez, D; Porrini, E; Torres, A	Pretransplant evaluation and the risk of glucose metabolic alterations after renal transplantation: a prospective study	NEPHROLOGY DIALYSIS TRANSPLANTATION	6.1	Q1	Article	2023
AE-11	Fructuoso, AIS; Raba, AB; Deras, EB; Sánchez, LAV; San Cecilio, RV; Esteve, AF; Vega, LC; Martínez, E; Garcia, MEG; Coronado, PS; Morales, NDV; Larrondo, SZ; Cano, NR; Blanca, AM; Marrero, DH; Castello, IB; Ramos, JP; Ochoa, AS; Molas, CF; Roncero, FG; Ramírez, AT; Guldris, SC; Flores, IP	Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study	CLINICAL KIDNEY JOURNAL	4.6	Q1	Article	2023
AE-11	Pascual, J; Mazuecos, A; Sánchez-Antolín, G; Solé, A; Ventura-Aguiar, P; Crespo, M; Farrero, M; Fernández-Rivera, C; Garrido, IP; Gea, F; González-Monte, E; González-Rodriguez, A; Hernández-Gallego, R; Jiménez, C; López-Jiménez, V; Otero, A; Pascual, S; Rodríguez-Laiz, GP; Ruiz, JC; Sancho, A; Santos, F; Serrano, T; Tabernero, G; Zarraga, S; Delgado, JF	Best practices during COVID-19 pandemic in solid organ transplant programs in Spain	TRANSPLANTATION REVIEWS	4	Q2	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AE-11	Melendo-Viu, M; Dobarro, D; Roubin, SR; Pernas, CL; Cordón, CM; Lamas, MV; Esteban, MP; Martínez, MAV; Abu Assi, E; Romero, RP; Calderón, JJL; Romo, AI	Left Ventricular Assist Device as a Destination Therapy: Current Situation and the Importance of Patient Selection	LIFE-BASEL	3.2	Q2	Review	2023
AE-11	Caravaca-Fontán, F; Cavero, T; Diaz-Encarnación, M; Cabello, V; Ariceta, G; Quintana, LF; Marco, H; Barros, X; Ramos, N; Rodríguez-Mendiola, N; Cruz, S; Fernández-Juárez, G; Rodríguez, A; de Jose, AP; Rabasco, C; Rodado, R; Fernández, L; Pérez-Gómez, V; Avila, A; Bravo, L; Espinosa, N; Allende, N; de la Nieta, MDS; Rodríguez, E; Rivas, B; Melgosa, M; Huerta, A; Miquel, R; Mon, C; Fraga, G; de Lorenzo, A; Draibe, J; González, F; Shabaka, A; López-Rubio, ME; Fenollosa, MA; Martín-Penagos, L; Da Silva, I; Titos, JA; de Córdoba, SR; de Jorge, EG; Praga, M	Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy	KIDNEY360	2.7	Q2	Article	2023
AE-11	Hevilla, F; Padial, M; Blanca, M; Barril, G; Jimenez-Salcedo, T; Ramirez-Ortiz, M; Nogueira, A; Gentile, A; Garcia-Escobar, E; Romero-Zerbo, SY; Olveira, G	Effect on nutritional status and biomarkers of inflammation and oxidation of an oral nutritional supplement (with or without probiotics) in malnourished hemodialysis patients. A multicenter randomized clinical trial Renacare Trial	FRONTIERS IN NUTRITION	5	Q2	Article	2023
AE-11	Vazquez-Sanchez, T; Sanchez-Nino, MD; Ruiz-Esteban, P; Lopez, V; Leon, M; Caballero, A; Ruiz-Escalera, JF; Ortiz, A; Torres, A; Rodriguez, M; Hernandez, D	Time-Dependent Changes of Klotho and FGF- 23 Levels after Kidney Transplantation: Role of Cold Ischemia Time, Renal Function and Graft Inflammation	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
AE-11	Villanego, F; Vigara, LA; López, V; de Gracia, MD; Rodriguez-Benot, A; Bernal, G; Castro, P; Mazuecos, A	Changes over time in the causes of death with a functioning graft in kidney transplantation recipients	NEFROLOGIA	2.6	Q3	Article	2023
AE-11	López-Oliva, MO; Pérez-Flores, I; Molina, M; Aladrén, MJ; Trujilloe, H; Redondo-Pachón, D; López, V; Facundo, C; Villanego, F; Rodríguez, M; Ruizk, MC; Antón, P; Rivas-Oural, A; Cabello, S; Portolés, J; de la Vara, L; Tabernero, G; Valero, R; Galeano, C; Moral, E; Ventura, A; Coca, A; Nuñoz, MA; Hernández-Gallego, R; Shabaka, A; Ledesma, G; Bouarich, H; Rodríguez, MA; Tamajón, LP; Cruzado, L; Sánchez, JE; Jiménez, C	Management of immunosuppressive therapy in kidney transplant recipients with COVID-19. A multicentre national study derived from the Spanish Society of Nephrology. COVID registry	NEFROLOGIA	2.6	Q3	Article	2023
AE-11	Armas-Padron, AM; Sicilia-Sosvilla, M; Ruiz-Esteban, P; Torres, A; Hernandez, D	Association between Cardiovascular Health, C-Reactive Protein, and Comorbidities in Spanish Urban-Dwelling Overweight/Obese Hypertensive Patients	JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE	2.4	Q3	Article	2023
AE-11	Gonzalez-Delgado, A; Farina-Hernandez, A; Marrero, D; Franco-Maside, A; Hernandez-Barroso, G; Perez-Carreno, E; Acosta-Sorensen, C; Rodriguez-Rodriguez, AE; Collantes, T; Rodriguez-Munoz, AI; Rodriguez-Alvarez, C; Rivero, A; Sosa, AJ; Macia, M; Garcia, ET; Alvarez-Gonzalez, A; Rinne, AG; Rodriguez-Hernandez, A; De Bonis-Redondo, E; Adanero, CR; Hernandez, D; Ramirez, AT; Porrini, E	Inflammation on the waiting list is a risk factor for new-onset prediabetes and post-transplant diabetes mellitus: a prospective study.	NEPHRON	2.5	Q3	Article	2023
AE-11	Franco, A; Hernandez, D; Zarraga, S; Fructuoso, AS; Crespo, M; Mazuecos, A; Corte, CD; Benot, AR; Ruiz, JC; Beneyto, I	Lymphoproliferative disorders after renal transplantation along 2 decades: A large longitudinal study of 21,546 recipients	NEFROLOGIA	2.6	Q3	Article	2023
AE-11	Ventura-Aguiar, Pedro; Cabello, Mercedes; Beneyto, Isabel; Navarro Cabello, Dolores; Tabernero, Guadalupe; Alonso, Angel; Ruiz, Juan Carlos; Llorente, Santiago	Patient and graft survival in pancreas transplant recipients: The EFISPAN study.	NEFROLOGIA	2.6	Q3	Article	2023
AE-11	Hernández, D; Caballero, A	Kidney transplant in the next decade: Strategies, challenges and vision of the future	NEFROLOGIA	2.6	Q3	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AE-11	Lopez, Veronica; Mazuecos, Auxiliadora; Villanego, Florentino; Lopez-Oliva, Maria; Alonso, Angel; Beneyto, Isabel; Crespo, Marta; Diaz-Corte, Carmen; Franco, Antonio; Gonzalez-Roncero, Francisco; Guirado, Luis; Jimenez, Carlos; Juega, Javier; Llorente, Santiago; Paul, Javier; Rodriguez-Benot, Alberto; Ruiz, Juan Carlos; Sanchez-Fructuoso, Ana; Torregrosa, Vicente; Zarraga, Sofia; Rodrigo, Emilio; Hernandez, Domingo	Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients.	NEFROLOGIA	2.6	Q3	Review	2023
AE-11	Vazquez-Sanchez, Teresa; Lopez, Veronica; Schuldt, Ruben; Bouarich, Oumayma; Arrebola, Alba; Antunez, Paula; Ruiz, Elia; Ortega, Laura; Hernandez, Domingo	Importance of Frailty in Kidney Transplant Recipients.	Transplantation proceedings	0.9	Q4	Article	2023
AE-11	Lopez, Veronica; Salazar, Galo; Arrebola, Alba; Bouarich, Oumayma; Hernandez, Domingo	Results of Kidney Transplantation with Controlled Cardiac Death Donors Older Than 70 Years.	TRANSPLANTATION PROCEEDINGS	0.9	Q4	Article	2023
B-03	Lopez-Jaime, FJ; Fernandez-Bello, I; Calavia-Aranda, E; Reina-Monso, B; Montano, A	Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX-FP): A case report	CLINICAL CASE REPORTS	0.7		Article	2023
B-03	Dawson, Mark A.; Borthakur, Gautam; Huntly, Brian J. P.; Karadimitris, Anastasios; Alegre, Adrian; Chaidos, Aristeidis; Vogl, Dan T.; Pollyea, Daniel A.; Davies, Faith E.; Morgan, Gareth J.; Glass, Jacob L.; Kamdar, Manali; Mateos, Maria-Victoria; Tovar, Natalia; Yeh, Paul; Delgado, Regina Garcia; Basheer, Faisal; Marando, Ludovica; Gallipoli, Paolo; Wyce, Anastasia; Krishnatry, Anu Shilpa; Barbash, Olena; Bakirtzi, Evi; Ferron-Brady, Geraldine; Karpinich, Natalie O.; McCabe, Michael T.; Foley, Shawn W.; Horner, Thierry; Dhar, Arindam; Kremer, Brandon E.; Dickinson, Michael	A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies	CLINICAL CANCER RESEARCH	11.5	D1	Article	2023
B-03	Kayser, S; Martínez-Cuadrón, D; Rodriguez-Veiga, R; Hänel, M; Tormo, M; Schäfer-Eckart, K; Botella, C; Stölzel, F; del Castillo, TB; Keller, U; Rodriguez-Medina, C; Held, G; Amigo, ML; Schliemann, C; Colorado, M; Kaufmann, M; Garcia, MB; Krause, SW; Görner, M; Jost, E; Steffen, B; Zukunft, S; Platzbecker, U; Ho, AD; Baldus, CD; Serve, H; Müller-Tidow, C; Thiede, C; Bornhäuser, M; Montesinos, P; Röllig, C; Schlenk, RF	Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia	HAEMATOLOGICA	10.1	D1	Article	2023
B-03	Piñana, JL; Vazquez, L; Calabuig, M; López-Corral, L; Martin-Martin, G; Villalon, L; Sanz-Linares, G; Conesa-Garcia, V; Sanchez-Salinas, A; Gago, B; Facal, A; Risco-Gálvez, I; Olave, MT; Espigado, I; Lopez-Jimenez, J; Hernández-Rivas, JA; Avendaño-Pita, A; Arroyo, I; Ferrer, E; García-Cadenas, I; González-Santillana, C; Roldán-Pérez, A; Ferrer, B; Guerreiro, M; Suarez-Lledó, M; Camara, A; Campos-Beltrán, D; Navarro, D; Cedillo, A; Sureda, A; Solano, C; Martino, R	One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients	BLOOD CANCER JOURNAL	12.8	D1	Article	2023
B-03	García-Sancho, AM; Baile, M; Rodríguez, G; Dlouhy, I; Sancho, JM; Jarque, I; González-Barca, E; Salar, A; Espeso, M; Grande, C; Bergua, J; Montes-Moreno, S; Redondo, A; Enjuanes, A; Campo, E; López-Guillermo, A; Caballero, D; and González-Barca, E	Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO		6.5	Q1	Article	2023
B-03	Bailén, R; Alenda, R; Herruzo-Delgado, B; Acosta-Fleitas, C; Vallés, A; Esquirol, A; Fonseca, M; Solán, L; Sánchez-Vadillo, I; Bautista, G; Bento, L; López-Godino, O; Pérez-Martínez, A; Torrent, A; Zanabili, J; Calbacho, M; Moreno, MA; Pascual-Cascón, MJ; Guerra-Domínguez, L; Chinea, A; García-Cadenas, I; López-Corral, L; Boix-Giner, F; Lórenzo, JLL; Humala, K; Duarte, R; Sampol, A; Heras, I; Vicario, JL; Balas, A; Oarbeascoa, G; Fernández-Caldas, P; Anguita, J; Kwon, M	Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy	FRONTIERS IN IMMUNOLOGY	7.3	Q1	Article	2023
B-03	Mussetti, A; Bento, L; Bastos-Oreiro, M; Sansalvador, BR; Albo, C; Bailen, R; Barba, P; Benzaquén, A; Briones, J; Caballero, AC; Campos, A; Español, I; Ferra, C; López, SG; Sierra, PAG; Guerra, LM; Hernani, R; Iacoboni, G; Ubieto, AIJ; Kwon, M; Corral, LL; López-Godino, O; Munoz, MCM; Martínez-Cibrián, N; Gómez, JM; Pérez-Ortega, L; Ortf, G; Ortiz-Maldonado, V; Pascual, MJ; Perera, M; Perez, A; Reguera, JL; Sanchez, JM; Sanz, J; Torrent, A; Yáñez, L; Varela, R; Echechipia, IC; Caballero, D; Sureda, A	Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era	BONE MARROW TRANSPLANTATION	4.8	Q1	Article	2023
B-03	Pinana, JL; Martino, R; Vazquez, L; Lopez-Corral, L; Perez, A; Chorao, P; Avendano-Pita, A; Pascual, MJ; Sanchez-Salinas, A; Sanz-Linares, G; Olave, MT; Arroyo, I; Tormo, M; Villalon, L; Conesa-Garcia, V; Gago, B; Terol, MJ; Villalba, M; Garcia-Gutierrez, V; Cabero, A; Hernandez-Rivas, JA; Ferrer, E; Garcia-Cadenas, I; Teruel, A; Navarro, D; Cedillo, A; Sureda, A; Solano, C	SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS- CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination	BONE MARROW TRANSPLANTATION	4.8	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-03	Shah, NP; Garcia-Gutierrez, V; Jimenez-Velasco, A; Larson, SM; Saussele, S; Rea, D; Mahon, FX; Levy, MY; Gomez-Casares, MT; Mauro, MJ; Sy, O; Martin-Regueira, P; Lipton, JH	Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE	BRITISH JOURNAL OF HAEMATOLOGY	6.5	Q1	Article	2023
B-03	Moreno, C; Ramos-Elbal, E; Velasco, P; Aguilar, Y; Martínez, BG; Fuentes, C; Molinos, A; Guerra-García, P; Palomo, P; Verdu, J; Pedroso, RMA; Vagace, JM; López-Duarte, M; Regueiro, A; Tasso, M; Dapena, JL; Salinas, JA; Navarro, S; Bautista, F; Lassaletta, A; Lendínez, F; Rives, S; Pascual, A; Rodríguez, A; Pérez-Hurtado, JM; Fernández, JM; Pérez-Martínez, A; González-Vicent, M; de Heredia, CD; Fuster, JL	Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)	FRONTIERS IN PEDIATRICS	2.6	Q2	Article	2023
B-03	Chumbita, M; Puerta-Alcalde, P; Yáñez, L; Cuesta, MA; Chinea, A; Español-Morales, I; Fernandez-Abellán, P; Gudiol, C; González-Sierra, P; Rojas, R; Sánchez-Pina, JM; Vadillo, IS; Sánchez, M; Varela, R; Vázquez, L; Guerreiro, M; Monzo, P; Lopera, C; Aiello, TF; Peyrony, O; Soriano, A; Garcia-Vidal, C	High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations	MICROBIOLOGY SPECTRUM	3.7	Q2	Article	2023
B-03	Martínez, C; de Haro, ME; Romero, S; Gutiérrez, A; Domingo-Domènech, E; González-Rodríguez, AP; Zeberio, I; Martínez-Badas, MP; Rodríguez-Izquierdo, A; Carpio, C; Bastos-Oreiro, M; Hernández-Rivas, JA; Vallansot, R; Kelleher, N; Díaz-Gálvez, FJ; Torrado, T; Pereira, A; García-Sanz, R	Impact of pre-and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma	ANNALS OF HEMATOLOGY	3.5	Q2	Article	2023
B-03	Ramos, F; Hermosín, ML; Fuertes-Núñez, M; Martínez, P; Rodriguez-Medina, C; Barrios, M; Ibáñez, F; Bernal, T; Olave, MT; Alvarez, MA; Vahí, M; Caballero-Velázquez, T; González, B; Altés, A; García, L; Fernández, P; Durán, MA; López, R; Rafel, M; Serrano, J; Ranelletti, FO	Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice	JOURNAL OF PERSONALIZED MEDICINE	3.4	Q2	Article	2023
B-03	Vazquez-Sanchez, T; Sanchez-Niño, MD; Ruiz-Esteban, P; López, V; León, M; Caballero, A; Ruiz-Escalera, JF; Ortiz, A; Torres, A; Rodriguez, M; Hernandez, D	Time-Dependent Changes of Klotho and FGF- 23 Levels after Kidney Transplantation: Role of Cold Ischemia Time, Renal Function and Graft Inflammation	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
B-03	Perez-Lamas, L; Luna, A; Boque, C; Xicoy, B; Giraldo, P; Lopez, RP; Nuno, CR; de las Heras, N; Castera, EM; Marin, JL; Diaz, AS; Gomez, V; Tenza, PV; Pacho, MS; Goni, JAV; Vega, MM; Alvarez-Larran, A; Cortes, M; Encinas, MP; Mastell, PC; Angona, A; Rosell, A; Lakhwani, S; Colorado, M; Ramila, E; Cervero, C; Cuevas, B; Blanco, LV; de Paz, R; Coll, AP; Fernandez, MJ; Casado, LF; Alonso-Dominguez, JM; Arance, MMA; Cuenca, AS; Jimenez-Velasco, A; Prendes, SO; Santaliestra, M; Chulvi, MJL; Hernandez-Boluda, JC; Garcia-Gutierrez, V	Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors	CANCERS	5.2	Q2	Article	2023
B-03	Galán, V; Beléndez, C; Echecopar, C; Estival, P; Sissini, L; Olivas, R; Bueno, D; Molina, B; Fuentes, C; Regueiro, A; Benítez, I; Plaza, M; Margarit, A; Rifón, J; Pascual, A; Palomo, P; Urtasun, A; Fuster, JL; Fuster, L; de Heredia, CD; Navarro, JMF; González-Vicent, M; Ruz, B; Pérez-Martínez, A	Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)	TRANSPLANTATION AND CELLULAR THERAPY	3.2	Q2	Article	2023
B-03	Mingot-Castellano, Maria Eva; Canaro Hirnyk, Mariana; Sanchez-Gonzalez, Blanca; Alvarez-Roman, Maria Teresa; Barez-Garcia, Abelardo; Bernardo-Gutierrez, Angel; Bernat-Pablo, Silvia; Bolanos-Calderon, Estefania; Butta-Coll, Nora; Caballero-Navarro, Gonzalo; Caparros-Miranda, Isabel Socorro; Entrena-Urena, Laura; Fernandez-Fuertes, Luis Fernando; Garcia-Frade, Luis Javier; Gomez del Castillo, Maria del Carmen; Gonzalez-Lopez, Tomas Jose; Grande-Garcia, Carlos; Guinea de Castro, Jose Maria; Jarque-Ramos, Isidro; Jimenez-Barcenas, Reyes; Lopez-Ansoar, Elsa; Martinez-Carballeira, Daniel; Martinez-Robles, Violeta; Monteagudo-Montesinos, Emilio; Paramo-Fernandez, Jose Antonio; Perera-alvarez, Maria del Mar; Soto-Ortega, Inmaculada; Valcarcel-Ferreiras, David; Pascual-Izquierdo, Cristina	Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-03	Huntley, D; Giménez, E; Vázquez, L; Pascual, MJ; Amat, P; Remigia, MJ; Hernández-Boluda, JC; García, M; Gago, B; Torres, I; de la Asunción, CS; Hernani, R; Pérez, A; Albert, E; Piñana, JL; Solano, C; Navarro, D	Impact of cytomegalovirus immunodominant HLA-I donor-recipient matching on the incidence and features of virus DNAemia and virus-specific T-cell immune reconstitution in unmanipulated haploidentical hematopoietic stem cell transplantation	TRANSPLANT INFECTIOUS DISEASE	2.6	Q3	Article	2023
B-03	Velao, SR; Cadenas, IG; Cuesta, MA; Sanchez-Ortega, I; Fernández-Avilés, F; Roldan, E; Torrent, A; Viguria, MC; Villar, S; Bento, L; Yañez, L; Martino, R; Piñana, JL	Low rate of infectious enterocolitis in allogeneic stem cell transplant recipients with acute diarrhea: A prospective study by the GETH-TC.	ACTA HAEMATOLOGICA	2.4	Q3	Article	2023
B-03	Hernández, D; Caballero, A	Kidney transplant in the next decade: Strategies, challenges and vision of the future	NEFROLOGIA	2.6	Q3	Review	2023
B-03	Lopez-Jaime, FJ; Benitez, O; Jordan, BLD; Montano, A; Coll, J; Paris, LQ; Solano, MDGD	Expert opinion paper on the treatment of hemophilia a with emicizumab	HEMATOLOGY	1.9	Q4	Article	2023
B-04	Marrero, AD; Ortega-Vidal, J; Salido, S; Castilla, L; Vidal, I; Quesada, AR; Altarejos, J; Martinez-Poveda, B; Medina, MA	Anti-angiogenic effects of oleacein and oleocanthal: New bioactivities of compounds from Extra Virgin Olive Oil	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
B-04	Vidal, I; Torres-Vargas, JA; Sanchez, JM; Trigal, M; Garcia-Caballero, M; Medina, MA; Quesada, AR	Danthron, an Anthraquinone Isolated from a Marine Fungus, Is a New Inhibitor of Angiogenesis Exhibiting Interesting Antitumor and Antioxidant Properties	ANTIOXIDANTS	7	D1	Article	2023
B-04	Marrero, AD; Castilla, L; Bernal, M; Manrique, I; Posligua-Garcia, JD; Moya-Utrera, F; Porras-Alcala, C; Espartero, JL; Sarabia, F; Quesada, AR; Medina, MA; Martinez-Poveda, B	Inhibition of Endothelial Inflammatory Response by HT-C6, a Hydroxytyrosol Alkyl Ether Derivative	ANTIOXIDANTS	7	D1	Article	2023
B-04	Martín-Reyes F., Bernal M., Rodríguez-Díaz C., Rodríguez-de los Reyes D., Ho-Plagaro A., Rodríguez-Pacheco F., Camacho-Martel L., Camargo-Camero R., Rodríguez-González F.J., Alcain-Martínez G., Martín-Masot R., Navas-López V.M., Villanueva-Paz M., Lucena M.I., García-Fuentes E., López-Gómez C.	Mitochondrial Stress Links Environmental Triggers with Pro-Inflammatory Signaling in Crohn's Disease	ANTIOXIDANTS	7	D1	Article	2023
B-04	Zaldívar-López, S; Herrera-Uribe, J; Bautista, R; Jiménez, A; Moreno, A; Claros, MG; Garrido, JJ	Salmonella Typhimurium induces genome- wide expression and phosphorylation changes that modulate immune response, intracellular survival and vesicle transport in infected neutrophils	DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY	2.9	D1	Article	2023
B-04	Cerezo, IM; Pérez-Gómez, O; Bautista, R; Seoane, P; Esteban, MA; Balebona, MC; Moriñigo, MA; Tapia-Paniagua, ST	SpPdp11 Administration in Diet Modified the Transcriptomic Response and Its Microbiota Associated in Mechanically Induced Wound Sparus aurata Skin	ANIMALS	3	D1	Article	2023
B-04	Carrillo, P; Bernal, M; Tellez-Quijona, C; Marrero, AD; Vidal, I; Castilla, L; Caro, C; Dominguez, A; Garcia-Martin, ML; Quesada, AR; Medina, MA; Martinez-Poveda, B	The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
B-04	Allali-Boumara, I; Marrero, AD; Quesada, AR; Martinez-Poveda, B; Medina, MA	Pyroptosis Modulators: New Insights of Gasdermins in Health and Disease	ANTIOXIDANTS	7	D1	Review	2023
B-04	Alcalde, M; Toro, R; Bonet, F; Cordoba-Caballero, J; Martinez-Barrios, E; Ranea, JA; Vallverduu-Prats, M; Brugada, R; Meraviglia, V; Bellin, M; Sarquella-Brugada, G; Campuzano, O	Role of microRNAs in arrhythmogenic cardiomyopathy: translation as biomarkers into clinical practice	TRANSLATIONAL RESEARCH	7.8	D1	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-04	Marrero, AD; Quesada, AR; Martinez-Poveda, B; Medina, MA; Cardenas, C	A Proteomic Study of the Bioactivity of Annona muricata Leaf Extracts in HT-1080 Fibrosarcoma Cells	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
B-04	Asins, Maria J; Bullones, Amanda; Raga, Veronica; Romero-Aranda, Maria R; Espinosa, Jesus; Trivino, Juan C; Bernet, Guillermo P; Traverso, Jose A; Carbonell, Emilio A; Claros, M Gonzalo; Belver, Andres	Combining Genetic and Transcriptomic Approaches to Identify Transporter-Coding Genes as Likely Responsible for a Repeatable Salt Tolerance QTL in Citrus.	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
B-04	Corpas, M; de Mendoza, C; Moreno-Torres, V; Pintos, I; Seoane, P; Perkins, JR; Ranea, JAG; Fatumo, S; Korcsmaros, T; Martin-Villa, JM; Barreiro, P; Corral, O; Soriano, V	Genetic signature detected in T cell receptors from patients with severe COVID-19	ISCIENCE	5.8	Q1	Article	2023
B-04	Ocaña, MC; Bernal, M; Yang, CD; Caro, C; Domínguez, A; Vu, HS; Cárdenas, C; García-Martín, ML; Deberardinis, RJ; Quesada, AR; Martínez-Poveda, B; Medina, MA	New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo	COMMUNICATIONS BIOLOGY	5.9	Q1	Article	2023
B-04	Bullones, A; Castro, AJ; Lima-Cabello, E; Alche, JD; Luque, F; Claros, MG; Fernandez-Pozo, N	OliveAtlas: A Gene Expression Atlas Tool for Olea europaea	PLANTS-BASEL	4.5	Q1	Article	2023
B-04	Bullones, A; Castro, AJ; Lima-Cabello, E; Fernandez-Pozo, N; Bautista, R; Alche, JD; Claros, MG	Transcriptomic Insight into the Pollen Tube Growth of Olea europaea L. subsp. europaea Reveals Reprogramming and Pollen-Specific Genes Including New Transcription Factors	PLANTS-BASEL	4.5	Q1	Article	2023
B-04	Aguilera-Cobos, L; Garcia-Sanz, P; Rosario-Lozano, MP; Claros, MG; Blasco-Amaro, JA	An innovative framework to determine the implementation level of personalized medicine: A systematic review	FRONTIERS IN PUBLIC HEALTH	5.2	Q1	Review	2023
B-04	Castilla-Vallmanya, L; Centeno-Pla, M; Serrano, M; Franco-Valls, H; Martinez-Cabrera, R; Prat-Planas, A; Rojano, E; Ranea, JAG; Seoane, P; Oliva, C; Paredes-Fuentes, AJ; Marfany, G; Artuch, R; Grinberg, D; Rabionet, R; Balcells, S; Urreizti, R	Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2	JOURNAL OF MEDICAL GENETICS	4	Q2	Article	2023
B-04	Gonzalez-Flo, E; Kheirabadi, E; Rodriguez-Caso, C; Macfa, J	Evolutionary algorithm for the optimization of meal intake and insulin administration in patients with type 2 diabetes	FRONTIERS IN PHYSIOLOGY	4	Q2	Article	2023
B-04	Cisneros, E; Martinez-Padilla, A; Cardenas, C; Marquez, J; de Mues, AO; Roza, C	Identification of Potential Visceral Pain Biomarkers in Colon Exudates from Mice with Experimental Colitis: An Exploratory In Vitro Study	JOURNAL OF PAIN	4	Q2	Article	2023
B-04	Monterde, B; Rojano, E; Cordoba-Caballero, J; Seoane, P; Perkins, JR; Medina, MA; Ranea, JAG	Integrating differential expression, co- expression and gene network analysis for the identification of common genes associated with tumor angiogenesis deregulation	JOURNAL OF BIOMEDICAL INFORMATICS	4.5	Q2	Article	2023
B-04	Lobera, ES; Varela, MA; Jimenez, RL; Moreno, RB	miRNA as biomarker in lung cancer	MOLECULAR BIOLOGY REPORTS	2.8	Q3	Review	2023
B-04	Garcia, EE; Varela, MA; Jimenez, RL; Gomez-Maldonado, J; Dols, MAC; Claros, MG; Moreno, RB	Construction of miRNA-mRNA networks for the identification of lung cancer biomarkers in liquid biopsies	CLINICAL & TRANSLATIONAL ONCOLOGY	3.4	Q3	Article	2023
B-07	Cisneros, E; Martinez-Padilla, A; Cardenas, C; Marquez, J; de Mues, AO; Roza, C	Identification of Potential Visceral Pain Biomarkers in Colon Exudates from Mice with Experimental Colitis: An Exploratory In Vitro Study	JOURNAL OF PAIN	4	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-07	De los Santos-Jimenez, J; Rosales, T; Ko, B; Campos-Sandoval, JA; Alonso, FJ; Marquez, J; DeBerardinis, RJ; Mates, JM	Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines	CANCERS	5.2	Q2	Article	2023
B-07	Infantes-Lopez, MI; Nieto-Quero, A; Chaves-Pena, P; Zambrana-Infantes, E; Cifuentes, M; Marquez, J; Pedraza, C; Perez-Martin, M	New insights into hypothalamic neurogenesis disruption after acute and intense stress: implications for microglia and inflammation	FRONTIERS IN NEUROSCIENCE	4.3	Q2	Article	2023
B-07	Nieto-Quero, A; Infantes-López, MI; Zambrana-Infantes, E; Chaves-Peña, P; Gavito, AL; Munoz-Martin, J; Tabbai, S; Márquez, J; de Fonseca, FR; García-Fernández, MI; Santín, LJ; Pedraza, C; Pérez-Martin, M	Unveiling the Secrets of the Stressed Hippocampus: Exploring Proteomic Changes and Neurobiology of Posttraumatic Stress Disorder	CELLS	6	Q2	Article	2023
B-10	Galvan-Casas, C; Ortiz-Alvarez, J; Martinez-Garcia, E; Corbacho-Monne, M	Recommendations from the spanish academy of dermatology and venereology (aedv) for the management of sexual transmitted parasitosis, scabies, and pediculosis pubis.	ACTAS DERMO- SIFILIOGRAFICAS	3.2		Article	2023
B-10	Martín, MD; Aguilar, S; Aguilera-Arjona, J; Rivas-Ruiz, F; Rodríguez-Martínez, A; de Castro-Maqueda, G; Cambil-Martín, J; de Galvez-Aranda, V; Blázquez-Sánchez, N	Risk assessment of occupational skin cancer among outdoor workers in southern Spain: local pilot study	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE	4.9	Q1	Article	2023
B-10	Ruiz-Villaverde, R; Herrera-Acosta, E; de Casas, AR; Villegas-Romero, IM; Moreno-Suárez, FG; Vílchez-Márquez, F; Galán-Gutiérrez, M; Vázquez-Bayo, MC; Cases-Mérida, S; Almazán-Fernández, FM	Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
B-10	de Galvez, Maria Victoria; Castillo-Munoz, Rosa Maria; Lopez-Navarro, Norberto; Lopez-Jimenez, Patricio; Navarrete-de Galvez, Enrique; Bosch-Garcia, Ricardo; Herrera-Acosta, Enrique; Aguilera, Jose	Summer and spring elbow rashes is a variant of polymorphous light eruption: confirmation by photoprovocation and histopathology in a series of five cases.	FRONTIERS IN MEDICINE	3.9	Q2	Article	2023
B-10	Aguilera, J; Navarrete-de Galvez, E; Sanchez-Roldan, C; Herrera-Ceballos, E; de Galvez, MV	Sun-protective Properties of Technical Sportswear Fabrics 100% Polyester: The Influence of Moisture and Sweat on Protection against Different Biological Effects of Ultraviolet (UV) Radiation	PHOTOCHEMISTRY AND PHOTOBIOLOGY	3.3	Q2	Article	2023
B-10	Gutiérrez-Manzanedo, JV; Pardal, CV; Blázquez-Sánchez, N; De Gálvez, MV; Aguilera-Arjona, J; González-Montesinos, JL; Ruiz, FR; De Troya-Martín, M	Ultraviolet exposure of competitors during a Tokyo Olympic Sailing Regatta Test Event	PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE	2.6	Q2	Article	2023
B-10	Salman Monte, Tarek Carlos; Mateo, Patricia Fanlo; Izquierdo, Maria Galindo; Cervera, Ricard; Lopez, Norberto; Pallares, Lucio; Angel Torres, Maria Jose; Ortega, Silvia Perez	An online survey of the Spanish Lupus Patient Association (FELUPUS): patient perceptions and experiences	CLINICAL RHEUMATOLOGY	3.4	Q3	Article	2023
B-10	Barón, DR; Sánchez, NB; Ruiz, FR; Martínez, AR; Arjona, JA; Maqueda, GD; Araujo, IG; Aranda, MVD; Martínez, AR; Martín, MD	Occupational Sun Exposure Among Physical Education Teachers in Primary and Secondary Schools in Andalusia, Spain	JOURNAL OF CANCER EDUCATION	1.6	Q3	Article	2023
B-10	Gutiérrez-Manzanedo, JV; González-Montesinos, JL; Aguilera-Arjona, J; Rodríguez-Martínez, A; Vaz-Pardal, C; España-Romero, V; Rivas-Ruiz, F; Blázquez-Sánchez, N; De Gálvez-Aranda, MV; De Troya-Martín, M	Ultraviolet sun exposure and sun protection behaviors in outdoor rock climbers	PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES	3.1	Q3	Article	2023
B-11	Pook, D; Geynisman, DM; Carles, J; de Braud, F; Joshua, AM; Pérez-Gracia, JL; Pérez, CL; Shin, SJ; Fang, BN; Barve, M; Maruzzo, M; Bracarda, S; Kim, M; Kerloeguen, Y; Gallo, JD; Maund, SL; Harris, A; Huang, KC; Poon, V; Sutaria, DS; Gurney, H	A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer	CLINICAL CANCER RESEARCH	11.5	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
B-11	Matsubara, N; de Bono, J; Olmos, D; Procopio, G; Kawakami, S; Urun, Y; van Alphen, R; Flechon, A; Carducci, MA; Choi, YD; Hotte, SJ; Korbenfeld, E; Kramer, G; Agarwal, N; Chi, KN; Dearden, S; Gresty, C; Kang, JY; Poehlein, C; Harrington, EA; Hussain, M	Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA	CLINICAL CANCER RESEARCH	11.5	D1	Article	2023
B-11	Pollock, Y; Smith, MR; Saad, F; Chowdhury, S; Oudard, S; Hadaschik, B; Olmos, D; Lee, JY; Uemura, H; Bhaumik, A; Londhe, A; Rooney, B; Brookman-May, SD; De Porre, P; Mundle, SD; Small, EJ	Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide	PROSTATE CANCER AND PROSTATIC DISEASES	4.8	Q1	Article	2023
B-11	Lozano, R; Castro, E;-Campos, FL; Thorne, H; Ramirez-Backhaus, M; Aragon, IM; Cendon-Florez, Y; Gutierrez-Pecharroman, A; Salles, DC; Romero-Laorden, N; Lorente, D; Gonzalez-Peramato, P; Calatrava, A; Alonso, C; Anido, U; Arevalo-Lobera, S; Balmana, J; Chirivella, I; Juan-Fita, MJ; Llort, G; Cajal, TRY; Almagro, E; Alameda, D; Lopez-Casas, PP; Herrera, B; Mateo, J; Pritchard, CC; Antonarakis, ES; Lotan, TL; Rubio-Briones, J; Sandhu, S; Olmos, D	Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers	EUROPEAN JOURNAL OF CANCER	8.4	Q1	Article	2023
B-11	Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; James, ND; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, CJ; Tombal, B; Antonarakis, ES; Aparicio, AM; Armstrong, AJ; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, RG; Bulbul, M; Caffo, O; Castellano, D; Castro, E; Cheng, HH; Chi, KN; Chowdhury, S; Clarke, CS; Clarke, N; Daugaard, G; De Santis, M; Duran, I; Eeles, R; Efstathiou, E; Efstathiou, J; Ekeke, ON; Evans, CP; Fanti, S; Feng, FY; Fonteyne, V; Fossati, N; Frydenberg, M; George, D; Gleave, M; Gravis, G; Halabi, S; Heinrich, D; Herrmann, K; Higano, C; Hofman, MS; Horvath, LG; Hussain, M; Jereczek-Fossa, BA; Jones, R; Kanesvaran, R; Kellokumpu-Lehtinen, PL; Khauli, RB; Klotz, L; Kramer, G; Leibowitz, R; Logothetis, C; Mahal, B; Maluf, F; Mateo, J; Matheson, D; Mehra, N; Merseburger, A; Morgans, AK; Morris, MJ; Mrabti, H; Mukherji, D; Murphy, DG; Murthy, V; Nguyen, PL; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Pezaro, CJ; Poon, DMC; Pritchard, CC; Rabah, DM; Rathkopf, D; Reiter, RE; Rubin, MA; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Sharifi, N; Skoneczna, I; Soule, H; Spratt, DE; Srinivas, S; Sternberg, CN; Steuber, T; Suzuki, H; Sydes, MR; Taplin, ME; Tilki, D; Turkeri, L; Turco, F; Uemura, H; Uemura, H; Urun, Y; Vale, CL; van Oort, I; Vapiwala, N; Walz, J; Yamoah, K; Ye, DW; Yu, EY; Zapatero, A; Zilli, T; Omlin, A	Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022	EUROPEAN JOURNAL OF CANCER	8.4	Q1	Article	2023
B-11	Kullmann, F; Strissel, PL; Strick, R; Stoehr, R; Eckstein, M; Bertz, S; Wullich, B; Sikic, D; Wach, S; Taubert, H; Olbert, P; Heers, H; Lara, MF; Macias, ML; Matas-Rico, E; Lozano, MJ; Prieto, D; Hierro, I; van Doeveren, T; Bieche, I; Masliah-Planchon, J; Beaurepere, R; Boormans, JL; Allory, Y; Herrera-Imbroda, B; Hartmann, A; Weyerer, V	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort	JOURNAL OF CLINICAL PATHOLOGY	3.4	Q2	Article	2023
B-11	Avila-Gámiz, F; Pérez-Cano, AM; Pérez-Berlanga, JM; Mullor-Vigo, RM; Zambrana-Infantes, EN; Santín, LJ; de Guevara-Miranda, DL	Sequential treadmill exercise and cognitive training synergistically increase adult hippocampal neurogenesis in mice	PHYSIOLOGY & BEHAVIOR	2.9	Q2	Article	2023
B-11	Alvarez Alvarez, Rosa; Manzano, Aranzazu; Agra Pujol, Carolina; Artigas Raventos, Vicente; Correa, Raquel; Cruz Jurado, Josefina; Fernandez, Juan Angel; Garcia del Muro, Xavier; Gonzalez, Jose Antonio; Hindi, Nadia; Lozano Lominchar, Pablo; Martinez-Trufero, Javier; Mendez, Ramiro; Munoz, Mercedes; Munoz Casares, Cristobal; Orbis Castellanos, Francisco; Orellana Fernandez, Ruth; Paniagua Gonzalez, Miguel; Redondo, Andres; Valverde Morales, Claudia; Asencio, Jose Manuel	Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)	CANCERS	5.2	Q2	Review	2023
BA-16	Gomez-Ramirez, Susana; Brilli, Elisa; Tarantino, Germano; Girelli, Domenico; Munoz, Manuel	Sucrosomial Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency.	PHARMACEUTICALS	4.6	Q2	Review	2023
BA-16	Vallejo-Feria, R; Gómez-Salgado, J; Ruiz, AR; Romero-Serrano, R; Cruz-Salgado, O; Guillén-Gestoso, C; García-Iglesias, JJ	Impact of COVID-19 on stress, anxiety and depression in people with Obsessive-Compulsive Disorder: a systematic review	REVISTA ESPANOLA DE SALUD PUBLICA	1.1	Q4	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BA-20	Muscaritoli, M; Bar-Sela, G; Battisti, NML; Belev, B; Contreras-Martínez, J; Cortesi, E; de Brito-Ashurst, I; Prado, CM; Ravasco, P; Yalcin, S	Oncology-Led Early Identification of Nutritional Risk: A Pragmatic, Evidence- Based Protocol (PRONTO)	CANCERS	5.2	Q2	Article	2023
BA-20	Galve-Calvo, E; Alonso-Babarro, A; Martínez-García, M; Pi-Figueras, M; Villalba, G; Alonso, S; Contreras, J	Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients	ADVANCES IN THERAPY	3.8	Q2	Review	2023
BA-20	Sosa-Fajardo, P; Blanco-Suarez, JM; Pineda-Munguía, A; Rubí-Olea, L; Peleteiro-Higuero, P; Gajate, P; Zafra-Martín, J; Siva, S; Bossi, A; López-Campos, F; Couñago, F	Stereotactic body radiation therapy for kidney cancer. Where do we stand?	INTERNATIONAL JOURNAL OF UROLOGY	2.6	Q3	Review	2023
BE-15	de Vera, MTD; Cuadra, JDP; Pinos, DD; Martin, IH	Pleural empyema secondary to perforated diverticulosis due to biliary neoplasia infiltration	BMJ CASE REPORTS	0.9		Article	2023
BE-15	Pilo, J; García-Flores, LA; Clemente-Postigo, M; Arranz-Salas, I; Alcaide, J; Ramos-Fernandez, M; Lozano, J; Boughanem, H; Kompella, P; Macías-González, M	8-Oxoguanine DNA Glycosylase 1 Upregulation as a Risk Factor for Obesity and Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
BE-15	Jimenez-Rodriguez, B; Alba-Bernal, A; Lopez-Lopez, E; Quiros-Ortega, ME; Carbajosa, G; Garrido-Aranda, A; Alvarez, M; Godoy-Ortiz, A; Queipo-Ortuno, MI; Vicioso, L; Diaz-Cordoba, G; Roldan-Diaz, MD; Velasco-Suelto, J; Hernando, C; Bermejo, B; Julve-Parreno, A; Lluch, A; Pascual, J; Comino-Mendez, I; Alba, E	Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
BE-15	López-Villodres, JA; Escamilla, A; Mercado-Sáenz, S; Alba-Tercedor, C; Rodriguez-Perez, LM; Arranz-Salas, I; Sanchez-Varo, R; Bermúdez, D	Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice	BIOMEDICINES	4.7	Q1	Review	2023
BE-15	Kullmann, F; Strissel, PL; Strick, R; Stoehr, R; Eckstein, M; Bertz, S; Wullich, B; Sikic, D; Wach, S; Taubert, H; Olbert, P; Heers, H; Lara, MF; Macias, ML; Matas-Rico, E; Lozano, MJ; Prieto, D; Hierro, I; van Doeveren, T; Bieche, I; Masliah-Planchon, J; Beaurepere, R; Boormans, JL; Allory, Y; Herrera-Imbroda, B; Hartmann, A; Weyerer, V	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort	JOURNAL OF CLINICAL PATHOLOGY	3.4	Q2	Article	2023
BE-15	Robles-Mezcua, A; Ruíz-Salas, A; Medina-Palomo, C; Robles-Mezcua, M; Díaz-Expósito, A; Ortega- Jiménez, MV; Gimeno-Blanes, JR; Jiménez-Navarro, MF; García-Pinilla, JM	The Novel Variant NP_00454563.2 (p.Glu259Glyfs*77) in Gene PKP2 Associated with Arrhythmogenic Cardiomyopathy in 8 Families from Malaga, Spain	GENES	3.5	Q2	Article	2023
BE-17	Forne, AF; Anaya, MJG; Guillot, SJS; Andrade, IP; Fernandez, LD; Ocon, MJL; Perez, YL; Queipo-Ortuno, MI; Gomez-Millan, J	Influence of the microbiome on radiotherapy- induced oral mucositis and its management: A comprehensive review	ORAL ONCOLOGY	4.8	D1	Review	2023
BE-17	Cerezo, MV; Soria-Reyes, LM; Pajares, B; Gomez-Millan, J; Blanca, MJ	Development and psychometric properties of the Stressors in Breast Cancer Scale	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article	2023
BE-17	García-Anaya, MJ; Segado-Guillot, S; Cabrera-Rodríguez, J; Toledo-Serrano, MD; Medina-Carmona, JA; Gómez-Millán, J	Dose and volume de-escalation of radiotherapy in head and neck cancer	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	6.2	Q1	Review	2023
BE-18	Vidal, I; Torres-Vargas, JA; Sanchez, JM; Trigal, M; Garcia-Caballero, M; Medina, MA; Quesada, AR	Danthron, an Anthraquinone Isolated from a Marine Fungus, Is a New Inhibitor of Angiogenesis Exhibiting Interesting Antitumor and Antioxidant Properties	ANTIOXIDANTS	7	D1	Article	2023
BE-18	Montenegro-Navarro N., García-Báez C., García-Caballero M.	Molecular and metabolic orchestration of the lymphatic vasculature in physiology and pathology	NATURE COMMUNICATIONS	16.6	D1	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
BE-18	Viudez-Pareja, C; Kreft, E; Garcia-Caballero, M	Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment	FRONTIERS IN IMMUNOLOGY	7.3	Q1	Review	2023
BE-19	Aguado-Linares, P; Sendra-Portero, F	Gamification: basic concepts and applications in radiology	RADIOLOGIA	1.3		Article	2023
BE-19	Portero, FS; Pinos, DD; Bayarri, MS	The current situation of Radiology training in medical studies in Spain	RADIOLOGIA	1.3		Article	2023
BE-19	Baena, AVP; Portero, FS	The objective structured clinical examination (OSCE): main aspects and the role of imaging	RADIOLOGIA	1.3		Article	2023
BE-19	Gonzalez-Vidal, A; Mercado-Saenz, S; Burgos-Molina, AM; Alamilla-Presuel, JC; Alcaraz, M; Sendra-Portero, F; Ruiz-Gomez, MJ	Molecular Mechanisms of Resistance to Ionizing Radiation in S. cerevisiae and Its Relationship with Aging, Oxidative Stress, and Antioxidant Activity	ANTIOXIDANTS	7	D1	Article	2023
BE-19	López-Díaz, B; Mercado-Sáenz, S; Burgos-Molina, AM; González-Vidal, A; Sendra-Portero, F; Ruiz-Gómez, MJ	Genomic DNA damage induced by co- exposure to DNA damaging agents and pulsed magnetic field	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY	2.6	Q1	Article	2023
BE-19	Francisco Sendra-Portero, Miguel Souto, Minerva Becker, Vicky Goh	Undergraduate radiology education in Europe in 2022: a survey from the European Society of Radiology (ESR)	INSIGHTS INTO IMAGING	4.7	Q1	Article	2023
BE-19	López-Villodres, JA; Escamilla, A; Mercado-Sáenz, S; Alba-Tercedor, C; Rodriguez-Perez, LM; Arranz-Salas, I; Sanchez-Varo, R; Bermúdez, D	Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice	BIOMEDICINES	4.7	Q1	Review	2023
BE-19	Bravo, MJ; Burgos-Molina, AM; García-Aranda, M; Redondo, M; Téllez, T	Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy	CANCERS	5.2	Q2	Review	2023
BE-19	Mercado-Sáenz, S; González-Vidal, A; Burgos-Molina, AM; López-Díaz, B; Sendra-Portero, F; Ruiz-Gómez, MJ	Pulsed magnetic field increases the effect of ultraviolet C radiation and thermal shock in aged yeasts	INTERNATIONAL MICROBIOLOGY	3.1	Q3	Article	2023
BE-19	Adarve Castro A, D. Domínguez Pinosa, V. Soria Utrillac, J.A. O'Farrell del Campob, F. Sendra Portero y M.J. Ruiz-Gómez	Update in imaging tests used for the localization of parathyroid pathology	RADIOLOGÍA	1.3	Q4	Review	2023
C-01	de la Maza, SS; Gómez-Ballesteros, R; Borges, M; Martín-Martínez, J; Sotoca, J; Alonso, A; Caminero, AB; Borrega, L; Sánchez-Menoyo, JL; Barrero-Hernández, FJ; Calles, C; Brieva, L; Blasco-Quílez, MR; García-Soto, JD; del Campo-Amigo, M; Navarro-Cantó, L; Agüera, E; Garcés-Redondo, M; Carmona, O; Gabaldón-Torres, L; Forero, L; Hervàs, M; Medrano, N; Maurino, J; Castillo-Triviño, T	Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach	MULTIPLE SCLEROSIS JOURNAL- EXPERIMENTAL TRANSLATIONAL AND CLINICAL	2.8		Article	2023
C-01	Mena-Vazquez, Natalia; Redondo-Rodriguez, Rocio; Cabezudo-Garcia, Pablo; Garcia-Studer, Aimara; Ortiz-Marquez, Fernando; Borregon-Garrido, Paula; Martin-Valverde, Manuel; Urena-Garnica, Inmaculada; Manrique-Arija, Sara; Cano-Garcia, Laura; Fernandez-Nebro, Antonio	Interstitial Lung Disease Is Associated with Sleep Disorders in Rheumatoid Arthritis Patients.	CLOCKS & SLEEP	3.1		Article	2023
C-01	Villagrán-García, M; Farina, A; Muñiz-Castrillo, S; Wucher, V; Dhairi, M; Timestit, N; Ciano-Petersen, NL; Vogrig, A; Picard, G; Benaiteau, M; Psimaras, D; Petrova, AV; Alberto, T; Aupy, J; Giry, M; Rogemond, V; Desestret, V; Joubert, B; Honnorat, J	Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis	BRAIN COMMUNICATIONS	4.8		Article	2023
C-01	Serrano-Castro, Pedro J; Rodriguez-Uranga, Juan J; Cabezudo-Garcia, Pablo; Garcia-Martin, Guillermina; Romero-Godoy, Jorge; Estivill-Torrus, Guillermo; Ciano-Petersen, Nicolas Lundahl; Oliver, Begona; Ortega-Pinazo, Jesus; Lopez-Moreno, Yolanda; Aguilar-Castillo, Maria J; Gutierrez-Cardo, Antonio L; Ramirez-Garcia, Teresa; Sanchez-Godoy, Lorenzo; Carreno, Mar	Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune- Associated Epilepsy With Anti-Gad65 Antibodies.	Neurology(R) neuroimmunology & neuroinflammation	8.8	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-01	Ciano-Petersen, Nicolas Lundahl; Robert, Melisse; Muniz-Castrillo, Sergio; Wucher, Valentin; Klich, Amna; Vogrig, Alberto; Villagran Garcia, Macarena; Farina, Antonio; Goncalves, David; Picard, Geraldine; Rogemond, Veronique; Joubert, Bastien; Oliver-Martos, Begona; Serrano-Castro, Pedro J; Maucort-Boulch, Delphine; Honnorat, Jerome	Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis.	Neurology(R) neuroimmunology & neuroinflammation	8.8	D1	Article	2023
C-01	Ruiz-Viroga, V; de Ceglia, M; Morelli, L; Castano, EM; Calvo, EB; Suarez, J; de Fonseca, FR; Galeano, P; Lagos, P	Acute intrahippocampal administration of melanin-concentrating hormone impairs memory consolidation and decreases the expression of MCHR-1 and TrkB receptors	PROGRESS IN NEU- RO-PSYCHOPHARMA- COLOGY & BIOLOGICAL PSYCHIATRY	5.6	Q1	Article	2023
C-01	Barroso, P; Acevedo, P; Risalde, MA; García-Bocanegra, I; Montoro, V; Martínez-Padilla, AB; Torres, MJ; Soriguer, RC; Vicente, J	Co-exposure to pathogens in wild ungulates from Donana National Park, South Spain	RESEARCH IN VETERINARY SCIENCE	2.4	Q1	Article	2023
C-01	Mena-Vazquez, N; Godoy-Navarrete, FJ; Lisbona-Montanez, JM; Redondo-Rodriguez, R; Manrique-Arija, S; Rioja, J; Mucientes, A; Ruiz-Limon, P; Garcia-Studer, A; Ortiz-Marquez, F; Oliver-Martos, B; Cano-Garcia, L; Fernandez-Nebro, A	Inflammatory Biomarkers in the Diagnosis and Prognosis of Rheumatoid Arthritis- Associated Interstitial Lung Disease	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-01	Ciano-Petersen, NL; Aliaga-Gaspar, P; Hurtado-Guerrero, I; Reyes, V; Rodriguez-Bada, JL; Rodriguez-Traver, E; Brichette-Mieg, I; Fernandez, LL; Serrano-Castro, P; Alonso, A; Oliver-Martos, B	Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations	FRONTIERS IN IMMUNOLOGY	7.3	Q1	Article	2023
C-01	Villagran-Garcia, M; Muniz-Castrillo, S; Ciano-Petersen, NL; Vogrig, A; Farina, A; Villard, M; Psimaras, D; Alentorn, A; Goncalves, D; Fabien, N; Rogemond, V; Joubert, B; Honnorat, J	Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review	JOURNAL OF NEUROLOGY	6	Q1	Article	2023
C-01	Requena-Ocana, N; Araos, P; Serrano-Castro, PJ; Flores-Lopez, M; Garcia-Marchena, N; Oliver-Martos, B; Ruiz, JJ; Gavito, A; Pavon, FJ; Serrano, A; Mayoral, F; Suarez, J; de Fonseca, FR	Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-01	Pacheco-Sanchez, B; Tovar, R; Rabaa, MB; Sanchez-Salido, L; Vargas, A; Suarez, J; de Fonseca, FR; Rivera, P	Sex-Dependent Altered Expression of Cannabinoid Signaling in Hippocampal Astrocytes of the Triple Transgenic Mouse Model of Alzheimer's Disease: Implications for Controlling Astroglial Activity	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-01	Manas-Padilla, MC; Melgar-Locatelli, S; Vicente, L; Gil-Rodriguez, S; Rivera, P; Rodriguez-Perez, C; Castilla-Ortega, E	Temozolomide treatment inhibits spontaneous motivation for exploring a complex object in mice: A potential role of adult hippocampal neurogenesis in curiosity	JOURNAL OF COMPARATIVE NEUROLOGY	2.5	Q1	Article	2023
C-01	Meca-Lallana, JE; González, JMP; Rodríguez, ABC; Urtaza, JO; Alonso, AM; Ferreras, ED; Espinosa, R; Dotor, J; Romera, M; Luque, AA; Ruiz, DP; Calles, C; Hernández, MA; García, MH; Rodríguez, AM; Montero, YB; Téllez, N; Varó, NH; Sotoca, J; Presas-Rodríguez, S; Gutierrez, LAQ; Pujol, MH; Nadal, J; Ozaeta, GM; Lillo, LG; Yélamos, SM; Ramió-Torrentà, L; Frechin, JM; Benavides, AB; Gascón-Giménez, F; Casanova, B; Pascual, LL; Berenguer, L; Navarro, L; Gutierrez, MG; Durán, C; Regal, AR; Alvarez, E; García-Estévez, DA; Real, AML; González, MAL; Sola, MEM; Sánchez-Menoyo, JL; Oterino, A; González, RV; Castillo-Triviño, T; de Arcaya, A; Llarena, C	Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study	NEUROLOGY AND THERAPY	3.7	Q2	Article	2023
C-01	Larrazabal, LC; Botella, GI; Sanjuán, AR; López, BR; Moroño, SI; Sánchez, MAA	Neuroendoscopic transventricular transchoroidal approach for access to the posterior zone of the third ventricle or pineal region	NEUROSURGICAL REVIEW	2.8	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-01	Fuenmayora, SB; Castrob, PJS; Subiranac, PQ; Palmerod, SL; Mullore, MR; Carreño, TP	Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain	NEUROLOGIA	3.9	Q2	Article	2023
C-01	Infantes-Lopez, MI; Nieto-Quero, A; Chaves-Pena, P; Zambrana-Infantes, E; Cifuentes, M; Marquez, J; Pedraza, C; Perez-Martin, M	New insights into hypothalamic neurogenesis disruption after acute and intense stress: implications for microglia and inflammation	FRONTIERS IN NEUROSCIENCE	4.3	Q2	Article	2023
C-01	Avila-Gamiz, F; Perez-Cano, AM; Perez-Berlanga, JM; Mullor-Vigo, RM; Zambrana-Infantes, EN; Santin, LJ; de Guevara-Miranda, DL	Sequential treadmill exercise and cognitive training synergistically increase adult hippocampal neurogenesis in mice	PHYSIOLOGY & BEHAVIOR	2.9	Q2	Article	2023
C-01	Moreno-Fernández, RD; Sampedro-Piquero, P; Gómez-Salas, FJ; Nieto-Quero, A; Estivill-Torrús, G; de Fonseca, FR; Santín, LJ; Pedraza, C	Social avoidance and altered hypothalamic- pituitary-adrenal axis in a mouse model of anxious depression: The role of LPA1 receptor	BEHAVIOURAL BRAIN RESEARCH	2.7	Q2	Article	2023
C-01	Nieto-Quero, A; Infantes-López, MI; Zambrana-Infantes, E; Chaves-Peña, P; Gavito, AL; Munoz-Martin, J; Tabbai, S; Márquez, J; de Fonseca, FR; García-Fernández, MI; Santín, LJ; Pedraza, C; Pérez-Martin, M	Unveiling the Secrets of the Stressed Hippocampus: Exploring Proteomic Changes and Neurobiology of Posttraumatic Stress Disorder	CELLS	6	Q2	Article	2023
C-01	Melgar-Locatelli, S; de Ceglia, M; Mañas-Padilla, MC; Rodriguez-Pérez, C; Castilla-Ortega, E; Castro-Zavala, A; Rivera, P	Nutrition and adult neurogenesis in the hippocampus: Does what you eat help you remember?	FRONTIERS IN NEUROSCIENCE	4.3	Q2	Review	2023
C-01	Ortega-Pinazo, J; Pacheco-Rodríguez, MJ; Serrano-Castro, PJ; Martínez, B; Pinto-Medel, MJ; Gómez-Zumaquero, JM; Lago-Sampedro, A; Garcia-Díaz, B; Estivill-Torrús, G; Gallego, PEF	Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices	MOLECULAR BIOLOGY REPORTS	2.8	Q3	Article	2023
C-01	Manas-Padilla, MC; Tezanos, P; Cintado, E; Vicente, L; Sanchez-Salido, L; Gil-Rodriguez, S; Trejo, JL; Santin, LJ; Castilla-Ortega, E	Environmental enrichment alleviates cognitive and psychomotor alterations and increases adult hippocampal neurogenesis in cocaine withdrawn mice	ADDICTION BIOLOGY	3.4	Q3	Article	2023
C-01	Sainz de la Maza, Susana; Maurino, Jorge; Castillo-Trivino, Tamara; Borges, Monica; Sebastian Torres, Berta; Sotoca, Javier; Alonso Torres, Ana Maria; Caminero, Ana B; Borrega, Laura; Sanchez-Menoyo, Jose L; Barrero-Hernandez, Francisco J; Calles, Carmen; Brieva, Luis; Blasco, Maria Rosario; Dotor Garcia-Soto, Julio; Rodriguez-Regal, Ana; Navarro-Canto, Laura; Aguera-Morales, Eduardo; Garces, Moises; Carmona, Olga; Gabaldon-Torres, Laura; Forero, Lucia; Hervas, Mariona; Gomez-Ballesteros, Rocio	Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.	Patient preference and adherence	2.2	Q3	Article	2023
C-01	Diaz, T; Ortega-Pinazo, J; Martinez, B; Jimenez, A; Gomez-Zumaquero, JM; Caracuel, Z; Hortas, ML; Ferro, P	Measurement of yield and quality of DNA in human buffy coat is extraction method dependent	PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY	2.9	Q3	Article	2023
C-01	Armas-Melián, K; Ros, B; Gómez-Barreno, L; Iglesias, S; Arráez, MA	Neuroendoscopic septostomy in unilateral and bilateral ventricular hydrocephalus	CHILDS NERVOUS SYSTEM	1.4	Q3	Article	2023
C-01	Villanueva, V; Santos-Carrasco, D; Cabezudo-Garcia, P; Gomez-Ibanez, A; Garces, M; Serrano-Castro, P; Castro-Vilanova, MD; Sayas, D; Lopez-Gonzalez, FJ; Rodriguez-Osorio, X; Torres-Gaona, G; Saiz-Diaz, RA; Hampel, KG; Martinez-Ferri, M; Aguilar-Amat, MJ; Mercedes-Alvarez, B; Garcia-Morales, V; del Villar-Igea, A; Massot-Tarrus, A; Rodriguez-Uranga, JJ	Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program	EPILEPSIA OPEN	3	Q3	Article	2023
C-01	Fernandez, O; Montalban, X; Aguera, E; Aladro, Y; Alonso, A; Arroyo, R; Brieva, L; Calles, C; Costa-Frossard, L; Eichau, S; Garcia-Dominguez, JM; Hernandez, MA; Landete, L; Llufriu, MLS; Meca-Lallana, JE; Meca-Lallana, V; Mongay-Ochoa, N; Moral, E; Oreja-Guevara, C; Ramio-Torrenta, L; Tellez, N; Romero-Pinel, L; Rodriguez-Antiguedad, A	15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)	REVISTA DE NEUROLOGIA	1.2	Q4	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-01	Francisco, Diana Vidal-de; Rosa-Garrido, Carmen; Arcos, Maria Ruiz-de; Romero-Villarrubia, Ana; Romera-Tellado, Mercedes; Alonso-Torres, Ana M.; Delgado-Gil, Virginia; Aguera-Morales, Eduardo; Diaz-Sanchez, Maria; Pinar-Morales, Raquel; Munoz-Fernandez, Carmen; Pacheco-Cortegana, Eva M.; Duran-Ferreras, Eduardo; Arnal-Garcia, M. Carmen; Mendibe-Bilbao, M. Mar; Rodriguez-Antiguedad, Alfredo	Family planning in men and women with multiple sclerosis. Analysis of the Andalusian Registry (2018-2022)	REVISTA DE NEUROLOGIA	1.2	Q4	Article	2023
C-01	Fernandez, O; Montalban, X; Aguera, E; Aladro, Y; Alonso, A; Arroyo, R; Brieva, L; Calles, C; Costa-Frossard, L; Eichau, S; Garcia-Dominguez, JM; Hernandez, MA; Landete, L; Llaneza, M; Llufriu, S; Meca-Lallana, JE; Meca-Lallana, V; Mongay-Ochoa, N; Moral, E; Oreja-Guevara, C; Torrenta, LRI; Tellez, N; Romero-Pinel, L; Rodriguez-Antiguedad, A	15(th) Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)	REVISTA DE NEUROLOGIA	1.2	Q4	Review	2023
C-01	Selfa, A; Arráez, C; Ros, A; Linares, J; Cerro, L; Arráez, MA	Ectopic recurrence of craniopharyngioma in the posterior fossa: Case report and review of the literature	NEUROCIRUGIA	0.8	Q4	Review	2023
C-02	Martínez, YB; de Velasco, CLM; Guillén, IF; Revuelta, MR; Echeverría, AC; Cobos, FM	Functional improvement in frail older adults through the Vivifrail exercise program, during two years of pandemic	MEDICINA DE FAMILIA- SEMERGEN	1.1		Article	2023
C-02	Gomez-Gomez, I; Benitez, I; Bellon, J; Moreno-Peral, P; Olivan-Blazquez, B; Claveria, A; Zabaleta-del-Olmo, E; Llobera, J; Serrano-Ripoll, MJ; Tamayo-Morales, O; Motrico, E	Utility of PHQ-2, PHQ-8 and PHQ-9 for detecting major depression in primary health care: a validation study in Spain	PSYCHOLOGICAL MEDICINE	6.9	D1	Article	2023
C-02	Gomez-Gomez, I; Motrico, E; Moreno-Peral, P; Casajuana-Closas, M; Lopez-Jimenez, T; Zabaleta-del-Olmo, E; Claveria, A; LLobera, J; Marti-Lluch, R; Ramos, R; Maderuelo-Fernandez, JA; Vicens, C; Dominguez-Garcia, M; Bartolome-Moreno, C; Recio-Rodriguez, JI; Bellon, JA	A multiple health behaviour change intervention to prevent depression: A randomized controlled trial	GENERAL HOSPITAL PSYCHIATRY	7	Q1	Article	2023
C-02	Moreno-Peral P., Rodríguez-Morejón A., Bellón J.A., García-Huércano C., Martínez-Vispo C., Campos-Paino H., Galán S., Reyes-Martín S., Sánchez Aguadero N., Rangel-Henriques M., Motrico E., Conejo-Cerón S.	Effectiveness of a universal personalized intervention for the prevention of anxiety disorders: Protocol of a randomized controlled trial (the prevANS project)	INTERNET INTERVENTIONS- THE APPLICATION OF INFORMATION TECHNOLOGY IN MENTAL AND BEHAVIOURAL HEALTH	4.3	Q1	Article	2023
C-02	Ruiz-Garcia, I; Ortiz-Flores, R; Badia, R; Garcia-Borrego, A; Garcia-Fernandez, M; Lara, E; Martin-Montanez, E; Garcia-Serrano, S; Valdes, S; Gonzalo, M; Tapia-Guerrero, SMJ; Fernandez-Garcia, JC; Sanchez-Garcia, A; Munoz-Cobos, F; Calderon-Cid, M; El-Bekay, R; Covas, MI; Rojo-Martinez, G; Olveira, G; Romero-Zerbo, SY; Bermudez-Silva, FJ	Rich oleocanthal and oleacein extra virgin olive oil and inflammatory and antioxidant status in people with obesity and prediabetes. The APRIL study: A randomised, controlled crossover study	CLINICAL NUTRITION	6.3	Q1	Article	2023
C-02	Motrico, E; Bina, R; Kassianos, AP; Le, HN; Mateus, V; Oztekin, D; Rodriguez-Munoz, MF; Moreno-Peral, P; Conejo-Ceron, S	Effectiveness of interventions to prevent perinatal depression: An umbrella review of systematic reviews and meta-analysis	GENERAL HOSPITAL PSYCHIATRY	7	Q1	Review	2023
C-02	Campos-Paino, H; Moreno-Peral, P; Gomez-Gomez, I; Conejo-Ceron, S; Galan, S; Reyes-Martin, S; Bellon, JA	Effectiveness of social support-based interventions in preventing depression in people without clinical depression: A systematic review and meta-analysis of randomized controlled trials	INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY	7.5	Q1	Review	2023
C-02	Bellon, JA; Rodriguez-Morejon, A; Conejo-Ceron, S; Campos-Paino, H; Rodriguez-Bayon, A; Ballesta-Rodriguez, MI; Rodriguez-Sanchez, E; Mendive, JM; del Hoyo, YL; Luna, JD; Tamayo-Morales, O; Moreno-Peral, P	A personalized intervention to prevent depression in primary care based on risk predictive algorithms and decision support systems: protocol of the e-predictD study	FRONTIERS IN PSYCHIATRY	4.7	Q2	Article	2023
C-02	Nieto-Quero, A; Infantes-López, MI; Zambrana-Infantes, E; Chaves-Peña, P; Gavito, AL; Munoz-Martin, J; Tabbai, S; Márquez, J; de Fonseca, FR; García-Fernández, MI; Santín, LJ; Pedraza, C; Pérez-Martin, M	Unveiling the Secrets of the Stressed Hippocampus: Exploring Proteomic Changes and Neurobiology of Posttraumatic Stress Disorder	CELLS	6	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-02	Ribas, BB; Llobera-Canaves, J; Garcia-Ortiz, L; Bellon, JA; Ramos, R; Garcia-Campayo, J; Sanchez-Perez, A; Claveria, A; Martinez, V; Vicens, E; Minue, C; Gil-Guillen, V; Berenguera, A; Moleras-Serra, A	The Research Network on Preventive Activities and Health Promotion (redIAPP): a reference network and promoter of primary care research	ATENCION PRIMARIA	2.5	Q3	Article	2023
C-03	Ramos-Martin, J; Contreras-Penalver, MA; Moreno-Kustner, B	Classification of suicidal behavior calls in emergency medical services: a systematic review	INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE	3.2		Review	2023
C-03	Goodman-Casanova, JM; Guzman-Parra, J; Duran-Jimenez, FJ; Garcia-Gallardo, M; Cuesta-Lozano, D; Mayoral-Cleries, F	Effectiveness of museum-based participatory arts in mental health recovery	INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING	5.6	D1	Article	2023
C-03	Docherty, Anna R; Mullins, Niamh; Ashley-Koch, Allison E; Qin, Xuejun; Coleman, Jonathan R I; Shabalin, Andrey; Kang, JooEur; Murnyak, Balasz; Wendt, Frank; Adams, Mark; Campos, Adrian I; DiBlasi, Emily; Fullerton, Janice M; Krazler, Henry R; Bakian, Amanda V; Monson, Eric T; Renteria, Miguel E; Walss-Bass, Consuelo; Andreassen, Ole A; Behera, Chittaranjan; Bulik, Cynthia M; Edenberg, Howard J; Kessler, Ronald C; Mann, JJohn; Nurnberger, John I J; Pistis, Giorgio; Streit, Fabian, Ursano, Robert J; Polimanti, Renato; Dennis, Michelle; Garertt, Melanie; Hair, Lauren; Harvey, Philip; Hauser, Elizabeth R; Hauser, Michael A; Huffman, Jennifer, Jacobson, Daniel; Madduri, Ravi; McMahon, Benjamin; Oslin, David W; Trafton, Jodie, Awasthi, Swapnil; Berrettini, Wade H; Bohus, Martin; Chang, Xiao; Chen, Hsi-Chung; Chen, Wei J; Christensen, Erik D; Crow, Scott; Duriez, Philibert; Edwards, Alexis C; Fernandez-Aranda, Fernando, Galfafuy, Hanga, Gandal, Michael; Gorwood, Philip; Guo, Viran; Hafferty, Jonathan D; Hakonarson, Hakon; Halmi, Katherine A; Hishimoto, Akitoyo; Jain, Sonia; Jamain, Stephane; Jimenez-Murcia, Susana; Johnson, Craig; Kaplan, Allan S; Kaye, Walter H; Keel, Pamela K; Kennedy, James L; Kim, Minsoo; Klump, Kelly L; Levey, Daniel F; Li, Dong; Liao, Shih-Cheng; Lieb, Klaus; Lilenfeld, Lias; Marshall, Christian R; Mitchell, James E; Okazaki, Satoshi, Otsuka, Ikuo, Pinto, Dallia; Powers, A Bigail; Ramoz, Nicolas; Ripke, Stephan; Roepke, Stefan; Rozanov, Vsevolod; Scherer, Stephen W; Schmahl, Christian; Sokolowski, Marcus; Starnawska, Anna; Strober, Michael; Su, Mei-Hsin; Thornton, Laura M; Treasure, Janet; Ware, Erin B; Watson, Hunna J; Witt, Stephanie H; Woodside, D Blake; Yilmaz, Zeynep; Zillich, Lez, Adolfsson, Rolf; Agartz, Ingrid; Alda, Martin; Alfredsson, Lars; Appadural, Vivek; Artigas, Maria Soler; Van der Auwera, Sandra; Azevedo, M Helena; Bass, Nicholas; Bau, Claiton H D; Baune, Bernhard T; Bellivier, Frank; Berger, Klaus; Biernacka, Joanna M; Bigdeli, Tim B; Binder, Elisabeth B; Gebonhe, Michael; Bok,	GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors.	The American journal of psychiatry	17.7	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-03	Courtet, Philippe; Amiot, Odile; Baca-Garcia, Enrique; Bellardita, Lara; Cerveri, Giancarlo; Clair, Anne-Helene; De Leo, Diego; Drapier, Dominique; Fakra, Eric; Gheysen, Francis; Giner, Lucas; Gonzalez-Pinto, Ana; Gussoni, Gualberto; Haffen, Emmanuel; Lecardeur, Laurent; Mayoral-Cleries, Fermin; Mennini, Francesco Saverio; Saiz, Pilar A; Vieta, Eduard; Hidalgo, Diego Alberto; Volpe, Umberto	Understanding the potential of digital therapies in implementing the standard of care for depression in Europe.	EUROPEAN PSYCHIATRY	7.8	D1	Article	2023
C-03	Gentile, AM; Lhamyani, S; Mesa, MM; Pavón-Morón, FJ; Pearson, JR; Salas, J; Clemente-Postigo, M; Costillas, LP; Fuster, GO; Rizky, RE	A Network Comprised of miR-15b and miR- 29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-03	Herrera-Imbroda, Jesus; Flores-Lopez, Maria; Requena-Ocana, Nerea; Araos, Pedro; Garcia-Marchena, Nuria; Ropero, Jessica; Bordallo, Antonio; Suarez, Juan; Pavon-Moron, Francisco J; Serrano, Antonia; Mayoral, Fermin; Rodriguez de Fonseca, Fernando	Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients.	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-03	Herrera-Imbroda, J; Flores-Lopez, M; Requena-Ocana, N; Araos, P; Ropero, J; Garcia-Marchena, N; Bordallo, A; Suarez, J; Pavon-Moron, FJ; Serrano, A; Mayoral, F; de Fonseca, FR	Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-03	Requena-Ocana, N; Araos, P; Serrano-Castro, PJ; Flores-Lopez, M; Garcia-Marchena, N; Oliver-Martos, B; Ruiz, JJ; Gavito, A; Pavon, FJ; Serrano, A; Mayoral, F; Suarez, J; de Fonseca, FR	Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-03	Goodman-Casanova, JM; Cuesta-Lozano, D; Alupoaei, C; Bello, EMG; Herrera-Imbroda, J; Mayoral-Cleries, F; Guzman-Parra, J	Psychometric validation of the 15-item Questionnaire about the Process of Recovery in Spain (QPR-15-SP)	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article	2023
C-03	Herrera-Imbroda, J; Guzman-Parra, J; Bordallo-Aragon, A; Moreno-Kustner, B; Mayoral-Cleries, F	Risk of psychiatric readmission in the homeless population: A 10-year follow-up study	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article	2023
C-03	Guzman-Parra, J; Sanchez-Alvarez, N; Guzik, J; Bergero-Miguel, T; de Diego-Otero, Y; Perez-Costillas, L	The Impact of Stressful Life Events on Suicidal Ideation in Gender Dysphoria: A Moderator Effect of Perceived Social Support	ARCHIVES OF SEXUAL BEHAVIOR	3.8	Q1	Article	2023
C-03	Barceló-Soler, A; García-Campayo, J; Araya, R; Doukani, A; Gili, M; García-Palacios, A; Mayoral, F; Montero-Marin, J	Working alliance in low-intensity internet- based cognitive behavioral therapy for depression in primary care in Spain: A qualitative study	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article	2023
C-03	Herrera-Imbroda, J; Flores-Lopez, M; Ruiz-Sastre, P; Gomez-Sanchez-Lafuente, C; Bordallo-Aragon, A; de Fonseca, FR; Mayoral-Cleries, F	The Inflammatory Signals Associated with Psychosis: Impact of Comorbid Drug Abuse	BIOMEDICINES	4.7	Q1	Review	2023
C-03	Aguilera-Serrano, C; Goodman-Casanova, JM; Bordallo-Aragon, A; Garcia-Sanchez, JA; Mayoral-Cleries, F; Guzman-Parra, J	Attitudes about Mechanical Restraint Use in Mental Health Hospitalization Services: A Spanish Survey	HEALTHCARE	2.8	Q2	Article	2023
C-03	Cuesta-Vargas, Al; Biro, A; Escriche-Escuder, A; Trinidad-Fernandez, M; Garcia-Conejo, C; Jimenez, CRR; Tang, W; Salvatore, A; Nikolova, B; Muro-Culebras, A; Martin-Martin, J; Gonzalez-Sanchez, M; Ruiz-Munoz, M; Mayoral, F	Effectiveness of a gamified digital intervention based on lifestyle modification (iGAME) in secondary prevention: a protocol for a randomised controlled trial	BMJ OPEN	2.9	Q2	Article	2023
C-03	Figueredo, MCS; Morilla-Herrera, JC; Uttumchandani, SK; Pérez, ED; Giraldos, MS; del Val, MAN; Martín, MJH; Borrego, ABG; Irazusta, MG; González, MG; Morales-Asencio, JM	Longitudinal assessment of the eating pattern of people with dementia and its association with problems for feeding and malnutrition: a prospective follow-up study protocol	BMJ OPEN	2.9	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-03	Ramos-Martin, J; Perez-Berlanga, JM; Oliver, J; Moreno-Kustner, B	Non-lethal suicidal behavior in university students of Spain during COVID-19	FRONTIERS IN PSYCHIATRY	4.7	Q2	Article	2023
C-03	Sastre-Buades, A; Caro-Canizares, I; Ochoa, S; Lorente-Rovira, E; Barajas, A; Gutierrez-Zotes, A; Sánchez-Alonso, S; López-Carrilero, R; Grasa, E; Pousa, E; Pélaez, T; Cid, J; González-Higueras, F; Ruiz-Delgado, I; Baca-Garcia, E; Barrigon, ML	Relationship between cognition and suicidal behavior in recent-onset psychosis	SCHIZOPHRENIA RESEARCH	4.5	Q2	Article	2023
C-03	Ramos-Martin, J; Sanchez-Lafuente, CG; Martinez-Garcia, AI; Castillo-Jimenez, P; Guzman-Parra, J; Moreno-Kustner, B	Suicidal behavior in persons attended in out- of-hospital emergency services in Spain	FRONTIERS IN PSYCHIATRY	4.7	Q2	Article	2023
C-03	Garcia-Vazquez, Blanca; Martinez-Ales, Gonzalo; Fernandez-Jimenez, Eduardo; Andreo-Jover, Jorge; Moreno-Kustner, Berta; Minue, Sergio; Jaramillo, Fabiola; Moran-Sanchez, Ines; Martinez-Morata, Irene; Ayuso-Mateos, Jose Luis; Bayon, Carmen; Bravo-Ortiz, Maria-Fe; Mediavilla, Roberto	Use of psychological interventions among healthcare workers over the 2-year period following the COVID-19 pandemic: A longitudinal study.	PLOS ONE	3.7	Q2	Article	2023
C-03	Ladrón-Arana, S; Orzanco-Garralda, R; Escalada-Hernández, P; Aguilera-Serrano, C; Gutiérrez-Valencia, M; Urbiola-Castillo, J	Efficacy of educational interventions in adolescent population with feeding and eating disorders: a systematic review	EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY	2.9	Q3	Review	2023
C-03	Nogueras, EV; Cantero, N; Macias, M; Morales-Asencio, JM; Perez-Bryan, JMGH; Hurtado, MM	A multifaceted provider-centred intervention versus usual care to improve the recognition and diagnosis of depression in primary health care: a hybrid study	PRIMARY HEALTH CARE RESEARCH AND DEVELOPMENT	1.6	Q4	Article	2023
C-05	de Vera, MTD; Cuadra, JDP; Pinos, DD; Martín, IH	Pleural empyema secondary to perforated diverticulosis due to biliary neoplasia infiltration	BMJ CASE REPORTS	0.9		Article	2023
C-05	Portero, FS; Pinos, DD; Bayarri, MS	The current situation of Radiology training in medical studies in Spain	RADIOLOGIA	1.3		Article	2023
C-05	Garcia-Bonilla, M; Ojeda-Perez, B; Shumilov, K; Rodriguez-Perez, LM; Dominguez-Pinos, D; Vitorica, J; Jimenez, S; Ramirez-Lorca, R; Echevarria, M; Cardenas-Garcia, C; Iglesias, T; Gutierrez, A; McAllister, JP; Limbrick, DD; Paez-Gonzalez, P; Jimenez, AJ	Generation of Periventricular Reactive Astrocytes Overexpressing Aquaporin 4 Is Stimulated by Mesenchymal Stem Cell Therapy	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-05	López-Villodres, JA; Escamilla, A; Mercado-Sáenz, S; Alba-Tercedor, C; Rodriguez-Perez, LM; Arranz-Salas, I; Sanchez-Varo, R; Bermúdez, D	Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice	BIOMEDICINES	4.7	Q1	Review	2023
C-05	Paez-Gonzalez, P; Lopez-de-San-Sebastian, J; Ceron-Funez, R; Jimenez, AJ; Rodriguez-Perez, LM	Therapeutic strategies to recover ependymal barrier after inflammatory damage: relevance for recovering neurogenesis during development	FRONTIERS IN NEUROSCIENCE	4.3	Q2	Review	2023
C-05	Armas-Melián, K; Ros, B; Gómez-Barreno, L; Iglesias, S; Arráez, MA	Neuroendoscopic septostomy in unilateral and bilateral ventricular hydrocephalus	CHILDS NERVOUS SYSTEM	1.4	Q3	Article	2023
C-06	Medina-Vera D., Enache D., Tambaro S., Abuhashish E., Rosell-Valle C., Winblad B., Rodríguez De Fonseca F., Bereczki E., Nilsson P.	Translational potential of synaptic alterations in Alzheimer's disease patients and amyloid precursor protein knock-in mice	BRAIN COMMUNICATIONS	4.8		Article	2023
C-06	Serrano-Castro, Pedro J; Rodriguez-Uranga, Juan J; Cabezudo-Garcia, Pablo; Garcia-Martin, Guillermina; Romero-Godoy, Jorge; Estivill-Torrus, Guillermo; Ciano-Petersen, Nicolas Lundahl; Oliver, Begona; Ortega-Pinazo, Jesus; Lopez-Moreno, Yolanda; Aguilar-Castillo, Maria J; Gutierrez-Cardo, Antonio L; Ramirez-Garcia, Teresa; Sanchez-Godoy, Lorenzo; Carreno, Mar	Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune- Associated Epilepsy With Anti-Gad65 Antibodies.	Neurology(R) neuroimmunology & neuroinflammation	8.8	D1	Article	2023
C-06	Razola-Diaz, MD; Aznar-Ramos, MJ; Verardo, V; Melgar-Locatelli, S; Castilla-Ortega, E; Rodriguez-Perez, C	Exploring the Nutritional Composition and Bioactive Compounds in Different Cocoa Powders	ANTIOXIDANTS	7	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-06	Gonzalez-Portilla, M; Mellado, S; Montagud-Romero, S; de Fonseca, FR; Pascual, M; Rodriguez-Arias, M	Oleoylethanolamide attenuates cocaine- primed reinstatement and alters dopaminergic gene expression in the striatum	BEHAVIORAL AND BRAIN FUNCTIONS	5.1	D1	Article	2023
C-06	Palma-Morales, M; Melgar-Locatelli, S; Castilla-Ortega, E; Rodriguez-Perez, C	How Healthy Is It to Fortify Cocoa- Based Products with Cocoa Flavanols? A Comprehensive Review	ANTIOXIDANTS	7	D1	Review	2023
C-06	Esteban-Martos, A; Brokate-Llanos, AM; Real, LM; Melgar-Locatelli, S; de Rojas, I; Castro-Zavala, A; Bravo, MJ; Manas-Padilla, MD; Garcia-Gonzalez, P; Ruiz-Galdon, M; Pacheco-Sanchez, B; Polvillo, R; de Fonseca, FR; Gonzalez, I; Castilla-Ortega, E; Munoz, MJ; Rivera, P; Reyes-Engel, A; Ruiz, A; Royo, JL	A Functional Pipeline of Genome-Wide Association Data Leads to Midostaurin as a Repurposed Drug for Alzheimer's Disease	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-06	Ruiz-Viroga, V; de Ceglia, M; Morelli, L; Castano, EM; Calvo, EB; Suarez, J; de Fonseca, FR; Galeano, P; Lagos, P	Acute intrahippocampal administration of melanin-concentrating hormone impairs memory consolidation and decreases the expression of MCHR-1 and TrkB receptors	PROGRESS IN NEU- RO-PSYCHOPHARMA- COLOGY & BIOLOGICAL PSYCHIATRY	5.6	Q1	Article	2023
C-06	Tovar, Ruben; de Ceglia, Marialuisa; Ubaldi, Massimo; Rodriguez-Pozo, Miguel; Soverchia, Laura; Cifani, Carlo; Rojo, Gema; Gavito, Ana; Hernandez-Folgado, Laura; Jagerovic, Nadine; Ciccocioppo, Roberto; Baixeras, Elena; Rodriguez de Fonseca, Fernando; Decara, Juan	Administration of Linoleoylethanolamide Reduced Weight Gain, Dyslipidemia, and Inflammation Associated with High-Fat-Diet- Induced Obesity.	NUTRIENTS	5.9	Q1	Article	2023
C-06	Herrera-Imbroda, Jesus; Flores-Lopez, Maria; Requena-Ocana, Nerea; Araos, Pedro; Garcia-Marchena, Nuria; Ropero, Jessica; Bordallo, Antonio; Suarez, Juan; Pavon-Moron, Francisco J; Serrano, Antonia; Mayoral, Fermin; Rodriguez de Fonseca, Fernando	Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients.	INTERNATIONAL JOUR- NAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-06	Herrera-Imbroda, J; Flores-Lopez, M; Requena-Ocana, N; Araos, P; Ropero, J; Garcia-Marchena, N; Bordallo, A; Suarez, J; Pavon-Moron, FJ; Serrano, A; Mayoral, F; de Fonseca, FR	Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder	INTERNATIONAL JOUR- NAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-06	de Ceglia, M; Di Bonaventura, MVM; Romano, A; Friuli, M; Di Bonaventura, EM; Gavito, AL; Botticelli, L; Gaetani, S; de Fonseca, FR; Cifani, C	Anxiety associated with palatable food withdrawal is reversed by the selective FAAH inhibitor PF-3845: A regional analysis of the contribution of endocannabinoid signaling machinery	INTERNATIONAL JOUR- NAL OF EATING DISOR- DERS	5.5	Q1	Article	2023
C-06	Kouhnavardi, S; Cabatic, M; Manas-Padilla, MC; Malabanan, MA; Smani, T; Cicvaric, A; Aranzalez, EAM; Koenig, X; Urban, E; Lubec, G; Castilla-Ortega, E; Monje, FJ	miRNA-132/212 Deficiency Disrupts Selective Corticosterone Modulation of Dorsal vs. Ventral Hippocampal Metaplasticity	INTERNATIONAL JOUR- NAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-06	Ciano-Petersen, NL; Aliaga-Gaspar, P; Hurtado-Guerrero, I; Reyes, V; Rodriguez-Bada, JL; Rodriguez- Traver, E; Brichette-Mieg, I; Fernández, LL; Serrano-Castro, P; Alonso, A; Oliver-Martos, B	Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations	FRONTIERS IN IMMU- NOLOGY	7.3	Q1	Article	2023
C-06	Gonzalez-Portilla, M; Moya, M; Montagud-Romero, S; de Fonseca, FR; Orio, L; Rodriguez-Arias, M	Oleoylethanolamide attenuates the stress-mediated potentiation of rewarding properties of cocaine associated with an increased TLR4 proinflammatory response	PROGRESS IN NEU- RO-PSYCHOPHARMA- COLOGY & BIOLOGICAL PSYCHIATRY	5.6	Q1	Article	2023
C-06	Rubio, L; Suarez, J; Martin-de-las-Heras, S; Zapico, SC	Partners in Postmortem Interval Estimation: X-ray Diffraction and Fourier Transform Spectroscopy	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-06	Flores-Lopez, M; Garcia-Marchena, N; Pavon-Moron, FJ; Requena-Ocana, N; Sanchez-Marin, L; Martin-Chaves, L; Garcia-Medina, M; Pedraza, C; Castilla-Ortega, E; Ruiz, JJ; de Fonseca, FR; Araos, P; Serrano, A	Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders	TRANSLATIONAL PSYCHIATRY	6.8	Q1	Article	2023
C-06	Requena-Ocana, N; Araos, P; Serrano-Castro, PJ; Flores-Lopez, M; Garcia-Marchena, N; Oliver-Martos, B; Ruiz, JJ; Gavito, A; Pavon, FJ; Serrano, A; Mayoral, F; Suarez, J; de Fonseca, FR	Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-06	Requena-Ocaña, N; Flores-López, M; García-Marchena, N; Pavón-Morón, FJ; Pedraza, C; Wallace, A; Castilla-Ortega, E; de Fonseca, FR; Serrano, A; Araos, P	Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-06	Goodman-Casanova, JM; Cuesta-Lozano, D; Alupoaei, C; Bello, EMG; Herrera-Imbroda, J; Mayoral-Cleries, F; Guzman-Parra, J	Psychometric validation of the 15-item Questionnaire about the Process of Recovery in Spain (QPR-15-SP)	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article	2023
C-06	Herrera-Imbroda, J; Guzman-Parra, J; Bordallo-Aragon, A; Moreno-Kustner, B; Mayoral-Cleries, F	Risk of psychiatric readmission in the homeless population: A 10-year follow-up study	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article	2023
C-06	Pacheco-Sanchez, B; Tovar, R; Rabaa, MB; Sanchez-Salido, L; Vargas, A; Suarez, J; de Fonseca, FR; Rivera, P	Sex-Dependent Altered Expression of Cannabinoid Signaling in Hippocampal Astrocytes of the Triple Transgenic Mouse Model of Alzheimer's Disease: Implications for Controlling Astroglial Activity	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-06	Manas-Padilla, MC; Melgar-Locatelli, S; Vicente, L; Gil-Rodriguez, S; Rivera, P; Rodriguez-Perez, C; Castilla-Ortega, E	Temozolomide treatment inhibits spontaneous motivation for exploring a complex object in mice: A potential role of adult hippocampal neurogenesis in curiosity	JOURNAL OF COMPARATIVE NEUROLOGY	2.5	Q1	Article	2023
C-06	Galeano P., de Ceglia M., Mastrogiovanni M., Campanelli L., Medina-Vera D., Campolo N., Novack G.V., Rosell-Valle C., Suárez J., Aicardo A., Campuzano K., Castaño E.M., Do Carmo S., Cuello A.C., Bartesaghi S., Radi R., Rodríguez de Fonseca F., Morelli L.	The Effect of Fat Intake with Increased Omega-6-to-Omega-3 Polyunsaturated Fatty Acid Ratio in Animal Models of Early and Late Alzheimer's Disease-like Pathogenesis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-06	Medina-Vera, D; Zambrana-Infantes, EN; López-Gambero, AJ; Verheul-Campos, J; Santín, LJ; Baixeras, E; Suarez, J; Pavon, FJ; Rosell-Valle, C; Fonseca, FRD	Transcending the amyloid-beta dominance paradigm in Alzheimer's disease: An exploration of behavioural, metabolic, and gut microbiota phenotypes in 5xFAD mice	NEUROBIOLOGY OF DISEASE	6.1	Q1	Article	2023
C-06	Herrera-Imbroda, J; Flores-Lopez, M; Ruiz-Sastre, P; Gomez-Sanchez-Lafuente, C; Bordallo-Aragon, A; de Fonseca, FR; Mayoral-Cleries, F	The Inflammatory Signals Associated with Psychosis: Impact of Comorbid Drug Abuse	BIOMEDICINES	4.7	Q1	Review	2023
C-06	Hernandez-Rubio, A; Sanvisens, A; Barbier-Torres, L; Blanes, R; Miquel, L; Torrens, M; Rubio, G; Bolao, F; Zuluaga, P; Fuster, D; de Fonseca, FR; Farre, M; Muga, R	Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorder	DRUG AND ALCOHOL DEPENDENCE	4.2	Q2	Article	2023
C-06	Moreno-Fernández, RD; Sampedro-Piquero, P; Gómez-Salas, FJ; Nieto-Quero, A; Estivill-Torrús, G; de Fonseca, FR; Santín, LJ; Pedraza, C	Social avoidance and altered hypothalamic- pituitary-adrenal axis in a mouse model of anxious depression: The role of LPA1 receptor	BEHAVIOURAL BRAIN RESEARCH	2.7	Q2	Article	2023
C-06	Ramos-Martín, J; Sánchez-Lafuente, CG; Martínez-García, AI; Castillo-Jiménez, P; Guzmán-Parra, J; Moreno-Küstner, B	Suicidal behavior in persons attended in out- of-hospital emergency services in Spain	FRONTIERS IN PSYCHIATRY	4.7	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-06	Medina-Vera, D; Zhao, HJ; Bereczki, E; Rosell-Valle, C; Shimozawa, M; Chen, GF; de Fonseca, FR; Nilsson, P; Tambaro, S	The Expression of the Endocannabinoid Receptors CB2 and GPR55 Is Highly Increased during the Progression of Alzheimer's Disease in App(NL-G-F) Knock-In Mice	BIOLOGY-BASEL	4.2	Q2	Article	2023
C-06	Nieto-Quero, A; Infantes-López, MI; Zambrana-Infantes, E; Chaves-Peña, P; Gavito, AL; Munoz-Martin, J; Tabbai, S; Márquez, J; de Fonseca, FR; García-Fernández, MI; Santín, LJ; Pedraza, C; Pérez-Martin, M	Unveiling the Secrets of the Stressed Hippocampus: Exploring Proteomic Changes and Neurobiology of Posttraumatic Stress Disorder	CELLS	6	Q2	Article	2023
C-06	Melgar-Locatelli, S; de Ceglia, M; Mañas-Padilla, MC; Rodriguez-Pérez, C; Castilla-Ortega, E; Castro-Zavala, A; Rivera, P	Nutrition and adult neurogenesis in the hippocampus: Does what you eat help you remember?	FRONTIERS IN NEUROSCIENCE	4.3	Q2	Review	2023
C-06	Calleja-Conde, J; Echeverry-Alzate, V; Bnhler, KM; Morales-García, JA; Segovia-Rodríguez, L; Durán-González, P; Olmos, P; de Fonseca, FR; Giné, E; López-Moreno, JA	Dissecting operant alcohol self- administration using saccharin-fading procedure	NEUROPSYCHOPHARMA- COLOGY REPORTS	2.5	Q3	Article	2023
C-06	Manas-Padilla, MC; Tezanos, P; Cintado, E; Vicente, L; Sanchez-Salido, L; Gil-Rodriguez, S; Trejo, JL; Santin, LJ; Castilla-Ortega, E	Environmental enrichment alleviates cognitive and psychomotor alterations and increases adult hippocampal neurogenesis in cocaine withdrawn mice	ADDICTION BIOLOGY	3.4	Q3	Article	2023
C-06	Fraguas, D; Gallego, DA; Arques-Egea, S; Gómez-Revuelta, M; Sánchez-Lafuente, CG; Huerta, DH; Arias, DN; Plasencia-García, BO; Torres, CP; Romero-Guillena, SL; Cucurul, ER; Alamo, C	Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice	INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE	3	Q3	Review	2023
C-06	Herrera-Imbroda, J	Changing the Paradigm in Treatment- Resistant Depression: A Review of Long-Term Efficacy and Tolerability of Esketamine Nasal Spray	EXPERIMENTAL AND CLINICAL PSYCHO- PHARMACOLOGY	2.3	Q3	Review	2023
C-07	Diaz-Sanchez, E; Lopez-Salas, A; Mirchandani-Duque, M; Alvarez-Contino, JE; Sanchez-Perez, JA; Fuxe, K; Borroto-Escuela, DO; Garcia-Casares, N; Narvaez, M	Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
C-07	García-Casares, N; González-González, G; de la Cruz-Cosme, C; Garzón-Maldonado, FJ; de Rojas-Leal, C; Ariza, MJ; Narváez, M; Barbancho, MA; García-Arnés, JA; Tinahones, FJ	Effects of GLP-1 receptor agonists on neurological complications of diabetes	REVIEWS IN ENDOCRINE & METABOLIC DISORDERS	8.2	D1	Article	2023
C-07	Jerez, PA; Alcantud, JL; de los Reyes-Ramirez, L; Moore, A; Ruz, C; Montero, FV; Rodriguez-Losada, N; Saini, P; Gan-Or, Z; Alvarado, CX; Makarious, MB; Billingsley, KJ; Blauwendraat, C; Noyce, AJ; Singleton, AB; Duran, R; Bandres-Ciga, S	Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinson's disease	NPJ PARKINSONS DISEASE	8.7	D1	Article	2023
C-07	Belloso-Iguerategui, Arantzazu; Zamarbide, Marta; Merino-Galan, Leyre; Rodriguez-Chinchilla, Tatiana; Gago, Belen; Santamaria, Enrique; Fernandez-Irigoyen, Joaquin; Cotman, Carl W; Prieto, G Aleph; Quiroga-Varela, Ana; Rodriguez-Oroz, Maria Cruz	Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.	Brain: a journal of neurology	14.5	D1	Article	2023
C-07	Garcia-Garcia, I; Fernandez-Andujar, M; Narvaez, M; Garcia-Casares, N	Assessing adipokines as potential biomarkers of dementia, Alzheimer's disease, and mild cognitive impairment: A systematic review and meta-analysis	OBESITY REVIEWS	8.9	D1	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-07	Ambrogini, P; Lattanzi, D; Pagliarini, M; Di Palma, M; Sartini, S; Cuppini, R; Fuxe, K; Borroto-Escuela, DO	5HT1AR-FGFR1 Heteroreceptor Complexes Differently Modulate GIRK Currents in the Dorsal Hippocampus and the Dorsal Raphe Serotonin Nucleus of Control Rats and of a Genetic Rat Model of Depression	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-07	Chao-Ecija, A; Dawid-Milner, M S	BaroWavelet: An R-based tool for dynamic baroreflex evaluation through wavelet analysis techniques.	COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE	6.1	Q1	Article	2023
C-07	Vazquez-Gonzalez, Noemi; Leiva-Fernandez, Jose; Cotta-Luque, Victor M; Leiva-Fernandez, Francisca; Rius-Diaz, Francisca; Martos-Crespo, Francisco; Martin-Montanez, Elisa; Barnestein-Fonseca, Pilar	Effectiveness of an educational intervention about inhalation technique in healthcare professionals in primary care: a cluster randomized trial.	FRONTIERS IN PHARMACOLOGY	5.6	Q1	Article	2023
C-07	Hernández-Mondragón, JC; Hernández-Hernández, DA; Crespo-Ramírez, M; Prospero-García, O; Rocha-Arrieta, L; Fuxe, K; Borroto-Escuela, DO; de la Mora, MP	Evidence for the existence of facilitatory interactions between the dopamine D2 receptor and the oxytocin receptor in the amygdala of the rat. Relevance for anxiolytic actions	FRONTIERS IN PHARMACOLOGY	5.6	Q1	Article	2023
C-07	Alvarez-Contino, JE; Diaz-Sanchez, E; Mirchandani-Duque, M; Sanchez-Perez, JA; Barbancho, MA; Lopez-Salas, A; Garcia-Casares, N; Fuxe, K; Borroto-Escuela, DO; Narvaez, M	GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions	JOURNAL OF CELLULAR PHYSIOLOGY	5.6	Q1	Article	2023
C-07	Gonzalez-Garcia, M; Carrillo-Franco, L; Peinado-Aragones, CA; Diaz-Casares, A; Gago, B; Lopez-Gonzalez, MV; Dawid-Milner, MS	Impact of the glutamatergic neurotransmission within the A5 region on the cardiorespiratory response evoked from the midbrain dlPAG	PFLUGERS ARCHIV- EUROPEAN JOURNAL OF PHYSIOLOGY	4.5	Q1	Article	2023
C-07	Casas, BM; Linares, JLC; Aranda, IB; Villodres, JR; Bohórquez, VM; Jiménez, AG; Corral, MAR; Bosch, R; Chaparro, MAS; Fernández, MG; Valdivielso, P	Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-07	Ruiz-Garcia, I; Ortiz-Flores, R; Badia, R; Garcia-Borrego, A; Garcia-Fernandez, M; Lara, E; Martin-Montanez, E; Garcia-Serrano, S; Valdes, S; Gonzalo, M; Tapia-Guerrero, SMJ; Fernandez-Garcia, JC; Sanchez-Garcia, A; Munoz-Cobos, F; Calderon-Cid, M; El-Bekay, R; Covas, MI; Rojo-Martinez, G; Olveira, G; Romero-Zerbo, SY; Bermudez-Silva, FJ	Rich oleocanthal and oleacein extra virgin olive oil and inflammatory and antioxidant status in people with obesity and prediabetes. The APRIL study: A randomised, controlled crossover study	CLINICAL NUTRITION	6.3	Q1	Article	2023
C-07	Florido-Santiago, M; Perez-Belmonte, LM; Osuna-Sanchez, J; Barbancho, MA; Ricci, M; Millan-Gomez, M; Bernal-Lopez, MR; Gomez-Huelgas, R; Lara, JP	Assessment of long-term cognitive dysfunction in older patients who undergo heart surgery	NEUROLOGIA	3.9	Q2	Article	2023
C-07	Chao-Ecija, Alvaro; Lopez-Gonzalez, Manuel Victor; Dawid-Milner, Marc Stefan	CardioRVAR: A New R Package and Shiny Application for the Evaluation of Closed-Loop Cardiovascular Interactions.	Biology	4.2	Q2	Article	2023
C-07	Borroto-Escuela, DO; Lopez-Salas, A; Wydra, K; Bartolini, M; Zhou, ZL; Frankowska, M; Suder, A; Benitez-Porres, J; Romero-Fernandez, W; Filip, M; Fuxe, K	Combined treatment with Sigma1R and A2AR agonists fails to inhibit cocaine self-administration despite causing strong antagonistic accumbal A2AR-D2R complex interactions: the potential role of astrocytes	FRONTIERS IN MOLECULAR NEUROSCIENCE	4.8	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-07	Romero-Fernandez, W; Carvajal-Tapia, C; Prusky, A; Katdare, KA; Wang, EMLE; Shostak, A; Ventura-Antunes, L; Harmsen, HJ; Lippmann, ES; Fuxe, K; MacGurn, JA; Borroto-Escuela, DO; Schrag, MS	Detection, visualization and quantification of protein complexes in human Alzheimer's disease brains using proximity ligation assay	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
C-07	García-Alberca, JM; De la Rosaa, MD; De Zaldívar, PS; Ledesmaa, M; Oltra, E; Gris, E; Ocejo, O; Torrecilla, J; Zafra, C; Sánchez-Fernández, A; Mancilla, T; López-Romero, M; Jerez, R; Santana, N; Lara, JP; Barbancho, MA; Blanco-Reina, E	Effect of Nordic Sensi® Chair on Behavioral and Psychological Symptoms of Dementia in Nursing Homes Residents: A Randomized Controlled Trial	JOURNAL OF ALZHEIMERS DISEASE	4	Q2	Article	2023
C-07	Arcos, J; Grunenwald, F; Sepulveda, D; Jerez, C; Urbina, V; Huerta, T; Troncoso-Escudero, P; Tirado, D; Perez, A; Diaz-Espinoza, R; Nova, E; Kubitscheck, U; Rodriguez-Gatica, JE; Hetz, C; Toledo, J; Ahumada, P; Rojas-Rivera, D; Martin-Montañez, E; Garcia-Fernandez, M; Vidal, RL	IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson's disease models	CELL DEATH DISCOVERY	7	Q2	Article	2023
C-07	Carrasco-Gomez, D; Chao-ecija, A; Lopez-González, MV; Dawid-Milner, MS	Impact of a peer-to-peer escape room activity in the learning of Human Physiology of medical students from the university of Malaga	FRONTIERS IN PHYSIOLOGY	4	Q2	Article	2023
C-07	Moreno-Gutierrez, JA; Leal, CD; Lopez-Gonzalez, MV; Chao-Ecija, A; Dawid-Milner, MS	Impact of music performance anxiety on cardiovascular blood pressure responses, autonomic tone and baroreceptor sensitivity to a western classical music piano-concert	FRONTIERS IN NEUROSCIENCE	4.3	Q2	Article	2023
C-07	Carrasco-Fernández, L; García-Sillero, M; Jurado-Castro, JM; Borroto-Escuela, DO; García-Romero, J; Benítez-Porres, J	Influence of limb dominance on body and jump asymmetries in elite female handball	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
C-07	Perez-Belmonte, Luis M; Osuna-Sanchez, Julio; Ricci, Michele; Millan-Gomez, Mercedes; Lopez-Carmona, Maria D; Barbancho, Miguel A; Bernal-Lopez, Maria R; Jansen-Chaparro, Sergio; Lara, Jose P; Gomez-Huelgas, Ricardo	Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older study.	PANMINERVA MEDICA	4.3	Q2	Article	2023
C-07	Simón-Frapolli, VJ; Vegas-Aguilar, IM; Fernández-Jiménez, R; Cornejo-Pareja, IM; Sanchez-García, AM; Martínez-López, P; Nuevo-Ortega, P; Reina-Artacho, C; Estecha-Foncea, MA; Gómez-González, AM; González-Jiménez, MB; Avanesi-Molina, E; Tinahones-Madueño, FJ; García-Almeida, JM	Phase angle and rectus femoris cross- sectional area as predictors of severe malnutrition and their relationship with complications in outpatients with post- critical SARS-CoV2 disease	FRONTIERS IN NUTRITION	5	Q2	Article	2023
C-07	Sánchez-García, AM; Martínez-López, P; Gómez-González, AM; Rodriguez-Capitán, J; Pavón-Morón, FJ; Jiménez-López, RJ; García-Almeida, JM; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abad, V; Molina-Ramos, AI; Cabrera-César, E; Ben-Abdellatif, I; Gordillo-Resina, M; Pérez-Mesa, E; Nieto-González, M; Nuevo-Ortega, P; Reina-Artacho, C; Sánchez-Fernández, PL; Jiménez-Navarro, MF; Estecha-Foncea, MA	Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES	3.6	Q2	Article	2023
C-07	García-Durán, L; Claros, S; Zamorano-González, P; Gonáalez-García, M; Carrillo-Franco, L; Ponce-Velasco, M; Gago, B; García-Fernández, M; López-González, MV; Aiastui, A	Teaching the physiology of the human body in non-formal spaces: pilot experience of a Service-Learning methodology and the interaction between students of different educational levels	FRONTIERS IN PHYSIOLOGY	4	Q2	Article	2023
C-07	Nieto-Quero, A; Infantes-López, MI; Zambrana-Infantes, E; Chaves-Peña, P; Gavito, AL; Munoz-Martin, J; Tabbai, S; Márquez, J; de Fonseca, FR; García-Fernández, MI; Santín, LJ; Pedraza, C; Pérez-Martin, M	Unveiling the Secrets of the Stressed Hippocampus: Exploring Proteomic Changes and Neurobiology of Posttraumatic Stress Disorder	CELLS	6	Q2	Article	2023
C-07	Sanchez-Garcia, AM; Martinez-Lopez, P; Gomez-Gonzalez, AM; Rodriguez-Capitan, J; Jimenez-Lopez, RJ; Almeida, JMG; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abada, V; Molina-Ramos, AI; Cabrera-Cesar, E; Ben-Abdellatif, I; Gordillo-Resina, M; Perez-Mesa, E; Nieto-Gonzalez, M; Nuevo-Ortega, P; Reina-Artacho, C; Fernandez, PLS; Jimenez-Navarro, MF; Estecha-Foncea, MA	Multidisciplinary approach of the sequelae one month after hospital discharge in patients with severe bilateral COVID-19 pneumonia, are there differences depending on the respiratory therapy used during admission to intensive care?	MEDICINA INTENSIVA	3	Q3	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-08	Mendoza, LG; Rey, JG; Carrero, JAT; Salmerón, PP	Protocol for the management of patients with chronic obstructive pulmonary disease after exacerbation in the emergency department	MEDICINA DE FAMILIA- SEMERGEN	1.1		Article	2023
C-08	Vazquez-Gonzalez, Noemi; Leiva-Fernandez, Jose; Cotta-Luque, Victor M; Leiva-Fernandez, Francisca; Rius-Diaz, Francisca; Martos-Crespo, Francisco; Martin-Montanez, Elisa; Barnestein-Fonseca, Pilar	Effectiveness of an educational intervention about inhalation technique in healthcare professionals in primary care: a cluster randomized trial.	FRONTIERS IN PHARMACOLOGY	5.6	Q1	Article	2023
C-08	Barnestein-Fonseca, P; Cotta-Luque, V; Aguiar-Leiva, V; Leiva-Fernandez, J; Martos-Crespo, F; Leiva-Fernandez, F	The importance of reminders and patient preferences to improve inhaler technique in older adults with COPD	FRONTIERS IN PHARMACOLOGY	5.6	Q1	Article	2023
C-08	Maravilla-Herrera, P; Merino, M; Zamora, SA; Filgueiras, JB; Carrillo, JMC; Sanchez, OD; Sinisterra, FD; Garcia-Ruiz, A; Pinto, PH; Manfredi, A; Olmos, JM; Luna, PMD; Puig, L; Ros, S; Hidalgo-Vega, A	The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain	FRONTIERS IN PUBLIC HEALTH	5.2	Q1	Article	2023
C-08	Prieto-Díaz, MA; Pallares-Carratala, V; Micó-Pérez, RM; Escobar-Cervantes, C; Martin-Sanchez, V; Coca, A; Barquilla-Garcia, A; Velilla-Zancada, SM; Polo-García, J; Segura-Fragoso, A; Ginel-Mendoza, L; Hermida-Ameijerias, A; Cinza-Sanjurjo, S	Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study	FRONTIERS IN CARDIOVASCULAR MEDICINE	3.6	Q2	Article	2023
C-08	Antelo-Pais, P; Prieto-Díaz, MA; Micó-Pérez, RM; Pallarés-Carratalá, V; Velilla-Zancada, S; Polo-García, J; Barquilla-García, A; Ginel-Mendoza, L; Segura-Fragoso, A; Vitelli-Storelli, F; Martín-Sánchez, V; Hermida-Ameijerias, A; Cinza-Sanjurjo, S	Prevalence of Hyperuricemia and Its Association with Cardiovascular Risk Factors and Subclinical Target Organ Damage	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
C-08	Valero-Cantero, I; Casals, C; Espinar-Toledo, M; Baron-Lopez, FJ; Soler, NGA; Vazquez-Sanchez, MA	Effects of Music on the Quality of Life of Family Caregivers of Terminal Cancer Patients: A Randomised Controlled Trial	HEALTHCARE	2.8	Q2	Article	2023
C-08	Martín-Cazorla, F; Ramos-Medina, V; Rubio-Lamia, L; Santos-Amaya, I; Jódar-Sánchez, F	How much does a forensic autopsy cost in Spain?	FORENSIC SCIENCE MEDICINE AND PATHOLOGY	1.8	Q2	Article	2023
C-08	Barnestein-Fonseca, P; Vibora-Martín, E; Ruiz-Torreras, I; Chapinal-Bascón, H; Martín-Roselló, ML; Gómez-García, R	ITV-Pal programme: protocol of evaluation of the implementation of tech-volunteer programme in palliative care services	BMJ OPEN	2.9	Q2	Article	2023
C-08	Munoz, JLG; Soler, NGA; Ruiz, AJG	Study Protocol on Social Return on Investment (SROI) Project of the Surgical Waiting List Management System	HEALTHCARE	2.8	Q2	Article	2023
C-08	Iglesias, S; Munarriz, PM; Saceda, J; Catalán-Uribarrena, G; Miranda, P; Vidal, JM; Fustero, D; Giménez-Pando, J; Rius, F	Multicentric and collaborative study of Spanish neurosurgical management of pediatric craniopharyngiomas: S-PedCPG.co	NEUROCIRUGIA	0.8	Q4	Article	2023
C-09	Quan, L; Moreno-Gonzalez, I; Xie, ZG; Gamez, N; Vegas-Gomez, L; Song, QY; Gu, JH; Lin, WH; Gomez-Gutierrez, R; Wu, TF	A near-infrared probe for detecting and interposing amyloid beta oligomerization in early Alzheimer's disease	ALZHEIMERS & DEMENTIA	14	D1	Article	2023
C-09	Garcia-Bonilla, M; Ojeda-Perez, B; Shumilov, K; Rodriguez-Perez, LM; Dominguez-Pinos, D; Vitorica, J; Jimenez, S; Ramirez-Lorca, R; Echevarria, M; Cardenas-Garcia, C; Iglesias, T; Gutierrez, A; McAllister, JP; Limbrick, DD; Paez-Gonzalez, P; Jimenez, AJ	Generation of Periventricular Reactive Astrocytes Overexpressing Aquaporin 4 Is Stimulated by Mesenchymal Stem Cell Therapy	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
C-09	Munoz-Castro, C; Mejias-Ortega, M; Sanchez-Mejias, E; Navarro, V; Trujillo-Estrada, L; Jimenez, S; Garcia-Leon, JA; Fernandez-Valenzuela, JJ; Sanchez-Mico, MV; Romero-Molina, C; Moreno-Gonzalez, I; Baglietto-Vargas, D; Vizuete, M; Gutierrez, A; Vitorica, J	Monocyte-derived cells invade brain parenchyma and amyloid plaques in human Alzheimer's disease hippocampus	ACTA NEUROPATHOLOGICA COMMUNICATIONS	7.1	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-09	Gomez-Gutierrez, R; Ghosh, U; Yau, WM; Gamez, N; Do, K; Kramm, C; Shirani, H; Vegas-Gomez, L; Schulz, J; Moreno-Gonzalez, I; Gutierrez, A; Nilsson, KPR; Tycko, R; Soto, C; Morales, R	Two structurally defined A & beta; polymorphs promote different pathological changes in susceptible mice	EMBO REPORTS	7.7	Q1	Article	2023
C-09	Lopez-Villodres, JA; Escamilla, A; Mercado-Saenz, S; Alba-Tercedor, C; Rodriguez-Perez, LM; Arranz-Salas, I; Sanchez-Varo, R; Bermudez, D	Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice	BIOMEDICINES	4.7	Q1	Review	2023
C-09	Kilian, JG; Mejias-Ortega, M; Hsu, HW; Herman, DA; Vidal, J; Arechavala, RJ; Renusch, S; Dalal, H; Hasen, I; Ting, AMD; Rodriguez-Ortiz, CJ; Lim, SL; Lin, XM; Vu, J; Saito, T; Saido, TC; Kleinman, MT; Kitazawa, M	Exposure to quasi-ultrafine particulate matter accelerates memory impairment and Alzheimer's disease-like neuropathology in the App(NL-G-F) knock-in mouse model	TOXICOLOGICAL SCIENCES	3.8	Q2	Article	2023
C-09	Szabo, L; Grimm, A; Garcia-Leon, JA; Verfaillie, CM; Eckert, A	Genetically Engineered Triple MAPT-Mutant Human-Induced Pluripotent Stem Cells (N279K, P301L, and E10+16 Mutations) Exhibit Impairments in Mitochondrial Bioenergetics and Dynamics	CELLS	6	Q2	Article	2023
C-09	Rodriguez-Ortiz, CJ; Thorwald, MA; Rodriguez, R; Mejias-Ortega, M; Kieu, Z; Maitra, N; Hawkins, C; Valenzuela, J; Peng, M; Nishiyama, A; Ortiz, RM; Kitazawa, M	Angiotensin receptor blockade with olmesartan alleviates brain pathology in obese OLETF rats	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY	2.9	Q3	Article	2023
C-11	Sainero-Tirado, G; Ramirez-Maestre, C; Lopez-Martinez, AE; Esteve, R	Distress intolerance and pain catastrophizing as mediating variables in PTSD and chronic noncancer pain comorbidity	SCANDINAVIAN JOURNAL OF PAIN	1.6		Article	2023
C-11	de la Vega, R; Palermo, TM	Mediating Role of Treatment Perceptions in the Relationship Between Individual Characteristics and Engagement With a Digital Psychological Intervention for Pediatric Chronic Pain: Secondary Data Analysis	JMIR PEDIATRICS AND PARENTING	3.7		Article	2023
C-11	López-Martínez, AE; Sainero-Tirado, G; Esteve, R; Reyes-Pérez, A; Ruiz-Párraga, GT; de la Vega, R; Serrano-Ibáñez, ER; Ramírez-Maestre, C	Does Pain Catastrophizing and Distress Intolerance Mediate the Relationship Between PTSD and Prescribed Opioid Misuse in People With Chronic Noncancer Pain?	PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY	6.3	D1	Article	2023
C-11	Lopez-Martinez, AE; Serrano-Ibanez, ER; Solis-Serrano, L; Ramirez-Maestre, C; Esteve, R	Empathy among health science undergraduates toward the diagnosis of chronic pain: An experimental study	NURSE EDUCATION TODAY	3.9	D1	Article	2023
C-11	Reyes-Pérez, A; López-Martínez, AE; Esteve, R; Ramírez-Maestre, C	Spanish Validation of the COMM Scale to Assess the Misuse of Prescription Opioids in Patients with Chronic Noncancer Pain	INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION	8	D1	Article	2023
C-11	de la Vega, R; Serrano-Ibáñez, ER; Ruiz-Párraga, GT; Palermo, TM; Wicksell, R; Fernández-Jiménez, E; Oliva, S; Roldán, S; Monfort, L; Peláez, MJ; Carmona, ML; Ramírez-Maestre, C; López-Martínez, AE; Miró, J; Esteve, R	Protocol for a multi-phase, multi-center, real- world, hybrid effectiveness-implementation study of a digital intervention for pediatric chronic pain co-designed with patients (Digital SPA)	DIGITAL HEALTH	3.9	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-11	Varela, C; Montero, M; Serrano-Ibáñez, ER; de la Vega, A; Pulido, MAG	Psychological interventions for healthcare professionals during the COVID-19 pandemic: A systematic review	STRESS AND HEALTH	4.1	Q1	Review	2023
C-11	Serrano-Ibáñez, ER; de la Vega-castelo, AM; Varela, C; Montero-Matellanes, MM; Gómez-Pulido, A	The Current Mental Health of Healthcare Workers 3 Years After the Start of the Pandemic: The Relationship Between Coping Strategies and Indices of Mental Health	SAGE OPEN	2	Q2	Article	2023
C-11	de la Vega, Rocio; Heinisuo, Irina A; Lopez-Martinez, Alicia E; Serrano-Ibanez, Elena R; Ruiz-Parraga, Gema T; Ramirez-Maestre, Carmen; Esteve, Rosa	ANF therapy for pain management, feasibility, satisfaction, perceived symptom reduction and side effects: a real-world multisite observational study.	Journal of physical therapy science	0,39	Q4	Article	2023
C-12	Lopez-Barroso, D; Paredes-Pacheco, J; Torres-Prioris, M; Davila, G; Berthier, ML	Brain structural and functional correlates of the heterogenous progression of mixed transcortical aphasia	BRAIN STRUCTURE & FUNCTION	3.1	D1	Article	2023
C-12	Frisoni, GB; Altomare, D; Ribaldi, F; Villain, N; Brayne, C; Mukadam, N; Abramowicz, M; Barkhof, F; Berthier, M; Bieler-Aeschlimann, M; Blennow, K; Guevara, AB; Carrera, E; Chételat, G; Csajka, C; Demonet, JF; Dodich, A; Garibotto, V; Georges, J; Hurst, S; Jessen, F; Kivipelto, M; Llewellyn, DJ; McWhirter, L; Milne, R; Minguillón, C; Miniussi, C; LuisMolinuevo, J; Nilsson, PM; Noyce, A; Ranson, JM; Grau-Rivera, O; Schott, JM; Solomon, A; Stephen, R; van der Flier, W; van Duijn, C; Vellas, B; Visser, LNC; Cummings, JL; Scheltens, P; Ritchie, C; Dubois, B	Dementia prevention in memory clinics: recommendations from the European task force for brain health services	LANCET REGIONAL HEALTH-EUROPE	20.9	D1	Article	2023
C-12	Berthier, ML; Edelkraut, L; Lopez-Gonzalez, FJ; Lopez-Barroso, D; Mohr, B; Pulvermuller, F; Starkstein, SE; Jorge, RE; Torres-Prioris, MJ; Davila, G	Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study	BRAIN AND LANGUAGE	2.5	Q1	Article	2023
C-12	Davila, G; Torres-Prioris, MJ; Lopez-Barroso, D; Berthier, ML	Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System	CNS DRUGS	6	Q1	Review	2023
C-12	Moreno-Torres, I; Lozano, A; Bermúdez, R; Pino, J; Méndez, MDG; Nava, E	Unmasking Nasality to Assess Hypernasality	APPLIED SCIENCES- BASEL	2.7	Q2	Article	2023
C-12	Berthier, ML; Davila, G	Pharmacotherapy for post-stroke aphasia: what are the options?	EXPERT OPINION ON PHARMACOTHERAPY	3.2	Q3	Article	2023
C-13	López-Muñoz, C; Aranda-Gallardo, M; Rivas-Ruiz, F; Moya-Suárez, AB; Morales-Asencio, JM; Canca-Sanchez, JC	Clinical and functional assessment in patients admitted with pluripathological dysphagia according to the mode of feeding: Through a gastrostomy tube or oral	ENFERMERIA CLINICA	0.5		Article	2023
C-13	Ruzafa-Martinez, M; Garcia-Gonzalez, J; Morales-Asencio, JM; Leal-Costa, C; Hernandez-Mendez, S; Hernandez-Lopez, MJ; Albarracin-Olmedo, J; Ramos-Morcillo, AJ	Consequences of the Covid-19 pandemic on complex multimorbid elderly: Follow-up of a community-based cohort. SAMAC3 Study	JOURNAL OF NURSING SCHOLARSHIP	3.4	D1	Review	2023
C-13	Vázquez-Sánchez, MA; Casals-Vázquez, A; López-Leiva, I; Sánchez-Ojeda, MA; Del Río-Urenda, S; Navarro-Prado, S; García-Gámez, M; Casals, C	Cultural adaptation and validation of the Family Nursing Practice Scale (FNPS) for use with Spanish-speaking Nursing Degree students	NURSE EDUCATION IN PRACTICE	3.2	Q1	Article	2023
C-13	Pelaez-Cantero, MJ; Morales-Asencio, JM; Navarro-Mingorance, A; Madrid-Rodriguez, A; Tavera-Tolmo, A; Escobosa-Sanchez, O; Martino-Alba, R	End of life in patients attended by pediatric palliative care teams: what factors influence the place of death and compliance with family preferences?	EUROPEAN JOURNAL OF PEDIATRICS	3.6	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-13	Mertens, MG; Meeus, M; Verborgt, O; Girbes, EL; Mena-Del Horno, S; Aguilar-Rodriguez, M; Dueñas, L; Navarro-Ledesma, S; Fernandez-Sanchez, M; Luque-Suarez, A; Struyf, F	Exploration of the clinical course of frozen shoulder: A longitudinal multicenter prospective study of functional impairments	BRAZILIAN JOURNAL OF PHYSICAL THERAPY	3.4	Q1	Article	2023
C-13	Prieto-Molina, A; Aranda-Gallardo, M; Moya-Suárez, AB; Rivas-Ruiz, F; Peláez-Cherino, J; Canca-Sánchez, JC	Patient transfers from emergency departments to other in-hospital areas: a failure mode and effects analysis	EMERGENCIAS	5.5	Q1	Article	2023
C-13	Cervera-Garvi, P; Marchena-Rodriguez, A; Lopezosa-Reca, E; Diaz-Miguel, S; Ortega-Avila, AB	Systematic review of the methodological quality of patient-reported outcome measure for patients with chronic ankle instability	CLINICAL REHABILITATION	3	Q1	Review	2023
C-13	Jerez-Roig, Javier; Bezerra de Souza, Dyego L; Cambra-Badii, Irene; March-Amengual, Jaume-Miquel; Comella, Agusti; Maso-Aguado, Montse; Ramon-Aribau, Anna; Luque-Suarez, Alejandro; Feito Grande, Lydia; Terribas, Nuria; Vivanco, Luis; Busquets-Alibes, Ester	Change in demand for health-related undergraduate studies in Spain during 2015-2021: a temporal series study.	PEERJ	2.7	Q2	Article	2023
C-13	Perelló-Campaner, C; González-Trujillo, A; Alorda-Terrassa, C; González-Gascúe, M; Pérez-Castelló, JA; Morales-Asencio, JM; Molina-Mula, J	Determinants of Communication Failure in Intubated Critically III Patients: A Qualitative Phenomenological Study from the Perspective of Critical Care Nurses	HEALTHCARE	2.8	Q2	Article	2023
C-13	Martinez-Rico, M; Ortega-Avila, AB; Pineda-Galan, C; Gijon-Nogueron, G; Rios, MP; Alabua-Dasi, R; Marchena-Rodriguez, A	Effect of Spatiotemporal Parameters on the Gait of Children Aged from 6 to 12 Years in Podiatric Tests: A Cross Sectional Study	HEALTHCARE	2.8	Q2	Article	2023
C-13	Lopezosa-Reca, E; Martinez-Nova, A; Sanchez-Rodriguez, R; Gijon-Nogueron, G; Marchena-Rodriguez, A; Martinez-Rico, M; Alabau-Dasi, R	Effectiveness of hyaluronic acid in post-surgical cures following partial matricectomies with the phenol/alcohol technique: A randomized clinical trial	JOURNAL OF TISSUE VIABILITY	2.5	Q2	Article	2023
C-13	Cavaggion, C; Juul-Kristensen, B; Luque-Suarez, A; Voogt, L; Wollants, G; Conaire, EO; Struyf, F	Exercise into pain in chronic rotator cuff related shoulder pain: a prospective single-group feasibility study	BMJ OPEN	2.9	Q2	Article	2023
C-13	Mertens, MGCAM; Struyf, F; Verborgt, O; Dueñas, L; Balasch-Berrat, M; Navarro-Ledesma, S; Fernandez-Sanchez, M; Luque-Suarez, A; Girbes, EL; Meeus, M	Exploration of the clinical course and longitudinal correlations in frozen shoulder: The role of autonomic function, central pain processing, and psychological variables. A longitudinal multicenter prospective observational study	MUSCULOSKELETAL SCIENCE AND PRACTICE	2.3	Q2	Article	2023
C-13	Reinoso-Cobo, Andres; Ortega-Avila, Ana-Belen; Pineda-Galan, Consolacion; Alabau-Dasi, Raquel; Exposito-Ruiz, Manuela; Banwell, George; Ramos-Petersen, Laura; Gijon-Nogueron, Gabriel	Follow-up of health-related quality of life and pain in a cohort of patients with rheumatoid arthritis before and after COVID-19	FOOT AND ANKLE SURGERY	2.5	Q2	Article	2023
C-13	Alabau-Dasi, Raquel; Dominguez-Maldonado, Gabriel; Gijon-Nogueron, Gabriel; Ortega-Avila, Ana Belen; Delacroix, Sebastian	How susceptible are our Achilles Tendons? Sonoanatomical assessment. A cross- sectional study.	JOURNAL OF TISSUE VIABILITY	2.5	Q2	Article	2023
C-13	Lopez-Munoz, Sara; Gracia-Vesga, Miguel Angel; Gracia-Sanchez, Alba; Zunica-Garcia, Sara; Gijon-Nogueron, Gabriel; Chicharro-Luna, Esther	Impact of fibromyalgia and related factors on foot function and quality of life: Crosssectional study.	FOOT AND ANKLE SURGERY	2.5	Q2	Article	2023
C-13	Tejero, S; Gonzalez-Martin, D; Martinez-Franco, A; Jimenez-Diaz, F; Gijon-Nogueron, G; Herrera-Perez, M	Intraoperative checking of the first ray rotation and sesamoid position through sonographic assistance	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY	2.3	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-13	Mena-del Horno; Balasch-Bernat, M; Louw, A; Luque-Suarez, A; Rodriguez-Brazzarola, P; Navarro-Ledesma, S; Murillo, C; Duenas, L; Lluch, E	Is there any benefit of adding a central nervous system-focused intervention to a manual therapy and home stretching program for people with frozen shoulder? A randomized controlled trial	JOURNAL OF SHOULDER AND ELBOW SURGERY	3	Q2	Article	2023
C-13	Figueredo, MCS; Morilla-Herrera, JC; Uttumchandani, SK; Perez, ED; Giraldos, MS; del Val, MAN; Martin, MJH; Borrego, ABG; Irazusta, MG; Gonzalez, MG; Morales-Asencio, JM	Longitudinal assessment of the eating pattern of people with dementia and its association with problems for feeding and malnutrition: a prospective follow-up study protocol	BMJ OPEN	2.9	Q2	Article	2023
C-13	Cavaggion, C; Navarro-Ledesma, S; Juul-Kristensen, B; Luque-Suarez, A; Voogt, L; Struyf, F	Reliability of coracohumeral distance and subcoracoid tendons in subacromial pain syndrome	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
C-13	Cavaggion, C; Navarro-Ledesma, S; Luque-Suarez, A; Juul-Kristensen, B; Voogt, L; Struyf, F	Subacromial space measured by ultrasound imaging in asymptomatic subjects and patients with subacromial shoulder pain: an inter-rater reliability study	PHYSIOTHERAPY THEORY AND PRACTICE	2	Q2	Article	2023
C-13	Ortega-Avila, AB; Gijon-Nogueron, G; Cervera-Garvi, P; Guerra-Marmolejo, C; Chicharro-Luna, E; Reinoso-Cobo, A; Marchena-Rodriguez, A	Transcultural adaptation and validation of the Spanish version of the Global Pain Scale	JOURNAL OF ORTHOPAEDIC RESEARCH	2.8	Q2	Article	2023
C-13	Martinez-Calderon, J; Flores-Cortes, M; Morales-Asencio, JM; Pineda-Galan, C; Garcia-Rios, MC; Torrontegui-Duarte, M; Luque-Suarez, A	Is it Possible to Reduce Pain-Related Fear in Individuals with Knee Osteoarthritis? a Systematic Review of Randomised Clinical Trials	PHYSIOTHERAPY THEORY AND PRACTICE	2	Q2	Review	2023
C-13	Nieto-Gil, P; Marco-Lledo, J; Garcia-Campos, J; Ruiz-Munoz, M; Gijon-Nogueron, G; Ramos-Petersen, L	Risk factors and associated factors for calcaneal apophysitis (Sever's disease): a systematic review	BMJ OPEN	2.9	Q2	Review	2023
C-13	Reinoso-Cobo, A; Ortega-Avila, AB; Ramos-Petersen, L; Garcia-Campos, J; Banwell, G; Gijon-Nogueron, G; Lopezosa-Reca, E	Relationship between Kinesiophobia, Foot Pain and Foot Function, and Disease Activity in Patients with Rheumatoid Arthritis: A Cross-Sectional Study	MEDICINA-LITHUANIA	2.6	Q3	Article	2023
C-13	Artero, PMA; Rios, MP; Greif, R; Cervantes, ABO; Gijon-Nogueron, G; Barcala-Furelos, R; Aranda-Garcia, S; Petersen, LR	Efficiency of virtual reality for cardiopulmonary resuscitation training of adult laypersons: A systematic review	MEDICINE	1.6	Q3	Review	2023
C-13	Guerra-Armas, J; Flores-Cortes, M; Pineda-Galan, C; Luque-Suarez, A; La Touche, R	Role of Immersive Virtual Reality in Motor Behaviour Decision-Making in Chronic Pain Patients	BRAIN SCIENCES	3.3	Q3	Review	2023
C-13	Flores-Cortes, Mar; Guerra-Armas, Javier; Pineda-Galan, Consolacion; La Touche, Roy; Luque-Suarez, Alejandro	Sensorimotor Uncertainty of Immersive Virtual Reality Environments for People in Pain: Scoping Review.	BRAIN SCIENCES	3.3	Q3	Review	2023
C-13	Nogueras, EV; Cantero, N; Macias, M; Morales-Asencio, JM; Perez-Bryan, JMGH; Hurtado, MM	A multifaceted provider-centred intervention versus usual care to improve the recognition and diagnosis of depression in primary health care: a hybrid study	PRIMARY HEALTH CARE RESEARCH AND DEVELOPMENT	1.6	Q4	Article	2023
C-16	Linares-Pineda, T; Pena-Montero, N; Fragoso-Bargas, N; Gutiérrez-Repiso, C; Lima-Rubio, F; Suarez-Arana, M; Sánchez-Pozo, A; Tinahones, FJ; Molina-Vega, M; Picón-César, MJ; Sommer, C; Morcillo, S	Epigenetic marks associated with gestational diabetes mellitus across two time points during pregnancy	CLINICAL EPIGENETICS	5.7	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
C-16	de Graaf, H; Mitchell, K; Clifton, S; Lara, MF; Dewaele, A; Dupont, J; Klapilova, K; Lazdane, G; Briken, P; Træen, B; Bajos, N; Ljungcrantz, D; Kontula, O	Sex Surveys in Europe: Reflections on over Four Decades of Sexual Behavior and Sexual Health Surveillance	JOURNAL OF SEX RESEARCH	3.6	Q1	Review	2023
C-16	Gonzalez-Mesa, E; Rengel-Diaz, C; Riklikiene, O; Thomson, G; Cazorla-Granados, O; Abreu, W; Morgado-Neves, D; Isbir, GG; Jonsdottir, SS; Karlsdottir, SI; Lalor, J	Assessment of the attitude towards childbirth in health sciences students-development and validation of the questionnaire Cave-St	CURRENT PSYCHOLOGY	2.8	Q2	Article	2023
C-16	Lubián-López, DM; Butrón-Hinojo, CA; Menjón-Beltrán, S; González-Mesa, E; Tapiador-Albertos, S; Rodríguez-Jiménez, B; Fiol-Ruiz, G	Effects of Non-Ablative Solid-State Vaginal Laser (SSVL) for the Treatment of Vulvovaginal Atrophy in Breast Cancer Survivors after Adjuvant Aromatase Inhibitor Therapy: Preliminary Results	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
C-16	Kullmann, F; Strissel, PL; Strick, R; Stoehr, R; Eckstein, M; Bertz, S; Wullich, B; Sikic, D; Wach, S; Taubert, H; Olbert, P; Heers, H; Lara, MF; Macias, ML; Matas-Rico, E; Lozano, MJ; Prieto, D; Hierro, I; van Doeveren, T; Bieche, I; Masliah-Planchon, J; Beaurepere, R; Boormans, JL; Allory, Y; Herrera-Imbroda, B; Hartmann, A; Weyerer, V	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort	JOURNAL OF CLINICAL PATHOLOGY	3.4	Q2	Article	2023
C-16	Díaz-Mohedo, E; Aguirre, IO; García, EM; Infantes-Rosales, MA; Hita-Contreras, F	Functional Exercise Versus Specific Pelvic Floor Exercise: Observational Pilot Study in Female University Students	HEALTHCARE	2.8	Q2	Article	2023
C-16	García-Mejido, JA; Martín-Martinez, A; González-Diaz, E; Núñez-Matas, MJ; Fernández-Palacín, A; Carballo-Rastrilla, S; Fernández-Fernández, C; Sainz-Bueno, JA	Identification of Surgical Uterine Prolapse in Premenopausal Patients With Clinical or Ultrasound Criteria? A Multicenter Comparative Study	JOURNAL OF ULTRASOUND IN MEDICINE	2.3	Q2	Article	2023
C-16	Díaz-Mohedo, E; González-Roldán, G; Muñoz-Gámez, I; Padilla-Romero, V; Castro-Martín, E; Cabrera-Martos, I; Sánchez-García, C	Implicit Motor Imagery for Chronic Pelvic Pain: A Cross-Sectional Case-Control Study	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
C-16	García-Mejido, JA; Martín-Martinez, A; González-Diaz, E; Núñez-Matas, MJ; Fernández-Palacin, A; Carballo-Rastrilla, S; Fernández-Fernández, C; García-Jimenez, R; Sainz-Bueno, JA	Is It Possible to Diagnose Surgical Uterine Prolapse With Transperineal Ultrasound? Multicenter Validation of Diagnostic Software	JOURNAL OF ULTRASOUND IN MEDICINE	2.3	Q2	Article	2023
C-16	Mozas-Moreno, J; Sanchez-Fernandez, M; Gonzalez-Mesa, E; Olmedo-Requena, R; Amezcua-Prieto, C; Jimenez-Moleon, JJ	Perinatal and Maternal Outcomes According to the Accurate Term Antepartum Ultrasound Estimation of Extreme Fetal Weights	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
C-16	Marin, MJB; Alonso, MB; Mesa, EG	Prenatal Predictors of Neurobehavioral Outcome in Children with Fetal Growth Restriction at 6 Years of Age: A Retrospective Cohort Study	CHILDREN-BASEL	2.4	Q2	Article	2023
C-16	Banos Candenas, Laura; Abehsera Davo, Daniel; Castano Frias, Lucia; Gonzalez Mesa, Ernesto	Retrospective Study of First Trimester Metrorrhagia: Pregnancy Follow-Up and Relationship with the Appearance of Gestational Complications.	Medicina (Kaunas, Lithuania)	2.6	Q2	Article	2023
C-16	Medrano-Sánchez, EM; Pérez-Carricondo, A; Beteta-Romero, P; Díaz-Mohedo, E	Spanish Cross-Cultural Adaptation of the Australian Pelvic Floor Questionnaire	JOURNAL OF PERSONALIZED MEDICINE	3.4	Q2	Article	2023
CA-10	Luna, R; Vadillo, MA; Luque, D	Model-free decision making resists improved instructions and is enhanced by stimulus-response associations	CORTEX	3.6	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CA-10	Cobos, PL; Valle, TM; Quintero, MJ; Lopez, FJ	Individual Differences in Vulnerability Factors for Anxiety Disorders: A Study on the Acquisition, Extinction, and Renewal of Avoidance, and the Concomitant Dynamics of Relief	COLLABRA- PSYCHOLOGY	2.5	Q2	Article	2023
CE-17	Maroto-Garcia, J; Martinez-Escribano, A; Delgado-Gil, V; Manez, M; Mugueta, C; Varo, N; de la Torre, AG; Ruiz-Galdon, M	Biochemical biomarkers for multiple sclerosis	CLINICA CHIMICA ACTA	5	Q1	Article	2023
CE-17	Pascual-Izquierdo, Cristina; Pinera Salmeron, Pascual; Temboury Ruiz, Francisco; Valcarcel Ferreiras, David; Jimenez Hernandez, Sonia; Salinas Argente, Ramon; del Arco Galan, Carmen; de la Rubia Comos, Javier	Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments - an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES)	EMERGENCIAS	5.5	Q1	Review	2023
CE-18	Rubio, L; Suarez, J; Martin-de-las-Heras, S; Zapico, SC	Partners in Postmortem Interval Estimation: X-ray Diffraction and Fourier Transform Spectroscopy	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
CE-18	Zapata-Calvente, AL; Martin-de-las-Heras, S; Cavanillas, AB; Andreasen, K; Rasch, V; Khan, KS	E-health psychological intervention in pregnant women exposed to intimate partner violence (eIPV): A protocol for a pilot randomised controlled trial	PLOS ONE	3.7	Q2	Article	2023
CE-18	Martín-Cazorla, F; Ramos-Medina, V; Rubio-Lamia, L; Santos-Amaya, I; Jódar-Sánchez, F	How much does a forensic autopsy cost in Spain?	FORENSIC SCIENCE MEDICINE AND PATHOLOGY	1.8	Q2	Article	2023
CE-18	Andreasen, K; Zapata-Calvente, AL; Martin-de-las-Heras, S; Bueno-Cavanillas, A; Schei, B; Dokkedahl, S; de León, SD; Lopez, RF; Oviedo-Gutiérrez, A; Ankerstjerne, LBS; Megias, JL; Khan, KS; Rasch, V; Linde, DS	Video Consultations and Safety App Targeting Pregnant Women Exposed to Intimate Partner Violence in Denmark and Spain: Nested Cohort Intervention Study (STOP Study)	JMIR FORMATIVE RESEARCH	2.2	Q3	Article	2023
CIMO-01	Yubero, Alfonso; Estevez, Purificacion; Barquin, Aranzazu; Sanchez, Luisa; Santaballa, Ana; Pajares, Bella; Reche, Piedad; Salvador, Carmen; Manso, Luis; Marquez, Raul; Gonzalez-Martin, Antonio	Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program	GYNECOLOGIC ONCOLOGY REPORTS	1.2		Article	2023
CIMO-01	Toledano-Fonseca, M; Gomez-Espana, MA; Elez, E; Gravalos, C; Garcia-Alfonso, P; Rodriguez, R; Losa, F; Diaz, IA; Grana, B; Valladares-Ayerbes, M; Garcia-Ortiz, MV; Polo, E; Salgado, M; Rivera, F; Safont, MJ; Salud, A; Ruiz-Casado, A; Tabernero, JM; Riesco, MC; Rodriguez-Ariza, A; Aranda, E	A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
CIMO-01	Huebner, A; Black, JRM; Sarno, F; Pazo, R; Juez, I; Medina, L; Garcia-Carbonero, R; Guillen, C; Feliu, J; Alonso, C; Arenillas, C; Moreno-Cardenas, AB; Verdaguer, H; Macarulla, T; Hidalgo, M; McGranahan, N; Toledo, RA	ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA	GENOME MEDICINE	12.3	D1	Article	2023
CIMO-01	André, T; Berton, D; Curigliano, G; Sabatier, R; Tinker, AV; Oaknin, A; Ellard, S; de Braud, F; Arkenau, HT; Trigo, J; Gravina, A; Kristeleit, R; Moreno, V; Abdeddaim, C; Vano, YA; Samouëlian, V; Miller, R; Boni, V; Torres, AA; Gilbert, L; Brown, J; Dewal, N; Dabrowski, C; Antony, G; Zografos, E; Veneris, J; Banerjee, S	Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors A Nonrandomized Controlled Trial	JAMA NETWORK OPEN	13.8	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CIMO-01	Pascual, Javier; Gil-Gil, Miguel; Proszek, Paula; Zielinski, Christoph; Reay, Alistair; Ruiz-Borrego, Manuel; Cutts, Rosalind; Ciruelos Gil, Eva M; Feber, Andrew; Munoz-Mateu, Montserrat; Swift, Claire; Bermejo, Begona; Herranz, Jesus; Margeli Vila, Mireia; Anton, Antonio; Kahan, Zsuzsanna; Csoszi, Tibor; Liu, Yuan; Fernandez-Garcia, Daniel; Garcia-Murillas, Isaac; Hubank, Michael; Turner, Nicholas C; Martin, Miguel	Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER- Positive/HER2-Negative Metastatic Breast Cancer Patients.	Clinical cancer research : an official journal of the American Association for Cancer Research	11.5	D1	Article	2023
CIMO-01	Guerrero-Zotano, A; Belli, S; Zielinski, C; Gil-Gil, M; Fernandez-Serra, A; Ruiz-Borrego, M; Gil, EMC; Pascual, J; Munoz-Mateu, M; Bermejo, B; Vila, MM; Anton, A; Murillo, L; Nissenbaum, B; Liu, Y; Herranz, J; Fernandez-Garcia, D; Caballero, R; Lopez-Guerrero, JA; Bianco, R; Formisano, L; Turner, N; Martin, M	CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer	CLINICAL CANCER RESEARCH	11.5	D1	Article	2023
CIMO-01	Reina-Pérez, I; Artacho-Cordó, F; Mustieles, V; Castellano-Castillo, D; Cardona, F; Jiménez-Díaz, I; López-Medina, JA; Alcaide, J; Ocaña-Wilhelmi, L; Iribarne-Durán, LM; Arrebola, JP; Olea, N; Tinahones, FJ; Fernández, MF	Cross-sectional associations of persistent organic pollutants measured in adipose tissue and metabolic syndrome in clinically diagnosed middle-aged adults	ENVIRONMENTAL RESEARCH	8.3	D1	Article	2023
CIMO-01	Laborda-Illanes, A; Sanchez-Alcoholado, L; Castellano-Castillo, D; Boutriq, S; Plaza-Andrades, I; Aranega-Martin, L; Peralta-Linero, J; Alba, E; Gonzalez-Gonzalez, A; Queipo-Ortuno, MI	Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
CIMO-01	Capdevila, J; Hernando, J; Teule, A; Lopez, C; Garcia-Carbonero, R; Benavent, M; Custodio, A; Garcia-Alvarez, A; Cubillo, A; Alonso, V; Carmona-Bayonas, A; Alonso-Gordoa, T; Crespo, G; Jimenez-Fonseca, P; Blanco, M; Viudez, A; La Casta, A; Sevilla, I; Segura, A; Llanos, M; Landolfi, S; Nuciforo, P; Manzano, JL	Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin	NATURE COMMUNICATIONS	16.6	D1	Article	2023
CIMO-01	Castelo-Branco, L; Pellat, A; Martins-Branco, D; Valachis, A; Derksen, J W G; Suijkerbuijk, K P M; Dafni, U; Dellaporta, T; Vogel, A; Prelaj, A; Groenwold, R H H; Martins, H; Stahel, R; Bliss, J; Kather, J; Ribelles, N; Perrone, F; Hall, P S; Dienstmann, R; Booth, C M; Pentheroudakis, G; Delaloge, S; Koopman, M	ESMO Guidance for Reporting Oncology real- World evidence (GROW).	ANNALS OF ONCOLOGY	50.5	D1	Article	2023
CIMO-01	Vidal, J; Fernandez-Rodriguez, MC; Casadevall, D; Garcia-Alfonso, P; Paez, D; Guix, M; Alonso, V; Cano, MT; Santos, C; Duran, G; Elez, E; Manzano, JL; Garcia-Carbonero, R; Ferreiro, R; Losa, F; Pineda, E; Sastre, J; Rivera, F; Bellosillo, B; Tabernero, J; Aranda, E; Salazar, R; Montagut, C	Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study	CLINICAL CANCER RESEARCH	11.5	D1	Article	2023
CIMO-01	GillTssen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; James, ND; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, C; Tombal, B; Antonarakis, ES; Aparicio, AM; Armstrong, AJ; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, RG; Bulbul, M; Caffo, O; Castellano, D; Castro, E; Cheng, HH; Chi, KN; Chowdhury, S; Clarke, CS; Clarke, N; Daugaard, G; De, MR; Duran, I; Eeles, R; Efstathiou, E; Efstathiou, J; Ekeke, ON; Evans, CP; Fanti, S; Feng, FY; Fonteyne, V; Fossati, N; Frydenberg, M; Daniel, V; Gleave, M; Gravis, G; Halabi, S; Heinrich, D; Herrmann, K; Higano, C; Hofmanfff, MS; Horvath, LG; Hussain, M; Jereczek-Fossakkk, BA; Jonesmmm, R; Kanesvaran, R; Kellokumpu-Lehtinen, PL; Khauli, RB; Klotz, L; Kramer, G; Leibowitz, R; Logothetisp, CJ; Mahal, BA; Maluf, F; Mateo, J; Matheson, D; Mehra, N; Merseburger, A; Morgans, AK; Morris, MJ; Mrabti, H; Mukherji, D; Murphy, DG; Murthy, V; Nguyen, PL; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Pezaro, C; Poon, DMC; Pritchard, CC; Rabah, DM; Rathkopf, D; Reiter, RE; Rubin, MA; Ryan, CJ; Saad, F; Sade, JP; Sartor, OA; Scher, HI; Sharifi, N; Skoneczna, I; Soule, H; Spratt, DE; Srinivas, S; Sternberg, CN; Steuber, T; Suzuki, H; Sydes, MR; Taplin, ME; Tilki, D; Turkeri, L; Turco, F; Uemura, H; Uemura, H; Urun, Y; Vale, CL; van Oort, I; Vapiwala, N; Walz, J; Yamoah, K; Ye, DW; Yu, EY; Zapatero, A; Zilli, T; Omlin, A	Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/ High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022	EUROPEAN UROLOGY	23.4	D1	Article	2023
CIMO-01	Sánchez-Quintero, MJ; Delgado, J; Chaves, LM; Medina-Vera, D; Murri, M; Becerra-Muñoz, VM; Estévez, M; Crespo-Leiro, MG; López, GP; González-Jiménez, A; Ranea, JAG; Queipo-Ortuño, MI; Plaza-Andrades, I; Rodríguez-Capitán, J; Pavón-Morón, FJ; Jiménez-Navarro, MF	Multi-Omics Approach Reveals Prebiotic and Potential Antioxidant Effects of Essential Oils from the Mediterranean Diet on Cardiometabolic Disorder Using Humanized Gnotobiotic Mice.	ANTIOXIDANTS	7	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CIMO-01	Martin-Broto, J; Martinez-Garcia, J; Moura, DS; Redondo, A; Gutierrez, A; Lopez-Pousa, A; Martinez-Trufero, J; Sevilla, I; Diaz-Beveridge, R; Solis-Hernandez, MP; Carnero, A; Perez, M; Marcilla, D; Garcia-Foncillas, J; Romero, P; Fernandez-Jara, J; Lopez-Lopez, D; Arribas, I; Hindi, N	Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A	SIGNAL TRANSDUCTION AND TARGETED THERAPY	39.3	D1	Article	2023
CIMO-01	Fizazi, K; Piulats, JM; Reaume, MN; Ostler, P; McDermott, R; Gingerich, JR; Pintus, E; Sridhar, SS; Bambury, RM; Emmenegger, U; Lindberg, H; Morris, D; Nole, F; Staffurth, J; Redfern, C; Saez, MI; Abida, W; Daugaard, G; Heidenreich, A; Krieger, L; Sautois, B; Loehr, A; Despain, D; Heyes, CA; Watkins, SP; Chowdhury, S; Ryan, CJ; Bryce, AH	Rucaparib or Physician's Choice in Metastatic Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE	158.5	D1	Article	2023
CIMO-01	Forne, AF; Anaya, MJG; Guillot, SJS; Andrade, IP; Fernandez, LD; Ocon, MJL; Perez, YL; Queipo-Ortuno, MI; Gomez-Millan, J	Influence of the microbiome on radiotherapy- induced oral mucositis and its management: A comprehensive review	ORAL ONCOLOGY	4.8	D1	Review	2023
CIMO-01	Pilo, J; García-Flores, LA; Clemente-Postigo, M; Arranz-Salas, I; Alcaide, J; Ramos-Fernandez, M; Lozano, J; Boughanem, H; Kompella, P; Macías-González, M	8-Oxoguanine DNA Glycosylase 1 Upregulation as a Risk Factor for Obesity and Colorectal Cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
CIMO-01	Javier, GC; Alberto, I; Azucena, GNE; Ivan, V; Debora, M; David, P; Laura, A; Andrea, MS; Esther, S; Oleguer, C; Paula, B; Laura, M; Nuria, V; Miquel, N; Patricia, G; Barbara, A; Neus, B; Tamara, S; Manel, J; Aleix, P; Francesco, S	Determinants of activity and efficacy of anti- PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study	CANCER IMMUNOLOGY IMMUNOTHERAPY	5.8	Q1	Article	2023
CIMO-01	Cerezo, MV; Soria-Reyes, LM; Pajares, B; Gomez-Millan, J; Blanca, MJ	Development and psychometric properties of the Stressors in Breast Cancer Scale	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article	2023
CIMO-01	Jimenez-Rodriguez, B; Alba-Bernal, A; Lopez-Lopez, E; Quiros-Ortega, ME; Carbajosa, G; Garrido-Aranda, A; Alvarez, M; Godoy-Ortiz, A; Queipo-Ortuno, MI; Vicioso, L; Diaz-Cordoba, G; Roldan-Diaz, MD; Velasco-Suelto, J; Hernando, C; Bermejo, B; Julve-Parreno, A; Lluch, A; Pascual, J; Comino-Mendez, I; Alba, E	Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
CIMO-01	Gutiérrez-Repiso, C; Cantarero-Cuenca, A; González-Jiménez, A; Linares-Pineda, T; Peña-Montero, N; Ocaña-Wilhelmi, L; Tinahones, FJ; Morcillo, S	Epigenetic Marks as Predictors of Metabolic Response to Bariatric Surgery: Validation from an Epigenome Wide Association Study	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
CIMO-01	Adeyelu, T; Bordin, N; Waman, VP; Sadlej, M; Sillitoe, I; Moya-Garcia, AA; Orengo, CA	KinFams: De-Novo Classification of Protein Kinases Using CATH Functional Units	BIOMOLECULES	5.5	Q1	Article	2023
CIMO-01	Ocaña, MC; Bernal, M; Yang, CD; Caro, C; Domínguez, A; Vu, HS; Cárdenas, C; García-Martín, ML; Deberardinis, RJ; Quesada, AR; Martínez-Poveda, B; Medina, MA	New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo	COMMUNICATIONS BIOLOGY	5.9	Q1	Article	2023
CIMO-01	Martinez-Sanchez, MA; Balaguer-Roman, A; Fernandez-Ruiz, VE; Almansa-Saura, S; Garcia-Zafra, V; Ferrer-Gomez, M; Frutos, MD; Queipo-Ortuno, MI; Ruiz-Alcaraz, AJ; Nunez-Sanchez, MA; Ramos-Molina, B	Plasma short-chain fatty acid changes after bariatric surgery in patients with severe obesity	SURGERY FOR OBESITY AND RELATED DISEASES	3.1	Q1	Article	2023
CIMO-01	Montes, AF; Orduna, VA; Martinez, EA; Salas, NR; Torres, E; Lavin, DC; Alonso, RMR; Falco, E; Oliva, JC; Cirera, L; Gomez, JG; Pericay, C	The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer	ONCOLOGIST	5.8	Q1	Article	2023
CIMO-01	Heredia-Soto, V; Gutierrez-Sainz, L; Ghanem, I; Guerra, L; Palacios, E; de Uribe, M; Trilla-Fuertes, L; de Miguel, M; Cejas, P; Medina, L; Calderon, JM; Vinal, D; Mendiola, M; Feliu, J	The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectable Pancreatic Adenocarcinoma	BIOMEDICINES	4.7	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CIMO-01	Schmid, Peter; Cortes, Javier; Joaquim, Ana; Janez, Noelia Martinez; Morales, Serafin; Diaz-Redondo, Tamara; Blau, Sibel; Neven, Patrick; Lemieux, Julie; Garcia-Saenz, Jose Angel; Hart, Lowell; Biyukov, Tsvetan; Baktash, Navid; Massey, Dan; Burris, Howard A., III; Rugo, Hope S.	XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease	BREAST CANCER RESEARCH	7.4	Q1	Article	2023
CIMO-01	Fernandez-Perez, MP; Perez-Navarro, E; Alonso-Gordoa, T; Conteduca, V; Font, A; Vazquez-Estevez, S; Gonzalez-del-Alba, A; Wetterskog, D; Antonarakis, ES; Mellado, B; Fernandez-Calvo, O; Mendez-Vidal, MJ; Climent, MA; Duran, I; Gallardo, E; Sanchez, AR; Santander, C; Saez, MI; Puente, J; Tudela, J; Martinez, A; Lopez-Andreo, MJ; Padilla, J; Lozano, R; Hervas, D; Luo, J; de Giorgi, U; Castellano, D; Attard, G; Grande, E; Gonzalez-Billalabeitia, E	A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide	PROSTATE	2.8	Q2	Article	2023
CIMO-01	Nadal, E; Saleh, M; Aix, SP; Ochoa-de-Olza, M; Patel, SP; Antonia, S; Zhao, YM; Gueorguieva, I; Man, MC; Estrem, ST; Liu, JA; Avsar, E; Lin, WH; Benhadji, KA; Gandhi, L; Guba, SC; Diaz, IA	A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer	BMC CANCER	3.8	Q2	Article	2023
CIMO-01	Chouaid, C; Bosquet, L; Girard, N; Kron, A; Scheffler, M; Griesinger, F; Sebastian, M; Trigo, J; Viteri, S; Knott, C; Rodrigues, B; Rahhali, N; Cabrieto, J; Diels, J; Perualila, NJ; Schioppa, CA; Sermon, J; Toueg, R; Erdmann, N; Mielke, J; Nematian-Samani, M; Martin-Fernandez, C; Pfaira, I; Li, T; Mahadevia, P; Wolf, J	An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations	ADVANCES IN THERAPY	3.8	Q2	Article	2023
CIMO-01	Lorite, MI; Cuadros, AM; Rivera-Izquierdo, M; Sanchez-Martin, V; Cuadros, M	Benefits for cardiovascular system, bone density, and quality of life of a long-term hormone therapy in hysterectomized women: a 20-year follow-up study	MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY	2.7	Q2	Article	2023
CIMO-01	Cuesta-Vargas, A; Buchan, J; Alba, E; Campos, MI; Roldan-Jimenez, C; Pajares, B	Development of a functional assessment task in metastatic breast cancer patients: the 30-second lie-to-sit test	DISABILITY AND REHABILITATION	2.2	Q2	Article	2023
CIMO-01	Errazquin, R; Carrasco, E; Del Marro, S; Suñol, A; Peral, J; Ortiz, J; Rubio, JC; Segrelles, C; Dueñas, M; Garrido-Aranda, A; Alvarez, M; Belendez, C; Balmaña, J; Garcia-Escudero, R	Early Diagnosis of Oral Cancer and Lesions in Fanconi Anemia Patients: A Prospective and Longitudinal Study Using Saliva and Plasma	CANCERS	5.2	Q2	Article	2023
CIMO-01	Lopez-Garcia, G; Jerez, JM; Ribelles, N; Alba, E; Veredas, FJ	Explainable clinical coding with in-domain adapted transformers	JOURNAL OF BIOMEDICAL INFORMATICS	4.5	Q2	Article	2023
CIMO-01	Roldan-Jimenez, C; Martin-Martin, J; Pajares, B; Ribelles, N; Alba, E; Cuesta-Vargas, Al	Factors associated with upper limb function in breast cancer survivors	PM&R	2.1	Q2	Article	2023
CIMO-01	Mena-del Horno, S; Balasch-Bernat, M; Louw, A; Luque-Suarez, A; Rodríguez-Brazzarola, P; Navarro-Ledesma, S; Murillo, C; Duenas, L; Lluch, E	Is there any benefit of adding a central nervous system-focused intervention to a manual therapy and home stretching program for people with frozen shoulder? A randomized controlled trial	JOURNAL OF SHOULDER AND ELBOW SURGERY	3	Q2	Article	2023
CIMO-01	Yoshino, T; Andre, T; Kim, TW; Yong, WP; Shiu, KK; Jensen, BV; Jensen, LH; Punt, CJA; Smith, D; Garcia-Carbonero, R; Alcaide-Garcia, J; Gibbs, P; De la Fouchardiere, C; Rivera, F; Elez, E; Le, DT; Adachi, N; Fogelman, D; Marinello, P; Diaz, LA	Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer	CANCER SCIENCE	5.7	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CIMO-01	Pericay, C; Montes, AF; Orduña, VA; Declara, IM; Martinez, EA; Salas, NR; Torres, E; Lavín, DC; Alonso, RMR; Falcó, E; Oliva, JC; Cirera, L	Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study	CANCERS	5.2	Q2	Article	2023
CIMO-01	Pesantez, David; Indacochea, Alberto; Angelats, Laura; Sirico, Marianna; Victoria, Ivan; Sanfeliu, Esther; Teixido, Cristina; Gonzalez-Navarro, Azucena E; Galvan, Patricia; Braso-Maristany, Fara; Jares, Pedro; Juan, Manel; Prat, Aleix; Schettini, Francesco; Garcia-Corbacho, Javier	Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.	JCO precision oncology	4.6	Q2	Article	2023
CIMO-01	Perez-Fidalgo, JA; Ortega, E; Ponce, J; Redondo, A; Sevilla, I; Valverde, C; Verdum, JI; de Alava, E; Lopez, MG; Marquina, G; Sebio, A	Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY	4.9	Q2	Review	2023
CIMO-01	Carles, J; Medina-Lopez, RA; Puente, J; Gomez-Ferrer, A; Nebra, JC; Medina, MIS; Ribal, MJ; Antolin, AR; Alvarez-Ossorio, JL; Novo, JFS; Agut, CM; Srinivasan, S; Ortiz, J; Fizazi, K	Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis	FUTURE ONCOLOGY	3.3	Q3	Article	2023
CIMO-01	Fuentes-Abolafio, IJ; Roldan-Jimenez, C; Campos, MI; Pajares-Hachero, BI; Alba-Conejo, E; Cuesta-Vargas, A	Forearm Muscle Activity During the Handgrip Test in Breast Cancer Survivors: A Cross- Sectional Study	CLINICAL BREAST CANCER	3.1	Q3	Article	2023
CIMO-01	Garcia-Saenz, JA; Blancas, I; Echavarria, I; Hinojo, C; Margeli, M; Moreno, F; Pernas, S; Cajal, TRY; Ribelles, N; Bellet, M	SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)	CLINICAL & TRANSLATIONAL ONCOLOGY	3.4	Q3	Article	2023
CIMO-01	Serrano, Cesar; Alvarez, Rosa; Carrasco, Juan Antonio; Marquina, Gloria; Martinez-Garcia, Jeronimo; Martinez-Marin, Virginia; Sala, Maria angeles; Sebio, Ana; Sevilla, Isabel; Martin-Broto, Javier	SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)	CLINICAL & TRANSLATIONAL ONCOLOGY	3.4	Q3	Article	2023
CIMO-01	Vazquez, JC; Antolin, S; Ruiz-Borrego, M; Servitja, S; Alba, E; Barnadas, A; Lluch, A; Martin, M; Rodriguez-Lescure, A; Sola, I; Bonfill, X; Urrutia, G; Sanchez-Rovira, P	Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis	CLINICAL & TRANSLATIONAL ONCOLOGY	3.4	Q3	Review	2023
CIMO-01	Vazquez, JC; Pinero, A; de Castro, FJ; Lluch, A; Martin, M; Barnadas, A; Alba, E; Rodriguez-Lescure, A; Rojo, F; Gimenez, J; Sola, I; Quintana, MJ; Bonfill, X; Urrutia, G; Sanchez-Rovira, P	The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review	CLINICAL & TRANSLATIONAL ONCOLOGY	3.4	Q3	Review	2023
CIMO-01	Trujillo-Martín, MM; de Armas-Castellano, A; González-Hernández, Y; González-Pacheco, H; Infante-Ventura, D; del Pino-Sedeño, T; Ramallo-Fariña, Y; Sack, AA; Domínguez, AR; Serrano-Aguilar, P	Scalp cooling for the prevention of alopecia secondary to chemotherapy: systematic review and meta-analysis	REVISTA ESPANOLA DE SALUD PUBLICA	1.1	Q4	Review	2023
CIMO-02	Provencio, M; Ortega, AL; Coves-Sarto, J; Calvo, V; Marsé-Fabregat, R; Dómine, M; Guirado, M; Carcereny, E; Fernández, N; Alvarez, R; Blanco, R; León-Mateos, L; Sánchez-Torres, JM; Sullivan, IG; Cobo, M; Sánchez-Hernández, A; Massuti, B; Sierra-Rodero, B; Mártinez-Toledo, C; Serna-Blasco, R; Romero, A; Cruz-Bermúdez, A	Atezolizumab Plus Bevacizumab as First- line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden A Nonrandomized Controlled Trial	JAMA ONCOLOGY	28.4	D1	Article	2023
CIMO-02	Cho, Byoung Chul; Lee, Jong Seok; Wu, Yi-Long; Cicin, Irfan; Dols, Manuel Cobo; Ahn, Myung-Ju; Cuppens, Kristof; Veillon, Remi; Nadal, Ernest; Dias, Josiane Mourao; Martin, Claudio; Reck, Martin; Garon, Edward B.; Felip, Enriqueta; Paz-Ares, Luis; Mornex, Francoise; Vokes, Everett E.; Adjei, Alex A.; Robinson, Clifford; Sato, Masashi; Vugmeyster, Yulia; Machl, Andreas; Audhuy, Francois; Chaudhary, Surendra; Barlesi, Fabrice	Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial	JOURNAL OF THORACIC ONCOLOGY	20.4	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CIMO-02	Paz-Ares, LG; Ciuleanu, TE; Cobo, M; Bennouna, J; Schenker, M; Cheng, Y; Juan-Vidal, O; Mizutani, H; Lingua, A; Reyes-Cosmelli, F; Reinmuth, N; Menezes, J; Jassem, J; Protsenko, S; Richardet, E; Felip, E; Feeney, K; Zurawski, B; Alexandru, A; Jimenez, ED; Dakhil, S; Lu, S; Reck, M; John, T; Hu, N; Zhang, XQ; Sylvester, J; Eccles, LJ; Grootendorst, DJ; Balli, D; Neely, J; Carbone, DP	First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations	JOURNAL OF THORACIC ONCOLOGY	20.4	D1	Article	2023
CIMO-02	Fernández-Miranda, I; Pedrosa, L; Llanos, M; Franco, FF; Gómez, S; Martín-Acosta, P; García-Arroyo, FR; Gumá, J; Horcajo, B; Ballesteros, AK; Gálvez, L; Martínez, N; Marín, M; Sequero, S; Navarro, M; Yanguas-Casás, N; Calvo, V; Rueda-Domínguez, A; Provencio, M; Sánchez-Beato, M	Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study	CLINICAL CANCER RESEARCH	11.5	D1	Article	2023
CIMO-02	Provencio, M; Nadal, E; Gonzalez-Larriba, JL; Martinez-Marti, A; Bernabe, R; Bosch-Barrera, J; Casal-Rubio, J; Calvo, V; Insa, A; Ponce, S; Reguart, N; de Castro, J; Mosquera, J; Cobo, M; Aguilar, A; Vivanco, GL; Camps, C; Lopez-Castro, R; Moran, T; Barneto, I; Rodriguez-Abreu, D; Serna-Blasco, R; Benitez, R; de la Rosa, CA; Palmero, R; Hernando-Trancho, F; Martin-Lopez, J; Cruz-Bermudez, A; Massuti, B; Romero, A	Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE	158.5	D1	Article	2023
CIMO-02	Besse, B; Felip, E; Campelo, RG; Cobo, M; Mascaux, C; Madroszyk, A; Cappuzzo, F; Hilgers, W; Romano, G; Denis, F; Viteri, S; Debieuvre, D; Galetta, D; Baldini, E; Razaq, M; Robinet, G; Maio, M; Delmonte, A; Roch, B; Masson, P; Schuette, W; Zer, A; Remon, J; Costantini, D; Vasseur, B; Dziadziuszko, R	Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1	ANNALS OF ONCOLOGY	50.5	D1	Article	2023
CIMO-02	Leal, T; Kotecha, R; Ramlau, R; Zhang, L; Milanowski, J; Cobo, M; Roubec, J; Petruzelka, L; Havel, L; Kalmadi, S; Ward, J; Andric, Z; Berghmans, T; Gerber, DE; Kloecker, G; Panikkar, R; Aerts, J; Delmonte, A; Pless, M; Greil, R; Rolfo, C; Akerley, W; Eaton, M; Iqbal, M; Langer, C	Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study	LANCET ONCOLOGY	51.1	D1	Article	2023
CIMO-02	Clingan, Philip; Ladwa, Rahul; Brungs, Daniel; Harris, Dean Laurence; McGrath, Margaret; Arnold, Susan; Coward, Jermaine; Fourie, Samuel; Kurochkin, Andriy; Malan, Daniel R; Mant, Andrew; Sharma, Vinay; Shue, Hong; Tazbirkova, Andrea; Berciano-Guerrero, Miguel-Angel; Charoentum, Chaiyut; Dalle, Stephane; Dechaphunkul, Arunee; Dudnichenko, Oleksandr; Koralewski, Piotr; Lugowska, Iwona; Montaudie, Henri; Munoz-Couselo, Eva; Sriuranpong, Virote; Oliviero, James; Desai, Jayesh	Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.	JOURNAL FOR IMMUNOTHERAPY OF CANCER	10.9	Q1	Article	2023
CIMO-02	Reck, M; Ciuleanu, TE; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Cheng, Y; Sakai, H; Paz-Ares, L; Lu, S; John, T; Sun, XW; Moisei, A; Taylor, F; Lawrance, R; Zhang, XQ; Sylvester, J; Yuan, Y; Blum, SI; Penrod, JR; Carbone, DP	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes	EUROPEAN JOURNAL OF CANCER	8.4	Q1	Article	2023
CIMO-02	Villena-Salinas, J; Ortega-Lozano, SJ; Amrani-Raissouni, T; Aguüra, E; Caballero-Villarraso, J	Follow-Up Findings in Multiple System Atrophy from [1231]Ioflupane Single-Photon Emission Computed Tomography (SPECT): A Prospective Study	BIOMEDICINES	4.7	Q1	Article	2023
CIMO-02	Bebia, Z; Reyes, O; Jeanfreau, R; Kantele, A; De Leon, RG; Sánchez, MG; Banooni, P; Gardener, GJ; Rasero, JLB; Pardilla, MBE; Langley, JM; Di Leo, CM; Botelho-Nevers, E; Buttery, J; Laurichesse, H; Madhi, SA; García, AM; Stanley, T; Barjat, T; Griffith, R; Castrejón-Alba, MM; de Heusch, M; Dieussaert, I; Hercor, M; Lese, P; Qian, H; Tullio, AN; Henry, O	Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial	JOURNAL OF INFECTIOUS DISEASES	6.4	Q1	Article	2023
CIMO-02	Trilla-Fuertes, L; Gamez-Pozo, A; Nogue, M; Busquier, I; Arias, F; Lopez-Campos, F; Fernandez-Montes, A; Ruiz, A; Velazquez, C; Martin-Bravo, C; Perez-Ruiz, E; Asensio, E; Hernandez-Yague, X; Rodrigues, A; Ghanem, I; Lopez-Vacas, R; Hafez, A; Arias, P; Dapia, I; Solis, M; Dittmann, A; Ramos, R; Llorens, C; Maurel, J; Campos-Barros, A; Vara, JAF; Feliu, J	Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma	CANCER	6.2	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CIMO-02	López-Villodres, JA; Escamilla, A; Mercado-Sáenz, S; Alba-Tercedor, C; Rodriguez-Perez, LM; Arranz-Salas, I; Sanchez-Varo, R; Bermúdez, D	Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice	BIOMEDICINES	4.7	Q1	Review	2023
CIMO-02	Chaves, P; Garrido, M; Oliver, J; Perez-Ruiz, E; Barragan, I; Rueda-Dominguez, A	Preclinical models in head and neck squamous cell carcinoma	BRITISH JOURNAL OF CANCER	8.8	Q1	Review	2023
CIMO-02	Candal-Pedreira, C; Ruano-Ravina, A; de Juan, VC; Cobo, M; Trigo, JM; Carcereny, E; Cucurull, M; Castro, RL; García, ES; Sánchez-Gastaldo, A; Massuti, B; Rodríguez-Abreu, D; Estival, A; Risueño, MG; Ramón, MP; Campelo, RG; Alonso-Jáudenes, G; Camps, C; Morillo, ED; Ojea, CG; Dómine, M; Sanchez-Hernandez, A; Bosch-Barrera, J; González, MAS; Provencio, M	Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study	ERJ OPEN RESEARCH	4.6	Q2	Article	2023
CIMO-02	Villena-Salinas, J; Ortega-Lozano, SJ; Amrani-Raissouni, T; Agüera, E; Caballero-Villarraso, J	Diagnostic Effectiveness of [1231]Ioflupane Single Photon Emission Computed Tomography (SPECT) in Multiple System Atrophy	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
CIMO-02	Oliver, J; Onieva, JL; Garrido-Barros, M; Cobo-Dols, M; Martinez-Galvez, B; Garcia-Pelicano, AI; Dubbelman, J; Benitez, JC; Martin, JZ; Cantero, A; Perez-Ruiz, E; Rueda-Dominguez, A; Barragan, I	Fluorometric Quantification of Total Cell- Free DNA as a Prognostic Biomarker in Non- Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade	CANCERS	5.2	Q2	Article	2023
CIMO-02	Trilla-Fuertes, L; Gamez-Pozo, A; Prado-Vazquez, G; Lopez-Vacas, R; Soriano, V; Garicano, F; Lecumberri, MJ; de la Borbolla, MR; Majem, M; Perez-Ruiz, E; Gonzalez-Cao, M; Oramas, J; Magdaleno, A; Fra, J; Martin-Carnicero, A; Corral, M; Puertolas, T; Ramos-Ruiz, R; Dittmann, A; Nanni, P; Vara, JAF; Espinosa, E	Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma	CANCERS	5.2	Q2	Article	2023
CIMO-02	Isla, D; Sanchez, A; Casal, J; Cobo, M; Majem, M; Reguart, N; Zugazagoitia, J; Bernabe, R	PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
CIMO-02	Provencio, M; Carcereny, E; Castro, RL; Calvo, V; Abreu, DR; Cobo, M; Ortega, AL; Bernabe, R; Guirado, M; Massuti, B; del Barco-Morillo, E; Bosch-Barrera, J; Camps, C; Carroll, R; Rault, C; Chaib, C; Penrod, J; Vo, L; Ralphs, E; Daumont, MJ	Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study	TRANSLATIONAL LUNG CANCER RESEARCH	4	Q2	Article	2023
CIMO-02	Timilsina, M; Fey, D; Buosi, S; Janik, A; Costabello, L; Carcereny, E; Abreu, DR; Cobo, M; Castro, RL; Bernabe, R; Minervini, P; Torrente, M; Provencio, M; Novacek, V	Synergy between imputed genetic pathway and clinical information for predicting recurrence in early stage non-small cell lung cancer	JOURNAL OF BIOMEDICAL INFORMATICS	4.5	Q2	Article	2023
CIMO-02	Rubió-Casadevall, J; Cirauqui, BC; Trufero, JM; Serrahima, MP; Castaño, AG; Maseda, AC; Docampo, LI; Segura, PP; Lenza, IC; Calderón, VG; Salvà, JF; Alvarez, CP; Hernandez, I; Morillo, ED; Conde, MC; Galán, JM; Sánchez, MD; Quiroga, V; Ortega, E; Mesia, R	TTCC-2019-02: real-world evidence of first- line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck	FRONTIERS IN ONCOLOGY	4.7	Q2	Article	2023
CIMO-02	Rodriguez, JD; Ramos-Garcia, V; Infante-Ventura, D; Suarez-Herrera, JC; Rueda-Dominguez, A; Serrano-Aguilar, P; Trujillo-Martin, MD	Ethical, legal, organizational and social issues related to the use of scalp cooling for the prevention of chemotherapy-induced alopecia: A systematic review	HEALTH EXPECTATIONS	3.2	Q2	Review	2023
CIMO-02	Gómez-Aparicio, MA; López-Campos, F; Lozano, AJ; Maldonado, X; Caballero, B; Zafra, J; Suarez, V; Moreno, E; Arcangeli, S; Scorsetti, M; Couñago, F	Novel Approaches in the Systemic Management of High-Risk Prostate Cancer	CLINICAL GENITOURINARY CANCER	3.2	Q2	Review	2023
CIMO-02	De Pablos-Rodriguez, P; Del Pino-Sedeno, T; Infante-Ventura, D; De Armas-Castellano, A; Backhaus, MR; Ferrer, JFL; De Pablos-Velasco, P; Rueda-Dominguez, A; Trujillo-Martin, MM	Prognostic Impact of Sarcopenia in Patients with Advanced Prostate Carcinoma: A Systematic Review	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CIMO-02	Chicas-Sett, R; Martinez, JC; Blanquisett, AH; Zafra, J; Pastor-Peidro, J	Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer	FRONTIERS IN ONCOLOGY	4.7	Q2	Review	2023
CIMO-02	Garcia, EE; Varela, MA; Jimenez, RL; Gomez-Maldonado, J; Dols, MAC; Claros, MG; Moreno, RB	Construction of miRNA-mRNA networks for the identification of lung cancer biomarkers in liquid biopsies	CLINICAL & TRANSLATIONAL ONCOLOGY	3.4	Q3	Article	2023
CIMO-02	Duque-Santana, V; López-Campos, F; Martin-Martin, M; Valero, M; Zafra-Martín, J; Couñago, F; Sancho, S	Neutrophil-to-lymphocyte ratio and platelet- to-lymphocyte ratio as prognostic factors in locally advanced rectal cancer	ONCOLOGY	3.5	Q3	Article	2023
CIMO-02	Dols, MC; Zambrano, CB; Cabezón-Gutiérrez, L; Chicas-Sett, R; López-Barajas, MIB; Navalón, FJG; Pérez, JLF; Bermúdez, GS; Torres, PT; Mingorance, ID; Marín, AG; Oriol, AL; Lario, AP; Mauriño, PS; Gómez, OH; Muñoz, DM; González, IH; Sanz-Yagüe, A; López, BS	One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study	BMJ SUPPORTIVE & PALLIATIVE CARE	2.7	Q3	Article	2023
CIMO-02	Guma, J; Palazon-Carrion, N; Rueda-Dominguez, A; Sequero, S; Calvo, V; Garcia-Arroyo, R; Gomez-Codina, J; Llanos, M; Martinez-Banaclocha, N; Provencio, M	SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)	CLINICAL & TRANSLATIONAL ONCOLOGY	3.4	Q3	Article	2023
CIMO-02	Los Arcos, Marta Barrado; Lopez-Campos, Fernando; Valcarcel, Marta Lopez; Rubio, Manuel Galdeano; de Manzanos, Ignacio Visus Fernandez; Duque-Santana, Victor; Aparicio, Marian Gomez; Martin, Juan Zafra; Kishan, Amar U.; Achard, Verane; Siva, Shankar; Counago, Felipe	Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?	CLINICAL GENITOURINARY CANCER	3.2	Q3	Review	2023
CIMO-02	Sosa-Fajardo, P; Blanco-Suarez, JM; Pineda-Munguia, A; Rubi-Olea, L; Peleteiro-Higuero, P; Gajate, P; Zafra-Martin, J; Siva, S; Bossi, A; Lopez-Campos, F; Counago, F	Stereotactic body radiation therapy for kidney cancer. Where do we stand?	INTERNATIONAL JOURNAL OF UROLOGY	2.6	Q3	Review	2023
CIMO-02	Moreno-Olmedo, Elena; Suarez-Gironzini, Vladimir; Fusco, Juan Pablo; Ruiz, Lucrecia; Begara, Jose; Guijarro, Marcos; Gonzalez San Segundo, Carmen; Zafra, Juan; Lopez Campos, Fernando; Counago, Felipe	Prostate Cancer: Management of Biochemical Recurrence after Surgery.	ARCHIVOS ESPANOLES DE UROLOGIA	0.5	Q4	Review	2023
CIMO-02	Amaya, Enrique; Carrasco, Eliseo; Lopez, Marta; Gomez-Aparicio, Maria Antonia; Pelari-Mici, Lira; Duque-Santana, Victor; Zafra, Juan; Achard, Verane; Sargos, Paul; Lopez Campos, Fernando; Counago, Felipe	Role of Radiotherapy and Hormone Therapy in Patients with Node-Positive Locally Advanced Prostate Cancer.	ARCHIVOS ESPANOLES DE UROLOGIA	0.5	Q4	Review	2023
CIMO-03	Cervera-Garvi, P; Aguilar-Nunez, D; Paez-Moguer, J; Jerez, JM; Navarro-Ledesma, S	Differences in the Impact of Plantar Fasciopathy on the Spatio-Temporal Gait Parameters between Participants with Bilateral Plantar Fasciopathy and Healthy Subjects: A Cross-Sectional Study	APPLIED SCIENCES- BASEL	2.7	Q2	Article	2023
CIMO-03	López-García, G; Jerez, JM; Ribelles, N; Alba, E; Veredas, FJ	Explainable clinical coding with in-domain adapted transformers	JOURNAL OF BIOMEDICAL INFORMATICS	4.5	Q2	Article	2023
D-01	Merchante, Nicolas; Herrero, Rocio; Valverde-Fredet, Maria Dolores; Rodriguez-Fernandez, Miguel; Pinagorte, Hector; Martinez-Marcos, Francisco J.; Gil-Anguita, Concepcion; Garcia-Lopez, Maria; Pitarch, Maria Tasias; De Medrano, Vicente Abril Lopez; Lorite, Miguel Nicolas Navarrete; Gomez-Ayerbe, Cristina; Leon, Eva; Gonazlez-De La Aleja, Pilar; Castillo, Ana Ruiz; Aller, Ana, I; Rodriguez, Juan Carlos; Fonseca, Julia Ternero; Corzo, Juan E.; Perez, Alberto Naranjo; Trigo-Rodriguez, Marta; Merino, Esperanza	Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin	JAC-ANTIMICROBIAL RESISTANCE	3.5		Article	2023
D-01	Polo, R; García-Albéniz, X; Terán, C; Morales, M; Rial-Crestelo, D; Garcinuño, MA; del Toro, MG; Hita, C; Gómez-Sirvent, JL; Buzón, L; de Santiago, AD; Arellano, JP; Sanz, J; Bachiller, P; Alfaro, EM; Díaz-Brito, V; Masiá, M; Hernández-Torres, A; Guerra, JM; Santos, J; Arazo, P; Muñoz, L; Arribas, JR; de Salazar, PM; Moreno, S; Hernán, MA; Del Amo, J	Daily tenofovir disoproxil fumarate/ emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers	CLINICAL MICROBIOLOGY AND INFECTION	14.2	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-01	Escrihuela-Vidal, F; Berbel, D; Fernandez-Hidalgo, N; Escola-Verge, L; Munoz, P; Olmedo, M; Goenaga, MA; Goikoetxea, J; Farinas, MC; De Alarcon, A; Miro, JM; Ojeda, G; Plata, A; Cuervo, G; Carratala, J; GAMES Investigators	Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci	CLINICAL INFECTIOUS DISEASES	11.8	D1	Article	2023
D-01	Vizcarra, Pilar; Moreno, Ana; Vivancos, Maria J.; Garcia, Alfonso Muriel; Schacke, Margarita Ramirez; Gonzalez-Garcia, Juan; Curran, Adrian; Palacios, Rosario; Guirao, Antonio Jesus Sanchez; Banuls, Sergio Reus; Guillen, Santiago Moreno; Casado, Jose L.; Spanish HIV Res Network CoRIS	A Risk Assessment Tool for Predicting Fragility Fractures in People with HIV: Derivation and Internal Validation of the FRESIA Model	JOURNAL OF BONE AND MINERAL RESEARCH	6.2	Q1	Article	2023
D-01	Lopez-Lopez, Pedro; Frias, Mario; Perez-Jimenez, Ana Belen; Freyre-Carrillo, Carolina A.; Pineda, Juan A.; Aguilera, Antonio; Fuentes, Ana; Alados, Juan Carlos; Reina, Gabriel; Ramirez-Arellano, Encarnacion; Viciana, Isabel; Mesquita, Joao; Caballero-Gomez, Javier; Rivero-Juarez, Antonio; Rivero, Antonio	Optimization of the molecular diagnosis of the acute hepatitis E virus infection	MICROBIAL BIOTECHNOLOGY	5.7	Q1	Article	2023
D-01	Lopez-Lopez, Pedro; Frias, Mario; Perez-Jimenez, Ana Belen; Freyre-Carrillo, Carolina; Pineda, Juan A.; Fuentes, Ana; Alados, Juan Carlos; Ramirez-Arellano, Encarnacion; Viciana, Isabel; Corona-Mata, Diana; Caballero-Gomez, Javier; Garcia-Bocanegra, Ignacio; Risalde, Maria A.; Rivero-Juarez, Antonio; Rivero, Antonio	Temporal changes in the genotypes of Paslahepevirus balayani in southern Spain and their possible link with changes in pig trade imports	ONE HEALTH	5	Q1	Article	2023
D-01	Ramos-Martinez, Antonio; Dominguez, Fernando; Munoz, Patricia; Marin, Mercedes; Pedraz, Alvaro; Farinas, M. Carmen; Tascon, Valentin; de Alarcon, Aristides; Rodriguez-Garcia, Raquel; Miro, Jose Maria; Goikoetxea, Josune; Ojeda-Burgos, Guillermo; Escrihuela-Vidal, Francesc; Calderon-Parra, Jorge	Clinical presentation, microbiology, and prognostic factors of prosthetic valve endocarditis. Lessons learned from a large prospective registry	PLOS ONE	3.7	Q2	Article	2023
D-01	Pinazo-Bandera, JM; Aranda, J; García-García, AM; Alcantara, R; Ortega-Alonso, A; Del Campo-Herrera, E; Clavijo, E; Garcia-Escaño, MD; Ruiz, JJR; Morales-Herrera, M; Valle-López, V; Martin-Alarcón, R; Viciana, I; Jiménez, JB; Fernández-García, F; Toro-Ortiz, JP; Sanchez-Yáñez, E; Alvarez-alvarez, I; Andrade, RJ; Robles-Díaz, M; Garcia-Cortés, M	Hepatitis C virus point-of-care microelimination approach in a vulnerable population in the South of Spain	GASTROENTEROLOGY REPORT	3.6	Q2	Article	2023
D-01	Palacios, R; Gómez-Ayerbe, C; Casado, JL; Tejerina, F; Montes, ML; Castaño, M; Ocampo, A; Rial, D; Ribera, E; Galindo, MJ; Hidalgo, C; Fariñas, C; Montero, M; Payeras, T; Fanjul, F; de la Torre, J; Santos, J	Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119	HIV MEDICINE	3	Q3	Article	2023
D-03	Mena-Vazquez, Natalia; Redondo-Rodriguez, Rocio; Cabezudo-Garcia, Pablo; Garcia-Studer, Aimara; Ortiz-Marquez, Fernando; Borregon-Garrido, Paula; Martin-Valverde, Manuel; Urena-Garnica, Inmaculada; Manrique-Arija, Sara; Cano-Garcia, Laura; Fernandez-Nebro, Antonio	Interstitial Lung Disease Is Associated with Sleep Disorders in Rheumatoid Arthritis Patients.	CLOCKS & SLEEP	3.1		Article	2023
D-03	Bethencourt-Baute, JJ; Montero, N; Zacarias, AM; Nieto, JC; López-Corbeto, M; Boteanu, A; Medrano, M; Rego, GDC; Vargas-Lebron, C; Machín-García, S; Expósito, L; Cacheda, AP; Bernabeu, P; Veroz-González, R; Fernández, O; Merayo, EE; Torrente-Segarra, V; Fernández-Alba, MD; Gamir, ML; López-Robledillo, JC; Antón, J; Otero, L; Bustabad, S	Juvenile idiopathic arthritis in the young adult. Methodology, objectives, and initial data from the JUVENSER registry	REUMATOLOGIA CLINICA	1.5		Article	2023
D-03	Narváez, J; Aburto, M; Seoane-Mato, D; Bonilla, G; Acosta, O; Candelas, G; Cano-Jiménez, E; Castellví, I; González-Ruiz, JM; Corominas, H; López-Muñiz, B; Martín-López, M; Robles-Pérez, A; Mena-Vázquez, N; Rodríguez-Portal, JA; Ortiz, AM; Sabater-Abad, C; Castrejón, I; dos Santos, R; Garrote-Corral, S; Maese, J; Silva-Fernández, L; Castañeda, S; Valenzuela, C	Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology	REUMATOLOGIA CLINICA	1.5		Article	2023
D-03	Cano Garcia, Laura; Dominguez Quesada, Carmen; Rodriguez Vargas, Ana Isabel; Trujillo Martin, Elisa; Martin Martin, Jose Maria	Nursing Recommendations in the Management of Systemic Lupus Erythematosus: A Delphi Consensus.	HISPANIC HEALTH CARE INTERNATIONAL	1.2		Review	2023
D-03	Mena-Vazquez, N; Ruiz-Limon, P; Moreno-Indias, I; Manrique-Arija, S; Lisbona-Montanez, JM; Rioja, J; Mucientes, A; Martin-Nunez, GM; Cano-Garcia, L; Tinahones, FJ; Fernandez-Nebro, A	Adiposity is associated with expansion of the genus Dialister in rheumatoid arthritis patients	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-03	Mena-Vazquez, N; Rojas-Gimenez, M; Romero-Barco, CM; Gandia-Martinez, M; Perez-Gomez, N; Godoy-Navarrete, FJ; Manrique-Arija, S; Garcia-Studer, A; Calvo-Gutierrez, J; Varela, CF; Morales-Garrido, P; Perez, PC; Mourino-Rodriguez, C; Anon-Onate, I; Espildora, F; Aguilar-Hurtado, MC; Redondo, R; Conde, AH; de los Rios, RAD; Cesar, EC; Velloso-Feijoo, ML; Fernandez-Nebro, A	Analysis of comorbidity in rheumatoid arthritis-associated interstitial lung disease: a nested case-cohort study	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
D-03	Boughanem, H; Ruiz-Limón, P; Pilo, J; Lisbona-Montañez, JM; Tinahones, FJ; Indias, IM; Macías-González, M	Linking serum vitamin D levels with gut microbiota after 1-year lifestyle intervention with Mediterranean diet in patients with obesity and metabolic syndrome: a nested cross-sectional and prospective study	GUT MICROBES	12.2	D1	Article	2023
D-03	Martín-López, M; Galindo, M; Pego-Reigosa, JM; Jiménez, N; Marqués, AO; Tomero, E; Freire, M; Martínez-Barrio, J; Boteanu, A; Salgado-Perez, E; Fernández-Nebro, A; Calvo, J; Menor-Almagro, R; Rúa-Figueroa, I	Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study	RHEUMATOLOGY	5.5	Q1	Article	2023
D-03	Alvaro-Gracia, JM; Sanchez-Piedra, C; Culqui, D; Rosello, R; Garcia-Dorta, A; Campos, C; Manrique-Arija, S; Ruiz-Montesinos, D; Ros-Vilamajo, I; Rodríguez-Lozano, C; Freire-González, M; Caliz, R; Bohorquez, C; Soria, LM; Busquets, N; Castrejon, I; Sánchez-Alonso, F; González-Dávila, E; Diaz-Gonzalez, F	Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study	RMD OPEN	6.2	Q1	Article	2023
D-03	Mena-Vazquez, N; Godoy-Navarrete, FJ; Lisbona-Montanez, JM; Redondo-Rodriguez, R; Manrique-Arija, S; Rioja, J; Mucientes, A; Ruiz-Limon, P; Garcia-Studer, A; Ortiz-Marquez, F; Oliver-Martos, B; Cano-Garcia, L; Fernandez-Nebro, A	Inflammatory Biomarkers in the Diagnosis and Prognosis of Rheumatoid Arthritis- Associated Interstitial Lung Disease	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
D-03	Cano-Garcia, L; Redondo-Rodriguez, R; Manrique-Arija, S; Dominguez-Quesada, C; Vacas, JC; Armenteros-Ortiz, P; Ruiz-Vilchez, D; Martin-Martin, JM; Garcia-Studer, A; Ortiz-Marquez, F; Mena-Vazquez, N; Fernandez-Nebro, A	Prevalence of Malnutrition and Associated Factors in Older Patients with Rheumatoid Arthritis: A Cross-Sectional Study	NUTRIENTS	5.9	Q1	Article	2023
D-03	Cano-Garcia, L; Manrique-Arija, S; Dominguez-Quesada, C; Vacas-Perez, JC; Armenteros-Ortiz, PJ; Ruiz-Vilchez, D; Martfi-Martiin, JM; Redondo-Rodriguez, R; Garcia-Studer, A; Ortiz-Marquez, F; Mena-Vazquez, N; Fernandez-Nebro, A	Sarcopenia and Nutrition in Elderly Rheumatoid Arthritis Patients: A Cross- Sectional Study to Determine Prevalence and Risk Factors	NUTRIENTS	5.9	Q1	Article	2023
D-03	Magro-Checa, C; Ramiro, S; Rúa-Figueroa, I; Jimenez, N; del Campo-Pérez, V; Martinez-Barrio, J; Galindo-Izquierdo, M; Calvo-Alén, J; Uriarte-Isacelaya, E; Tomero-Muriel, E; Freire-González, M; Martínez-Taboada, V; Salgado, E; Vela, P; Mena-Vázquez, N; Olivé, A; Narváez, J; Menor-Almagro, R; Santos-Soler, G; Hernández-Beriaín, JA; Manero-Ruiz, J; Aurrecoechea-Aguinaga, E; Ibarguengoitia, O; Montilla-Morales, C; Bonilla-Hernán, G; Torrente-Segarra, V; Salman-Monte, T; Ros-Vilamajo, I; García-Villanueva, MJ; Moriano-Morales, C; Fito-Manteca, C; Lozano-Rivas, N; Bohórquez, C; Pego-Reigosa, JM	Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)	SEMINARS IN ARTHRITIS AND RHEUMATISM	5	Q2	Article	2023
D-03	Valero, M; Sánchez-Piedra, C; Freire, M; Colazo, M; Busquets, N; Meriño-Ibarra, E; Rodríguez-Lozano, C; Manrique, S; Campos, C; Sánchez-Alonso, F; Castrejón, I	Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry	ARTHRITIS RESEARCH & THERAPY	4.9	Q2	Article	2023
D-03	Fernández-Carballido, C; Sanchez-Piedra, C; Valls, R; Garg, K; Sánchez-Alonso, F; Artigas, L; Mas, JM; Jovaní, V; Manrique, S; Campos, C; Freire, M; Martínez-González, O; Castrejón, I; Perella, C; Coma, M; Van der Horst-Bruinsma, IE	Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence- Based Data Analyses of a National Multicenter Prospective Registry	ARTHRITIS CARE & RESEARCH	4.7	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-03	Laiño-Piñeiro, MC; Rúa-Figueroa, I; Jiménez, N; Lozano, MJC; Martínez-Barrio, J; Serrano, B; Galindo-Izquierdo, M; Nack, A; Loricera, J; Tomero-Muriel, E; Ibáñez-Barceló, M; Vázquez, NM; Manrique-Arija, S; Lorenzo, NA; Narváez, J; Rosas, J; Menor-Almagro, R; Martínez-Taboada, VM; Aurrecoechea-Aguinaga, E; Horcada, L; Ruiz-Lucea, E; Raya, E; Toyos, FJ; Expósito, L; Vela, P; Freire-González, M; Moriano-Morales, C; Bonilla-Hernán, G; Ibáñez, TC; Lozano-Rivas, N; Moreno, M; Andreu, JL; Ubiaga, CLI; Torrente-Segarra, V; Valls, E; Velloso-Feijoo, ML; Alcázar, JL; Pego-Reigosa, J	Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)	SEMINARS IN ARTHRITIS AND RHEUMATISM	5	Q2	Article	2023
D-03	Joven, B; Manteca, CF; Rubio, E; Raya, E; Pérez, A; Hernández, R; Manrique, S; Núñez, M; Díaz-Cerezo, S; Moyano, S; Lacetera, A; García-Vicuña, R	Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study	ADVANCES IN THERAPY	3.8	Q2	Article	2023
D-03	Benavent, D; Muñoz-Fernández, S; De la Morena, I; Fernández-Nebro, A; Marín-Corral, J; Rosa, EC; Taberna, M; Sanabra, C; Sastre, C	Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study	THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE	4.2	Q2	Article	2023
D-03	Mayordomo, L; Molina-Collada, J; Uson, J; Vivar, ML; Sturchio, GA; Corrales, A; Castillo-Gallego, C; Hernández, F; Vicente-Rabaneda, EF; Núñez, FG; Gómez, I; Villar, M; Moragues, C; Corredor, D; de Miera, FJ; De Agustin, J; Molinero, MR; Sancho, JJ; Coronel, L; Huaranga, MA; Ruiz-Montesino, M; Collado-Ramos, P; Peñas, M; Miguélez, R; Fernández, E; Valera-Ribera, C; Naredo, E	Ultrasonography in rheumatology: time to learn from patient views	CLINICAL RHEUMATOLOGY	3.4	Q3	Article	2023
D-04	Céspedes J.A., Fernández-Santamaría R., Ariza A., Bogas G., Doña I., Rondón C., Salas M., Labella M., Frecha C., Mayorga C., Torres M.J., Fernández T.D.	Diagnosis of immediate reactions to amoxicillin: Comparison of basophil activation markers CD63 and CD203c in a prospective study	ALLERGY	12.4	D1	Article	2023
D-04	Salas-Casinello, Maria; Saenz-de Santa Maria, Rocio; Lopez-Sanchez, Jose Damian; Cornejo-Garcia, Jose Antonio; Perez-Sanchez, Natalia; Casas, Rocio; Bartra, Joan; Laguna, Jose Julio; Cortes-Collado, Juan Jose; Dona, Inmaculada; Torres, Maria Jose	Different Patterns of Response in Hypersensitivity Reactions to Arylpropionic Acid Derivatives.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	9.4	D1	Article	2023
D-04	Dramburg, S; Hilger, C; Santos, AF; de las Vecillas, L; Aalberse, RC; Acevedo, N; Aglas, L; Altmann, F; Arruda, KL; Asero, R; Ballmer-Weber, B; Barber, D; Beyer, K; Biedermann, T; Bilo, MB; Blank, S; Bosshard, PP; Breiteneder, H; Brough, HA; Bublin, M; Campbell, D; Caraballo, L; Caubet, JC; Celi, G; Chapman, MD; Chruszcz, M; Custovic, A; Czolk, R; Davies, J; Douladiris, N; Eberlein, B; Ebisawa, M; Ehlers, A; Eigenmann, P; Gadermaier, G; Giovannini, M; Gomez, F; Grohman, R; Guillet, C; Hafner, C; Hamilton, RG; Hauser, M; Hawranek, T; Hoffmann, HJ; Holzhauser, T; Iizuka, T; Jacquet, A; Jakob, T; Janssen-Weets, B; Jappe, U; Jutel, M; Kalic, T; Kamath, S; Kespohl, S; Kleine-Tebbe, J; Knol, E; Knulst, A; Konradsen, JR; Korosec, P; Kuehn, A; Lack, G; Le, TM; Lopata, A; Luengo, O; Makela, M; Marra, AM; Mills, C; Morisset, M; Muraro, A; Nowak-Wegrzyn, A; Nugraha, R; Ollert, M; Palosuo, K; Pastorello, EA; Patil, SU; Platts-Mills, T; Pomes, A; Poncet, P; Potapova, E; Poulsen, LK; Radauer, C; Radulovic, S; Raulf, M; Rouge, P; Sastre, J; Sato, S; Scala, E; Schmid, JM; Schmid-Grendelmeier, P; Schrama, D; Senechal, H; Traidl-Hoffmann, C; Valverde-Monge, M; van Ree, R; Verhoeckx, K; Vieths, S; Wickman, M; Zakzuk, J; Matricardi, PM; Hoffmann-Sommergruber, K	EAACI Molecular Allergology User's Guide 2.0	PEDIATRIC ALLERGY AND IMMUNOLOGY	4.4	D1	Article	2023
D-04	Paris, JL; Monio, C; Perez-Moreno, AM; Jurado-Escobar, R; Bogas, G; Fernandez, TD; Montanez, MI; Mayorga, C; Torres, MJ	Influence of Pore Size in Protein G'-Grafted Mesoporous Silica Nanoparticles as a Serum Pretreatment System for In Vitro Allergy Diagnosis	ADVANCED HEALTHCARE MATERIALS	10	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-04	Cho, SH; Nanda, A; Keswani, A; Adinoff, A; Baroody, FM; Bernstein, JA; Gherasim, A; Han, JK; Koepke, JW; Ledford, DK; Pepper, AN; Rondon, C; Schiffman, A; Wagenmann, M; Campo, P	Nasal allergen challenge (NAC): Practical aspects and applications from an EU/US perspective-a Work Group Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	14.2	D1	Article	2023
D-04	Jutel, M; Agache, I; Zemelka-Wiacek, M; Akdis, M; Chivato, T; del Giacco, S; Gajdanowicz, P; Gracia, IE; Klimek, L; Lauerma, A; Ollert, M; O'Mahony, L; Schwarze, J; Shamji, MH; Skypala, I; Palomares, O; Pfaar, O; Torres, MJ; Bernstein, JA; Cruz, AA; Durham, SR; Galli, SJ; Gómez, RM; Guttman-Yassky, E; Haahtela, T; Holgate, ST; Izuhara, K; Kabashima, K; Larenas-Linnemann, DE; von Mutius, E; Nadeau, KC; Pawankar, R; Platts-Mills, TAE; Sicherer, SH; Park, HS; Vieths, S; Wong, G; Zhang, L; Bilò, MB; Akdis, CA	Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper	ALLERGY	12.4	D1	Article	2023
D-04	Tanno, LK; Briand, Y; Mary, M; Khan, DA; Sublett, JL; Corbett, ML; Pawankar, R; Del Giacco, S; Torres, MJ; Ansontegui, IJ; Ebisawa, M; Martin, B; Demoly, P	Optimization of the allergen classification of the International Classification Of Diseases, 11th Revision (ICD-11)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	14.2	D1	Article	2023
D-04	Grewling, L; Ribeiro, H; Antunes, C; Apangu, GP; Çelenk, S; Costa, A; Eguiluz-Gracia, I; Galveias, A; Roldan, NG; Lika, M; Magyar, D; Martinez-Bracero, M; Orby, P; O'Connor, D; Penha, AM; Pereira, S; Perez-Badia, R; Rodinkova, V; Xhetani, M; Sauliene, I; Skjoth, CA	Outdoor airborne allergens: Characterization, behavior and monitoring in Europe	SCIENCE OF THE TOTAL ENVIRONMENT	9.8	D1	Article	2023
D-04	Dona, I; Guidolin, L; Bogas, G; Olivieri, E; Labella, M; Schiappoli, M; Maria, RSD; Dama, A; Salas, M; Senna, G; Bonadonna, P; Torres, MJ	Resensitization in suspected penicillin allergy	ALLERGY	12.4	D1	Article	2023
D-04	Paris, JL; Gaspar, R; Coelho, F; De Beule, PAA; Silva, BFB	Stability Criterion for the Assembly of Core-Shell Lipid-Polymer-Nucleic Acid Nanoparticles	ACS NANO	17.1	D1	Article	2023
D-04	Jutel, M; Mosnaim, GS; Bernstein, JA; del Giacco, S; Khan, DA; Nadeau, KC; Pali-Scholl, I; Torres, MJ; Zemelka-Wiacek, M; Agache, I	The One Health approach for allergic diseases and asthma	ALLERGY	12.4	D1	Article	2023
D-04	Cabanillas, B; Murdaca, G; Guemari, A; Torres, MJ; Azkur, AK; Aksoy, E; Vitte, J; de las Vecillas, L; Giovannini, M; Fernandez-Santamaria, R; Castagnoli, R; Orsi, A; Amato, R; Giberti, I; Catala, A; Ambrozej, D; Schaub, B; Tramper-Stranders, GA; Novak, N; Nadeau, KC; Agache, I; Akdis, M; Akdis, CA	A compilation answering 50 questions on Monkeypox virus and the current Monkeypox outbreak	ALLERGY	12.4	D1	Review	2023
D-04	Saretta, F; Tomei, L; Mori, F; Mayorga, C	In vitro diagnostic testing for drug allergy in children	PEDIATRIC ALLERGY AND IMMUNOLOGY	4.4	D1	Review	2023
D-04	Paris, JL; Vora, LK; Torres, MJ; Mayorga, C; Donnelly, RF	Microneedle array patches for allergen- specific immunotherapy	DRUG DISCOVERY TODAY	7.4	D1	Review	2023
D-04	Fauquert, JL; Alba-Linero, C; Gherasim, A; Testera-Montes, A; Bentabol-Ramos, G; Maria-Garcia, RSD; Torres, MJ; Eguiluz-Gracia, I; Rondon, C	Organ-specific allergen challenges in airway allergy: Current utilities and future directions	ALLERGY	12.4	D1	Review	2023
D-04	Bousquet, J; Shamji, MH; Anto, JM; Schunemann, HJ; Canonica, GW; Jutel, M; Del Giacco, S; Zuberbier, T; Pfaar, O; Fonseca, JA; Sousa-Pinto, B; Klimek, L; Czarlewski, W; Bedbrook, A; Amaral, R; Ansotegui, IJ; Bosnic-Anticevich, S; Braido, F; Loureiro, CC; Gemicioglu, B; Haahtela, T; Kulus, M; Kuna, P; Kupczyk, M; Matricardi, PM; Regateiro, FS; Samolinski, B; Sofiev, M; Toppila-Salmi, S; Valiulis, A; Ventura, MT; Barbara, C; Bergmann, KC; Bewick, M; Blain, H; Bonini, M; Boulet, LP; Bourret, R; Brusselle, G; Brussino, L; Buhl, R; Cardona, V; Casale, T; Cecchi, L; Charpin, D; Cherrez-Ojeda, I; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; Devillier, P; Dramburg, S; Fokkens, WJ; Gotua, M; Heffler, E; Ispayeva, Z; Ivancevich, JC; Joos, G; Kaidashev, I; Kraxner, H; Kvedariene, V; Larenas-Linnemann, DE; Laune, D; Lourenco, O; Louis, R; Makela, M; Makris, M; Maurer, M; Melen, E; Micheli, Y; Morais-Almeida, M; Mullol, J; Niedoszytko, M; O'Hehir, R; Okamoto, Y; Olze, H; Papadopoulos, NG; Papi, A; Patella, V; Petre, B; Pham-Thi, N; Puggioni, F; Quirce, S; Roche, N; Rouadi, PW; Sa-Sousa, A; Sagara, H; Sastre, J; Scichilone, N; Sheikh, A; Sova, M; Ulrik, CS; Taborda-Barata, L; Todo-Bom, A; Torres, MJ; Tsiligianni, I; Usmani, OS; Valovirta, E; Vasankari, T; Vieira, RJ; Wallace, D; Waserman, S; Zidarn, M; Yorgancioglu, A; Zhang, L; Chivato, T; Ollert, M	Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report	ALLERGY	12.4	D1	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-04	Bousquet, J; Melen, E; Haahtela, T; Koppelman, GH; Togias, A; Valenta, R; Akdis, CA; Czarlewski, W; Rothenberg, M; Valiulis, A; Wickman, M; Akdis, M; Aguilar, D; Bedbrook, A; Bindslev-Jensen, C; Bosnic-Anticevich, S; Boulet, LP; Brightling, CE; Brussino, L; Burte, E; Bustamante, M; Canonica, GW; Cecchi, L; Celedon, JC; Loureiro, CC; Costa, E; Cruz, AA; Erhola, M; Gemicioglu, B; Fokkens, WJ; Garcia-Aymerich, J; Guerra, S; Heinrich, J; Ivancevich, JC; Keil, T; Klimek, L; Kuna, P; Kupczyk, M; Kvedariene, V; Larenas-Linnemann, DE; Lemonnier, N; Carlsen, KCL; Louis, R; Makela, M; Makris, M; Maurer, M; Momas, I; Morais-Almeida, M; Mullol, J; Naclerio, RN; Nadeau, K; Nadif, R; Niedoszytko, M; Osmoto, Y; Ollert, M; Papadopoulos, NG; Passalacqua, G; Patella, V; Pawankar, R; Pham-Thi, N; Pfaar, O; Regateiro, FS; Ring, J; Rouadi, PW; Samolinski, B; Sastre, J; Savoure, M; Scichilone, N; Shamiji, MH; Sheikh, A; Siroux, V; Sousa-Pinto, B; Standl, M; Sunyer, J; Taborda-Barata, L; Toppila-Salmi, S; Torres, MJ; Tsiligianni, I; Valovirta, E; Vandenplas, O; Ventura, MT; Weiss, S; Yorgancioglu, A; Zhang, L; Latiff, AHA; Aberer, W; Agache, I; Al-Ahmad, M; Alobid, I; Ansotegui, IJ; Arshad, SH; Asayag, E; Barbara, C; Baharudin, A; Battur, L; Bennoor, KS; Berghea, EC; Bergmann, KC; Bernstein, D; Bewick, M; Blain, H; Bonini, M; Braido, F; Buhl, R; Bumbacea, RS; Bush, A; Calderon, M; Calvo-Gil, M; Camargos, P; Caraballo, L; Cardona, V; Carr, W; Carreiro-Martins, P; Casale, T; Sarabia, AMC; Chandrasekharan, R; Charpin, D; Chen, YZ; Cherrez-Ojeda, I; Chivato, T; Chkhartishvili, E; Christoff, G; Chu, DK; Cingi, C; de Sousa, JC; Corrigan, C; Custovic, A; D'Amato, G; Del Giacco, S; De Blay, F; Devillier, P; Didier, A; Teixeira, MD; Dokic, D; Douagui, H; Doulaptsi, M; Durham, S; Dykewicz, M; Ewegger, T; El-Sayed, ZA; Emuzyte, R; Fiocchi, A; Fyhrquist, D; Cape, R; Ruf, Gotua, M; Guzman, MA; Hagemann, J; Hamamah, S; Halken, S; Halpin, DMG; Hofmann, M; Hossny, E; Hrubisko, M; Irani, C; Ispayeva, Z; Jares, E; Jartti, T; Jassem, E; Julge, K; Just,	Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis	ALLERGY	12.4	D1	Review	2023
D-04	Nunez, R; Rodriguez, MJ; Lebron-Martin, C; Martin-Astorga, MD; Ramos-Soriano, J; Rojo, J; Torres, MJ; Canas, JA; Mayorga, C	A synthetic glycodendropeptide induces methylation changes on regulatory T cells linked to tolerant responses in anaphylactic- mice	FRONTIERS IN IMMUNOLOGY	7.3	Q1	Article	2023
D-04	Pano-Pardo, JR; Moreno, RE; Cobo, SS; Cubero, SJL; Perianez, PL; del Pozo, LJL; Retamar-Gentil, P; Rodriguez, OA; Torres, JMJ; Vidal-Cortes, P; Colas, SC	Management of Patients with Suspected or Confirmed Antibiotic Allergy: Executive Summary of Guidelines from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC)	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY	7.2	Q1	Article	2023
D-04	Safar, R; Oussalah, A; Mayorga, L; Vieths, S; Barber, D; Torres, MJ; Gueant, JL	Epigenome alterations in food allergy: A systematic review of candidate gene and epigenome-wide association studies	CLINICAL AND EXPERIMENTAL ALLERGY	6.1	Q1	Review	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-04	Ingen-Housz-Oro, S; Schmidt, V; Ameri, MM; Abe, R; Brassard, A; Mostaghimi, A; Paller, AS; Romano, A; Didona, B; Kaffenberger, BH; Ben Said, B; Thong, BYH; Ramsay, B; Brezinova, E; Milpied, B; Mortz, CG; Chu, CY; Sotozono, C; Gueudry, J; Fortune, DG; Dridi, SM; Tartar, D; Do-Pham, G; Gabison, E; Phillips, EJ; Lewis, F; Salavastru, C; Horvath, B; Dart, J; Setterfield, J; Newman, J; Schulz, JT; Delcampe, A; Brockow, K; Seminario-Vidal, L; Joerg, L; Watson, MP; Gontalo, M; Lucas, M; Torres, M; Noe, MH; Hama, N; Shear, NH; O'Reilly, P; Wolkenstein, P; Romanelli, P; Dodiuk-Gad, RP; Micheletti, RG; Tiplica, GS; Sheridan, R; Rauz, S; Ahmad, S; Chua, SL; Flynn, TH; Pichler, W; Le, ST; Maverakis, E; Walsh, S; French, LE; Brueggen, MC	Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus	ORPHANET JOURNAL OF RARE DISEASES	3.7	Q2	Article	2023
D-04	Doan, S; Papadopoulos, NG; Lee, JK; Leonardi, S; Manti, S; Lau, S; Rondon, C; Sharma, V; Pleyer, U; Jaumont, X; Lazarewicz, SB	Vernal keratoconjunctivitis: Current immunological and clinical evidence and the role of omalizumab	WORLD ALLERGY ORGANIZATION JOURNAL	5.1	Q2	Article	2023
D-04	Espada-Sanchez, M; de Santa Maria, RS; Martin-Astorga, MD; Lebron-Martin, C; Delgado, MJ; Eguiluz-Gracia, I; Rondon, C; Mayorga, C; Torres, MJ; Aranda, CJ; Canas, JA	Diagnosis and Treatment in Asthma and Allergic Rhinitis: Past, Present, and Future	APPLIED SCIENCES- BASEL	2.7	Q2	Review	2023
D-04	Labella, M; Maria, RSD; Bogas, G; Salas, M; Fernandez, TD; Mayorga, C; Torres, MJ; Dona, I	Drug-induced Anaphylaxis	CURRENT PHARMACEUTICAL DESIGN	3.1	Q3	Review	2023
D-04	Maria, RSD; Labella, M; Bogas, G; Dona, I; Torres, MJ	Hypersensitivity to gadolinium-based contrast	CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY	2.8	Q3	Review	2023
D-05	Monte-Boquet, Emilio; Florez, Angeles; Martinez, Guillermo Jose Alcain; Sellas, Agusti	Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain	REUMATOLOGIA CLINICA	1.5		Article	2023
D-05	Liang, JX; Ampuero, J; Niu, H; Imajo, K; Noureddin, M; Behari, J; Lee, DH; Ehman, RL; Rorsman, F; Vessby, J; Lacalle, JR; Mózes, FE; Pavlides, M; Anstee, QM; Harrison, SA; Castell, J; Loomba, R; Romero-Gómez, M	An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography	JOURNAL OF HEPATOLOGY	25.7	D1	Article	2023
D-05	Nicoletti, P; Dellinger, A; Li, YJ; Barnhart, HX; Chalasani, N; Fontana, RJ; Odin, JA; Serrano, J; Stolz, A; Etheridge, AS; Innocenti, F; Govaere, O; Grove, JI; Stephens, C; Aithal, GP; Andrade, RJ; Bjornsson, ES; Daly, AK; Lucena, MI; Watkins, PB	Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate	GASTROENTEROLOGY	29.4	D1	Article	2023
D-05	Caballano-Infantes, E; Ho-Plagaro, A; Lopez-Gomez, C; Martin-Reyes, F; Rodriguez-Pacheco, F; Taminiau, B; Daube, G; Garrido-Sanchez, L; Alcain-Martinez, G; Andrade, RJ; Garcia-Cortes, M; Lucena, MI; Garcia-Fuentes, E; Rodriguez-Diaz, C	Membrane Vesicles of Toxigenic Clostridioides difficile Affect the Metabolism of Liver HepG2 Cells	ANTIOXIDANTS	7	D1	Article	2023
D-05	Martín-Reyes F., Bernal M., Rodríguez-Díaz C., Rodríguez-de los Reyes D., Ho-Plagaro A., Rodríguez-Pacheco F., Camacho-Martel L., Camargo-Camero R., Rodríguez-González F.J., Alcain-Martínez G., Martín-Masot R., Navas-López V.M., Villanueva-Paz M., Lucena M.I., García-Fuentes E., López-Gómez C.	Mitochondrial Stress Links Environmental Triggers with Pro-Inflammatory Signaling in Crohn's Disease	ANTIOXIDANTS	7	D1	Article	2023
D-05	Bessone, F; Ferrari, A; Hernandez, N; Mendizabal, M; Ridruejo, E; Zerega, A; Tanno, F; Reggiardo, MV; Vorobioff, J; Tanno, H; Arrese, M; Nunes, V; Tagle, M; Medina-Caliz, I; Robles-Diaz, M; Niu, H; Alvarez-Alvarez, I; Stephens, C; Lucena, MI; Andrade, RJ	Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries	ARCHIVES OF TOXICOLOGY	6.1	D1	Article	2023
D-05	Andrade, RJ; Aithal, GP; de Boer, YS; Liberal, R; Gerbes, A; Regev, A; Beretta-Piccoli, BT; Schramm, C; Kleiner, DE; De Martin, E; Kullak-Ublick, GA; Stirnimann, G; Devarbhavi, H; Vierling, JM; Manns, MP; Sebode, M; Londoño, MC; Avigan, M; Robles-Diaz, M; García-Cortes, M; Atallah, E; Heneghan, M; Chalasani, N; Trivedi, PJ; Hayashi, PH; Taubert, R; Fontana, RJ; Weber, S; Oo, YH; Zen, Y; Licata, A; Lucena, MI; Mieli-Vergani, G; Vergani, D; Björnsson, ES	Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report	JOURNAL OF HEPATOLOGY	25.7	D1	Article	2023
D-05	Martin-Reyes, F; Ho-Plagaro, A; Rodriguez-Diaz, C; Lopez-Gomez, C; Garcia-Serrano, S; de los Reyes, DR; Gonzalo, M; Fernandez-Garcia, JC; Montiel-Casado, C; Fernandez-Aguilar, JL; Fernandez, JR; Garcia-Fuentes, E; Rodriguez-Pacheco, F	Oleic acid regulates the circadian rhythm of adipose tissue in obesity	PHARMACOLOGICAL RESEARCH	9.3	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-05	Niu, H; Ma, JY; Medina-Caliz, I; Robles-Diaz, M; Bonilla-Toyos, E; Ghabril, M; Lucena, MI; Alvarez-Alvarez, I; Andrade, RJ	Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis	ALIMENTARY PHARMACOLOGY & THERAPEUTICS	7.6	D1	Article	2023
D-05	Ravindra, KC; Vaidya, VS; Wang, ZY; Federspiel, JD; Virgen-Slane, R; Everley, RA; Grove, JI; Stephens, C; Ocana, MF; Robles-Díaz, M; Isabel Lucena, M; Andrade, RJ; Atallah, E; Gerbes, AL; Weber, S; Cortez-Pinto, H; Fowell, AJ; Hussaini, H; Bjornsson, ES; Patel, J; Stirnimann, G; Verma, S; Elsharkawy, AM; Griffiths, WJH; Hyde, C; Dear, JW; Aithal, GP; Ramaiah, SK	Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans	NATURE COMMUNICATIONS	16.6	D1	Article	2023
D-05	Fontana, RJ; Bjornsson, ES; Reddy, R; Andrade, RJ	The Evolving Profile of Idiosyncratic Drug- Induced Liver Injury	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY	12.6	D1	Article	2023
D-05	Rodriguez C., Mith H., Taminiau B., Korsak N., Garcia-Fuentes E., Daube G.	Microbial Food Safety Assessment of Organic Food and Feed: Notifications in the EU RASFF during 2020–2022. A Systematic Review	TRANSBOUNDARY AND EMERGING DISEASES	4.3	D1	Review	2023
D-05	Bjornsson, ES; Stephens, C; Atallah, E; Robles-Diaz, M; Alvarez-Alvarez, I; Gerbes, A; Weber, S; Stirnimann, G; Kullak-Ublick, G; Cortez-Pinto, H; Grove, JI; Lucena, MI; Andrade, RJ; Aithal, GP	A new framework for advancing in drug- induced liver injury research. The Prospective European DILI Registry	LIVER INTERNATIONAL	6.7	Q1	Article	2023
D-05	Suzuki, A; Tillmann, H; Williams, J; Hauser, RG; Frund, J; Suzuki, M; Prior, F; Aithal, GP; Lucena, MI; Andrade, RJ; Tong, WD; Hunt, CM	Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration	DRUG SAFETY	4.2	Q1	Article	2023
D-05	Garcia-Cortes, M; Ortega-Alonso, A; Matilla-Cabello, G; Medina-Caliz, I; Castiella, A; Conde, I; Bonilla-Toyos, E; Pinazo-Bandera, J; Hernandez, N; Tagle, M; Nunes, V; Parana, R; Bessone, F; Kaplowitz, N; Lucena, MI; Alvarez-Alvarez, I; Robles-Diaz, M; Andrade, RJ	Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries	LIVER INTERNATIONAL	6.7	Q1	Article	2023
D-05	Codoni, G; Kirchner, T; Engel, B; Villamil, AM; Efe, C; Stattermayer, AF; Weltzsch, JP; Sebode, M; Bernsmeier, C; Lleo, A; Gevers, TJ; Kupcinskas, L; Castiella, A; Pinazo, J; De Martin, E; Bobis, I; Sandahl, TD; Pedica, F; Invernizzi, F; Del Poggio, P; Bruns, T; Kolev, M; Semmo, N; Bessone, F; Giguet, B; Poggi, G; Ueno, M; Jang, H; Elpek, GOO; Soylu, NK; Cerny, A; Wedemeyer, H; Vergani, D; Mieli-Vergani, G; Lucena, MI; Andrade, RJ; Zen, YH; Taubert, R; Beretta-Piccoli, BT	Histological and serological features of acute liver injury after SARS-CoV-2 vaccination	JHEP REPORTS	8.3	Q1	Article	2023
D-05	Guillamón, E; Mut-Salud, N; Rodríguez-Sojo, MJ; Ruiz-Malagón, AJ; Cuberos-Escobar, A; Martínez-Férez, A; Rodríguez-Nogales, A; Gálvez, J; Baños, A	In Vitro Antitumor and Anti-Inflammatory Activities of Allium-Derived Compounds Propyl Propane Thiosulfonate (PTSO) and Propyl Propane Thiosulfinate (PTS)	NUTRIENTS	5.9	Q1	Article	2023
D-05	Gentile, AM; Lhamyani, S; Mengual-Mesa, M; García-Fuentes, E; Bermúdez-Silva, FJ; Rojo-Martinez, G; Clemente-Postigo, M; Rodriguez-Cañete, A; Olveira, G; El Bekay, R	MiR-221-3p/222-3p Cluster Expression in Human Adipose Tissue Is Related to Obesity and Type 2 Diabetes	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
D-05	Rodriguez-Diaz, C; Martin-Reyes, F; Taminiau, B; Ho-Plagaro, A; Camargo, R; Fernandez-Garcia, F; Pinazo-Bandera, J; Toro-Ortiz, JP; Gonzalo, M; Lopez-Gomez, C; Rodriguez-Pacheco, F; de los Rios, DR; Daube, G; Alcain-Martinez, G; Garcia-Fuentes, E	The Metagenomic Composition and Effects of Fecal-Microbe-Derived Extracellular Vesicles on Intestinal Permeability Depend on the Patient's Disease	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
D-05	Mela, V; Agüera, Z; Alvarez-Bermudez, MD; Martín-Reyes, F; Granero, R; Sanchez-García, A; Oliva-Olivera, W; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sánchez-Gallegos, P; Martínez-Moreno, JM; Sancho-Marín, R; Fernández-Aranda, F; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	The Relationship between Depressive Symptoms, Quality of Life and miRNAs 8 Years after Bariatric Surgery	NUTRIENTS	5.9	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-05	Zachou, K; Azariadis, K; Lytvyak, E; Snijders, RJALM; Takahashi, A; Gatselis, NK; Robles, M; Andrade, RJ; Schramm, C; Lohse, AW; Tanaka, A; Drenth, JPH; Montano-Loza, AJ; Dalekos, GN; Group, IAHGIAH	Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease	JHEP REPORTS	8.3	Q1	Article	2023
D-05	Sánchez-Quintero M.J., Rodríguez-Díaz C., Rodríguez-González F.J., Fernández-Castañer A., García-Fuentes E., López-Gómez C.	Role of Mitochondria in Inflammatory Bowel Diseases: A Systematic Review	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Review	2023
D-05	García-Alberca, JM; De la Rosaa, MD; De Zaldívar, PS; Ledesmaa, M; Oltra, E; Gris, E; Ocejo, O; Torrecilla, J; Zafra, C; Sánchez-Fernández, A; Mancilla, T; López-Romero, M; Jerez, R; Santana, N; Lara, JP; Barbancho, MA; Blanco-Reina, E	Effect of Nordic Sensi® Chair on Behavioral and Psychological Symptoms of Dementia in Nursing Homes Residents: A Randomized Controlled Trial	JOURNAL OF ALZHEIMERS DISEASE	4	Q2	Article	2023
D-05	Cueto-Sanchez, A; Niu, H; Alvarez-Alvarez, I; Lopez-Longarela, B; Del Campo-Herrera, E; Ortega-Alonso, A; Garcia-Cortes, M; Pinazo-Bandera, J; Sanabria-Cabrera, J; Diaz-Mochon, JJ; Lucena, MI; Andrade, RJ; Stephens, C; Robles-Diaz, M	Evaluation of diagnostic and prognostic candidate biomarkers in drug-induced liver injury vs. other forms of acute liver damage	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY	3.4	Q2	Article	2023
D-05	Pinazo-Bandera, JM; Aranda, J; García-García, AM; Alcantara, R; Ortega-Alonso, A; Del Campo-Herrera, E; Clavijo, E; Garcia-Escaño, MD; Ruiz, JJR; Morales-Herrera, M; Valle-López, V; Martin-Alarcón, R; Viciana, I; Jiménez, JB; Fernández-García, F; Toro-Ortiz, JP; Sanchez-Yáñez, E; Alvarez-alvarez, I; Andrade, RJ; Robles-Díaz, M; Garcia-Cortés, M	Hepatitis C virus point-of-care microelimination approach in a vulnerable population in the South of Spain	GASTROENTEROLOGY REPORT	3.6	Q2	Article	2023
D-05	Martínez-Montoro, JI; Generoso-Piñar, M; Ocaña-Wilhelmi, L; Gutiérrez-Repiso, C; Sánchez-García, A; Soler-Humanes, R; Fernández-Serrano, JL; Sánchez-Gallego, P; Martínez-Moreno, JM; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	Hypertension and hypercholesterolemia are predictive factors associated with type 2 diabetes persistence after metabolic surgery: A prospective study	DIABETES RESEARCH AND CLINICAL PRACTICE	5.1	Q2	Article	2023
D-05	Mehta, G; Riva, A; Ballester, MP; Uson, E; Pujadas, M; Carvalho-Gomes, A; Sahuco, I; Bono, A; D'Amico, F; Viganò, R; Diago, E; Lanseros, BT; Inglese, E; Vazquez, DM; Sharma, R; Tsou, HLP; Harris, N; Broekhoven, A; Kikkert, M; Morales, SPT; Myeni, SK; Riveiro-Barciela, M; Palom, A; Zeni, N; Brocca, A; Cussigh, A; Cmet, S; Escudero-García, D; Stocco, M; Natola, LA; Ieluzzi, D; Paon, V; Sangiovanni, A; Farina, E; di Benedetto, C; Sánchez-Torrijos, Y; Lucena-Varela, A; Román, E; Sánchez, E; Sánchez-Aldehuelo, R; López-Cardona, J; Canas-Perez, I; Eastgate, C; Jeyanesan, D; Morocho, AE; Di Cola, S; Lapenna, L; Zaccherini, G; Bongiovanni, D; Zanaga, P; Sayaf, K; Hossain, S; Crespo, J; Robles-Díaz, M; Madejón, A; Degroote, H; Fernández, J; Korenjak, M; Verhelst, X; García-Samaniego, J; Andrade, RJ; Iruzubieta, P; Wright, G; Caraceni, P; Merli, M; Patel, VC; Gander, A; Albillos, A; Soriano, G; Donato, MF; Sacerdoti, D; Toniutto, P; Buti, M; Duvoux, C; Grossi, PA; Berg, T; Polak, WG; Puoti, M; Bosch-Comas, A; Belli, L; Burra, P; Russo, FP; Coenraad, M; Calleja, JL; Perricone, G; Berenguer, M; Claria, J; Moreau, R; Arroyo, V; Angeli, P; Sánchez, C; Ampuero, J; Piano, S; Chokshi, S; Jalan, R	Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant	HEPATOLOGY COMMUNICATIONS	5.1	Q2	Article	2023
D-05	Sancho-Lopez, Arantxa; Ruiz-Antoran, Belen; Hernangomez, Teresa Iglesias; Ramirez-Garcia, Almudena; Gomez-Estevez, Irene; Sanabria-Cabrera, Judith; Llop Rius, Roser; Pedros, Consuelo; Campodonico, Diana; Jimenez-Jorge, Silvia; Garcia Luque, Amelia; Costa Frossad Franca, Lucienne; Montane, Eva; Aldea-Perona, Ana; Tellez Lara, Nieves; Bosch Ferrer, Montserrat; Rodriguez Jimenez, Consuelo; Bonilla-Toyos, Elvira; Sabin Munoz, Julia; Avendano-Sola, Cristina; Blasco Quilez, Maria Rosario; On Behalf Of The Realhes-Study Group	The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study).	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
D-05	Berenguer, Marina; Vergara, Mercedes; Almohalla, Carolina; Hernandez, Alicia; Blanco, Sonia; Testillano, Milagros; Girona, Eva; Casado, Marta; Garcia, Miren; Catalina, Maria-Vega; Munoz, Carolina; Gutierrez, Maria Luisa; Molina, Esther; Romero, Miriam; Otero, Alejandra; Hernaez-Alsina, Tania; Bernal-Monterde, Vanessa; Lorente, Sara; Masnou, Helena; Bonet, Lucia; Soto, Susana; Gisbert, Concha; Valer, Maria-Paz; Gomez, Judith; Pacheco, Gemma; Morillas, Julia; Gonzalez, Martha; Dominguez, Nuria; Lazaro, Maria; Pascual, Sonia; Castello, Immaculada; GEMHEP	Significant heterogeneity in the diagnosis and long-term management of Wilson disease: Results from a large multicenter Spanish study	GASTROENTEROLOGIA Y HEPATOLOGIA	1.9	Q4	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
D-05	Garcia-Garcia, AM; Pinazo-Bandera, JM; Asady, B; Garcia-Cortes, M; Andrade, RJ	The influence of the SARS-CoV-2 pandemic on in-hospital mortality in a gastroenterology service	GASTROENTEROLOGIA Y HEPATOLOGIA	1.9	Q4	Article	2023
DA-06	Padilla-Galo, Alicia; Carmona, Isabel Moya; Ausin, Pilar; Fernandez, Luis Carazo; Garcia-Moguel, Ismael; Velasco-Garrido, Jose Luis; Andujar-Espinosa, Ruben; Casas-Maldonado, Francisco; Martinez-Moragon, Eva; Rivera, Carlos Martinez; Solsona, Elisabet Vera; Lopez, Fernando Sanchez-Toril; Alonso, Andrea Trisan; Aparicio, Marina Blanco; Valverde-Monge, Marcela; Azcona, Borja Valencia; Cervera, Marta Palop; Nuevo, Javier; Tena, Jesus Sanchez; Resler, Gustavo; Luzon, Elisa; Naon, Alberto Levy	Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study	RESPIRATORY RESEARCH	5.8	Q1	Article	2023
DA-06	Gomez-Vaquero, Carmen; Hernandez, Jose Luis; Olmos, Jose Manuel; Cerda, Dacia; Calleja, Cristina Hidalgo; Lopez, Juan Antonio Martinez; Arboleya, Luis; Rey, Francisco Javier Aguilar del; Pardo, Silvia Martinez; Vilamajo, Inmaculada Ros; Armangue, Xavier Suris; Grados, Dolors; Audera, Chesus Beltran; Suero-Rosario, Evelyn; Gracia, Inmaculada Gomez; Chamizo, Asuncion Salmoral; Martin-Esteve, Irene; Florez, Helena; Naranjo, Antonio; Castaneda, Santos; Bruno, Soledad Ojeda; Carazo, Sara Garcia; Garcia-Vadillo, Alberto; Vives, Laura Lopez; Martinez-Ferrert, Angels; Panos, Helena Borrell; Acin, Pilar Aguado; Castellanos-Moreira, Raul; Satorra, Pau; Tebe, Cristian; Guanabens, Nuria	High incidence of clinical fragility fractures in postmenopausal women with rheumatoid arthritis. A case-control study	BONE	4.1	Q2	Article	2023
DA-06	Sanchez-Yanez, Elena; Jose Huertas-Fernandez, Maria; de las Aguas Robustillo-Cortes, Maria; Ramos-Guerrero, Rosa; Fernandez-Espinola, Sergio; Diaz-Acedo, Rocio; Montero-Martin, Violeta; Morillo-Verdugo, Ramon	Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project	REVISTA ESPANOLA DE QUIMIOTERAPIA	1.9	Q4	Article	2023
DE-02	Rodríguez, DJS; Ciézar, AJP; Román, DG; Carrillo, CAU	The dog, valves' best friend: infective endocarditis due to Capnocytophaga canimorsus-a case report	EUROPEAN HEART JOURNAL-CASE REPORTS	1		Article	2023
DE-02	Polo, R; García-Albéniz, X; Terán, C; Morales, M; Rial-Crestelo, D; Garcinuño, MA; del Toro, MG; Hita, C; Gómez-Sirvent, JL; Buzón, L; de Santiago, AD; Arellano, JP; Sanz, J; Bachiller, P; Alfaro, EM; Díaz-Brito, V; Masiá, M; Hernández-Torres, A; Guerra, JM; Santos, J; Arazo, P; Muñoz, L; Arribas, JR; de Salazar, PM; Moreno, S; Hernán, MA; Del Amo, J	Daily tenofovir disoproxil fumarate/ emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers	CLINICAL MICROBIOLOGY AND INFECTION	14.2	D1	Article	2023
DE-02	Hidalgo-Tenorio, C; Sadyrbaeva-Dolgova, S; Enríquez-Gómez, A; Muñoz, P; Plata-Ciezar, A; Miró, JM; Alarcón, A; Martínez-Marcos, FJ; Loeches, B; Escrihuela-Vidal, F; Vinuesa, D; Herrero, C; Boix-Palop, L; Arenas, MD; Vázquez, EG; de las Revillas, FA	EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS	10.8	D1	Article	2023
DE-02	Escrihuela-Vidal, F; Berbel, D; Fernandez-Hidalgo, N; Escola-Verge, L; Munoz, P; Olmedo, M; Goenaga, MA; Goikoetxea, J; Farinas, MC; De Alarcon, A; Miro, JM; Ojeda, G; Plata, A; Cuervo, G; Carratala, J; GAMES Investigators	Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci	CLINICAL INFECTIOUS DISEASES	11.8	D1	Article	2023
DE-02	Perez-Galera, S; Bravo-Ferrer, JM; Paniagua, M; Kostyanev, T; de Kraker, MEA; Feifel, J; Sojo-Dorado, J; Schotsman, J; Canton, R; Daikos, GL; Carevic, B; Dragovac, G; Tan, LK; Raka, L; Hristea, A; Viale, P; Akova, M; Reguera, JM; de Santis, LV; Torre-Cisneros, J; Cano, A; Roilides, E; Radulovic, L; Kirakli, C; Shaw, E; Falagas, ME; Pintado, V; Goossens, H; Bonten, MJ; Gutierrez-Gutierrez, B; Rodriguez-Bano, J	Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)	ECLINICALMEDICINE	15.1	D1	Article	2023
DE-02	Castillo-Fernandez, N; Perez-Crespo, PMM; Salamanca-Rivera, E; Herrera-Hidalgo, L; de Alarcon, A; Navarro-Amuedo, MD; Ciordia, TM; Perez-Rodriguez, MT; Sevilla-Blanco, J; Jover-Saenz, A; Fernandez-Suarez, J; Arminanzas-Castillo, C; Reguera-Iglesias, JM; Kindelan, CN; Boix-Palop, L; Jimenez, EL; Galan-Sanchez, F; Jimenez, AD; Bahamonde-Carrasco, A; Garcia, DV; Amat, AS; Pedragosa, JC; Molina, IMR; Camacho, IP; de Lucas, EM; Gutierrez-Gutierrez, B; Bano, JR; Cortes, LEL	Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort	ANTIBIOTICS-BASEL	4.8	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-02	Núñez-Pereira, S; Benavent, E; Ulldemolins, M; Sobrino-Díaz, B; Iribarren, JA; Escudero-Sánchez, R; Del Toro, MD; Nodar, A; Sorli, L; Bahamonde, A; Vilchez, HH; Gasch, O; Muñez, E; Rodríguez-Montserrat, D; García-País, MJ; Haddad, S; Sellarés-Nadal, J; Murillo, O; Rodríguez-Pardo, D	Cutibacterium spp. Infections after Instrumented Spine Surgery Have a Good Prognosis Regardless of Rifampin Use: A Cross-Sectional Study	ANTIBIOTICS-BASEL	4.8	Q1	Article	2023
DE-02	Benavent, E; Kortajarena, X; Sobrino-Diaz, B; Gasch, O; Rodríguez-Pardo, D; Escudero-Sanchez, R; Bahamonde, A; Rodriguez-Montserrat, D; García-País, MJ; López, MDD; Sorli, L; Nodar, A; Vilchez, HH; Muñez, E; Iribarren, JA; Ariza, J; Murillo, O	Vertebral osteomyelitis after spine instrumentation surgery: risk factors and management	JOURNAL OF HOSPITAL INFECTION	6.9	Q1	Article	2023
DE-02	Villar, J; González-Martin, JM; Añón, JM; Ferrando, C; Soler, JA; Mosteiro, F; Mora-Ordoñez, JM; Ambrós, A; Fernández, L; Montiel, R; Vidal, A; Muñoz, T; Pérez-Méndez, L; Rodríguez-Suárez, P; Fernández, C; Fernández, RL; Szakmany, T; Burns, KEA; Steyerberg, EW; Slutsky, AS	Clinical relevance of timing of assessment of ICU mortality in patients with moderate-to-severe Acute Respiratory Distress Syndrome	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
DE-02	Alonso-Menchen, D; Bouza, E; Valerio, M; de Alarcon, A; Gutierrez-Carretero, E; Miro, JM; Goenaga-Sanchez, MA; Plata-Ciezar, A; Gonzalez-Rico, C; Lopez-Cortes, LE; Esteban, MAR; Martinez-Marcos, FJ; Munoz, P	Non-nosocomial Healthcare-Associated Infective Endocarditis: A Distinct Entity? Data From the GAMES Series (2008-2021)	OPEN FORUM INFECTIOUS DISEASES	4.2	Q2	Article	2023
DE-02	Trigo-Rodriguez, M; Carcel, S; Navas, A; Espindola-Gomez, R; Garrido-Gracia, JC; Moreno, MAE; Leon-Lopez, R; Perez-Crespo, PMM; Alonso, EA; Vinuesa, D; Romero-Palacios, A; Perez-Camacho, I; Gutierrez-Gutierrez, B; Martinez-Marcos, FJ; Fernandez-Roldan, C; Leon, E; Cano, AA; Corzo-Delgado, JE; Perez-Nadales, E; Riazzo, C; de la Fuente, C; Jurado, A; Torre-Cisneros, J; Merchante, N	Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial	OPEN FORUM INFECTIOUS DISEASES	4.2	Q2	Article	2023
DE-02	Palacios, R; Gómez-Ayerbe, C; Casado, JL; Tejerina, F; Montes, ML; Castaño, M; Ocampo, A; Rial, D; Ribera, E; Galindo, MJ; Hidalgo, C; Fariñas, C; Montero, M; Payeras, T; Fanjul, F; de la Torre, J; Santos, J	Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119	HIV MEDICINE	3	Q3	Article	2023
DE-02	López-Cerero, L; Ballesta, S; López, CE; Sánchez-Yebra, W; Rojo-Martin, MD; Pascual, A	Evaluation of three commercial methods of susceptibility testing for ceftolozane/ tazobactam against carbapenem-resistant Pseudomonas aeruginosa	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.5	Q4	Article	2023
DE-07	Lopez-Delgado, JC; Grau-Carmona, T; Mor-Marco, E; Bordeje-Laguna, ML; Portugal-Rodriguez, E; Lorencio-Cardenas, C; Vera-Artazcoz, P; Macaya-Redin, L; Llorente-Ruiz, B; Iglesias-Rodriguez, R; Monge-Donaire, D; Martinez-Carmona, JF; Sanchez-Ales, L; Sanchez-Miralles, A; Crespo-Gomez, M; Leon-Cinto, C; Flordelis-Lasierra, JL; Servia-Goixart, L	Parenteral Nutrition: Current Use, Complications, and Nutrition Delivery in Critically Ill Patients	NUTRIENTS	5.9	Q1	Article	2023
DE-07	González-Fernández, M; Quilez-Trasobares, N; Barea-Mendoza, JA; Molina-Collado, Z; Arias-Verdu, D; Barrueco-Francioni, J; Seller-Pérez, G; Herrera-Gutiérrez, ME; Riera, JASI	Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
DE-07	Lopez-Delgado, JC; Servia-Goixart, L; Grau-Carmona, T; Bordeje-Laguna, L; Portugal-Rodriguez, E; Lorencio-Cardenas, C; Vera-Artazcoz, P; Macaya-Redin, L; Martinez-Carmona, JF; Corral, JM; Flordelís-Lasierra, JL; Seron-Arbeloa, C; Alcazar-Espin, MD; Navas-Moya, E; Aldunate-Calvo, S; Martino, BN; de Lagran, IM	Factors associated with the need of parenteral nutrition in critically ill patients after the initiation of enteral nutrition therapy	FRONTIERS IN NUTRITION	5	Q2	Article	2023
DE-08	Fundora, Y; Hessheimer, AJ; Del Prete, L; Maroni, L; Lanari, J; Barrios, O; Clarysse, M; Gastaca, M; Gómez, MB; Bonadona, A; Janek, J; Boscà, A; Martínez, JMA; Zozaya, G; Garnica, DL; Magistri, P; León, F; Magini, G; Patrono, D; Nicovsky, J; Hakeem, AR; Nadalin, S; McCormack, L; Palacios, P; Zieniewicz, K; Blanco, G; Nuño, J; Saborido, BP; Echeverri, J; Bynon, JS; Martins, PN; López, VL; Dayangac, M; Lodge, JPA; Romagnoli, R; Toso, C; Santoyo, J; Di Benedetto, F; Gómez-Gavara, C; Rotellar, F; Gómez-Bravo, MA; Andújar, RL; Girard, E; Valdivieso, A; Pirenne, J; Lladó, L; Germani, G; Cescon, M; Hashimoto, K; Quintini, C; Cillo, U; Polak, WG; Fondevila, C	Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis	JOURNAL OF HEPATOLOGY	25.7	D1	Article	2023
DE-08	Bazaga, S; García-Alonso, FJ; Tormo, JRA; Moreno, BM; Sanchiz, V; Suria, C; Garcia-Sumalla, A; Gornals, JB; Chavarria, C; Loras, C; García-Fernandez, FJ; Terán, A; Vazquez-Sequeiros, E; Sanz, RP; Pérez-Carazo, L; Súbtil, JC; Pérez-Millan, A; Porta, FU; Bea, VB; de la Serna-Higuera, C; Garcia, IP; Colán-Hernández, J; Huertas, C; Guarner-Argente, C; Perez-Miranda, M	Endoscopic removal of lumen-apposing metal stents-risk factors for stent embedment, complex removals, and adverse events: analysis from a multicenter prospective case series	ENDOSCOPY	9.3	D1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-08	Martín-Reyes, F; Ho-Plagaro, A; Rodríguez-Díaz, C; Lopez-Gómez, C; Garcia-Serrano, S; de los Reyes, DR; Gonzalo, M; Fernández-Garcia, JC; Montiel-Casado, C; Fernández-Aguilar, JL; Fernández, JR; García-Fuentes, E; Rodríguez-Pacheco, F	Oleic acid regulates the circadian rhythm of adipose tissue in obesity	PHARMACOLOGICAL RESEARCH	9.3	D1	Article	2023
DE-08	Mela, V; Agüera, Z; Alvarez-Bermudez, MD; Martín-Reyes, F; Granero, R; Sanchez-García, A; Oliva-Olivera, W; Tomé, M; Moreno-Ruiz, FJ; Soler-Humanes, R; Fernández-Serrano, JL; Sánchez-Gallegos, P; Martínez-Moreno, JM; Sancho-Marín, R; Fernández-Aranda, F; García-Fuentes, E; Tinahones, FJ; Garrido-Sánchez, L	The Relationship between Depressive Symptoms, Quality of Life and miRNAs 8 Years after Bariatric Surgery	NUTRIENTS	5.9	Q1	Article	2023
DE-08	Manzanedo, I; Pereira, F; Cascales-Campos, P; Muñoz-Casares, C; Asensio, E; Torres-Melero, J; Prada-Villaverde, A; Caravaca-García, I; Gutiérrez-Calvo, A; Vaqué, J; Ortega, G; Titos-García, A; González-Sánchez, L; Pérez-Viejo, E; Serrano, A; Martínez-Torres, B	Treatment of Peritoneal Surface Malignancies by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Spain: Results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP)	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
DE-08	Gonzalez Grande, Rocio; Bravo Aranda, Ana; Santaella Leiva, Inmaculada; Lopez Ortega, Susana; Jimenez Perez, Miguel	Acute liver failure secondary to malignant infiltration: A single center experience.	SEMINARS IN ONCOLOGY	4	Q2	Review	2023
DE-08	Reyes, MP; Pérez, BS; Díaz, FJL; Daga, JP; Fernández, IM; Santoyo, JS	Implementation of an ERAS protocol on elderly patients in liver resection	CIRUGIA ESPANOLA	1.9	Q3	Article	2023
DE-08	Campos-Serra, A; Pérez-Díaz, L; Rey-Valcárcel, C; Montmany-Vioque, S; Artiles-Armas, M; Aparicio-Sánchez, D; Tallón-Aguilar, L; Gutiérrez-Andreu, M; Bernal-Tirapo, J; Nisa, FGM; Vera-Mansilla, C; González-Conde, R; Gómez-Viana, L; Titos-García, A	Results of the Spanish National Polytrauma Registry. Where are we and where are we heading?	CIRUGIA ESPANOLA	1.9	Q3	Article	2023
DE-08	Burgos, MM; Grande, RG; Ortega, SL; Leiva, IS; Lombardo, JD; Santoyo, JS; Pérez, MJ	Analysis of the Survival of Patients Transplanted for Hepatocarcinoma According to Age at Transplantation	TRANSPLANTATION PROCEEDINGS	0.9	Q4	Article	2023
DE-08	Olmedo-Martín, R; Vázquez-Morón, JM; Martín-Rodríguez, MD; Lázaro-Sáez, M; Hernández-Martínez, A; Argüelles-Arias, F	Effectiveness and safety of ustekinumab dose escalation in Crohn's disease: a multicenter observational study.	REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS	2	Q4	Article	2023
DE-08	Burgos, MM; Grande, RG; Ortega, SL; Leiva, IS; Lombardo, JD; Santoyo, JS; Perez, MJ	Impact of HCV Treatment on Recurrence of Hepatocarcinoma After Liver Transplantation	TRANSPLANTATION PROCEEDINGS	0.9	Q4	Article	2023
DE-08	Sanchez, Ana Isabel Fernandez; Reyes, Maria Perez; Perez, Belinda Sanchez; Villalba, Julio Santoyo; Narvaez, Jose Manuel Aranda; Santoyo, Julio Santoyo	Liver Transplant With Double Portal Anastomose: A Case Report.	TRANSPLANTATION PROCEEDINGS	0.9	Q4	Article	2023
DE-09	Burnap, SA; Ortega-Prieto, AM; Jimenez-Guardeño, JM; Ali, H; Takov, K; Fish, M; Shankar-Hari, M; Giacca, M; Malim, MH; Mayr, M	Cross-Linking Mass Spectrometry Uncovers Interactions Between High-Density Lipoproteins and the SARS-CoV-2 Spike Glycoprotein	MOLECULAR & CELLULAR PROTEOMICS	7	D1	Article	2023
DE-09	López-Vázquez, C; Souto, S; Olveira, JG; Riaza, A; González, O; Brea, C; Labella, AM; Castro, D; Bandín, I	Nervous Necrosis Virus (NNV) Booster Vaccination Increases Senegalese Sole Survival and Enhances Immunoprotection	ANIMALS	3	D1	Article	2023
DE-09	Pallett, LJ; Swadling, L; Diniz, M; Maini, AA; Schwabenland, M; Gasull, AD; Davies, J; Kucykowicz, S; Skelton, JK; Thomas, N; Schmidt, NM; Amin, OE; Gill, US; Stegmann, KA; Burton, AR; Stephenson, E; Reynolds, G; Whelan, M; Sanchez, J; de Maeyer, R; Thakker, C; Suveizdyte, K; Uddin, I; Ortega-Prieto, AM; Grant, C; Froghi, F; Fusai, G; Lens, S; Perez-del-Pulgar, S; Al-Akkad, W; Mazza, G; Noursadeghi, M; Akbar, A; Kennedy, PTF; Davidson, BR; Prinz, M; Chain, BM; Haniffa, M; Gilroy, DW; Dorner, M; Bengsch, B; Schurich, A; Maini, MK	Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS	NATURE	64.8	D1	Article	2023
DE-09	Leiva-Rebollo, R; Gemez-Mata, J; Castro, D; Borrego, JJ; Labella, AM	Immune response of DNA vaccinated- gilthead seabream (Sparus aurata) against LCDV-Sa infection: relevance of the inflammatory process	FRONTIERS IN IMMUNOLOGY	7.3	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
DE-09	De Tena, PB; Paniagua, STT; Sevilla, JAV; Clavijo, E; Manzanares, EM; Gonzalez-Domenech, CM; Azzaroli, F	Unusual Surge of Acute Hepatitis A Cases in 2016 and 2017 in Malaga, Southern Spain: Characterization and Relationship with Other Concurrent European Outbreaks	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
DE-09	Martínez-Fernández, DE; Fernández-Quezada, D; Casillas-Muñoz, FAG; Carrillo-Ballesteros, FJ; Ortega-Prieto, AM; Jimenez-Guardeño, JM; Regla-Nava, JA	Human Monkeypox: A Comprehensive Overview of Epidemiology, Pathogenesis, Diagnosis, Treatment, and Prevention Strategies	PATHOGENS	3.7	Q2	Review	2023
DE-09	Barrios-Rodríguez, R; Salcedo-Bellido, I; Jiménez-Moleón, JJ; Lozano-Lorca, M; Galiano-Castillo, N; Cobos, EJ; Rienda, JDV; Olmedo-Requena, R; Amezcua-Prieto, C; Martín-Peláez, S; Domenech, CMG; Moreno, JPA; Rica, RA; García-Rubiño, ME; Requena, P	Peer review of teaching: using the nominal group technique to improve a program in a university setting with no previous experience	INTERNATIONAL JOURNAL FOR ACADEMIC DEVELOPMENT	1.3	Q4	Article	2023
DE-10	Fauquert, JL; Alba-Linero, C; Gherasim, A; Testera-Montes, A; Bentabol-Ramos, G; Maria-Garcia, RSD; Torres, MJ; Eguiluz-Gracia, I; Rondon, C	Organ-specific allergen challenges in airway allergy: Current utilities and future directions	ALLERGY	12.4	D1	Review	2023
DE-10	Casas, BM; Linares, JLC; Aranda, IB; Villodres, JR; Bohorquez, VM; Jimenez, AG; Corral, MAR; Bosch, R; Chaparro, MAS; Fernandez, MG; Valdivielso, P	Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
DE-10	Santos-Ortega, A; Alba-Linero, C; Urbinati, F; Rocha-de-Lossada, C; Orti, R; Reyes-Bueno, JA; Garzón-Maldonado, FJ; Serrano, V; de Rojas-Leal, C; de la Cruz-Cosme, C; España-Contreras, M; Rodríguez-Calvo-de-Mora, M; García-Casares, N	Structural and Functional Retinal Changes in Patients with Mild Cognitive Impairment with and without Diabetes.	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
DE-10	Carazo-Barrios, L; Cabrera-Maestre, A; Alba-Linero, C; Gutierrez-Bedmar, M; Garzon-Maldonado, FJ; Serrano, V; de la Cruz-cosme, C; Garcia-Casares, N	Retinal Neurodegeneration Measured With Optical Coherence Tomography and Neuroimaging in Alzheimer Disease: A Systematic Review	JOURNAL OF NEURO- OPHTHALMOLOGY	2.9	Q2	Review	2023
ECAI GENOMICA	García L.M., Velescu A., Lacambra M., Jesús Pinto M., Díaz C., Clarà A., Elosua R.	Association between DNA methylation and smoking in patients with chronic limb-threatening ischemia	Angiologia	0.1		Article	2023
ECAI NANOIMAGEN	Molina-Gil, S; Sotillos, S; Espinosa-Vázquez, JM; Almudi, I; Hombría, JCG	Interlocking of co-opted developmental gene networks in Drosophila and the evolution of pre-adaptive novelty	NATURE COMMUNICATIONS	16.6	D1	Article	2023
F-02	Fernandez-Rodriguez, JD; Garcia-Gonzalez, J; Benitez-Rochel, R; Molina-Cabello, MA; Ramos-Jimenez, G; Lopez-Rubio, E	Automated detection of vehicles with anomalous trajectories in traffic surveillance videos	INTEGRATED COMPUTER-AIDED ENGINEERING	6.5	Q1	Article	2023
F-02	Fernandez-Rodriguez, JD; Palomo, EJ; Ortiz-De-Lazcano-Lobato, JM; Ramos-Jimenez, G; Lopez-Rubio, E	Dynamic learning rates for continual unsupervised learning	INTEGRATED COMPUTER-AIDED ENGINEERING	6.5	Q1	Article	2023
F-02	Teran-Pineda, D; Thurnhofer-Hemsi, K; Dominguez, E	Human Gait Activity Recognition Using Multimodal Sensors	INTERNATIONAL JOURNAL OF NEURAL SYSTEMS	8	Q1	Article	2023
F-02	Garcia-Aguilar, I; Garcia-Gonzalez, J; Luque-Baena, RM; Lopez-Rubio, E; Dominguez, E	Optimized instance segmentation by super- resolution and maximal clique generation	INTEGRATED COMPUTER-AIDED ENGINEERING	6.5	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-02	Fernandez-Rodriguez, JD; Palomo, EJ; Benito-Picazo, J; Domfnguez, E; Lopez-Rubio, E; Ortega-Zamorano, F	A convolutional autoencoder and a neural gas model based on Bregman divergences for hierarchical color quantization	NEUROCOMPUTING	6	Q2	Article	2023
F-02	Fuentes-Fino, R; Calderon-Ramirez, S; Dominguez, E; Lopez-Rubio, E; Elizondo, D; Molina-Cabello, MA	An uncertainty estimator method based on the application of feature density to classify mammograms for breast cancer detection	NEURAL COMPUTING & APPLICATIONS	6	Q2	Article	2023
F-02	Molina-Cabello M.A., Thurnhofer-Hemsi K., Molina-Cabello D., Palomo E.J.	Are learning styles useful? A new software to analyze correlations with grades and a case study in engineering	Computer Applications in Engineering Education	2.9	Q2	Article	2023
F-02	Garcia-Aguilar, I; Garcia-Gonzalez, J; Luque-Baena, RM; Lopez-Rubio, E	Automated labeling of training data for improved object detection in traffic videos by fine-tuned deep convolutional neural networks	PATTERN RECOGNITION LETTERS	5.1	Q2	Article	2023
F-02	Garcia-Aguilar, I; Garcia-Gonzalez, J; Luque-Baena, RM; Lopez-Rubio, E	Object detection in traffic videos: an optimized approach using super-resolution and maximal clique algorithm	NEURAL COMPUTING & APPLICATIONS	6	Q2	Article	2023
F-02	Maza-Quiroga, R; Thurnhofer-Hemsi, K; López-Rodríguez, D; López-Rubio, E	Regression of the Rician Noise Level in 3D Magnetic Resonance Images from the Distribution of the First Significant Digit	AXIOMS	2	Q2	Article	2023
F-02	Garcia-Aguilar, I; Luque-Baena, RM; Dominguez, E; Lopez-Rubio, E	Small-Scale Urban Object Anomaly Detection Using Convolutional Neural Networks with Probability Estimation	SENSORS	3.9	Q2	Article	2023
F-02	Requena, F; García-Moreno, JM	The Economy that Lies Ahead. The Effects of Digital Social Relations on Work Productivity, Coordination and Independence	REVISTA ESPANOLA DE INVESTIGACIONES SOCIOLOGICAS	1.1	Q4	Article	2023
F-03	Pérez-Armenta, C; Ortega-Moñux, A; Luque-González, JM; Halir, R; Schmid, J; Cheben, P; Molina-Fernández, I; Wangüemert-Pérez, JG	Polarization insensitive metamaterial engineered multimode interference coupler in a 220 nm silicon-on-insulator platform	OPTICS AND LASER TECHNOLOGY	5	Q1	Article	2023
F-03	Pérez-Armenta, C; Mackay, KK; Hadij-ElHouati, A; Ortega-Moñux, A; Molina-Fernández, I; Wangüemert-Pérez, JG; Schmid, JH; Cheben, P; Ye, WN	Thermally induced sideband generation in silicon-on-insulator cladding modulated Bragg notch filters	OPTICS EXPRESS	3.8	Q2	Article	2023
F-04	Castellano-Quero, M; Castillo-López, M; Fernández-Madrigal, JA; Arévalo-Espejo, V; Voos, H; García-Cerezo, A	A multidimensional Bayesian architecture for real-time anomaly detection and recovery in mobile robot sensory systems	ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE	8	D1	Article	2023
F-04	Garcia-Salguero, M; Gonzalez-Jimenez, J	Fast certifiable relative pose estimation with gravity prior*	ARTIFICIAL INTELLIGENCE	14.4	D1	Article	2023
F-04	Gómez-de-Gabriel, JM; Fernández-Madrigal, JA; Rey-Merchán, MD; López-Arquillos, A	A Safety System based on Bluetooth Low Energy (BLE) to prevent the misuse of Personal Protection Equipment (PPE) in construction	SAFETY SCIENCE	6.1	Q1	Article	2023
F-04	Jaenal, A; Moreno, FA; Gonzalez-Jimenez, J	Sequential Monte Carlo localization in topometric appearance maps	INTERNATIONAL JOURNAL OF ROBOTICS RESEARCH	9.2	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-04	Garcia-Salguero, M; Gonzalez-Jimenez, J	Certifiable Solver for Real-Time N-View Triangulation	IEEE ROBOTICS AND AUTOMATION LETTERS	5.2	Q2	Article	2023
F-04	Luperto, M; Monroy, J; Renoux, J; Lunardini, F; Basilico, N; Bulgheroni, M; Cangelosi, A; Cesari, M; Cid, M; Ianes, A; Gonzalez-Jimenez, J; Kounoudes, A; Mari, D; Prisacariu, V; Savanovic, A; Ferrante, S; Borghese, NA	Integrating Social Assistive Robots, IoT, Virtual Communities and Smart Objects to Assist at-Home Independently Living Elders: the MoveCare Project	INTERNATIONAL JOURNAL OF SOCIAL ROBOTICS	4.7	Q2	Article	2023
F-04	Luperto, M; Monroy, J; Moreno, FA; Lunardini, F; Renoux, J; Krpic, A; Galindo, C; Ferrante, S; Basilico, N; Gonzalez-Jimenez, J; Borghese, NA	Seeking at-home long-term autonomy of assistive mobile robots through the integration with an IoT-based monitoring system	ROBOTICS AND AUTONOMOUS SYSTEMS	4.3	Q2	Article	2023
F-04	Ambrosio-Cestero, G; Ruiz-Sarmiento, JR; Gonzalez-Jimenez, J	The Robot@Home2 dataset: A new release with improved usability tools	SOFTWAREX	3.4	Q2	Article	2023
F-04	Gongora, A; Monroy, J; Rahbar, F; Ercolani, C; Gonzalez-Jimenez, J; Martinoli, A	Information-Driven Gas Distribution Mapping for Autonomous Mobile Robots	SENSORS	4.9	Q3	Article	2023
F-04	Ojeda, P; Monroy, J; Gonzalez-Jimenez, J	VGR Dataset: A CFD-based Gas Dispersion Dataset for Mobile Robotic Olfaction	JOURNAL OF INTELLIGENT & ROBOTIC SYSTEMS	3.3	Q3	Article	2023
F-05	Costoya, C; Muñoz, V; Tocino, A; Viruel, A	Automorphism groups of Cayley evolution algebras	REVISTA DE LA REAL ACADEMIA DE CIENCIAS EXACTAS FISICAS Y NATURALES SERIE A-MATEMATICAS	2.9	D1	Article	2023
F-05	Ror, AK; Gupta, R; Jelínek, M; Pandey, SB; Castro-Tirado, AJ; Hu, YD; Malenáková, A; Strobl, J; Thöne, CC; Hudec, R; Karpov, S; Kumar, A; Aryan, A; Oates, SR; Fernández-García, E; del Pulgar, CP; Caballero-García, MD; Castellón, A; Carrasco-García, IM; Pérez-García, ; Terol, AJR; Rendon, F	Prompt Emission and Early Optical Afterglow of Very-high-energy Detected GRB 201015A and GRB 201216C: Onset of the External Forward Shock	ASTROPHYSICAL JOURNAL	4.9	Q1	Article	2023
F-05	Paz-Delgado, GJ; Sánchez-Ibáñez, JR; Domínguez, R; Pérez-Del-Pulgar, CJ; Kirchner, F; García-Cerezo, A	Combined Path and Motion Planning for Workspace Restricted Mobile Manipulators in Planetary Exploration	IEEE ACCESS	3.9	Q2	Article	2023
F-05	Hu, YD; Fernández-García, E; Caballero-García, MD; Pérez-García, I; Carrasco-García, IM; Castellón, A; del Pulgar, CP; Terol, AJR; Castro-Tirado, AJ	The burst observer and optical transient exploring system in the multi-messenger astronomy era	FRONTIERS IN ASTRONOMY AND SPACE SCIENCES	3	Q2	Article	2023
F-05	Juan, CG; Bronchalo, E; Potelon, B; Quendo, C; Muñoz, VF; Ferrández-Vicente, JM; Sabater-Navarro, JM	On the Selectivity of Planar Microwave Glucose Sensors with Multicomponent Solutions	ELECTRONICS	2.9	Q3	Article	2023
F-05	Vargas, HF; Muñoz, V; Vivas, A	Automated suturing: sharp wound recognition and planning with surgical robot	ADVANCED ROBOTICS	2	Q4	Article	2023
F-05	Paz-Delgado, GJ; Pérez-del-Pulgar, CJ; Azkarate, M; Kirchner, F; García-Cerezo, A	Multi-stage warm started optimal motion planning for over-actuated mobile platforms	INTELLIGENT SERVICE ROBOTICS	2.5	Q4	Article	2023
F-05	Sánchez-Ibáñez, JR; Pérez-Del-Pulgar, CJ; Serón, J; García-Cerezo, A	Optimal path planning using a continuous anisotropic model for navigation on irregular terrains	INTELLIGENT SERVICE ROBOTICS	2.5	Q4	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-09	Granados-Ortiz, FJ; Gómez-Merino, AI; Jiménez-Galea, JJ; Santos-Ráez, IM; Fernandez-Lozano, JJ; Gómez-de-Gabriel, JM; Ortega-Casanova, J	Design and Assessment of Survey in a 360-Degree Feedback Environment for Student Satisfaction Analysis Applied to Industrial Engineering Degrees in Spain	EDUCATION SCIENCES	3		Article	2023
F-09	Navas-González, R; Oballe-Peinado, O; Castellanos-Ramos, J; Rosas-Cervantes, D; Sánchez-Durán, JA	Practice Projects for an FPGA-Based Remote Laboratory to Teach and Learn Digital Electronics	INFORMATION	3.1		Article	2023
F-09	Gómez-de-Gabriel, JM; Fernández-Madrigal, JA; Rey-Merchán, MD; López-Arquillos, A	A Safety System based on Bluetooth Low Energy (BLE) to prevent the misuse of Personal Protection Equipment (PPE) in construction	SAFETY SCIENCE	6.1	Q1	Article	2023
F-09	Martínez-Cesteros, J; Medrano-Sánchez, C; Castellanos-Ramos, J; Sánchez-Durán, JA; Plaza-García, I	Creep and Hysteresis Compensation in Pressure-Sensitive Mats for Improving Center-of-Pressure Measurements	IEEE SENSORS JOURNAL	4.3	Q1	Article	2023
F-09	Hidalgo-Lopez, JA; Castellanos-Ramos, J	Simplifying Capacitive Sensor Readout Using a New Direct Interface Circuit	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT	5.6	Q1	Article	2023
F-09	Lora-Rivera, R; Oballe-Peinado, O; Vidal-Verdu, F	Texture Detection With Feature Extraction on Embedded FPGA	IEEE SENSORS JOURNAL	4.3	Q1	Article	2023
F-09	Hidalgo-Lopez, JA; Castellanos-Ramos, J	Two proposals to simplify resistive sensor readout based on Resistance-to-Time-to-Digital conversion	MEASUREMENT	5.6	Q1	Article	2023
F-09	Pinto-Salamanca, ML; Castellanos-Ramos, J; Pérez-Holguín, WJ; Hidalgo-López, JA	An estimation of triaxial forces from normal stress tactile sensor arrays	MECHATRONICS	3.3	Q2	Article	2023
F-09	Lora-Rivera, R; Oballe-Peinado, O; Vidal-Verdu, F	Proposal and Implementation of a Procedure for Compliance Recognition of Objects with Smart Tactile Sensors	SENSORS	3.9	Q2	Article	2023
F-10	Silva, Maria J S A; Zhang, Yiyi; Vinck, Robin; Santos, Fabio M F; Antonio, Joao P M; Gourdon-Grunewaldt, Lisa; Zaouter, Charlotte; Castonguay, Annie; Patten, Shunmoogum A; Cariou, Kevin; Bosca, Francisco; Najera, Francisco; Arteaga, Jesus F; Gasser, Gilles; Pischel, Uwe; Gois, Pedro M P	BASHY Dyes Are Highly Efficient Lipid Droplet-Targeting Photosensitizers that Induce Ferroptosis through Lipid Peroxidation.	BIOCONJUGATE CHEMISTRY	4.7	D1	Article	2023
F-10	Dominguez-Alfaro, A; Pais, VF; Guzman-Rios, DB; Collado, D; Najera, F; Perez-Inestrosa, E; Pischel, U	Energy-transfer sensitization of BODIPY fluorescence in a dyad with a two-photon absorbing antenna chromophore	DYES AND PIGMENTS	4.5	D1	Article	2023
F-10	Dreos, A; Ge, JY; Najera, F; Tebikachew, BE; Perez-Inestrosa, E; Moth-Poulsen, K; Blennow, K; Zetterberg, H; Hanrieder, J	Investigating New Applications of a Photoswitchable Fluorescent Norbornadiene as a Multifunctional Probe for Delineation of Amyloid Plaque Polymorphism	ACS SENSORS	8.9	D1	Article	2023
F-10	Chen-Wu, J; Guzman-Rios, DB; Remon, P; Gonzalez-Delgado, JA; Martinez-Martinez, AJ; Najera, F; Arteaga, JF; Pischel, U	Photofunctional Scope of Fluorescent Dithienylethene Conjugates with Aza- Heteroaromatic Cations	ADVANCED MATERIALS	29.4	D1	Article	2023
F-10	Royo, R; Mainik, P; Benitez-Martin, C; Andreu, R; Blasco, E; Najera, F; Villacampa, B	Highly Efficient Photoninitiators Based on 4H-Pyranylidene Derivatives for Two-Photon Laser Printing	ADVANCED MATERIALS TECHNOLOGIES	6.8	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-10	Fernández-Palacios, S; Matamoros, E; Rojas, IM; Navarrete, JTL; Delgado, MCR; Vida, Y; Perez-Inestrosa, E	New Insights into Acylhydrazones E/Z Isomerization: An Experimental and Theoretical Approach	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Article	2023
F-10	Felicidade, J; Santos, FMF; Arteaga, JF; Remon, P; Campos-Gonzalez, R; Nguyen, H; Najera, F; Bosca, F; Ng, DYW; Gois, PMP; Pischel, U	Engineering the BASHY Dye Platform toward Architectures with Responsive Fluorescence	CHEMISTRY-A EUROPEAN JOURNAL	4.3	Q2	Article	2023
F-10	Zanocco, RP; Bresoli-Obach, R; Najera, F; Perez-Inestrosa, E; Zanocco, AL; Lemp, E; Nonell, S	NanoFN10: A High-Contrast Turn-On Fluorescence Nanoprobe for Multiphoton Singlet Oxygen Imaging	SENSORS	3.9	Q2	Article	2023
F-14	Simón-Pérez, E; Jiménez-Martín, R; Cicchinelli, LD; Yagüe, JF; Simón-Pérez, C; Paez-Moguer, J; Cortés-Rodríguez, A; Castillo-Domínguez, A	A 28-Year-Old Woman with Down Syndrome, Congenital Heart Disease, and a History of Knee Surgery and Plantar Fasciitis, with Hallux Abducto Valgus (Bunion) and Lapiplasty Three-Dimensional Correction Surgery	AMERICAN JOURNAL OF CASE REPORTS	1.2		Article	2023
F-14	Perez-Cruzado, D; Gonzalez-Sanchez, M; Cuesta-Vargas, AI	Differences in kinematic variables in single leg stance test between young and elderly people	INTERNATIONAL JOURNAL OF BIOMEDICAL ENGINEERING AND TECHNOLOGY	1.1		Article	2023
F-14	Marks, GA; Curti, F; Marsocci, A; Mariotti, D; Calvo, E; Barni, L; Gonzalez-Sanchez, M; Magnifica, F	Psychometric Properties of the Italian Version of the Total Disability Index in Patients with Spine Pain and Disability: An Italian Cross-Cultural Adaptation, Validation and Translation	MLTJ-MUSCLES LIGAMENTS AND TENDONS JOURNAL	0.8		Article	2023
F-14	Adams, N; McVeigh, JM; Cuesta-Vargas, A; Abokdeer, S	Evidence-based approaches for the management of fibromyalgia syndrome: a scoping review	PHYSICAL THERAPY REVIEWS	0.7		Review	2023
F-14	Vázquez-Sánchez, MA; Ayllón-Pérez, V; Gutiérrez-Sánchez, D; Valero-Cantero, I; Fernandez-Ordoñez, E; García-Gámez, M; Casals, C	Professional grief among nurses in Spanish public health centers after caring for COVID-19 patients	JOURNAL OF NURSING SCHOLARSHIP	3.4	D1	Article	2023
F-14	Nijs, J; Lahousse, A; Fernandez-de-las-Penas, C; Madeleine, P; Fontaine, C; Nishigami, T; Desmedt, C; Vanhoeij, M; Mostaqim, K; Cuesta-Vargas, AI; Kapreli, E; Bilika, P; Polli, A; Leysen, L; Elma, O; Roose, E; Rheel, E; Yilmaz, ST; De Baets, L; Huyamans, E; Turk, A; Saracoglu, I	Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria	BRITISH JOURNAL OF ANAESTHESIA	9.8	D1	Article	2023
F-14	Carrasco-Vega, E; Martinez-Moya, M; Barni, L; Guiducci, S; Nacci, F; Gonzalez-Sanchez, M	Questionnaires for the subjective evaluation of patients with fibromyalgia: a systematic review	EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE	4.5	D1	Review	2023
F-14	Sandoval-Hernández, I; Molina-Torres, G; León-Morillas, F; Ropero-Padilla, C; González-Sánchez, M; Martínez-Cal, J	Analysis of different gamification-based teaching resources for physiotherapy students: a comparative study	BMC MEDICAL EDUCATION	3.6	Q1	Article	2023
F-14	Cuesta-Vargas, A; Buchan, J; Alba, E; Campos, MI; Roldan-Jimenez, C; Pajares, B	Development of a functional assessment task in metastatic breast cancer patients: the 30-second lie-to-sit test	DISABILITY AND REHABILITATION	2.2	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-14	Cervera-Garvi, P; Aguilar-Nunez, D; Paez-Moguer, J; Jerez, JM; Navarro-Ledesma, S	Differences in the Impact of Plantar Fasciopathy on the Spatio-Temporal Gait Parameters between Participants with Bilateral Plantar Fasciopathy and Healthy Subjects: A Cross-Sectional Study	APPLIED SCIENCES- BASEL	2.7	Q2	Article	2023
F-14	Roldan-Jimenez, C; Cuadros-Romero, M; Bennett, P; Cuesta-Vargas, AI	Differences in Tridimensional Shoulder Kinematics between Asymptomatic Subjects and Subjects Suffering from Rotator Cuff Tears by Means of Inertial Sensors: A Cross- Sectional Study	SENSORS	3.9	Q2	Article	2023
F-14	Cuesta-Vargas, AI; Biro, A; Escriche-Escuder, A; Trinidad-Fernandez, M; Garcia-Conejo, C; Jimenez, CRR; Tang, W; Salvatore, A; Nikolova, B; Muro-Culebras, A; Martin-Martin, J; Gonzalez-Sanchez, M; Ruiz-Munoz, M; Mayoral, F	Effectiveness of a gamified digital intervention based on lifestyle modification (iGAME) in secondary prevention: a protocol for a randomised controlled trial	BMJ OPEN	2.9	Q2	Article	2023
F-14	Roldan-Jimenez, C; Martin-Martin, J; Pajares, B; Ribelles, N; Alba, E; Cuesta-Vargas, Al	Factors associated with upper limb function in breast cancer survivors	PM&R	2.1	Q2	Article	2023
F-14	Trinidad-Fernandez, M; Bossavit, B; Salgado-Fernandez, J; Abbate-Chica, S; Fernandez-Leiva, AJ; Cuesta-Vargas, AI	Head-Mounted Display for Clinical Evaluation of Neck Movement Validation with Meta Quest 2	SENSORS	3.9	Q2	Article	2023
F-14	Carrasco-Fernández, L; García-Sillero, M; Jurado-Castro, JM; Borroto-Escuela, DO; García-Romero, J; Benítez-Porres, J	Influence of limb dominance on body and jump asymmetries in elite female handball	SCIENTIFIC REPORTS	4.6	Q2	Article	2023
F-14	Fuentes-Abolafio, IJ; Trinidad-Fernandez, M; Escriche-Escuder, A; Roldan-Jimenez, C; Arjona-Caballero, JM; Bernal-Lopez, MR; Ricci, M; Gomez-Huelgas, R; Perez-Belmonte, LM; Cuesta-Vargas, AI	Kinematic Parameters That Can Discriminate in Levels of Functionality in the Six-Minute Walk Test in Patients with Heart Failure with a Preserved Ejection Fraction	JOURNAL OF CLINICAL MEDICINE	3.9	Q2	Article	2023
F-14	Biro, A; Szilagyi, SM; Szilagyi, L; Martin-Martin, J; Cuesta-Vargas, AI	Machine Learning on Prediction of Relative Physical Activity Intensity Using Medical Radar Sensor and 3D Accelerometer	SENSORS	3.9	Q2	Article	2023
F-14	Alvero-Cruz, JR; Alarcón-Martín, E; García-Romero, J; Ruiz-Galdon, M; Carrillo-Albornoz-Gil, M; Polvillo, R; González, I; Reyes-Engel, A; Royo, JL	Moderate exercise reveals the influence of ACTN3 R577X and ACE I/D polymorphisms on physical performance in non-athlete active subjects	GENE	3.5	Q2	Article	2023
F-14	Perez-Garcia, JJ; Molina-Torres, G; Ventura-Miranda, MI; Sandoval-Hernandez, I; Ruiz-Fernandez, MD; Martinez-Cal, J; Gonzalez-Sanchez, M	Spanish Cross-Cultural Adaptation and Validation of Neck Bournemouth Questionnaire (NBQ) for Neck Pain Patients	HEALTHCARE	2.8	Q2	Article	2023
F-14	Martinez-Cal, J; Molina-Torres, G; Carrasco-Vega, E; Barni, L; Ventura-Miranda, MI; Gonzalez-Sanchez, M	Spanish Cross-Cultural Adaptation and Validation of the Oslo Sports Trauma Research Centre (OSTRC) Overuse Injury Questionnaire in Handball Players	HEALTHCARE	2.8	Q2	Article	2023
F-14	Cavaggion, C; Navarro-Ledesma, S; Luque-Suarez, A; Juul-Kristensen, B; Voogt, L; Struyf, F	Subacromial space measured by ultrasound imaging in asymptomatic subjects and patients with subacromial shoulder pain: an inter-rater reliability study	PHYSIOTHERAPY THEORY AND PRACTICE	2	Q2	Article	2023
F-14	Biro, A; Cuesta-Vargas, AI; Martin-Martin, J; Szilagyi, L; Szilagyi, SM	Synthetized Multilanguage OCR Using CRNN and SVTR Models for Realtime Collaborative Tools	APPLIED SCIENCES- BASEL	2.7	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-14	Romero-Galisteo, RP; Pinero-Pinto, E; Palomo-Carrión, R; Luque-Moreno, C; Molina-Torres, G; González-Sánchez, M	Translation, cross-cultural adaptation and validation of the Rett syndrome motor evaluation scale (RESMES): Spanish version	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY	3.1	Q2	Article	2023
F-14	Roldan-Jimenez, C	What are the physiologic effects of Resistance Exercise behind breast cancer- related lymphedema prevention?	MEDICAL HYPOTHESES	4.7	Q2	Article	2023
F-14	Escriche-Escuder, A; Nijs, J; Silbernagel, KG; van Wilgen, CP; Plinsinga, ML; Casana, J; Cuesta-Vargas, AI	Pain neuroscience education in persistent painful tendinopathies: A scoping review from the Tendon PNE Network	PHYSICAL THERAPY IN SPORT	2.4	Q2	Review	2023
F-14	Nieto-Gil, P; Marco-Lledó, J; García-Campos, J; Ruiz-Muñoz, M; Gijon-Nogueron, G; Ramos-Petersen, L	Risk factors and associated factors for calcaneal apophysitis (Sever's disease): a systematic review		2.9	Q2	Review	2023
F-14	Cuesta-Vargas, Antonio Ignacio; Fuentes-Abolafio, Ivan Jose; Garcia-Conejo, Celia; Diaz-Balboa, Estibaliz; Trinidad-Fernandez, Manuel; Gutierrez-Sanchez, Daniel; Escriche-Escuder, Adrian; Cobos-Palacios, Lidia; Lopez-Sampalo, Almudena; Perez-Ruiz, Jose Maria; Roldan-Jimenez, Cristina; Perez-Velasco, Miguel Angel; Mora-Robles, Javier; Lopez-Carmona, M Dolores; Perez-Cruzado, David; Martin-Martin, Jaime; Perez-Belmonte, Luis Miguel	Effectiveness of a cardiac rehabilitation program on biomechanical, imaging, and physiological biomarkers in elderly patients with heart failure with preserved ejection fraction (HFpEF): FUNNEL+study protocol		2.1	Q3	Article	2023
F-14	Fuentes-Abolafio, IJ; Roldan-Jimenez, C; Campos, MI; Pajares-Hachero, BI; Alba-Conejo, E; Cuesta-Vargas, A	Forearm Muscle Activity During the Handgrip Test in Breast Cancer Survivors: A Cross- Sectional Study	CLINICAL BREAST CANCER	3.1	Q3	Article	2023
F-14	Mongin, D; Chabert, C; Courvoisier, DS; García-Romero, J; Alvero-Cruz, JR	Heart rate recovery to assess fitness: comparison of different calculation methods in a large cross-sectional study	RESEARCH IN SPORTS MEDICINE	2.4	Q3	Article	2023
F-14	Biró, A; Cuesta-Vargas, AI; Szilágyi, L	Precognition of mental health and neurogenerative disorders using Al-parsed text and sentiment analysis	ACTA UNIVERSITATIS SAPIENTIAE INFORMATICA	0.3	Q4	Article	2023
F-15	Gómez, MLA; González, CB; Delgado, IN	Advancing Climate Change Resilience through Ecosystems and Biodiversity Monitoring and Analysis	ERCIM NEWS	0.1		Article	2023
F-15	Nematzadeh, H; Garcia-Nieto, J; Navas-Delgado, I; Aldana-Montes, JF	Ensemble-based genetic algorithm explainer with automized image segmentation: A case study on melanoma detection dataset	COMPUTERS IN BIOLOGY AND MEDICINE	7.7	D1	Article	2023
F-15	Segura-Ortiz, A; Garcia-Nieto, J; Aldana-Montes, JF; Navas-Delgado, I	GENECI: A novel evolutionary machine learning consensus-based approach for the inference of gene regulatory networks	COMPUTERS IN BIOLOGY AND MEDICINE	7.7	D1	Article	2023
F-15	Rodríguez-Revello, J; Barba-González, C; Rybinski, M; Navas-Delgado, I	KNIT: Ontology reusability through knowledge graph exploration	EXPERT SYSTEMS WITH APPLICATIONS	8.5	D1	Article	2023
F-15	Burgueño, AM; Aldana-Martín, JF; Vázquez-Pendón, M; Barba-González, C; Gómez, YJ; Millán, VG; Navas- Delgado, I	Scalable approach for high-resolution land cover: a case study in the Mediterranean Basin JOURNAL OF BIG DATA		8.1	D1	Article	2023
F-15	Cardas, C; Aldana-Martín, JF; Burgueño-Romero, AM; Nebro, AJ; Mateos, JM; Sánchez, JJ	On the performance of SQL scalable systems on Kubernetes: a comparative study	CLUSTER COMPUTING- THE JOURNAL OF NETWORKS SOFTWARE TOOLS AND APPLICATIONS	4.4	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
F-15	Aldana-Martín, JF; Durillo, JJ; Nebro, AJ	Evolver: Meta-optimizing multi-objective metaheuristics	SOFTWAREX	3.4	Q2	Article	2023
F-15	Benítez-Hidalgo, A; Navas-Delgado, I; Roldán-García, MD	NORA: Scalable OWL reasoner based on NoSQL databases and Apache Spark	SOFTWARE-PRACTICE & EXPERIENCE	3.5	Q2	Article	2023
F-15	Benitez-Hidalgo, A; Aldana-Montes, JF; Navas-Delgado, I; Roldan-Garcia, MD	SALON ontology for the formal description of sequence alignments	BMC BIOINFORMATICS	3	Q2	Article	2023
F-15	Hurtado, S; Garcia-Nieto, J; Popov, A; Navas-Delgado, I	Human Activity Recognition From Sensorised Patient 's Data in Healthcare: A Streaming Deep Learning-Based Approach INTERNATIONAL JOURNAL OF INTERACTIVE MULTIMEDIA AND ARTIFICIAL INTELLIGENCE		3.6	Q3	Article	2023
FA-07	Maghnie, M; Semler, O; Guillen-Navarro, E; Selicorni, A; Heath, KE; Haeusler, G; Hagenas, L; Merker, A; Leiva-Gea, A; Gonzalez, VL; Raimann, A; Rehberg, M; Santos-Simarro, F; Ertl, DA; Gregersen, PA; Onesimo, R; Landfeldt, E; Jarrett, J; Quinn, J; Rowell, R; Pimenta, J; Cohen, S; Butt, T; Shediac, R; Mukherjee, S; Mohnike, K	Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study	ORPHANET JOURNAL OF RARE DISEASES	3.7	Q2	Article	2023
FA-08	Moreno-Torres, I; Lozano, A; Bermúdez, R; Pino, J; Méndez, MDG; Nava, E	Unmasking Nasality to Assess Hypernasality	APPLIED SCIENCES- BASEL	2.7	Q2	Article	2023
FE-17	Cruz-Gambero, Leire; Tuljak, Alejandra Lucia; Garcia Orza, Santiago; Villafane, Jorge H; Cantero-Tellez, Raquel	Effectiveness of proprioception training in functional recovery of thumb osteoarthritis. Single, multicenter, non-blind randomized clinical trial.	REUMATOLOGIA CLINICA	1.5		Article	2023
FE-17	Cantero-Tellez, Raquel; Martin Mateos, Ana; Cuesta Garcia, Cesar; Cruz Gambero, Leire; Garcia Orza, Santiago; Valdes, Kristin	The predictive value of self-efficacy in the evolution of rheumatoid arthritis and its relationship with pain and function.	REUMATOLOGIA CLINICA	1.5		Article	2023
FE-17	Di Benedetto, S; Battaglino, A; Abuín-Porras, V; Sánchez-Romero, EA; Cantero-Tellez, R; Valdes, K; Villafañe, JH	Evaluation of the factors that impact upper limb coordination in children with cerebral palsy: A narrative review	RETOS-NUEVAS TENDENCIAS EN EDUCACION FISICA DEPORTE Y RECREACION	1.3		Review	2023
FE-17	Salazar-Frías, D; Funes, M; Merchán-Baeza, J; Ricchetti, G; Torralba-Muñoz, J; Rodríguez-Bailón, M	Translation, cross-cultural adaptation and validation of the 10-item Weekly Calendar Planning Activity in Spanish-speaking ABI patients: a multicenter study	FRONTIERS IN PSYCHOLOGY	3.8	Q1	Article	2023
FE-17	Capdevila, E; Rodríguez-Bailón, M; Szot, AC; Gálvez-Ruiz, P; Portell, M	Cross-cultural adaptation and validation of the Spanish version of the Client-Centred Rehabilitation Questionnaire (CCRQ)	DISABILITY AND REHABILITATION	2.2	Q2	Article	2023
FE-17	Estudillo, AJ; Lee, YJ; Alvarez-Montesinos, JA; García-Orza, J	High-frequency transcranial random noise stimulation enhances unfamiliar face matching of high resolution and pixelated faces	BRAIN AND COGNITION	2.5	Q2	Article	2023
FE-17	Moreels, T; Cruyt, E; De Baets, S; Andries, L; Arts-Tielemans, M; Rodriguez-Bailon, M; Bergström, A; Boete, K; Bormans, I; Costa, U; Declercq, H; Dekelver, S; Dekyvere, V; Delooz, E; Engels, C; Helderweirt, S; Jarrey, M; Lenaerts, A; Leyman, A; Lim, KH; Meynen, L; Satink, T; Schoenmakers, F; Senn, D; Slembrouck, L; Van Meensel, E; Vangenechten, D; Van Paepeghem, B; De Vriendt, P; van de Velde, D	Self-Management Analysis in Chronic Conditions (SMACC) checklist: an international consensus-based tool to develop, compare and evaluate self- management support programmes	BMJ OPEN	2.9	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
FE-17	Valdes, K; Naughton, N; Téllez, RC; Szekeres, M	The use of occupation-based interventions and assessments in hand therapy: A cross-sectional survey	JOURNAL OF HAND THERAPY	2	Q2	Article	2023
FE-17	Requejo-Herrero, P; Pineda-Galan, C; Medina-Porqueres, I	Anterior cruciate ligament ruptures in Spanish soccer first division: An epidemiological retrospective study	KNEE	1.9	Q3	Article	2023
FE-17	Garcia-Orza, J; Gutierrez-Cordero, I; Larios, C; Csilinko, A; Alvarez-Montesinos, JA	Length is not all that matters: testing the role of number identity and the ratio of fillers in comparisons of multi-digits with different digit length	PSYCHOLOGICAL RESEARCH- PSYCHOLOGISCHE FORSCHUNG	2.3	Q3	Article	2023
FE-17	Rodriguez-Bailón, M; Fernández-Solano, AJ; Vidaña-Moya, L; Merchán-Baeza, JA; Cruyt, E; De Letter, M; Vlerick, P; Calders, P; De Pauw, R; Oostra, K; Szmalec, A; van de Velde, D; De Vriendt, P	The contribution of participation in meaningful activities on mental health during the COVID-19 lockdown in the Spanish population	ANALES DE PSICOLOGIA	1.7	Q3	Article	2023
FE-17	Fernández-Solano, AJ; Rodríguez-Bailón, M; Del Baño-Aledo, ME	Increasing occupational participation: A qualitative analysis within the Occupational Self-Analysis program	BRITISH JOURNAL OF OCCUPATIONAL THERAPY	1.3	Q4	Article	2023
FE-18	Simón-Frapolli, VJ; Vegas-Aguilar, IM; Fernández-Jiménez, R; Cornejo-Pareja, IM; Sanchez-García, AM; Martínez-López, P; Nuevo-Ortega, P; Reina-Artacho, C; Estecha-Foncea, MA; Gómez-González, AM; González-Jiménez, MB; Avanesi-Molina, E; Tinahones-Madueño, FJ; García-Almeida, JM	Phase angle and rectus femoris cross- sectional area as predictors of severe malnutrition and their relationship with complications in outpatients with post- critical SARS-CoV2 disease	FRONTIERS IN NUTRITION	5	Q2	Article	2023
FE-18	Sánchez-García, AM; Martínez-López, P; Gómez-González, AM; Rodriguez-Capitán, J; Pavón-Morón, FJ; Jiménez-López, RJ; García-Almeida, JM; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abad, V; Molina-Ramos, AI; Cabrera-César, E; Ben-Abdellatif, I; Gordillo-Resina, M; Pérez-Mesa, E; Nieto-González, M; Nuevo-Ortega, P; Reina-Artacho, C; Sánchez-Fernández, PL; Jiménez-Navarro, MF; Estecha-Foncea, MA	Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES	3.6	Q2	Article	2023
FE-18	Sanchez-Garcia, AM; Martinez-Lopez, P; Gomez-Gonzalez, AM; Rodriguez-Capitan, J; Jimenez-Lopez, RJ; Almeida, JMG; Avanesi-Molina, E; Zamboschi, N; Rueda-Molina, C; Doncel-Abada, V; Molina-Ramos, AI; Cabrera-Cesar, E; Ben-Abdellatif, I; Gordillo-Resina, M; Perez-Mesa, E; Nieto-Gonzalez, M; Nuevo-Ortega, P; Reina-Artacho, C; Fernandez, PLS; Jimenez-Navarro, MF; Estecha-Foncea, MA	Multidisciplinary approach of the sequelae one month after hospital discharge in patients with severe bilateral COVID-19 pneumonia, are there differences depending on the respiratory therapy used during admission to intensive care?	MEDICINA INTENSIVA	3	Q3	Article	2023
G-01	Fernandez-Rodriguez, MA; Orozco-Barrera, S; Sun, W; Gamez, F; Caro, C; Garcia-Martin, ML; Rica, RA	Hot Brownian Motion of Thermoresponsive Microgels in Optical Tweezers Shows Discontinuous Volume Phase Transition and Bistability	SMALL	13.3	D1	Article	2023
G-01	Ortiz-Rivero E., Orozco-Barrera S., Chatterjee H., González-Gómez C.D., Caro C., García-Martín ML., González P.H., Rica R.A., Gámez F.	Light-to-Heat Conversion of Optically Trapped Hot Brownian Particles	ACS NANO	17.1	D1	Article	2023
G-01	Carrillo, P; Bernal, M; Téllez-Quijona, C; Marrero, AD; Vidal, I; Castilla, L; Caro, C; Domínguez, A; García-Martín, ML; Quesada, AR; Medina, MA; Martínez-Poveda, B	The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer	BIOMEDICINE & PHARMACOTHERAPY	7.5	D1	Article	2023
G-01	Gomez-Gonzalez, E; Nunez, NO; Caro, C; Garcia-Martin, ML; Ocana, M	Carboxylate functionalized NaDy(MoO4)(2) nanoparticles with tunable size and shape as high magnetic field MRI contrast agents	JOURNAL OF COLLOID AND INTERFACE SCIENCE	9.9	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
G-01	Gomez-Gonzalez, E; Gonzalez-Mancebo, D; Nunez, NO; Caro, C; Garcia-Martin, ML; Becerro, AI; Ocana, M	Lanthanide vanadate-based trimodal probes for near-infrared luminescent bioimaging, high-field magnetic resonance imaging, and X-ray computed tomography	JOURNAL OF COLLOID AND INTERFACE SCIENCE	9.9	Q1	Article	2023
G-01	Pomary, PK; Eichau, S; Amigo, N; Barrios, L; Matesanz, F; Garcia-Valdecasas, M; Hrom, I; Sanchez, MIG; Garcia-Martin, ML	Multifaceted Analysis of Cerebrospinal Fluid and Serum from Progressive Multiple Sclerosis Patients: Potential Role of Vitamin C and Metal Ion Imbalance in the Divergence of Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis	JOURNAL OF PROTEOME RESEARCH	4.4	Q1	Article	2023
G-01	Ocaña, MC; Bernal, M; Yang, CD; Caro, C; Domínguez, A; Vu, HS; Cárdenas, C; García-Martín, ML; Deberardinis, RJ; Quesada, AR; Martínez-Poveda, B; Medina, MA	New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo	COMMUNICATIONS BIOLOGY	5.9	Q1	Article	2023
G-01	Paez-Muñoz, JM; Gámez, F; Fernández-Afonso, Y; Gallardo, R; Leal, MP; Gutiérrez, L; de la Fuente, JM; Caro, C; Garcia-Martín, ML	Optimization of iron oxide nanoparticles for MRI-guided magnetic hyperthermia tumor therapy: reassessing the role of shape in their magnetocaloric effect	JOURNAL OF MATERIALS CHEMISTRY B	7	Q1	Article	2023
G-01	Miranda, J; Paules, C; Noell, G; Youssef, L; Paternina-Caicedo, A; Crovetto, F; Cañellas, N; Garcia-Martín, ML; Amigó, N; Eixarch, E; Faner, R; Figueras, F; Simos, R; Crispi, F; Gratacós, E	Similarity network fusion to identify phenotypes of small-for-gestational-age fetuses	ISCIENCE	5.8	Q1	Article	2023
G-01	Avasthi, A; Caro, C; Garcia-Martin, ML; Leal, MP	Deciphering the parameters to produce highly reproducible and scalable iron oxide nanoparticles	REACTION CHEMISTRY & ENGINEERING	3.9	Q2	Article	2023
G-01	García-García, G; Caro, C; Fernández-Alvarez, F; García-Martín, ML; Arias, JL	Multi-stimuli-responsive chitosan- functionalized magnetite/poly(\mathbb{	NANOMEDICINE- NANOTECHNOLOGY BIOLOGY AND MEDICINE	5.4	Q2	Article	2023
H-02	Nualart, F; Cifuentes, M; Ramirez, E; Martínez, F; Barahona, MJ; Ferrada, L; Saldivia, N; Bongarzone, ER; Thorens, B; Salazar, K	Hyperglycemia increases SCO-spondin and Wnt5a secretion into the cerebrospinal fluid to regulate ependymal cell beating and glucose sensing	PLOS BIOLOGY	9.8	D1	Article	2023
H-02	Castro-Varela, P; Rubilar, M; Rodrigues, B; Pacheco, MJ; Caneda-Santiago, CT; Mari-Beffa, M; Figueroa, FL; Abdala-Diaz, R	A sequential recovery extraction and biological activity of water-soluble sulfated polysaccharides from the polar red macroalgae Sarcopeltis skottsbergii	ALGAL RESEARCH- BIOMASS BIOFUELS AND BIOPRODUCTS	5.1	Q1	Article	2023
H-02	Csukasi, F; Bosakova, M; Barta, T; Martin, JH; Arcedo, J; Barad, M; Rico-Llanos, GA; Zieba, J; Becerra, J; Krejci, P; Duran, I; Krakow, D	Skeletal diseases caused by mutations in PTH1R show aberrant differentiation of skeletal progenitors due to dysregulation of DEPTOR	FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY	5.5	Q1	Article	2023
H-02	Bergen, DJM; Maurizi, A; Formosa, MM; McDonald, GLK; El-Gazzar, A; Hassan, N; Brandi, ML; Riancho, JA; Rivadeneira, F; Ntzani, E; Duncan, EL; Gregson, CL; Kiel, DP; Zillikens, MC; Sangiorgi, L; Högler, W; Duran, I; Mäkitie, O; Van Hul, W; Hendrickx, G	High Bone Mass Disorders: New Insights From Connecting the Clinic and the Bench	JOURNAL OF BONE AND MINERAL RESEARCH	6.2	Q1	Review	2023
H-02	Garcia-Marquez, J; Moreira, BR; Valverde-Guillen, P; Latorre-Redoli, S; Caneda-Santiago, CT; Acien, G; Martinez-Manzanares, E; Mari-Beffa, M; Abdala-Diaz, RT	In Vitro and In Vivo Effects of Ulvan Polysaccharides from Ulva rigida	PHARMACEUTICALS	4.6	Q2	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
H-03	Siguero-Alvarez, M; Salguero-Jimenez, A; Grego-Bessa, J; de la Barrera, J; MacGrogan, D; Prados, B; Sanchez-Saez, F; Pineiro-Sabaris, R; Felipe-Medina, N; Torroja, C; Gomez, MJ; Sabater-Molina, M; Escriba, R; Richaud-Patin, I; Iglesias-Garcia, O; Sbroggio, M; Callejas, S; O'Regan, DP; McGurk, KA; Dopazo, A; Giovinazzo, G; Ibanez, B; Monserrat, L; Perez-Pomares, JM; Sanchez-Cabo, F; Pendas, AM; Raya, A; Gimeno-Blanes, JR; de la Pompa, JL	A Human Hereditary Cardiomyopathy Shares a Genetic Substrate With Bicuspid Aortic Valve	CIRCULATION	37.8	D1	Article	2023
H-03	Tamura, M; Ishikawa, R; Nakanishi, Y; Pascual-Anaya, J; Fukui, M; Saitou, T; Sugahara, F; Rijli, FM; Kuratani, S; Suzuki, DG; Murakami, Y	Comparative analysis of Hmx expression and the distribution of neuronal somata in the trigeminal ganglion in lamprey and shark: insights into the homology of the trigeminal nerve branches and the evolutionary origin of the vertebrate jaw	ZOOLOGICAL LETTERS	2.7	D1	Article	2023
H-03	Coppiello, Giulia; Barlabe, Paula; Moya-Jodar, Marta; Abizanda, Gloria; Pogontke, Cristina; Barreda, Carolina; Iglesias, Elena; Linares, Javier; Arellano-Viera, Estibaliz; Larequi, Eduardo; San Martin-Uriz, Patxi; Carvajal-Vergara, Xonia; Pelacho, Beatriz; Mazo, Manuel Maria; Perez-Pomares, Jose Maria; Ruiz-Villalba, Adrian; Ullate-Agote, Asier; Prosper, Felipe; Aranguren, Xabier L	Generation of heart and vascular system in rodents by blastocyst complementation.	DEVELOPMENTAL CELL	11.8	D1	Article	2023
H-03	Palmquist-Gomes, P; Ruiz-Villalba, A; Guadix, JA; Romero, JP; Bessieres, B; MacGrogan, D; Conejo, L; Ortiz, A; Picazo, B; Houyel, L; Gomez-Cabrero, D; Meilhac, SM; de la Pompa, JL; Perez-Pomares, JM	Origin of congenital coronary arterioventricular fistulae from anomalous epicardial and myocardial development	EXPERIMENTAL AND MOLECULAR MEDICINE	12.8	D1	Article	2023
H-03	Ducic, T; Sanchez-Mata, A; Castillo-Sanchez, J; Algarra, M; Gonzalez-Munoz, E	Monitoring oocyte-based human pluripotency acquisition using synchrotron-based FTIR microspectroscopy reveals specific biomolecular trajectories	SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY	4.4	Q1	Article	2023
H-03	Sugahara, F; Pascual-Anaya, J	High-quality total RNA extraction from early- stage lamprey embryos	BIOTECHNIQUES	2.7	Q3	Article	2023
HE-01	Ducic, T; Sanchez-Mata, A; Castillo-Sanchez, J; Algarra, M; Gonzalez-Munoz, E	Monitoring oocyte-based human pluripotency acquisition using synchrotron-based FTIR microspectroscopy reveals specific biomolecular trajectories	SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY	4.4	Q1	Article	2023



External associated grups

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
AA-24	Sánchez-Yáñez, E; Huertas-Fernández, MJ; Robustillo-Cortes, MD; Ramos-Guerrero, R; Fernández-Espínola, S; Diaz-Acedo, R; Montero-Martin, V; Morillo-Verdugo, R	Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project	REVISTA ESPANOLA DE QUIMIOTERAPIA	1.9	Q4	Article	2023
AA-25	Oliva-Damaso, N; Tangri, N; Delanaye, P; Glassock, RJ	Bridging the gap of referral to nephrology care	NATURE REVIEWS NEPHROLOGY	41.5	D1	Editorial Material	2023
AA-25	Oliva-Damaso, N; Nuñez, J; Soler, MJ	Spot Urinary Sodium as a Biomarker of Diuretic Response in Acute Heart Failure	JOURNAL OF THE AMERICAN HEART ASSOCIATION	5.4	Q2	Editorial Material	2023
AA-25	Visiedo, L; Pérez, R; Rivas-Ruiz, F; Payan, JJ; Rey, L; Tortajada, B; Abilés, J	Hypovitaminosis D and its relationship with nutritional status and quality of life in patients undergoing haemodialysis.	NUTRICION HOSPITALARIA	1.2	Q4	Article	2023
BA-14	Téllez, T; Martin-García, D; Redondo, M; García-Aranda, M	Clusterin Expression in Colorectal Carcinomas	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	5.6	Q1	Review	2023
BA-14	Garcia-Gutierrez, S; Villanueva, A; Lafuente, I; Rodriguez, I; Lozano-Bahamonde, A; Murga, N; Orus, J; Camacho, ER; Quintana, JM; Quiros, R	Factors related to early readmissions after acute heart failure: a nested case-control study	BMC CARDIOVASCULAR DISORDERS	2.1	Q3	Article	2023
BA-14	Bravo, MJ; Burgos-Molina, AM; García-Aranda, M; Redondo, M; Téllez, T	Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy	CANCERS	5.2	Q2	Review	2023
BA-14	León-Salas, B; Hernández-Yumara, A; Infante-Ventura, D; Castellano, AD; Hernández, YG; Linertová, R; Santana, TT; de Pablos-Velasco, P; Trujillo-Martín, MM	Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies: A systematic review, meta-analysis and economic evaluation	ENDOCRINOLOGIA DIABETES Y NUTRICION	1.9	Q4	Review	2023
BA-14	Quintana, JM; Anton-Ladislao, A; Lázaro, S; Gonzalez, N; Bare, M; de Larrea, NF; Redondo, M; Escobar, A; Sarasqueta, C; Garcia-Gutierrez, S; Aguirre, U; Briones, E	Quality Indicators and Outcomes in a Prospective Cohort of Colorectal Cancer Patients	JOURNAL OF GASTROINTESTINAL CANCER	1.6		Article	2023
BA-14	Miret, C; Orive, M; Sala, M; García-Gutiérrez, S; Sarasqueta, C; Legarreta, MJ; Redondo, M; Rivero, A; Castells, X; Quintana, JM; Garin, O; Ferrer, M	Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after	QUALITY OF LIFE RESEARCH	3.5	Q2	Article	2023
BA-14	Martin-Garcia, D; Tellez, T; Redondo, M; Garcia-Aranda, M	Calcium Homeostasis in the Development of Resistant Breast Tumors	CANCERS	5.2	Q2	Review	2023
BA-14	Orive, Miren; Barrio, Irantzu; Lazaro, Santiago; Gonzalez, Nerea; Bare, Marisa; de Larrea, Nerea Fernandez; Redondo, Maximino; Cortajarena, Sarai; Bilbao, Amaia; Aguirre, Urko; Sarasqueta, Cristina; Quintana, Jose M	Five-year follow-up mortality prognostic index for colorectal patients.	International journal of colorectal disease	2.8	Q2	Article	2023
CA-14	De la Torre-Lima, Javier; Oteo, Jose Antonio; Pinilla, Javier; Mansilla, Rosa; Zamora, Carmen; Ayala Vargas, Victoria; Morillo-Verdugo, Ramon; Moreno, Santiago; Fuster-Ruiz de Apodaca, Maria Jose; Perez-Molina, Jose A; Colom, Joan	Study on the approach to HIV: health management and the healthcare process in Spain.	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA	2.5	Q4	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CA-14	Ramos-Rincon, JM; Lopez-Sampalo, A; Cobos-Palacios, L; Ricci, M; Rubio-Rivas, M; Diaz-Simon, R; Martin-Escalante, MD; Castaneda-Perez, S; Fernandez-Madera-Martinez, R; Beato-Perez, JL; Garcia-Garcia, GM; Garcia-Andreu, MD; Arnalich-Fernandez, F; Molinos-Castro, S; Vargas-Nunez, JA; Artero, A; Freire-Castro, SJ; Fernandez-Gomez, J; Cubo-Romano, P; Hernandez-Milian, A; Ines-Revuelta, SM; Boixeda, R; Fernandez-Pedregal, E; Gomez-Huelgas, R	Nosocomial COVID-19: A Nationwide Spanish Study	GERONTOLOGY	3.5	Q3	Article	2023
CA-14	Baron, DR; Sanchez, NB; Ruiz, FR; Martinez, AR; Arjona, JA; Maqueda, GD; Araujo, IG; Aranda, MVD; Martinez, AR; Martin, MD	Occupational Sun Exposure Among Physical Education Teachers in Primary and Secondary Schools in Andalusia, Spain	JOURNAL OF CANCER EDUCATION	1.6	Q3	Article	2023
CA-14	Visiedo, Lucia; Perez Abud, Rocio; Rivas-Ruiz, Francisco; Payan, Juan Jesus; Rey, Laura; Tortajada, Begona; Abiles, Jimena	Hypovitaminosis D and its relationship with nutritional status and quality of life in patients undergoing haemodialysis.	NUTRICION HOSPITALARIA	1.2	Q4	Article	2023
CA-14	Diez-Manglano, J; Carretero-Gomez, J; Chimeno-Vinas, M M; Martin-Escalante, M D; Recio-Iglesias, J; Manzano-Espinosa, L; Zapatero-Gaviria, A; Del Prado, N; Elola, J	RECALMIN IV. Evolution in the activity of internal medicine units of the National Health System (2008-2021).	REVISTA CLINICA ESPANOLA	2.9	Q2	Article	2023
CA-15	Barnestein-Fonseca, P; Cotta-Luque, V; Aguiar-Leiva, V; Leiva-Fernández, J; Martos-Crespo, F; Leiva-Fernández, F	The importance of reminders and patient preferences to improve inhaler technique in older adults with COPD	FRONTIERS IN PHARMACOLOGY	5.6	Q1	Article	2023
CA-15	Vázquez-González, N; Leiva-Fernández, J; Cotta-Luque, VM; Leiva-Fernández, F; Rius-Díaz, F; Martos-Crespo, F; Martín-Montañez, E; Barnestein-Fonseca, P	Effectiveness of an educational intervention about inhalation technique in healthcare professionals in primary care: a cluster randomized trial.	FRONTIERS IN PHARMACOLOGY	5.6	Q1	Article	2023
CA-15	Barnestein-Fonseca, P; Vibora-Martín, E; Ruiz-Torreras, I; Chapinal-Bascón, H; Martín-Roselló, ML; Gómez-García, R	ITV-Pal programme: protocol of evaluation of the implementation of tech-volunteer programme in palliative care services	BMJ OPEN	2.9	Q2	Article	2023
CA-19	Domínguez-Rodríguez, A; Hernandez-Vaquero, D; Suero-Mendez, C; Burillo-PutzE, G; Gil, V; Calvo-Rodriguez, R; Piñera-Salmeron, P; Llorens, P; Martín-Sánchez, FJ; Abreu-Gonzalez, P	Effects of MIdazolam versus MOrphine in acute cardiogenic pulmonary edema and chronic obstructive pulmonary disease: An analysis of MIMO trial	AMERICAN JOURNAL OF EMERGENCY MEDICINE	3.6	Q1	Article	2023
CA-19	Domínguez-Rodríguez, A; Hernández-Vaquero, D; Suero-Méndez, C; Burillo-Putze, G; Gil, V; Calvo-Rodríguez, R; Piñera-Salmerón, P; Llorens, P; Martín-Sánchez, FJ; Abreu-González, P; Formica, F; Miró, O	Effects of midazolam vs morphine in patients with acute pulmonary edema with left ventricular systolic dysfunction: a secondary analysis of data from the MIMO trial	EMERGENCIAS	5.5	Q1	Article	2023
CA-19	Montero-Pérez, FJ; Requena, AMC; del Castillo, JG; Jacob, J; García-Lamberechts, EJ; Salmerón, PP; Alquezar-Arbé, A; Aguiló, S; Alonso, CF; Burillo-Putze, G; Caro, MC; Salado, AID; Mojarro, EM; Eiroa-Hernández, P; Parra-Esquivel, P; Perez, JJL; Grinspan, MR; Quispe, IGO; Tejera, MG; Lázaro, LS; Fernández, BE; Fuentes, L; Méndez, CS; Toro-Gallardo, MDV; Chaib, FB; Ramírez, PP; Miró, O	Impact of the COVID-19 pandemic on demand for emergency department care for older patients: the EDEN-7 COVID cohort study	EMERGENCIAS	5.5	Q1	Article	2023
CA-19	Alquézar-Arbé, A; Osorio, GI; Jacob, J; García-Lamberechts, EJ; Salmerón, PP; Llorens, P; Burillo-Putze, G; Requena, AC; Gil, A; Fernández, C; Aguiló, S; Jiménez, S; Blázquez, BE; Mesinoi, DR; Mojarroj, EM; Vaswani-Bulchandk, A; Rodríguez-Cabreral, M; Martínez, PA; Gioya, GD; González, FXA; Tejera, MG; García, MB; Fernández, BE; Llopis, F; Méndez, CS; del Castillo, JG; SIESTA Network	Influence of type of household on prognosis at one year in patients ≥65 years attending hospital emergency departments in Spain. The EDEN-6 study	MATURITAS	4.9	Q1	Article	2023
CA-19	Domínguez-Rodríguez, A; Hernandez-Vaquero, D; Suero-Mendez, C; Burillo-Putze, G; Gil, V; Calvo-Rodriguez, R; Piñera-Salmeron, P; Llorens, P; Martín-Sánchez, FJ; Abreu-Gonzalez, P; Miró, O	Midazolam versus morphine in acute cardiogenic pulmonary edema patients with and without atrial fibrillation: findings from the MIMO trial	EUROPEAN JOURNAL OF EMERGENCY MEDICINE	4.4	Q1	Article	2023

Group	Authors	Article Title	Source Title	IF	Q/D	Document Type	Publication Year
CA-19	Florido-Santiago, M; Pérez-Belmonte, LM; Osuna-Sánchez, J; Barbancho, MA; Ricci, M; Millán-Gómez, M; Bernal- López, MR; Gómez-Huelgas, R; Lara, JP	Assessment of long-term cognitive dysfunction in older patients who undergo heart surgery	NEUROLOGIA	3.9	Q2	Article	2023
CA-19	Perez-Belmonte, LM; Osuna-Sánchez, J; Ricci, M; Millán-Gómez, M; López-Carmona, MD; Barbancho, MA; Bernal- López, MR; Jansen-Chaparro, S; Lara, JP; Gómez-Huelgas, R	Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older study.	PANMINERVA MEDICA	4.3	Q2	Article	2023
CA-19	Demelo-Rodriguez, P; Alonso-Beato, R; Jara-Palomares, L; Galeano-Valle, F; Bura-Riviere, A; Visonà, A; Francisco, I; Vidal, G; López-Ruiz, A; Monreal, M	COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding	RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS	4.6	Q2	Article	2023
CA-19	Suero, C; Martín, A; Coll-Vinent, B; González-Torrecilla, E; Ormaetxe, J; Alvarez, M; del Arco, C; Cancio, M; Varona, M; Sánchez, S; Sánchez, J; Fernández-Lozano, I; Arribas, F; Martín-Méndez, M; Peinado, R	Long-term prognosis and emergency management for patients with an implantable cardioverter defibrillator: the EMERGE-ICD study	EMERGENCIAS	5.5	Q1	Article	2023
CA-19	Lopez-Sampalo, A; Hernandez-Negrin, H; Bernal-Lopez, M-R; Rubio-Rivas, M; Martin-Escalante, M D; Wikman-Jogersen, P; Garcia-Reyne, A; Fernandez-Madera Martinez, R; Gomez-Antunez, M; Beato-Perez, J L; Torres-Pena, J D; Martin-Oterino, J A; Loureiro-Amigo, J; Vicente de la Sota, J; Gil-Sanchez, R; Lorenzo-Lopez Reboiro, M; Bernal-Roman, B; Fernandez-Sola, J; Amoros-Martinez, F; Vicente-Lopez, N; Valle-Bernard, R; Lopez-Ruiz, A; Ramos-Rincon, J-M; Gomez-Huelgas, R	The impact of frailty on intra-hospital survival in older patients with COVID-19 infection: the importance of early identification. SEMI-COVID National Registry.	REVISTA CLINICA ESPANOLA	2.9	Q2	Article	2023
FA-16	Tamimi, A; Hassuneh, M; Tamimi, I; Juweid, M; Shibli, D; AlMasri, B; Tamimi, F	Admission criteria and academic performance in medical school	BMC MEDICAL EDUCATION	3.6	Q1	Article	2023
FA-16	Joeris, A; Sprague, S; Blauth, M; Gosch, M; Wattanapanom, P; Jarayabhand, R; Poeze, M; Wong, MK; Kwek, EBK; Hegeman, JH; Perez-Uribarri, C; Guerado, E; Revak, TJ; Zohner, S; Joseph, D; Phillips, MR	Cost-effectiveness analysis of the Geriatric Fracture Center (GFC) concept: a prospective multicentre cohort study	BMJ OPEN	2.9	Q2	Article	2023
FA-16	Tamimi, I; García-Meléndez, G; Vieitez-Riestra, I; Palacios-Penedo, S; Garceso, DM; Sanchez, A; Tamimi, F; Guerado, E; Milner, MSD; de Quevedo, DG; Gonzalez-Quevedo, D	The Use of \(\bigcirc -Blockers\) and the Risk of Undergoing a Knee Arthroplasty: A Nested Case-Control Study	JOURNAL OF BONE AND JOINT SURGERY- AMERICAN VOLUME	5.3	D1	Article	2023
FA-16	Gonzalez-Quevedo, D; Fernandez-Arroyabe, N; Moriel-Garceso, D J; Martinez-Malo, F J; Martin-Garcia, F; Arenas-Ros, J; Zambrana-Vico, S; Puerta-Migueles, L; Saez-Casado, M; Sanchez-Garcia, A; Tamimi, I	Reverse total shoulder arthroplasty for proximal humerus fractures: Primary or delayed after failed treatment?	Injury	2.5	Q2	Article	2023

COMPETITIVE RESEARCH GRANTS ACTIVE IN 2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-01	PMP21-00006. ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2	GEMMA ROJO MARTINEZ	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2021
A-01	PI18-01041 Efecto de un suplemento oral sobre el estado nutricional y funcional y niveles de expresión de microRNAs circulantes así como sus genes dianas, en personas desnutridas en hemodiálisis.	GABRIEL OLVEIRA FUSTER	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2018
A-01	The Effectiveness of MyDiaMate, a Self-guided Web-based App for Mental Health in Type 1 Diabetes: a Multinational Randomized Controlled Trial	MARÍA TERESA ANARTE ORTÍZ	INTERNATIONAL NON-EU	RG	JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL	2022
A-01	PI20/01322 Valor predictivo de los miRNA séricos en el desarrollo de enfermedades metabólicas y su relación con el grado de exposición a partículas y otros contaminantes del aire	GEMMA ROJO MARTINEZ	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2020
A-01	CPP2022-010108 MetabPlus: a flexible and efficient multi-IEM Newborn Screening Program.	RAQUEL YAHYAOUI MACÍAS	NATIONAL	RG	STATE RESEARCH AGENCY	2023
A-01	AP177082021 DETECCION PRECOZ Y TRATAMIENTO DE PACIENTES AFECTADOS DE ADRENOLEUCODISTROFIA LIGADA AL CROMOSOMA X: UN ESTUDIO POBLACIONAL PROSPECTIVO.	RAQUEL YAHYAOUI MACÍAS	NATIONAL	RG	MUTUA MADRILEÑA FOUNDATION	2021
A-01	PI18-00785 Estudio del efecto del complejo microRNA21-nanopartículas de oro sobre el browning: Una nueva herramienta terapéutica para la obesidad y resistencia a la insulina.	RAJAA EL BEKAY RIZKY	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2018
A-01	PY20_01274 Desarrollo de nuevo sistema de conducción de miR21-AuNPs dirigido específicamente al tejido adiposo. Una terapia experimental pionera contra la obesidad, la resistencia a la insulina y la diabetes tipo 2.	RAJAA EL BEKAY RIZKY	REGIONAL	RG	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2020
A-01	PI21-01924 Papel de los miARNs exosomales inflamatorios en la comunicación entre tejido adiposo- cerebro. Nuevos mecanismos subyacentes de las comorbilidades neuropsiquiátricas relacionadas con la obesidad	RAJAA EL BEKAY RIZKY	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2021
A-01	4050-22_miR21-AuNPs dirigido específicamente al tejido adiposo como terapia pionera contra la obesidad, la resistencia a la insulina y la diabetes tipo 2	RAJAA EL BEKAY RIZKY	NATIONAL	RG	FOUNDATION FOR INNOVATION AND FORESIGHT IN HEALTH IN SPAIN	2022
A-01	PID2021-1289260A-I00_REgulación del receptor de cannabinoide tipo 1 en la fisiología del islote humano y en el contexto de la Diabetes de tipo 1	NATALIA COLOMO RODRIGUEZ	NATIONAL	RG	STATE RESEARCH AGENCY	2021
A-01	INV-CLIN-01-2023 Evaluación del perfil clínico y analítico de los pacientes con diabetes mellitus tipo 2 en Endocrinología: Un estudio multicéntrico nacional (estudio REDIEN).	JOSÉ CARLOS FERNÁNDEZ GARCÍA	NATIONAL	RG	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION FOUNDATION	2023
A-01	PI-02-2021_SANCYD-VEGENAT-OB_IR. Acciones beneficiosas del aceite de oliva virgen extra sobre la meta-inflamación y procesos relacionados en personas con obesidad y pre-diabetes	IGNACIO RUIZ GARCÍA	REGIONAL	RG	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2021
A-01	FSEEN22_OBESIDAD_01 Impacto del aceite de oliva virgen extra (AOVE) sobre algunos microRNAs (miRNAs) y su efecto sobre la meta-inflamación y estrés oxidativo en personas con obesidad y prediabetes.	IGNACIO RUIZ GARCÍA	NATIONAL	RG	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION FOUNDATION	2022
A-01	SED-2022-03 DISEÑO Y EVALUACIÓN DEL IMPACTO DE UN PROGRAMA DE INTERVENCIÓN GRUPAL ONLINE PARA LA REDUCCIÓN DEL IMPACTO BIOPSICOLÓGICO CAUSADO POR EL COVID-19 EN PERSONAS CON DIABETES MELLITUS TIPO 1. ESTUDIO PSICOVIDI@BETES.	MÓNICA CARREIRA SOLER	NATIONAL	RG	SPANISH DIABETES SOCIETY	2022
A-01	SED-2022-01 Estudio del papel regulador del receptor de cannabinoide 1 de la célula beta en el inicio y desarrollo de la insulitis en humanos mediante ablación génica por CRISPR/saCas9	ISABEL GONZALEZ MARISCAL	NATIONAL	RG	SPANISH DIABETES SOCIETY	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-01	UMA20-FEDERJA-008 Eficacia y coste-eficacia de una aplicación WEB para tratar síntomas depresivos en personas adultas con diabetes tipo 1: un ensayo clínico contralado (WEB_TDDI1 study)	MARÍA TERESA ANARTE ORTÍZ	LOCAL	RG	UNIVERSITY OF MÁLAGA	2020
A-01	Efecto neuroprotector del IGF-II en un modelo celular de enfermedad de Parkinson con acumulación de agregados tóxicos de 🗓-sinucleína	w	REGIONAL	RG	UNIVERSITY OF MÁLAGA	2022
A-01	ESTUDIO MOLECULAR DE LA DISBACTERIOSIS ORAL EN PERSONAS CON PREDIABETES Y DIABETES. ESTUDIO SMILE	М	REGIONAL	RG	UNIVERSITY OF MÁLAGA	2022
A-01	Metabolic fatty liver disease in people with Type 1 Diabetes in Spain. Prevalence, physiological determinants, and clinical relevance	w	NATIONAL	RG	CIBER	2023
A-01	CARACTERIZACIÓN DE LAS ALTERACIONES OFTALMOLÓGICAS EN PACIENTES CON FIBROSIS QUÍSTICA Y BRONQUIECTASIAS NO DEBIDAS A FIBROSIS QUÍSTICA	w	NATIONAL	RG	Spanish Society of Pulmonology and Thoracic Surgery (Separ)	2023
A-01	Análisis de marcadores de inflamación, oxidación y adipoquinas en pacientes con linfedema secundario a cáncer de mama y con sobrepeso u obesidad, en respuesta a un programa estructurado de ejercicio y pérdida de peso.	w	REGIONAL	RG	UNIVERSITY OF MÁLAGA	2022
A-01	ERASMUS+: Research in murine models of type 1 diabetes - Chrysa Eleni Petraki	ISABEL GONZALEZ MARISCAL	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2022
A-01	POEJ-00039-11 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Gabriel Olveira Fuster	GABRIEL OLVEIRA FUSTER	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-01	RH-0023-2021_YDO_Impulso a la investigación traslacional en enfermedades raras y medicina personalizada en el grupo de Endocrinología y Nutrición	MARÍA YOLANDA DE DIEGO OTERO	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
A-01	RC-0003-2021 Renovación II del Programa Nicolás Monardes 2013. Gemma Rojo Martínez	GEMMA ROJO MARTINEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
A-01	RC-0001-2021 Renovación II del Programa Nicolás Monardo 2013. Francisco Javier Bermúdez Silva	FRANCISCO JAVIER BERMÚDEZ SILVA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
A-01	B-0002-2017_Acción B Clínicos investigadores_Natalia Colomo	GABRIEL OLVEIRA FUSTER	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2017
A-01	IFI20/00034 Contratos I-PFIS: Doctorados IIS-Empresa en ciencias y tecnologías de la salud. Candidate: Marina Padial Barranco, Group Leader: Gabriel Olveira Fuster	GABRIEL OLVEIRA FUSTER	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-01	CA17117 (EVBRES) -Towards an International Network for Evidence-based Research in Clinical Health Research	JOSÉ CARLOS FERNÁNDEZ GARCÍA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2018
A-01	C1-0018-2019 SOLICITUD PARA EL PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2019	ISABEL GONZALEZ MARISCAL	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
A-01	DOC_01138 Incorporación de ayudas posdoctorales. Candidate: Said Lhamyani, Group Leader: Rajaa El Bekay Rizky	RAJAA EL BEKAY RIZKY	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2019
A-01	A1-0010-2022 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS).IP: GABRIEL OLVEIRA.	GABRIEL OLVEIRA FUSTER	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
A-01	CM20/00225 Contratos Rio Hortega 2020 Ignacio Ruiz García. Group Leader: Gabriel Olveira Fuster	GABRIEL OLVEIRA FUSTER	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-01	FI21-00040 Contratos predoctorales de formación en investigación de salud. Wasima Oualla Bachiri group leader Gemma Rojo Martínez.	GEMMA ROJO MARTINEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-01	PLAN PROPIO_INT-F1-2-2304_2023 IP Francisco Javier Bermúdez Silva	FRANCISCO JAVIER BERMÚDEZ SILVA	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
A-01	MV22-00113 Nutrición en enfermedad renal crónica (ERC). Estancia predoctoral.	MARINA PADIAL BARRANCO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-01	CPC22218 ZINKINN_02. Tratamiento microRNA para controlar la obesidad y la diabetes	RAJAA EL BEKAY RIZKY	REGIONAL	AWARDS	ROCHE FARMA, S.A.	2021
A-01	A1-0044-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: SERGIO VALDES HERNANDEZ AND JOSE CARLOS FERNANDEZ GARCIA.	SERGIO VALDÉS HERNÁNDEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-01	CD23-00110 Contrato Sara Borrel 2023_Alicia Gonzalez Gonzalez_Jefe de Grupo: Jose Carlos Fernandez Garcia	JOSÉ CARLOS FERNÁNDEZ GARCÍA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-01	MV23-00073 APLICACIÓN DE LA METABOLÓMICA Y LA EPIGENÉTICA AL ESTUDIO DE LAS REACCIONES DE HIPERSENSIBILIDAD A ANTI-INFLAMATORIOS NO ESTEROIDEOS	ISABEL MARIA JIMENEZ SANCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-01	PR_INNV23-01 PREMIO A LAS INNOVACIONES TRASLADADAS A LA PRÁCTICA CLÍNICA EN ÚLTIMO AÑO.IP: RAQUEL YAHYAOUI	RAQUEL YAHYAOUI MACÍAS	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
A-01	RB-0001-2023_Acción B Clínicos investigadores_Natalia Colomo	NATALIA COLOMO RODRIGUEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-01	SENPE PI JOVENES_01_2023 Implantación de un protocolo de cribado, valoración e intervención nutricional en paciente frágil con insuficiencia cardiaca.	FRANCISCO JOSE SÁNCHEZ TORRALVO	NATIONAL	AWARDS	SPANISH SOCIETY OF CLINICAL NUTRITION AND METABOLISM	2023
A-01	BOURSE D'ALTERNANCE 2022 - Fatma Arrari	FRANCISCO JAVIER BERMÚDEZ SILVA	INTERNATIONAL NON-EU	HR	UNIVERSITY OF JENDOUBA	2022
A-01	ECFS Grant 2022 - Gabriel Olveira Fuster	GABRIEL OLVEIRA FUSTER	INTERNATIONAL NON-EU	COMPLEMENTARY ACTIONS	EUROPEAN CYSTIC FIBROSIS SOCIETY	2022
A-01/A-02	PI20/01559 Glomerulopatía asociada a Obesidad: Evaluación de la eficacia de una dieta de muy bajo contenido calórico o de la inhibición de SGLT2 sobre albuminuria y función renal	JOSÉ CARLOS FERNÁNDEZ GARCÍA	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2020
A-01/A-19	PI21-01042 Detección precoz y tratamiento de niños afectados de adrenoleucodistrofia ligada al X: un estudio poblacional prospectivo	RAQUEL YAHYAOUI MACÍAS	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2021
A-02	Susceptibilidad genética para predecir la pérdida de peso tras cirugía bariátrica.	w	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2022
A-02	Respuesta mitocondrial al abordaje dietético de la obesidad y sus complicaciones. Ayuno intermitente, cetosis y cronobiología	М	REGIONAL	RG	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-02	PI18/01175 Efecto de la diabetes gestacional sobre el epigenoma de la madre y de la descendencia en los 1000 primeros días. Identificación de potenciales biomarcadores epigenéticos de riesgo de DM2	MARÍA JOSÉ PICÓN CESAR	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2018
A-02	PI21-01864 Definiendo la heterogeneidad en la Diabetes Gestacional: hacia una medicina de precisión. Una ventana crítica para parar el ciclo vicioso de diabetes-obesidad.	Mª SONSOLES MORCILLO ESPINA	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-02	PI18/01160 PAPEL DE LOS CUERPOS CETONICOS Y LA MICROBIOTA EN EL ABORDAJE DIETETICO DE LA OBESIDAD	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2018
A-02	PI21-01677 Medicina personalizada o de precisión en el abordaje dietético de la obesidad	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2021
A-02	RIC-0539-2018: NETWORK OF CLINICAL TRIALS ON METABOLISM: DIABETES, OBESITY, AND DYSLIPIDEMIA	FRANCISCO JOSÉ TINAHONES MADUEÑO	REGIONAL	RG	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2018
A-02	PI19/00507 Fitness mitocondrial diana para la terapia contra la prediabetes IP MORA MURRI PIERRI	MORA MURRI PIERRI	NATIONAL	RG	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
A-02	CP20-00066:Impact of glucose-lowering strategies on gut microbiota. Proyecto Miguel Servet 2020 Carolina Gutierrez Repiso	CAROLINA GUTIÉRREZ REPISO	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2020
A-02	PI-0108-2022 BÚSQUEDA DE POTENCIALES BIOMARCADORES DE DIAGNÓSTICO / EVOLUCION DE LA ESTEATOHEPATITIS NO ALCOHÓLICA EN PACIENTES CON OBESIDAD MÓRBIDA SOMETIDOS A CIRUGÍA BARIÁTRICA	LOURDES GARRIDO SÁNCHEZ	REGIONAL	RG	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
A-02	CP20-00060:Footprint of an early nutritional intervention on breastfeeding mothers in the quality of the breast milk and health of the infant. Proyecto Miguel Servet 2020 Almudena Ortega Gomez	ALMUDENA ORTEGA GOMEZ	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2020
A-02	SED-2021-001 DISFUNCIÓN VENTRICULAR E INSUFICIENCIA CARDIACA EN PACIENTES CON DIABETES TIPO 1. PAPEL DE LA MICROBIOTA INTESTINAL EN LA AFECTACIÓN MIOCÁRDICA EN DIABETES TIPO 1.	ANA MARIA GOMEZ PEREZ	NATIONAL	RG	SPANISH DIABETES SOCIETY	2021
A-02	SED-2018-02 DIFERENCIAS EN MICROBIOTA ENTRE PACIENTES CON DIABETES MELLITUS GESTACIONAL TRATADAS CON INSULINA FRENTE A AQUELLAS TRATADAS CON METFORMINA Y SU POSIBLE PAPEL EN EL CONTROL METABÓLICO, LA INFLAMACIÓN Y LOS RESULTADOS OBSTÉTRICOS Y PERINATALES. LR: María Molina Vega	MARIA MOLINA VEGA	NATIONAL	RG	SPANISH DIABETES SOCIETY	2018
A-02	PY20_01270 Rastreos genómicos de tipo CRISPR/Cas para la identificación y caracterización funcional de nuevos biomarcadores en cáncer colorrectal asociado a obesidad	MANUEL MACIAS GONZÁLEZ	REGIONAL	RG	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2020
A-02	PI-0235-2021. miRNoma circulante asociado a diferentes estrategias nutricionales para el abordaje personalizado de la obesidad. NutrimiRs: caracterización y potencial terapéutico.	MARIA MERCEDES CLEMENTE POSTIGO	REGIONAL	RG	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
A-02	Lifestyle Interventions, metabolites, microbiome, and diabetes risk	FRANCISCO JOSÉ TINAHONES MADUEÑO	INTERNATIONAL NON-EU	RG	NATIONAL INSTITUTES OF HEALTH	2020
A-02	MOV22-012 MBD2 and KAISO regulation as result to exposure of dietary factors in human normal and malignant intestinal organoids. Hatim Boughanem	HATIM BOUGHANEM LAKHAL	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2022
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	ISABEL MORENO INDIAS	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2021
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	PATRICIA RUIZ LIMON	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
A-02	CA20128 (PIMENTO): Promoting Innovation of fermented foods	CAROLINA GUTIÉRREZ REPISO	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
A-02	CA18124 (ESMN) - European Sexual Medicine Network	MORA MURRI PIERRI	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2019

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-02	RC-0008-2021 Renovación I Acción C (Programa Nicolás Monardes) Convocatoria 2017. LR: Sonsoles Morecillo	Mª SONSOLES MORCILLO ESPINA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
A-02	POEJ-00039-18 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Sonsoles Morcillo Espina	Mª SONSOLES MORCILLO ESPINA	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-02	MS22-00033 Contrato Miguel Servet 2022_Virginia Mela Rivas	VIRGINIA MELA RIVAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	CM20/00183 Contratos Río Hortega 2020 Miiguel Damas Fuentes. Group Leader: Francisco J. Tinahones Madueño	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-02	IFEQ21-00148. Equipamiento para la Unidad de Investigación en Cardio-Metabolismo	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	INFRASTRUCTURE	CARLOS III INSTITUTE OF HEALTH	2021
A-02	CD22/00144 Contrato Sara Borrell_Violeta Heras Dominguez_Jefe de Grupo Francisco Jose Tinahones Madueño.	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	RB-0001-2019 RENOVACIÓN ACCION B CONVOCATORIA 2014 EN LAS UNIDADES DE GESTIÓN CLÍNICA (UGC) DEL SERVICIO ANDALUZ DE SALUD (SAS)	FRANCISCO JOSÉ TINAHONES MADUEÑO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
A-02	POEJ-00039-06 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Francisco Tinahones Madueño	FRANCISCO JOSÉ TINAHONES MADUEÑO	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-02	RC-0001-2018 Acción C Nicolás Monardes Manuel Macias	MANUEL MACIAS GONZÁLEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2018
A-02	RC1-0002-2023 Renovación II del Programa Nicolás Monardes 2023	MANUEL MACIAS GONZÁLEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-02	MS17/00133 Miguel Servet Tipo I 2017 Mora Murri Perri	MORA MURRI PIERRI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2017
A-02	CPII22-00013 Contratos Miguel Servet Tipo II 2022 Mora Murri	MORA MURRI PIERRI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	CA18131 (ML4Microbiome) - Statistical and machine learning techniques in human microbiome studies	ISABEL MORENO INDIAS	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
A-02	CPII21-00013 Contratos Miguel Servet Tipo II 2021 Isabel Moreno Indias	ISABEL MORENO INDIAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-02	FI22-00193 Contratos predoctorales de formación en investigación de salud. BN: Alba Subiri Verdugo IP Isabel Morneo Indias	ISABEL MORENO INDIAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	POEJ-00039-12 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Isabel Moreno Indias	ISABEL MORENO INDIAS	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-02	C-0028-2018 Acciones para el refuerzo con recursos humanos de la actividad investigadora en las Unidades de Gestión Clinica del Servicio Andaluz de Salud 2018. Acción C. Vinculación de investigadores a las UGC del SAS. Programa Nicola Monardes. Lourdes Garrido	LOURDES GARRIDO SÁNCHEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2018
A-02	CP20-00066 Contratos Miguel Servet 2020 Carolina Gutierrez Repiso	CAROLINA GUTIÉRREZ REPISO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-02	POEJ-00039-19 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Carolina Gutierrez Repiso	CAROLINA GUTIÉRREZ REPISO	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-02	CD19-00216 Contratos Sara Borrell 2019 Patricia Ruiz Limón Jefe de Grupo: Francisco José Tinahones Madueño	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
A-02	MS22-00096 Contrato Miguel Servet 2022. IP Patricia Ruiz Limon.	PATRICIA RUIZ LIMON	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	JR19-00054 Contratos Juan Rodes 2019 Isabel María Cornejo Pareja	ISABEL MARÍA CORNEJO PAREJA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
A-02	POEJ-00039-13 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Isabel Cornejo Pareja	ISABEL MARÍA CORNEJO PAREJA	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-02	JR20-00040 Contratos Juan Rodes 2020 Maria Molina Vega	MARIA MOLINA VEGA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-02	PR-COVID-2-2021.A vueltas con el diagnóstico de la diabetes gestacional: ¿tienen cabida los criterios COVID a largo plazo para las pacientes no identificadas mediante los criterios tradicionales?	MARIA MOLINA VEGA	NATIONAL	AWARDS	SPANISH DIABETES SOCIETY	2021
A-02	FSEEN22_ARTICULOS_01 Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial	MARÍA JOSÉ PICÓN CESAR	NATIONAL	AWARDS	SPANISH SOCIETY OF ENDOCRINOLOGY AND NUTRITION FOUNDATION	2022
A-02	FI19-00178 Contratos predoctorales de formación en investigación en salud Teresa María Linares Pineda Jefe de grupo: Sonsoles Morcillo Espina	Mª SONSOLES MORCILLO ESPINA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
A-02	CP20-00060 Contratos Miguel Servet 2020 Almudena Ortega Gomez	ALMUDENA ORTEGA GOMEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-02	POEJ-00039-25 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Almudena Ortega Gómez	ALMUDENA ORTEGA GOMEZ	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-02	PREDOC20_002 Contrato Predoctoral. Candidate: Hatim Boughanem Lakhal, Group Leader: Manuel Macías González	MANUEL MACIAS GONZÁLEZ	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2020
A-02	DOC_01095 Incorporación de ayudas posdoctorales. Candidate: Wilfredo Oliva Olivera, Group Leader: Lourdes Garrido Sánchez	LOURDES GARRIDO SÁNCHEZ	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2019
A-02	SOLICITUD FPU CANDIDATA CLAUDIA CORONO CASTRO. JEFE DE GRUPO FRANCISCO TINAHONES MADUEÑAS. FPU20-03732	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	HR	MINISTRY OF SCIENCE, INNOVATION, AND UNIVERSITIES	2020
A-02	CD21-00131 Contratos Sara Borrell 2021 Libia Alejandra Garcia Flores jefe de grupo Manuel Macías González	MANUEL MACIAS GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-02	CM22-00217 Contrato Rio Hortega 2022 Jose Ignacio Martinez Montoro_Jefe de Grupo Francisco Jose Tinahones Madueño.	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-02	PLAN PROPIO_INT-F1-1-2307_2023 IP Manuel Macías González	MANUEL MACIAS GONZÁLEZ	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
A-02	PLAN PROPIO_INT-F1-4-2301_2023 IP Virginia Mela Rivas	VIRGINIA MELA RIVAS	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-02	MOV23-02 Aprendizaje de la caracterización del viroma intestinal.	PATRICIA RUIZ LIMON	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
A-02	MOV23-04 "Caracterización de poblaciones leucocitarias por citometría espectral" / "Characterization of leukocyte populations with spectral cytometry"	ALMUDENA ORTEGA GOMEZ	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
A-02	CD23-00111 Contrato Sara Borrel 2023_Daniel Hinojosa-Nogueira_Jefe de Grupo: Isabel Moreno Indias	ISABEL MORENO INDIAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-02	FI23-00104 Contratos predoctorales de formación en investigación de salud. BN: GEMA GOMEZ CASADO.IP:ALMUDENA ORTEGA GOMEZ.	ALMUDENA ORTEGA GOMEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-02	A1-0064-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: FRANCISCO JOSE TINAHONES.	FRANCISCO JOSÉ TINAHONES MADUEÑO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-02	CM23-00128 Contrato Rio Hortega 2023_Cristina Maria Diaz Perdigones_Jefe de Grupo:Isabel Moreno Indias.	ISABEL MORENO INDIAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-02/A-10	PMP21/00106 AVANCES EN MEDICINA DE PRECISIÓN DE LA OBESIDAD: ANÁLISIS MULTIÓMICO Y DINÁMICO PARA EL DESCUBRIMIENTO Y VALIDACIÓN DE BIOMARCADORES PREDICTORES DE PÉRDIDA DE PESO TRAS INTERVENCIÓN EN PERSONAS DE ALTO RIESGO"	DOLORES CORELLA PIQUER/ FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2021
A-02/C-16	PI22-01813 El papel de los neutrófilos de leche materna de madres con enfermedades metabólicas tras una intervención nutricional. Impacto en el desarrollo del niño y respuesta a infecciones pulmonares	ALMUDENA ORTEGA GOMEZ	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2022
A-02/CIMO-01	PI21-00633 El estado de inflamación como principal impulsor de la metilación aberrante del ADN-ARN en el cáncer colorrectal.	MANUEL MACIAS GONZÁLEZ	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2021
A-03	PI22/00570 Relación de la microbiota fecal y oral, y sus metabolitos, con la presencia de arterias coronarias lisas, irregulares y con lesión IP Fco Manuel Jimenez obstructiva significativa	MANUEL FRANCISCO JIMÉNEZ NAVARRO	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2022
A-03	PI-0131-2020 Evaluación de marcadores inflamatorios y de estrés oxidativo en pacientes de edad avanzada con cardiopatía isquémica: Estratificación pronóstica combinada tras una revascularización coronaria percutánea.	ANTONIO JESÚS MUÑOZ GARCÍA	REGIONAL	RG	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
A-03	PI-0245-2021. Caracterización de Pacientes con Hipertensión Pulmonar Basada en la Función Mitocondrial para el Desarrollo de una Prueba Diagnóstica	JUAN JOSÉ GÓMEZ DOBLAS	REGIONAL	RG	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
A-03	Proy_Excel_01009 Identificación de marcadores moleculares de aortopatía bicúspide (MaMolAo)	GEMMA SÁNCHEZ ESPÍN	REGIONAL	RG	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
A-03	PI22-01833 Caracterización de Marcadores de Estrés Cardíaco y Quimioquinas en Pacientes con Trastorno por Uso de Alcohol para Evaluar el Riesgo de Cardiopatía Isquémica: Biomarcadores Específicos.	FRANCISCO JAVIER PAVÓN MORÓN	NATIONAL	RG	CARLOS III INSTITUTE OF HEALTH	2022
A-03	PI19/00886 Estrés y alcohol como factores de riesgo Psiquiátrico y cardiovascular asociados a inflamación: Evaluación antiinflamatoria del sistema quimioquina CX3CL1/CX3CR1. IP FRANCISCO JAVIER PAVON MORON	FRANCISCO JAVIER PAVÓN MORÓN	NATIONAL	RG	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
A-03	AFFIRMO-ATRIAL FIBRILLATION INTEGRATED APPROACH IN FRAIL, MULTIMORBID, AND POLYMEDICATED OLDER PEOPLE	JORGE RODRIGUEZ CAPITAN	UNIÓN EUROPEA	PI	EUROPEAN COMMISSION	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-03	UMA20-FEDERJA-074 Evaluación de marcadores inflamatorios y de estrés oxidativo en pacientes de edad avanzada con cardiopatía isquémica: Estratificación pronóstica combinada tras una revascularización coronaria percutánea	FRANCISCO JAVIER PAVÓN MORÓN	LOCAL	PI	UNIVERSITY OF MÁLAGA	2020
A-03	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	MARIA JOSE SANCHEZ QUINTERO	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
A-03	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	MARIA JOSE SANCHEZ QUINTERO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2021
A-03	ERASMUS+: Inflammatory signaling of the cardiovascular system in stress models - Dimitra Andrikopoulou	FRANCISCO JAVIER PAVÓN MORÓN	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2022
A-03	CA22169 (EU-METAHEART): EUropean network to tackle METAbolic alterations in HEART failure	MARIA JOSE SANCHEZ QUINTERO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
A-03	FI20/00227 Contratos predoctorales de formación en investigación en salud. Candidate: Dina Medina Vera: Group Leader: Francisco Javier Pavón Morón	FRANCISCO JAVIER PAVÓN MORÓN	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-03	MV22/00112 Efectos del alcohol sobre la expresión del sistema de señalización CX3CL1/R1 y marcadores inflamatorios en tejido cardíaco en un modelo preclínico de síndrome alcohólico.	DINA MEDINA VERA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-03	CA18118 (IRENE) - Implementation Research Network in Stroke Care Quality	MANUEL FRANCISCO JIMÉNEZ NAVARRO	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
A-03	C1-0049-2019 SOLICITUD PARA EL PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2019	FRANCISCO JAVIER PAVÓN MORÓN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
A-03	POEJ-00039-20 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Francisco Javier Pavón Morón	FRANCISCO JAVIER PAVÓN MORÓN	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	JORGE RODRIGUEZ CAPITAN	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
A-03	RH-0095-2020 Estratificación pronóstica combinada de pacientes de edad avanzada con cardiopatía isquémica: Evaluación de variables clínicas y bioquímicas	MANUEL FRANCISCO JIMÉNEZ NAVARRO	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
A-03	CM21-00027 Contratos Rio Hortega 2021 Ana Isabel Molina Ramos. Group Leader Francisco Javier Pavón Morón	FRANCISCO JAVIER PAVÓN MORÓN	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-03	RH-0078-2021-MJS.Caracterización de Pacientes con Hipertensión Pulmonar Basada en la Función Mitocondrial para el Desarrollo de una Prueba Diagnóstica	MANUEL FRANCISCO JIMÉNEZ NAVARRO	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
A-03	POSTDOC-21-00134 Incorporación de ayudas posdoctorales. Candidate: Karl-Khader Thurnhofer Hemsi. Team leader: Manuel Francisco Jiménez Navarro	MANUEL FRANCISCO JIMÉNEZ NAVARRO	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-03	CA18101 (SOURDOmICS) - SOURDOugh biotechnology network towards novel, healthier and sustainable food and bloproCesseS	JOSUE DELGADO PERON	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
A-03	JR22-00067 Contratos Juan Rodes 2022 Victor Manuel Becerra Muñoz	VICTOR MANUEL BECERRA MUÑOZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-03	MOV23-11. Analysis, study and characterization of bacterial metabolites from biological samples	SILVANA TERESA TAPIA PANIAGUA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-03	ORACLE - Optimize risk prediction after myocardial infarction through artificial intelligence and multidimensional evaluation	FRANCESCO COSTA	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2022
A-03	FI23-00016 Contratos predoctorales de formación en investigación de salud.BN: ADA DEL MAR CARMONA SEGOVIA. LR: MANUEL FRANCISCO JIMENEZ NAVARRO.	MANUEL FRANCISCO JIMÉNEZ NAVARRO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-03	A1-0063-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: JUAN JOSE GOMEZ DOBLAS AND MANUEL FRANCISCO JIMENEZ NAVARRO.	MANUEL FRANCISCO JIMÉNEZ NAVARRO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-03	CM23-00125 Contrato Rio Hortega 2023 Ainhoa Robles Mezcua_Jefe de grupo: Manuel Francisco Jimenez Navarro.	MANUEL FRANCISCO JIMÉNEZ NAVARRO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-03	INT23-00033 Contrato intensificación Manuel Jiimenez	MANUEL FRANCISCO JIMÉNEZ NAVARRO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-03	JR23-00033 Contratos Juan Rodes 2023 Francesco Costa	FRANCESCO COSTA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
A-03/F-02	Inteligencia Artificial para el modelado de un Sistema de Apoyo a la Decisión Clínica aplicado a las enfermedades cardiovasculares	MANUEL FRANCISCO JIMÉNEZ NAVARRO	INTERNATIONAL NON-EU	HR	NATIONAL RESEARCH AND INNOVATION AGENCY OF URUGUAY	2023
A-06	3TR - Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory and Allergic Conditions	CARLOS ROMERO GOMEZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2018
A-06	PI21/00465 Envejecimiento saludable: enfoque multidisciplinario del impacto del estilo de vida en la salud humana. Estudio HEAG	MARÍA ROSA BERNAL LÓPEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
A-06	IDelBIMA_001_2018 Impacto de la modificación del estilo de vida sobre la función muscular y cognitiva de una población obesa metabólicamente sana de edad avanzada.	RICARDO GÓMEZ HUELGAS	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2018
A-06	Secoiridoides del olivo en la terapia nutricional del lupus eritematoso sistémico: implicaciones epigenéticas. SerLES Study	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
A-06	CA21147 (ENOTTA) - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases	MARIA DEL MAR AYALA GUTIÉRREZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
A-06	CA18216 (VascAgeNet) - Network for Research in Vascular Ageing	MARÍA ROSA BERNAL LÓPEZ	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
A-06	CPII20/00014 Contratos Miguel Servet Tipo II 2020 María Rosa Bernal López	MARÍA ROSA BERNAL LÓPEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-06	MV22/00091 Riesgo Cardiometabólico de las enfermedades crónicas no trasmisibles. Medicina Personalizada en la edad avanzada.	MARÍA ROSA BERNAL LÓPEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-06	FI22/00294 Contratos predoctorales de formación en investigación de salud. BN: María de los Ángeles Silva Soto IP Rosa Bernal Lopez	MARÍA ROSA BERNAL LÓPEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-06	RH-0025-2021_PCF_Obesidad metabólicamente sana (OMS), Obesidad metabólicamente enferma (OME), modificación de estilo de vida, tecnología multiómica, epigenética (nuclear y mitocondrial), dinámica mitocondrial (Opa1, Mfn2), cadena de transporte electrónico, daño oxidativo	MARÍA ROSA BERNAL LÓPEZ	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
A-06	POEJ-00039-23 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Rosa Bernal López	MARÍA ROSA BERNAL LÓPEZ	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-06	IHMC22/00011 Impact of lipid stress on sperm cytoskeleton: -omic study and damage reversal strategy through diet	ESTEFANÍA SAEZ LANCELLOTTI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-06	CM20/00125 Contratos Rio Hortega 2020 Lidia Cobos Palacios. Group Leader: Ricardo Gómez Huelgas	RICARDO GÓMEZ HUELGAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-06	CM20/00212 Contratos Rio Hortega 2020 Jaime Sanz Canovas . Group Leader: Luis Miguel Pérez Belmonte	LUIS MIGUEL PÉREZ BELMONTE	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
A-06	CM21/00110 Contratos Rio Hortega 2021 Almudena López Sampalo jefe de grupo M Rosa Bernal López	MARÍA ROSA BERNAL LÓPEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-06	CM22/00155 Contrato Rio Hortega 2022 Michele Ricci Jefe de Grupo Ricardo Gomez Huelgas.	RICARDO GÓMEZ HUELGAS	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-06	CM22/00225 Contrato Rio Hortega 2022 Miguel Angel Perez Velasco_Jefe de Grupo Luis Miguel Perez Belmonte.	LUIS MIGUEL PÉREZ BELMONTE	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
A-06	GPC23-02 Executive summary: Updates to the dietary treatment of prediabetes and type 2 diabetes mellitus IP:Ricardo Gomez Huelgas	RICARDO GÓMEZ HUELGAS	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
A-06	A1-0047-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: RICARDO GOMEZ HUELGAS	RICARDO GÓMEZ HUELGAS	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
A-07	Efecto de polifenoles del aceite de oliva virgen extra sobre las complicaciones macro y microangiopáticas en un modelo experimental de diabetes mellitus tipo 2	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
A-07	PS17174 NUTRADAF,ITC-20161265 Caracterización de las fracciones funcionales de la aceituna, formulación de nuevos productos y análisis de sus defectos	JOSÉ PEDRO DE LA CRUZ CORTÉS	NATIONAL	PI	CENTER FOR TECHNOLOGICAL DEVELOPMENT AND INNOVATION	2016
A-07	PS17173 NUTRADAF,ITC-20161265 Caracterización de las fracciones funcionales de la aceituna, formulación de nuevos productos y análisis de sus defectos	JOSÉ ANTONIO GONZÁLEZ CORREA	NATIONAL	PI	CENTER FOR TECHNOLOGICAL DEVELOPMENT AND INNOVATION	2016
A-07	PI-0120-2020 Efectividad de la asociación aceite de oliva virgen extra-ácido acetilsalicílico vs. ácido acetilsalicílico cada 12 h sobre la resistencia al tratamiento antiagregante en pacientes con diabetes mellitus tipo 2.	JOSÉ ANTONIO GONZÁLEZ CORREA	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
A-09	Pl19/01375 Biomarcadores de deterioro cognitivo mediante neuroimagen estructural (tractografía) y funcional (conectividad cerebal) en pacientes con diabetes tipo 2.	NATALIA GARCÍA CASARES	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
A-09	PI18-01809 PROYECTO IBERSCORE-2: ELABORACION DE FUNCIONES PREDICTIVAS DE RIESGO CARDIOVASCULAR TRAS UN SEGUIMIENTO DE 10 AÑOS DE LA COHORTE ICARIA.	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
A-09	POEJ-00039-22 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Pedro Valdivielso Felices	PEDRO VALDIVIELSO FELICES	REGIONAL	HR	DEPARTMENT OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
A-10	Actividad física y sueño medidos de manera objetiva con acelerometría en escolares de 8 y 9 años en Andalucía	М	REGIONAL	Pl	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-10	PI-0067-2022. Influencia de los Entornos Obesogénicos Durante una Intervención para la Pérdida de Peso en el contexto andaluz del ensayo PREDIMED-PLUS. (PRE-ENVIRONS ANDALUCÍA)	JULIA WARNBERG	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
A-10	RH-0024-2021-ACF Influencia de los Entornos Obesogénicos Durante una Intervención para la Pérdida de Peso en el contexto andaluz del ensayo PREDIMED-PLUS. (PRE-ENVIRONS ANDALUCÍA)	JULIA WARNBERG	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
A-10	CM21-00214 Contratos Rio Hortega 2021 Viyey Kishore Doulatram Gamgaram Jefe de grupo José Carlos Fernández García	JOSÉ CARLOS FERNÁNDEZ GARCÍA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
A-17	Identificación de nuevos marcadores moleculares y factores etiológicos de la aortopatía bicúspide	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
A-19	SEGHNP-2022-01. ANÁLISIS DE LA RESPUESTA FISIOLÓGICA AL AYUNO DE NIÑOS Y ADOLESCENTES CON OBESIDAD, EN COMPARACIÓN CON ADULTOS, Y TRAS UNA INTERVENCIÓN DE RESTRICCIÓN TEMPORAL DE LA INGESTA DE ALIMENTOS	RAFAEL MARTIN MASOT	NATIONAL	PI	SPANISH SOCIETY OF GASTROENTEROLOGY, HEPATOLOGY, AND PEDIATRIC NUTRITION	2022
A-19	PUNI-003_2018:TELEMEDICINA EN LA ATENCIÓN A NIÑOS CRÓNICOS COMPLEJOS- PLURIPATOLÓGICOS Y SUBSIDIARIOS DE CUIDADOS PALIATIVOS PEDIÁTRICOS	AURORA MADRID RODRÍGUEZ	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2018
A-19	CONECT4CHILDREN - European Paediatric Clinical Trials Network	ESMERALDA NUÑEZ CUADROS	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2017
A-19	PIGE-0533-2019. Implantación de un programa de seguimiento telemático para pacientes con Diabetes Mellitus tipo 1 usuarios de montorización Free Style Libre y valoración de su impacto en variables metabólicas, calidad de vida y costes sanitarios.	ISABEL LEIVA GEA	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2019
A-19	AI-01-2023. ESTUDIO A NIVEL DE CÉLULA ÚNICA DEL EFECTO DE UNA DIETA SIN GLUTEN EN EL PERFIL INMUNOLÓGICO SISTÉMICO DE PACIENTES PEDIÁTRICOS CON ENFERMEDAD CELÍACA	RAFAEL MARTIN MASOT	REGIONAL	PI	ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	2023
A-19	BECA_SPAO_2022 ANÁLISIS DE LA RESPUESTA FISIOLÓGICA AL AYUNO DE NIÑOS Y ADOLESCENTES CON OBESIDAD, EN COMPARACIÓN CON ADULTOS, Y TRAS UNA INTERVENCIÓN DE RESTRICCIÓN TEMPORAL DE LA INGESTA DE ALIMENTOS	RAFAEL MARTIN MASOT	REGIONAL	PI	ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	2022
A-19	SEGHNP-2021-01. RESTRICCIÓN HORARIA DE LA INGESTA DE ALIMENTOS EN NIÑOS Y ADOLESCENTES CON OBESIDAD Y COMORBILIDADES METABÓLICAS: ESTUDIO PILOTO	VÍCTOR MANUEL NAVAS LÓPEZ	NATIONAL	PI	SPANISH SOCIETY OF GASTROENTEROLOGY, HEPATOLOGY, AND PEDIATRIC NUTRITION	2021
A-19	AI-02-2023 MICROBIOMA ORAL Y SU RELACIÓN CON EL DESARROLLO DE CARIES EN LA ENFERMEDAD CELIACA EN NIÑOS.	ENCARNACION TORCUATO RUBIO	REGIONAL	PI	ANDALUSIAN SOCIETY OF PEDIATRICS OF EASTERN ANDALUSIA	2023
A-19	Estudio de factores predictivos para la alteración del crecimiento intrauterino mediante la identificación de biomarcadores clínicos, metabólicos y metagenómicos	М	NATIONAL	PI		2022
A-19	CA21145 (EURESTOP) - European Network for diagnosis and treatment of antibiotic-resistant bacterial infections	PILAR SÁNCHEZ YAÑEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
A-19	CA21168 (JIR-CliPS) - Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice strategies	ROCIO GALINDO ZAVALA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
A-19	ECFS Grant 2022 - Estela Pérez Ruiz	ESTELA PÉREZ RUIZ	INTERNATIONAL NON-EU	COMPLEMENTARY ACTIONS	EUROPEAN CYSTIC FIBROSIS SOCIETY	2022
A-19	CA19115 (HyperChildNET) - Network for blood pressure research in children and adolescents	VERONICA MARTINEZ RIVERA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
A-19	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	ISABEL LEIVA GEA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
A-19	PR_INN23-02 PREMIO A LAS INNOVACIONES TRASLADADAS A LA PRÁCTICA CLÍNICA EN ÚLTIMO AÑO. IP:ISABEL LEIVA	ISABEL LEIVA GEA	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
A-21	PI18-00701 miRNAs: definición de perfil de expresión génico para la guía de la terapéutica en el paciente con cardiopatía isquémica; papel en el acondicionamiento miocárdico anestésico.	JOSE LUIS GUERRERO ORRIACH	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
A-21	AAEAR23_01 "Variación de la recidiva oncológica en el perioperatorio de cirugía tumoral de mama: comparación de anestesia libre de opiáceos e hipnóticos intravenosos vs opiáceos e hipnóticos inhalatorios. Papel de los circRNA como biomarcadores en este grupo de pacientes".	AIDA RAIGÓN PONFERRADA	REGIONAL	Pl	ANDALUSIA-EXTREMADURA ASSOCIATION OF ANESTHESIOLOGY, RESUSCITATION, AND PAIN THERAPEUTICS	2023
A-21	CA21152 (INE-CSC) - Implementation Network Europe for Cancer Survivorship Care	AIDA RAIGÓN PONFERRADA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
A-21	PREDOC20_003 Contrato Predoctoral. Candidate: Laura González Álvarez, Group leader: José Luis Guerrero Orriach	JOSE LUIS GUERRERO ORRIACH	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2020
A-21	A1-0065-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP:JOSE LUIS GUERRERO ORRIACH	JOSE LUIS GUERRERO ORRIACH	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
AA-20	CA19133 (FOSTREN) - Fostering and strengthening approaches to reducing coercion in European mental health services	DANIEL MORENO SANJUÁN	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
AA-20	CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims	DANIEL MORENO SANJUÁN	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
AA-22	CA18205 (WORCK) - Worlds of Related Coercions in Work	FRANCISCO JAVIER ALCALDE DE HOYOS	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
AA-22	MOV23-06 Evaluación de las habilidades motoras en pacientes con Síndrome de Rett tratados con leriglitazona	RITA PILAR ROMERO GALISTEO	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
AE-11	SEN22_01 Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico: estudio prospectivo, controlado y aleatorizado de grupos paralelos	ARMANDO TORRES RAMÍREZ	NATIONAL	ΡΙ	SPANISH NEPHROLOGY SOCIETY	2022
AE-11	RD21-0005-0012 Red de Enfermedaes Inflamatorias IP: Domingo Hernández Marrero	Domingo Hernández Marrero	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
B-04	PID2019-108096RB-C21 Aproximaciones sistémicas basadas en asociaciones fenotipo-genotipo para mejorar el diagnóstico de pacientes con enfermedades raras. Funding Entity	М	NATIONAL	PI	MINISTRY OF ECONOMIC AFFAIRS AND DIGITAL TRANSFORMATION	2019

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
B-04	PI21/00653 Discovery of new therapeutic targets to battle cancer and prevent lymphatic metastasis / Descubrimiento de Nuevas Dianas Terapéuticas en la Lucha Contra el Cáncer y la Prevención de las Metástasis Linfáticas	MELISSA GARCÍA CABALLERO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
B-04	Análisis bioinformático de polimorfismos y expresión génica en los tejidos reproductivos del olivo (Olea europaea) como fuente de marcadores de interés agroalimentario e inmunitario (BioInfOliv)	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
B-04	Identificación bioinformática de vías compensatorias en enfermedades raras y cáncer para su tratamiento.	М	REGIONAL	Pl	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
B-04	Inhibición de la Linf/angiogénesis Patológica: Búsqueda y Caracterización de Nuevos y Mejores Fármacos, e Identificación de Nuevas Estrategias Terapéuticas	w	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
B-04	Comprehensive Platform for the Sustainable Development of Therapies Based On Oligonucleotides	М	NATIONAL	PI	CENTER FOR TECHNOLOGICAL DEVELOPMENT AND INNOVATION	2021
B-04	IMPaCT-Data: IMPaCT Data Science Program. Research Program: IMPacT: Precision Medicine Infrastructure associated with Science and Technology	М	NATIONAL	PI	MICINN, ISCIII	2021
B-04	Papel de los Condensados Biomoleculares en la Patofisiología de las Enfermedades Raras	w	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
B-04	Integración de fenotipo, genotipo y transcriptómica en una plataforma bioinformática para ayudar en el diagnóstico de enfermedades raras	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
B-04	RH-0079-2021-ERR. Estrategias sistémicas para identificar genes implicados en enfermedades raras relacionadas con alteraciones del neurodesarrollo y las capacidades neuromotoras	MIGUEL ÁNGEL MEDINA TORRES	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
B-04	PLAN PROPIO_INT-F2-2304_2023 IP Miguel Ángel Medina Torres	MIGUEL ÁNGEL MEDINA TORRES	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
B-04	PR_DIVULGA_01_2023 Deepening the knowledge of rare diseases dependent on angiogenesis through semantic similarity clustering and network analysis.	MIGUEL ÁNGEL MEDINA TORRES	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
B-04/CIMO- 03/ F-09	Altas de expresión del olivo (OXA) para interrogación prospectiva del olivo en estrés salino	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
B-07	EL DIALOGO ENTRE GLS Y GLS2 COMO DIANA TERAPEUTICA EN CANCER	Male	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
B-10	EFICACIA DE LOS FOTOPROTECTORES TÓPICOS EN PACIENTES CON FOTODERMATOSIS. NUEVOS MÉTODOS ENFOTODIAGNÓSTICO	M/H	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
B-11	AEU21-001 EVALUACIÓN CLÍNICO-RADIOLÓGICA Y GENÉTICA EN PACIENTES CON CÁNCER DE PRÓSTATA METASTÁSICO HORMONOSENSIBLE TRATADOS CON ANTIANDRÓGENOS DE NUEVA GENERACIÓN. CPC21065	BERNARDO HERRERA IMBRODA	NATIONAL	PI	SPANISH ASSOCIATION OF UROLOGY	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
B-11	LABAE223471MATA: LAB AECC_01 LA SEÑALIZACIÓN POR AUTOTAXINA-ÁCIDO LISOFOSFATIDICO COMO DIANA TERAPEUTICA PARA MEJORAR LA EFICACIA DE LA INMUNOTERAPIA EN EL CÁNCER UROTELIAL DE VEJIGA. LABAE223471MATA	ELISA MATAS RICO	NATIONAL	Pl	SPANISH ASSOCIATION AGAINST CANCER	2022
B-11	AC18/00088 MOLCARUTUC - Comprehensive genomic. characterization of upper urinary tract urothelial carcinoma and paired bladder	BERNARDO HERRERA IMBRODA	EUROPEAN UNION	PI	CARLOS III INSTITUTE OF HEALTH	2018
B-11	CPP2022-010045 Desarrollo y validación de nuevo sistema automático de predicción, diagnóstico y análisis temprano de patologías del tracto urinario inferior, a través de nuevas técnicas de procesado de señal e investigación de IA usando martwatch (SWALU23)	BERNARDO HERRERA IMBRODA	NATIONAL	PI	STATE RESEARCH AGENCY	2023
B-11	PID2021-1253850B-100 Abordando el papel del ATX como una nueva diana terapéutica en el cáncer de vejiga urotelial	ELISA MATAS RICO	NATIONAL	PI	STATE RESEARCH AGENCY	2021
B-11	CA18124 (ESMN) - European Sexual Medicine Network	MARÍA FERNANDA LARA CABANÁS	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
B-11	RH-0124-2020 Utilidad pronóstica y predictiva de biomarcadores basados en la combinación de secuenciación masiva del genoma completo a baja resolución y paneles específicos para cáncer de próstata	BERNARDO HERRERA IMBRODA	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
B-11	AECC_JUNIOR_01_Validación de marcadores y nuevas dianas de tratamiento en cáncer urotelia. Candidate. Fernando Alberca	ELISA MATAS RICO	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2023
BA-16	CGEE-PI-2021. Influencia en la calidad de vida, adherencia al tratamiento y mejora de conocimientos en pacientes anticoagulados con? anti-vitamina K (AVK)	ADOLFO ROMERO RUIZ	NATIONAL	AWARDS	GENERAL NURSING COUNCIL OF SPAIN	2021
BE-18	Targeting the non tumor players of the tumor microenvironment to improve the efficacy of the current therapies	w	NATIONAL	PI	SPANISH ASSOCIATION AGAINST CANCER	2021
BE-18	Discovery of new therapeutic targets to battle cancer and prevent lymphatic metastasis / Descubrimiento de Nuevas Dianas Terapéuticas en la Lucha Contra el Cáncer y la Prevención de las Metástasis Linfáticas	w	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
BE-18	Interacción vasculatura tumoral-compartimento inmune en melanoma	W	NATIONAL	PI	L'Óreal Women in Science	2022
BE-18	PREDOC-003-2023 Caracterización de la vasculatura tumoral linfática y descubrimiento de prometedoras dianas terapéuticas.	MELISSA GARCÍA CABALLERO	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2022
BE-19	Elaboración de un protocolo nacional en dosimetría biológica	М	NATIONAL	PI	Nuclear Safety Council	2022
C-01	ICI19/00027 Ensayo clínico fase IIb para confirmar la seguridad y eficacia de la administración intralesional de dos dosis de células mesenquimales de tejido adiposo alogénicas en pacientes con incotinencia fecal. IP. Laura Leyva Fernández	LAURA LEYVA FERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
C-01	PECOVID-0099-2020 Estudio Neuro-Covid: secuelas neurológicas y estudio de biomarcadores en pacientes incidentes con infección por Coronavirus SARS-CoV-2.	GUILLERMO ESTIVILL TORRÚS	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
C-01	PI18/00551 Evaluación de los receptores de citoquinas solubles y de membrana como biomarcadores no invasivos en EM: descubrimiento y validación.	LAURA LEYVA FERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
C-01	Modulation of oligodendrocyte metabolism via blood vessel remodeling as target to promote remyelination	BEATRIZ GARCIA DIAZ	EUROPEAN UNION	PI	NEURATRIS - TRANSLATIONAL RESEARCH INFRASTRUCTURE FOR BIOTHERAPY IN NEUROSCIENCE	2021
C-01	PI22-00596 Caracterización genética y evaluación funcional de la respuesta de interferón tipo I en pacientes con encefalitis anti-receptor NMDA (IFN-NMDAR).	BEGOÑA OLIVER MARTOS	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-01	PI21-01668 Biomarcadores pronósticos de evolución clínica en pacientes con esclerosis múltiple remitente recurrente de diagnóstico reciente: volumetría de la médula espinal	LAURA LEYVA FERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-01	4070-22 Desarrolo de una proteína recombiante como fármaco antiviral	BEGOÑA OLIVER MARTOS	NATIONAL	PI	FOUNDATION FOR INNOVATION AND FORESIGHT IN HEALTH IN SPAIN	2022
C-01	CPP2021-008512 PRIMER KIT DEL MERCADO PARA EL DIAGNÓSTICO TEMPRANO DE LA ESCLEROSIS MÚLTIPLE EN SANGRE	BEGOÑA OLIVER MARTOS	NATIONAL	PI	STATE RESEARCH AGENCY	2022
C-01	PI22-01141 Papel de los vasos sanguíneos en las alteraciones en el patrón de mielina asociado al abuso de alcohol durante la adolescencia: una nueva vía terapéutica para el tratamiento de las adicciones.	BEATRIZ GARCIA DIAZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-01	CP20-00049:The role of BVs in remyelination. Contratos Miguel Servet 2020 Beatriz García Díaz	BEATRIZ GARCIA DIAZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
C-01	RIC-0111-2019. ANDALUSIAN NETWORK FOR CLINICAL AND TRANSLATIONAL RESEARCH IN NEUROLOGY (NEURO-RECA)	PEDRO JESÚS SERRANO CASTRO	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
C-01	BECA SAN2019-1 Aplicación de la caracterización clínica e inmunológica para el diagnóstico de epilepsias focales del adulto de origen autoinmune. Nicolás Lundahl Ciano Petersen.	NICOLAS LUNDAHL CIANO PETERSEN	REGIONAL	PI	ANDALUSIAN SOCIETY OF NEUROLOGY	2019
C-01	The Lysophosphatidic acid pathway modulation to treat the Pelizaeus-Merzbacher disease	BEATRIZ GARCIA DIAZ	INTERNATIONAL NON-EU	PI	INTERNATIONAL BRAIN RESEARCH ORGANIZATION	2020
C-01	NEURORECA-0003-2022 CARACTERIZACION CLINICO-ELECTROENCEFALOGRÁFICA E INMUNOLOGICA DE LA EPILEPSIA ASOCIADA A AUTOINMUNIDAD.	PABLO CABEZUDO GARCÍA	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2022
C-01	CPP2021-008689 SISTEMA PORTABLE INTELIGENTE DE MONITORIZACIÓN Y TERAPIA PARA TRASTORNOS DEL SUEÑO REM (SMOTTS).	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2022
C-01	PID2019-110855RJ-100 Modulacion de la via de señalizacion del acido lisofosfatidico como terapia para la enfermedad de Pelizaeus-Merzbacher. Beatriz García Díaz.	BEATRIZ GARCIA DIAZ	NATIONAL	PI	STATE RESEARCH AGENCY	2019
C-01	ProyExcel_00996 Evaluation of the Lysophosphatidic acid signalling pathway as a high potential target for the Pelizaeus-Merzbacher disease treatment.	BEATRIZ GARCIA DIAZ	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
C-01	EME-REEM 2021 Evaluación de factores solubles y de membrana como biomarcadores no invasivos en PP-MS: fase de validación	LAURA LEYVA FERNÁNDEZ	NATIONAL	PI	MULTIPLE SCLEROSIS ASSOCIATION SPAIN	2021
C-01	Blood vessel remodelling modulates remyelination by oligodendrocyte metabolic reprogramming.	BEATRIZ GARCIA DIAZ	INTERNATIONAL NON-EU	PI	FONDATION ARSEP	2021
C-01	PID2020-117464RB-I00 EL RECEPTOR LPA1 COMO POSIBLE BIOMARCADOR VULNERABILIDAD A LA DEPRESION. PAPEL EN LA SENSIBILIZACION MICROGLIAL Y EN LOS CAMBIOS NEUROGENICOS INDUCIDOS POR ESTRES JUVENIL	CARMEN PEDRAZA BENÍTEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2020
C-01	CA20121 (BenBedPhar) - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	BEATRIZ GARCIA DIAZ	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
C-01	RC-0002-2021 Renovación II del Proyecto Nicolás Monardes 2013. Guillermo Estivill Torrús	GUILLERMO ESTIVILL TORRÚS	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
C-01	RC-0002-2019 Renovación de la Acción C (Programa Nicolás Monardes) de la Convocatoria 2015.	LAURA LEYVA FERNÁNDEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
C-01	MS20-00049 Contratos Miguel Servet 2020 Beatriz García Díaz	BEATRIZ GARCIA DIAZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
C-01	FI19-00139 Contratos predoctorales de formación e investigación en salud Isabel Brichette Mieg Jefe de grupo: Laura Leyva Fernández	LAURA LEYVA FERNÁNDEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-01	A1-0008-2022 OLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS).IP: PEDRO JESUS SERRANO CASTRO	PEDRO JESÚS SERRANO CASTRO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
C-01	IFEQ22_00032 Equipamiento para dotación de equipamiento para ECAI Genómica	PEDRO JESÚS SERRANO CASTRO	NATIONAL	INFRASTRUCTURE	CARLOS III INSTITUTE OF HEALTH	2022
C-01	IFEQ22_00098 Síntetizador de péptidos para dotación de la Unidad de Química de IBIMA-Plataforma Bionand	PEDRO JESÚS SERRANO CASTRO	NATIONAL	INFRASTRUCTURE	CARLOS III INSTITUTE OF HEALTH	2022
C-01	MOV23-05 Análisis funcional del receptor P2X4R para el estudio de su evaluación como biomarcador diagnóstico diferencial en Esclerosis Múltiple.	ISABEL BRICHETTE MIEG	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-01	RB-0005-2018 ANÁLISIS AVANZADO DE NEUROIMAGEN EN ENFERMEDADES NEUROLÓGICAS UGC de Neurociencias del HRUM	PEDRO JESÚS SERRANO CASTRO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2018
C-01	A1-0003-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS).IP: PEDRO J SERRANO CASTRO.	PEDRO JESÚS SERRANO CASTRO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-01	RBL-0001-2023_Renovación 2023 Acción B-Refuerzos de larga duración	PEDRO JESÚS SERRANO CASTRO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-02	Prevención universal de la depresión y ansiedad en población general mediante una intervención personalizada basada en algoritmos de riesgo, TICs y sistemas de ayuda a las decisiones: ensayo controlado aleatorio. El estudio ?PredictPlusPrevent?. PE-0280-2018.	JUAN ÁNGEL BELLÓN SAAMEÑO	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2018
C-02	PI18-01307 Prevención de la depresión en el medio laboral mediante una intervención personalizada basada en algoritmos de riesgo, TICs y sistemas de ayuda a las decisiones: ensayo controlado aleatorio	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
C-02	AP-0212-2019 Estudio Cualitativo Sobre el Espacio Colaborativo Atención primaria-Salud Mental	FRANCISCA MUÑOZ COBOS	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2019
C-02	PI21-01695 Prevención de la ansiedad y depresión por evaluación de riesgos: ensayo controlado aleatorio (El Estudio PANDORA)	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-02	IMP/00021 Impact Programa de Medicina Predictiva.	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
C-02	INT-C-0001-2021. DISCOVERY: New tools for automatic detection of individuals at risk of depression and anxiety and their real world implementation	JUAN ÁNGEL BELLÓN SAAMEÑO	REGIONAL	Pl	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2021
C-02	AP-0210-2021-C2-F2 Prevención de la depresión en población trabajadora, mediante una intervención personalizada basada en algoritmos de riesgo, TICs y sistemas de ayuda a las decisiones: ensayo controlado aleatorio	JUAN ÁNGEL BELLÓN SAAMEÑO	REGIONAL	Pl	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2021
C-02	CP19/00056: Prevention of depression and anxiety. Proyecto Miguel Servet Patricia Moreno Peral	PATRICIA MORENO PERAL	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
C-02	PID2020-119652RA-I00 Efectividad de una intervención personalizada a través de internet basada en un algoritmo de riesgo para la prevención universal de la ansiedad. El estudio prevANS.	PATRICIA MORENO PERAL	NATIONAL	PI	STATE RESEARCH AGENCY	2020
C-02	CA18138 (Riseup-PPD - Research Innovation and Sustainable Pan-European Network in Peripartum Depression Disorder)	PATRICIA MORENO PERAL	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2019

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-02	POSTDOC-21-00620 Incorporación de ayudas posdoctorales. Candidato:Sonia Conejo Cerón Jefe de equipo: Juan Angel Bellon Saameño	JUAN ÁNGEL BELLÓN SAAMEÑO	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-02	FI22-00221 Contratos predoctorales de formación en investigación de salud. BN: Carmen María Garrido González IP: Juan Ángel Bellón Saameño	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
C-02	Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS) LR: Juan Ángel Bellón Saameño	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
C-02	JF-2017-01_JA Bellon PREMIO DR.J.FONT	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	AWARDS	MUTUAL MÉDICA, MUTUALIDAD DE PREVISION SOCIAL A PRIMA UNICA	2017
C-02	CD19/00022 Contratos Sara Borrell 2019 Santiago Galan Ortega Jefe de Grupo: Juan Angel Bellón Saameño	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
C-02	MS19/00056 Contratos Miguel Servet. Patricia Moreno Peral	PATRICIA MORENO PERAL	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
C-02	PRE2021-098359 AYUDAS PARA CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE DOCTORES 2021.	PATRICIA MORENO PERAL	NATIONAL	HR	STATE RESEARCH AGENCY	2021
C-02	CA18138 (Riseup-PPD-Research Innovation and Sustainable Pan-European Network in Peripartum Depression Disorder)	SONIA CONEJO CERÓN	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
C-02	PREDOC_02151. Impacto de las medidas de aislamiento por COVID-19 en personas mayores con deterioro cognitivo y sus cuidadores.	JUAN ÁNGEL BELLÓN SAAMEÑO	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-02	INT22-00103 Prevención de la ansiedad y depresión por evaluación de riesgos: ensayo controlado aleatorio (El Estudio PANDORA).	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
C-02	CD23-00096 Contrato Sara Borrell 2023_Maria Rodriguez Garcia_Jefe de grupo: Juan Angel Bellon.	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
C-02	FPU22-04269 CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE PROFESORADO UNIVERSITARIO-FPU 2022. CANDIDATE: MARIA CRISTINA GONZALEZ MONROY	JUAN ÁNGEL BELLÓN SAAMEÑO	NATIONAL	HR	MINISTRY OF UNIVERSITIES	2023
C-03	PI19/01131 Evaluación de la implementación de un programa de terapia psicológica online para el tratamiento de la depresión en atención primaria: Estudio multicéntrico con diseño híbrido. IP FERMIN MAYORAL CLERIES	FERMÍN MAYORAL CLERIES	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
C-03	PI21-01328 Eficacia e implementación de un programa online de psicoterapia para la prevención de los efectos de la pandemia de la COVID-19 en la salud mental de los profesionales sociosanitarios	JOSÉ GUZMAN PARRA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-03	Gilead20-001 Eficacia de un programa de acompañamiento de enfermería para la microeliminación de la hepatitis C en pacientes con diagnóstico psquiátrico grave PSIQUIÁTRICO GRAVE	CASTA QUEMADA GONZÁLEZ	NATIONAL	PI	GILEAD SCIENCES EUROPE LTD.	2020
C-03	Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia	FERMÍN MAYORAL CLERIES	EUROPEAN UNION	AWARDS	EUROPEAN COMMISSION	2021
C-03	iGAME - Multi-dimensional Intervention Support Architecture for Gamified eHealth and mHealth Products	FERMÍN MAYORAL CLERIES/MARINA TIRADO REYES	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2018
C-03	CA17130 (PSYNET) - Enhancing Psychiatric Genetic Counselling, Testing, and Training in Europe	FERMÍN MAYORAL CLERIES	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2017
C-03	POEJ-00039-01 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: José Guzmán Parra.	JOSÉ GUZMAN PARRA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-03	CA19101 (DE-PASS) - Determinants of Physical Activities in Settings	ANA BELEN PABA DOTES	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
C-03	A1-0004-2022 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS).	FERMÍN MAYORAL CLERIES	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
C-03	CM20/00177 Contratos Rio Hortega 2020 Jessica Marian Goodman Casanova. Group Leader: Fermín Mayoral Cleries	FERMÍN MAYORAL CLERIES	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
C-03	CM22-00232 Contrato Rio Hortega 2022 Vera Carbonell Aranda_Jefe de Grupo Jose Guzman Parra.	JOSÉ GUZMAN PARRA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
C-03	RB-0005-2019 RENOVACIÓN ACCION B CONVOCATORIA 2014 EN LAS UNIDADES DE GESTIÓN CLÍNICA (UGC) DEL SERVICIO ANDALUZ DE SALUD (SAS)	ANTONIO BORDALLO ARAGÓN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
C-03	A1-0024-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: JOSE GUZMAN PARRAS.	JOSÉ GUZMAN PARRA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-03	CD23-00074 Contrato Sara Borrell 2023_Alberto Barcelo Soler_Jefe de grupo Jose Guzman Parra	JOSÉ GUZMAN PARRA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
C-03	JR23-00008 Contratos Juan Rodes 2023 Jessica Marian Goodman Casanova	JESSICA MARIAN GOODMAN CASANOVA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
c-03	PR_DIVULGA_02_2023 Measuring mental health recovery: Cross-cultural adaptation of the 15-item Questionnaire about the Process of Recovery in Spain (QPR-15-SP)	JOSÉ GUZMAN PARRA	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-05	PI19/00778 Testing non-embryonic based stem cells as regenerative cell sources for treating neonates with intraventricular hemorrhages that develop posthemorrhagic hydrocephalus. IP ANTONIO JESUS JIMENEZ LARA	ANTONIO JESÚS JIMÉNEZ LARA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
C-05	PID2022-141741NB-I00 Efectos de la microglía condicionada sobre el eje hipotálamo-hipofisario-adrenal y la respuesta al estrés. Modulación farmacológica con un inhibidor de CSF1R y cannabidiol	w	NATIONAL	PI	Ministry of Science, Innovation, and Universities	2022
C-06	DTS22/00021 DESARROLLO DE LOS INOSITOLES D-PINITOL Y D-CHIROINOSITOL COMO TRATAMIENTO DE ENFERMEDADES QUE CURSAN CON ACUMULACIÓN DE PROTEÍNA TAU FOSFORILADA (TAUOPATHIES)	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-06	PI22/00427 PAPEL DEL BDNF Y LAS ACILETANOLAMIDAS EN EL DETERIORO COGNITIVO ASOCIADO A LOS TRASTORNOS POR USO DE ALCOHOL: UN ESTUDIO TRASLACIONAL.	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-06	202212-32_Towards understanding and predicting treatment resistance in major depression.	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	FUNDACIÓ LA MARATO DE TV3	2022
C-06	SUBV23/00030: ESTUDIO DE LA ASOCIACIÓN JUEGO PATOLÓGICO-USO ANÓMALO DEL MÓVIL EN LA POBLACIÓN GENERAL ESPAÑOLA: DETERMINANTES SOCIALES E INDIVIDUALES	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	MINISTRY OF CONSUMER AFFAIRS	2023
C-06	PND2020/048 La exposición a alcohol perinatal como factor de riesgo en la enfermedad de Alzheimer	PATRICIA RIVERA GONZÁLEZ	NATIONAL	PI	MINISTRY OF EQUALITY	2020
C-06	PI20/01399 Papel de la señalización lipídica mediada por monoacilgliceroles y ácido lisofosfatídico en la Asociación entre trastornos por uso de alcohol y Depresión: Identificación de Biomarcadores	ANTONIA SERRANO CRIADO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
C-06	CP19/00068: Perinatal caloric restriction-induced metabolic alterations in offspring. role of hypothalamic astrocytes. Proyecto Miguel Servet Patricia Rivera González	PATRICIA RIVERA GONZÁLEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
C-06	CONECTA 02 Bienestar Social mediante la Neuropsicología, aumento en la tasa de rehabilitación y detec-ción de abandono en adicciones a sustancias.	ESTELA CASTILLA ORTEGA	NATIONAL	PI	LA CAIXA FOUNDATION	2021
C-06	CP21/00021 Proyecto Miguel Servet 2021 Juan Manuel Decara del Olmo	JUAN MANUEL DECARA DEL OLMO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-06	RTC2019-007329-1 Obtención de principios activos antioxidantes a partir de la vaina del algarrobo y validación de su potencial terapéutico. Fernando Rodriguez de Fonseca.	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	STATE RESEARCH AGENCY	2019
C-06	2022I020 BIOMARCADORES DE DETERIORO COGNITIVO EN EL TRASTONO POR USO DE ALCOHOL: UN ESTUDIO TRASLACIONAL	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	PI	MINISTRY OF HEALTH	2022
C-06	PID2020-114374RB-I00 Estrategias nutricionales para potenciar la neurogénesis y la función hipocampal: uso de cacao como nuevo tratamiento para las alteraciones cognitivas inducidas por la cocaína (CHOCOvsCOCA)	ESTELA CASTILLA ORTEGA	NATIONAL	PI	STATE RESEARCH AGENCY	2020
C-06	Análisis del papel neuroprotector del fitocannabinoide no-psicoactivo cannabidiol en defectos del neurodesarrollo por intoxicación etílica: evaluación de las alteraciones morfológicas, neurogénicas y cognitivo-emocionales	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2022
C-06	Biomarcadores de respuesta de Interferón tipo I en pacientes con enfermedades neurológicas y su posible efecto agravante en modelo animal de Alzheimer con intoxicación etílica.	М	REGIONAL	PI	University of Málaga	2022
C-06	MV22/00094 The impact of emerging new psychoactive substances, synthetic cannabinoids, in the Member States of the European Union.	MARIA FLORES LOPEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
C-06	CA20135 (TEATIME): Improving biomedical research by automated behaviour monitoring in the animal home-cage	JUAN SUÁREZ PÉREZ	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2021
C-06	AURORA GRANT - Role of lipid signaling systems in models of alcohol and early stress	FERNANDO RODRÍGUEZ DE FONSECA	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2022
C-06	CA22114 (TREASURE): Maternal Perinatal Stress and Adverse Outcomes in the Offspring: Maximising infants' development	ADRIANA CASTRO ZAVALA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-06	MS19/00068 Contrato Miguel Servet Patricia Rivera González	PATRICIA RIVERA GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
C-06	RD21/0009/0003 Red de Investigación en Atención Primaria de Adicciones (RIAPAd) IP: Fernando Antonio Rodríguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
C-06	RC-0003-2018 Acción C Nicolás Monarde F.Rodríguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2018
C-06	RH-0081-2021_MFC. PAPEL DE LAS ACILETANOLAMIDAS NO CANNABINOIDES EN LAS COMORBILIDADES MÉDICAS ASOCIADAS AL TRASTORNO POR USO DE ALCOHOL: ESTUDIO TRASLACIONAL EN ADICCIÓN, ESTEATOHEPATITIS Y DETERIORO COGNITIVO	FERNANDO RODRÍGUEZ DE FONSECA	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
C-06	RC1-0001-2023 Renovación II del Programa Nicolás Monardes 2023.	FERNANDO RODRÍGUEZ DE FONSECA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-06	POEJ-00039-08 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Fernando Rodríguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-06	CPII19/00031 Contratos Miguel Servet Tipo II 2019 Antonia Serrano Criado	ANTONIA SERRANO CRIADO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
C-06	C1-0005-2022 PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2022. CANDIDATE ANTONIA MARIA SERRANO CRIADO. CARACTERIZACIÓN DE SISTEMAS DE SEÑALIZACIÓN LIPÍDICOS ASOCIADOS A LA COMORBILIDAD PSIQUIÁTRICA EN LOS TRASTORNOS POR USO DE SUSTANCIAS: IDENTIFICACIÓN DE BIOMARCADORES Y DIANAS TERAPÉUTICAS.	ANTONIA SERRANO CRIADO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
C-06	CD20/00192 Contratos Sara Borrell 2020 Sara Peñasco Iglesias. Group Leader: Fernando Rodriguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-06	DOC_01153 Incorporación de ayudas posdoctorales. Candidate: Mª Mar Fernández Arjona. Team leader: Juan Suárez Pérez	JUAN SUÁREZ PÉREZ	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2019
C-06	CPII19/00022 Contratos Miguel Servet Tipo II 2019 Francisco Javier Pavón Moron	FRANCISCO JAVIER PAVÓN MORÓN	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
C-06	MS21/00021 Contrato Miguel Servet 2021 Juan Manuel Decara del Olmo	JUAN MANUEL DECARA DEL OLMO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
C-06	FI18/00249 Contrato PFIS 2018 María Flores López Jefa de Grupo: Antonia Mª Serrano Criado	ANTONIA SERRANO CRIADO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2018
C-06	IFI18/00042 Contrato I-PFIS 2018 Antonio Jesús López Gambero Jefe de Grupo: Juan Suárez Pérez	JUAN SUÁREZ PÉREZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2018
C-06	IFI21/00024: Contratos I-PFIS 2021 Beatriz Pacheco Sánchez. Group leader: Fernando Rodríguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
C-06	CM19/00025 Contratos Río Hortega 2019 Amanda Vega Núñez. Group leader: Juan Suarez Pérez	JUAN SUÁREZ PÉREZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
C-06	CM20/00241 Contratos Rio Hortega 2020 Mónica García Medina. Group Leader: Antonia María Serrano Criado	ANTONIA SERRANO CRIADO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
C-06	CM21/00097 Contratos Río Hortega 2021 Paloma Ruiz Sastre jefa de grupo Patricia Rivera	PATRICIA RIVERA GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
C-06	CM21/00255 Contratos Rio Hortega 2021 Jesús Herrera Imbroda Jefe de grupo fernando Antonio Rodríguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
C-06	PLAN PROPIO_INT-F1-1-2305_2023 IP Fernando Rodríguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-06	PLAN PROPIO_INT-F1-2-2303_2023 IP Fernando Rodríguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-06	MOV23-07 Bienestar Social mediante la Neuropsicología, aumento en la tasa de rehabilitación y detección de abandono en adicciones a sustancias	NEREA REQUENA OCAÑA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-06	CA22111 (ENVIRO-DEV): A European consortium to determine how complex, real-world environments influence brain development	ANTONIA SERRANO CRIADO	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
C-06	CM23-00150 Contrato Rio Hortega 2023_ Yolanda Lopez Moreno_Jefe de Grupo: Fernando Rodriguez de Fonseca	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
C-06	MV23-00058 Estancia formativa en el Karolinska Institute para investigar el papel de los receptores CB2 y GPR55 en modelos de Alzheimer	BEATRIZ PACHECO SANCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
C-06	PR23_DOCTOR_05 Premio IBIMA - Doctor al mejor expediente de último año. IP:NEREA REQUENA OCAÑA	NEREA REQUENA OCAÑA	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-06	Contrato Personal Investigador Ayudas María Zambrano para la atracción de talento internacional. Jefe de Grupo: Juan Suárez Pérez	Isaac Hurtado Guerrero	NATIONAL	HR	MINISTRY OF SCIENCE, INNOVATION, AND UNIVERSITIES	2021
C-07	Aislamiento social en la pandemia de COVID-19 y consumo de alcohol: Combinación Galanina (1-15)- Naltrexona como estrategia terapéutica.	М	NATIONAL	PI	Plan Nacional Sobre drogas, Ministerio de Sanidad	2022
C-07	Depression: From classical neurotransmitters to Neuropeptides.	М	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
C-07	PI-0083-2019. ESTUDIO TRASLACIONAL DE LA PARTICIPACIÓN DEL FRAGMENTO N-TERMINAL 1-15 DE LA GALANINA EN LA DEPENDENCIA ALCOHOLICA: NUEVAS ESTRATEGIAS TERAPÉUTICAS Y EVALUACIÓN DE BIOMARCADORES EN ADICCIÓN.	CARMELO MILLÓN PEÑUELA	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
C-07	UMA20-FEDERJA-122-Evaluación preclínica de un agonista D4R para el tratamiento del dolor con fármacos opioides	ALICIA RIVERA RAMÍREZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2020
C-07	COMBINACIÓN GALANINA(1-15)-FLUOXETINA: NUEVA ESTRATEGIA DE POTENCIACIÓN EN EL TRATAMIENTO DE LA DEPRESIÓN	w	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-07	USO DE IGF-II PARA EL TRATAMIENTO DE LAS ALTERACIONES HIPOCAMPALES Y CONDUCTUALES INDUCIDAS POR EL CONSUMO CRONICO DE COCAINA DURANTE LA ADOLESCENCIA		NATIONAL	PI	Ministerio de Ciencia e Innovación	2020
C-07	NUEVA TERAPIA DE POTENCIACION: GALANINA(1-15) Y LOS INHIBIDORES DE LA RECAPTACION DE SEROTONINA PARA EL TRATAMIENTO DE LA DEPRESION Y OTROS DESORDENES PSICOTICOS	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
C-07	DEPRESION RESISTENTE AL TRATAMIENTO: UNA NUEVA ESTRATEGIA FARMACOLOGICA UTILIZANDO GALANINA(1-15)	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2020
C-08	PI18-01812 Efectividad de la intervención MultiPAP Plus en ancianos jóvenes con multimorbilidad y polimedicación para mejorar la prescripción en atención primaria: ECA por conglomerados	JUAN DANIEL PRADOS TORRES	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
C-08	PI22-01651 Multimorbilidad en el Sistema Nacional de Salud: Caracterización poblacional e impacto de sus patrones y trayectorias en personas mayores (Proyecto MM-SNS)	FRANCISCA LEIVA FERNÁNDEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
C-08	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	FRANCISCA LEIVA FERNÁNDEZ	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
C-09	Descifrando el papel de los astrocitos en la patología de la enfermedad de Alzheimer: abordar las consecuencias funcionales de portar el factor de riesgo APOE4 empleando células derivadas de pacientes	м	NATIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-09	Impacto del tejido adiposo en la patología de la enfermedad de Alzheimer	W	LOCAL	PI	Asociac	2022
C-09	Ref. PI18-RT-2233. Astrogliopatía como mecanismo patogénico en la enfermedad de Alzheimer: nuevas opciones terapéuticas	w	REGIONAL	PI	JUNTA DE ANDALUCÍA	2020
C-09	Diabetes y Alzheimer. Mecanismos moleculares de coagregación proteica	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2019
C-09	Propagación de la patología amiloidea en un modelo esporádico de la enfermedad de Alzheimer: descifrando nuevos meanismos patogénicos y dianas terapéuticas	м	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2019
C-09	Depression as risk factor for converting mild cognitive impairment into Alzheimer's disease.	w	INTERNATIONAL NON-EU	PI	NASSARD	2018
C-09	AGREGADOS TAU EN SANGRE. UNA VENTANA A LA PATOGENESIS PERIFERICA Y LA INTERVENCION TERAPEUTICA	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-09	Ayuda BEATRIZ GALINDO SENIOR	David Baglietto Vargas	NATIONAL	HR	REGIONAL GOVERNMENT OF ANDALUSIA, Ministry of Universities	2018
C-09	RYC-2017-21879. Ayuda Ramón y Cajal	Ines Moreno González	NATIONAL	HR	Ministry of Science, Innovation, and Universities	2017
C-09	Contrato Predoctoral FPI asociado al proyecto PID2019-107090RA-100. Título: Diabetes y Alzheimer. Mecanismos moleculares de coagregación proteica	INÉS MORENO GONZÁLEZ	NATIONAL	HR	MINISTRY OF SCIENCE, INNOVATION, AND UNIVERSITIES	2020
C-09	Contrato predoctoral FPI asociado al proyecto PID2019-108911RA-100. Título: Propagación de la patología amiloidea en un modelo esporádico de la enfermedad de Alzheimer: descifrando nuevos meanismos patogénicos y dianas terapéuticas	DAVID BAGLIETTO VARGAS	NATIONAL	HR	MINISTRY OF SCIENCE, INNOVATION, AND UNIVERSITIES	2020
C-09	Convocatoria Contratos Predoctorales del Plan Propio de la UMA. Convocatoria 2018	ANTONIA GUTIÉRREZ PÉREZ	REGIONAL	HR	University of Málaga	2019
C-09	Contrato Postdoctoral Junta Andalucía. Elisabeth Sanchez	ANTONIA GUTIÉRREZ PÉREZ/Elisabeth Sánchez Mejías	REGIONAL	HR	JUNTA DE ANDALUCÍA	2020
C-09	Connecting microglial metabolic dysfunction with tau pathology:clinical relevance for Alzheimer's disease	ANTONIA GUTIÉRREZ PÉREZ	NATIONAL	RETICs	CIBERNED-ISCiii	2022
C-09	Impact of white adipose tissue on tau pathology in transgenic mice	DAVID BAGLIETTO VARGAS	INTERNATIONAL NON-EU	PI	ALZHEIMER'S ASSOCIATION	2022
C-09	PI21/00915 Descifrando la transición de fase presintomática a clínica en la enfermedad de Alzheimer: el eje microglía-astroglía como diana terapéutica clave para prevenir el desarrollo de la enfermedad	ANTONIA GUTIÉRREZ PÉREZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-09	Generación de microglía humana a partir de células madre pluripotentes inducidas (iPSCs) de pacientes con la Enfermedad de Alzheimer: nuevo modelo traslacional con interés clínico	Н/М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
C-09	Depresión durante la edad adulta y enfermedad del Alzheimer:evaluación de biomarcadores y terapias preventivas	W	REGIONAL	Pl	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
C-09	RH-0026-2021_JFV EVALUANDO EL PAPEL DE TREM2 EN LA RESPUESTA MICROGLIAL FRENTE A LA PATOLOGÍA DE TAU: BÚSQUEDA DE NUEVAS DIANAS TERAPÉUTICAS	ANTONIA GUTIÉRREZ PÉREZ	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
C-09	MOV23-01 Estudio de la toxicidad astrocitaria mediante sistemas in vitro	ELBA LÓPEZ OLIVA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-09	MOV23-08 Evaluación de toxicidad y biodistribución de nanopartículas en modelos in vivo.	LAURA VEGAS GÓMEZ	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-09	CTS-950 Subvención grupos PAIDI año 2022	W	REGIONAL	COMPLEMENTARY ACTIONS	JUNTA DE ANDALUCÍA	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-09	CIBERNED CB06/05/1116 Subvención anual (2022) para nuestro grupo CIBERNED	w	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH (ISCiii)	2022
C-11	Efectividad e implementación de una intervención digital para el dolor crónico infantil co-diseñada con pacientes (Digital SPA)	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
C-11	Variables predictoras del abuso de opioides prescritos en los pacientes con dolor crónico no oncológico. (VAPREABOPI)	W	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
C-11	Variables predictoras del abuso de opioides prescritos en los pacientes con dolor crónico no oncológico: desarrollo de una escala de detección de riesgo	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2019
C-11	MOV23-10. Mejora de la adherencia a los tratamientos para el dolor en adolescentes administrados mediante aplicaciones móviles	ROCIO DE LA VEGA DE CARRANZA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
C-12	Telerrehabilitación en afasia: evaluación de no inferioridad frente a terapia presencial e identificación de biomarcadores predictores de eficacia	w	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
C-12	Comprendiendo las diferencias interindividuales en el aprendizaje de palabras a través de la neuroimagen y la neuromodulación	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
C-12	Automatic assessment of Hypernasality in Spanish language using running Speech	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
C-13	AP-0245-2020 Componentes de la Gestión de Casos en Demencias: Estudio de Métodos Mixtos (Gecade)	JUAN CARLOS MORILLA HERRERA	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2020
C-13	AP-0244-2020 Calidad de Vida, Salud Física y Mental, y Evaluación Económica de Cuidadores Familiares de Población Infantil Dependiente y Con Enfermedad Crónica: (Seguimiento Cohorte Infaprint)	MAGDALENA CUEVAS FERNÁNDEZ-GALLEGO	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2019
C-13	AP-0174-2021-C2-F2 Efectividad de los ácidos grasos hiperoxigenados y aceite de oliva virgen extra en la prevención de las úlceras por presión relacionada con la perfusión y oxigenación tisular periférica.	INMACULADA LUPIÁÑEZ PÉREZ	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2021
C-13	PI21-01197 Perfusión y Oxigenación Tisular Periférica en zonas de riesgo de deterioro de la integridad cutánea sometidas a tratamiento con Ácidos Grasos Hiperoxigenados vs Aceite de Oliva Virgen	INMACULADA LUPIÁÑEZ PÉREZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
C-13	PI-0107-2020 Desarrollo de una regla de predicción clínica para eventos adversos en pacientes con multimorbilidad que ingresan en hospitalización aguda y Urgencias. Estudio PREDI-CUIDD-HU	MARTA ARANDA GALLARDO	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
C-13	AP-0065-2020-C1-F2. Valoración del patrón de alimentación de personas con demencia en la comunidad a través de la escala Edinburgh Feeding Evaluation in Dementia Scale (EdFED). Seguimiento Longitudinal	MARIA CARMEN SAUCEDO FIGUEREDO	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2020
C-13	SEM23-01 Valoración del patrón de alimentación de personas con demencia en la comunidad a través de la escala edinburgh feeding evaluation in dementia scale (edfed). Seguimiento longitudinal.	MARIA CARMEN SAUCEDO FIGUEREDO	LOCAL	Pl	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
C-13	AP-0228-2021-C2-F2 Barreras de Autocuidado y Complicaciones micro/macrovasculares asociadas en Diabetes Mellitus tipo 2 (Estudio BACA-DM2).	MARIA CARMEN PEREZ LOPEZ	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2021
C-13	PRYES235081MORA Validation and evaluation of the Cui-DAR Cudeca Plan in people in the last days of life versus conventional care. Asociación Española contra el Cáncer	JOSE MIGUEL MORALES ASENSIO	NATIONAL	PI	SPANISH ASSOCIATION AGAINST CANCER	2023
C-13	CA19137 (PARQ): Sudden cardiac arrest prediction and resuscitation network: Improving the quality of care	EVA TIMONET ANDREU	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2020
C-13	CA19113 (TheERNSTGroup) - The European Researchers Network Working on Second Victims	JOSÉ CARLOS CANCA SÁNCHEZ	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
C-13	A1-0069-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: MARTA ARANDA GALLARDO, RAUL QUIROS LOPEZ	RAUL QUIROS LÓPEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-13	A2-0049-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP:JORGE CARO BAUTISTA	JORGE CARO BAUTISTA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-13	A2-0055-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: INMACULADA LUPIAÑEZ PEREZ.	INMACULADA LUPIÁÑEZ PÉREZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-13	A2-0068-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP:MARIA DEL CARMEN SAUCEDO	MARIA CARMEN SAUCEDO FIGUEREDO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
C-16	CA18211 (DEVOTION) - Perinatal Mental Health and Birth-Related Trauma: Maximising best practice and optimal outcomes	ERNESTO GONZÁLEZ MESA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
C-16	El sistema inmune innato de la leche materna; efecto de la dieta y obesidad de la madre	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2022
C-16	EMG22-005 Propiedades de la leche materna tras diabetes gestacional: sistema inmune innato y la respuesta del lactante ante infecciones respiratorias	MARTA BLASCO ALONSO	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2022
CA-10	Investigando experimentalmente la formación de nuevos hábitos en humanos	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
CA-10	Aprendizaje de nuevos hábitos en humanos: una perspectiva multiproceso	М	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
CE-18	CA22106 (MDVI): Migrant Disaster Victim Identification	LETICIA OLGA RUBIO LAMIA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
CE-18	STOP, STop intimate partner viOlence in Pregnancy	w	EUROPEAN UNION	PI	European Commission	2019
CIMO-01	PE-0106-2019. Papel de la microbiota mamaria e intestinal en los diferentes subtipos intrínsecos de cáncer de mama y en su respuesta al tratamiento. IP.Maria Isabel Queipo	MARÍA ISABEL QUEIPO ORTUÑO	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
CIMO-01	PI18-00453 Microbiota Intestinal y Regulación del Apetito en la Obesidad. Efectividad sobre Reducción Ponderal de una Dieta Mediterránea Hipocalórica o Ayuno Intermitente y de un Probiótico.	MARÍA ISABEL QUEIPO ORTUÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
CIMO-01	PI-0291-2019. ENSAYOS MULTI-OMICOS PARA DETERMINAR EL RIESGO A RECAÍDA Y DETECTAR ENFERMEDAD MÍNIMA RESIDUAL EN PACIENTES CON CÁNCER DE MAMA TEMPRANO USANDO BIOPSIAS LÍQUIDAS	IÑAKI COMINO MENDEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2019
CIMO-01	PY20_01314 Biopsia líquida en el uso multi-ómico de los componentes tumorales circulantes: Caracterización del riesgo a recaída y detección de enfermedad mínima residual en pacientes con cáncer de mama temprano.	IÑAKI COMINO MENDEZ	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2020
CIMO-01	PI18-00620 Caracterización de subtipos moleculares definidos por PAM50 y estudio del comportamiento clínico del fenotipo basal en pacientes con cáncer de mama, endometrio y vejiga.	EMILIO ALBA CONEJO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
CIMO-01	PI21-00321Impacto del microbioma intestinal e intratumoral en la respuesta a la quimioterapia neoadyuvante en pacientes con cáncer de mama triple negativo (TNBC).	MARÍA ISABEL QUEIPO ORTUÑO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
CIMO-01	CPC21211-SEOM. 68-GAPSMA como utilidad diagnóstica en pacientes con cáncer de mama subtipo triple negativo en estadios precoces y avanzados	MARIA EMILIA DOMINGUEZ RECIO	NATIONAL	PI	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2021
CIMO-01	MV22-00045 Desarrollo de organoides derivados de pacientes con cáncer de mama para el estudio de la relación entre obesidad y cáncer y la valoración de la respuesta al tratamiento.	AURORA LABORDA ILLANES	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
CIMO-01	BOURSE D'ALTERNANCE 2022 - Nouha Dakhli	MARÍA ISABEL QUEIPO ORTUÑO/MIGUEL ÁNGEL MEDINA TORRES	INTERNATIONAL NON-EU	HR	UNIVERSITY OF JENDOUBA	2022
CIMO-01	POEJ-00039-16 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: María Isabel Queipo Ortuño	MARÍA ISABEL QUEIPO ORTUÑO	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
CIMO-01	FI19/00112 Contratos predoctorales de formación en investigación en salud Aurora Laborda Illanes Jefe de grupo: Maria Isabel Queipo Ortuño	MARÍA ISABEL QUEIPO ORTUÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
CIMO-01	7024 ENSAYOS MULTI-OMICOS PARA DETERMINAR RIESGO A RECAÍDA Y DETECTAR ENFERMEDAD MÍNIMA RESIDUAL EN PACIENTES CON CÁNCER DE MAMA TEMPRANO USANDO BIOPSIAS LÍQUIDAS	EMILIO ALBA CONEJO	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2018
CIMO-01	AECC_01_2021 ENSAYOS MULTI-OMICOS PARA DETERMINAR RIESGO A RECAÍDA Y DETECTAR ENFERMEDAD MÍNIMA RESIDUAL EN PACIENTES CON CÁNCER DE MAMA TEMPRANO USANDO BIOPSIAS LÍQUIDAS	EMILIO ALBA CONEJO	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2018
CIMO-01	RH-0083-2021_LSA Cáncer de mama, microbiota intestinal, microbiota intratumoral, permeabilidad intestinal, respuesta inmune, quimioterapia neoadyuvante, microentorno tumoral	EMILIO ALBA CONEJO	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
CIMO-01	POEJ-00039-10 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Emilio Alba Conejo	EMILIO ALBA CONEJO	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
CIMO-01	PREDOC-001-2023 Caracterización de subtipos moleculares definidos por PAM50 y estudio del comportamiento clínico del fenotipo basal en distintas localizaciones tumorales.	EMILIO ALBA CONEJO	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2022
CIMO-01	CD21-00164 Contratos Sara Borrell 2021 Daniel Castellano Castillo jefe de grupo Emilio Alba Conejo	EMILIO ALBA CONEJO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
CIMO-01	CM21-00124 Contratos Rio Hortega 2021 Laura Galvez Carvajal Jefe de grupo Emilio Alba Conejo	EMILIO ALBA CONEJO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
CIMO-01	SEOM20_001_RETORNO ARN circulante tumoral como herramienta para la caracterización tumoral y respuesta a terapia neoadyuvante en cáncer de mama localizado	FRANCISCO JAVIER PASCUAL LOPEZ	NATIONAL	HR	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
CIMO-01	POEJ-00039-21 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Isabel Barragán Mallofret	MARIA ISABEL BARRAGÁN MALLOFRET	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
CIMO-01	RH-0090-2020 Desarrollo y validación de biomarcadores de pronóstico en cáncer: hacia una Oncología de Precisión	EMILIO ALBA CONEJO	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
CIMO-01	MOV23-09. Polyphenol Metabolites Improve the Treatment Basis of Triple Negative Breast Cancer (TNBC)	LIDIA SÁNCHEZ ALCOHOLADO	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
CIMO-01/ CIMO-02	PI18-01592 Integración de ómicas para la terapia dirigida en inmunoterapia: hacia la biopsia líquida	ALFONSO SÁNCHEZ MUÑOZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
CIMO-02	Proy_Excel_01002 Farmacogenomica de precisión aplicada al tratamiento de inmunoterapia en Cáncer de pulmón y Cabeza y Cuello.	FRANCISCO JAVIER OLIVER MARTOS	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
CIMO-02	Pl22-01816 Biomarcadores de resistencia a la inmunoterapia: integrando Efecto Abscopal y epigenética en una estrategia de medicina de precisión no invasiva.	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
CIMO-02	PI-0121-2020 Estudio longitudinal y prospectivo de variantes genéticas, epigenéticas y poblaciones celulares como marcadores de respuesta a inhibidores de punto de control inmune en melanoma.	MARIA ISABEL BARRAGÁN MALLOFRET	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
CIMO-02	CPC21201_SEOM Detección temprana de metástasis hepáticas en cáncer de mama basado en el estudio de patrones de metilación e hidroximetilación en el adn libre circulante en sangre	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	PI	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2021
CIMO-02	PY20_01326 Detección temprana de metástasis hepáticas en cáncer de mama basado en el estudio de patrones de metilación e hidroximetilación en el ADN libre circulante en sangre.	MARIA ISABEL BARRAGÁN MALLOFRET	REGIONAL	Pl	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2020
CIMO-02	CPC21210-SEOM Micro-RNAs como huellas en la caracterización y detección precoz del efecto de cancerización de campo en el carcinoma escamoso de cavidad oral.	ELISABETH PEREZ RUIZ	NATIONAL	PI	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2021
CIMO-02	GEM23_01 "Ex vivo characterization of the mechanisms associated with Abscopal Response".	MARIA ISABEL BARRAGÁN MALLOFRET	LOCAL	PI	SPANISH MULTIDISCIPLINARY MELANOMA GROUP (GEM)	2023
CIMO-02	Estudio del infiltrado de linfocitos B en pacientes con melanoma metastásico mediante la validación interna de ¿	М	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
CIMO-02	ISMB/ECCB 2023 Award for the Best Poster at TransMed	JUAN LUIS ONIEVA ZAFRA	INTERNATIONAL NON-EU	AWARDS	INTERNATIONAL SOCIETY FOR COMPUTATIONAL BIOLOGY	2023
CIMO-02	PREDOC_01691 Integración de ómicas para la identificación de marcadores predictivos de respuesta a inmunoterapia del cáncer.	JUAN LUIS ONIEVA ZAFRA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
CIMO-02	CLJUN223421CANT. AYUDAS TALENTO EN EL TERRITORIO: CLÍNICO JUNIOR. Candidate: Alejandra Cantero González. Jefe de Grupo: Manuel Ángel Cobo Dols	MANUEL COBO DOLS	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2022
CIMO-02	RC-0009-2021 Renovación I Acción C (Programa Nicolás Monardes) Convocatoria 2017. LR: Isabel Barragán	MARIA ISABEL BARRAGÁN MALLOFRET	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
CIMO-02	MCO-SEOM2022 "Cuantifi cación precoz del DNA circulante(cfDNA) como marcador de respuesta y supervivencia en pacientes tratados con inmunoterapia	ELISABETH PEREZ RUIZ	NATIONAL	AWARDS	SPANISH SOCIETY OF MEDICAL ONCOLOGY	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
CIMO-02	CLJUN211613ZAFR_Radio-inmunoterapia en cáncer metastásico. JUAN ZAFRA.	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	HR	SPANISH ASSOCIATION AGAINST CANCER	2021
CIMO-02	A1-0046-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP:MANUEL COBOS DOLS	MANUEL COBO DOLS	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
CIMO-02	CNS2023-145629 Multi-modal and Multi-scale Modeling based on Artificial Intelligence Pathways and Spatial Transcriptomics to reveal Lung Cancer Distant Relapse predictors (MAPS-LUNG)	MARIA ISABEL BARRAGÁN MALLOFRET	NATIONAL	HR	STATE RESEARCH AGENCY	2023
CIMO-02	FPU22-02455 CONTRATOS PREDOCTORALES PARA LA FORMACIÓN DE PROFESORADO UNIVERSITARIO-FPU 2022. CANDIDATE: LOURDES GONZALEZ VINCEIRO	ANTONIO RUEDA DOMÍNGUEZ	NATIONAL	HR	MINISTRY OF UNIVERSITIES	2023
CIMO-03	AIOMICS: Aplicaciones de técnicas de Inteligencia Artificial a conjuntos de datos ómicos para la predicción en cáncer	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
CIMO-03	PID2020-116898RB-I00 INTELIGENCIA ARTIFICIAL PARA PROCESAMIENTO DE LENGUAJE NATURAL DE TEXTO CLÍNICO EN ESPAÑOL PARA ANÁLISIS DE REAL-WORLD-DATA (Text2RWD)	JOSÉ MANUEL JEREZ ARAGONÉS	NATIONAL	PI	STATE RESEARCH AGENCY	2020
CIMO-03	MOV23-12. Desarrollo de técnicas basadas en el procesamiento del lenguaje natural para la extracción y normalización de entidades clínicas	GUILLERMO LOPEZ GARCIA	LOCAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
D-03	PI18-00824 Análisis de las relaciones entre actividad inflamatoria, microbiota intestinal y epigenoma de pacientes con artritis reumatoide establecida: Un estudio de cohortes.	ANTONIO FERNÁNDEZ NEBRO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
D-03	PI-0293-2019. NUEVO PAPEL DE LA HIDROXIMETILACIÓN DEL ADN EN GENES ANTAGONISTAS DE LA VÍA WNT-B CATENINA, FTO Y EL EPITRANSCRIPTOMA (m6A) EN LA GÉNESIS DEL CANCER ASOCIADO A OBESIDAD.	GRACIA MARIA MARTIN NUÑEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2019
D-03	FAR2021-001. Identificación de biomarcadores de Enfermedad Pulmonar Intersticial (EPI) asociada a Artritis Reumatoide (AR)	ANTONIO FERNÁNDEZ NEBRO	REGIONAL	PI	ANDALUSIAN FOUNDATION OF RHEUMATOLOGY	2021
D-03	PI22-01207 Análisis integral de datos clínicos, metagenómicos y transcriptómicos para identificar biomarcadores de respuesta a tratamiento Anti-TNF en pacientes con artritis reumatoide	NATALIA MENA VAZQUEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-03	Análisis de las relaciones del viroma y bacterioma intestinal con el metiloma de pacientes con artritis reumatoide establecida	М	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-03	PAPEL DE LA HIDROXIMETILACIÓN DEL ADN (5hmC) Y LA RELACIÓN CON LA MICROBIOTA INTESTINAL EN PACIENTES CON ARTRITIS REUMATOIDE	H/M	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
D-03	RD21-0002-0037 Red de Enfermedades Inflamatorias LR: Antonio Fernández Nebro	ANTONIO FERNÁNDEZ NEBRO	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
D-03	CM22-00124 Contrato Rio Hortega_Rocio Redondo Rodriguez Jefe de Grupo Antonio Fernandez Nebro.	ANTONIO FERNÁNDEZ NEBRO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-03	A1-0009-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP:ANTONIO FERNANDEZ NEBRO.	ANTONIO FERNÁNDEZ NEBRO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-03	FI23-00084 Contratos predoctorales de formación en investigación de salud. BN:JOSE MANUEL LISBONA MONTAÑEZ_LR:ANTONIO FERNANDEZ NEBRO.	ANTONIO FERNÁNDEZ NEBRO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-03	GPC23-01 Consenso para el rol de la enfermera en el cuidado de los pacientes con artritis reumatoide (AR) y enfermedad pulmonar intersticial (EPID). LR:Natalia Mena	NATALIA MENA VAZQUEZ	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
D-03	INT23-00030 Contrato de intensificación Natalia Mena	NATALIA MENA VAZQUEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-03	INT-SER-01-2022 INTENSIFICACIÓN DE LA ACTIVIDAD INVESTIGADORA PARA FACULTATIVOS ESPECIALISTAS. NATALIA MENA VAZQUEZ.	NATALIA MENA VAZQUEZ	NATIONAL	HR	SPANISH SOCIETY OF RHEUMATOLOGY	2023
D-03	PR_IR_COIR23_02 Premio a la nueva IR CO-IR de grupo del último año. LR:Natalia Mena Vazquez	NATALIA MENA VAZQUEZ	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
D-03	Personal laboral técnico de apoyo y de gestión de la I+D+i, en el marco del Sistema Nacional de Garantía Juvenil y del Programa Operativo de Empleo Juvenil 2014-2020	-	LOCAL	HR	UNIVERSIDAD DE MÁLAGA	2021
D-04	AC19/00082 DrNanoDAll - Nanodiagnosis for Betalactam Hypersensitivity	MARÍA JOSÉ TORRES JAÉN	EUROPEAN UNION	PI	CARLOS III INSTITUTE OF HEALTH	2019
D-04	CPP2022-009994 Development of a photonic point of care device for multiplexed detection of biomarkers, tryptase, IL-6, and PAF in the events of hypersensitivity during oncological or biological agent administration, and anaesthesia"	MARÍA JOSÉ TORRES JAÉN	NATIONAL	PI	STATE RESEARCH AGENCY	2023
D-04	PID2022-1427810A-I00 Nanoingeniería de tolerancia inmunitaria para alergia: interacción de nanomateriales y vía de administración (NANO-TOLERANCE)	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	PI	STATE RESEARCH AGENCY	2023
D-04	PI18/00095 Aproximación diagnóstica al paciente alérgico a betalactámicos mediante modelos matemáticos y pruebas in vitro. Estrategia innovadora de tratamiento basada en nano-estructuras.	MARÍA JOSÉ TORRES JAÉN	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
D-04	PI21/00329 Optimización diagnóstica en alergia a betalactámicos: de la estandarización y racionalización de las pruebas in vivo, al desarrollo de test in vitro innovadores basados en nanotecnología y metabolómica. test in vitro innovadores basados en nanotecnología y metabolómica.	MARÍA JOSÉ TORRES JAÉN	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
D-04	PI-0047-2022. Biomarcadores diagnósticos y de gravedad clínica para la optimización del fenotipado de pacientes con alergia a LTP	NATALIA ISABEL PÉREZ SÁNCHEZ	REGIONAL	Pl	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
D-04	PE-0039-2018. Intervención con prebióticos para el tratamiento de alergia a alimentos	CRISTOBALINA MAYORGA MAYORGA	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2018
D-04	PUNI-017-2016 Desarrollo de un microarray con conjugados betalactámico-proteína y betalactámico-nanoestructura para el diagnóstico de alergia a antibióticos	MARÍA ISABEL MONTAÑEZ VEGA	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2016
D-04	PI-0127-2020 Aproximación diagnóstica al paciente alérgico a antibióticos betalactámicos mediante la optimización del test de activación de basófilos profundizando en los mecanismos de degranulación del basófilo y la sensibilización pasiva.	ADRIANA ARIZA VEGUILLAS	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
D-04	PI20/01540 Hipersensibilidad a anti-inflamatorios no esteroides: Fenotipado preciso e historia natural. Papel de la atopía y de una respuesta inmute innata	INMACULADA DOÑA DÍAZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
D-04	PI21/01391 Fenotipado clínico e inmunologico de pacientes con alergia a LTP	FRANCISCA GÓMEZ PÉREZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-04	ProyExcel_00971 Diseño de Nanoestructuras Multivalentes Conjugadas a Antibióticos para el Estudio de la Activación de Células Efectoras. Aplicación Diagnóstica en Reacciones Alérgicas a Antibióticos Betalactámicos	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
D-04	PI20/01734 Nanoarquitecturas altamente eficientes para un entrecruzamiento eficaz de la IgE en mastocitos y basófilos. Aplicación al diagnóstico de reacciones alérgicas a amoxicilina y ácido clavulánico	MARÍA ISABEL MONTAÑEZ VEGA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
D-04	PI20/01715 Estudio de la prevalencia, clarificación de la inmunopatología e identificaicón de biomarcadores diagnósticos de alergia respiratoria local en fenotipos graves y de díficil control de rinitis y asma	IBON EGUILUZ GRACIA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
D-04	PI-0076-2019. CARACTERIZACIÓN DEL FENOTIPO-ENDOTIPO E IDENTIFICACIÓN DE BIOMARCADORES EN REACCIONES DE HIPERSENSIBILIDAD A QUIMIOTERÁPICOS (SALES DE PLATINO Y TAXANOS)	GADOR BOGAS HERRERA	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2019
D-04	PIN-0113-2020: Biosensores Fotónicos en tándem con nanopartículas mesoporosas de sílice para diagnóstico de alergia a betalactámicos	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
D-04	PI-0099-2020 Papel de las células linfoides innatas tipo 2 (ILC2) en las reacciones alérgicas a alimentos y su implicación en la respuesta inmunológica durante la inmunoterapia especifica.	MARÍA FRANCISCA PALOMARES JEREZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
D-04	PI22/01119 Biomarcadores endofenotípicos y pronósticos en las reacciones de hipersensibilidad por quimioterápicos. Gestión del riesgo de la administración controlada y desensibilización	GADOR BOGAS HERRERA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-04	PI-0129-2021 Aplicabilidad del aprendizaje automático y la inteligencia artificial en el diagnóstico de la hipersensibilidad a anti-inflamatorios no esteroideos. Papel del test de activación de basófilo en las reacciones selectivas.	MARÍA SALAS CASSINELLO	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021
D-04	De rol van autoreactieve T cellen en autoreactive IgE antilichamen in atopisch eczeem; van het labo naar de patient en terug	IBON EGUILUZ GRACIA	INTERNATIONAL NON-EU	PI	RESEARCH FOUNDATION FLANDERS	2021
D-04	AC18/00031 DIFAMEM - Dietary Intervention in Food Allergy: Microbiome, Epigenomic and Metabolomic interactions	MARÍA JOSÉ TORRES JAÉN	EUROPEAN UNION	PI	CARLOS III INSTITUTE OF HEALTH	2018
D-04	PE-0172-2018. Aplicación de nano-partículas y búsqueda de biomarcadores para el diagnóstico in vitro de alergia a betalactámicos.	MARÍA JOSÉ TORRES JAÉN	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2018
D-04	PI18/00288 Biomarcadores inmunológicos y epigenéticos de tolerancia a alérgenos alimentarios inducida por inmunoterapia basada en nanoestructuras oligodendriméricas y epítopos T	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
D-04	PI21/00346 Microagujas y nanopartículas como estrategia innovadora para la administración de inmunoterapia epicutánea en enfermedades alérgicas. Identificación de biomarcadores para una tolerancia duradera.	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
D-04	RYC2021-034536-I Proyecto Ramon y Cajal. IP.Juan Luis Paris.	М	NATIONAL	PI	STATE RESEARCH AGENCY	2022
D-04	PRE-BIT - Understanding the role of B cell phenotypes as a predictor of the efficacy and prognosis of allergen immunotherapy using allergic rhinitis to house dust mite as a model	CARLOS ARANDA CLEMENTE	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2022
D-04	CD22/00112 Contrato Sara Borrell_Patricia Diez Echave_Jefe de Grupo Maria Jose Torres Jaen.	MARÍA JOSÉ TORRES JAÉN	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	FI22/00199 Contratos predoctorales de formación en investigación de salud. BN Jose Antonio Céspedes Lago LR: Maria Jose Torres Jaen	MARÍA JOSÉ TORRES JAÉN	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	RD21/0002/0008 Red de Enfermedades Inflamatorias LR: María José Torres Jaén	MARÍA JOSÉ TORRES JAÉN	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-04	POEJ-00039-04 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: María José Torres Jaén	MARÍA JOSÉ TORRES JAÉN	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-04	CPII19/00006 Contrato Miguel Server Tipo II 2019 Jose Antonio Cornejo Garcia	JOSÉ ANTONIO CORNEJO GARCÍA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
D-04	C1-0006-2022 PROGRAMA NICOLÁS MONARDES, CONVOCATORIA 2022. CANDIDATO JOSE ANTONIO CORNEJO. Mecanismos moleculares y base genética de las reacciones de hipersensibilidad a anti-inflamatorios no esteroideos.	JOSÉ ANTONIO CORNEJO GARCÍA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
D-04	POEJ-00039-14 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: José Antonio Cornejo García	JOSÉ ANTONIO CORNEJO GARCÍA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-04	CA17136 (INDAIRPOLLET) - Indoor Air Pollution Network	CARMEN RONDÓN SEGOVIA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2018
D-04	CA18227 (COMFA) - The Core Outcome Measures for Food Allergy	CRISTOBALINA MAYORGA MAYORGA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
D-04	FI22/00106 Contratos predoctorales de formación en investigación de salud. BN: María Del Carmen Martín Astorga LR: Cristobalina Mayorga	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	RC-0004-2021 Renovación II del Programa Nicolás Monardes 2013. Cristobalina Mayorga	CRISTOBALINA MAYORGA MAYORGA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2021
D-04	POEJ-00039-07 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Cristobalina Mayorga	CRISTOBALINA MAYORGA MAYORGA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-04	RYC2021-034536-I Contrato Ramon y Cajal. Juan Luis Paris	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	HR	STATE RESEARCH AGENCY	2022
D-04	RYC2021-034536-I Proyecto Ramon y Cajal. IP.Juan Luis Paris.	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	HR	STATE RESEARCH AGENCY	2022
D-04	POEJ-00039-15 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Juan Luis Paris Fernández de la Puente	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-04	POEJ-00039-03 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: María Isabel Montañez Vega	MARÍA ISABEL MONTAÑEZ VEGA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-04	RH-0099-2020_AAV Optimización del diagnóstico y tratamiento de las enfermedades alérgicas	ADRIANA ARIZA VEGUILLAS	REGIONAL	HR	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
D-04	POEJ-00039-24 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Adriana Ariza Veguillas	ADRIANA ARIZA VEGUILLAS	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-04	FI21/00274 Contratos predoctorales de formación en investigación en salud. Isabel María Jiménez Sánchez jefe de grupo Inmaculada Doña Diaz .	INMACULADA DOÑA DÍAZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	B-0001-2017_Acción B Clínicos investigadores_Inmaculada Doña	MARÍA JOSÉ TORRES JAÉN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2017
D-04	CD20/00085 Contracts Sara Borrell 2020 José Antonio Cañas Mañas. Jefe de Grupo: Cristobalina Mayorga Mayorga	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-04	CA18226 (ADOPT)- New approaches for the detection of pathogens and aeroallergens	IBON EGUILUZ GRACIA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2019
D-04	POEJ-00039-02 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Ibon Eguíluz Gracia	IBON EGUILUZ GRACIA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-04	JR18/00054 Contrato Juan Rodés 2018 GADOR BOGAS HERRERA	GADOR BOGAS HERRERA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2018
D-04	POEJ-00039-09 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Francisca Palomares Jerez	MARÍA FRANCISCA PALOMARES JEREZ	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-04	FI18/00133 Contrato PFIS 2018 Raquel Jurado Escobar. Group leader: José Antonio Cornejo García	JOSÉ ANTONIO CORNEJO GARCÍA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2018
D-04	CD21/00034 Contratos Sara Borrell 2021 Carlos José Aranda Clemente. Group leader: Ibon Eguíluz Gracia	IBON EGUILUZ GRACIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	FI21/00066: Contrato PFIS 2021 Marta Espada Sánchez. Group leader: Ibon Eguíluz Gracia	IBON EGUILUZ GRACIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	FI21/00116: Contrato PFIS 2021 Pablo Torres Fernández. Group leader: Maria Isabel Montañez Vega.	MARÍA ISABEL MONTAÑEZ VEGA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	B-0005-2019 ACCIONES PARA EL REFUERZO CON RECURSOS HUMANOS DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES DE GESTIÓN CLÍNICA DEL SERVICIO ANDALUZ DE SALUD 2019. ACCIÓN B CLÍNICOS INVESTIGADORES.	MARÍA JOSÉ TORRES JAÉN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
D-04	CM21/00262 Contratos Rio Hortega 2021 Carmen Alba Linero. Group leader: Ibon Eguíluz Gracia	IBON EGUILUZ GRACIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	INT22/00075 Estudio de la prevalencia, clarificación de la inmunopatología e identificación de biomarcadores diagnósticos de alergia respiratoria local en fenotipos graves y de difícil control de rinitis y asma.	CARMEN RONDÓN SEGOVIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	PLAN PROPIO_INT-F1-4-2306_2023 LR Carlos Aranda Clemente	CARLOS ARANDA CLEMENTE	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
D-04	PLAN PROPIO_INT-F2-2302_2023 LR Ibon Eguiluz Gracia	IBON EGUILUZ GRACIA	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
D-04	JR19/00029 Contratos Juan Rodés 2019 Ibon Eguiluz Gracia	IBON EGUILUZ GRACIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
D-04	JR21/00024 Contratos Juan Rodes 2021 Natalia Isabel Pérez Sánchez	NATALIA ISABEL PÉREZ SÁNCHEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-04	JR22/00048 Contratos Juan Rodes 2022 Almudena Testera Montes	ALMUDENA TESTERA MONTES	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-04	ASSERT-Development of a nanotechnology-based innovative assay for the diagnosis of allergy to Betalactams	MARÍA JOSÉ TORRES JAÉN	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2020

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-04	PR_INV_EMERG23_02 Premio a la investigadora emergente del año.IP:Natalia Perez	NATALIA PEREZ SANCHEZ	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
D-04	RB-0001-2018 Estudio de mecanismos inmunológicos y búsqueda de biomarcadores en hipersensibilidad a fármacos, alergia respiratoria y alergia a alimentos. UGC Alergología del HRUM	MARÍA JOSÉ TORRES JAÉN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2018
D-04	PID2022-1427810A-I00 AYUDAS CONCEDIDAS PARA LA FORMACIÓN DE PERSONAL INVESTIGADOR PREDOCTORAL	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	HR	STATE RESEARCH AGENCY	2023
D-04	FI23/00027 Contratos predoctorales de formación en investigación de salud,BN: CLARA ENCARNACION LEBRON MARTIN. LR: GADOR BOGAS HERRERA	GADOR BOGAS HERRERA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	A1-0008-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS) IP: CARMEN RONDON SEGOVIA AND INMACULADA DOÑA DIAZ.	INMACULADA DOÑA DÍAZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-04	CM23/00092 Contrato Rio Hortega 2023_ Guillermo Bentabol Ramos_Jefe de Grupo: Carmen Rondon Segovia	CARMEN RONDÓN SEGOVIA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	CM23/00130 Contrato Rio Hortega 2023_ Marta Libertad Andugar Moreno.Jefe de Grupo: Cristobalina Mayorga Mayorga	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	CM23/00151_Contrato Rio Hortega 2023_LR:Rocio Saenz de Santa Maria Garcia_Group leader: Maria Jose Torres Jaen	MARÍA JOSÉ TORRES JAÉN	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	CNS2023-145123 Papel del sistema inmune innato en alergia a alimentos y en la inducción de tolerancia específica. (INNA-TOOLS)	CRISTOBALINA MAYORGA MAYORGA	NATIONAL	HR	STATE RESEARCH AGENCY	2023
D-04	CNS2023-145619 Nanopartículas de ARNm para inmunoterapia inductora de tolerancia en alergia (mRNA-TOLERANCE)	JUAN LUIS PARIS FERNANDEZ DE LA PUENTE	NATIONAL	HR	STATE RESEARCH AGENCY	2023
D-04	DOCS23-001-PLAN PROPIO Ayuda de bienvenida para nuevas incorporaciones de doctores seniors. LR: Carlos Aranda Clemente.	CARLOS ARANDA CLEMENTE	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
D-04	JR23/00039 Contratos Juan Rodes 2023 Marina Labella Alvarez	MARINA LABELLA ALVAREZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	MV23-00104 Procesamiento y análisis de datos poblacionales del estudio estadounidense BLSA enfocado en diabetes y estudio de los mecanismos moleculares implicados en la patogenia de la diabetes en relación a la proteína SPD	WASIMA OUALLA BACHIRI	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-04	PR23_DOCTOR_03 Premio IBIMA - Doctor al mejor expediente de último año. LR: Rubén Fernández Santamaría	RUBEN FERNANDEZ SANTAMARIA	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
D-04	RB-0002-2023_Acción B Clínicos investigadores_Francisca Gomez	FRANCISCA GÓMEZ PÉREZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-04	RBL-0002-2023_Renovación 2023 Acción B-Refuerzos de larga duración	MARÍA JOSÉ TORRES JAÉN	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-05	CPC22/00050 Contrato Miguel Servet 2022. LR Carlos Lopez	CARLOS LOPEZ GOMEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-05	BECA_GETECCU_FRESENIUS_2021. Búsqueda de biomarcadores de respuesta terapéutica al Ustekinumab en Enfermedad de Crohn. LR: Carlos López Gómez	CARLOS LOPEZ GOMEZ	NATIONAL	PI	GETECCU	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-05	Exosomas, Respuesta Inmunitaria y Su Modulación Por la Microbiota Intestinal en la Identificación de Biomarcadores Mecanísticos y Pronósticos en Hepatotoxicidad.	w	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2018
D-05	Ayudas para la constitución de redes temáticas-Convocatoria 2022 para el proyecto: Creación de un registro multicéntrico internacional de pacientes con hepatitis autoimmunelike por fármacos o suplementos dietéticos, incluidas vacunas	w	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2022
D-05	Procedimiento de selección de personal investigador doctor (Plan andaluz de investigación, desarrollo e innovación - PAIDI 2020). Contrated: Hao Niu. Research Group: CTS-649	MARÍA ISABEL LUCENA GONZÁLEZ	REGIONAL	HR	University of Málaga	2020
D-05	Contrato del Programa Investigo de la Consejería de Empleo. Empresa y Trabajo Autónomo enmarcado en el Decreto-ley 27/2021, de 14 de diciembre, modificado por el Decreto-ley 1/2022, de 15 de marzo, realizando funciones de apoyo a los investigadores. Contratado: Carlos Clemente.	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	HR	University of Málaga	2022
D-05	Acción de formación predoctoral Jaume Bosch CIBEREHD 2022. Contrated: Antonio Segovia Zafra	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
D-05	PI-0117-2022 Multiómicas para la identificación de biomarcadores microbianos predictivos de la respuesta a Ustekinumab en pacientes con enfermedad de Crohn	EDUARDO GARCÍA FUENTES	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2022
D-05	PE-0098-2019. Nueva estrategia terapéutica en la obesidad basada en las vesículas extracelulares bacterianas	EDUARDO GARCÍA FUENTES	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
D-05	CP18/00042: Role of adipose tissue in the development of intestinal fibrosis in patients with crohn's disease. Proyecto asociado Miguel Servet Tipo I 2018 Francisca Rodriguez Pacheco	FRANCISCA RODRIGUEZ PACHECO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
D-05	PI20/00455 Papel de la regulación circadiana y epigenética de los corticoides y sus receptores en la resistencia a estos fármacos en la enfermedad de Crohn	FRANCISCA RODRIGUEZ PACHECO	NACIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
D-05	TRANSBIOLINE - Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease	RAÚL J. ANDRADE BELLIDO	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2018
D-05	PI21-01248 Fenotipado y caracterización mecanística de la lesión hepática inducida por fármacos, la esteatosis inducida por fármacos y la enfermedad del hígado graso asociado al metabolismo	RAÚL J. ANDRADE BELLIDO	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
D-05	PEMP-0127-2020 Hepatotoxicidad idiosincrásica (DILI): un enfoque personalizado en la identificación de las vías de daño celular y potenciales biomarcadores mediante caracterización de las poblaciones linfocitarias (CyTOF) y células de la piel procedentes de pacientes.	MARÍA ISABEL LUCENA GONZÁLEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
D-05	DIAGNÓSTICO Y ELIMINACIÓN DE HEPATITIS CRÓNICA C EN CENTROS DE SALUD MENTAL DE LA PROVINCIA DE MÁLAGA.	MIREN GARCÍA CORTÉS	NATIONAL	PI	GILEAD SCIENCES EUROPE LTD.	2021
D-05	PI19/00883 Análisis de las poblaciones linfocitarias inmunoreguladoras en hepatoxicidad mediante citometría de masas (CyTOF): detectando la huella dactilar inmunológica de la hepatotoxicidad inducida por fármacos. LR MARIA ISABEL LUCENA GONZALEZ	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2019
D-05	PI18-01652 Implicación de las vesículas extracelulares de origen bacteriano en la evolución de la enfermedad de Crohn	EDUARDO GARCÍA FUENTES	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
D-05	PID2021-127764OB-I00_Uso de biomarcadores como medicina personalizada en la predicción de la respuesta terapéutica a fármacos biológicos en la enfermedad de Crohn (BIORESCROHN)	EDUARDO GARCÍA FUENTES	NATIONAL	PI	STATE RESEARCH AGENCY	2021
D-05	PI18-00901 Análisis de metabolómica y panel de biomarcadores en pacientes con hepatitis aguda. Búsqueda de un test diagnóstico en hepatotoxicidad.	MERCEDES ROBLES DÍAZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
D-05	PI-0244-2021. Búsqueda de biomarcadores de respuesta terapéutica a fármacos biológicos en enfermedad de Crohn. Un enfoque desde la medicina personalizada de precisión.	CARLOS LOPEZ GOMEZ	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-05	PID2022-1401690B-C21 Funcionalidad mitocondrial y estrés oxidativo en un estudio fase II para evaluar la eficacia y seguridad del tratamiento con corticoides en hepatotoxicidad	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2023
D-05	halt-RONIN - Discovering chronic inflammation biomarkers that define key stages in the Healthy-to- NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies	RAÚL J. ANDRADE BELLIDO	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2022
D-05	PROYECTO iPHARMGx: Estudio colaborativo nacional para evaluar la efectividad y eficiencia de la implementación de biomarcadores farmacogenéticos mediante una estrategia de genotipado anticipado en el SNS	JUDITH ADRIANA SANABRIA CABRERA	REGIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
D-05	PI-08-2021_SANCYD-VEGENAT-OB_EGarciaFuentes. Efecto de distintos tipos de aceites presentes en la dieta sobre la intercomunicación entre el intestino y el resto de órganos,	EDUARDO GARCÍA FUENTES	REGIONAL	PI	ANDALUSIAN FOUNDATION OF CLINICAL NUTRITION AND DIETETICS	2021
D-05	Análisis integrado del perfil epigenético y del exposoma en pacientes con daño hepático inducido por fármacos. IBIMA-UMA-13	JUDITH ADRIANA SANABRIA CABRERA	LOCAL	PI	UNIVERSITY OF MÁLAGA	2023
D-05	CA20140 (CorEuStem): The European Network for Stem Cell Core Facilities	CARLOS LOPEZ GOMEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2021
D-05	CM21-00074 Contratos Rio Hortega 2021 José María Pinazo Bander. Group Leader Raúl J. Andrade Bellido	RAÚL J. ANDRADE BELLIDO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-05	RC-0005-2020 Renovación de la Acción C (Programa Nicolás Monardes) de la Convocatoria 2016.	EDUARDO GARCÍA FUENTES	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2020
D-05	POEJ-00039-17 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Eduardo García Fuentes	EDUARDO GARCÍA FUENTES	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-05	MS18-00042 Miguel Servet Tipo I 2018 FRANCISCA RODRIGUEZ PACHECO	FRANCISCA RODRIGUEZ PACHECO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2018
D-05	FI19/00189 Contratos predoctorales de formación en investigación en salud Flores Martin Reyes Jefe de grupo: Eduardo Garcia Fuentes	FLORES MARTIN REYES	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
D-05	CA17112 (PRO-EURO-DILI NET) - PROSPECTIVE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK	RAÚL J. ANDRADE BELLIDO	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2017
D-05	POEJ-00039-41 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Raul J. Andrade Bellido	RAÚL J. ANDRADE BELLIDO	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
D-05	B-0002-2019 REFUERZO CON RECURSOS HUMANOS DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES DE GESTIÓN CLÍNICA DEL SERVICIO ANDALUZ DE SALUD 2019. ACCIÓN B CLÍNICOS INVESTIGADORES	RAÚL J. ANDRADE BELLIDO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
D-05	DOC_01610 Incorporación de ayudas posdoctorales. Candidate: Cristina Rodríguez Díaz, Group leader: Eduardo García Fuentes	EDUARDO GARCÍA FUENTES	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2019
D-05	IFI18-00047 I-PFIS 2018 Alejandro Cueto Sánchez Group leader: Maria Isabel Lucena Gonzalez	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2018
D-05	CD20/00083 Contratos Sara Borrell 2020 Ismael Álvarez Álvarez. Group leader: Raúl Jesús Andrade Bellido	RAÚL J. ANDRADE BELLIDO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2020
D-05	IFI21-00034 Contratos I-PFIS: Doctorados IIS -Empresas de ciencias y tecnología en salud.Daniel Enrique Di Zeo Sánchez jefe de grupo Raúl J. Andrade Bellido	RAÚL J. ANDRADE BELLIDO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-05	CD21-00198 Contratos Sara Borrell 2021 Marina Villanueva jefe de grupo Maria Isabel Lucena Gonzalez	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
D-05	JR21-00066 Contratos Juan Rodes 2021 Judith Adriana Sanabria Cabrera	JUDITH ADRIANA SANABRIA CABRERA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2021
D-05	CD23/00117 Contrato Sara Borrell 2023_Antonio Jesus Ruiz Malagon_Group Leader: Eduardo Garcia Fuentes	EDUARDO GARCÍA FUENTES	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-05	PID2022-1401690B-C21 AYUDAS CONCEDIDAS PARA LA FORMACIÓN DE PERSONAL INVESTIGADOR PREDOCTORAL-PREP2022-000511	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	HR	STATE RESEARCH AGENCY	2023
D-05	CP23/00088 Contrato Miguel Servert 2023 Cristina Rodriguez Diaz	CRISTINA RODRIGUEZ DIAZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-05	A1-0027-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS): RAUL JESUS ANDRADES.	RAÚL J. ANDRADE BELLIDO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
D-05	CM23-00126 Contrato Rio Hortega 2023_ Juan Pedro Toro Ortiz_Jefe de Grupo:Raul Jesús Andrade Bellido	RAÚL J. ANDRADE BELLIDO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-05	IFI23-00008 Contratos I-PFIS: Doctorados IIS-Empresa en ciencias y tecnologías de la salud BN: Gonzalo Matilla LR: M Isabel Lucena	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
D-05	INT-AEEH-01-2023. Beca de intensificación para investigadores	MIREN GARCÍA CORTÉS	NATIONAL	HR	SPANISH FOUNDATION FOR THE STUDY OF THE LIVER	2023
D-05	Contratación temporal de personal laboral técnico de apoyo y de gestión de la I+D+i, en el Marco del Sistema Nacional de Garantía Juvenil y del Programa Operativo de Empleo Juvenil 2014 – 2020, Fase V-VI . LR: Raul J. Andrade Bellido	RAÚL J. ANDRADE BELLIDO	LOCAL	HR	University of Málaga	2021
D-05	Ayuda del Programa de Formación de Profesorado Universitario. Contrated: Gonzalo Matilla Cabello	RAÚL J. ANDRADE BELLIDO	NATIONAL	HR	University of Málaga	2022
D-05	AYUDAS PARA LA ADQUISICIÓN DE INFRAESTRUCTURAS CIENTÍFICAS Y EQUIPAMIENTOS DE I+D+i, EN RÉGIMEN DE CONCURRENCIA COMPETITIVA, EN EL MARCO DEL II PLAN PROPIO DE INVESTIGACIÓN, TRANSFERENCIA Y DIVULGACIÓN CIENTÍFICA.	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	IF	University of Málaga	2023
D-05	CM23-00103 Contrato Rio Hortega 2023_ Irene Diaz Alberola_Group leader: Maria Isabel Lucena Gonzalez.	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2023
DE-02	COMBACTE-CARE EURECA - Combatting Bacterial Resistance in Europe - Carbapenem Resistance	JOSÉ MARÍA REGUERA IGLESIAS	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2012
DE-02/H-02	PIGE-0178-2020 Implementacion de 4-Fenilbutirato sodico como tratamiento de procesos inflamatorios en pacientes de gravedad COVID19 y enferemdades relacionadas	JOSÉ MARÍA REGUERA IGLESIAS	REGIONAL	PI	REGIONAL MINISTRY OF HEALTH AND CONSUMER AFFAIRS	2020
DE-07	ECRAID-Base - European Clinical Research Alliance on Infectious Diseases	MANUEL ENRIQUE HERRERA GUTIERREZ	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2020
DE-09	Virus-host interactions in human infectious diseases	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
DE-09	Validación de una vacuna DNA frente al virus de la enfermedad de linfocistis en dorada cultivada	M	REGIONAL	PI	JUNTA DE ANDALUCÍA	2021
DE-09	Innate immune response to SARS-CoV-2 infection and mechanisms of viral immunopathology	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
DE-09	Immune response and immunopathology mechanisms against viruses of biomedical relevance	М	REGIONAL	PI	UNIVERSITY OF MÁLAGA	2023
DE-10	Estudio de biomarcadores en humor acuoso y sangre en LHON	М	NATIONAL	PI	CHESI	2022
DE-10	PR_IR_COIR23_01 Premio a la nueva IR CO-IR de grupo del último año. LR: Carmen Alba Linero.	CARMEN ALBA LINERO	LOCAL	AWARDS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
F-02	Detección, caracterización y valor pronóstico de la enfermedad coronaria no obstructiva mediante aprendizaje profundo.	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
F-02	Detección Automática de Epilepsia Focal No Lesional mediante Modelos Neuronales Profundos de Difusión Probabilística	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
F-02	Detección de trayectorias anómalas de vehículos en cámaras de tráfico	М	REGIONAL	PI	University of Málaga	2022
F-02	PID2020-115673RB-I00 La emoción racional a través de las redes de sociabilidad presenciales y los ecosistemas digitales	JOSÉ IGNACIO PELÁEZ SÁNCHEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2020
F-02	UMA20-FEDERJA-015 Nuevas estrategias para el desarrollo socioeconómico de Andalucía	LUIS AYUSO SANCHEZ	LOCAL	PI	UNIVERSITY OF MÁLAGA	2020
F-02	IFI19/00009 Contratos I-PFIS: Doctorados IIS-Empresa en ciencias y tecnologías de la salud Rosa Maria Maza Quiroga. Group leader: Ezequiel Lopez Rubio	EZEQUIEL LÓPEZ RUBIO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
F-02 / A-03	PUNI-003_2023 Sistema Inteligente de Ayuda al Diagnóstico Clínico de la Enfermedad Coronaria No Obstructiva en Coronariografías	ESTEBAN JOSÉ PALOMO FERRER	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
F-03	Sensores de campo lejano en fotónica del silicio	M	NATIONAL	PI		2022
F-03	Fotónica integrada para escaneo de haces ópticos en aplicaciones LIDAR	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
F-03	Diseño Inverso Inteligente para Fotónica Integrada Avanzada usando Metamateriales Sublongitud de Onda	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
F-04	HOUNDBOT: Creación de mapa de gas y localización de fuente con un robot móvil	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
F-04	HOUNDBOT: Creación de mapa de gas y localización de fuente con un robot móvil	М	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
F-04	PID2020-117057GB-I00 Percepción robotica avanzada para construccion de mapas y localizacion	JAVIER GONZÁLEZ JIMÉNEZ	NATIONAL	PI	STATE RESEARCH AGENCY	2020
F-05	Planificador de tareas con aprendizaje para la colaboración humano-robot en un sistema industrial ciber-físico.	М	NATIONAL	PI		2022
F-05	Robot quirúrgico para el aspirado autónomo de sangrado durante una intervención laparoscópica	W	NATIONAL	PI		2022
F-05	Papel de la transcriptómica y metabolómica en la búsqueda de biomarcadores en el abordaje de la obesidad mórbida en respuesta a la pérdida de peso tras la cirugía bariátrica	W	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
F-05	Asistente robótico colaborativo para mejorar la cirugía laparoscópica del hígado	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
F-09	INSTRUMENTACION INTELIGENTE Y APLICACION EN SALUD	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
F-09	Percepción en manos robóticas para asistencia a humanos (HANDCARE)	М	REGIONAL	Pl	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
F-10	Preparación, funcionalización química y validación clínica de un biosensor fotónico integrado de bajo coste para la detección de anticuerpos	М	REGIONAL	Pl	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
F-10	Peptidos Glicomimeticos para el diagnostico y tratamiento de tumores metastásicos	М	REGIONAL	Pl	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
F-10	SISTEMAS MULTIVALENTES Y MARCADORES LUMINISCENTES PARA APLICACIONES BIOMEDICAS	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
F-10	ioglicósidos: epítopos de glicano no hydrolizables para el desarrollo de vacunas sintéticas basadas en carbohidratos contra el VIH. (HIVTHIOVAC)	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
F-10	CPP2022-009994 Development of a photonic point of care device for multiplexed detection of biomarkers, tryptase, IL-6, and PAF in the events of hypersensitivity during oncological or biological agent administration, and anaesthesia	EZEQUIEL PÉREZ-INESTROSA VILLATORO	NATIONAL	Pl	STATE RESEARCH AGENCY	2023
F-10	MIG-20231023 Investigación para la integración de nuevas arquitecturas sensoras de fotónica integrada multiplexada y terahercios hiperespectrales para un sistema microfluídico in vitro para monitorizar tratamientos farmacológicos contra el cáncer	EZEQUIEL PÉREZ-INESTROSA VILLATORO	NATIONAL	PI	CENTER FOR TECHNOLOGICAL DEVELOPMENT AND INNOVATION	2023
F-14	CA21110 (NetwOArk) - Building an open European Network on OsteoArthritis research	RAQUEL CANTERO TELLEZ	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2022
F-14	AP-0158-2018 Protocolo de Adaptación Transcultural y Validación del Wijma Delivery Expectancy/ Experience Questionnaire A y B.	MARÍA GARRIDO LÓPEZ	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2018
F-14	Competencias y actitudes frente a los cuidades paliativos en estudiantes y profesionales en Ciencias de la Salud	М	REGIONAL	PI	University of Málaga	2022
F-14/A-06	PI22-00315 Efectividad de un programa de rehabilitación cardiaca en biomarcadores cinemáticos, estructurales y fisiológicos en pacientes de edad avanzada con insuficiencia cardíaca. FUNNEL+	ANTONIO CUESTA VARGAS	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
					REGIONAL	
F-15	SEMAGRI: Explotación de la Semántica de Dominio para Análisis de Datos en Agricultura de Precisión	M	REGIONAL	PI	MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2021
F-15	5G+TACTILE_3. Gestión "zero touch" de los servicios con IA aplicada a datos masivos en redes B5G/6G	М	NATIONAL	PI	Ministry of Economic Affairs and Digital Transformation	2021
F-15	PID2020-112540RB-C41 Una aproximación holística de smart data para el análisis de datos guiado por el contexto: explotación de semántica y contexto.	JOSÉ FRANCISCO ALDANA MONTES	NATIONAL	PI	STATE RESEARCH AGENCY	2020

572 EXTERNAL ASSOCIATED GRUPS 2023 SCIENTIFIC REPORT 573

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
FA-07	EMG23_02_EFICACIA Y SEGURIDAD DEL TRATAMIENTO MÉDICO CON VOSOROTIDE EN POBLACIÓN PEDIÁTRICA CON ACONDROPLASIA. LR: ANTONIO LEIVA GEA	ANTONIO LEIVA GEA	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
FA-07	SECOT-001 ESTABILIDAD EN LA CARGA AXIAL DEL FIJADOR EXTERNO Francisco Javier Duran Garrido.	FRANCISCO JAVIER DURAN GARRIDO	NATIONAL	PI	SPANISH SOCIETY OF ORTHOPEDIC SURGERY AND TRAUMATOLOGY	2019
FE-17	Mecanismos cerebrales y cognitivos de los errores del habla en la afasia	М	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
G-01	Targeting strategies of multifunctional magnetic nanosystems for therapy and in vivo imaging of high-grade gliomas: validation in PDOX models	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
H-02	ESTUDIO DE INTERACCIONES VASCULO-ESQUELETICAS COMO MECANISMO DIANA DE PATOLOGÍA ÓSEA Y DESARROLLA DE UN NUEVO BIOMATERIAL BIOMIMETICO PARA EL TRATAMIENTO DE CONDICIONES ÓSEAS	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2021
H-02	Cellular Stress And Senescence As a Crosstalk Mechanism Of Disease In Bone Fragility	М	REGIONAL	PI	REGIONAL MINISTRY OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE, AND UNIVERSITIES	2020
H-02	Mechanisms of bone pathologies caused by alteration of skeletal differentiation towards adipogenesis and its link with metabolism	W	REGIONAL	PI	JUNTA DE ANDALUCÍA	2022
H-02	PI22-01627 Evaluación preclínica de implantes personalizados, fabricados por bioimpresión, para la corrección quirúrgica de defectos críticos cráneo-maxilofaciales en pacientes pediátricos	LEONOR SANTOS RUIZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2022
H-02	Mechanisms of skeletal stem cells differentiation in skeletal diseases	FABIANA CSUKASI CABRERA	EUROPEAN UNION	PI	STATE RESEARCH AGENCY	2021
H-03	Estratificación de fibroblastos cardíacos: origen y segregación espacial de fibroblastos activados en la fisiopatología cardiovascular	М	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
H-03	Estudio evolutivo del sistema sanguíneo en peces cartilaginosos: implicaciones sobre el origen de la hematopoyesis en vertebrados	М	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2022
H-03	SECFEC-INV-BAS 22016 Nueva perspectiva en los mecanismos fisiopatológícos de la Enfermedad de Kawasaki	ADRIÁN RUIZ VILLALBA	NATIONAL	PI	SPANISH SOCIETY OF CARDIOLOGY	2022
H-03	PID2020-119430RJ-100 DESENMARAÑANDO EL INTERACTOMA CELULAR CARDIACO POST-INFARTO: HACIA LAREGULACION DE LA CICATRIZACION FIBROTICA	ADRIÁN RUIZ VILLALBA	NATIONAL	PI	STATE RESEARCH AGENCY	2020
H-03	Papel de la diversidad celular en la fisiopatología de la fibrosis cardíaca	М	REGIONAL	PI	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
H-03	Engineering a living human Mini-heart and a swimming Bio-robot	М	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2021
H-03	CA17129 (CardioRNA): Catalysing transcriptomics research in cardiovascular disease	ADRIÁN RUIZ VILLALBA	EUROPEAN UNION	OTHER	EUROPEAN COMMISSION	2018

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
H-03	PLAN PROPIO_INT-F1-1-2302_2023 IP Adrián Ruiz Villalba	ADRIÁN RUIZ VILLALBA	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
H-03	Integrated research network in organic fibrosis	JOSE MARIA PEREZ POMARES	NATIONAL	NETWORKS AND STRUCTURES	Ministry of Science and Innovation-	2022
HE-01	Reprogramación Celular y modelos de enfermedad	W	LOCAL	PI	UNIVERSITY OF MÁLAGA	2021
HE-01	Pluripotencia adquirida: Análisis de la reprogramación celular usando factores del ovocito para estudiar los estados de pluripotencia humana para aplicaciones biomédicas	w	NATIONAL	PI	MINISTRY OF SCIENCE AND INNOVATION	2022
ECAI BIOBANCO	PT20/00101 Plataforma Biobanco y Biomodelos	FRANCISCO JOSÉ TINAHONES MADUEÑO/ANTONIO RODRÍGUEZ ACOSTA	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2020
ECAI BIOBANCO	POEJ-00039-29 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Tatiana Diaz	TATIANA DÍAZ CORDOBA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
ECAI BIOBANCO	772160002: RF2-0008-2019: SOLICITUD PARA LA VINCULACIÓN DE TÉCNICOS A LAS ESTRUCTURAS COMUNES DE APOYO A LA INVESTIGACIÓN (ECAI) DE LOS CENTROS SANITARIOS DEL SERVICIO ANDALUZ DE SALUD (SAS),	TATIANA DÍAZ CORDOBA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
ECAI BIOBANK	RF2-0003-2023 SOLICITUD PARA LA VINCULACIÓN DE TÉCNICOS A LAS ESTRUCTURAS COMUNES DE APOYO A LA INVESTIGACIÓN (ECAI) DE LOS CENTROS SANITARIOS DEL SERVICIO ANDALUZ DE SALUD (SAS)Tatiana Diaz Cordoba	MARIA LUISA HORTAS NIETO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
ECAI BIOBANK	PT23/00049 Plataforma Biobanco y Biomodelos piedra angular de la Medicina de Precisión: ampliación, virtualización e internacionalización del servicio. Generation of organoids	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
ECAI BIOIN- FORMATICS	F2-0026-2022 MEMORIA DESCRIPTIVA DE LA ECAI: ORGANIZACIÓN, RECURSOS Y ACTIVIDAD DE LA ECAI.	FRANCISCO JOSÉ TINAHONES MADUEÑO	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
ECAI BIOIN- FORMATICS	POEJ-00039-26 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. IP: Andrés Gonzalez	ANDRES GONZÁLEZ JIMENEZ	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
ECAI CELL BIOLOGY	PTA2018-015682-I AYUDAS PARA PERSONAL TÉCNICO DE APOYO 2018	VERÓNICA PRADOS MANIVIESA	NATIONAL	HR	STATE RESEARCH AGENCY	2019
ECAI GENOMICA	PTA2022-021673-I Ayudas personal tecnico de apoyo 2022 IP: Laura Virginia Castilla Ruiz	LAURA VIRGINIA CASTILLA RUIZ	NATIONAL	HR	STATE RESEARCH AGENCY	2023
ECAI GENOMICA	PTA2019-016629-I Ayudas para personal Técnico de Apoyo 2019 Maria Jesús Pinto Medel	JUAN MIGUEL GÓMEZ ZUMAQUERO	NATIONAL	HR	STATE RESEARCH AGENCY	2020
ECAI GENOMICA	PTA2019-017960-I Ayudas para personal Técnico de Apoyo 2019 Ana María Lago Sampedro	JUAN MIGUEL GÓMEZ ZUMAQUERO	NATIONAL	HR	STATE RESEARCH AGENCY	2020
ECAI GENOMICS	PR-SAEDYN-2021. Validación de un algoritmo desarrollado con PCR-hs y miRNAs circulantes como biomarcadores de HNF1A-MODY en pacientes previamente diagnosticados por Sangre	ANA MARIA LAGO SAMPEDRO	NATIONAL	AWARDS	ANDALUSIAN SOCIETY OF ENDOCRINOLOGY, DIABETES AND NUTRITION	2021
ECAI CLINICAL RESEARCH	RF2-0002-2023 SOLICITUD PARA LA VINCULACIÓN DE TÉCNICOS A LAS ESTRUCTURAS COMUNES DE APOYO A LA INVESTIGACIÓN (ECAI) DE LOS CENTROS SANITARIOS DEL SERVICIO ANDALUZ DE SALUD (SAS), Gloria Luque	MARÍA ISABEL LUCENA GONZÁLEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
ECAI CLINICAL RESEARCH	PT23/00137 Unidad de Investigación Clínica y Ensayos Clínicos, UICEC IBIMA_Plataforma BIONAND. ISCiii Clinical Research Platform: Consolidation of its international projection, comprehensive management, collaboration, and transfer.	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
ECAI CLINICAL RESEARCH	PT20/00127 Plataforma Soporte para la investigación clínica independiente y Ensayos Clínicos	MARÍA ISABEL LUCENA GONZÁLEZ	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2020
ECAI CLINICAL RESEARCH	POEJ-00039-28 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. IP: María Isabel Lucena	MARÍA ISABEL LUCENA GONZÁLEZ	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
ECAI CLINICAL RESEARCH	773160002: RF2-0007-2019: SOLICITUD PARA LA VINCULACIÓN DE TÉCNICOS A LAS ESTRUCTURAS COMUNES DE APOYO A LA INVESTIGACIÓN (ECAI) DE LOS CENTROS SANITARIOS DEL SERVICIO ANDALUZ DE SALUD (SAS),	GLORIA LUQUE FERNÁNDEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2019
ECAI NANOIMAGEN	PTA2020-019744 AYUDAS PERSONAL TÉCNICO DE APOYO . ECAI NANOIMAGING. IBIMA PLATAFORMA BIONAND. CANDIDATE: MÓNICA FEIJÓO CUARESMA	MARIA LUISA GARCIA MARTIN	NATIONAL	HR	STATE RESEARCH AGENCY	2021
ECAI NANOIMAGEN	PTA2022-022189-I Ayudas personal tecnico de apoyo 2022. LR: Cinzia Guzzi	CINZIA GUZZI	NATIONAL	HR	STATE RESEARCH AGENCY	2023
ECAI NANOIMAGEN	ICT2022-007849_Actualización de la infraestructura del nodo BIONAND de NANBIOSIS. (NANBIOSISBIONAND 2022)	MARIA LUISA GARCIA MARTIN	NATIONAL	INFRASTRUCTURE	MINISTRY OF SCIENCE, INNOVATION, AND UNIVERSITIES	2022
ECAI GMP Room	PLAN PROPIO_INT-F2-2301_2023 IP Antonio Rodríguez Acosta	ANTONIO RODRÍGUEZ ACOSTA	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
ECAI GMP Room	RF2-0004-2022 Vinculación de Técnicos a las Estructuras Comunes de Apoyo a la Investigación. Renovación de los refuerzos de la actividad investigadora cuyas ayudas vencen en 2022 Tecnio Superior: Rafael Maldonado	RAFAEL MALDONADO SÁNCHEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2022
ECAI GMP Room	RF2-0004-2020 Vinculación de técnicos a estructuras comunes de apoyo a la investigación. Segunda renovación de los refuerzos aprobados en la convocatoria 2012	ANTONIO RODRÍGUEZ ACOSTA	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2020
ECAI GMP Room	POEJ-00039-27 Contrato de jóvenes investigadores y técnicos de apoyo de I+D+i. Empleo Juvenil. LR: Antonio Rodríguez Acosta	ANTONIO RODRÍGUEZ ACOSTA	REGIONAL	HR	REGIONAL MINISTRY OF UNIVERSITIES, RESEARCH, AND INNOVATION	2021
ECAI GMP Room	PIN-0348-2019 Creación del Primer Programa de Garantía Externa de la Calidad en Terapias Avanzadas.	ANTONIO RODRÍGUEZ ACOSTA	REGIONAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2019
ECAI CLINICAL RESEARCH	LIVERaTION - Unravelling the impact of Radiofrequency in liver surgery: the key to decrease local recurrence?	MIRIAM ROL GARCIA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2022
ECAI CLINICAL RESEARCH	ORTHOALLOUNION - ORTHOpaedic treatment with Allogeneic combined ATMP in long bone fracture delayed UNION and non-union	MIRIAM ROL GARCIA	EUROPEAN UNION	Pl	EUROPEAN COMMISSION	2023
ECAI CLINICAL RESEARCH	ERA4Health-Fostering a European Research Area for Health Research	MIRIAM ROL GARCIA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2022

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
IBIMA ESTRUCTURA	CERT22-00034. Networked State Consortium for the Development of Medicines for Advanced Therapies (CERTERA)	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
IBIMA GESTION	PT23/00082 Unidad de Innovación de IBIMA Plataforma BIONAND. Promotion of technological valorization, knowledge transfer, and consolidation of the industrial network.	FERNANDO RODRÍGUEZ DE FONSECA	NATIONAL	NETWORKS AND STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2023
IBIMA- GESTION	GIS19-00013 Contrato de gestión en Investigación en Salud en IIS	FRANCISCO JOSÉ TINAHONES MADUEÑO	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2019
IBIMA- GESTION	INT-P-0009-2021. Apoyo a la internacionalización de la investigación biomédica en la provincia de Málaga	JOSE MIGUEL GUZMÁN DE DAMAS	REGIONAL	HR	ANDALUSIAN PUBLIC FOUNDATION FOR PROGRESS AND HEALTH M.P.	2021
IBIMA- GESTION	INN23 Ayudas para el apoyo a actuaciones de Innovación, Desarrollo y Transferencia de Conocimiento.	ISABEL MARÍA GUERRERO MOLINA	LOCAL	COMPLEMENTARY ACTIONS	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023

580 EXTERNAL ASSOCIATED GRUPS 2023 SCIENTIFIC REPORT 581

ASSOCIATED GROUPS. COMPETITIVE RESEARCH GRANTS ACTIVE IN 2023

Group	Title	LR Name	Scope	Subtype	Name of the Funding Entity	Year of Call
AA-24	CA20104 (PhysAgeNet) - Network on evidence-based physical activity in old age	JESUS OLMEDO LLANES	EUROPEAN UNION	NETWORKS AND STRUCTURES	EUROPEAN COMMISSION	2021
AA-24	A3-0071-2023 SOLICITUD PARA EL REFUERZO ANUAL DE LA ACTIVIDAD INVESTIGADORA EN LAS UNIDADES ASISTENCIALES DEL SERVICIO ANDALUZ DE SALUD (SAS)	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	REGIONAL	HR	ANDALUSIAN HEALTH SERVICE	2023
BA-14	INTERACT-EUROPE 100	MARILINA GARCÍA ARANDA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023
BA-14	MOV_IBIMA_COST_ STSM_Nanocarriers for the personalized treatment of multidrug resistant tumors_ Marilina García	MARILINA GARCÍA ARANDA	EUROPEAN UNION	HR	EUROPEAN COMMISSION	2023
BA-14	PI18-01181 Identificación de factores de riesgo de eventos adversos y Calidad de Vida en pacientessupervivientes de cáncer de colon y recto a 8 y 10 años de seguimiento post-cirugía.	MAXIMINO REDONDO BAUTISTA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2018
BA-14	PI21-00252 Estudio del estado de salud y calidad de vida en pacientes supervivientes de cáncer de colon y recto a 12 años de seguimiento postcirugía	MAXIMINO REDONDO BAUTISTA	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2021
BA-14	RD21-0016-0015 Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS). LR: Maximino Redondo Bautista	MAXIMINO REDONDO BAUTISTA	NATIONAL	STABLE STRUCTURES	CARLOS III INSTITUTE OF HEALTH	2021
BA-14	CA17115 (MyWAVE) - European network for advancing Electromagnetic hyperthermic medical	IRENE ZARCOS PEDRINACI	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2018
BA-14	INT22-00055 Contrato de intensificación Maximino Redondo	MAXIMINO REDONDO BAUTISTA	NATIONAL	HR	CARLOS III INSTITUTE OF HEALTH	2022
BA-14	RH-0055-2020 INVESTIGACIÓN BÁSICA Y TRASLACIONAL EN CÁNCER Y ENFERMEDADES INFECCIOSAS EMERGENTES	MAXIMINO REDONDO BAUTISTA	REGIONAL	HR	Andalusian Agency for Knowledge. Regional Ministry of Economy, Knowledge, Business, and Universities	2020
CA-14	PROVIDE - Prediction and prevention of cardiovascular diseases in pre-diabetes and diabetes	JOSÉ JAVIER GARCÍA ALEGRÍA	EUROPEAN UNION	PI	EUROPEAN COMMISSION	2023
CA-14	PI20/00783 Efectividad de la asistencia sanitaria a los pacientes con Insuficiencia Cardiaca utilizando datos del mundo real	RAUL QUIROS LÓPEZ	NATIONAL	PI	CARLOS III INSTITUTE OF HEALTH	2020
CA-15	CA19132 (ENABLE) - European Network to Advance best practices & technology on medication adherence	PILAR BARNESTEIN FONSECA	EUROPEAN UNION	STABLE STRUCTURES	EUROPEAN COMMISSION	2020
CA-19	EMG23_01 Propuesta de aprendizaje de la competencia digital desde la biblioteca de salud. LR: Antonia Fernandez Luque	ANTONIA Mª FERNANDEZ LUQUE	LOCAL	PI	ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH AND BIOMEDICAL RESEARCH IN MÁLAGA	2023
FA-16	SECOT_02.Estudio del transcriptoma con identificación de nuevos biomarcadores no invasivos para el diagnóstico de la escoliosis idiopática del adolescente.	ENRIQUE GUERADO PARRA	NATIONAL	PI	SPANISH SOCIETY OF ORTHOPEDIC SURGERY AND TRAUMATOLOGY	2022

582 EXTERNAL ASSOCIATED GRUPS 2023 SCIENTIFIC REPORT 583

CLINICAL STUDIES ACTIVE IN 2023

Group	Title	Subtype	LR Name	Phase
A-01	Real-world patient experience with weekly injectable dulaglutide versus daily oral semaglutide in Spain TRU-Experience Study	OBSERVATIONAL STUDY WITH DRUGS	GABRIEL OLVEIRA FUSTER	NA
A-01	Estudio observacional restrospectivo del uso de evolucumab en unidades españolas de endocrinología (Retrospective Observational Study of Evalocumab Use in Spain Endocrinology Units [RETOSS-Endo]). Sponsor Code: 20160140	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZÁLEZ MOLERO	OD
A-01	Estudio fase III, multicéntrico, aleatorizado, doble ciego, de 48 semanas, con un periodo inicial de 12 semanas controlado con placebo, para evaluar la seguridad y la eficacia de osilodrostat en pacientes con enfermedad de Cushing	COMMERCIAL CLINICAL TRIAL	INMACULADA GONZÁLEZ MOLERO	III
A-01	Ensayo en fase III, aleatorizado, con enmascaramiento doble, comparativo con placebo y multicéntrico para evaluar la eficacia y la seguridad de Diamyd® en la conservación del funcionamiento de las células ß endógenas en adolescentes y adultos con un diagnóstico reciente de diabetes de tipo 1 que presentan el haplotipo genético HLA DR3-DQ2. DIAGNODE-3	COMMERCIAL CLINICAL TRIAL	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	III
A-01	Accu-Chek Solo Country Implementation Observational Network SCION	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	NA
A-01	Estudio Fase IIb, 2-brazos, aleatorizado, Doble-ciego, Placebo-Controlado, Multicéntrico para Optimizar la terapia de Diamyd® Administrada dentro de los ganglios linfáticos combinados con la vitamina D oral para investigar el impacto en la progresión de la diabetes tipo 1.	COMMERCIAL CLINICAL TRIAL	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	II
A-01	Estudio de fase 2b, aleatorizado, doble ciego, controlado con placebo y multicéntrico de 52 semanas de duración con una extensión ciega de 52 semanas que evalúa la seguridad y la eficacia de frexalimab, un anticuerpo monoclonal antagonista de CD40L, para la preservación de la función de las células ß pancreáticas en adultos y adolescentes con diagnóstico reciente de diabetes tipo 1 en tratamiento con insulina	CLINICAL TRIAL WITH DRUGS	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	II
A-01	Impacto sobre el estrés oxidativo de los distintos análogos de insulina en personas con diabetes tipo 1. Ensayo clínico de bajo nivel de intervención. Estudio Ineox	INDEPENDENT CLINICAL TRIAL	MARÍA SOLEDAD RUÍZ DE ADANA NAVAS	IV
A-01	Eficacia del tratamiento con metformina en diabetes gestacional no controlada con dieta frente al uso de insulinoterapia. Estudio MeDiGes	INDEPENDENT CLINICAL TRIAL	STELLA GONZÁLEZ ROMERO	IV
A-01	Valoración de la calidad de vida, el estado nutricional y la capacidad funcional en personas con enfermedad renal crónica avanzada (ERCA) tras la implantación de un plan de educación nutricional e intervención dietética individualizada.	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	GABRIEL OLVEIRA FUSTER	NA
A-01	A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly	CLINICAL TRIAL WITH DRUGS	INMACULADA GONZÁLEZ MOLERO	III
A-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, de olezarsen (ISIS 678354) administrado por vía subcutánea a pacientes con hipertrigliceridemia grave	CLINICAL TRIAL WITH DRUGS	INMACULADA GONZÁLEZ MOLERO	III
A-01	"Protocolo maestro para investigar la eficacia y la seguridad de LY3437943 administrado una vez a la semana en participantes con diabetes mellitus de tipo 2 y obesidad o sobrepeso: un estudio aleatorizado, doble ciego y controlado con placebo (TRIUMPH-2)"	CLINICAL TRIAL WITH DRUGS	GABRIEL OLVEIRA FUSTER	III
A-01	Pemafibrato para reducir los episodios cardiovasculares mediante la reducción de los triglicéridos en pacientes con diabetes (PROMINENT)	COMMERCIAL CLINICAL TRIAL	INMACULADA GONZÁLEZ MOLERO	III
A-01	Estudio multicéntrico, prospectivo, no intervencionista y de un solo grupo, para investigar los parámetros clínicos asociados al uiso de semaglutida por vía oral una vez al día en una ploblación adulta no restringida con diabetes detipo 2 en España.	OBSERVATIONAL STUDY WITH DRUGS	GABRIEL OLVEIRA FUSTER	NA
A-01	Estudio europeo, observacional, de pasireotida LAR en acromegalia. Estudio ACRONIS. CSOM230CIC05	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZÁLEZ MOLERO	SP

Group	Title	Subtype	LR Name	Phase
A-01	Cumplimiento de un Suplemento Nutricional Oral (SNO) de alto contenido energético y bajo volumen	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	GABRIEL OLVEIRA FUSTER	0
A-01	Estudio observacional, prospectivo y multicéntrico de práctica clínica real (RWE) para evaluar el grado de adherencia a un programa de soporte nutricional y su relación con el estado nutricional evaluado mediante valoración morfofuncional en pacientes oncológicos desnutridos	OBSERVATIONAL STUDY WITH DRUGS	GABRIEL OLVEIRA FUSTER	NA
A-01	Estudio observacional, trasversal y multicéntrico, para valorar el grado de actividad de la enfermedad de los pacientes acromegálicos en España según la escala ACRODAT (ACROmegaly Disease Activity Tool). ACROVAL Study	COMMERCIAL POST-AUTHORIZATION STUDY	INMACULADA GONZÁLEZ MOLERO	OD
A-01	Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, multicéntrico y en 2 partes para evaluar la eficacia, la seguridad y la tolerabilidad de RGH-706 en el síndrome de Prader-Willi	CLINICAL TRIAL WITH DRUGS	JOSÉ CARLOS FERNÁNDEZ GARCÍA	П
A-01	Registro español informatizado de pacientes con Bronquiectasias.	NON-POST-AUTHORIZATION STUDY	CASILDA OLVEIRA FUSTER	NO
A-01	Efecto de un suplemento dietético con propiedades antioxidantes y antiinflamatorias sobre la microbiota intestinal en pacientes con cáncer de colon. Ensayo clínico aleatorizado y controlado con placebo. Estudio TERATROFO.	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	GABRIEL OLVEIRA FUSTER	NA
A-02	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar el impacto de evolocumab sobre los acontecimientos cardiovasculares mayores en pacientes con riesgo cardiovascular elevado sin infarto de miocardio o ictus previo	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessingthe Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	I
A-02	Estudio de fase 2, aleatorizado, controlado con placebo, doble ciego y de búsqueda de dosis para evaluar la eficacia, seguridad y tolerabilidad de AMG 133 en sujetos adultos con sobrepeso u obesidad, con o sin diabetes mellitus tipo 2	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Correlación en el mundo real del tiempo dentro del rango con los resultados notificados por los pacientes y el uso de recursos sanitarios en pacientes con diabetes en España: estudio CorrelaTIR	REST OF OBSERVATIONAL STUDIES WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	OD
A-02	Estudio multicéntrico y transversal para caracterizar la distribución de los niveles de lipoproteína(a) entre pacientes con antecedentes documentados de enfermedad cardiovascular aterosclerótica (ECVA).	OBSERVATIONAL STUDY WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	NA
A-02	"Estudio fase IIa, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad, tolerabilidad, farmacocinética e interacción con la diana de GSK3858279 en participantes adultos con dolor neuropático diabético periférico crónico (DNPC)"	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la seguridad y eficacia a largo plazo de lanifibranor en pacientes adultos con esteatohepatitis no alcohólica (EHNA) sin cirrosis y estadio de fibrosis hepática grado 2 (F2)/grado 3 (F3)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio observacional restrospectivo del uso de evolucumab en unidades españolas de endocrinología (Retrospective Observational Study of Evalocumab Use in Spain Endocrinology Units [RETOSS-Endo]). Sponsor Code: 20160140	COMMERCIAL POST-AUTHORIZATION STUDY	JOSE ANTONIO LÓPEZ MEDINA	OD
A-02	Estudio observacional multinacional para evaluar la seguridad de Repatha en el embarazo. (20150162, 200150162)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	LA
A-02	Estudio aleatorizado, multicéntrico, doble ciego, de grupos paralelos y controlado con placebo y con comparador para comparar los efectos glucémicos, la seguridad y la tolerabilidad de comprimidos de liberación prolongada de clorhidrato de metformina en pacientes con diabetes mellitus de tipo 2 con función renal variable desde normal hasta IRC 3B	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio aleatorizado, doble ciego (investigador y sujeto) y controlado con placebo para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia de CFZ533 en niños y adultos jóvenes con diabetes mellitus de tipo 1 (DMT1) de nueva aparición	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II

Group	Title	Subtype	LR Name	Phase
A-02	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisirán en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1 Prevent).	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de extensión sin enmascaramiento de la seguridad de relacorilant (CORT125134) en el tratamiento de los signos y síntomas del síndrome de Cushing endógeno	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Antagonismo del receptor de glucocorticoides en el tratamiento del síndrome de Cushing estudio (GRACE): ensayo en fase III, con doble enmascaramiento, controlado con placebo y con retirada aleatorizada sobre la eficacia y la seguridad del relacorilant.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Antagonismo del receptor de glucocorticoides en el tratamiento del hipercortisolismo en pacientes con adenomas suprarrenales que secretan cortisol o hiperplasia (GRADIENT): Estudio de fase III, aleatorizado, doble ciego y comparado con placebo sobre la eficacia y la seguridad de relacorilant	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	A Phase 2b Multicentre, Randomised, Double-Blind, PlaceboControlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2 (Zenith-CKD)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Ensayo fase IIb/III, aleatorizado, doble ciego, comparado con placebo para evaluar la seguridad y eficacia de la cotadutida en pacientes con esteatohepatitis no alcohólica no cirrótica con fibrosis. (Estudio PROXYMO-ADVANCE)	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio aleatorizado, doble ciego, controlado con placebo sobre la relación dosis-respuesta para evaluar la eficacia y la seguridad de MEDI7352 en pacientes con neuropatía diabética dolorosa	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio fase IIa, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y farmacodinámica de AZD4831 en pacientes con esteatohepatitis no alcohólica (EHNA) no cirrótica con fibrosis (COSMOS)	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Ensayo fase IIb, aleatorizado, doble ciego, multicéntrico, comparado con placebo para evaluar eficacia, seguridad y tolerabilidad de AZD2693 en pacientes con esteatohepatitis no alcohólica no cirrótica con fibrosis portadores del alelo de riesgo PNPLA3 rs738409 148M (FORTUNA)	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Efectos de semaglutida en los resultados cardiovasculares en personas con sobrepeso u obesidad. SELECT	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de resultados cardiovasculares con semaglutida en pacientes con diabetes tipo 2 Estudio ALMA	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio Metabolómico de Potenciales Factores Involucrados en la Cardioprotección. Inhibición de SGLT- 2 y Enfermedad Cardiovascular	INDEPENDENT CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	IV
A-02	Eficacia del tratamiento con metformina en diabetes gestacional no controlada con dieta frente al uso de insulinoterapia. Estudio MeDiGes.	INDEPENDENT CLINICAL TRIAL	MARÍA JOSÉ PICÓN CESAR	IV
A-02	Red global de ensayos de pacientes renales.	NON-POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	NO
A-02	Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (SURPASS-CVOT)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 3, aleatorizado, doble ciego, comparativo con un placebo, para investigar el efecto de tirzepatida sobre la reducción de la morbimortalidad en adultos con obesidad	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2, aleatorizado, sin enmascaramiento, con un tratamiento comparativo y grupos paralelos, para evaluar la seguridad y la eficacia de LY3209590 en pacientes con diabetes mellitus de tipo 1 que anteriormente han recibido tratamiento con varias inyecciones diarias.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase 3, multicéntrico, aleatorizado, sin enmascaramiento, con grupos paralelos, para evaluar la eficacia y la seguridad de LY3209590 en comparación con la insulina degludec en participantes con diabetes de tipo 2 actualmente tratados con insulina basal (QWINT-3)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III

Group	Title	Subtype	LR Name	Phase
A-02	Estudio de fase 3, aleatorizado, comparativo, sin enmascaramiento, con grupos paralelos, para comparar la eficacia y la seguridad de LY3209590 como insulina basal semanal con la de la insulina glargina en adultos con diabetes de tipo 2 que reciben múltiples inyecciones diarias	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Ensayo clínico para valorar el Impacto de un suplemento nutricional en la Recuperación del Estadio Nutricional de pacientes ancianos con fractura Espontánea de cadera	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MANUEL GARCÍA ALMEIDA	0
A-02	Protocolo maestro para investigar la eficacia y la seguirdd del LY3437943 administrado una vez a la semana en participantes con diabetes mellitus de tipo 2 y obesidad o sobrepeso: un estudio aleatorizado, doble ciego y controlado con placebo (TRIUMPH-2)	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	111
A-02	"Estudio de fase 3, aleatorizado, doble ciego para investigar la eficacia y la seguridad de LY3437943 administrado una vez a la semana en comparación con placebo en participantes con obesidad severa y con enfermedad cardiovascular establecida (TRIUMPH-3)"	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	"Estudio de fase 3, aleatorizado, doble ciego, para investigar la eficacia y seguridad de LY3502970 administrado una vez al día por vía oral en comparación con placebo en participantes adultos con obesidad o sobrepeso con comorbilidades relacionadas con el peso (ATTAIN-1)."	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Eficacia de dos fórmulas de suplementación nutricional oral sobre parámetros metabólicos y de monitorización glucémica en pacientes en riesgo nutricional con diabetes mellitus tipo 2. PS19089 Estudio JGA-DIACARE-2018-01 Bi1	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MANUEL GARCÍA ALMEIDA	0
A-02	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de MK-0616 para reducir las complicaciones cardiovasculares graves en participantes con riesgo cardiovascular elevado	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio de fase 2a, abierto, aleatorizado y controlado con un producto comparativo activo, para evaluar la eficacia y la seguridad de efinopegdutida (MK-6024) en participantes con esteatosis hepática no alcohólica	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio de fase 2b, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de la efinopegdutida (MK-6024) en adultos con esteatohepatitis no alcohólica precirrótica.	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Cambios en la capacidad de digestión y secreción pancreática exocrina en pacientes tras una cirugía gástrica	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA ALMEIDA	SP
A-02	Eficacia y seguridad de insulina icodec una vez a la semana en comparación con 100 unidades/ml una vez al día de insulina degludec, ambas en combinación con insulina aspart, en adultos con diabetes de tipo 1. Ensayo de tratamiento hasta conseguir el objetivo, de 26 semanas de duración, aleatorizado, multicéntrico, abierto, con control activo, de grupos paralelos y con dos brazos para investigar el efecto sobre el control de la glucemia y la seguridad del tratamiento con insulina icodec una vez a la semana en comparación con insulina degludec una vez al día, ambas en combinación con insulina aspart en adultos con diabetes de tipo 1, con una extensión de 26 semanas para investigar la seguridad a largo plazo. (ONWARDS 6)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio para evaluar la eficacia y seguridad de la insulina Icodec de administración semanal al cambiar de insulinas basales diarias en comparación con 100 UI de insulina glargina una vez al día en adultos con diabetes tipo 2	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Estudio observacional, prospectivo y multicéntrico de práctica clínica real (RWE) para evaluar el grado de adherencia a un programa de soporte nutricional y su relación con el estado nutricional evaluado mediante valoración morfofuncional en pacientes oncológicos desnutridos	OBSERVATIONAL STUDY WITH DRUGS	JOSÉ MANUEL GARCÍA ALMEIDA	NA

Group	Title	Subtype	LR Name	Phase
A-02	Estrategias de control y estudio farmacogenético para el tratamiento personalizado del hígado graso asociado a disfunción metabólica en pacientes con prediabetes.	INDEPENDENT CLINICAL TRIAL	LOURDES GARRIDO SÁNCHEZ	III
A-02	Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, multicéntrico y en 2 partes para evaluar la eficacia, la seguridad y la tolerabilidad de RGH-706 en el síndrome de Prader-Willi	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio en fase II, doble ciego y controlado con placebo de setmelanotide en pacientes con defectos genéticos específicos en la vía del receptor de la melanocortina 4, en dos etapas (preinclusión abierta seguida de retirada aleatorizada)	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	II
A-02	Estudio en fase III, aleatorizado a doble ciego y controlado con placebo: 5 subestudios independientes de setmelanotide en pacientes con defectos en los genes POMC, PCSK1, LEPR, SRC1, SH2B1 o PCSK1 N221D en la vía del receptor 4 de melanocortina	CLINICAL TRIAL WITH DRUGS	FRANCISCO JOSÉ TINAHONES MADUEÑO	III
A-02	Registro Nacional de pacientes con Diabetes tipo 1	INDEPENDENT POST-AUTHORIZATION STUDY	FRANCISCO JOSÉ TINAHONES MADUEÑO	OD
A-03	Estudio aleatorizado, doble ciego y controlado con placebo para evaluar los efectos del ácido bempedoico (ETC 1002) sobre la aparición de episodios cardiovasculares mayores en pacientes con enfermedad cardiovascular, o con riesgo elevado de enfermedad cardiovascular, e intoleracia a las estatinas.	COMMERCIAL CLINICAL TRIAL	MANUEL FRANCISCO JIMÉNEZ NAVARRO	III
A-03	Estudio prospectivo y contemporáneo que evalúa la experiencia en el mundo real del rendimiento y la seguridad de los dispositivos MitraClip de última generación. Estudio MitraClip EXPAND	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	Ensayo clínico multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para evaluar la eficacia y la seguridad de finerenona sobre la morbilidad y la mortalidad en participantes con insuficiencia cardíaca (NYHA II-IV) y fracción de eyección del ventrículo izquierdo =40 % (FEVI =40 %).	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Ensayo clínico fase Ib, multicéntrico, doble ciego, aleatorizado, controlado con placebo y con titulación de dosis para evaluar la seguridad, la tolerabilidad y la farmacocinética del tratamiento de 4 semanas con BAY 2413555, en participantes con insuficiencia cardíaca y desfibrilador automático implantable o dispositivos de resincronización cardíaca	CLINICAL TRIAL WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	I
A-03	Post-Authorization Safety Study (PASS): Revisión retrospectiva de las historias clínicas de los pacientes con HAP tratados recientemente con Uptravi® (selexipag) o cualquier otro tratamiento específico para la HAP	OBSERVATIONAL STUDY WITH DRUGS	VICTOR MANUEL BECERRA MUÑOZ	NA
A-03	Estudio en fase III, prospectivo, aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos y flexible con ampliación abierta para evaluar la eficacia y la seguridad de macitentán 75 mg en la hipertensión pulmonar tromboembólica crónica inoperable o persistente/recurrente. Macitentán en la hipertensión pulmonar tromboembólica crónica inoperable o persistente/recurrente (MACiTEPH)	COMMERCIAL CLINICAL TRIAL	VICTOR MANUEL BECERRA MUÑOZ	III
A-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y motivado por los acontecimientos para demostrar la eficacia y seguridad de milvexian, un inhibidor oral del factor XIa, después de padecer un síndrome coronario agudo reciente	CLINICAL TRIAL WITH DRUGS	MANUEL FRANCISCO JIMÉNEZ NAVARRO	III
A-03	A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation	CLINICAL TRIAL WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	Ш
A-03	Tratamiento de la fibrilación auricular en pacientes con hipertensión arterial que son tratados por ablación venosa pulmonar en combinación y con la denervación arterial renal o solo ablación venosa pulmonar. Estudio ASAF	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de vutrisirán en pacientes con amiloidosis cardiaca por transtiretina (amiloidosis por ATTR con miocardiopatía). HELIOS-B.	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III

Group	Title	Subtype	LR Name	Phase
A-03	Registo Prospectivo observacional de pacientes con enfermedad de Fabry. Sponsor Code: AT1001-030	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	LA
A-03	Estudio observacional retrospectivo del uso de evolocumab en unidades españolas de cardiología - RETrospective Observational Study of Evolocumab Use in Spanish Cardiology Units RETOSS-Cardio. 20160139	COMMERCIAL POST-AUTHORIZATION STUDY	ELOY CARLOS RUEDA CALLE	OD
A-03	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaLuar la eficacia y la seguridad de abeLacimab en pacientes de alto riesgo con fibrilación Auricular que no se consideren adecuados para la antiCoagulación oral (LILAC)	CLINICAL TRIAL WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	III
A-03	IMPAHCT: Estudio de fase IIb/III, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis de 24 semanas y confirmatorio para evaluar la seguridad y eficacia de AV-101 en pacientes con hipertensión arterial pulmonar (HAP)	CLINICAL TRIAL WITH DRUGS	VICTOR MANUEL BECERRA MUÑOZ	III
A-03	IMPAHCT-FUL: Estudio multicéntrico y de extensión a largo plazo de la seguridad de AV-101 en sujetos con hipertensión arterial pulmonar (HAP) que han completado el estudio AV-101-002	CLINICAL TRIAL WITH DRUGS	VICTOR MANUEL BECERRA MUÑOZ	III
A-03	Estudio sobre la PRevalencia de Amiloidosis Cardiaca por Transtiretina en pacientes con Insuficiencia CArdiaca con fracción de eyección preservada. Estudio PRACTICA	NON-POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	NO
A-03	Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria	INDEPENDENT CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	IV
A-03	Ensayo fase III multicéntrico, internacional, aleatorizado, controlado con un comparador activo, doble ciego, con doble simulación y 2 grupos paralelos, para comparar la eficacia y la seguridad del inhibidor oral de FXIa asundexian (BAY 2433334) con apixaban para la prevención del ictus o embolia sistémica en participantes masculinos y femeninos de 18 años o más con fibrilación auricular y riesgo de ictus.	CLINICAL TRIAL WITH DRUGS	ALEJANDRO ISIDORO PEREZ CABEZA	III
A-03	Evaluación de la eficacia de la Atorvastatina en la progresión de la dilatación aórtica y la degeneración valvular en pacientes con válvula aórtica bicúspide (BICATOR)	INDEPENDENT CLINICAL TRIAL	JUAN MANUEL ROBLEDO CARMONA	III
A-03	Precisión en la Monitorización de Pacientes con Insuficiencia Cardíaca mediante HeartLogic. PREEMPT-HF	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Estudio de fase 2, doble ciego, aleatorizado, controlado con placebo, de 4 grupos para estudiar los síntomas, la funcionalidad, la calidad de vida relacionada con la salud y la seguridad de la administración subcutánea repetida de ponsegromab comparado con placebo en participantes adultos con insuficiencia cardíaca.	CLINICAL TRIAL WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	П
A-03	Estudio de fase II, multicéntrico, aleatorizado, paralelo, de tres grupos y controlado con placebo para evaluar la eficacia y la seguridad de CDR132L en pacientes con fracción de eyección ventricular izquierda reducida (=45 %) después de un infarto de miocardio (HF-REVERT)	INDEPENDENT CLINICAL TRIAL	JUAN JOSÉ GÓMEZ DOBLAS	II
A-03	Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa el impacto de inclisirán en los acontecimientos cardiovasculares adversos mayores (MACE) en participantes con enfermedad cardiovascular establecida (ECV) (VICTORION-2 PREVENT)	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	Ш
A-03	Ensayo prospectivo de INRA frente a inhibidor de la ECA para determinar la superioridad en reducir los acontecimientos de insuficiencia cardíaca tras infarto de miocardio. Estudio multicéntrico, aleatorizado, doble ciego, controlado con tratamiento activo, de grupos paralelos, de fase 3 para evaluar la eficacia y seguridad de LCZ696 comparado con ramipril en la morbimortalidad en pacientes de alto riesgo tras un infarto agudo de miocardio. PARADISE-MI:	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Estudio multicntrico, aleatorizado, doble ciego (paciente e investigador) y controlado con placebo para estudiar la eficacia de sacubitrilo/valsartán por vía oral en pacientes adultos con miocardiopatía hipertrófica no obstructiva (MCH no obstructiva).	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	П
A-03	Estudio aleatorizado, doble ciego (participante e investigador) y controlado con placebo en el que se investigan la eficacia, la seguridad y la tolerabilidad de LTP001 en participantes con hipertensión arterial pulmonar.	CLINICAL TRIAL WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II

Group	Title	Subtype	LR Name	Phase
A-03	Estudio de extensión abierto en el que se investigan la eficacia, la seguridad y la tolerabilidad de LTP001 en participantes con hipertensión arterial pulmonar	CLINICAL TRIAL WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Observación de la Asistencia Clínica Habitual en los pacientes con insuficiencia cardiaca y dispositivos de TRC BIOTRONIK implantados	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Mayor respuesta a la terapia de resicronizacion cardiaca (TRC) con Estimulacion Multisitio. MORE-CRT MPP	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Crioablación de venas pulmonares vs fármacos antiarrítmicos en fibrilación auricular persistente (CRAFT)	INDEPENDENT CLINICAL TRIAL	ALBERTO BARRERA CORDERO	IV
A-03	Eficacia de choque de cardioversión/desfibrilación, un estudio aleatorizado que compara la Pendiente Fija y la Anchura de Impulso Fija en una población general con desfibrilador automático implantable, EFICAZ.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Xience 28 Global Study	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	Sync Av estudio post-comercializacion	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Seguimiento clínico retrospectivo, prospectivo y multicéntrico de pacientes con regurgitación tricúspidea severa tras tratamiento con el sistema de válvulas bicavales transcatéter TricValve TRICUS REGISTRY	OBSERVATIONAL STUDY WITH DRUGS	JOSÉ MARÍA HERNÁNDEZ GARCÍA	NA
A-03	VIVA Estudio pivotal/de viabilidad de primera aplicación en seres humanos (PASH) en dos fases del sistema autoexpandible de válvula aórtica Vienna	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	JOSÉ MARÍA HERNÁNDEZ GARCÍA	NA
A-03	Estudio clínico aleatorizado, doble ciego y controlado con placebo para evaluar mavacamten en adultos con cardiomiopatía hipertrófica sintomática no obstructiva	CLINICAL TRIAL WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Estudio preliminar en fase IIa, abierto para evaluar la eficacia, la farmacocinética, la farmacodinámica, la seguridad y la tolerabilidad de MYK-224 en participantes con miocardiopatía hipertrófica sintomática y obstrucción del conducto de salida del ventriculo izquierdo	CLINICAL TRIAL WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	Ш
A-03	Estudio de fase 2b, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento por vía oral con AZD9977 y dapagliflozina en pacientes con insuficiencia cardíaca (con fracción de eyección del ventrículo izquierdo por debajo del 55%) y nefropatía crónica (MIRACLE)	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	II
A-03	Estudio en fase IV, de doble ciego, controlado con placebo, de retirada aleatorizada, para evaluar el uso de ciclosilicato de sodio y zirconio (CSZ) para el tratamiento de la hiperpotasemia en pacioentes con insuficiencia cardíaca sintomática con fracción de eyección reducida y que reciben espironolactona (REALIZE-K)	CLINICAL TRIAL WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	IV
A-03	Registro prospectivo, de brazo único, multicéntrico, observacional, de utilización de stent liberador de zotarolimus RESOLUTE-ONYXTM en el intervencionismo coronario percutáneo en vasos pequeños	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	Modulación de la Contractilidad Cardíaca (CCM©) en Pacientes con Insuficiencia Cardíaca en Andalucía. Registro DOLMEN ART-VIII-2018	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Estudio no intervencionista sobre el tratamiento con edoxabán en la práctica clínica habitual para pacientes con fibrilación auricular no valvular (ETNA-AF-Europe)	COMMERCIAL POST-AUTHORIZATION STUDY	JUAN JOSÉ GÓMEZ DOBLAS	SP
A-03	Estudio observacional para evaluar el beneficio clínico neto del edoxabán en pacientes con fibrilación auricular no valvular, según la práctica clínica habitual en España Registro BENEFIT. Observational study to evaluate the Net Clinical Benefit of edoxaban in non-valvular Atrial Fibrillation patients, according to the routine clinical practice in Spain BENEFIT Registry	COMMERCIAL POST-AUTHORIZATION STUDY	ALEJANDRO ISIDORO PEREZ CABEZA	OD

Group	Title	Subtype	LR Name	Phase
A-03	Inicio temprano de tratamiento con Candesartan vs Placebo en portadores genéticos de mutaciones causales de MCD sin evidencia de enfermedad (EARLY-GENE trial).	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Concordancia entre FFR e iFR para la valoración de lesiones intermedias en el tronco común izquierdo. Aplicación prospectiva de un valor de iFR predefinido para la valoración de lesiones intermedias en el tronco común izquierdo. Estudio iLITRO.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	Registo prospectivo, de brazo único, multicéntrico, observacional para la evaluación de la seguridad y eficacia del Stent Ultimaster Tnasei en pacientes con lesiones coronarias complejas. Estudio TANSEI	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	Registro prospectivo del stent ihtDEStiny en práctica clínica habitual(Estudio VELAZQUEZ)	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	JOSÉ MARÍA HERNÁNDEZ GARCÍA	NA
A-03	IMPACTO DE DAPAGLIFOZINA EN EL REMODELADO AURICULAR DE PACIENTES CON INSUFICIENCIA CARDIACA: MODA study	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo de FDY-5301 intravenoso en pacientes con infarto de miocardio con elevación del segmento ST anterior. IOCYTE AMI-3	COMMERCIAL CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	Ш
A-03	Estudio intervencionista posterior a la comercialización del sistema CoreValve Evolut PRO	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	DIFERENCIAS DE GÉNERO EN EL MANEJO TEMPRANO Y POSTERIOR AL ALTA DESPUÉS DE UN INFARTO AGUDO DE MIOCARDIO-GENAMI PREVENTION	OBSERVATIONAL STUDY WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	NA
A-03	Insuficiencia cardíaca Reducción de eventos con Monitorización Remota y Soporte de Salud Iniciada por el investigador. (Heart failure Events reduction with Remote Moni toring and eHealth Support Investigator Initiated Trial)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MANUEL GARCÍA PINILLA	0
A-03	Tratamiento cardiovascular y renal en pacientes con insuficiencia cardíaca con hiperpotasemia o con alto riesgo de hiperpotasemia (CARE-HK en el registro de IC)	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	OD
A-03	COVID-19 en pacientes con insuficicnecia cardiaca y cardiopatías familiares. CDC	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	AS
A-03	Beneficio del bloqueo del sistema renina-angiotensina sobre la evolución clínica y el remodelado ventricular tras la colocación de una prótesis percutánea aórtica	INDEPENDENT CLINICAL TRIAL	JUAN HORACIO ALONSO BRIALES	IV
A-03	Eficacia de la transposición de un pedículo adiposo pericárdico sobre el infarto de miocardio en pacientes (AGTP II trial).)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MANUEL FRANCISCO JIMÉNEZ NAVARRO	0
A-03	New pathophysiological pathways involved in iron metabolism disorder in hear failure: The IRON PATH II investigator initiated Study.	OBSERVATIONAL STUDY WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	NA
A-03	Retirada de tratamiento farmacologico en pacientes respondedores a terapia de resincronización cardiaca: Estudio abierto y aleatorizado	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	IV
A-03	Estudio de fase 2, aleatorizado, con enmascaramiento doble, comparativo con un placebo, para investigar la eficacia y la seguridad de LY3540378 en adultos con empeoramiento de la insuficiencia cardíaca crónica con fracción de eyección preservada (ICFEp)	CLINICAL TRIAL WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	П
A-03	Efectividad de la titulación de fármacos por la enfermera especializada en pacientes de Insuficiencia Cardiaca (IC). Proyecto ETIFIC (Enfermera Titular Fármacos en IC).	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	AS
A-03	LCZ696 en pacientes con insuficiencia cardiaca con fracción de eyección deprimida y elevada comorbilidad: efecto en el remodelado y fibrosis de ventrículo izquierdo valorado por nuevos biomarcadores de insuficiencia cardiaca y resonancia magnética cardíaca.	INDEPENDENT CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	IV
A-03	Seguridad y rendimiento de las Sondas DF4 ventriculares invicta con fijación activa. Estudio APOLLO	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ALBERTO BARRERA CORDERO	0
A-03	Evaluación de seguridad y comportamiento eléctrico de las sondas INVICTA equipadas con conector DF4. FRIENDS	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ALBERTO BARRERA CORDERO	0

Group	Title	Subtype	LR Name	Phase
A-03	Registro Observacional prospectivo de pacientes con implante de stent bioabsorbible de magnesio MAGMARIS ES en la práctica clínica habitual	NON-POST-AUTHORIZATION STUDY	JOSÉ MARÍA HERNÁNDEZ GARCÍA	NO
A-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de la eficacia y seguridad del espray nasal de etripamil para la resolución de episodios espontáneos de taquicardia supraventricular paroxística. El estudio RAPID (NODE-301 Parte 2)	COMMERCIAL CLINICAL TRIAL	MARÍA DEL CARMEN MEDINA PALOMO	III
A-03	Estudio aleatorizado, simple ciego, para demostrar la seguridad y la eficacia de la terapia corticosteroidea a altas dosis para tratar pacientes con miocarditis aguda complicada/fulminante. (Single blind randomized controlled trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant acute myocarditis)	CLINICAL TRIAL WITH DRUGS	JOSÉ MANUEL GARCÍA PINILLA	III
A-03	Non-vitamin K antagonist Oral anticoagulants in patients with Atrial high rate episodes	INDEPENDENT CLINICAL TRIAL	JUAN JOSÉ GÓMEZ DOBLAS	III
A-03	Estudio de resultados clínicos del NVT ALLEGRA TAVI System TF en pacientes tratados con válvulas aórticas calcificadas en la vida real en una población de pacientes con riesgo quirúrgico elevado (FOLLOW)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	nvEstigation of the safety and perforMance of the NVT ALLEGRA THV System with a new delivery system in Patients with severe calcified aortic stenosis or failed suRgical aortic bioprosthEsis	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	JOSÉ MARÍA HERNÁNDEZ GARCÍA	NA
A-03	Prevalencia en España de mal control de la anticoagulación en pacientes con fibrilación auricular 'no valvular' tratados con antagonistas de la Vitamina K. (20230228)	OBSERVATIONAL STUDY WITH DRUGS	ALEJANDRO ISIDORO PEREZ CABEZA	NA
A-03	OpSens dPR para la evaluación fisiológica de lesiones coronarias iintermedias en estenosis aórtica.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	Estudio de fase III multicéntrico, abierto y de un solo grupo de PB2452 en pacientes tratados con ticagrelor con hemorragia mayor o potencialmente mortal no controlada o que requieran una intervención quirúrgica o un procedimiento invasivo urgentes	COMMERCIAL CLINICAL TRIAL	JUAN JOSÉ GÓMEZ DOBLAS	Ш
A-03	Tratamiento antiplaquetario único con ticagrelor frente a aspirina después del implante percutáneo de válvula aórtica: ensayo clínico aleatorizado multicéntrico. REAC TAVI 2	CLINICAL TRIAL WITH DRUGS	ANTONIO JESÚS MUÑOZ GARCÍA	IV
A-03	Registro Nacional de Pacientes con Insuficiencia Cardíaca tratados con Modulación de la Contractilidad Cardíaca en España	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Plan de investigación de seguimiento clínico de poscomercialización (PMCF) para evaluar la seguridad y efectividad clínica de los dispositivos iVascular para el tratamiento de las enfermedades coronarias	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	JUAN HORACIO ALONSO BRIALES	NA
A-03	Registro Español de pacientes portadores de dispositivos cardiacos implantables que requieran una prueba de imagen diagnóstica con Resonancia Magnética Nuclear	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Estudio observacional de terapias inapropiadas tras recambio de DAI. Estudio OSIRIS	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	AMALIO RUIZ SALAS	0
A-03	Registro PERSEO: Prevención de eventos Embólicos tras una hemoRragia SEvera en pacientes anticoagulados con fibrilaciOn auricular.	OBSERVATIONAL STUDY WITH DRUGS	ALEJANDRO ISIDORO PEREZ CABEZA	NA
A-03	Un registro multicéntrico para evaluar la calidad del tratamiento antitrombótico en pacientes con fibrilación auricular y cáncer activo. Registro CANAC-FA (CÁNcer ACtivo y Fibrilación Auricular):	INDEPENDENT POST-AUTHORIZATION STUDY	ALEJANDRO ISIDORO PEREZ CABEZA	OD
A-03	SAvvyWire TM Eficacia y seguridad en los procedimientos de implantación transcatéter de válvulas aórticas.	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	ANTONIO JESÚS MUÑOZ GARCÍA	NA
A-03	Dapagliflozina después del implante de prótesis valvular aórtica percutánea. DAPATAVI	INDEPENDENT CLINICAL TRIAL	ANTONIO JESÚS MUÑOZ GARCÍA	III
A-03	SEC-FA-2022-1 Registro SEC-EXCELENTE FA: una herramienta para la mejora de la calidad de la atención médica a pacientes con fibrilación auricular en España.	OBSERVATIONAL STUDY WITH DRUGS	ALEJANDRO ISIDORO PEREZ CABEZA	NA
A-03	Registro Observacional Prospectivo de Pacientes con Insuficiencia Cardíaca	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MANUEL GARCÍA PINILLA	SP

Group	Title	Subtype	LR Name	Phase
A-03	Estudio prospectivo, aleatorizado, multicéntrico, abierto, guiado por eventos, para evaluar la no inferioridad de una estrategia personalizada de precisión para la prevención de la muerte súbita en pacientes con miocardiopatía dilatada no isquémica. ESTUDIO CIBER-SPANISH I.	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	JOSÉ MANUEL GARCÍA PINILLA	NA
A-03	Eficacia y Seguridad de la Furosemida Intravenosa administrada con Suero Salino Hipertónico en el Hospital de día de Insuficiencia Cardiaca. Estudio SSH-IC	COMMERCIAL CLINICAL TRIAL	JOSÉ MANUEL GARCÍA PINILLA	IV
A-03	Sustitución quirúrgica e implantación percutánea de válvula aórtica	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA HERNÁNDEZ GARCÍA	0
A-03	Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies.	CLINICAL TRIAL WITH DRUGS	JUAN JOSÉ GÓMEZ DOBLAS	III
A-03	Prevención de terapias inapropiadas y eventos adversos cardiacos y cerebrovasculares graves con un Desfibrilador Automático Implantable monocameral con detección auricular con dipolo flotante DX. Estudio PREVENT DX	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	FRANCISCO JAVIER ALZUETA RODRÍGUEZ	0
A-03	Registro prospectivo, multicéntrico e internacional de pacientes de ambos sexos con diagnóstico recientes de fibrilación auricular (GARFIELD)	INDEPENDENT POST-AUTHORIZATION STUDY	MANUEL FRANCISCO JIMÉNEZ NAVARRO	SP
A-03	Estrategia de cruzar dos técnicas de ablación (Criobalón y Radiofrecuencia) tras la recurrencia de FA paroxística y la necesidad de un nuevo procedimiento. X-TRA (Cross therapy for Re-Do Ablation)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ALBERTO BARRERA CORDERO	0
A-06	Estudio de seguridad post autorización PASS: estudio observacional de cohorte con pacientes HAP tratados por primera vez con Uptravi selexipag u otra terapia específica contra la hipertensión arterial pulmonar HAP en la práctica clínica. EXPOSURE, AC-065A401	COMMERCIAL POST-AUTHORIZATION STUDY	MARIA DEL MAR AYALA GUTIÉRREZ	LA
A-06	Estudio de fase IV, multicéntrico, aleatorizado, doble ciego y controlado con placebo de la eficacia, seguridad, tolerabilidad y calidad de vida de un tratamiento en curso hipolipemiante, optimizado individualmente, con o sin inclisirán (KJX839), en participantes con hipercolesterolemia.	COMMERCIAL CLINICAL TRIAL	SERGIO JANSEN CHAPARRO	IV
A-06	Estudio muilticéntrico, aleatoriazdo, doble ciegoy controlado con placebo ene l que se evalúa el efecto de inclisirán en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-PREVENT)	CLINICAL TRIAL WITH DRUGS	SERGIO JANSEN CHAPARRO	III
A-06	Prevención y tratamiento con Calcifediol del síndrome respiratorio agudo (SARS) inducido por Coronavirus COVID-19 (COVID-19)	INDEPENDENT CLINICAL TRIAL	RICARDO GÓMEZ HUELGAS	II
A-06	Valoración del manejo y adecuación del tratamiento antitrombótico de los pacientes con Fibrilación Auricular No Valvular que ingresan en los Servicios de Medicina Interna de España.	COMMERCIAL POST-AUTHORIZATION STUDY	MARIA GUIL GARCIA	0
A-06	Seguridad de edoxabán en pacientes con fibrilación auricular no valvular (FANV) y diabetes mellitus tipo 2 (DM2). SEMI-FADIA-2020	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA GUIL GARCIA	SP
A-06	Evaluación de la seguridad de Edoxabán en pacientes ancianos con criterios de fragilidad	OBSERVATIONAL STUDY WITH DRUGS	RICARDO GÓMEZ HUELGAS	NA
A-06	Prevención temprana de complicaciones por diabetes en personas con hiperglucemia en Europa (e-PREDICE)	INDEPENDENT CLINICAL TRIAL	RICARDO GÓMEZ HUELGAS	III
A-06	Cribado de la enfermedad de Pompe de inicio tardío mediante muestra de sangre seca de pacientes provenientes de Unidades de Medicina Interna. Estudio POMPE	NON-POST-AUTHORIZATION STUDY	IVÁN PÉREZ DE PEDRO	NO
A-06	Efectos de semaglutida sobre la capacidad funcional en pacientes con diabetes tipo 2 y arteriopatía periférica	COMMERCIAL CLINICAL TRIAL	MARIA DOLORES LÓPEZ CARMONA	III
A-06	Prevención de infección por COVID19 mediante administración de hidroxicloroquina en mayores institucionalizados y personal asistencial de residencias. Ensayo clínico controlado, abierto y aleatorizado escalonado (stepped-wedge) por clusters. CDC	INDEPENDENT CLINICAL TRIAL	RICARDO GÓMEZ HUELGAS	III

Group	Title	Subtype	LR Name	Phase
A-06	Estrategias de control y estudio farmacogenético para el tratamiento personalizado del hígado graso asociado a disfunción metabólica en pacientes con prediabetes.	INDEPENDENT CLINICAL TRIAL	RICARDO GÓMEZ HUELGAS	III
A-06	Registro de la Sociedad española de Medicina Interna (SEMI) de pacientes hospitalizados por COVID-19	NON-POST-AUTHORIZATION STUDY	RICARDO GÓMEZ HUELGAS	NO
A-06	Registro de pacientes con enfermedad del Hígado graso no alcohólico	NON-POST-AUTHORIZATION STUDY	SERGIO JANSEN CHAPARRO	NO
A-06	Estudio de fase II, prospectivo, en doble ciego, aleatorizado, de grupos paralelos, controlado con placebo y multicéntrico, para investigar la eficacia, el efecto neutralizador de los autoanticuerpos frente a los receptores acoplados a la proteína G (GPCR), la seguridad y la tolerabilidad del BC 007 en participantes con COVID-19 persistente	CLINICAL TRIAL WITH DRUGS	RICARDO GÓMEZ HUELGAS	II
A-09	"Estudio de fase 2b, multinacional, aleatorizado y doble ciego para investigar la eficacia y la seguridad de redasemtide (S-005151) comparado con placebo en pacientes mayores de edad con ictus isquémico agudo que no son candidatos a tratamiento con activador tisular del plasminógeno o trombectomía"	CLINICAL TRIAL WITH DRUGS	ALEJANDRO GALLARDO TUR	II
A-09	Estudio de seguridad posterior a la autorización y registro de producto de WAYLIVRA. (WAY4001)	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO VALDIVIELSO FELICES	LA
A-09	Revisión observacional en serie de historias clínicas del uso de Repath® en sujetos europeos con hiperlipidemia (20130296)	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	SP
A-09	Estudio multicéntrico, aleatorizado y de dos partes (inclisirán doble ciego frente a placebo [año 1] y a continuación inclisirán abierto [año 2]) para evaluar la seguridad, tolerabilidad y eficacia de inclisirán en adolescentes (de 12 a menos de 18 años de edad) con hipercolesterolemia familiar heterocigótica y colesterol LDL elevado (ORION-16).	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	III
A-09	Estudio epidemiológico, multicéntrico y transversal para caracterizar la prevalencia y distribución de los niveles de lipoproteína (a) en pacientes con enfermedad cardiovascular establecida.	NON-POST-AUTHORIZATION STUDY	PEDRO VALDIVIELSO FELICES	NO
A-09	Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar el efecto de la disminución de la lipoproteína (a) con TQJ230 sobre los acontecimientos cardiovasculares mayores en pacientes con enfermedad cardiovascular (ECV) establecida.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	III
A-09	Valoración del manejo y adecuación del tratamiento antitrombótico de los pacientes con Fibrilación Auricular No Valvular que ingresan en los Servicios de Medicina Interna de España.	COMMERCIAL POST-AUTHORIZATION STUDY	MARIA JOSE BENITEZ TOLEDO	0
A-09	Tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención de eventos cardiovasculares en Europa - Estudio Multinacional Observacional. Estudio SANTORINI (DSE-HCL-01-19)	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO VALDIVIELSO FELICES	SP
A-09	Seguridad de edoxabán en pacientes con fibrilación auricular no valvular (FANV) y diabetes mellitus tipo 2 (DM2). SEMI-FADIA-2020	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA JOSE BENITEZ TOLEDO	SP
A-09	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CARLOS DE LA CRUZ COSME	0
A-09	Estudio multicéntrico sobre comorbilidad no infecciosa e inmunodeficiencia común variable	INDEPENDENT POST-AUTHORIZATION STUDY	JUAN LUIS CARRILLO LINARES	OD
A-09	Estudio de fase 3, aaleatorizado, doble ciego, controlado con placebo, de olezarsen (ISIS678354) asministrado por vía subcutánea a pacientes con hipertrigliceridemia grave.	CLINICAL TRIAL WITH DRUGS	PEDRO VALDIVIELSO FELICES	III
A-09	Estudio de fase III, aleatorizado, doble ciego, comparativo con placebo, de olezarsén (ISIS 679354) en pacientes con hipertrigliceridemia y enfermedad cardiovascular ateroesclerótica (establecida o con mayor riesgo de ella), o con hipertrigliceridemia grave	CLINICAL TRIAL WITH DRUGS	PEDRO VALDIVIELSO FELICES	Ш
A-09	Registro de pacientes con enfermedad del Hígado graso no alcohólico	NON-POST-AUTHORIZATION STUDY	PEDRO VALDIVIELSO FELICES	NO
A-09	Registro informatizado de la enfermedad tromboembólica (RIETE)	NON-POST-AUTHORIZATION STUDY	RADKA IVANOVA GIORGIEVA	NO
A-09	Manejo del paciente dislipémico pre-diabético en las unidades de lípidos. Estudio PRELIPID	INDEPENDENT POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL SÁNCHEZ CHAPARRO	OD

Group	Title	Subtype	LR Name	Phase
A-09	Obicetrapib añadido a tratamientos modificadores de los lípidos máximos tolerados (BROOKLYN): Estudio de fase 3, aleatorizado, con doble enmascaramiento y comparativo con placebo para evaluar el efecto de 10?mg de obicetrapib en participantes con antecedentes de HFHe y C-LDL =70?mg/dl no controlados adecuadamente con sus tratamientos modificadores de los lípidos	CLINICAL TRIAL WITH DRUGS	PEDRO VALDIVIELSO FELICES	III
A-19	Estudio de seguimiento para evaluar la seguridad y los resultados a largo plazo en lactantes nacidos de madres que participaron en los estudios de tratamiento con retosibán	COMMERCIAL CLINICAL TRIAL	TOMÁS SÁNCHEZ TAMAYO	III
A-19	Ensayo de extensión de seguridad de 18 meses, abierto y de un solo brazo, de un régimen de finerenona oral, ajustado por edad y peso corporal, añadido a un IECA o ARA II para el tratamiento de pacientes pediátricos y adultos jóvenes de 1 a 18 años con enfermedad renal crónica y proteinuria.	CLINICAL TRIAL WITH DRUGS	VERONICA MARTINEZ RIVERA	Ш
A-19	Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al Virus Respiratorio Sincitial (VRS), administrada por vía IM a gestantes de 18 a 49 años de edad, para la prevención de la Enfermedad vías respiratorias Bajas (EVRB) asociada al VRS en sus hijos hasta los 6 meses de edad. RSV-MAT-009	COMMERCIAL CLINICAL TRIAL	BEGOÑA CARAZO GALLEGO	Ш
A-19	Estudio de cohortes prospectivo, observacional, de canasta e integral de niños y adolescentes menores de 18 años con anemia asociada a la enfermedad renal crónica que requieren o no diálisis.	OBSERVATIONAL STUDY WITH DRUGS	FRANCISCO ANTONIO NIETO VEGA	NA
A-19	Estudio integral, en canasta, abierto, sobre la seguridad y la farmacocinética de Daprodustat para tratar la anemia asociada a la enfermedad renal crónica en niños y adolescentes de ambos sexos de entre 3 meses y menos de 18 años, necesiten o no diálisis.	CLINICAL TRIAL WITH DRUGS	FRANCISCO ANTONIO NIETO VEGA	Ш
A-19	Estudio multicéntrico, abierto, de búsqueda de dosis, de dosis única y múltiples, con una extensión abierta opcional para evaluar la seguridad, tolerabilidad y farmacocinética del ácido obeticólico en sujetos pediátricos con atresia biliar	COMMERCIAL CLINICAL TRIAL	JAVIER BLASCO ALONSO	П
A-19	Estudio de inducción abierto y de mantenimiento de CP-690,550 (Tofacitinib) oral en niños con colitis ulcerosa de moderada a gravemente activa	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	Ш
A-19	Un registro no intervencionista a largo plazo para evaluar la seguridad y efectividad de HUMIRA (adalimumab) en pacientes pediátricos con enfermedad de Crohn (EdC) activa entre moderada y grave (CAPE). P11-292	COMMERCIAL POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	LA
A-19	Alergopediátrica. Estudio epidemiológico de las enfermedades alérgicas pediátricas en España	CLINICAL TRIAL WITH DRUGS	CANDELARIA MUÑOZ ROMAN	NA
A-19	Registro observacional sobre la enfermedad y los resultados clínicos de pacientes con deficiencia de lipasa ácida lisosomal (LAL)	NON-POST-AUTHORIZATION STUDY	JAVIER BLASCO ALONSO	NO
A-19	Estudio multicéntrico, aleatorizado, controlado, abierto y ciego para el evaluador para evaluar la eficacia, la seguridad, la farmacocinética y la farmacodinámica de ALXN1840 en comparación con el tratamiento habitual en participantes pediátricos con enfermedad de Wilson	COMMERCIAL CLINICAL TRIAL	RAFAEL MARTIN MASOT	Ш
A-19	Estudio con enmascaramiento doble, controlado con placebo, de aumento progresivo de la dosis ara evaluar la eficacia, la seguridad y la farmacocinética de la voclosporina en adolescentes con nefritis lúpica	COMMERCIAL CLINICAL TRIAL	FRANCISCO ANTONIO NIETO VEGA	Ш
A-19	Ensayo de 6 meses multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad, farmacocinética y farmacodinámica de un régimen de finerenona oral, ajustado por edad y peso corporal, añadido a un IECA o ARA II para el tratamiento de pacientes pediátricos de 6 meses a <18 años con enfermedad renal crónica y proteinuria	COMMERCIAL CLINICAL TRIAL	VERONICA MARTINEZ RIVERA	Ш
A-19	Estudio en fase III para evaluar la seguridad y farmacocinética de la profilaxis con berotralstat en niños de 2 a <12 años con angioedema hereditario	CLINICAL TRIAL WITH DRUGS	CANDELARIA MUÑOZ ROMAN	Ш
A-19	Estudio aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de taldefgrobep alfa en participantes ambulatorios y no ambulatorios con atrofia muscular espinal con extensión abierta (RESILIENT)	CLINICAL TRIAL WITH DRUGS	ROCIO CALVO MEDINA	III

Group	Title	Subtype	LR Name	Phase
A-19	Registro de Pfizer de los resultados en la investigación sobre la hormona del crecimiento (PROGRES) Estudio de cohortes prospectivo, no intervencionista e internacional entre pacientes con tratamientos con hormona del crecimiento humana (hGH) bajo atención clínica habitual	CLINICAL TRIAL WITH DRUGS	JUAN PEDRO LÓPEZ SIGUERO	NA
A-19	ESTUDIO DE FASE I, ABIERTO Y ALEATORIZADO PARA EVALUAR LA FARMACOCINÉTICA, LA FARMACODINAMIA Y LA SEGURIDAD DE ETROLIZUMAB SEGUIDO DE UNA EXTENSIÓN ABIERTA Y UNA VIGILANCIA DE LA SEGURIDAD EN PACIENTES PEDIÁTRICOS DE ENTRE 4 Y MENOS DE 18 AÑOS DE EDAD CON COLITIS ULCEROSA O ENFERMEDAD DE CROHN MODERADA O GRAVE	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	I
A-19	Estudio observacional y abierto en niños y adolescentes con asma grave con fenotipo eosinofílico tratados con mepolizumab. Estudio CASAM	REST OF OBSERVATIONAL STUDIES WITH DRUGS	PILAR CARO AGUILERA	OD
A-19	Estudio fase 3 aleatorizado, abierto, para evaluar la Eficacia, Seguridad y Farmacocinética del tratamiento de Golimumab, un anticuerpo humano monoclonal anti-TNFa, administrado por vía subcutánea en pacientes pediátricos con Colitis Ulcerosa activa de moderada a severa.	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	Manejo terapéutico y situación actual de uso de recursos y costes de la Atrofia Muscular Espinal (AME) en España: análisis retrospectivo, multicéntrico de revisión de historias clínicas" Estudio TREaSURE	CLINICAL TRIAL WITH DRUGS	ROCIO CALVO MEDINA	NA
A-19	Ensayo clínico aleatorizado doble ciego comparando noradrenalina más placebo versus noradrenalina más terlipresina en shock séptico	INDEPENDENT CLINICAL TRIAL	PILAR CARO AGUILERA	III
A-19	Estudio en fase II/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en niños de alto riesgo (MEDLEY)	COMMERCIAL CLINICAL TRIAL	PILAR CARO AGUILERA	III
A-19	Estudio en fase II/III aleatorizado, doble ciego, controlado con palivizumab para evaluar la seguridad de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en niños de alto riesgo (MEDLEY)	COMMERCIAL CLINICAL TRIAL	JOSE DAVID MARTINEZ PAJARES	III
A-19	Estudio de Fase III, Abierto y Multicéntrico para Evaluar la Eficacia y Seguridad de Darvadstrocel en el Tratamiento de la Fístula Perianal Compleja en Población Pediátrica con Enfermedad de Crohn Durante 24 Semanas y un período de seguimiento extendido de hasta 52 semanas	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	Estudio Fase IIb, 2-brazos, aleatorizado, Doble-ciego, Placebo-Controlado, Multicéntrico para Optimizar la terapia de Diamyd [®] Administrada dentro de los ganglios linfáticos combinados con la vitamina D oral para investigar el impacto en la progresión de la diabetes tipo 1.	COMMERCIAL CLINICAL TRIAL	JUAN PEDRO LÓPEZ SIGUERO	II
A-19	Investigación integrada y guías para diagnóstico y terapia estandarizados de tumores de riñón en niños, adolescentes y adultos jóvenes. UMBRELLA SIOP-RTSG 2016	NON-POST-AUTHORIZATION STUDY	GUIOMAR GUTIERREZ SCHIAFFINO	NO
A-19	Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de 2 partes, para evaluar pautas de tratamiento de EDP-938 en pacientes de 28 días a 24 meses de edad con infección por el virus respiratorio sincitial (VRS) RSVPEDs	COMMERCIAL CLINICAL TRIAL	PILAR CARO AGUILERA	II
A-19	Kuvan Adult Maternal Pediatric European Registry (KAMPER)	NON-POST-AUTHORIZATION STUDY	JAVIER BLASCO ALONSO	NO
A-19	European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	П
A-19	Un estudio global para niños y adultos con Rabdomiosarcoma recién diagnosticado y recidivante. FaR-RMS	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	I
A-19	Validación de la dosis única diaria de isoniazida a 10 mg/kg de peso en el lactante menor de 3 meses de vida.	INDEPENDENT POST-AUTHORIZATION STUDY	DAVID MORENO PÉREZ	OD
A-19	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. GIS-DUMBO-2018	INDEPENDENT POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	AS
A-19	Beneficio de los programas de transición de pediatría a gastroenterólogos de adultos en pacientes con enfermedad inflamatoria intestinal. Estudio BUTTERFLY	INDEPENDENT POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	OD

Group	Title	Subtype	LR Name	Phase
A-19	Ensayo aleatorizado y doble ciego de fase IIIb para evaluar la seguridad y la eficacia de 2 regímenes de tratamiento con Aztreonam 75 mg polvo y disolvente para solución para inhalación por nebulizador / Aztreonam solución para inhalación (AZLI) en pacientes pediátricos con fibrosis quística (FQ) e infección/colonización de las vías respiratorias por Pseudomonas aeruginosa (PA) de nueva aparición	COMMERCIAL CLINICAL TRIAL	ESTELA PÉREZ RUIZ	III
A-19	Ensayo clínico para evaluar la eficacia y seguridadd de la adición de la granulocitoféresis al tratamiento con Infliximab en pacientes pediátricos con colitis ulcerosa corticorresistente	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	VÍCTOR MANUEL NAVAS LÓPEZ	0
A-19	Estudio abierto, aleatorizado, controlado en grupos paralelos para evaluar la seguridad, la farmacocinética y el control de amonio de RAVICTI® (fenilbutirato de glicerol [GPB]) líquido oral y del fenilbutirato de sodio (NaPBA) en pacientes que padecen trastornos del ciclo de la urea (TCU) y que no han recibido previamente tratamiento con fenilbutirato	COMMERCIAL CLINICAL TRIAL	JAVIER BLASCO ALONSO	III
A-19	Estudio multicéntrico, sin enmascaramiento, con un grupo de referencia con adalimumab, para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de ixekizumab por vía subcutánea en niños con los subtipos de artritis idiopática juvenil: artritis relacionada con entesitis (incluida la espondilitis anquilosante de aparición durante la infancia) y artritis psoriásica juvenil	COMMERCIAL CLINICAL TRIAL	ESMERALDA NUÑEZ CUADROS	III
A-19	Observational multicentre RWE study to characterize neurofibromatosis type1 (NF1) diagnosed patients with plexiform neurofibromas (PN) in Spain. "MULtyMAtin Study	CLINICAL TRIAL WITH DRUGS	LAURA GARCIA HIDALGO	NA
A-19	Marcadores genéticos, transcriptómicos y celulares de respuesta a terapia biológica en enfermedad inflamatoria intestinal pediátrica	INDEPENDENT POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	AS
A-19	LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	II
A-19	A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated with Distributive Shock	COMMERCIAL CLINICAL TRIAL	ANTONIO MORALES MARTINEZ	II
A-19	Factores farmacogenómicos y monitorización terapéutica como predictores de respuesta a anti-TNFs en enfermedad inflamatoria intestinal en niños	INDEPENDENT POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	AS
A-19	Estudio de fase 3 multicéntrico para evaluar la eficacia, seguridad y farmacocinética de la inducción de upadacitinib en régimen abierto, aleatorizado, mantenimiento doble ciego y extensión abierta a largo plazo en sujetos pediátricos con colitis ulcerosa activa de moderada a severa y con respuesta insuficiente, intolerancia o contraindicaciones médicas al tratamiento con corticosteroides, inmunosupresores o terapias biológicas.	CLINICAL TRIAL WITH DRUGS	RAFAEL MARTIN MASOT	III
A-19	Phase 3 multicenter study to evaluate the pharmacokinetics, efficacy and safety of risankizumab in open-label induction period, randomized double-blind maintenance and long-term extension periods in pediatric patients (aged 2 to < 18 years) with moderate to severe active Crohn's disease	CLINICAL TRIAL WITH DRUGS	PILAR ORTIZ PEREZ	III
A-19	Estudio de fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de vedolizumab intravenoso como tratamiento de mantenimiento en pacientes pediátricos con colitis ulcerosa activa moderada a grave que lograron una respuesta clínica después del tratamiento intravenoso abierto con vedolizumab	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	Estudio de fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de vedolizumab intravenoso como tratamiento de mantenimiento en pacientes pediátricos con enfermedad de Crohn activa moderada a grave que lograron una respuesta clínica después del tratamiento intravenoso abierto con vedolizumab	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	Ensayo de fase III, para evaluación de la eficacia y la seguridad de los comprimidos sublinguales de inmunoterapia frente a ácaros del polvo doméstico, en niños y adolescentes (de 5 a 17 años) con asma alérgica inducida por ácaros del polvo doméstico	COMMERCIAL CLINICAL TRIAL	CANDELARIA MUÑOZ ROMAN	III
A-19	Estudio observacional multicéntrico de pacientes con parálisis cerebral: aspectos neurológicos y nutricionales	NON-POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	NO

Group	Title	Subtype	LR Name	Phase
A-19	Efectos de la suplementación con probióticos durante el periodo neonatal sobre el recién nacido prematuro.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	TOMÁS SÁNCHEZ TAMAYO	0
A-19	Estudio prospectivo internacional de Meduloblastoma riesgo estándar clínico en niños de 3 a 5 años con perfil bajo de riesgo biológico (PNET 5 MB-LR) o perfil-medio de riesgo biologico (PNET 5 MB-SR)	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	II
A-19	Ensayo Clínico Fase I para establecer la seguridad del uso de células mesenquimales troncales fetales alogénicas de cordón umbilical expandidas en pacientes prematuros con displasia broncopulmonar	INDEPENDENT CLINICAL TRIAL	TOMÁS SÁNCHEZ TAMAYO	1
A-19	Ensayo Clínico Fase II para establecer la seguridad del uso de células mesenquimales troncales fetales alogénicas de cordón umbilical expandidas en pacientes prematuros con displasia broncopulmonar	CLINICAL TRIAL WITH DRUGS	NATALIA SALDAÑA GARCÍA	II
A-19	Ensayo internacional, aleatorizado y controlado de quimioterapia para el tratamiento del sarcoma de Ewing recurrente o refractario	INDEPENDENT CLINICAL TRIAL	LAURA GARCIA HIDALGO	II
A-19	Ensayo internacional pediátrico en tumor hepático	INDEPENDENT CLINICAL TRIAL	GUIOMAR GUTIERREZ SCHIAFFINO	III
A-19	Registro español informatizado de pacientes con Bronquiectasias	NON-POST-AUTHORIZATION STUDY	ESTELA PÉREZ RUIZ	NO
A-19	Diseño y validación psicométrica de un conjunto de cuestionarios "Toolbox" para evaluar los resultados de salud en atrofia muscular espinal desde el punto de vista del paciente. Estudio SMA TOOL. Spnosor protocol code: ML41962	NON-POST-AUTHORIZATION STUDY	ROCIO CALVO MEDINA	NO
A-19	VIGILANCIA POSTCOMERCIALIZACIÓN PARA CONTROLAR LA SEGURIDAD Y EFICACIA A LARGO PLAZO DE OMNITROPE EN NIÑOS Y ADOLESCENTES (PATRO CHILDREN)	COMMERCIAL POST-AUTHORIZATION STUDY	JUAN PEDRO LÓPEZ SIGUERO	LA
A-19	Registro ALERGODATA	INDEPENDENT POST-AUTHORIZATION STUDY	CANDELARIA MUÑOZ ROMAN	SP
A-19	Estudio aleatorizado con control activo para comparar la eficacia y la seguridad de isoflurano inhalado administrado mediante el dispositivo AnaConDa-S (dispositivo de conservación de anestésico) con midazolam intravenoso para la sedación en pacientes pediátricos con ventilación mecánica de entre 3 y 17 años (menos de 18 años). IsoCOMFORT Study	COMMERCIAL CLINICAL TRIAL	PILAR SÁNCHEZ YAÑEZ	III
A-19	Registro Nacional de pacientes con Diabetes tipo 1	INDEPENDENT POST-AUTHORIZATION STUDY	JUAN PEDRO LÓPEZ SIGUERO	OD
A-19	Estudio Nacional de vigilancia de infección nosocomial en UCI. (ENVIN-HELICS)	INDEPENDENT POST-AUTHORIZATION STUDY	PATRICIA GARCÍA SOLER	AS
A-19	Registro Español de Artritis Idiopática Juvenil Sistémica (AIJS) y Enfermedad de Still del Adulto	NON-POST-AUTHORIZATION STUDY	ESMERALDA NUÑEZ CUADROS	NO
A-19	Estudio postautorización de seguridad (EPAS) no intervencional para evaluar la seguridad a largo plazo del tratamiento con Orfadin en la Tirosinemia hereditaria tipo 1 (TH-1) en la práctica clínica estándar	COMMERCIAL POST-AUTHORIZATION STUDY	VÍCTOR MANUEL NAVAS LÓPEZ	SP
A-19	"ESTUDIO OBSERVACIONAL RETROSPECTIVO PARA EVALUAR EL MANEJO DIAGNÓSTICO Y TERAPÉUTICO DEL SÍNDROME DE NOONAN EN ESPAÑA/ RETROSPECTIVE OBSERVATIONAL STUDY TO ASSESS THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF NOONAN SYNDROME IN SPAIN	CLINICAL TRIAL WITH DRUGS	JUAN PEDRO LÓPEZ SIGUERO	NA
A-19	Estudio aleatorizado de fase III, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de la inmunoterapia epicutánea con DBV712 250 µg en niños de entre 4 y 7 años con alergia al cacahuete.	CLINICAL TRIAL WITH DRUGS	CANDELARIA MUÑOZ ROMAN	III
A-19	Estudio en fase 3, aleatorizado, enmascarado para el evaluador y multicéntrico para evaluar la eficiacia y seguridad de ALXN1840 administrado durante 48 semanas en comparación con el tratamiento de referencuia en pacientes con enfermedad de Wilson de 12 años de edad o más con un período de extensión de hasta 60 mesesmeses	COMMERCIAL CLINICAL TRIAL	VÍCTOR MANUEL NAVAS LÓPEZ	III
A-19	ESTUDIO ALEATORIZADO. DOBLE CIEGO, CONTROLADO CON PLACEBO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LA TERAPIA ADYUVANTE DE CENOBAMATO EN PACIENTES CON CRISIS TÓNICO-CLÓNICAS GENERALIZADAS PRIMARIAS	CLINICAL TRIALS WITH DRUGS	ROCIO CALVO MEDINA	III
A-21	Análisis de la expresión de microRNAs en pacientes sometidos a cirugía cardíaca tratados con anestésicos halogenados. Identificación de microRNAs relacionados con el efecto cardioDWprotector	INDEPENDENT CLINICAL TRIAL	JOSE LUIS GUERRERO ORRIACH	IV

612 EXTERNAL ASSOCIATED GRUPS 2023 SCIENTIFIC REPORT 613

Group	Title	Subtype	LR Name	Phase
A-21	Evaluación de la nefroprotección en cirugía cardiaca de sustitución valvular aórtica del desflurano en comparación con el propofol	INDEPENDENT POST-AUTHORIZATION STUDY	JOSE LUIS GUERRERO ORRIACH	SP
A-21	Mecanismos de cardio y nefroprotección en pacientes que van a ser intervenidos de cirugía cardiaca con disfunción ventricular derecha, con tratamiento preoperatorio de levosimendán en comparación con placebo. (PRELEVD-Estudio piloto)	INDEPENDENT CLINICAL TRIAL	JOSE LUIS GUERRERO ORRIACH	III
A-23	A prospective study to evaluate the immune status in the elderly after receiving a booster dose under the Covid-19 vaccination program in Spain. N Covid Senior II, a substudy of Covidvac@spain.	CLINICAL TRIAL WITH DRUGS	BLANCA O'DONNELL CORTÉS	NA
A-23	A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19	CLINICAL TRIALS WITH DRUGS	MARIA JESUS LOPEZ FERNANDEZ	П
A-23	: A Phase IIb/III, open label, single arm, multi-centre, clinical trial to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.	CLINICAL TRIAL WITH DRUGS	MARIA JESUS LOPEZ FERNANDEZ	III
A-23	Un estudio de no inferioridad de fase IIb, doble ciego, aleatorizado, con control activo, multicéntrico, seguido de un estudio de fase III, de un solo brazo y abierto, para evaluar la inmunogenicidad y la seguridad de una vacuna de refuerzo con un candidato de proteína recombinante dimérica de fusión RBD (PHH-1V) contra el SARS-CoV-2, en adultos completamente vacunados contra COVID-19	COMMERCIAL CLINICAL TRIAL	MARIA DEL MAR VAZQUEZ JIMENEZ	П
A-23	Estudio fase III, no ciego, de un único brazo, multicéntrico para valorar la seguridad y inmunogenicidad de una vacunación de booster con el candidato de proteína recombinante RBD fusion heterodimer (PHH-1V) contra SARS-CoV-2, en adultos previamente vacunados contra la COVID-19	COMMERCIAL CLINICAL TRIAL	MARIA DEL MAR VAZQUEZ JIMENEZ	Ш
AA-04	Tratamiento antiagregante en el síndrome coronario agudo. Seguridad y eficacia del cruce entre antiagregantes.	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA NIETO GONZÁLEZ	SP
AA-04	Tratamiento antiplaquetario en síndromes coronarios agudos. Seguridad y eficacia del cambio de antiplaquetario. Seguridad y eficacia de Tricagrelor VS Clopidogrel en pacientes con síndrome coronario agudo. Antiplatelet treatment in acute coronary syndromes. safety and efficacy of antiplatelet switching. Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients with Acute Coronary Syndrome.	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ANTONIA ESTECHA FONCEA	OD
AA-04	STrategic Reperfusion in elderly patients Early After Myocardial Infarction. STREAM-2	INDEPENDENT CLINICAL TRIAL	MARÍA NIETO GONZÁLEZ	IV
AA-04	Conjunto mínimo base datos – Unidades de Cuidados Intensivos (CMBD-UCI)	NON-POST-AUTHORIZATION STUDY	-	NO
AA-15	Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria	INDEPENDENT CLINICAL TRIAL	CRISTOBAL ANTONIO URBANO CARRILLO	IV
AA-15	Factores de riesgo asociados con la progresión de la Insuficiencia Cardíaca (IC) en pacientes con fibrilación auricular tratados con un anticoagulante oral directo (rivaroxaban). Estudio FARAONIC	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ MARÍA PÉREZ RUIZ	SP
AA-15	Establecimiento de una referencia para la utilización de recursos y la calidad de asistencia en pacientes sometidos a la implantación transcatéter de una válvula aórtica en Europa	REST OF OBSERVATIONAL STUDIES WITH DRUGS	CRISTOBAL ANTONIO URBANO CARRILLO	OD
AA-15	Estudio observacional para evaluar el beneficio clínico neto del edoxabán en pacientes con fibrilación auricular no valvular, según la práctica clínica habitual en España Registro BENEFIT. Observational study to evaluate the Net Clinical Benefit of edoxaban in non-valvular Atrial Fibrillation patients, according to the routine clinical practice in Spain BENEFIT Registry	COMMERCIAL POST-AUTHORIZATION STUDY	ANA MARÍA GARCÍA BELLÓN	OD
AA-15	EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial).	CLINICAL TRIALS WITH DRUGS	ANA MARÍA GONZALEZ GONZALEZ	III
AA-15	Ensayo VERifyNow para Optimizar la iNhibición plaquetarla en el síndrome Coronario Agudo (VERONICA)	CLINICAL TRIALS WITH DRUGS	CRISTOBAL ANTONIO URBANO CARRILLO	IV

AA-15			LR Name	Phase
	Estudio aleatorizado paralelo para evaluar la utilidad de la revisión angiográfica rutinaria 6 meses después del intervencionismo percutáneo en el tronco coronario izquierdo. Estudio ANGELINE	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CRISTOBAL ANTONIO URBANO CARRILLO	0
AA-15	Registro prospectivo del stent ihtDEStiny en práctica clínica habitual(Estudio VELAZQUEZ)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CRISTOBAL ANTONIO URBANO CARRILLO	0
AA-15	Un estudio prospectivo, aleatorizado, multicéntrico para evaluar la seguridad y la eficacia del sistema de stent coronario liberador de sirolimus en el tratamiento de pacientes con hasta tres lesiones arteriales coronarias de novo o reestenóticas". Estudio BIOFLOW-V	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CRISTOBAL ANTONIO URBANO CARRILLO	0
AA-15	Registro de seguimiento clínico postcomercialización en cirugía cardiaca de Medtronic - Cardiac Surgery Post Market (CSPM) Clinical Follow up Registry	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	ENRIQUE RUIZ ALONSO	NA
AA-15	Estudio observacional para evaluar la evolución clínica de pacientes de alto riesgo sometidos a intervención coronaria percutánea (ICP), con implante de stents liberadores de everolimus, utilizando técnicas intracoronarias para guiar y optimizar la ICP	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	CRISTOBAL ANTONIO URBANO CARRILLO	0
AA-15	AF en la práctica real sobre el manejo de la anticoagulación oral - AFIRMA 4.0 (B0661131)	COMMERCIAL POST-AUTHORIZATION STUDY	JOSÉ LUIS DELGADO PRIETO	OD
AA-15	Plan de investigación de seguimiento poscomercialización (PMCF) para evaluar la seguridad y efectividad del dispositivo liberador de paclitaxel SEQUENT PLEASE NEO en pacientes con enfermedad arterial coronaria	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	CRISTOBAL ANTONIO URBANO CARRILLO	NA
AA-15	Registro PERSEO: Prevención de eventos Embólicos tras una hemoRragia SEvera en pacientes anticoagulados con fibrilaciOn auricular.	CLINICAL TRIAL WITH DRUGS	JOSÉ LUIS DELGADO PRIETO	NA
AA-15	Registro Observacional Prospectivo de Pacientes con Insuficiencia Cardíaca	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MARÍA PÉREZ RUIZ	SP
AA-15	Ensayo clínico multicéntrico fase III, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia de la infusión intracoronaria de células mononucleares troncales adultas autólogas de médula ósea no expandidas sobre la recuperación funcional en pacientes con miocardiopatía dilatada en insuficiencia cardiaca.	INDEPENDENT CLINICAL TRIAL	-	III
AA-15	Tratamiento con betabloqueantes tras infarto de miocardio sin fraccion de eyeccion reducida	INDEPENDENT CLINICAL TRIAL	-	IV
AA-15	Estudio ODYSSEY LEGACY de observación de la enfermedad: Efectos de memoria metabólica a largo plazo de la disminución de C-LDL con alirocumab: seguimiento observacional del estudio ODYSSEY OUTCOME Código Protocolo Promotor: BS15072/ ODYSSEY LEGACY	COMMERCIAL POST-AUTHORIZATION STUDY	-	SP
AE-11	Registro nacional de rechazo humoral:Estudio epidemiológico multicéntrico observacional prospectivo para evaluar las carasteristicas clínicas, serológicas e histológicas y la evolución a 5 años del rechazo humoral post-traspante renal en España	NON-POST-AUTHORIZATION STUDY	DOMINGO HERNÁNDEZ MARRERO	NO
AE-11	Estudio de fase II, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de ravulizumab en participantes adultos con nefritis lúpica (NL) proliferativa o nefropatía por inmunoglobulina A (NIgA)	COMMERCIAL CLINICAL TRIAL	REMEDIOS TOLEDO ROJAS	II
AE-11	Estudio de fase II, aleatorizado, doble ciego y controlado con placebo de búsqueda de dosis para evaluar la eficacia y la seguridad de ALXN2050 en participantes adultos con nefritis lúpica (NL) proliferativa o nefropatía por inmunoglobulina A (NIgA).	CLINICAL TRIALS WITH DRUGS	REMEDIOS TOLEDO ROJAS	II
AE-11	Impacto de los niveles de tacrólimus en la prevención del rechazo en pacientes de edad avanzada receptores de trasplante renal de novo: estudio observacional prospectivo en las condiciones de la práctica clínica habitual. Estudio BITÁCORA	COMMERCIAL POST-AUTHORIZATION STUDY	VERONICA LÓPEZ JIMÉNEZ	SP
AE-11	Desarrollo y validación de la escala Neuro-Score for Transplanted Patients para la detección del deterioro cognitivo en pacientes con trasplante renal o hepático tratados con inmunosupresores	NON-POST-AUTHORIZATION STUDY	VERONICA LÓPEZ JIMÉNEZ	NO
AE-11	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de LNP023 en pacientes con nefropatía por IgA primaria. APPLAUSE	CLINICAL TRIALS WITH DRUGS	REMEDIOS TOLEDO ROJAS	Ш

Group	Title	Subtype	LR Name	Phase
AE-11	Estudio de fase 2b, aleatorizado, en doble ciego, controlado con principio activo y multicéntrico, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento por vía oral con AZD9977 y dapagliflozina en pacientes con insuficiencia cardíaca y nefropatía crónica	CLINICAL TRIALS WITH DRUGS	REMEDIOS TOLEDO ROJAS	II
AE-11	Prevalencia de fragilidad en pacientes con enfermedad renal crónica en lista de espera de trasplante renal en España: un estudio multicéntrico	COMMERCIAL POST-AUTHORIZATION STUDY	VERONICA LÓPEZ JIMÉNEZ	OD
AE-11	Tratamiento de las lesiones inflamatorias borderline precoces en pacientes con trasplante renal de bajo riesgo inmunológico: estudio prospectivo, controlado y aleatorizado de grupos paralelos (TRAINING)	INDEPENDENT CLINICAL TRIAL	VERÓNICA LÓPEZ JIMÉNEZ	IV
AE-11	Estudio prospectivo observacional para evaluar el cambio en la calidad de vida relacionada con la salud y la productividad laboral en pacientes con síndrome hemolítico urémico atípico primario tratados con eculizumab y cambian a ravulizumab en España. Estudio PROMET-SHUa.	CLINICAL TRIAL WITH DRUGS	VERONICA LÓPEZ JIMÉNEZ	NA
AE-11	Estudio posautorización de seguridad multicéntrico y no intervencionista de 6 años de duración realizado en pacientes a los que se ha recetado JINARC debido a poliquistosis renal autosómica dominante. Estudio 156-12-299	COMMERCIAL POST-AUTHORIZATION STUDY	Mª DOLORES MARTÍNEZ ESTEBAN	LA
AE-11	Escrutinio de la enfermedad de FABRY en pacientes con Glomeruloesclerosis Focal Segmentaria.	NON-POST-AUTHORIZATION STUDY	DOMINGO HERNÁNDEZ MARRERO	NO
B-03	Ensayo adaptativo de fase 3 aleatorizado, abierto y controlado para investigar la eficacia, seguridad y tolerabilidad del anticuerpo BiTE® blinatumomab como tratamiento de consolidación frente a la quimioterapia de consolidación convencional en sujetos pediátricos con leucemia linfoblástica aguda (LLA) de precursores B en primera recaída de alto riesgo	COMMERCIAL CLINICAL TRIAL	ANTONIA PASCUAL MARTÍNEZ	III
B-03	Estudio de fase I/II internacional, abierto y multicéntrico de la seguridad y del aumento de dosis de BAX 888, un vector de virus adenoasociado de serotipo 8 (VAA8) que expresa un factor VIII con el dominio B eliminado (B-Domain Deleted Factor VIII, BDD-FVIII) en sujetos con hemofilia A grave administrado como infusión única por vía intravenosa.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	I
B-03	Estudio multicéntrico, de extensión abierto y de seguridad, para describir la experiencia clínica a largo plazo con mepolizumab en pacientes con síndrome hipereosinofílico (HES) procedentes del estudio 200622	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
B-03	Estudio de los parámetros clínicos y biológicos determinantes de respuesta en pacientes con LLC tratados en primera línea con Ibrutinib (IBROMICS)	CLINICAL TRIAL WITH DRUGS	MACARENA ORTIZ PAREJA	OD
B-03	ESTUDIO RETROSPECTIVO OBSERVACIONAL DEL TRATAMIENTO DE LA MACROGLOBULINEMIA DE WALDENSTRÖM CON IBRUTINIB EN LA PRÁCTICA CLÍNICA HABITUAL EN ESPAÑA. Estudio MACRO	OBSERVATIONAL STUDY WITH DRUGS	MAGDALENA ALCALÁ PEÑA	NA
B-03	ENHANCE: Estudio multicéntrico, doble ciego y aleatorizado para comparar magrolimab en combinación con azacitidina frente a azacitidina más placebo en pacientes con síndrome mielodisplásico de alto riesgo sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
B-03	Efectividad comparada en la vida real del belumosudil frente al mejor tratamiento disponible elegido por el médico para la enfermedad crónica de injerto contra huésped: Estudio retrospectivo basado en las historias clínicas de los pacientes	OBSERVATIONAL STUDY WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	NA
B-03	Análisis retrospectivo de la evolución clínica de los pacientes con leucemia linfocítica crónica (LLC) tratados con venetoclax en la práctica real en España. Estudio VENARES	COMMERCIAL POST-AUTHORIZATION STUDY	MACARENA ORTIZ PAREJA	OD
B-03	Estudio de fase 3, abierto y aleatorizado para comparar la eficacia y la seguridad de luspatercept (ACE-536) frente a epoetina alfa para el tratamiento de la anemia debida a síndromes mielodisplásicos (SMD) de riesgo muy bajo, bajo o intermedio según la clasificación IPSS-R en pacientes sin tratamiento previo con estimulantes de la eritropoyesis que necesitan transfusiones de glóbulos rojos.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
B-03	Impacto del disbalance del metaboloma y microbioma intestinales de receptores de trasplante hematopoyético en el desarrollo de enfermedad injerto contra huésped	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA JESÚS PASCUAL CASCÓN	0
B-03	Trasplante alogénico de células madre en niños y adolescentes con leucemia linfoblástica aguda - FORUM (Para omitir radioterapia por debajo de la mayoría de edad)	INDEPENDENT CLINICAL TRIAL	ANTONIA PASCUAL MARTÍNEZ	III

Group	Title	Subtype	LR Name	Phase
B-03	Estudio de fase III, abierto, aleatorizado y multicéntrico de ravulizumab en pacientes adultos y adolescentes que presentan microangiopatía trombótica (MAT) después de un trasplante de células madre hematopoyéticas (TCMH)	COMMERCIAL CLINICAL TRIAL	MARÍA JESÚS PASCUAL CASCÓN	III
B-03	Estudio en fase II, de dosis múltiples ascendentes, aleatorizado, doble ciego y controlado con placebo de ALXN1830 administrado por vía subcutánea en pacientes con anemia hemolítica autoinmunitaria por anticuerpos calientes (WAIHA)	COMMERCIAL CLINICAL TRIAL	MAGDALENA ALCALÁ PEÑA	II
B-03	Estudio de fase III de Danicopan (ALXN2040) como tratamiento suplementario de un inhibidor de la C5 (Eculizumab o Ravulizumab) en pacientes con hemoglobinuria paroxística nocturna que tienen hemólisis extravascular clínicamente evidente (HEV)	COMMERCIAL CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
B-03	Ensayo multicéntrico en fase III, no enmascarado, aleatorizado, para evaluar la eficacia y la seguridad de CPI-613 en combinación con dosis altas de citarabina y mitoxantrona (CHAM) comparado con dosis altas de citarabina y mitoxantrona (HAM) en pacientes de edad avanzada (=60 años) con leucemia mieloide aguda (LMA) en recaída o refractaria	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
B-03	Estudio global, abierto y de diseño adaptativo para investigar la eficacia y la seguridad de SerpinPC en pacientes con hemofilia A grave o con hemofilia B de moderadamente grave a grave	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	III
B-03	A Global, Non-interventional Study to Prospectively Evaluate Bleeding Episodes and Treatment Use in Patients with Hemophilia. 7037209	OBSERVATIONAL STUDY WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	NA
B-03	Ensayo de fase 3, multicéntrico, doble ciego y controlado con placebo de Viralym-M (ALVR105) en el tratamiento de pacientes con cistitis hemorrágica asociada a virus tras un alotrasplante de células hematopoyéticas	COMMERCIAL CLINICAL TRIAL	MARÍA JESÚS PASCUAL CASCÓN	III
B-03	Ensayo fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico del inhibidor PI3K intravenoso Copanlisib en combinación con inmunoquimioterapia estándar versus inmunoquimioterapia estándar en pacientes con linfoma no Hodgkin indolente tras recaída	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	III
B-03	HA-SAFE: Estudio observacional para evaluar la seguridad a largo plazo del tratamiento con damoctocog alfa pegol en práctica habitual en pacientes con hemofilia A tratados previamente	OBSERVATIONAL STUDY WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	NA
B-03	Estudio de fase IV multinacional para evaluar el patrón de tratamiento en la vida real en pacientes con hemofilia A tratados previamente que reciben KOVALTRY (octocog alfa) para la profilaxis habitual. TAURUS	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	SP
B-03	Estudio de fase III, aleatorizado, abierto y multicéntrico, para comparar zanubrutinib (BGB-3111) más rituximab frente a bendamustina más rituximab en pacientes con linfoma de células del manto no tratados previamente que no son aptos para recibir un trasplante de células madre.	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	III
B-03	Estudio en fase III, aleatorizado, abierto, con control activo, multicéntrico, para evaluar la eficacia y la seguridad de Crovalimab frente a Eculizumab en pacientes adultos y adolescentes con hemoglobinuria paroxística nocturna (HPN) actualmente tratada con inhibidores del complemento. Estudio COMMODORE	COMMERCIAL CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	Ш
B-03	ESTUDIO EN FASE III, ABIERTO, DE 2 GRUPOS, MULTICÉNTRICO Y ALEATORIZADO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDA EN COMPARACIÓN CON DARATUMUMAB + LENALIDOMIDA + DEXAMETASONA EN PARTICIPANTES CON MIELOMA MÚLTIPLE DE DIAGNÓSTICO RECIENTE NO APTOS PARA TRASPLANTE	CLINICAL TRIALS WITH DRUGS	MAGDALENA ALCALÁ PEÑA	III
B-03	Efectividad y seguridad para el retratamiento con Brentuximab-Vedotin (BV) en pacientes con neoplasias malignas CD30+ recidivantes/refractarias (R/R): un estudio retrospectivo de revisión de historias clínicas en España. El estudio BELIEVE	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL ESPESO DE HARO	OD
B-03	Estudio de fase 3, de dos etapas, aleatorizado, multicéntrico, abierto, para comparar CC 92480 (BMS-986348), carfilzomib y dexametasona (480Kd) frente a carfilzomib y dexametasona (Kd) en participantes con mieloma múltiple en recidiva o refractario (MMRR)	CLINICAL TRIALS WITH DRUGS	MAGDALENA ALCALÁ PEÑA	III

Group	Title	Subtype	LR Name	Phase
B-03	Estudio posautorización de seguridad, no intervencionista, en pacientes con linfoma recurrente o resistente de células del manto, para seguir investigando y caracterizando la asociación de lenalidomida con la reacción de exacerbación tumoral y carga tumoral elevada. Code Sponsor's Protocol: CC-5013-MCL-005	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL ESPESO DE HARO	OD
B-03	Estudio observacional prospectivo sobre la supervivencia global y la calidad de vida en pacientes mayores de 60 años diagnosticados de leucemia mieloide aguda en España, tratados según la práctica clínica habitual. (Estudio SvLMA).	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL BARRIOS GARCÍA	SP
B-03	Estudio observacional para valorar la carga de la enfermedad, en términos de Calidad de Vida Relacionada con la Salud y costes sanitarios directos, en pacientes con Mieloma Múltiple de nuevo diagnóstico no candidatos a trasplante autólogo de progenitores hematopoyéticos en España. QoLMMBuS	COMMERCIAL POST-AUTHORIZATION STUDY	MAGDALENA ALCALÁ PEÑA	SP
B-03	Estudio de fase II, multicéntrico, abierto, de un solo brazo, de ruxolitinib añadido a corticosteroides en sujetos pediátricos con enfermedad de injerto contra huésped crónica moderada y grave tras trasplante alogénico de células madre.	COMMERCIAL CLINICAL TRIAL	ANTONIA PASCUAL MARTÍNEZ	II
B-03	Estudio de fase I/II, aleatorizado, abierto y de plataforma abierta en el que se evalúa la seguridad y eficacia de nuevas combinaciones de ruxolitinib en pacientes con mielofibrosis. (ADORE)	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	Estudio de Fase 2, multicéntrico, aleatorizado y abierto, que evalúa la seguridad y eficacia de tres regímenes diferentes de panobinostat en combinación con bortezomib subcutáneo y dexametasona oral en pacientes con mieloma múltiple recidivante o recidivante/refractario que hayan sido previamente expuestos a agentes inmunomoduladores.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	Estudio de fase 1/2 de dos partes para determinar la seguridad, tolerabilidad, farmacocinética y actividad de K0706, un nuevo inhibidor de la tirosina cinasa (ITC), en pacientes sanos y pacientes con leucemia mieloide crónica (LMC) o leucemia linfoblástica aguda (LLA) positiva para el cromosoma Filadelfia	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	II
B-03	Estudio de fase II, multicéntrico, aleatorizado, controlado con placebo y doble ciego de MBG453 intravenoso en combinación con fármacos hipometilantes en pacientes adultos con síndrome mielodisplásico (SMD) de riesgo intermedio, alto o muy alto según los criterios del IPSS-R.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	Estudio de fase III aleatorizado, doble ciego y controlado con principio activo de CPI-0610 y ruxolitinib frente a placebo y ruxolitinib en pacientes con MF sin tratamiento previo con iJAK (NZA68438)	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
B-03	Ambispective Non-Interventional Study to Assess the Effectiveness of Recombinant Fusion Protein linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) in Hemophilia B in a Real-World Setting	OBSERVATIONAL STUDY WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	NA
B-03	Estudio de fase 2b, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de EDP-938 en adultos receptores de un trasplante de células hematopoyéticas con infección aguda de las vías respiratorias altas por el virus respiratorio sincitial	COMMERCIAL CLINICAL TRIAL	MARÍA ÁNGELES CUESTA CASAS	II
B-03	Estudio fase II, exploratorio, multicéntrico, abierto, no controlado, para evaluar la reinducción y la segunda parada a un TKI como ponatinib en pacientes con LMC en respuesta molecular (ResToP).	INDEPENDENT CLINICAL TRIAL	ANTONIO JIMÉNEZ VELASCO	II
B-03	Estudio fase II, exploratorio, multicéntrico, abierto, no controlado, para evaluar la reinducción y la segunda parada a un TKI como ponatinib en pacientes con LMC en respuesta molecular (ResToP).	INDEPENDENT CLINICAL TRIAL	ANA ISABEL ROSELL MAS	II
B-03	Estudio en fase III, multicéntrico, abierto y aleatorizado para evaluar la eficacia y la seguridad del fedratinib comparado con la mejor terapia disponible en pacientes con mielofibrosis primaria de riesgo intermedio o alto riesgo según el Sistema dinámico internacional de puntuación pronóstica (DIPSS), mielofibrosis post-policitemia vera o mielofibrosis post-trombocitemia esencial tratados previamente con ruxolitinib	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
B-03	Estudio de discontinuación de inhibidores de la tirosina quinasa en LMC-FC	INDEPENDENT POST-AUTHORIZATION STUDY	ANA ISABEL ROSELL MAS	SP

Group	Title	Subtype	LR Name	Phase
B-03	Estudio observacional prospectivo para evaluar la precocidad, estabilidad y profundidad de la respuesta molecular en pacientes recién diagnosticados de leucemia mieloide crónica en fase crónica (LMC-FC) tratados con inhibidores de la actividad tirosina-quinasa (ITK) como tratamiento de primera línea en la práctica clínica	INDEPENDENT POST-AUTHORIZATION STUDY	CONCEPCIÓN RUÍZ NUÑO	SP
B-03	Un ensayo aleatorizado multicéntrico de fosfomicina frente a ciprofloxacino para la neutropenia febril en pacientes hematológicos: eficacia y seguridad microbiológica.	INDEPENDENT CLINICAL TRIAL	MARÍA ÁNGELES CUESTA CASAS	III
B-03	Estudio de la prevalencia de la Enfermedad déficit de esfingomielinasa ácida (ASMD) y Enfermedad de Gaucher en pacientes con Gammapatías Monoclonales y/o Mieloma	OBSERVATIONAL STUDY WITH DRUGS	ALEJANDRO CONTENTO GONZALO	NA
B-03	Ensayo de fase III en pacientes con MMND candidatos a TASPE para comparar VRD extendido hasta 18 ciclos más intervención temprana de rescate vs. Isatuximab-VRD vs. Isatuximab-V-iberdomida-D	CLINICAL TRIALS WITH DRUGS	MAGDALENA ALCALÁ PEÑA	III
B-03	Estudio observacional prospectivo para identificar los aspectos clínicos que conducen a la toma de decisiones terapéuticas en pacientes con mielofibrosis. Estudio TRATABILIDAD	INDEPENDENT POST-AUTHORIZATION STUDY	REGINA GARCÍA DELGADO	SP
B-03	Transformando la mielofibrosis y la policitemia vera incontrolada en enfermedades cuantificables y de diagnóstico precoz. Estudio de casos y controles	NON-POST-AUTHORIZATION STUDY	REGINA GARCÍA DELGADO	NO
B-03	Estudio prospectivo español de pacientes hematológicos pre y postrasplante hematopoyético que ingresan en unidades de cuidados intensivos: análisis de la práctica clínica, resultados en salud, factores pronósticos y utilización de recursos sanitarios.	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ÁNGELES CUESTA CASAS	SP
B-03	Estudio de fase 3, aleatorizado y abierto, para evaluar imetelstat (GRN163L) frente al mejor tratamiento disponible en pacientes con mielofibrosis de riesgo intermedio 2 o alto resistente a inhibidores de las cinasas Jano	CLINICAL TRIALS WITH DRUGS	REGINA GARCÍA DELGADO	III
B-03	Estudio en fase III, aleatorizado, abierto, para evaluar la seguridad y la eficacia de magrolimab en combinación con azacitidina frente a la elección del médico de venetoclax más azacitidina o quimioterapia intensiva, en pacientes con leucemia mieloide aguda y TP53 mutado no tratados previamente	INDEPENDENT CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
B-03	Estudio en fase III, aleatorizado, con doble enmascaramiento y controlado con placebo para evaluar la seguridad y la eficacia de magrolimab frente a placebo en combinación con venetoclax y azacitidina en pacientes con leucemia mieloide aguda recién diagnosticados, no tratados previamente y que no son aptos para la quimioterapia intensiva	INDEPENDENT CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
B-03	Fundación de la Sociedad Española de Hematología y Oncología Pediátricas, actuando en nombre y representación del Promotor International BFM Study Group	OBSERVATIONAL STUDY WITH DRUGS	ANA ISABEL RODRÍGUEZ JIMÉNEZ	NA
B-03	Estudio observacional ambispectivo para evaluar la incidencia y el manejo de la aplasia medular en el Estado Español (IMAS)	INDEPENDENT POST-AUTHORIZATION STUDY	ANA ISABEL ROSELL MAS	SP
B-03	"Epidemiology of idiopathic multicentric Castleman disease in Spain".	OBSERVATIONAL STUDY WITH DRUGS	MANUEL ESPESO DE HARO	NA
B-03	Guía de recomendaciones de la SEHOP para el tratamiento de la Leucemia Linfobástica Aguda o Bifenotípica del lactante menor de 1 año	NON-POST-AUTHORIZATION STUDY	ANA ISABEL RODRÍGUEZ JIMÉNEZ	NO
B-03	Estudio internacional para el tratamiento de la LLA infantil de alto riesgo 2010. IntReALL HR 2010	INDEPENDENT CLINICAL TRIAL	ANA ISABEL RODRÍGUEZ JIMÉNEZ	II
B-03	Estudio observacional para describir la repercusión de los anticuerpos monoclonales como tratamiento de primera línea frente a otros regímenes estándar en pacientes con mieloma múltiple de nuevo diagnóstico que no sean candidatos a trasplante. Datos de práctica clínica habitual en España. Estudio CARINAE (54767414MMY4024)	COMMERCIAL POST-AUTHORIZATION STUDY	MAGDALENA ALCALÁ PEÑA	SP
B-03	Estudio en fase Ila/IIb abierto de KRT-232 en pacientes con mielofibrosis primaria (MFP), mielofibrosis post-policitemia vera (MF-post-PV) o mielofibrosis post-trombocitemia esencial (MF-post-TE) que no han respondido al tratamiento con ruxolitinib	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II

Group	Title	Subtype	LR Name	Phase
B-03	Estudio abierto, multicéntrico, de fase Ib/II de la seguridad y eficacia de KRT-232 en combinación con citarabina en dosis bajas (CDB) o decitabina en pacientes con leucemia mieloide aguda (LMA).	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	Estudio de fase Ib/II abierto y multicéntrico de la seguridad y eficacia de KRT-232 combinado con ruxolitinib en pacientes con mielofibrosis primaria (MFP), mielofibrosis post-policitemia vera (MF-post-PV) o mielofibrosis post-trombocitemia esencial (MF-post-TE) que tienen una respuesta subóptima a ruxolitinib	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	Estudio aleatorizado, doble ciego, controlado con placebo, Fase 3, de Venetoclax en combinación con Azacitidina en comparación con Azacitidina, en pacientes con leucemia mieloide aguda no tratados anteriormente y no elegibles para terapias de inducción estándar.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
B-03	Estudio de fase 3, controlado con placebo, aleatorizado y doble ciego de Navitoclax en combinación con Ruxolitinib comparado con Ruxolitinib en pacientes con Mielofibrosis	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	III
B-03	Estudio de fase 3 aleatorizado y abierto para evaluar la eficacia y la seguridad de navitoclax combinado con ruxolitinib en comparación con el mejor tratamiento disponible en pacientes con mielofibrosis en recaída/refractario (TRANSFORM-2)	COMMERCIAL CLINICAL TRIAL	CONCEPCIÓN RUÍZ NUÑO	III
B-03	Ensayo de fase III, aleatorizado, sin enmascaramiento y multicéntrico del tratamiento de primera línea con células mesenquimales estromales MC0518 en comparación con el mejor tratamiento disponible en sujetos adultos y adolescentes con enfermedad de injerto contra huésped aguda refractaria a esteroides después del trasplante alogénico de células madre hematopoyéticas (ensayo IDUNN)	CLINICAL TRIALS WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	III
B-03	Ensayo de fase II, aleatorizado, sin enmascaramiento, controlado y multicéntrico del tratamiento de primera línea con células mesenquimales estromales MC0518 en comparación con el mejor tratamiento disponible en participantes pediátricos con enfermedad de injerto contra huésped aguda refractaria a esteroides después del trasplante alogénico de células madre (ensayo BALDER)	CLINICAL TRIALS WITH DRUGS	ANTONIA PASCUAL MARTÍNEZ	II
B-03	Estudio aleatorizado, múlticéntrico, abierto, de fase II para evaluar la eficacia y la seguridad de azacitidina subcutánea en combinación con durvalumab (MEDI4736) en pacientes con síndromes mielodisplásicos (SMD) de alto riesgo no tratados previamente o en pacientes de edad avanzada (= 65 años) con leucemia mieloide aguda (LMA) que no son aptos para un trasplante de células madre hematopoyéticas (TCMH). Estudio de fusión SMD de alto riesgo/LMA de edad avanzada 001.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de la profilaxis con letermovir (LET) cuando se prolonga de 100 a 200 días después del trasplante en receptores seropositivos para el citomegalovirus (CMV) (R+) de un trasplante alogénico de células madre hematopoyéticas (TCMH)	COMMERCIAL CLINICAL TRIAL	MARÍA JESÚS PASCUAL CASCÓN	III
B-03	Estudio observacional para evaluar el impacto y la carga de la enfermedad en Hemofilia moderada y grave desde la perspectiva de enfermería y del paciente. Estudio NURSES WHO CARE	COMMERCIAL POST-AUTHORIZATION STUDY	BEATRIZ GAGO CABALLERO	0
B-03	ESTUDIO OBSERVACIONAL PARA DESCRIBIR EL IMPACTO CLÍNICO DE LOS PATRONES DE TRATAMIENTO EN PERSONAS CON HEMOFILIA A LEVE-MODERADA EN ESPAÑA (ESTUDIO LEMON).	OBSERVATIONAL STUDY WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	NA
B-03	Estudio de fase IV, multicéntrico y abierto para evaluar la Salud general, la actividad física y los resultados articulares en participantes de 13 años o más y menos de 70 años con Hemofilia a grave o moderada sin inhibidores del FVIII que reciben profilaxis con emicizumab	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	IV
B-03	Eficacia y seguridad de M281 en adultos con anemia hemolítica autoinmunitaria por anticuerpos calientes: estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo. Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled, Study with a Long-term Open label Extension	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	III
B-03	Estudio de fase Ib, abierto, aleatorizado, para evaluar la seguridad y la eficacia preliminar de Tafasitamab en combinación con R-CHOP o Tafasitamab más Lenalidomida en combinación con R-CHOP en pacientes con linfoma difuso de células B grandes (LDCBG) de nuevo diagnóstico-First-MIND	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	I

Group	Title	Subtype	LR Name	Phase
B-03	A First-In-Human Phase 1/2 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Hematological Tumors	CLINICAL TRIALS WITH DRUGS	REGINA GARCÍA DELGADO	II
B-03	Infusión de células Natural Killer como tratamiento de consolidación en niños y adolescentes con leucemia mieloblástica aguda.	INDEPENDENT CLINICAL TRIAL	ANTONIA PASCUAL MARTÍNEZ	II
B-03	Estudio postautorización internacional, prospectivo, abierto, no controlado y no intervencionista de turoctocog alfa pegol (N8-GP) durante la profilaxis habitual y tratamiento a largo plazo de los episodios de sangrados en pacientes con hemofilia A	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	OD
B-03	Estudio de investigación observacional sobre la salud de las articulaciones en personas con hemofilia que toman el medicamento Esperoct®	OBSERVATIONAL STUDY WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	NA
B-03	Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B sin inhibidores.	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	III
B-03	Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia A o B con inhibidores	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	III
B-03	Estudio abierto para investigar la eficacia, la seguridad y la farmacocinética de la profilaxis con concizumab en niños menores de 12 años con hemofilia A o B con o sin inhibidores NN7415-4616	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	III
B-03	A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease ESTUDIO MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DECITABINA-TETRAHIDROURIDINA ORAL (NDec) EN PACIENTES CON ANEMIA FALCIFORME	CLINICAL TRIALS WITH DRUGS	ALEJANDRO CONTENTO GONZALO	II
B-03	Seguridad, tolerabilidad, farmacocinética y farmacodinámica de dosis subcutáneas únicas y múltiples de NNC0365-3769 (Mim8) en pacientes sanos y en pacientes con hemofilia A con o sin inhibidores del factor VIII. (FRONTIER 1)	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	II
B-03	Ensayo multinacional, abierto, aleatorizado y controlado para investigar la eficacia y la seguridad de NNC0365-3769 (Mim8) en adultos y adolescentes con hemofilia A con o sin inhibidores	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	III
B-03	Estudio abierto de la seguridad y la eficacia a largo plazo de Mim8 en participantes con hemofilia A con o sin inhibidores	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	Ш
B-03	Estudio abierto de seguridad en adultos y adolescentes con hemofilia A con y sin inhibidores del FVIII que cambian directamente de la profilaxis con emicizumab a la profilaxis con NNC0365 3769 (Mim8)	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	III
B-03	Estudio prospectivo, multinacional y observacional en pacientes con hemofilia A y B, con o sin inhibidores, tratados según la práctica clínica habitual (explorer™6) Código Promotor: NN7415-4322	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	SP
B-03	Estudio observacional, internacional, multicéntrico, sobre el uso de ruxolitinib en el tratamiento de pacientes con policitemia vera que presentan resistencia o intolerancia a la hidroxiurea. Sponsor Code: CINC424BIC04	COMMERCIAL POST-AUTHORIZATION STUDY	REGINA GARCÍA DELGADO	SP
B-03	Estudio observacional, multinacional y no intervencionista con isatuximab en pacientes con mieloma múltiple recidivante o resistente al tratamiento (MMRR)	OBSERVATIONAL STUDY WITH DRUGS	MAGDALENA ALCALÁ PEÑA	NA
B-03	Ensayo en fase III, abierto, aleatorizado, controlado, de melflufen y dexametasona en comparación con pomalidomida y dexametasona en pacientes con mieloma múltiple en recaída y refractario que son resistentes al tratamiento con lenalidomida.	COMMERCIAL CLINICAL TRIAL	MAGDALENA ALCALÁ PEÑA	III
B-03	Estudio en fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de dosis paralelas para evaluar la eficacia y la seguridad de SKI-O-703 oral, un inhibidor de Quinasa SYK, en pacientes con trombocitopenia inmunitaria (TPI) persistente y crónica	COMMERCIAL CLINICAL TRIAL	FRANCISCO JOSE LOPEZ JAIME	II
B-03	Estudio en fase II/III, multicéntrico, aleatorizado, con enmascaramiento doble y comparativo con placebo para evaluar la eficacia y la seguridad del ALVR105 (Viralym-M) en comparación con un placebo en la prevención de infecciones y/o enfermedades provocadas por adenovirus, el virus BK, citomegalovirus, el virus de Epstein-Barr, el virus del herpes humano de tipo 6 y el virus John Cunningham, en pacientes de alto riesgo tras someterse a un trasplante de progenitores hematopoyéticos	COMMERCIAL CLINICAL TRIAL	MARÍA JESÚS PASCUAL CASCÓN	III

Group	Title	Subtype	LR Name	Phase
B-03	Registro mundial para el seguimiento a largo plazo de pacientes que participan en ensayos clínicos con posoleucel (ALVR105)	CLINICAL TRIALS WITH DRUGS	MARÍA JESÚS PASCUAL CASCÓN	III
B-03	PEGCET-304	OBSERVATIONAL STUDY WITH DRUGS	ALEJANDRO CONTENTO GONZALO	NA
B-03	Estudio fase III aleatorizado abierto para comparar el tratamiento con azacitidina más pevonedistat frente a azacitidina en adultos con LMA de nuevo diagnóstico ancianos y/o no candidatos a quimioterapia estándar de inducción	INDEPENDENT CLINICAL TRIAL	ALEJANDRO CONTENTO GONZALO	III
B-03	Estudio clínico de fase II, aleatorizado, controlado y abierto para comparar la eficacia y la seguridad de pevonedistat más azacitidina frente a azacitidina en monoterapia en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica y leucemia mielógena aguda pobre en blastos	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	Multicéntrico, abierto, brazo único, fase II, Estudio exploratorio para evaluar el efecto de un año de consolidación de tratamiento con ponatinib 15 mg en la tasa de paciente con leucemia mieloide crónica filadelfia positivo en remisión libre de tratamiento que previamente habían alcanzado respuesta molecular profunda con imatinib	INDEPENDENT CLINICAL TRIAL	ANTONIO JIMÉNEZ VELASCO	II
B-03	PRAME Protocolo de registro y análisis de macroglobulinemia de waldenströn en España	COMMERCIAL POST-AUTHORIZATION STUDY	MAGDALENA ALCALÁ PEÑA	OD
B-03	Estudio internacional del tratamiento y resultados de la leucemia mieloide crónica (LMC) en niños y adolescentes Código Promotor: I-CML-Ped Study	INDEPENDENT POST-AUTHORIZATION STUDY	ANTONIA PASCUAL MARTÍNEZ	SP
B-03	Estudio fase II con aleatorización 2:1 para comparar la eficacia y seguridad del tratamiento con quimioterapia estándar más quizartinib frente a quimioterapia estándar más placebo en pacientes adultos con LMA de nuevo diagnóstico con el gen FLT3 no mutado	INDEPENDENT CLINICAL TRIAL	MANUEL BARRIOS GARCÍA	II
B-03	Estudio observacional prospectivo para evaluar la calidad de vida en pacientes con hemofilia A sin inhibidores. Estudio HEMOLIFE (ML40944)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	SP
B-03	Estudio aleatorizado, doble ciego fase 3 de vadastuximab talirine (SGN-CD33A) frente a placebo en combinación con azacitidina o decitabina en el tratamiento de pacientes mayores con leucemia mieloide aguda de nuevo diagnóstico.	COMMERCIAL CLINICAL TRIAL	ANA ISABEL ROSELL MAS	III
B-03	Estudio en fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo y con comparador activo, de brentuximab vedotina o placebo en combinación con lenalidomida y rituximab en pacientes con linfoma difuso de células B grandes (LDCBG) recidivante o resistente	COMMERCIAL CLINICAL TRIAL	MANUEL ESPESO DE HARO	Ш
B-03	Estudio prospectivo de 24 meses, multicéntrico, no intervencional para evaluar la efectividad de Elocta en comparación con productos del factor convencional en el tratamiento profiláctico de pacientes con hemofilia A. (Sobi.Elocta-002)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	SP
B-03	Estudio observacional, multicéntrico de 48 meses de seguimiento para evaluar la eficacia a largo plazo de Elocta en la salud articular. Estudio A-MORE-ES	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	SP
B-03	ESTUDIO DE BAJO NIVEL DE INTERVENCIÓN, PROSPECTIVO, MULTICÉNTRICO, DE 18 MESES DE DURACIÓN PARA EVALUAR LOS RESULTADOS EN SALUD ARTICULAR DE PACIENTES CON HEMOFILIA A O B EN TRATAMIENTO PROFILÁCTICO CON EFMOROCTOCOG ALFA O EFTRENONACOG ALFA	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	IV
B-03	Real-World Evidence, Non-interventional Study on Clinical Characteristics, Epidemiology, Treatment Patterns and Patient Journey of Chronic Lymphocytic Leukemia Patients in Spain (SPARCLL)	OBSERVATIONAL STUDY WITH DRUGS	MACARENA ORTIZ PAREJA	NA
B-03	Evaluación de la seguridad a largo plazo de ADYNOVI/ADYNOVATE (factor antihemofílico [recombinante] pegilado, rurioctocog alfa pegol) en pacientes con hemofilia A: un estudio de seguridad posterior a la autorización (PASS) de ADYNOVI/ADYNOVATE. (TAK-660-403)	COMMERCIAL POST-AUTHORIZATION STUDY	FRANCISCO JOSE LOPEZ JAIME	LA

Group	Title	Subtype	LR Name	Phase
B-03	Estudio de fase 1/2, abierto, de aumento escalonado de la dosis para evaluar la seguridad, la tolerabilidad, la eficacia preliminar y la farmacocinética de TAK-981 en pacientes adultos con tumores sólidos avanzados o metastásicos o con neoplasias malignas hematológicas recidivantes/resistentes	INDEPENDENT CLINICAL TRIAL	MANUEL ESPESO DE HARO	II
B-03	Estudio observacional prospectivo para investigar la relación entre la duración del tratamiento (DoT) y la respuesta en pacientes con mieloma múltiple (MM) o amiloidosis sistémica (AL) tratados en condiciones de práctica clínica real. Estudio DOrianT Sponsor Code C16054	COMMERCIAL POST-AUTHORIZATION STUDY	MAGDALENA ALCALÁ PEÑA	SP
B-03	Estudio de fase 2, abierto y multicéntrico de TL-895 en pacientes con mielofibrosis recidivante/ resistente, mielofibrosis intolerante para el inhibidor de la cinasa de Janus y mielofibrosis no apta para el tratamiento con inhibidor de la cinasa de Janus	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	Estudio de fase 1b/2, abierto y multicéntrico para evaluar la seguridad y la eficacia de TL-895 combinado con ruxolitinib en sujetos con mielofibrosis (MF) sin tratamiento previo con inhibidores de la cinasa Janus (iJAK) y sujetos con mielofibrosis y respuesta subóptima a ruxolitinib.	COMMERCIAL CLINICAL TRIAL	REGINA GARCÍA DELGADO	II
B-03	ESTUDIO DE FASE I/II PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD, FARMACOCINÉTICA, FARMACODINÁMICA Y EFICACIA DE NXT007 EN PACIENTES CON HEMOFILIA A GRAVE O MODERADA	CLINICAL TRIALS WITH DRUGS	FRANCISCO JOSE LOPEZ JAIME	II
B-03	Ensayo de fase I/II, abierto, de seguridad y de búsqueda de dosis de BAY 2599023 (DTX201), una transferencia génica del factor VIII humano con el dominio B eliminado -mediada por el virus adenoasociado (VAA) del serotipo hu37-en adultos con hemofilia A grave	COMMERCIAL CLINICAL TRIAL	-	I
B-03	Estudio observacional, internacional, longitudinal, prospectivo en pacientes en tratamiento de Hemofilia A de moderada a grave para la evaluación de los resultados comunicados por los pacientes y la asociación con su enfermedad. ECHO.	COMMERCIAL POST-AUTHORIZATION STUDY	-	SP
B-10	Estudio observacional retrospectivo en pacientes con Dermatitis Atópica tratados con baricitinib en España (Estudio DAMA-S)	OBSERVATIONAL STUDY WITH DRUGS	ENRIQUE HERRERA ACOSTA	NA
B-10	Estudio multicéntrico, ambispectivo y observacional, en pacientes con psoriasis en placas de moderada a grave, para evaluar su satisfacción con el tratamiento con tildrakizumab.	OBSERVATIONAL STUDY WITH DRUGS	ENRIQUE HERRERA ACOSTA	NA
B-10	A multicenter, Prospective, observational study measuring tildrakizumab benefit in Achieving Therapeutic goals in patients with moderate-to-severe plaque psoriasis and inadequate response to previous biologic treatments in clinical practice in Spain.	OBSERVATIONAL STUDY WITH DRUGS	ENRIQUE HERRERA ACOSTA	NA
B-10	BIOBADATOP Registro Español de Dermatitis atópica	OBSERVATIONAL STUDY WITH DRUGS	ENRIQUE HERRERA ACOSTA	NA
B-10	Estudio observacional para evaluar la eficacia descriptiva en la práctica clínica real en pacientes con psoriasis en placas moderada a grave tratados con brodalumab. Estudio BROACTIVE	COMMERCIAL POST-AUTHORIZATION STUDY	ENRIQUE HERRERA ACOSTA	SP
B-10	Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and =120 kg body weight	CLINICAL TRIALS WITH DRUGS	ENRIQUE HERRERA ACOSTA	IV
B-10	Ensayo Clínico fase II para evaluar la seguridad y eficacia de dos modelos de piel autóloga creada mediante ingeniería de tejidos en la cirugía reconstructiva del carcinoma basocelular.	INDEPENDENT CLINICAL TRIAL	RICARDO BOSCH GARCÍA	II
B-10	Estudio observacional transversal para la caracterización del Paciente Adulto con Dermatitis Atópica (DA) moderada a grave y la estimación de la prevalencia de la DA en Unidades de Dermatología del ámbito hospitalario en España. (NIS-AD-2193). Estudio DACAR	NON-POST-AUTHORIZATION STUDY	ENRIQUE HERRERA ACOSTA	NO
B-10	Estudio observacional prospectivo con pacientes adultos en tratamiento con Dupixent para la dermatitis atópica	COMMERCIAL POST-AUTHORIZATION STUDY	JORGE ALONSO SUAREZ PEREZ	SP
B-10	P20-441 Uso en vida real de upadacitinib en pacientes adultos y adolescentes que padecen dermatitis atópica de moderada a grave (AD-VISE)	OBSERVATIONAL STUDY WITH DRUGS	ENRIQUE HERRERA ACOSTA	NA
B-10	Estudio de extensión abierto y multicéntrico para caracterizar la seguridad y la eficacia a largo plazo de BMS-986165 en pacientes con psoriasis en placas de moderada a grave	COMMERCIAL CLINICAL TRIAL	-	III

Group	Title	Subtype	LR Name	Phase
B-10	Estudio observacional prospectivo para evaluar la calidad de vida en pacientes con psoriassis en placa tratados con Enstilar por primera vez. QALIPSO NIS-ENSTILAR-1430	COMMERCIAL POST-AUTHORIZATION STUDY	-	SP
B-11	Estudio de fase II, abierto, guiado por biomarcadores de la eficacia de carboplatino en pacientes con cáncer de próstata resistente a la castración metastásico previamente tratados (CPRCm)-BioChiP	INDEPENDENT CLINICAL TRIAL	-	II
B-11	Ensayo aleatorizado en fase IIIb para comparar la irradiación más la supresión adyuvante de andrógenos a largo plazo con antagonista de la GnRH frente al agonista de la GnRH más prevención de los brotes en pacientes con riesgo muy alto de cáncer de próstata localizado o localmente avanzado. Estudio conjunto ROG y GUCG de la EORTC. Pegasus	INDEPENDENT CLINICAL TRIAL	ANA MARÍA OTERO ROMERO	III
B-11	Estudio clínico de fase 2b para evaluar la eficacia y seguridad de TAR-200 en combinación con cetrelimab, TAR-200 solo o cetrelimab solo en participantes con cáncer de vejiga no músculo-invasivo (CVNMI) de alto riesgo que no responde a la terapia del bacilo de Calmette-Guerin (BCG) intravesical y que no son candidatos o han elegido no someterse a cistectomía radical (SunRISe-1)	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio de fase 2, multicéntrico, aleatorizado y abierto, de TAR-200 en combinación con cetrelimab y monoterapia con cetrelimab en participantes con carcinoma urotelial de vejiga músculo-invasivo que se vayan a tratar con cistectomía radical y no sean elegibles o rechacen recibir tratamiento con quimioterapia neoadyuvante basada en platino Sunrise 4	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	II
B-11	Estudio en fase III abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de TAR200 en combinación con cetrelimab frente al bacilo de Calmette-Guérin (BCG) intravesical en pacientes con cáncer de vejiga no músculo-invasivo de alto riesgo (HR-NMIBC) sin tratamiento previo con el BCG. Sunrise 3	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	III
B-11	Estudio en fase III, aleatorizado, controlado con placebo y doble ciego de darolutamida además de tratamiento de privación de andrógenos (TPA) frente a placebo más TPA en hombres con cáncer de próstata metastásico sensible a las hormonas (CPMSH) (ARANOTE)	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	Estudio en fase III, aleatorizado, controlado con placebo y doble ciego de darolutamida más tratamiento de privación de andrógenos (TPA) en comparación con placebo más TPA en pacientes con cáncer de próstata con recurrencia bioquímica (RB) de alto riesgo	CLINICAL TRIALS WITH DRUGS	BERNARDO HERRERA IMBRODA	III
B-11	"Patrones de tratamiento y seguimiento prolongado de los pacientes con cáncer de próstata que recibieron darolutamida en el ensayo ARAMIS – PARASEC"	OBSERVATIONAL STUDY WITH DRUGS	JUAN ANDRES CANTERO MELLADO	NA
B-11	Estudio fase 3 aleatorizado, doble ciego y controlado con placebo de JNJ-56021927 en sujetos con cáncer de próstata localizado o localmente avanzado y de alto riesgo que estén recibiendo tratamiento con radioterapia primaria.	COMMERCIAL CLINICAL TRIAL	RAQUEL CORREA GENEROSO	III
B-11	Estudio fase III, aleatorizado, doble ciego y controlado con placebo sobre el uso de apalutamida en pacientes con cáncer de próstata de alto riesgo, localizado o localmente avanzado candidatos a una prostatectomía radical.PROTEUS	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	Estudio aleatorizado, controlado, multicéntrico y abierto para investigar la eficacia y la seguridad de añadir apalutamida a la radioterapia y al agonista de la HLHL en pacientes con cáncer de próstata hormonosensible positivos en PET con PSMA, con un seguimiento observacional de los pacientes negativos en PET con PSMA	COMMERCIAL CLINICAL TRIAL	-	III
B-11	"Estudio observacional, multinacional y prospectivo de resultados clínicos en pacientes con cáncer de próstata hormonosensible metastásico (CPHSm) tratados con ADT más apalutamida o enzalutamida en la práctica clínica habitual (Estudio ArtemisPRO).	OBSERVATIONAL STUDY WITH DRUGS	DAVID HERNANDEZ ALCARAZ	NA
B-11	An open-label, randomized study to assess the relative bioavailability (BA) and bioequivalence (BE) of fixed-dose Estudio abierto, aleatorizado para evaluar la biodisponibilidad (BD) relativa y la bioequivalencia (BE) en formulaciones de combinación a dosis fija (CDF) de niraparib y acetato de abiraterona (AA) comparado con niraparib y AA co-administrado como único agente en hombres con cáncer de próstata	COMMERCIAL CLINICAL TRIAL	-	1

Group	Title	Subtype	LR Name	Phase
B-11	Estudio observacional de darolutamida en pacientes con cáncer de próstata resistente a la castración no metastásico. DAROL	COMMERCIAL POST-AUTHORIZATION STUDY	BERNARDO HERRERA IMBRODA	OD
B-11	Estudio prospectivo observacional de parámetros clinicos y biomarcadores en cáncer de próstata avanzado en hospitales de España. IRONMAN-ES	INDEPENDENT POST-AUTHORIZATION STUDY	BERNARDO HERRERA IMBRODA	AS
B-11	Ensayo de fase 3, multicéntrico, abierto y aleatorizado para comparar la seguridad y la eficacia de 177Lu-PSMA-I&T frente al tratamiento hormonal en pacientes con cáncer de próstata resistente a la castración metastásico.	CLINICAL TRIALS WITH DRUGS	DAVID HERNANDEZ ALCARAZ	Ш
B-11	Ensayo mundial fase III, aleatorizado, abierto, multicéntrico de Durvalumab y el Bacilo de Calmette-Guerin (BCG) administrados como terapia combinada en comparación con BCG en monoterapia, en pacientes con cáncer de vejiga no músculo invasivo de alto riesgo sin tratamiento previo con BCG (POTOMAC)	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	Estudio en fase II, aleatorizado y abierto de ODM-201 oral frente al tratamiento de deprivación androgénica (TDA) con agonistas oantagonistas de LHRH en varones con cáncer de próstata sin tratamiento hormonal previo	INDEPENDENT CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	II
B-11	A PROSPECTIVE RANDOMISED PHASE III STUDY OF ANDROGEN DEPRIVATION THERAPY WITH OR WITHOUT LOCAL RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-NAÏVE PROSTATE CANCER	INDEPENDENT CLINICAL TRIAL	RAQUEL CORREA GENEROSO	III
B-11	Estudio de fase 3, multinacional, aleatorizado, doble ciego, de no inferioridad, para evaluar la eficacia y la seguridad de HC-1119 oral frente a enzalutamida en el cáncer de próstata resistente a la castración metastásico (CPRCm). PROCADE	COMMERCIAL CLINICAL TRIAL	DAVID HERNANDEZ ALCARAZ	III
B-11	Estudio multicéntrico de radioterapia postoperatoria hipofraccionada en pacientes diagnosticados de cáncer de próstata	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ANA MARÍA OTERO ROMERO	0
B-11	Estudio de fase III con un solo grupo para evaluar la eficacia y la seguridad de ONCOFID-P-B (conjugado paclitaxel-ácido hialurónico) administrado por vía intravesical a pacientes con carcinoma in situ de vejiga sin respuesta a BCG, con o sin enfermedad papilar Ta-T1	CLINICAL TRIALS WITH DRUGS	FELIPE SÁEZ BARRANQUERO	III
B-11	RECAP (Registro Español de Cáncer de Próstata). Tratamiento radioterápico en pacientes con cáncer de próstata conforme a la práctica clínica habitual en los servicios de oncología radioterápica españoles	INDEPENDENT POST-AUTHORIZATION STUDY	ANA MARÍA OTERO ROMERO	SP
B-11	Estudio de fase 3, en doble ciego, aleatorizado, controlado con placebo y multicéntrico, para evaluar la eficacia, seguridad y tolerabilidad de vibegrón en varones con síntomas de vejiga hiperactiva en tratamiento farmacológico por hiperplasia prostática benigna	COMMERCIAL CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	III
B-11	Estudio piloto de los efectos biológicos de la vitamina D en pacientes con carcinoma urotelial del tracto urinario resecable	INDEPENDENT CLINICAL TRIAL	BERNARDO HERRERA IMBRODA	IV
BA-20	IRRADIACIÓN PARCIAL ACELERADA DE LA MAMA: NUEVO FRACCIONAMIENTO ALTERADO	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSÉ MARÍA AZCOAGA BLASCO	0
BA-20	Estudio postautorización, multicéntrico, observacional, retrospectivo, de evaluación de seguridad, tolerabilidad y efectividad en el tratamiento con fármacos antiepilépticos en pacientes con crisis epilépticas secundarias a tumor cerebral tratados con radioterapia. NERAD	INDEPENDENT POST-AUTHORIZATION STUDY	ASUNCION VILLANUEVA ALVAREZ	OD
BA-20	Estudio multicéntrico de radioterapia postoperatoria hipofraccionada en pacientes diagnosticados de cáncer de próstata	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ISMAEL HERRUZO CABRERA	0
BA-20	Estudio pivotal, multinacional, aleatorizado, doble ciego y controlado con placebo, de SGX942 (Dusquetide) para el tratamiento de la mucositis oral en pacientes con carcinoma de células escamosas de cabeza y cuello tratado con quimiorradiación concomitante	COMMERCIAL CLINICAL TRIAL	JORGE CONTRERAS MARTÍNEZ	III

Group	Title	Subtype	LR Name	Phase
BA-20	Estudio de fase III (etapa pivotal) de NBTXR3 activado por radioterapia, en monoterapia o en combinación con cetuximab a elección del investigador, en pacientes ancianos con carcinoma de células escamosas de cabeza y cuello localmente avanzado, que no cumplen los requisitos para recibir quimioterapia basada en platino	OBSERVATIONAL STUDY WITH DRUGS	JORGE CONTRERAS MARTÍNEZ	NA
BA-20	Estudio de fase I de aumento escalonado de la dosis de NBTXR activado mediante radioterapia de intensidad modulada en pacientes con carcinoma de células escamosas localmente avanzado en la cavidad bucal o la orofaringe	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JORGE CONTRERAS MARTÍNEZ	0
BA-20	RECAP (Registro Español de Cáncer de Próstata). Tratamiento radioterápico en pacientes con cáncer de próstata conforme a la práctica clínica habitual en los servicios de oncología radioterápica españoles	INDEPENDENT POST-AUTHORIZATION STUDY	ASUNCION VILLANUEVA ALVAREZ	SP
BA-20	Efectividad de los nuevos tratamientos para el cáncer de próstata localizado de bajo riesgo	NON-POST-AUTHORIZATION STUDY	ISMAEL HERRUZO CABRERA	NO
BE-17	Optimización de la radiación a través de la Evaluación Molecular de ganglios linfáticos después del tratamiento sistémico primario (OPTIMAL IIa).	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ISABEL GARCIA RIOS	0
BE-17	Linfadenectomía axilar versus Radioterapia axilar en pacientes con cáncer de mama y ganglio centinela positivo tras terapia neoadyuvante. Estudio multicéntrico aleatorizado. (ADARNAT)	CLINICAL RESEARCH WITH MEDICAL PRODUCTS	ANGEL CALVO TUDELA	NA
C-01	Estudio en fase IIIb, aleatorizado, controlado, abierto y con enmascaramiento para los evaluadores sobre la eficacia, la seguridad y la tolerabilidad de un intervalo ampliado de 6 semanas de administración de natalizumab (BG00002) en sujetos con esclerosis múltiple recidivante-remitente que anteriormente recibían tratamiento con natalizumab en un intervalo estándar de administración (IEA) de 4 semanas en relación con el tratamiento de IEA continuado	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	IIIb
C-01	Ensayo en fase III, doble ciego, aleatorizado y controlado con placebo del tratamiento adyuvante con ganaxolona (GNX) en niños y adultos con epilepsia relacionada con el complejo de esclerosis tuberosa (CET) (TrustTSC)	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio abierto de fase III del tratamiento adyuvante con ganaxolona (GNX) en niños y adultos con epilepsia relacionada con el complejo de esclerosis tuberosa (CET) (TrustTSC OLE)	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	Ш
C-01	A 12-month, prospective, observational study in adult patients with focal onset seizures who are treated with adjunctive ASM in real world setting	OBSERVATIONAL STUDY WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	NA
C-01	Estudio de fase II, de 2 partes, multicéntrico, aleatorizado, ciego y controlado con principio activo para evaluar de forma secuencial la seguridad y la eficacia de BIIB091 en monoterapia y del tratamiento combinado de BIIB091 con fumarato de diroximel en participantes con formas recidivantes de esclerosis múltiple	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	II
C-01	Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y multicéntrico para evaluar la eficacia, la seguridad y la tolerabilidad de JNJ-40411813 como tratamiento complementario en sujetos con crisis epilépticas de inicio focal con respuesta subóptima a levetiracetam.	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio de extensión del estudio AC 058B201, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, para evauar la seguridad, tolerabilidad, y eficacia a largo plazo de 10, 20, y 40 mg/día de ACT-128800, un agonista oral de los receptores S1P1, en pacientes con esclerosis múltiple recurrenteremitente.	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	II
C-01	Estudio de extensión del ensayo AC-058B301, multicéntrico, no comparativo, para valorar la seguridad, tolerabilidad y control de la enfermedad a largo plazo de ponesimod 20 mg en sujetos con esclerosis múltiple recidivante	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	Ш
C-01	Estudio de fase 2, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar la eficacia, seguridad y farmacocinética de rozanolixizumab en adultos con encefalitis autoinmune asociada a anticuerpos dirigidos frente a la proteína 1 inactivada del glioma rica en leucina	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II

Group	Title	Subtype	LR Name	Phase
C-01	Estudio de fase III, sin enmascaramiento, de un único grupo, multicéntrico para evaluar la farmacocinética, la farmacodinámica, la eficacia, la seguridad y la inmunogenicidad del ravulizumab administrado por vía intravenosa en participantes pediátricos (de 6 a <18 años de edad) con miastenia grave generalizada (MGg)	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	III
C-01	Estudio multicéntrico, abierto, controlado con placebo externo y de fase III para evaluar la eficacia y la seguridad de ravulizumab en pacientes adultos con trastorno del espectro de neuromielitis óptica (NMOSD)	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	III
C-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, paralelo y multicéntrico para evaluar la seguridad y eficacia de ALXN1720 en adultos con miastenia gravis generalizada.	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	III
C-01	Estudio de fase 2, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de ALXN2050 en participantes adultos con miastenia grave generalizada	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	II
C-01	ESTUDIO MULTICÉNTRICO ABIERTO DE EXTENSIÓN A LARGO PLAZO DE LOS ESTUDIOS DE FASE III (BN29552/BN29553) DE CRENEZUMAB EN PACIENTES CON ENFERMEDAD DE ALZHEIMER	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio de Fase IIIb, multicéntrico, aleatorizado, doble ciego y controlado para evaluar la eficacia, la seguridad y la farmacocinética de una dosis más alta de Ocrelizumab en adultos con formas recurrentes de esclerosis múltiple.	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio en fase IIb, aleatorizado, con doble enmascaramiento, comparativo con placebo y multicéntrico, para evaluar la eficacia y la seguridad de prasinezumab intravenoso en participantes con enfermedad de parkinson incipiente	COMMERCIAL CLINICAL TRIAL	LUCIA GARCIA TRUJILLO	П
C-01	Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, con duración variable del tratamiento, que evalúa la eficacia y seguridad de Siponimod (BAF312) en pacientes con esclerosis múltiple secundaria progresiva	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	III
C-01	Estudio observacional retrospectivo para evaluar el uso de siponimod (MAyzent) en pacientes con Esclerosis Múltiple Secundaria Progresiva en la práctica clínica habitual en España. Estudio RESYZE	OBSERVATIONAL STUDY WITH DRUGS	ANA MARÍA ALONSO TORRES	NA
C-01	Estudio multicéntrico, aleatorizado, doble ciego, con control activo, de dos años de duración para evaluar la seguridad y la eficacia de fingolimod administrado por vía oral una vez al día frente a interferon ?-1a i.m. administrado una vez a la semana en pacientes pediátricos con esclerosis múltiple	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	III
C-01	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos y con fase de extensión para evaluar la eficacia y la seguridad de Dysport® en relación con la prevención de la migraña crónica en participantes adultos	CLINICAL TRIALS WITH DRUGS	LUCIA GARCIA TRUJILLO	III
C-01	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos y con fase de extensión para evaluar la eficacia y la seguridad de Dysport® en relación con la prevención de la migraña crónica en participantes adultos	CLINICAL TRIALS WITH DRUGS	LUCIA GARCIA TRUJILLO	III
C-01	Estudio aleatorizado, doble ciego con doble enmascaramiento y grupos paralelos en el que se compara la eficacia y seguridad de remibrutinib 100 mg b.i.d. frente a teriflunomida 14 mg q.d. en participantes con esclerosis múltiple recurrente, seguido de una extensión abierta del tratamiento con remibrutinib.	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Ensayo Clínico Fase II, Multicéntrico, Abierto, Controlado y Aleatorizado, para valorar la eficacia de la Infusión Intra arterial de células Mononucleadas de Médula Ósea Autóloga en Pacientes Con Ictus Isquémico	INDEPENDENT CLINICAL TRIAL	JOSE ANTONIO TAMAYO TOLEDO	П
C-01	Estudio de fase III de no inferioridad, aleatorizado, abierto, de grupos paralelos y multicéntrico para investigar la farmacocinética, la farmacodinámica, la seguridad y los efectos radiológicos y clínicos de Ocrelizumab subcutáneo en comparación con Ocrelizumab intravenoso en pacientes con Esclerosis Múltiple	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	Ш
C-01	Estudio de extensión abierto, de brazo único y multicéntrico, para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de ofatumumab, en pacientes con esclerosis múltiple que cursa con brotes	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III

Group	Title	Subtype	LR Name	Phase
C-01	Estudio abierto, aleatorizado, con evaluador ciego, multicéntrico, de brazos paralelos, con comparador activo para evaluar la eficacia y tolerabilidad de Ofatumumab 20 mg s.c. administrado mensualmente vs. TME de primera línea a elección del médico en el tratamiento de pacientes con Esclerosis Múltiple Recurrente (EMR) de reciente diagnóstico (STHENOS)	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio multicéntrico, aleatorizado, con enmascaramiento doble, controlado con placebo y de fase 2 en el que se evalúan la seguridad y la eficacia de CORT113176 (Dazucorilant) en pacientes con esclerosis lateral amiotrófica (DAZALS)	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	II
C-01	Estudio multicéntrico aleatorizado, doble ciego, controlado con placebo y de grupos paralelos acerca de CVL-865 como tratamiento complementario en adultos con crisis convulsivas de inicio focal resistentes a los fármacos (estudio REALIZE)	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio de extensión abierto, multicéntrico y con tratamiento activo de 57 semanas de CVL-865 como tratamiento complementario en adultos con crisis convulsivas de inicio focal resistentes a los fármacos	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	II
C-01	Estudio de eficacia y seguridad de fase 3, aleatorizado y doble ciego que compara SAR442168 con teriflunomida (Aubagio®) en participantes con formas recidivantes de esclerosis múltiple (GEMINI 1)	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio de fase 3, aleatorizado, doble ciego para evaluar la eficacia y seguridad del tratamiento con SAR442168 frente a teriflunomida (Aubagio®) en pacientes con esclerosis múltiple recidivante (GEMINI 2)	INDEPENDENT CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio en fase 3, aleatorizado, doble ciego para evaluar la eficacia y seguridad del tratamiento con SAR442168 frente a placebo en pacientes con esclerosis múltiple primaria progresiva (PERSEUS)	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio de eficacia y seguridad de fase 3, aleatorizado y doble ciego que compara SAR442168 con placebo en participantes con esclerosis múltiple secundaria progresiva no recidivante (HERCULES)	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio prospectivo, no intervencionista, observacional y multicéntrico para investigar la dosis, la eficacia y la seguridad de perampanel cuando se utiliza como primer tratamiento complementario en la asistencia clínica habitual de pacientes mayores de 12 años con crisis de inicio parcial con o sin generalización secundaria o con crisis tonicoclónicas generalizadas primarias asociadas a epilepsia generalizada idiopática (sponsor's code E2007-M044-512)	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO JESÚS SERRANO CASTRO	SP
C-01	ESTUDIO DE EXTENSIÓN ABIERTO Y MULTICÉNTRICO PARA EVALUAR LA SEGURIDAD Y EFICACIA A LARGO PLAZO DE LACOSAMIDA COMO TRATAMIENTO COMPLEMENTARIO PARA LAS CRISIS TÓNICO-CLÓNICAS GENERALIZADAS PRIMARIAS NO CONTROLADAS EN PACIENTES CON EPILEPSIA IDIOPÁTICA GENERALIZADA	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	III
C-01	Registro en España del uso de los inhibidores de la COMT en el manejo de pacientes con enfermedad de Parkinson que presentan fluctuaciones motoras tempranas. Estudio REONPARK	OBSERVATIONAL STUDY WITH DRUGS	LUCIA GARCIA TRUJILLO	NA
C-01	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY OF FAB122 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS. ADOREXT	CLINICAL TRIALS WITH DRUGS	VIRGINIA REYES GARRIDO	
C-01	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y seguridad de FAB122 en pacientes con esclerosis lateral amiotrófica	COMMERCIAL CLINICAL TRIAL	VIRGINIA REYES GARRIDO	III
C-01	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JOSE ANTONIO TAMAYO TOLEDO	0
C-01	Estudio fase III multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento y grupos paralelos para evaluar la eficacia y seguridad de Fenebrutinib comparado con Ocrelizumab en pacientes adultos con Esclerosis Múltiple Primaria Progresiva	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CON DOBLE ENMASCARAMIENTO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD FENEBRUTINIB EN COMPARACIÓN CON TERIFLUNOMIDA EN PACIENTES ADULTOS ESCLEROSIS MÚLTIPLE RECURRENTE	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	Ш

Group	Title	Subtype	LR Name	Phase
C-01	Observational, multicenter study to describe the persistence in relapsing remitting multiple sclerosis naive patients with low-moderate activity treated with Ozanimod (Zeposia ®) in clinical practice in Spain (AppreZiate Study)	OBSERVATIONAL STUDY WITH DRUGS	ANA MARÍA ALONSO TORRES	NA
C-01	Monitorización de la Movilidad de enfermos de Parkinson con fines terapéuticos - Ensayo Clínico. Estudio (oMoPa-EC.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	TERESA MUÑOZ RUIZ	0
C-01	Estudio intervencionista de extensión en fase III para investigar la seguridad y la tolerabilidad a largo plazo de tolebrutinib en participantes con esclerosis múltiple recidivante, esclerosis múltiple primaria progresiva o esclerosis múltiple secundaria progresiva no recidivante	CLINICAL TRIALS WITH DRUGS	ANA MARÍA ALONSO TORRES	III
C-01	Estudio de evidencia en práctica clínica real: Estudio de cohorte prospectivo no intervencional post- autorización para evaluar la efectividad, la seguridad y los resultados de salud a largo plazo del tratamiento de la esclerosis múltiple recurrente en la práctica clínica de rutina en España con cladribina comprimidos. Sponsor Code: MS700568_0073. MAVEN 4-	COMMERCIAL POST-AUTHORIZATION STUDY	ANA MARÍA ALONSO TORRES	SP
C-01	Estudio de prolongación multicéntrico, de un solo grupo, abierto y de extensión para evaluar la seguridad y la eficacia a largo plazo de ocrelizumab en pacientes con esclerosis múltiple	INDEPENDENT CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio en fase III, multicéntrico y aleatorizado, de grupos paralelos, doble ciego y doble simulación, controlado de forma activa, para evaluar la eficacia y seguridad de Evobrutinib en comparación con Teriflumonida, en participantes con esclerosis múltiple recidivante	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	EXTENSION MULTINACIONAL, MULTICENTRICA Y DE FASE ABIERTA CON TRATAMIENTO ACTIVO DEL ESTUDIO MS-LAQ-3012 (BRAVO) PARA EVALUAR LA SEGURIDAD A LARGO PLAZA, LA TOLERABILIDAD Y EL EFECTO SOBRE EL CURSO DE LA ENFERMEDAD DE LA ADMINISTRACION ORAL DE LAQUINIMOD 0,6 MG UNA VEZ AL DÍA EN PACIENTES CON ESCLEROSIS MÚLTIPLE	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	III
C-01	MEDIDAS DE SEGURIDAD Y TERAPÉUTICAS DE LA ESTIMULACIÓN CON CORRIENTE CONTINUA CATÓDICA TRANSCRANEAL (TDCS) EN PACIENTES CON EPILEPSIA FOCAL RESISTENTE AL TRATAMIENTO	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	
C-01	Estudio controlado aleatorizado y multicéntrico para evaluar la seguridad y eficacia de HEMOPATCH en comparación con la práctica habitual para el sellado de duramadre como refuerzo de la sutura dural para la prevención de fugas de líquido cefalorraquídeo (LCR) postoperatorias en pacientes sometidos a cirugía de fosa posterior.	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MIGUEL ANGEL ARRÁEZ SÁNCHEZ	0
C-01	Estudio de fase 2B, de 30 semanas, prospectivo, multicéntrico, cruzado, doble ciego, aleatorizado y controlado con placebo, seguido de un estudio de extensión abierto de 52 semanas, para evaluar la eficacia y seguridad de basimglurant como adyuvante de la terapia anticonvulsiva en curso en niños, adolescentes y adultos jóvenes con epilepsia asociada al complejo de esclerosis tuberosa	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	II
C-01	Registro español de alteraciones hematológicas durante el tratamiento con siponimod. Estudio REALhES.	OBSERVATIONAL STUDY WITH DRUGS	PATRICIA URBANEJA ROMERO	
C-01	Estudio multicéntrico no intervencional para evaluar la efectividad de ocrelizumab en pacientes con esclerosis múltiple recurrente o primaria progresiva en práctica clínica habitual. ESTUDIO MuSicalE (MN39889)	COMMERCIAL POST-AUTHORIZATION STUDY	ANA MARÍA ALONSO TORRES	SP
C-01	Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con LEMTRADA® (Alemtuzumab) en pacientes con formas recidivantes de esclerosis múltiple. (Estudio OBS13434)	COMMERCIAL POST-AUTHORIZATION STUDY	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	LA
C-01	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de soticlestat como tratamiento adyuvante en sujetos pediátricos y en adultos jóvenes con síndrome de Dravet (SD)	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	Ш
C-01	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de soticlestat como tratamiento adyuvante en sujetos pediátricos y en adultos con síndrome de Lennox-Gastaut (SLG)	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	Ш

Group	Title	Subtype	LR Name	Phase
C-01	Estudio fase 3 prospectivo, abierto, multicéntrico y de extensión de los estudios Fase 3, para evaluar la seguridad y tolerabilidad a largo plazo de Soticlestat como tratamiento adyuvante en pacientes con Síndrome Dravet o Síndrome de Lennox-Gastaut (ENDYMION 2)"	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-01	Estudio multinacional, observacional y no intervencionista de 12 meses para evaluar la efectividad, tolerabilidad y calidad de vida de la terapia añadida con brivaracetam en líneas de tratamiento precoz en pacientes adultos con antecedentes de crisis de inicio focales en la práctica clínica diaria. EP0103 UCB BRITOBA	COMMERCIAL POST-AUTHORIZATION STUDY	PEDRO JESÚS SERRANO CASTRO	SP
C-01	ESTUDIO ALEATORIZADO, DOBLE CIEGO, CON DOBLE SIMULACIÓN Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE OCRELIZUMAB EN COMPARACIÓN CON INTERFERÓN BETA-1A (REBIF) EN PACIENTES CON ESCLEROSIS MÚLTIPLE RECIDIVANTE	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	III
C-01	Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex como fármaco comtrol, para evaluara la eficacia, determinadas por las lesiones cerebrales que aparecen en la RMN y la seguridad de dos pautas terapéuticas de ocrelizumab en pacientes con EMRR	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	II
C-01	Estudio de fase III,multricentrico,aletorizado de grupos, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ocrelizumab en adultos con esclerosis multiple progresiva primaria.	COMMERCIAL CLINICAL TRIAL	VICTORIA EUGENIA FERNÁNDEZ SÁNCHEZ	Ш
C-01	Estudio de Fase IIIb, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Ocrelizumab en adultos con esclerosis múltiple progresiva primaria	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	Ш
C-01	ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CON DOBLE SIMULACIÓN PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE OCRELIZUMAB EN COMPARACIÓN CON FINGOLIMOD EN NIÑOS Y ADOLESCENTES CON ESCLEROSIS MÚLTIPLE ESCLEROSIS MÚLTIPLE REMITENTE-RECURRENTE	COMMERCIAL CLINICAL TRIAL	ANA MARÍA ALONSO TORRES	III
C-01	Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico, para evaluar la seguridad, la tolerabilidad y la eficacia del XEN1101 como tratamiento adyuvante en la epilepsia de inicio focal	COMMERCIAL CLINICAL TRIAL	PEDRO JESÚS SERRANO CASTRO	П
C-01	Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad y la eficacia de XEN1101 como tratamiento complementario de las crisis convulsivas de inicio focal_	CLINICAL TRIALS WITH DRUGS	PEDRO JESÚS SERRANO CASTRO	III
C-02	Prevención universal de la depresión y ansiedad en población general mediante una intervención personalizada basada en algoritmos de riesgo, TICs y sistemas de ayudas a las decisiones: Ensayo Aleatorio Controlado (Estudio PredictPlusPrevent)	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JUAN ÁNGEL BELLÓN SAAMEÑO	0
C-02	Prevención de la depresión a través de una intervención personalizada basada en TICs, algoritmos predictivos de riesgo, y DSS para pacientes y médicos de familia: estudio e-predictD	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JUAN ÁNGEL BELLÓN SAAMEÑO	0
C-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de lclepertina una vez al día durante un periodo de tratamiento de 26 semanas en pacientes con esquizofrenia (CONNEX-2)	CLINICAL TRIALS WITH DRUGS	FERMÍN MAYORAL CLERIES	III
C-03	Estudio de fase II, de 6 semanas, multicéntrico, aleatorizado, doble ciego, doble enmascaramiento, controlado con placebo y de grupos paralelos, con un grupo de quetiapina para evaluar la eficacia, tolerabilidad y seguridad de BI 1358894 oral en pacientes con trastorno depresivo mayor con respuesta inadecuada a los antidepresivos.	CLINICAL TRIALS WITH DRUGS	FERMÍN MAYORAL CLERIES	II
C-03	Estudio de extensión, abierto, de seguridad a largo plazo de esketamina en la depresión resistente al tratamiento. Seguridad y mantenimiento de la respuesta al tratamiento con esketamina con dosis repetidas en intervalos determinados por la gravedad de los síntomas (SUSTAIN-3).	COMMERCIAL CLINICAL TRIAL	FERMÍN MAYORAL CLERIES	III
C-03	"Un estudio aleatorizado, doble ciego, multicéntrico, de grupos paralelos y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de aticaprant 10 mg como tratamiento complementario en participantes adultos con trastorno depresivo mayor (TDM) con anhedonia moderada a grave y una respuesta insuficiente al tratamiento antidepresivo actual."	CLINICAL TRIALS WITH DRUGS	FERMÍN MAYORAL CLERIES	III

Group	Title	Subtype	LR Name	Phase
C-03	"UN ESTUDIO ABIERTO Y A LARGO PLAZO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE ATICAPRANT COMO TRATAMIENTO COMPLEMENTARIO EN PARTICIPANTES ADULTOS Y DE EDAD AVANZADA CON TRASTORNO DEPRESIVO MAYOR (TDM)"	CLINICAL TRIALS WITH DRUGS	FERMÍN MAYORAL CLERIES	III
C-03	Estudio de las características de la enfermedad y la eficacia del tratamiento habitual en la vida real en pacientes con trastorno depresivo mayor (TDM) con anhedonia y respuesta inadecuada al tratamiento antidepresivo actual, incluido un ISRS o un IRSN	OBSERVATIONAL STUDY WITH DRUGS	FERMÍN MAYORAL CLERIES	NA
C-03	Estudio observacional, prospectivo, de cohorte, de 12 meses para analizar los cambios en el perfil cardiometabólico del cambio a lurasidona en pacientes con esquizofrenia. Estudio RESPECT.	COMMERCIAL POST-AUTHORIZATION STUDY	FERMÍN MAYORAL CLERIES	SP
C-03	Estudio de fase 2, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de RO6889450 (ralmitaront) en pacientes con esquizofrenia o trastorno esquizoafectivo y síntomas negativos.	COMMERCIAL CLINICAL TRIAL	FERMÍN MAYORAL CLERIES	II
C-03	Ensayo clínico aleatorizado, multicéntrico, para evaluar la seguridad y tolerabilidad de clozapina vs tratamiento de práctica clínica habitual en psicosis resistente a tratamiento en personas adolescentes y adultos jóvenes con discapacidad intelectual.	INDEPENDENT CLINICAL TRIAL	FERMÍN MAYORAL CLERIES	II
C-06	Características clínicas de los pacientes tratados con lurasidona en España: análisis restrospectivo de la información recogida en las historias clínicas electrónicas mediante el Procesamiento del Lenguaje Natural	COMMERCIAL POST-AUTHORIZATION STUDY	CARLOS GOMEZ SANCHEZ-LAFUENTE	OD
C-08	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de bemnifosbuvir en pacientes ambulatorios de alto riesgo con COVID-19	CLINICAL TRIALS WITH DRUGS	LEOVIGILDO GINEL MENDOZA	III
C-08	A prospective study to evaluate the immune status in the elderly after receiving a booster dose under the Covid-19 vaccination program in Spain	OBSERVATIONAL STUDY WITH DRUGS	LEOVIGILDO GINEL MENDOZA	NA
C-08	Estudio observacional de cohortes de la seguridad posterior a la autorización (PAS) para cuantificar la incidencia y la seguridad comparativa de eventos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación UMEC /VI por inhalación o UMEC por inhalación en comparación con tiotropio. (Estudio 201038)	COMMERCIAL POST-AUTHORIZATION STUDY	LEOVIGILDO GINEL MENDOZA	LA
C-08	Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia analgésica y la seguridad de una combinación en dosis fijas por vía oral de dexketoprofeno trometamol y tramadol hidrocloruro en el dolor agudo de moderado a intenso en pacientes con lumbalgia aguda: estudio DANTE	COMMERCIAL CLINICAL TRIAL	LEOVIGILDO GINEL MENDOZA	IV
C-08	Estudio Observacional con Medicamento, para evaluar y documentar con monitorización continua de glucosa (MCG) la aparición de hipoglucemia en pacientes con diabetes mellitus tipo 2 (DM2) tratados con Glargina-100 en el ámbito de la Atención Primaria. Estudio GPDetect.	OBSERVATIONAL STUDY WITH DRUGS	JUAN PABLO GARCÍA PAINE	OD
C-08	Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®	CLINICAL TRIALS WITH DRUGS	LEOVIGILDO GINEL MENDOZA	IV
C-08	Registro de pacientes con psoriasis y riesgo cardiovascular en Atención Primaria	NON-POST-AUTHORIZATION STUDY	LEOVIGILDO GINEL MENDOZA	NO
C-11	Estudio nacional retrospectivo para evaluar la efectividad, tolerancia y seguridad del citrato de fentanilo sublingual en pacientes ancianos con dolor irruptivo oncológico. Estudio PODIO. Sponsor Code: FKAP-NIS-2001	COMMERCIAL POST-AUTHORIZATION STUDY	MARIANO FERNANDEZ BAENA	OD
C-12	Estudio de la eficacia y reorganización cerebral tras el tratamiento combinado con Donepezilo, rehabilitación intensiva y estimulación transcraneal de corriente directa en la afasia crónica. FIM-DON-2017-01. PI16/01514	INDEPENDENT CLINICAL TRIAL	-	IV
C-16	Estudio de extensión, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de linzagolix a largo plazo en pacientes con dolor asociado a endometriosis (Extensión del Edelweiss 3)	COMMERCIAL CLINICAL TRIAL	EMILIA VILLEGAS MUÑOZ	III

Group	Title	Subtype	LR Name	Phase
C-16	Estudio fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para demostrar la eficacia de una dosis única de la vacuna materna no adyuvada frente al Virus Respiratorio Sincitial (VRS), administrada por vía IM a gestantes de 18 a 49 años de edad, para la prevención de la Enfermedad vías respiratorias Bajas (EVRB) asociada al VRS en sus hijos hasta los 6 meses de edad. RSV-MAT-009	COMMERCIAL CLINICAL TRIAL	JESUS SALVADOR JIMENEZ LOPEZ	III
C-16	"Estudio de cohortes de fase 3b, no aleatorizado, abierto e internacional para describir la seguridad de las participantes que recibieron o la vacuna para inmunización materna RSVPreF3 (cualquier dosis) o el placebo (grupo control) en los estudios RSV MAT anteriores (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 y RSV MAT-039), durante cualquier embarazo posterior a la vacunación con la vacuna RSVPreF3 o el placebo."	CLINICAL TRIALS WITH DRUGS	JESUS SALVADOR JIMENEZ LOPEZ	III
C-16	Estudio de superioridad, multicéntrico, aleatorizado, doble ciego, de tres grupos paralelos en el que se evalúa la eficacia y seguridad de mifepristona (2,5 mg y 5 mg) frente a placebo en el tratamiento de la endometriosis en mujeres en edad fértil durante 24 semanas MÁS un seguimiento de la eficacia y seguridad en pacientes tratadas con 2,5 mg y 5 mg de mifepristona	COMMERCIAL CLINICAL TRIAL	JESUS SALVADOR JIMENEZ LOPEZ	III
C-16	Ensayo clínico de fase 2, multicéntrico, abierto, aleatorizado, para evaluar la inhibición de la ovulación de tres dosificaciones de levonorgestrel (LNG) en un sistema de liberación vaginal (SLV), que se libera durante 28 días de manera continua, frente a desogestrel (Cerazet®).	COMMERCIAL CLINICAL TRIAL	JESUS SALVADOR JIMENEZ LOPEZ	II
C-16	Ensayo clínico aleatorizado, abierto, multicéntrico de grupos paralelos y con grupo control, para explorar la eficacia del gel vaginal papilocare® en la reparación de la mucosa cervical con lesiones causadas por virus papiloma humano de alto riesgo	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JESUS SALVADOR JIMENEZ LOPEZ	0
C-16	Estudio de observación multicéntrico, prospectivo y multinacional para evaluar la seguridad a largo plazo de Esmya, especialmente la seguridad endometrial, y los patrones de prescripción y gestión actuales de Esmya en el contexto de un tratamiento a largo plazo. Estudio PGL14-001.	COMMERCIAL POST-AUTHORIZATION STUDY	EMILIA VILLEGAS MUÑOZ	LA
C-16	Estudio observacional, prospectivo y multicéntrico para evaluar el uso clínico de la prueba molecular GynEC-Dx para el descarte de cáncer de endometrio y posterior seguimiento en mujeres asintomáticas con formaciones polipoideas endometriales	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	JESUS SALVADOR JIMENEZ LOPEZ	0
CE-17	Un Ensayo de Fase III, Aleatorizado, Doble ciego y Controlado con placebo de?una solución para inhalación de acetato de flecainida?para la cardioversión de la fibrilación auricular sintomática de inicio reciente a ritmo sinusal (RESTORE-1)	CLINICAL TRIALS WITH DRUGS	FRANCISCO TEMBOURY RUIZ	111
CIMO-01	ORACLE: Observación de cáncer residual mediante evaluación por biopsia líquida (Observation of ResiduAl Cancer with Liquid biopsy Evaluation)	OBSERVATIONAL STUDY WITH DRUGS	EMILIO ALBA CONEJO	NA
CIMO-01	XENERA-1: Ensayo de Fase II multicéntrico, doble-ciego, controlado con placebo y aleatorizado para comparar la eficacia de xentuzumab en combinación con everolimus y exemestano frente a everolimus y exemestano en mujeres posmenopáusicas con cáncer de mama mestastásico HR+/HER2-y enfermedad no visceral. (XENERA)	COMMERCIAL CLINICAL TRIAL	TAMARA DÍAZ REDONDO	Ш
CIMO-01	Brightline-1: Ensayo de fase II/III, aleatorizado, abierto, multicéntrico de BI 907828 comparado con doxorrubicina como tratamiento de primera línea de pacientes con liposarcoma desdiferenciado avanzado	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
CIMO-01	Estudio abierto, de fase I de escalado de dosis, con confirmación y expansión de la dosis, de BI 1810631 en monoterapia en pacientes con tumores sólidos avanzados o metastásicos con aberraciones en HER2	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
CIMO-01	Ensayo en fase III global, multicéntrico, aleatorizado y controlado con placebo para comparar la eficacia y la seguridad de fruquintinib, más los mejores cuidados paliativos frente a placebo, más los mejores cuidados paliativos en pacientes con cáncer colorrectal metastásico resistente (FRESCO-2)	COMMERCIAL CLINICAL TRIAL	JULIA ALCAIDE GARCÍA	III
CIMO-01	Estudio de fase 3 aleatorizado, multicéntrico, doble ciego y controlado con placebo de bemarituzumab más quimioterapia frente a placebo más quimioterapia en sujetos con cáncer gástrico o de la unión gastroesofágica avanzado no tratado previamente con sobreexpresión de FGFR2b (FORTITUDE-101)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III

Group	Title	Subtype	LR Name	Phase
CIMO-01	Estudio tipo cesta de fase 1b/2, multicéntrico y abierto que evalúa la seguridad y eficacia de bemarituzumab en monoterapia en tumores sólidos con sobreexpresión de FGFR2b (FORTITUDE-301)	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	II
CIMO-01	2023-12144 Estudio observacional, internacional, retrospectivo de revisión de historias clínicas, para describir las características, patrones de tratamiento y resultados clínicos en los pacientes tratados con selpercatinib dentro de un Programa de Acceso Temprano en España y Portugal (Estudio SELPIBER).	OBSERVATIONAL STUDY WITH DRUGS	ANDRES MESAS RUIZ	NA
CIMO-01	Ensayo de fase II, aleatorizado, abierto, con diseño de plataforma que utiliza un protocolo maestro para estudiar nuevos regímenes en comparación con el tratamiento de referencia en participantes con CPNM	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	OPAL Protocolo Maestro: Estudio en paraguas de múltiples cohortes en fase IB/II para evaluar la seguridad y la eficacia de nuevos tratamientos y/o combinaciones de tratamientos en participantes con cáncer de ovario (OPAL). Cohorte C: Estudio de fase II, abierto, aleatorizado, controlado y multicéntrico para comparar niraparib frente a quimioterapia doble con platino-taxano como tratamiento neoadyuvante en participantes con cáncer de ovario en estadio III/IV con deficiencia de recombinación homóloga.	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	II
CIMO-01	Estudio de fase 2, aleatorizado y doble ciego para evaluar la eficacia de Dostarlimab más quimioterapia en comparación con Pembrolizumab más quimioterapia en el cáncer de pulmón no microcítico metastásico	COMMERCIAL CLINICAL TRIAL	ANDRES MESAS RUIZ	II
CIMO-01	Estudio de Fase 3, aleatorizado, doble ciego, para comparar la eficacia y seguridad de niraparib frente a placebo en participantes con cáncer de mama HER2 negativo con mutación en BRCA o cáncer de mama triple negativo, con enfermedad molecular basada en la presencia de ADN tumoral circulante después de una terapia definitiva (ZEST).	COMMERCIAL CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	Estudio abierto de fase 1, primera vez en humanos, con GSK4381562 administrado en monoterapia y en combinación con agentes antineoplásicos en participantes con tumores sólidos avanzados seleccionados.	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
CIMO-01	Estudio de fase III abierto, aleatorizado, perioperatorio de Dostarlimab en monoterapia frente al tratamiento estándar en pacientes con cáncer de colon resecable con pérdida del mecanismo de reparación de apareamiento de bases (dMMR)/inestabilidad de microsatélites alta (MSI-H), T4NO o estadio III, no tratado. AZUR 2	CLINICAL TRIALS WITH DRUGS	ESPERANZA TORRES SÁNCHEZ	III
CIMO-01	Estudio de fase I-II para evaluar la seguridad, tolerabilidad y eficacia de PM01183 y atezolizumab en pacientes con cáncer de pulmón de células pequeñas avanzado que hayan progresado tras una quimioterapia previa de platino	INDEPENDENT CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158)	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	II
CIMO-01	Estudio de fase III, aleatorizado y doble ciego de quimioterapia con carboplatino-paclitaxel/nab-paclitaxel con o sin pembrolizumab (MK-3475) en sujetos con cáncer de pulmón no microcítico, epidermoide, metastásico, en primera línea de tratamiento (KEYNOTE-407)	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	III
CIMO-01	Estudio de fase 1, de incremento de dosis y con ampliación de cohortes, de TSR-042, un anticuerpo monoclonal anti-PD-1, en pacientes con tumores sólidos avanzados. (PR-4010-01-001)	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
CIMO-01	Estudio en fase III, aleatorizado, doble ciego y multicéntrico de dostarlimab (TSR-042) más carboplatino-paclitaxel frente a placebo más carboplatino-paclitaxel en pacientes con cáncer de endometrio avanzado recidivante o primario (RUBY)	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	Ш
CIMO-01	Estudio de fase I, con aumento escalonado de la dosis y ampliación de cohortes, de TSR-022, un anticuerpo monoclonal anti-TIM-3, en pacientes con tumores sólidos avanzados (AMBER)	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I
CIMO-01	Estudio de Fase 1b-2 para evaluar la seguridad, eficacia, farmacocinética y farmacodinamia de erdafitinib más JNJ-63723283, un anticuerpo monoclonal anti-PD-1, en sujetos con cáncer urotelial metastásico o no resecable con determinadas alteraciones del gen del FGFR	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	II

Group	Title	Subtype	LR Name	Phase
CIMO-01	Evaluación de la Mitigación de las Reacciones Relacionadas con la Infusión de Amivantamab.	CLINICAL TRIALS WITH DRUGS	INMACULADA RAMOS GARCIA	II
CIMO-01	Estudio fase III, doble ciego, aleatorizado y controlado con placebo de niraparib en combinación con acetato de abiraterona y prednisona en comparación con acetato de abiraterona y prednisona para el tratamiento de sujetos con Cáncer de Próstata Metastásico	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	Ш
CIMO-01	Estudio fase I/II, abierto, multicéntrico para evaluar la seguridad, tolerabilidad, farmacocinética y actividad antitumoral de YH25448 en pacientes con cáncer de pulmón no microcítico avanzado con mutación EGFR positiva	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	Estudio fase 3 internacional, multicéntrico, doble ciego y aleatorizado, de la eficacia de zolbetuximab (IMAB362) más CAPOX, en comparación con placebo más CAPOX, como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico, claudin (CLDN)18.2 positivo y HER2 negativo	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Estudio no intervencionista de encuesta de salida para comprender el cambio significativo en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (UGE) localmente avanzado no resecable o metastásico positivo para claudina (CLDN) 18.2 y negativo para HER2 que interrumpieron el tratamiento en el estudio SPOTLIGHT o GLOW	OBSERVATIONAL STUDY WITH DRUGS	INMACULADA ALÉS DÍAZ	OD
CIMO-01	Estudio en fase II, aleatorizado y abierto para evaluar la eficacia y la seguridad de zolbetuximab (IMAB362) en combinación con nab paclitaxel y gemcitabina (Nab-P + GEM) como tratamiento de primera línea en pacientes con adenocarcinoma de páncreas metastásico con presencia de claudina-18.2 (CLDN18.2)	OBSERVATIONAL STUDY WITH DRUGS	INMACULADA ALÉS DÍAZ	II
CIMO-01	Estudio de fase IIIb, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de continuar el tratamiento con enzalutamida en pacientes con cáncer de próstata resistente a la castración metastásico, que no han recibido quimioterapia previa, que han experimentado progresión al tratamiento con enzalutamida sola, tratados con docetaxel más prednisolona. Estudio PRESIDE	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
CIMO-01	Estudio Fase II, aleatorizado, abierto de SAR439859 versus monoterapia endocrina a elección médica en pacientes premenopáusicas y postmenopáusicas con cáncer de mama con receptores de estrógeno positivos, HER2 negativo localmente avanzado o metastásico con exposición previa a terapias hormonales	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	II
CIMO-01	Ensayo de fase III aleatorizado de palbociclib con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar en cáncer de mama precoz con receptores hormonales positivos (RH+) y HER2-negativo	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	Ш
CIMO-01	Ensayo de fase III, aleatorizado y abierto para evaluar la eficacia y la seguridad de palbociclib + tratamiento anti-HER2 + tratamiento endocrino frente a tratamiento anti-HER2 + tratamiento endocrino tras el tratamiento de inducción para el cáncer de mama metastásico positivo para receptores hormonales (HR+)/positivo para HER2	COMMERCIAL CLINICAL TRIAL	ALFONSO SÁNCHEZ MUÑOZ	III
CIMO-01	Estudio de fase I/II, multicéntrico, en dos partes, abierto, orientado a evaluar la seguridad y tolerabilidad de la administración de dosis crecientes de AGI-134 en los tumores sólidos no operables/metastásicos.	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	Estudio de fase 1/1b para evaluar la seguridad y la tolerabilidad de AB308 en combinación con AB122 en participantes con neoplasias malignas avanzadas	CLINICAL TRIALS WITH DRUGS	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Ensayo fase 1, abierto, primer ensayo en humanos, de escalada de dosis y expansión, que evalúa la seguridad, tolerabilidad, máxima dosis tolerada o administrada, farmacocinética y farmacodinamia y perfil de respuesta tumoral del inhibidor de receptor de Aril Hidrocarburos BAY2416964 en participantes con tumores sólidos en estadío avanzado.	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	I
CIMO-01	Estudio de seguridad de la repetición del tratamiento de dicloruro de radio 223 en pacientes con cáncer de próstata resistente a la castración con metástasis ósea que recibieron un ciclo inicial de seis dosis de dicloruro de radio 223 de 50 kBq/kg cada cuatro semanas	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	П

Group	Title	Subtype	LR Name	Phase
CIMO-01	Estudio abierto, de un solo brazo, de continuación de tratamiento con darolutamida a pacientes incluidos previamente en estudios promovidos por Bayer.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
CIMO-01	Estudio clínico en fase III aleatorizado, doble ciego, controlado con placebo, para comparar la eficacia y la seguridad de tislelizumab (BGB-A317) más platino y fluoropirimidina frente a placebo más platino y fluoropirimidina como tratamiento de primera línea en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Estudio de fase 3, aleatorizado, controlado con placebo y en doble ciego, para evaluar la eficacia y la seguridad de tislelizumab (BGB-A317) en combinación con quimioterapia como tratamiento de primera línea en pacientes con carcinoma de esófago, recurrente, localmente avanzado o metastásico, no resecable.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Estudio de fase III, aleatorizado y abierto para comparar ociperlimab (BGB-A1217) más tislelizumab (BGB-A317) combinados con quimiorradioterapia simultánea (QRTs) seguida de ociperlimab más tislelizumab o tislelizumab más QRTs seguida de tislelizumab frente a QRTs seguida de durvalumab en pacientes con cáncer de pulmón no microcítico irresecable, localmente avanzado y sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	III
CIMO-01	Estudio de fase III aleatorizado y doble ciego de BGB-A1217, un anticuerpo anti-TIGIT, en combinación con tislelizumab frente a pembrolizumab en pacientes con cáncer de pulmón no microcítico irresecable o metastásico no tratado previamente, con expresión de PD-L1 y localmente avanzado. AdvanTIG-302	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	III
CIMO-01	Estudio multicéntrico, doble ciego, randomizado, controlado con placebo, para comparar quimioterapia más trastuzumab y placebo con quimioterapia más trastuzumab y pertuzumab, como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positivo operable	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
CIMO-01	Estudio en fase IIa, sin enmascaramiento y multicéntrico para analizar la seguridad y eficacia de la combinación de BL-8040 y pembrolizumab en pacientes con cáncer pancreático metastásico, el estudio COMBAT.	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	Estudio en fase II, multicéntrico, sin enmascaramiento, aleatorizado y controlado para comparar la eficacia de RO7198457 con la estrategia de actitud expectante en pacientes con cáncer colorrectal resecado en estadio II (riesgo elevado) y estadio III que presenten positividad de ADN tumoral circulante (ADNct) tras la resección tumoral.	CLINICAL TRIAL WITH DRUGS	JULIA ALCAIDE GARCÍA	II
CIMO-01	Ensayo en fase I/IIa, primero en el ser humano, de aumento de la dosis, multicéntrico y sin enmascaramiento, con cohortes de prolongación, para evaluar la seguridad y la eficacia preliminar de BNT142 en pacientes con tumores sólidos avanzados con presencia de CLDN6	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	II
CIMO-01	Estudio de Fase III, abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de trastuzumab emtansine versus trastuzumab como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positivo con presencia patológica de tumor residual en la mama o nódulo linfático axilar tras tratamiento preoperatorio. KATHERINE	COMMERCIAL CLINICAL TRIAL	FRANCISCO CARABANTES OCÓN	III
CIMO-01	A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	1
CIMO-01	Estudio de fase 3, aleatorizado, abierto, multicéntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con cáncer de mama avanzado con receptores estrogénicos, sin mutación del gen HER2 cuya enfermedad haya progresado después de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2)	CLINICAL TRIAL WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	ESTUDIO DE FASE 3, ALEATORIZADO, ABIERTO, MULTICÉNTRICO DE ARV-471 (PF07850327) MÁS PALBOCICLIB EN COMPARACIÓN CON LETROZOL MÁS PALBOCICLIB PARA EL TRATAMIENTO DE PARTICIPANTES CON CÁNCER DE MAMA CON RECEPTOR ESTROGÉNICO POSITIVO Y HER2 NEGATIVO QUE NO HAN RECIBIDO NINGÚN TRATAMIENTO ANTINEOPLÁSICO SISTÉMICO PREVIO PARA LA ENFERMEDAD AVANZADA (VERITAC-3).	CLINICAL TRIAL WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III

Group	Title	Subtype	LR Name	Phase
CIMO-01	Ensayo clínico fase 2, aleatorizado, abierto, de BMS-986012 en combinación con carboplatino, etopósido y nivolumab como tratamiento de primera línea en el cáncer de pulmón microcítico en estadio extendido	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	Estudio fase 3, aleatorizado, de quimioterapia neoadyuvante sola frente a quimioterapia neoadyuvante más Nivolumab o Nivolumab y BMS-986205, seguido por tratamiento continuado post-cirugía con Nivolumab o Nivolumab y BMS-986205 en pacientes con cáncer de vejiga músculo-invasivo.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
CIMO-01	Primer Estudio en seres humanos fase 1/2a, del anticuerpo monoclonal BMS-986218 en monoterapia y en combinación con nivolumab en tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	"Estudio fase 1/2 de BMS-986340 en monoterapia y en combinación con Nivolumab o Docetaxel en pacientes con tumores sólidos avanzados"	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	П
CIMO-01	Estudio fase 1/2 de BMS-986408 en monoterapia y en combinación con nivolumab o con nivolumab e ipilimumab en participantes con tumores sólidos avanzados	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	ı
CIMO-01	Estudio en fase II abierto y aleatorizado de MORAb-202 (farletuzumab ecteribulina), un conjugado de anticuerpo y fármaco dirigido al receptor a de folato, en participantes con adenocarcinoma (AC) de pulmón no microcítico (ACPNM) metastásico después de haber progresado con tratamientos anteriores	CLINICAL TRIAL WITH DRUGS	INMACULADA RAMOS GARCIA	П
CIMO-01	"Estudio fase 1/2 de BMS-986449 en monoterapia y en combinación con Nivolumab en pacientes con tumores sólidos avanzados"	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	ı
CIMO-01	Estudio fase 3, aleatorizado, multicéntrico, doble ciego, controlado con placebo, de nivolumab frente a placebo en combinación con quimioterapia neoadyuvante y tratamiento hormonal adyuvante en pacientes con cáncer de mama primario de alto riesgo, receptores estrogénicos positivos (RE+) y receptor del factor de crecimiento epidérmico humano 2 negativo (HER2-). (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
CIMO-01	Ensayo de fase I/II, para evaluar la farmacocinética, en múltiples tumores, de la formulación subcutánea de Nivolumab en monoterapia	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	П
CIMO-01	Estudio fase 1b/2, abierto, aleatorizado, no comparativo de nadunolimab en combinación con gemcitabina y carboplatino en pacientes con cáncer de mama avanzado triple negativo. "Estudio TRIFOUR".	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	II
CIMO-01	Un estudio de fase III, aleatorizado, doble ciego y controlado con placebo de alpelisib en combinación con fulvestrant para hombres y mujeres posmenopáusicas con cáncer de mama avanzado HR positivo, HER2 negativo con mutación en PIK3CA, que ha progresado durante o después del tratamiento con un inhibidor de la aromatasa y un inhibidor de CDK4/6. EPIK-B5	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
CIMO-01	Estudio de fase III, multicéntrico, aleatorizado (1:1), doble ciego, controlado con placebo, de dos partes para evaluar la eficacia y seguridad de alpelisib (BYL719) en combinación con trastuzumab y pertuzumab como terapia de mantenimiento en pacientes con cáncer de mama avanzado HER2 positivo con una mutación de PIK3CA. EPIK-B2	COMMERCIAL CLINICAL TRIAL	MARIA EMILIA DOMINGUEZ RECIO	III
CIMO-01	Estudio Fase 1, multicentrico, abierto, de busqueda de dosis para evaluar la seguridad, tolerabilidady eficacia preliminar de CC-90011 administrado en combinacioncon con Cisplatino y Etoposido, de primera linea para sujetos con cancer de pulmon de celulas pequeñas en estadio extenso	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Estudio de Fase I, abierto, de búsqueda de dosis de CC-95251, un anticuerpo monoclonal dirigido contra SIRPa, solo y en combinación con cetuximab o rituximab en sujetos con tumores sólidos y hematológicos avanzados	CLINICAL TRIAL WITH DRUGS	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Estudio fase II, multicéntrico, aleatorizado, abierto, de 2 brazos, para evaluar la eficacia y seguridad del retratamiento con cetuximab e irinotecán en tercera línea frente a la terapia de elección del investigador en pacientes con cáncer colorrectal metastásico seleccionados mediante análisis genómico de ADN tumoral circulante (ADNtc) (Estudio CITRIC)	CLINICAL TRIAL WITH DRUGS	JULIA ALCAIDE GARCÍA	11

Group	Title	Subtype	LR Name	Phase
CIMO-01	Estudio de fase Ib/II, multicéntrico, abierto y de escalada de dosis de JDQ443 en pacientes con tumores sólidos avanzados con mutación KRAS G12C	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	II
CIMO-01	Estudio fase III, aleatorizado, doble ciego, controlado con placebo de LEE011 o placebo en combinación con tamoxifeno y goserelina o de un inhibidor de la aromatasa no esteroideo (IANE) y goserelina para el tratamiento de mujeres premenopáusicas con cáncer de mama avanzado con receptor hormonal positivo, HER2 negativo. MONALEESA 7	COMMERCIAL CLINICAL TRIAL	FRANCISCO CARABANTES OCÓN	III
CIMO-01	Ensayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (nuevo ensayo clínico en adyuvancia con ribociclib-[LEE011]: NATALEE)	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
CIMO-01	Ensayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (nuevo ensayo clínico en adyuvancia con ribociclib-[LEE011]: NATALEE)	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
CIMO-01	Estudio aleatorizado, doble ciego, y controlado con placebo de nab-paclitaxel y gemcitabina con o sin SBP-101 en pacientes con adenocarcinoma ductal de páncreas metastásico no tratados previamente.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de Próstata resistente a la castración tratados con doceTAxel o Cabazitaxel. Estudio PROSABI	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	AS
CIMO-01	Estudio piloto para la evaluación de la utilidad clínica del SWITCH (o cambio) de predniona por dexametasona tras progresión bioquímica inicial en pacientes con cáncer de próstata resistentes a la castración (CPRC) tratados con abiraterona. Estudio SWITCH	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	AS
CIMO-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de Próstata resistente a la castración tratados con doceTAxel o Cabazitaxel. Estudio PROSTAC	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	AS
CIMO-01	Estudio prospectivo multicéntrico de factores pronósticos en cáncer de PROstata resistente a la castración tratados con RADUIM-223. PRORADIUM	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	AS
CIMO-01	Estudio multicéntrico, sin enmascaramiento, con un grupo de referencia aleatorizado para evaluar la eficacia, la seguridad y la farmacocinética de berubicina mediante infusión intravenosa en pacientes adultos con glioblastoma multiforme (grado IV de la OMS) recidivante tras el fracaso del tratamiento de referencia de primera línea	CLINICAL TRIAL WITH DRUGS	CRISTINA GARCÍA GONZÁLEZ	II
CIMO-01	Estudio en fase III, multicéntrico, aleatorizado y abierto de rucaparib frente al tratamiento elegido por el médico para pacientes con cáncer de próstata metastásico resistente a la castración asociado a una deficiencia en la recombinación homóloga. TRITON3	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
CIMO-01	ESTUDIO DE FASE II MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO DE RO7247669 EN COMBINACIÓN CON NAB-PACLITAXEL COMPARADO CON PEMBROLIZUMAB EN COMBINACIÓN CON NAB-PACLITAXEL EN PARTICIPANTES CON CÁNCER DE MAMA TRIPLE NEGATIVO PD-L1 POSITIVO LOCALMENTE AVANZADO NO RESECABLE O METASTÁSICO, NO TRATADOS PREVIAMENTE	CLINICAL TRIAL WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	II
CIMO-01	Ensayo en fase III adaptativo, abierto, controlado, aleatorizado para evaluar la seguridad y eficacia del EndoTAG-1 más Gemcitabina frente a Gemcitabina como monoterapia en pacientes con adenocarcinoma mensurable de páncreas metastásico y /o localmente avanzado que no respondieron al tratamiento con FOLFIRINOX	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	"Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2, que han finalizado el tratamiento local y la quimioterapia neoadyuvante o adyuvante". Estudio OLYMPIA.	COMMERCIAL CLINICAL TRIAL	ANTONIA MÁRQUEZ ARAGONÉS	III
CIMO-01	Ensayo en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo de olaparib y abiraterona en comparación con placebo y abiraterona como tratamiento de primera línea en varones con cáncer de próstata metastásico resistente a la castración.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III

Group	Title	Subtype	LR Name	Phase
CIMO-01	Ensayo Clínico de fase III, doble ciego y aleatorizado, para evaluar la eficacia y seguridad de capivasertib + paclitaxel en comparación con un placebo + paclitaxel como tratamiento de primera línea en pacientes con cáncer de mama triple negativo (CMTN) localmente avanzado (inoperable) o metastásico, confirmado histológicamente	COMMERCIAL CLINICAL TRIAL	BELLA ISABEL PAJARES HACHERO	Ш
CIMO-01	Estudio en fase III aleatorizado y doble ciego para evaluar la eficacia y la seguridad de capivasertib + fulvestrant frente a placebo + fulvestrant como tratamiento para el cáncer de mama localmente avanzado (inoperable) o metastásico con receptor hormonal positivo, receptor del factor de crecimiento epidérmico humano 2 negativo (HR+/HER2?) después de la recurrencia o la progresión durante o después del tratamiento con un inhibidor de la aromatasa (CAPItello-291)	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
CIMO-01	Ensayo fase II, de un solo brazo, para evaluar la eficacia de Osimertinib en combinación con Savolitinib en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico, con mutación EGFRm positivo y MET positivo, que hayan progresado después de un tratamiento con Osimertinib (ensayo SAVANNAH).	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	II
CIMO-01	Ensayo en Fase I/IIa Multicéntrico, Abierto, para evaluar la Seguridad, Tolerabilidad, Farmacocinética, Farmacodinámica y actividad antitumoral preliminar del AZD8205 en pacientes con tumores sólidos avanzados o metastásicos.	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	III
CIMO-01	Estudio en fase I, sin enmascaramiento, de aumento gradual y ampliación de la dosis para evaluar la seguridad, la tolerabilidad, la farmacocinética, la inmunogenia y la actividad antineoplásica de MEDI5752 en pacientes con tumores sólidos avanzados.	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Ensayo de fase III aleatorizado, multicéntrico, doble ciego, de AZD9833 (un SERD, Degradador selectivo del RE, oral) más palbociclib en comparación con anastrozol más palbociclib para el tratamiento de pacientes con cáncer de mama avanzado con receptores estrogénicos positivos y HER2 negativo que no han recibido ningún tratamiento sistémico para la enfermedad avanzada. (SERENA-4)	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
CIMO-01	Ensayo en fase III, doble ciego, aleatorizado para evaluar el cambio a AZD9833 (SERD oral de nueva generación) + inhibidor de CDK4/6 (palbociclib o abemaciclib) frente a continuar con un inhibidor de la aromatasa (letrozol o anastrozol) + inhibidor de CDK4/6 en pacientes con cáncer de mama mestastásico HR+/HER2-con mutación detectable del ESR1 sin progresión de la enfermedad durante el tratamiento de 1L con inhibidor de la aromatasa + inhibidor de CDK4/6: estudio de cambio temprano guiado por ADNtc. SERENA-6	COMMERCIAL CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	Estudio de plataforma multifármaco de fase II, abierto, multicéntrico y aleatorizado de durvalumab en monoterapia o en combinación con fármacos novedosos en sujetos con cáncer de pulmón no microcítico en fase III localmente avanzado e irresecable (COAST)	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	II
CIMO-01	Ensayo Fase III, Randomizado, Doble ciego y controlado con Placebo de Durvalumab y Quimioterapia FLOT Neoadyuvante-Adyuvante seguido de Durvalumab Adyuvante en pacientes con cáncer gástrico y de la unión gastroesofágica resecable (GC/GEJC) (MATTERHORN)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Ensayo clínico, fase III, abierto, aleatorizado de Dato-DXd en comparación con la quimioterapia a elección del investigador en pacientes con cáncer de mama inoperable o metastásico con receptores hormonales positivos, HER2 negativo, que han recibido una o dos líneas previas de quimioterapia sistémica (TROPION-Breast01)	COMMERCIAL CLINICAL TRIAL	MARIA EMILIA DOMINGUEZ RECIO	III
CIMO-01	Ensayo fase 3, abierto, aleatorizado, de Datopotamab Deruxtecan (Dato-DXd) en comparación con la quimioterapia de elección del investigador en pacientes con cáncer de mama triple negativo, localmente recurrente inoperable o metastásico, que no son candidatos a terapia con inhibidores de PD-1/PD-L1 en primera línea (TROPION-Breast02)	CLINICAL TRIAL WITH DRUGS	EMILIO ALBA CONEJO	III
CIMO-01	Protocolo maestro de fase II, multicéntrico, abierto, para evaluar la eficacia y seguridad de datopotamab deruxtecán (Dato-DXd) en monoterapia y en combinación con antineoplásicos, en pacientes con tumores sólidos en estadio avanzado o metastásico (TROPION-PanTumor03)	CLINICAL TRIAL WITH DRUGS	LAURA MEDINA RODRÍGUEZ	II

Group	Title	Subtype	LR Name	Phase
CIMO-01	Ensayo clínico aleatorizado, abierto, fase 3 de datopotamab deruxtecán (Dato-DXd) con o sin durvalumab frente al tratamiento de elección del investigador en pacientes con cáncer de mama triple negativo en estadio I-III que tienen enfermedad residual invasiva en la mama y/o en los ganglios linfáticos axilares en la resección quirúrgica después de tratamiento sistémico neoadyuvante (TROPION-Breast03)	CLINICAL TRIAL WITH DRUGS	EMILIO ALBA CONEJO	III
CIMO-01	Estudio en fase II, multicéntrico y sin enmascaramiento para evaluar la eficacia y la seguridad de la monoterapia con Olaparib y la combinación de Olaparib junto con Durvalumab como tratamiento neoadyuvante en pacientes con mutaciones BRCA y cáncer de mama HER2 negativo en fase temprana (OlympiaN)	CLINICAL TRIAL WITH DRUGS	ANTONIA MÁRQUEZ ARAGONÉS	II
CIMO-01	Un estudio modular de fase I/IIa, abierto, multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética, la farmacodinámica y la eficacia preliminar de dosis ascendentes de AZD5305 como monoterapia y en combinación con agentes anticancerígenos en pacientes con neoplasias malignas sólidas avanzadas (PETRA)	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	I
CIMO-01	Estudio en fase III, intervencionista, aleatorizado, multicéntrico y abierto de DCC-2618 frente a Sunitinib en Pacientes con Tumores del Estroma Gastrointestinal Avanzados tras el tratamiento con Imatinib	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
CIMO-01	Estudio en fase III, multicéntrico, aleatorizado, abierto y controlado con principio activo de DS-8201a, un conjugado de fármaco y anticuerpo anti-HER2, frente al tratamiento de elección del investigador para sujetos con cáncer de mama irresecable y/o metastásico que expresa HER-2 tratados previamente con tratamientos estándares para HER2, incluido T-DM1	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
CIMO-01	Estudio en fase III, multicéntrico, aleatorizado, abierto y controlado con principio activo de DS-8201a, un conjugado de fármaco y anticuerpo (CAF) anti-HER2, en comparación con el tratamiento elegido por el médico en sujetos con cáncer de mama irresecable o metastásico (o ambos) con expresión baja de HER-2	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
CIMO-01	Estudio de Fase III, multicéntrico, aleatorizado, abierto y controlado de Trastuzumab Deruxtecán (T-DXd) frente a Trastuzumab Emtansina (T-DM1) en pacientes con cáncer de mama primario HER2 positivo de alto riesgo que presentan enfermedad invasiva residual en mama o en ganglios linfáticos axilares trás el tratamiento neoadyuvante. Estudio DESTINY	COMMERCIAL CLINICAL TRIAL	MARIA EMILIA DOMINGUEZ RECIO	III
CIMO-01	Estudio de fase III, abierto, aleatorizado y multicéntrico de irinotecán liposómico inyectable, oxaliplatino, 5-fluorouracilo/leucovorina frente a nab-paclitaxel más gemcitabina en pacientes que no han recibido previamente quimioterapia para el adenocarcinoma de páncreas metastásico	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Estudio preliminar, de un solo grupo, del uso concomitante de campos eléctricos para el tratamiento de tumores (TTFields, 150 kHz) y atezolizumab, gemcitabina y nab-paclitaxel como tratamiento de primera línea del adenocarcinoma ductal pancreático etastásico (ADPm)	CLINICAL TRIAL WITH DRUGS	INMACULADA ALÉS DÍAZ	I
CIMO-01	Estudio de fase 3, aleatorizado, multicéntrico, doble ciego de SAR439859 más palbociclib en comparación con letrozol más palbociclib para el tratamiento de pacientes con cáncer de mama RE(+), HER2(-) que no han recibido ningún tratamiento antineoplásico sistémico previo para la enfermedad avanzada (AMEERA-5)	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
CIMO-01	Estudio fase III aleatorizado, multicéntrico, abierto de lapatinib, tratuzumab, la administración secuencial de ambos y la administración combinada de ambos como tratamiento adyuvante en pacientes on cáncer de mama HER/ErbB2 positivo	COMMERCIAL CLINICAL TRIAL	FRANCISCO CARABANTES OCÓN	III
CIMO-01	Ensayo de fase III de quimioterapia postoperatoria frente a ningún tratamiento posterior en pacientes con cáncer de endometrio de riesgo intermedio o alto, en estadios I o II, con ganglios negativos	INDEPENDENT CLINICAL TRIAL	ALFONSO SÁNCHEZ MUÑOZ	III
CIMO-01	Ensayo fase III, aleatorizado y doble ciego de quimioterapia basada en platino con o sin atezolizumab, seguida de mantenimiento con niraparib con o sin atezolizumab, en pacientes con cáncer de ovario, de trompa de Falopio o peritoneal recidivante e intervalo libre de tratamiento con platino (ILP) >6 meses.	INDEPENDENT CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
CIMO-01	Un estudio por módulos, abierto, de fase I/II para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia de EP0031 en pacientes con neoplasias malignas avanzadas con alteraciones en el gen RET	CLINICAL TRIAL WITH DRUGS	JAVIER GARCÍA CORBACHO	II

Group	Title	Subtype	LR Name	Phase
CIMO-01	Estudio Observacional multicéntrico prospectivo en pacientes con Cáncer de Origen Desconocido a los que se les realiza el test diagnóstico CODEPICUP	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	ESPERANZA TORRES SÁNCHEZ	0
CIMO-01	ESTUDIO AMBISPECTIVO DE PACIENTES CON CÁNCER DE MAMA TRIPLE NEGATIVO TRATADOS CON SACITUZUMAB GOVITECAN EN EL SUR DE ESPAÑA	OBSERVATIONAL STUDY WITH DRUGS	ANA GODOY ORTIZ	NA
CIMO-01	Atezolizumab, pertuzumab y trastuzumab con quimioterapia como tratamiento neoadyuvante en pacientes con cáncer de mama precoz y localmente avanzado HER2 positivo de alto riesgo. GEICAM/2017-05 (APTneo)	INDEPENDENT CLINICAL TRIAL	ALFONSO SÁNCHEZ MUÑOZ	III
CIMO-01	Estudio fase III de post-neoadyuvancia que evalúa Sacituzumab Govitecan, un anticuerpo conjugado, en pacientes con cáncer primario de mama HER2 negativo con alto riesgo de recaída tras el tratamiento neoadyuvante estándar - SASCIA	INDEPENDENT CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	Primer ensayo en humanos, abierto, de aumento escalonado de la dosis con cohortes de ampliación para evaluar la seguridad y actividad antitumoral de GEN1042 en sujetos con tumores sólidos malignos	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	Primer ensayo en humanos, abierto, de aumento escalonado de la dosis con cohortes de ampliación para evaluar la seguridad de GEN1046 en sujetos con tumores sólidos malignos	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	II
CIMO-01	Ensayo clínico de fase II de un solo brazo para evaluar la eficacia y seguridad de Bintrafusp alfa (M7824) en el mesotelioma pleural maligno avanzado previamente tratado (BIMES).	INDEPENDENT CLINICAL TRIAL	INMACULADA RAMOS GARCIA	II
CIMO-01	Ensayo Clínico Multicéntrico fase III, randomizado para la comparación de la combinación de epirubicina y ciclofosmamida (EC) seguido de docetaxel (T) con Epirubicina y docetaxel (ET) seguido de capecitabina (X) en el tratamiento adyuvante de pacientes con cáncer de mama operable y ganglios linfáticos axilares positivos	INDEPENDENT CLINICAL TRIAL	FRANCISCO CARABANTES OCÓN	III
CIMO-01	Ensayo clínico multicéntrico fase III, randomizado para la comparación de la combinación de Epirubicina y Ciclofosfamida (EC) seguido de Docetaxel (T) con Epirubicina y Docetaxel (ET) seguido de Capecitabina (X) en el tratamiento adyuvante de pacientes con cáncer de mama operable y ganglios linfáticos axilares positivos	INDEPENDENT CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
CIMO-01	Ensayo aleatorizado, fase III, de terapia endocrina adyuvante estándar +/-quimioterapia en pacientes con cáncer de mama positivo para receptores hormonales y negativo para HER2 con afectación de 1 a 3 ganglios y con un recurrence score (RS) de 25 o inferior	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	III
CIMO-01	Estudio prospectivo de registro de pacientes con cáncer de mama localmente avanzado, no resecable o mestastásico (CMM). RegistEM	NON-POST-AUTHORIZATION STUDY	TAMARA DÍAZ REDONDO	NO
CIMO-01	Phase II, multicenter, randomized, double-blind, parallel-group, double-blind study to compare the efficacy and tolerability of Fulvestrant (FaslodexTM) 500mg with placebo and Fulvestrant (FaslodexTM) 500mg in combination with PD-0332991 (Palbociclib) as first-line treatment for postmenopausal patients with hormone receptor positive metastatic breast cancer, who have completed at least 5 years of adjuvant endocrine therapy and who remain disease-free for more than 12 months after completion of adjuvant therapy or who have de novo metastatic disease "FLIPPER Study"	INDEPENDENT CLINICAL TRIAL	ALFONSO SÁNCHEZ MUÑOZ	II
CIMO-01	ESTUDIO DE LARGO SEGUIMIENTO DE PACIENTES CON CÁNCER DE MAMA INCLUIDOS EN ESTUDIOS EN ESTADIOS PRECOCES DEL GRUPO GEICAM	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	IV
CIMO-01	ESTUDIO DE LARGO SEGUIMIENTO DE PACIENTES CON CÁNCER DE MAMA INCLUIDOS EN ESTUDIOS EN ESTADIOS PRECOCES DEL GRUPO GEICAM	INDEPENDENT CLINICAL TRIAL	FRANCISCO CARABANTES OCÓN	IV
CIMO-01	Ensayo aleatorizado de fase III de trastuzumab + ALpelisib +/-fulvestrant frente a trastuzumab + quimioterapia en pacientes con cáncer de mama avanzado HER2+ con mutación de PIK3CA previamente tratadas. "Estudio ALPHABET"	INDEPENDENT CLINICAL TRIAL	ANA GODOY ORTIZ	III

Group	Title	Subtype	LR Name	Phase
CIMO-01	Estudio de fase II, aleatorizado, abierto, internacional y multicéntrico, para comparar la eficacia de la quimioterapia estándar frente a letrozol más abemaciclib como terapia neoadyuvante en pacientes con cáncer de mama con RH-positivo/HER2-negativo de riesgo alto/intermedio. "Estudio CARABELA"	INDEPENDENT CLINICAL TRIAL	EMILIO ALBA CONEJO	Ш
CIMO-01	Estudio Observacional Retrospectivo de Evolución de Casos de Cáncer de Mama en el Varón y Evaluación del Riesgo de Recidiva Mediante Secuenciación Genética. GEICAM/2016-04	INDEPENDENT POST-AUTHORIZATION STUDY	ALFONSO SÁNCHEZ MUÑOZ	OD
CIMO-01	Incidencia de mutaciones BRCA somáticas y germinales en una cohorte amplia de pacientes procedentes de hospitales españoles con cáncer de ovario epitelial no mucinoso con validación de técnica somática entre laboratorios (BoRNEO).	NON-POST-AUTHORIZATION STUDY	ANTONIA MÁRQUEZ ARAGONÉS	NO
CIMO-01	Registro clinico de pacientes diagnosticadas con cáncer ginecológico del Grupo Español de Investigación en Cáncer de Ovario (GEICO)	NON-POST-AUTHORIZATION STUDY	MARIA JOSE BERMEJO PEREZ	NO
CIMO-01	Ensayo abierto, multicéntrico, de un solo brazo, de fase II con avelumab en combinación con doxorrubicina liposomal pegilada en pacientes con cáncer endometrial recurrente o metastásico	INDEPENDENT CLINICAL TRIAL	ANTONIA MÁRQUEZ ARAGONÉS	II
CIMO-01	Ensayo aleatorizado, fase II, abierto, con el anti-PD1 TSR-042 como terapia de mantenimiento en pacientes con cáncer de cérvix localmente avanzado de alto riesgo después de quimioradioterapia	INDEPENDENT CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	II
CIMO-01	Ensayo clínico fase Ib, abierto, multicéntrico, de escalada de dosis intrapaciente para evaluar el perfil de seguridad de la combinación de Tilray FS Solución oral T10: C10 (THC + CBD) con temozolomida y radioterapia en pacientes con glioblastoma recién diagnosticado	INDEPENDENT CLINICAL TRIAL	CRISTINA GARCÍA GONZÁLEZ	I
CIMO-01	Estudio observacional, retrospectivo y multicéntrico para identificar el papel pronóstico y posibles implicaciones terapéuticas del receptor de la somatostatina (SSTR) en el tumor de estroma gastrointestinal (GIST) localizado (SOMAGIST). SOMAGIST	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	SP
CIMO-01	Ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados con sobreexpresión CDK4.	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	II
CIMO-01	Registro de sarcomas raros: Herramienta de ayuda para evaluar el número de casos de cada subtipo y su orientación terapéutica por el Grupo Español de Investigación en Sarcomas (GEIS)	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	SP
CIMO-01	Estudio observacional, retrospectivo y multicéntrico para identificar los perfiles de pacientes que más se benefician del tratamiento con Trabectedina en segunda línea en pacientes con sarcoma de tejidos blandos, localmente avanzados o metastáticos, que han progresado a un tratamiento de primera línea. GEIS 38	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	OD
CIMO-01	Estudio observacional para evaluar la estrategia de uso de las terapias dirigidas, en cáncer de colon metastásico. Estudio GEMCAD 1401	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	SP
CIMO-01	Registro español de tumores neuroendocrinos	NON-POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	NO
CIMO-01	Estudio abierto y aleatorizado para comparar la eficacia y la seguridad de everolimus seguido de quimioterapia con STZ-5FU tras la progresión o la secuencia invertida, quimioterapia con STZ-5FU seguida de everolimus tras la progresión, en tumores neuroendocrinos pancreáticos (TNEP) avanzados y progresivos (estudio SEQTOR)	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
CIMO-01	Estudio de fase II de durvalumab (MEDI4736) más tremelimumab para el tratamiento de pacientes con carcinoma tiroideo avanzado, resistente al tratamiento y progresivo (ensayo DUTHY)	INDEPENDENT CLINICAL TRIAL	SOFIA RUIZ MEDINA	II
CIMO-01	Estudio de fase II de quimioterapia basada en doblete de platino en combinación con nivolumab como tratamiento de primera línea en pacientes con neoplasia neuroendocrina (NNE) G3 irresecable, localmente avanzada o metastásica del tracto gastroenteropancreático (GEP) o de origen desconocido.	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	II
CIMO-01	Ensayo clínico exploratorio "basket" de cabozantinib más atezolizumab en neoplasias avanzadas y en progresión del sistema endocrino.	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	II
CIMO-01	Estudio aleatorizado de paclitaxel – carboplatino seguido de mantenimiento con niraparib en comparación con paclitaxel – carboplatino – bevacizumab seguido de mantenimiento con niraparib + bevacizumab en pacientes con cáncer de ovario avanzado después de una cirugía citorreductora completa de primera línea	CLINICAL TRIAL WITH DRUGS	MARIA JOSE BERMEJO PEREZ	II

Group	Title	Subtype	LR Name	Phase
CIMO-01	ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO PARA COMPARAR LA EFICACIA Y SEGURIDAD DE POLATUZUMAB VEDOTIN EN COMBINACIÓN CON RITUXIMAB Y CHP (R-CHP) EN COMPARACIÓN CON RITUXIMAB Y CHOP (R-CHOP) EN PACIENTES CON LINFOMA DIFUSO DE CÉLULAS GRANDES TIPO B NO TRATADO ANTERIORMENTE. POLARIX	COMMERCIAL CLINICAL TRIAL	LAURA GALVEZ CARVAJAL	III
CIMO-01	Estudio Cesto, abierto, multicéntrico, global, en fase II con Entrectinib para el tratamiento de pacientes con tumores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes NTRK1/2/3, ROS1 o ALK. STARTRK-2:	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	Estudio Fase III, aleatorizado, doble ciego y controlado con placebo de Atezolizumab más carboplatino y etopósido con o sin Tiragolumab (anticuerpo anti-TIGIT) en pacinetes con cáncer de pulmón microcítico en estadio avanzado no tratado	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	III
CIMO-01	Estudio de Fase IA/IB de aumento y ampliación de la dosis para evaluar la seguridad, la farmacocinética y la actividad de GDC-6036 en monoterapia y en combinación con otros tratamientos antineoplásicos en pacientes con tumores sólidos avanzados o metastásicos con la mutación KRAS G12C	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Estudio de fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de Giredestrant adyuvante en comparación con la monoterapia endocrina adyuvante elegida por el médico en pacientes con cáncer de mama incipiente con receptores estrogénicos positivos y HER2 negativo. LIDERA	COMMERCIAL CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	A PHASE Ia/lb, OPEN LABEL, MULTICENTER, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7502175 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	1
CIMO-01	Proyecto de colaboración global en CIC-DUX4, BCOR-CCN3, células redondas no diferenciadas de alto grado (URCS) GEIS-2l	NON-POST-AUTHORIZATION STUDY	MARÍA ISABEL SEVILLA GARCÍA	NO
CIMO-01	Estudio de fase III, aleatorizado, abierto de sacituzumab govitecán y pembrolizumab frente al tratamiento elegido por el médico y pembrolizumab en pacientes con cáncer de mama triple negativo localmente avanzado inoperable o metastásico, no tratado anteriormente cuyos tumores presenten expresión de PD-L1	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	Estudio de fase III, aleatorizado, abierto de sacituzumab govitecán frente al tratamiento elegido por el médico en pacientes con cáncer de mama triple negativo localmente avanzado, inoperable o metastásico, no tratado anteriormente cuyos tumores no presenten expresión de PD-L1 o en pacientes tratados previamente con agentes anti PD(L)1 en fase inicial cuyos tumores presenten expresión de PD-L1	INDEPENDENT CLINICAL TRIAL	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	Ensayo en fase 3 aleatorizado, multicéntrico, abierto, comparativo con tratamiento activo para evaluar la eficacia y seguridad de octreotida (CAM2029) subcutánea de liberación prolongada frente a octreotida LP o lanreotida ATG en pacientes con tumores neuroendocrinos gastroenteropancreáticos	COMMERCIAL CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
CIMO-01	Estudio en fase 3 aleatorizado, abierto, de abemaciclib en combinación con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar, en pacientes con cáncer de mama en estadios iniciales, de alto riesgo, con afectación ganglionar, receptores hormonales positivos, HER2 negativo.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	III
CIMO-01	Estudio para evaluar los desenlaces del embarazo y la seguridad de la interrupción del tratamiento endocrino de mujeres jóvenes con cáncer de mama y respuesta el tratamiento endocrino que deseen quedarse embarazadas. Estudio POSITIVE	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA JOSE BERMEJO PEREZ	SP
CIMO-01	Estudio de fase III, abierto, multicéntrico y aleatorizado de palbociclib como tratamiento adyuvante combinado con hormonoterapia en comparación con hormonoterapia sola en pacientes con recidiva locorregional aislada de cáncer de mama extirpado con receptor hormonal positivo y HER2 negativo. POLAR	INDEPENDENT CLINICAL TRIAL	NURIA RIBELLES ENTRENA	III
CIMO-01	Estudio multicéntrico en fase I, abierto, de INCA00186 en monoterapia o en combinación con inmunoterapia en participantes con tumores sólidos avanzados	INDEPENDENT CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	I

Group	Title	Subtype	LR Name	Phase
CIMO-01	Estudio en fase III, abierto, aleatorizado, multicéntrico y controlado con tratamiento activo para evaluar la eficacia y la seguridad de pemigatinib comparado con quimioterapia con gemcitabina y cisplatino en el tratamiento de primera línea de participantes con colangiocarcinoma no resecable o metastásico con reordenación del FGFR2 (FIGHT-302)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Ensayo en fase II con varios grupos (en canasta) para investigar la seguridad y eficacia de IO102-IO103 en combinación con pembrolizumab, como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico (CPNM) metastásico, carcinoma de células escamosas de cabeza y cuello (CCECC) o carcinoma urotelial de vejiga metastásico (CUVm)	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II
CIMO-01	Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye quimioterapia estándar vs histotipo-dirigida neoadyuvante	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
CIMO-01	Un ensayo multicéntrico, aleatorizado y abierto de fase 3 que compara selpercatinib con los medicamentos cabozantinib o vandetanib, preferidos por los médicos, en pacientes con cáncer medular de tiroides progresivo y avanzado con RET mutante y sin tratamiento anterior con inhibidores de quinasa (LIBRETTO-531)	COMMERCIAL CLINICAL TRIAL	SOFÍA RUIZ MEDINA	III
CIMO-01	Estudio observacional en pacientes con cáncer de mama metastásico HR+ y Her2-tratados con abemaciclib en el programa NPU (Programa de Uso Compasivo) en España-Estudio AbemusS	COMMERCIAL POST-AUTHORIZATION STUDY	ANTONIA MÁRQUEZ ARAGONÉS	OD
CIMO-01	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors	COMMERCIAL CLINICAL TRIAL	JAVIER GARCÍA CORBACHO	ı
CIMO-01	Estudio de fase I, primero en humanos, para evaluar la seguridad y eficacia de ABBV-637 en monoterapia o en combinación en pacientes adultos con tumores sólidos recidivantes y resistentes	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Estudio fase 1, primero en humanos, multicéntrico y abierto con ABBV-CLS579 solo y en combinación, en pacientes con tumores localmente avanzados o metastásicos	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
CIMO-01	Estudio en fase I, abierto, de aumento de la dosis, seguridad, tolerabilidad y eficacia preliminar de MCLA-145 en participantes con neoplasias malignas avanzadas o metastásicas. Estudio MERUS	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Estudio de fase II, internacional, multicéntrico, randomizado y abierto para evaluar la eficacia y la seguridad de la continuación de palbociclib en combinación con terapia endocrina de segunda línea en pacientes con cáncer de mama avanzado con receptores hormonales positivos y HER2 negativo tras beneficio clínico durante el tratamiento de primera línea basado en palbociclib. Estudio PALMIRA	COMMERCIAL CLINICAL TRIAL	TAMARA DÍAZ REDONDO	II
CIMO-01	Trastuzumab y pertuzumab sin quimioterapia en cáncer de mama HER2 positivo: estrategia adaptada en función de la respuesta evaluada por FDG-PET. Estudio PHERGain	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	II
CIMO-01	Multicenter, open-label, phase II trial to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2 negative breast cancer.	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	II
CIMO-01	Ensayo clínico de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de niraparib más inhibidores de aromatasa en el cáncer de mama metastásico con receptor hormonal (RH) positivo/ receptor del factor de crecimiento epidérmico humano 2 (HER2) negativo con o sin mutación de BRCA en línea germinal y con deficiencia en la recombinación homóloga (HRD) - La estrategia LUZERN.	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	II
CIMO-01	Ensayo de fase II randomizado para evaluar la actividad antitumoral del tratamiento con Enzalutamida y Talazoparib (PF-06944076) en pacientes con cáncer de próstata metastásico sin terapia hormonal previa. (ZZFIRST)	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	II
CIMO-01	ENSAYO DE FASE IIA, MULTICÉNTRICO, ABIERTO, NO COMPARATIVO Y DE TRES BRAZOS DE IPATASERTIB (GDC-0068) EN COMBINACIÓN CON QUIMIOTERAPIA SIN TAXANOS PARA PACIENTES CON CÁNCER DE MAMA TRIPLE-NEGATIVO LOCALMENTE AVANZADO IRRESECABLE O METASTÁSICO PREVIAMENTE TRATADAS CON TAXANOS (PATHFINDER)	COMMERCIAL CLINICAL TRIAL	NURIA RIBELLES ENTRENA	II

Group	Title	Subtype	LR Name	Phase
CIMO-01	Estudio de fase 2, multicéntrico y de varios grupos para evaluar MK-1308A (coformulación de quavonlimab (MK-1308)/ pembrolizumab) frente a otros tratamientos en participantes con cáncer colorrectal en estadio IV con inestabilidad de microsatélites alta (MSI-H) o con defectos en la reparación de los errores de emparejamiento (dMMR): (MK-1308A-008)	INDEPENDENT CLINICAL TRIAL	JULIA ALCAIDE GARCÍA	II
CIMO-01	Ensayo en fase III, aleatorizado, con el anticuerpo monoclonal anti-PD-1 pembrolizumab (MK-3475) en comparación con placebo para pacientes con CPNM en fase temprana después de resección y la finalización del tratamiento complementario de referencia (PEARLS)	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	III
CIMO-01	Ensayo de extensión de fase III, abierto y multicéntrico para estudiar la seguridad y la eficacia a largo plazo en participantes con tumores avanzados que actualmente están en tratamiento o en seguimiento en un ensayo de pembrolizumab.	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
CIMO-01	Ensayo de extensión de fase III, abierto y multicéntrico para estudiar la seguridad y la eficacia a largo plazo en participantes con tumores avanzados que actualmente están en tratamiento o en seguimiento en un ensayo de pembrolizumab	CLINICAL TRIALS WITH DRUGS	JULIA ALCAIDE GARCÍA	III
CIMO-01	Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab (MK-3475) más docetaxel más prednisona frente a un placebo más docetaxel más prednisona en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) sin quimioterapia previa que han mostrado progresión con un fármaco hormonal de última generación (FHUG) (KEYNOTE-921).	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
CIMO-01	Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab más gemcitabina/cisplatino en comparación con placebo más gemcitabina/cisplatino como tratamiento de primera línea en participantes con carcinoma de vías biliares avanzado o irresecable	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Estudio clínico de fase 1 para evaluar la biodisponibilidad de pembrolizumab administrado en inyección subcutánea de MK-3475A, una formulación de pembrolizumab con MK-5180, en participantes con tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Estudio de fase 3, aleatorizado y abierto de pembrolizumab (MK-3475) más lenvatinib (E7080/MK-7902) frente a quimioterapia para el tratamiento de primera línea del carcinoma endometrial avanzado o recurrente (LEAP-001)	COMMERCIAL CLINICAL TRIAL	TAMARA DÍAZ REDONDO	III
CIMO-01	Estudio de Fase III multicéntrico, doble ciego, randomizado, controlado con placebo para evaluar la eficacia y la seguridad de Atezolizumab más quimioterapia en pacientes con cáncer de mama triple negativo recurrente (localmente avanzado o metastásico inoperable) con recidiva precoz.	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
CIMO-01	ESTUDIO FASE IIIB MULTICÉNTRICO, ABIERTO, DE UN SOLO BRAZO, PARA EVALUAR LA SEGURIDAD DE ATEZOLIZUMAB (TECENTRIQ) EN COMBINACIÓN CON NAB-PACLITAXEL O PACLITAXEL PARA EL TRATAMIENTO DEL CÁNCER DE MAMA TRIPLE NEGATIVO INOPERABLE, LOCALMENTE AVANZADO O METASTÁSICO.	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
CIMO-01	Estudio de fase III aleatorizado, multicéntrico, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Trastuzumab Emtansina en combinación con Atezolizumab o placebo en pacientes con cáncer de mama localmente avanzado o metastásico positivio para HER2 y PD-L1 que hayan recibido previamente tratamiento basado en Trastuzumab (+/-Pertuzumab) y Taxanos	COMMERCIAL CLINICAL TRIAL	ANA GODOY ORTIZ	III
CIMO-01	Estudio de fase II multicéntrico, controlado con activo, aleatorizado para comparar la eficacia y seguridad de la terapia dirigida o inmunoterapia para el cáncer guiada por el perfil genómico frente a la quimioterapia basada en platino en pacientes con cáncer de origen primario desconocido que han recibido tres ciclos de quimioterapia con doblete de platino	COMMERCIAL CLINICAL TRIAL	ESPERANZA TORRES SÁNCHEZ	II
CIMO-01	Estudio en fase I del inhibidor de SHP2 BBP-398 (anteriormente conocido como IACS-15509) en combinación con el inhibidor de KRAS-G12C sotorasib en pacientes con tumores sólidos avanzados y una mutación de KRAS-G12C	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
CIMO-01	Estudio de fase I/II de NM21-1480 (anticuerpo triespecífico anti-PDL-1/anti-4-1BB/anti-HSA) en pacientes adultos con tumores sólidos avanzados	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	II

Group	Title	Subtype	LR Name	Phase
CIMO-01	Carolina conoce a HANNA - Análisis holístico de la supervivencia a largo plazo con cáncer de ovario. Sponsor Code: Expression VI	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA JOSE BERMEJO PEREZ	OD
CIMO-01	Estudio fase Ib/IIa para Evaluar la Seguridad y Eficacia del Tratamiento con el Inhibidor de la Ruta de Hedhegog NLM-001 Antes de Quimioterapia (Gemcitabina y Nab-Paclitaxel) más Zalifrelimab como Tratamiento de Primera Línea en Pacientes con Cáncer de Páncreas Avanzado.	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Estudio de fase II, aleatorizado, abierto, de optimización de la dosis/pauta de NUC-3373/leucovorina/irinotecán más bevacizumab (NUFIRI-bev) frente a 5-FU/leucovorina/irinotecán más bevacizumab (FOLFIRI-bev) para el tratamiento de pacientes con cáncer colorrectal metastásico irresecable previamente tratado	CLINICAL TRIALS WITH DRUGS	ESPERANZA TORRES SÁNCHEZ	II
CIMO-01	Evaluación de la resistencia temprana mecanismos para Osimertinib de primera línea en cáncer de pulmón de células no pequeñas mutante EGFR (NSCLC) utilizando transcriptomía espacial. Sponsor protocol code: ESR-20-20709	INDEPENDENT POST-AUTHORIZATION STUDY	INMACULADA RAMOS GARCIA	OD
CIMO-01	Estudio aleatorizado para investigar la eficacia y seguridad de la proteína de fusión humana L19TNF anticuerpo-citoquina dirigida a tumores en pacientes con sarcoma de tejidos blandos en estado avanzado o metastásico previamente tratados	CLINICAL TRIALS WITH DRUGS	MARÍA ISABEL SEVILLA GARCÍA	II
CIMO-01	Estudio observacional retrospectivo de los linfomas hodgkin (hdk) y no hodgkin (no-hdk) diagnosticados por el grupo cooperativo gotel para evaluar la supervivencia global y sus características.	INDEPENDENT POST-AUTHORIZATION STUDY	LAURA GALVEZ CARVAJAL	OD
CIMO-01	Estudio retrospectivo de casos y controles para la caracterización clínica y molecular del cáncer de próstata en pacientes con y sin defecto germinal en la reparación del DNA (BRCA1, BRCA2, Síndrome de Lynch)	NON-POST-AUTHORIZATION STUDY	ANTONIA MÁRQUEZ ARAGONÉS	NO
CIMO-01	Ensayo clínico en fase III abierto y aleatorizado de REGN2810 en comparación con el tratamiento de quimioterapia a elección del investigador para el carcinoma cervicouterino resistente a platino recurrente o metastásico	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	III
CIMO-01	Estudio observacional de cohortes retrospectivo que utiliza datos secundarios obtenidos de la práctica clínica para evaluar los patrones de tratamiento y el índice de abandono entre líneas de tratamiento en pacientes con cáncer de mama metastásico HER2+	OBSERVATIONAL STUDY WITH DRUGS	NURIA RIBELLES ENTRENA	NA
CIMO-01	Ensayo internacional, aleatorizado y controlado para el tratamiento del sarcoma de Ewing de diagnóstico reciente (EE2012)	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	III
CIMO-01	Ensayo internacional, aleatorizado y controlado de quimioterapia para el tratamiento del sarcoma de Ewing recurrente o refractario	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	II
CIMO-01	Estudio observacional, retrospectivo, para analizar el manejo de pacientes con adenocarcinoma ductal de páncreas en la práctica clínica habitual. Estudio PDAC2017	INDEPENDENT POST-AUTHORIZATION STUDY	INMACULADA ALÉS DÍAZ	OD
CIMO-01	Estudio aleatorizado, doble ciego y en fase III de tucatinib o placebo en combinación con trastuzumab y pertuzumab como tratamiento de mantenimiento para el cáncer de mama HER2+metastásico (HER2CLIMB-05)	CLINICAL TRIALS WITH DRUGS	EMILIO ALBA CONEJO	III
CIMO-01	Estudio en fase III, abierto y aleatorizado de tucatinib en combinación con trastuzumab y mFOLFOX6 frente a mFOLFOX6 administrado con o sin cetuximab o bevacizumab como tratamiento de primera línea para pacientes con cáncer colorrectal metastásico HER2+.	CLINICAL TRIALS WITH DRUGS	JULIA ALCAIDE GARCÍA	III
CIMO-01	Estudio en fase III multicéntrico, aleatorizado, doble ciego y controlado con placebo de fuzuloparib combinado con acetato de abiraterona y prednisona (AA-P) frente a placebo combinado con AA-P como tratamiento de primera línea en pacientes con cáncer de próstata resistente a la castración metastásico	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
CIMO-01	Estudio de fase 1b, abierto, de SL-172154 (SIRPa-Fc-CD40L) administrado con doxorubicina liposomal pegilada o con mirvetuximab soravtansina en sujetos con cáncer de ovario resistente al platino	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	I
CIMO-01	An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre-and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2-Breast Cancer with an ESR1 Mutation	CLINICAL TRIALS WITH DRUGS	ANA GODOY ORTIZ	Ш

Group	Title	Subtype	LR Name	Phase
CIMO-01	Cáncer de vejiga invasivo hacia una medicina de precisión. SOG-CVI-2014-05	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	OD
CIMO-01	Estudio prospectivo de la utilidad de la biopsia líquida como factor predictor y pronóstico en pacientes con carcinoma urotelial metastásico en progresión tras quimioterapia basada en platino	INDEPENDENT POST-AUTHORIZATION STUDY	MARIA ISABEL SÁEZ MEDINA	SP
CIMO-01	Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302. HER2-PREDICT	INDEPENDENT CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	II
CIMO-01	Estudio de fase III, multicéntrico y abierto de ribociclib en comparación con palbociclib en pacientes con cáncer de mama avanzado con receptores hormonales positivos/HER2-negativo/HER2-Enriquecido - ensayo HARMONIA	COMMERCIAL CLINICAL TRIAL	MARIA EMILIA DOMINGUEZ RECIO	III
CIMO-01	Estudio fase III randomizado en el que se compara el tratamiento con imatinib adyuvante durante 3 años frente a 5 años para pacientes con GIST operable con alto riesgo de recurrencia	INDEPENDENT CLINICAL TRIAL	MARÍA ISABEL SEVILLA GARCÍA	Ш
CIMO-01	TAK-788-5009 Características de los pacientes, patrones de tratamiento y resultados de los pacientes con cáncer de pulmón no microcítico avanzado con mutaciones de inserción en el exón 20 del EGFR: Revisión retrospectiva observacional no intervencionista de historias clínicas en España. Estudio ermEX-20	OBSERVATIONAL STUDY WITH DRUGS	INMACULADA RAMOS GARCIA	NA
CIMO-01	Ensayo de fase Ib/II que evalúa la combinación de TG4001 y avelumab en pacientes con tumores malignos recurrentes o metastásicos positivos para VPH-16 y cohorte de expansión a carcinoma de células escamosas de cabeza y cuello (CCECC)	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	Ш
CIMO-01	Estudio de fase III, aleatorizado, secuencial y abierto, para evaluar la eficacia de FOLFOX + panitumumab seguido por FOLFIRI + bevacizumab (Secuencia 1) frente a FOLFOX + bevacizumab seguido por FOLFIRI + panitumumab (Secuencia 2) en pacientes con cáncer colorrectal metastásico no resecable, RAS nativo, tumor primario en lado izquierdo, no tratado previamente: CR-SEQUENCE	INDEPENDENT CLINICAL TRIAL	ESPERANZA TORRES SÁNCHEZ	III
CIMO-01	Estudio epidemiológico observacional multicéntrico descriptivo sobre tumores digestivos. RETUD (Registro Español TUmores Digestivos)	NON-POST-AUTHORIZATION STUDY	INMACULADA ALÉS DÍAZ	NO
CIMO-01	Olaparib y durvalumab (MEDI4736) en pacientes con cáncer de páncreas metastásico y alteraciones en los genes de reparación de daño en el ADN	CLINICAL TRIALS WITH DRUGS	INMACULADA ALÉS DÍAZ	II
CIMO-01	Estudio de fase III, aleatorizado, para evaluar cabazitaxel y radioterapia pelviana en pacientes con cáncer de próstata localizado con alto riesgo de recaída, según un diseño factorial. PEACE 2	INDEPENDENT CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	Ш
CIMO-01	Ensayo en Fase 1B, abierto, con escalado de dosis, para determinar la seguridad y las respuestas inmunitarias dirigidas contra antígenos específicos provocadas por VB.01 NEO en combinación con ATEZOLIZUMAB en sujetos con tumores localmente avanzados y metastásicos	COMMERCIAL CLINICAL TRIAL	LAURA MEDINA RODRÍGUEZ	I
CIMO-01	Estudio en fase II de VS-6766 (inhibidor dual de RAF/MEK) como agente único y en combinación con defactinib (inhibidor de FAK) en el cáncer de pulmón no microcítico (CPNM) recurrente con mutación de KRAS (KRAS-MT)	COMMERCIAL CLINICAL TRIAL	INMACULADA RAMOS GARCIA	П
CIMO-01	Estudio plataforma, de fase II, abierto y multicéntrico para evaluar la eficacia y la seguridad de tratamientos basados en biomarcadores en pacientes con tumores epiteliales de ovario raros persistentes o recurrente	COMMERCIAL CLINICAL TRIAL	MARIA JOSE BERMEJO PEREZ	II
CIMO-01	eSTUDIO DE FASE III ALEATORIZADO, ABIERTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE GIREDESTRANT EN COMBINACIÓN CON PHESGO COMPARADO CON PHESGO TRAS TRATAMIENTO DE INDUCCIÓN CON PHESGO + TAXANO EN PACIENTES CON CÁNCER DE MAMA LOCALMENTE AVANZADO O METASTÁSICO HER2 POSITIVO Y RECEPTOR DE ESTRÓGENOS POSITIVO, NO TRATADOS PREVIAMENTE.	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	"ESTUDIO EN FASE III, MULTICÉNTRICO, ALEATORIZADO Y ABIERTO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE INAVOLISIB MÁS FULVESTRANT FRENTE A ALPELISIB MÁS FULVESTRANT EN PACIENTES CON CÁNCER DE MAMA CON RECEPTOR HORMONAL POSITIVO, HER2 NEGATIVO Y PIK3CA MUTADO, LOCALMENTE AVANZADO O METASTÁSICO QUE EXPERIMENTARON PROGRESIÓN DURANTE O DESPUÉS DEL TRATAMIENTO COMBINADO CON INHIBIDOR DE CDK4/6 Y TRATAMIENTO ENDOCRINO"	CLINICAL TRIALS WITH DRUGS	ANA GODOY ORTIZ	III

Group	Title	Subtype	LR Name	Phase
CIMO-01	ESTUDIO DE FASE III MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE INAVOLISIB EN COMBINACIÓN CON PHESGO® COMPARADO CON PLACEBO EN COMBINACIÓN CON PHESGO® COMO TRATAMIENTO DE MANTENIMIENTO TRAS TRATAMIENTO DE INDUCCIÓN DE PRIMERA LÍNEA EN PARTICIPANTES CON CÁNCER DE MAMA LOCALMENTE AVANZADO O METASTÁSICO HER2 POSITIVO CON MUTACIÓN PIK3CA	CLINICAL TRIALS WITH DRUGS	FRANCISCO JAVIER PASCUAL LOPEZ	III
CIMO-01	Estudio con aumento escalonado y ampliación de la dosis para evaluar la seguridad y la farmacocinética del XB002 en monoterapia y politerapia en pacientes con tumores sólidos localmente avanzados o metastásicos inoperables	CLINICAL TRIALS WITH DRUGS	JAVIER GARCÍA CORBACHO	II
CIMO-01	Estudio de fase Ib de aumento escalonado de la dosis de cabozantinib (XL184) solo o en combinación con atezolizumab en pacientes con tumores sólidos localmente avanzados o metastásicos	COMMERCIAL CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	1
CIMO-01	Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo, de cabozantinib (XL184) en pacientes con cáncer diferenciado de tiroides resistente a radioyodo que han progresado después de tratamiento dirigido previo con VEGFR	COMMERCIAL CLINICAL TRIAL	SOFÍA RUIZ MEDINA	III
CIMO-01	Estudio de fase 3, aleatorizado, abierto, controlado, de cabozantinib (XL184) en combinación con atezolizumab frente a una segunda terapia hormonal novedosa (THN) en pacientes con cáncer de próstata metastásico y resistente a la castración	INDEPENDENT CLINICAL TRIAL	MARIA ISABEL SÁEZ MEDINA	III
CIMO-01	Ensayo de fase III, multicéntrico, aleatorizado, controlado con placebo y con doble enmascaramiento sobre el tratamiento de mantenimiento con selinexor tras un tratamiento sistémico en pacientes con carcinoma endometrial avanzado o recurrente sin mutaciones en la proteína p53	CLINICAL TRIALS WITH DRUGS	MARIA JOSE BERMEJO PEREZ	III
CIMO-01	Estudio de Fase III, aleatorizado, doble ciego y controlado con placebo de Atezolizumab con o sin Tiragolumab (Anticuerpo Anti-TIGIT) en pacinetes con cardinoma epidermoide de esófago localmente avanzado irresecable.	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Estudio de fase 2a de ZW25 en combinación con palbociclib más fulvestrant	COMMERCIAL CLINICAL TRIAL	EMILIO ALBA CONEJO	II
CIMO-01	Estudio de fase III, multicéntrico y aleatorizado de zanidatamab en combinación con quimioterapia, con o sin tislelizumab, en sujetos con adenocarcinoma gastroesofágico (AGE) irresecable, localmente avanzado o metastásico, con HER-2 positivo (HERIZON-GEA-01)	COMMERCIAL CLINICAL TRIAL	INMACULADA ALÉS DÍAZ	III
CIMO-01	Análisis retrospectivo de la supervivencia global en pacientes con cáncer colorrectal metastásico (CCM) en España: análisis retrospectivo extendido de RWD	INDEPENDENT POST-AUTHORIZATION STUDY	-	OD
CIMO-01	Estudio fundamental, randomizado y en abierto del tratamiento simultáneo con TTFields (campos eléctricos para el tratamiento de tumores, 150 kHz) y gemcitabina y nab-paclitaxel (paclitaxel unido a albúmina en formulación de nanopartículas), como tratamiento de primera línea del adenocarcinoma pancreático en estadio localmente avanzado. PANOVA-3	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	-	0
CIMO-01	Análisis retrospectivo de la supervivencia global en pacientes con cáncer colorrectal metastásico (CCM) en España: análisis retrospectivo extendido de RWD	INDEPENDENT POST-AUTHORIZATION STUDY	-	OD
CIMO-01	Estudio fundamental, randomizado y en abierto del tratamiento simultáneo con TTFields (campos eléctricos para el tratamiento de tumores, 150 kHz) y gemcitabina y nab-paclitaxel (paclitaxel unido a albúmina en formulación de nanopartículas), como tratamiento de primera línea del adenocarcinoma pancreático en estadio localmente avanzado. PANOVA-3	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	-	0
CIMO-01	Análisis retrospectivo de la supervivencia global en pacientes con cáncer colorrectal metastásico (CCM) en España: análisis retrospectivo extendido de RWD	INDEPENDENT POST-AUTHORIZATION STUDY	-	OD
CIMO-01	Estudio fundamental, randomizado y en abierto del tratamiento simultáneo con TTFields (campos eléctricos para el tratamiento de tumores, 150 kHz) y gemcitabina y nab-paclitaxel (paclitaxel unido a albúmina en formulación de nanopartículas), como tratamiento de primera línea del adenocarcinoma pancreático en estadio localmente avanzado. PANOVA-3	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	-	0

Group	Title	Subtype	LR Name	Phase
CIMO-01	Análisis retrospectivo de la supervivencia global en pacientes con cáncer colorrectal metastásico (CCM) en España: análisis retrospectivo extendido de RWD	INDEPENDENT POST-AUTHORIZATION STUDY	-	OD
CIMO-01	Estudio fundamental, randomizado y en abierto del tratamiento simultáneo con TTFields (campos eléctricos para el tratamiento de tumores, 150 kHz) y gemcitabina y nab-paclitaxel (paclitaxel unido a albúmina en formulación de nanopartículas), como tratamiento de primera línea del adenocarcinoma pancreático en estadio localmente avanzado. PANOVA-3	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	-	0
CIMO-01	Estudio de fase I/IIa, abierto y multicéntrico, para evaluar la seguridad, tolerabilidad, farmacocinética y, de manera preliminar, la eficacia de ART0380, un inhibidor de la quinasa ATR, administrado por vía oral en monoterapia y en combinación a pacientes con tumores sólidos avanzados o metastásicos	CLINICAL TRIALS WITH DRUGS	-	II
CIMO-01	Estudio fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de copanlisib en combinación con rituximab en pacientes con linfoma no Hodgkin de células B indolente tras recidiva (LNHi)-CHRONOS 3	COMMERCIAL CLINICAL TRIAL	-	III
CIMO-01	Estudio en fase Ib, de escalada de la dosis, para determinar la dosis recomendada para la fase II de TAK-659 en combinación con bendamustina (± rituximab), gemcitabina, lenalidomida o ibrutinib para el tratamiento de pacientes con linfoma no-Hodgkin en estadio avanzado después de haber recibido al menos 1 línea de tratamiento anterior	COMMERCIAL CLINICAL TRIAL	-	I
CIMO-01	Ensayo fase III, internacional, multicéntrico, doble ciego, aleatorizado y controlado con placebo de Durvalumab tras el tratamiento con radioterapia estereotáctica corporal (SBRT), para el tratamiento de pacientes con cáncer de pulmón no microcítico, estadio I/II no resecado, con ganglios linfáticos negativos (PACIFIC-4/RTOG-3515)	COMMERCIAL CLINICAL TRIAL	-	III
CIMO-01	Ensayo de fase I, multicéntrico de inmunoterapia en combinación con quimiorradioterapia en pacientes con tumores sólidos avanzados (CLOVER)	COMMERCIAL CLINICAL TRIAL	-	I
CIMO-01	ARCHER 1050: Estudio en fase III, aleatorizado, abierto, sobre la eficacia y seguridad de Dacomitinib (PF-00299804) frente a Gefitinib, en el tratamiento de primera línea del cáncer de pulmón no microcítico localmente avanzado o metastásico en pacientes con mutacion(es) activadora(s) del receptor del factor de crecimiento epidérmico (EGFR)	COMMERCIAL CLINICAL TRIAL	-	III
CIMO-01	Ensayo de fase III, abierto y multicéntrico de avelumab (MSB0010718C) frente a docetaxel en sujetos con carcinoma pulmonar no microcítico que ha progresado tras un doblete con platino	COMMERCIAL CLINICAL TRIAL	-	III
CIMO-01	Estudio observacional de lenalidomida en pacientes con linfoma del manto en recaída/refractariedad. Resultados del programa español RRMCL.	INDEPENDENT POST-AUTHORIZATION STUDY	-	OD
CIMO-01	Estudio retrospectivo, observacional, multicéntrico en vida real de dostarlimab en pacientes con cáncer de endometrio recurrente o metastásico con deficiencia del sistema mismatch repair (MMR) o inestabilidad alta de microsatélites.	OBSERVATIONAL STUDY WITH DRUGS	-	NA
CIMO-01	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se evalúa abemaciclib con la hormonoterapia adyuvante de referencia en participantes con cáncer de mama HR+, HER-2+, de riesgo alto y con afectación ganglionar, que hayan completado un tratamiento adyuvante dirigido al HER2. eMonarcHER	COMMERCIAL CLINICAL TRIAL	-	III
CIMO-01	Estudio de fase 3, aleatorizado, con enmascaramiento doble ciego y controlado con placebo para comparar la eficacia de abemaciclib y fulvestrant con la del placebo y fulvestrant en participantes con cáncer de mama HR+ y HER2-en estadio avanzado o metastásico, tras la progresión durante un tratamiento con un inhibidor de las CDK4 y 6 y hormonoterapia (postMONARCH).	COMMERCIAL CLINICAL TRIAL	-	III
CIMO-01	Estudio de fase I, abierto, multicéntrico, en el que se evalúan ramucirumab y MEDI4736 en pacientes con neoplasias malignas gastrointestinales o torácicas localmente avanzadas e irresecables o metastásicas	COMMERCIAL CLINICAL TRIAL	-	I

Group	Title	Subtype	LR Name	Phase
CIMO-01	EMBER-4: Estudio de fase 3, aleatorizado, abierto, en el que se compara la administración adyuvante de imlunestrant versus terapia endocrina adyuvante estándar en pacientes que recibieron previamente de 2 a 5 años de terapia endocrina adyuvante para el cáncer de mama temprano ER+, HER2-con un mayor riesgo de recurrencia	CLINICAL TRIALS WITH DRUGS	-	Ш
CIMO-01	Estudio abierto, multicéntrico, de fase Ib, de escalado de dosis, de MEN1611, un inhibidor de PI3K combinado con trastuzumab ± fulvestrant, en sujetos con cáncer de mama irresecable y localmente recurrente (avanzado) o metastásico (a/m) HER2 positivo con mutación PIK3CA que ha progresado con un tratamiento basado en anti-HER2.	COMMERCIAL CLINICAL TRIAL	-	I
CIMO-01	Ensayo fase II para valorar la combinación de Lenalidomida con R-GDP (R2-GDP) en pacientes con linfoma difuso de células grandes B refractarios o en recaída (R/R LDCGB) no candidatos a quimioterapia a altas dosis y trasplante de células progenitoras hematopoyéticas	INDEPENDENT CLINICAL TRIAL	-	II
CIMO-01	ESTUDIO EN FASE III, MULTICÉNTRICO, ALEATORIZADO Y ABIERTO PARA COMPARAR ATEZOLIZUMAB (ANTICUERPO ANTI-PD-L1) EN COMBINACIÓN CON QUIMIOTERAPIA ADYUVANTE BASADA EN ANTRACICLINA/taxano FRENTE A SOLO QUIMIOTERAPIA EN PACIENTES CON CÁNCER DE MAMA TRIPLE NEGATIVO OPERABLE	COMMERCIAL CLINICAL TRIAL	-	III
CIMO-01	Ensayo Clínico de Fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento adyuvante con Atezolizumab o placebo y Trastuzumab Emtansina en el cáncer de mama con HER2+ y alta riesgo de recidiva después del tratamiento preoperatorio.	COMMERCIAL CLINICAL TRIAL	-	III
CIMO-02	DAREON _{TM} -5: Estudio abierto, multicéntrica fase II de selección de dosis intravenosa de BI 764532, un T cell engager dirigido a DLL3, en pacientes con cáncer extensivo de pulmón microcítico refractario o en recaída y en pacientes con otras carcinomas neuroendocrinos refractarios o en recaída.	CLINICAL TRIALS WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	II
CIMO-02	Un estudio en fase IV de seguimiento a largo plazo para definir el perfil de seguridad del dicloruro de radio 223	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	IV
CIMO-02	Estudio de fase 2 para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de AMG 757 en sujetos con cáncer de pulmón microcítico en recaída/refractario después de dos o más líneas de tratamiento previas	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
CIMO-02	Estudio aleatorizado y abierto de fase 3 en el que se compara tarlatamab con el tratamiento estándar en sujetos con cáncer de pulmón microcítico en recaída después de recibir quimioterapia de primera línea basada en platino (DeLLphi-304)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
CIMO-02	Estudio aleatorizado y doble ciego para evaluar la eficacia, seguridad e inmunogenicidad de ABP 206 en comparación con OPDIVO® (nivolumab) en pacientes con melanoma irresecable o metastásico no tratado anteriormente	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
CIMO-02	Estudio de fase 1b que evalúa la seguridad, tolerabilidad, farmacocinética y eficacia de bemarituzumab en monoterapia y en combinación con otra terapia contra el cancer en sujetos con cáncer de pulmón no microcítico escamoso (FORTITUDE-201)	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	1
CIMO-02	Estudio de fase IV, aleatorizado, abierto, multicéntrico de la eficacia y la seguridad de la dosis habitual de dicloruro de radio-223 en comparación con las dosis habituales de un tratamiento antihormonal nuevo (AHN) en pacientes con cáncer de próstata resistente a la castración metastásico predominante en huesos y en progresión durante/después de una línea de AHN.	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	IV
CIMO-02	Estudio de Fase II/III, aleatorizado, doble ciego, de diseño adaptativo, de GSK3359609 o placebo en combinación con pembrolizumab para el tratamiento en primera línea del carcinoma de células escamosas de cabeza y cuello recurrente o metástico con expresiónde PD-L1	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III
CIMO-02	Estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo, para comparar niraparib añadido a pembrolizumab versus placebo añadido a pembrolizumab como terapia de mantenimiento en participantes cuya enfermedad se haya mantenido estable o haya respondido a una primera línea de quimioterapia basada en platino y pembrolizumab en cáncer de pulmón no microcítico estadío IIIB o IV.	COMMERCIAL CLINICAL TRIAL	JOSE CARLOS BENITEZ MONTAÑEZ	III

Group	Title	Subtype	LR Name	Phase
CIMO-02	Estudio aleatorizado, abierto, de fase 2/3 para comparar cobolimab + dostarlimab + docetaxel, dostarlimab + docetaxel y docetaxel en monoterapia en participantes con cáncer de pulmón no microcítico avanzado que hayan progresado al tratamiento previo con anti-PD (L)1 y quimioterapia (COSTAR Lung).	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
CIMO-02	Estudio de plataforma de fase 2, aleatorizado, abierto que utiliza el protocolo maestro para evaluar nuevas combinaciones con inmunoterapia en participantes con cáncer de pulmón no microcítico localmente avanzado/metastásico, seleccionados según la expresión del ligando de muerte programada 1, que no han recibido tratamiento previo	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
CIMO-02	Ensayo clínico de fase III, aleatorizado y controlado de pembrolizumab con o sin poliquimioterapia a base de platino en comparación con quimioterapia en sujetos con carcinoma urotelial avanzado o metastásico. KEYNOTE-361	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	Ш
CIMO-02	Estudio aleatorizado de fase III de sitravatinib en combinación con nivolumab frente a docetaxel en pacientes con cáncer de pulmón no microcítico no escamoso avanzado con progresión de la enfermedad durante o después de la quimioterapia con platino y el tratamiento con inhibidor de punto de control (SAPPHIRE)	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	Ш
CIMO-02	Estudio en fase II abierto y de cohortes paralelas de amivantamab subcutáneo con diversas pautas posológicas en pacientes con tumores sólidos avanzados o metastásicos, incluido el cáncer de pulmón no microcítico con mutaciones en el gen EGFR. PALOMA-2	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
CIMO-02	Estudio Fase 3 abierto y aleatorizado de la combinación de la terapia Amivantamab y Carboplatino- Pemetrexed, frente a Carboplatino-Pemetrexed, en Pacientes con Cáncer de Pulmón No Microcítico Localmente Avanzado o Metastásico con EGFR mutado por inserciones en el Exon 20 (PAPILLON)	COMMERCIAL CLINICAL TRIAL	JOSE CARLOS BENITEZ MONTAÑEZ	Ш
CIMO-02	Estudio en fase III abierto y aleatorizado del tratamiento combinado de amivantamab y lazertinib con quimioterapia basada en platino en comparación con quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico con mutación del EGFR localmente avanzado o metastásico tras el fracaso de osimertinib. MARIPOSA 2	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio Fase 3, Abierto, Aleatorizado de Lazertinib con Amivantamab Subcutáneo Administrado por Inyección Manual, en Comparación con Amivantamab Intravenoso o Amivantamab Subcutáneo en un Sistema de Administración Corporal, en Pacientes con Cáncer de Pulmón No Microcítico Avanzado o Metastásico con mutación del EGFR tras la Progresión a Osimertinib y Quimioterapia. PALOMA-3.	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	Ш
CIMO-02	Estudio aleatorizado, doble ciego, controlado con placebo de fase III de niraparib en combinación con acetato de abiraterona y prednisona frente a acetato de abiraterona y prednisona para el tratamiento de participantes con cáncer de próstata metastásico sensible a la castración (CPSCm) con mutaciones deletéreas en la línea germinal o somáticas en los genes de reparación por recombinación homóloga (HRR)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
CIMO-02	Estudio Fase 3 aleatorizado de la combinación de Amivantamab y Lazertinib frente a Osimertinib como tratamiento de Primera Línea en Pacientes con Cáncer de Pulmón No Microcítico Localmente Avanzado o Metastásico con mutación del EGFR. MARIPOSA	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
CIMO-02	Estudio de fase 2 de MRTX849 en monoterapia y en combinación con pembrolizumab en pacientes con cáncer de pulmón no microcítico avanzado con mutación KRAS G12C	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
CIMO-02	Estudio en fase III aleatorizado de MRTX849 en comparación con docetaxel en pacientes con y mutación G12C de KRAS previamente tratado	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
CIMO-02	Estudio en fase II abierto, de un solo grupo y multicéntrico para evaluar la eficacia y la seguridad de taletrectinib en pacientes con CPNM ROS1 positivo avanzado o metastásico y otros tumores sólidos	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio de fase II abierto para evaluar la eficacia y la seguridad de tusamitamab ravtansina en participantes con carcinoma pulmonar no microcítico no escamoso (CPNM NE), con tumores con expresión negativa o moderada de CEACAM5 y niveles de ACE circulante elevados (CARMEN-LC06)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II

Group	Title	Subtype	LR Name	Phase
CIMO-02	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Nonsquamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
CIMO-02	Estudio observacional para describir las características genotípicas y las mutaciones de resistencia en el NSCLC ALK	INDEPENDENT POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	NO
CIMO-02	A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy-ARTISTRY-6	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
CIMO-02	Estudio BURAN sobre buparlisib (AN2025) en combinación con paclitaxel frente a paclitaxel en monoterapia, para pacientes con carcinoma de células escamosas de cabeza y cuello recurrente o metastásico Estudio BURAN	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
CIMO-02	Estudio de fase 2, abierto, de encorafenib + binimetinib en pacientes con cáncer de pulmón no microcítico con mutación BRAFV600E (C4221008)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio abierto en fase I/II de la seguridad, la farmacocinética y la actividad preliminar de ASTX295 en pacientes con tumores sólidos avanzados con TP53 de tipo natural	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
CIMO-02	ESTUDIO EN FASE II DE ALX148 EN COMBINACIÓN CON PEMBROLIZUMAB EN PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS DE CABEZA Y CUELLO AVANZADO (ASPEN-03)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
CIMO-02	Estudio en fase II de ALX148 en combinación con pembrolizumab y quimioterapia en pacientes con carcinoma de células escamosas de cabeza y cuello avanzado (ASPEN-04)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
CIMO-02	Estudio de un solo grupo de lorlatinib en participantes con cáncer de pulmón no microcítico (CPNM) positivo para cinasa del linfoma anaplásico (ALK) cuya enfermedad ha progresado después de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generación	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	IV
CIMO-02	Estudio de fase III, aleatorizado y abierto para comparar ociperlimab (BGB-A1217) más tislelizumab (BGB-A317) combinados con quimiorradioterapia simultánea (QRTs) seguida de ociperlimab más tislelizumab o tislelizumab más QRTs seguida de tislelizumab frente a QRTs seguida de durvalumab en pacientes con cáncer de pulmón no microcítico irresecable, localmente avanzado y sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	JOSÉ MIGUEL JURADO GARCÍA	III
CIMO-02	Ensayo de fase II abierto, aleatorizado, de BNT113 en combinación con pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) irresecable, recurrente o metastásico, que es positivo para el genotipo 16 del virus del papiloma humano (VPH16+) y expresa PD-L1	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
CIMO-02	ESTUDIO DE FASE II/III, MULTICÉNTRICO, PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE MÚLTIPLES TERAPIAS DIRIGIDAS COMO TRATAMIENTO PARA PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO (CPNM) AVANZADO O METASTÁSICO PORTADORES DE MUTACIONES SOMÁTICAS ACCIONABLES DETECTADAS EN SANGRE (B-FAST: PRIMER ANÁLISIS DE SCREENING EN SANGRE)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio de paraguas de fase Ib/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamiento basados en múltiples inmunoterapias en pacientes con carcinoma de pulmón no microcítico metastásico (Morpheus Pulmonar)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	ESTUDIO DE EXTENSIÓN Y OBSERVACIONAL A LARGO PLAZO MULTICÉNTRICO, ABIERTO EN PACIENTES INCLUIDOS PREVIAMENTE EN UN ESTUDIO CLÍNICO DE ATEZOLIZUMAB PROMOCIONADO POR GENENTECH Y/O F. HOFFMANN-LA ROCHE LTD.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	ESTUDIO DE FASE III, ABIERTO Y ALEATORIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE ALECTINIB ADYUVANTE FRENTE A LA QUIMIOTERAPIA ADYUVANTE CON UN DERIVADO DEL PLATINO EN PACIENTES CON CARCINOMA DE PULMÓN NO MICROCÍTICO POSITIVO PARA LA CINASA DEL LINFOMA ANAPLÁSICO EN ESTADIO IB (TUMORES = 4 CM) A IIIA COMPLETAMENTE EXTIRPADO	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III

Group	Title	Subtype	LR Name	Phase
CIMO-02	An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	IV
CIMO-02	ESTUDIO DE FASE III MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE MÚLTIPLES TRATAMIENTOS EN COHORTES DE PACIENTES SELECCIONADOS BASÁNDOSE EN EL ESTADO DE LOS BIOMARCADORES, CON CÁNCER DE PULMÓN NO MICROCÍTICO EN ESTADIO III LOCALMENTE AVANZADO, NO RESECABLE	CLINICAL TRIALS WITH DRUGS	JOSÉ MIGUEL JURADO GARCÍA	Ш
CIMO-02	Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera línea del cáncer de pulmón metastático no microcítico metastático positivo para el gen de fusión RET (BO42864)	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	Ш
CIMO-02	ESTUDIO DE FASE II MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO, DE RO7247669 MÁS QUIMIOTERAPIA BASADA EN PLATINO FRENTE A PEMBROLIZUMAB MÁS QUIMIOTERAPIA BASADA EN PLATINO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO LOCALMENTE AVANZADO O METASTÁSICO NO TRATADOS PREVIAMENTE	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	II
CIMO-02	Comparison of different techniques for testing BRAF V600 mutation in blood in melanoma patients. BRAFI	OBSERVATIONAL STUDY WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	NA
CIMO-02	Estudio en fase III, aleatorizado y abierto de brigatinib (ALUNBRIG®) en comparación con alectinib (ALECENSA®) en pacientes con cáncer de pulmón no microcítico avanzado positivo para cinasa de linfoma anaplásico que han progresado con crizotinib (XALKORI®)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio observacional, cuyo objetivo es evaluar la proporción de cáncer de cabeza y cuello (head and neck cancers, HNC) asociado al virus del papiloma humano (VPH), Estudio BROADEN.	NON-POST-AUTHORIZATION STUDY	ANTONIO RUEDA DOMÍNGUEZ	NO
CIMO-02	Estudio en Fase III, aleatorizado, doble ciego sobre los efectos de Encorafenib y Binimetinib más Pembrolizumab frente a placebo más Pembrolizumab en pacientes con diagnóstico de melanoma metastásico o melanoma localmente avanzado irresecable con mutación V600E/K en Braf positiva.	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	III
CIMO-02	ESTUDIO DE FASE II, ALEATORIZADO, ABIERTO, DE ENCORAFENIB Y BINIMETINIB MÁS PEMBROLIZUMAB FRENTE A NIVOLUMAB E IPILIMUMAB EN ARTICIPANTES CON MELANOMA POSITIVO PARA LA MUTACIÓN V600E/K EN BRAF QUE PROGRESÓ DURANTE O DESPUÉS DE UN TRATAMIENTO PREVIO CON ERAPIA ANTI-PD-1	CLINICAL TRIALS WITH DRUGS	ELISABETH PEREZ RUIZ	II
CIMO-02	PROTOCOLO MAESTRO DE ENCORAFENIB/BINIMETINIB: ESTUDIO ABIERTO DE CONTINUACIÓN PARA PARTICIPANTES QUE CONTINÚEN DESDE ENSAYOS CLÍNICOS DE ENCORAFENIB/BINIMETINIB	CLINICAL TRIALS WITH DRUGS	ALVARO MONTESA PINO	IV
CIMO-02	"Estudio fase 1b/2 de BMS-986442 en combinación con nivolumab o nivolumab y quimioterapias en participantes con tumores sólidos avanzados y cáncer de pulmón no microcítico"	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	Ш
CIMO-02	Ensayo fase 2 de nivolumab más ipilimumab, ipilimumab en monoterapia o cabazitaxel en varones con cáncer de próstata metastásico resistente a la castración	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	Ш
CIMO-02	Estudio farmacocinético en fase III, abierto, aleatorizado y de no inferioridad de nivolumab administrado por vía subcutánea (Nivo s.c.) en comparación con la administración intravenosa de nivolumab en participantes con melanoma en estadio IIIA/B/C/D o estadio IV tras la resección completa en un entorno adyuvante	INDEPENDENT CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	Ш
CIMO-02	Ensayo abierto y aleatorizado de nivolumab (BMS-936558) más pemetrexed/platino o nivolumab más ipilimumab (BMS-734016) frente a pemetrexed más platino en sujetos con cáncer de pulmón no microcítico (CPNM) en estadio IV o recurrente con mutación del receptor del factor de crecimiento epidérmico (EGFR), T790M negativo que no han respondido al tratamiento de primera línea con un inhibidor de la tirosina quinasa EGFR	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio fase 3, aleatorizado, a doble ciego, de inmunoterapia adyuvante con nivolumab frente a placebo después de resección completa de melanoma en estadio IIB/C (CheckMate 76K: Evaluación en ensayo clínico de la vía de punto de control y nivolumab 76K)	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	Ш

Group	Title	Subtype	LR Name	Phase
CIMO-02	Estudio aleatorizado, prospectivo y multicéntrico para evaluar el impacto de la detección temprana de metástasis cerebrales asintomáticas (metástasis cerebrales) frente al seguimiento estándar en la supervivencia libre de metástasis cerebrales sintomáticas (SBMFS) en pacientes con melanoma no tratado previamente, no resecable o metastásico.	OBSERVATIONAL STUDY WITH DRUGS	ELISABETH PEREZ RUIZ	OD
CIMO-02	Estudio fase 1, aleatorizado, doble ciego, paralelo, para comparar la farmacocinética de BMSCHO1- nivolumab de proceso D con la de nivolumab de proceso C después de la resección completa de melanoma en estadio IIIa/b/c/d o en estadio IV	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	I
CIMO-02	Estudio pantumoral para el seguimiento a largo plazo de supervivientes de cáncer que han participado en ensayos de investigación de nivolumab	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
CIMO-02	Ensayo de nivolumab más ipilimumab en combinación con quimioterapia frente a quimioterapia sola como tratamiento de primera línea en el cáncer de pulmón no microcítico (CPNM) en estadio IV	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio fase 1/2 de relatlimab (anticuerpo monoclonal anti-LAG-3) administrado en combinación con nivolumab (anticuerpo monoclonal anti-PD-1) y BMS-986205 (inhibidor de IDO1) o en combinación con nivolumab e ipilimumab (anticuerpo monoclonal anti-CTLA-4) en tumores malignos avanzados	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio en fase II, aleatorizado, doble ciego de relatlimab más nivolumab en combinación con quimioterapia frente a nivolumab en combinación con quimioterapia como tratamiento de primera línea para los participantes con cáncer de pulmón de células no pequeñas (CPCNP) en estadio IV o recurrente.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio de fase Ib de búsqueda de dosis que evalúa la seguridad y la actividad de [177Lu]Lu-DOTATATE en el cáncer de pulmón avanzado de células pequeñas de nuevo diagnóstico, en combinación con carboplatino, etopósido y tislelizumab en la fase de inducción y en combinación con tislelizumab en la fase de mantenimiento del tratamiento.	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	I
CIMO-02	Estudio de fase III, multicéntrico, aleatorizado y abierto en el que se compara 177Lu-PSMA-617 frente a un cambio de terapia dirigida al receptor de andrógenos en el tratamiento de hombres con cáncer de próstata metastásico progresivo resistente a la castración que no hayan recibido taxanos. (PSMAfore) PSMAddition	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	Ш
CIMO-02	Estudio fase III, aleatorizado, doble ciego, controlado con placebo que evalúa la eficacia y seguridad de pembrolizumab más quimioterapia basada en doblete de platino con o sin canakinumab, como terapia de primera línea para pacientes con cáncer de pulmón de células no pequeñas escamoso o no escamoso, localmente avanzado o metastásico (CANOPY-1)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio de fase Ib, abierto, global, multicéntrico, aleatorizado, de determinación y ampliación de la dosis, para determinar la dosis máxima tolerada y evaluar la seguridad, tolerabilidad, la farmacocinética y la eficacia preliminar de iberdomida (CC-220) en combinación con R-CHOP-21 y de CC-99282 en combinación con R-CHOP-21 en sujetos con linfoma de células B agresivo de bajo riesgo (IPI de 3 a 5) sin tratamiento previo.	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
CIMO-02	Estudio Fase I, multicéntrico, abierto, de búsqueda de dosis de CC-96673 en sujetos con linfoma no Hodgkin en recaída o refractario	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
CIMO-02	Estudio Fase 1, multicéntrico, abierto para determinar la seguridad, farmacocinética y eficacia preliminar de una molécula pequeña, CC-99282, disponible para administración oral en monoterapia y en combinación con rituximab en sujetos con linfoma no Hodgkin en recaída o refractario (LNH R/R)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
CIMO-02	Estudio global de Fase III, multicentrico, abierto, controlado y aleatorizado de capmatinib frente a la quimioterapia SoC con Docetaxel en pacientes previamente tratados con NSCLC localmente avanzado o metastasico (estadio IIIb/IIIC o IV) con mutacion MET exon 14 skipping (MET-exon14), EGFR wild type y ALK negative.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio de fase II, multicéntrico, aleatorizado y abierto que evalúa la eficacia y seguridad de capmatinib (INC280) más pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de primera línea para cáncer de pulmón de células no pequeñas localmente avanzado o metastásico con PD-L1 >/=50 %	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II

Group	Title	Subtype	LR Name	Phase
CIMO-02	Estudio de fase I, abierto, multicéntrico, con escalada de dosis de CK-301 administrado por vía intravenosa en monoterapia a pacientes con cánceres avanzados	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	I
CIMO-02	Estudio de extensión de fase IV, multicéntrico, abierto en pacientes con tumores malignos ALK positivo que hayan finalizado un estudio previo de ceritinib (LDK378) patrocinado por Novartis y que vayan a beneficiarse del tratamiento continuado con ceritinib según el criterio del investigador	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	IV
CIMO-02	Estudio en fase I/II, abierto, multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética, la farmacodinámica y la eficacia de CLN-081 en pacientes con carcinoma pulmonar no microcítico localmente avanzado o metastásico con mutaciones por inserción en el exón 20 del EGFR que han recibido anteriormente quimioterapia sistémica con un derivado del platino	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
CIMO-02	Estudio de fase III aleatorizado, de 3 brazos, abierto y multicéntrico de LGX818 más MEK162 y LGX818 en monoterapia comparado con vemurafenib en pacientes con melanoma BRAF V600 mutado no resecable o metastásico.	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
CIMO-02	ESTUDIO EN FASE III, MULTICÉNTRICO, RANDOMIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO PARA INVESTIGAR IPATASERTIB EN COMBINACIÓN CON ABIRATERONA MÁS PREDNISONA/PREDNISOLONA, COMPARADO CON PLACEBO EN COMBINACIÓN CON ABIRATERONA MÁS PREDNISONA/PREDNISOLONA, EN PACIENTES ADULTOS CON CÁNCER DE PRÓSTATA RESISTENTE A CASTRACIÓN METASTÁSICO, ASINTOMÁTICOS O LEVEMENTE SINTOMÁTICOS QUE NO HAN SIDO TRATADOS PREVIAMENTE	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
CIMO-02	Estudio de fase IB, sin enmascaramiento, multicéntrico, no aleatorizado, para evaluar la seguridad, la farmacocinética y la eficacia de mosunetuzumab en combinación con lenalidomida, o R07082859 en combinación con lenalidomida, o R07082859 en combinación con obinutuzumab más lenalidomida en pacientes con linfoma folicular resistente o recidivante	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
CIMO-02	ESTUDIO ALEATORIZADO, ABIERTO DE FASE III, PARA COMPARAR PRALSETINIB CON EL TRATAMIENTO ESTÁNDAR DEL CÁNCER MEDULAR DE TIROIDES CON MUTACIÓN EN RET	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	III
CIMO-02	Ensayo multicéntrico, de fase II, abierto y aleatorizado para evaluar la eficacia de Tedopi y docetaxel o Tedopi y nivolumab como tratamiento de segunda línea en el cáncer de pulmón de células no pequeñas metastásico y en progresión tras el tratamiento de primera línea con quimioinmunoterapia (Combi-TED)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
CIMO-02	Estudio prospectivo, no intervencionista, multicéntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con cáncer de pulmón de célula no pequeña resecable en estadío temprano en España. Prevalencia de mEGFR en pacientes con CPCNP resecable en estadío temprano en España (ORIGEN)	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	OD
CIMO-02	Estudio de fase III, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de capivasertib + docetaxel frente a placebo + docetaxel como tratamiento para pacientes con cáncer de próstata resistente a la castración metastásico (CPRCm)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
CIMO-02	Ensayo fase IIIB de un solo brazo, de Durvalumab en combinación con Platino-Etopósido para pacientes con cáncer de pulmón de célula pequeña en estadío extendido que no han recibido tratamiento, reflejando la práctica clínica real en España (CANTABRICO).	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	III
CIMO-02	Estudio fase III, abierto, aleatorizado y multicentrico con 3 grupos de tratamiento de savolitinib más durvalumab frente a sunitinib y durvalumab en monoterapia en participantes con carcinoma de células renales papilares (CCRP) irresecable y localmente avanzado o metastásico causado por mutación en MET (SAMETA)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
CIMO-02	Estudio fase III, randomizado, abierto con savolitinib en combinación con osimertinib versus quimioterapia basada en doblete de platino en participantes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo y que la enfermedad ha progresado tras haber recibido tratamiento con osimertinib (SAFFRON)	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	III

Group	Title	Subtype	LR Name	Phase
CIMO-02	Ensayo Fase III, randomizado, doble ciego, controlado con placebo, multicéntrico, internacional con Osimertinib como tratamiento de mantenimiento en pacientes con cáncer de pulmón no microcítico (estadio III) localmente avanzado e irresecable, con mutación de EGFR positiva, cuya enfermedad no ha progresado después de tratamiento definitivo con quimioradioterapia basada en platino (LAURA)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio de fase III, aleatorizado, en doble ciego y controlado con placebo, de platino y pemetrexed como quimioterapia más osimertinib frente a platino y pemetrexed como quimioterapia más placebo en pacientes con cáncer de pulmón no microcítico con mutación del EGFR, localmente avanzado o metastásico, que ha progresado extracranealmente tras el tratamiento de primera línea con osimertinib (COMPEL)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
CIMO-02	"Estudio de Fase III, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de AZD9291 frente a placebo en pacientes con carcinoma de pulmón no microcítico con mutación del receptor del factor de crecimiento epidérmico, en Estadio IB-IIIA, tras la resección completa del tumor, con o sin quimioterapia adyuvante (ADAURA)"	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	Ш
CIMO-02	Ensayo fase III, aleatorizado, controlado, multicéntrico de 3 brazos para evaluar osimertinib neoadyuvante en monoterapia o en combinación con quimioterapia, frente a la quimioterapia de referencia, para el tratamiento de pacientes con CPNM resecable con mutación del EGFR positiva (NeoADAURA)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio fase III, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia y seguridad del osimertinib en adyuvancia frente al placebo en pacientes con cáncer de pulmón de células macrociticas en estadio IA2-IA3 con mutación EGFR positiva, después de una resección tumoral completa. (ADAURA2)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio de fase 2, aleatorizado y abierto, de ceralasertib en monoterapia y ceralasertib más durvalumab en pacientes con melanoma irresecable o avanzado y con resistencia primaria o secundaria a la inhibición de PD (L)1. MONETTE	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
CIMO-02	Estudio de fase III, abierto, aleatorizado y multicéntrico, de ceralasertib más durvalumab frente a docetaxel en pacientes con cáncer de pulmón no microcítico avanzado o metastásico sin alteraciones genómicas aprovechables terapéuticamente y cuya enfermedad haya progresado durante o después del tratamiento previo con anti-PD-(L)1 y quimioterapia basada en el platino: LATIFY	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	Ш
CIMO-02	Estudio de fase II, abierto, multicéntrico y aleatorizado, del tratamiento neoadyuvante y adyuvante de pacientes con cáncer de pulmón no microcítico resecable, en estadio inicial (II a IIIA) (NeoCOAST-2)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
CIMO-02	Ensayo fase III, doble ciego, controlado con placebo, Internacional y multicéntrico de tratamiento neoadyuvante/adyuvante de Durvalumab para el tratamiento de pacientes con cáncer de pulmón no microcítico resecable en estadios II y III (AEGEAN)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio abierto, multicéntrico y global para evaluar la eficacia y la seguridad a largo plazo en pacientes que están recibiendo o que han recibido previamente durvalumab en otros protocolos (WAVE)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	IV
CIMO-02	Ensayo Fase III, Randomizado, Multicéntrico, Doble ciego, controlado con Placebo para determinar la eficacia de Durvalumab adyuvante en combinación con quimioterapia basada en platino en NSCLC estadio II-III tras resección completa (MeRmaiD-1)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Ensayo Fase III, Randomizado, Multicéntrico, Doble ciego, y controlado con Placebo de durvalumab en pacientes con cáncer no microcítico de pulmón estadio II-III con Enfermedad Mínima Residual tras Cirugía y Tratamiento con intención curativa (MERMAID-2)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Ensayo fase III, aleatorizado, abierto, controlado, multicéntrico, internacional de durvalumab en combinación con el tratamiento estándar con quimioterapia y durvalumab en combinación con tremelimumab y el tratamiento estándar con quimioterapia frente al tratamiento estándar con quimioterapia solo, en primera línea en pacientes con cáncer urotelial localmente avanzado irresecable o metastásico.	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III

Group	Title	Subtype	LR Name	Phase
CIMO-02	Ensayo de Fase 3, Abierto, Aleatorizado y Multicéntrico para Evaluar la Eficacia y Seguridad de Trastuzumab Deruxtecan como Tratamiento de Primera Línea en Cáncer de Pulmón No Microcítico, no Resecable y localmente Avanzado o Metastásico que presenta mutación del Exon 19 o 20 de HER2 (Destiny-Lung04)	COMMERCIAL CLINICAL TRIAL	ALEJANDRA CANTERO GONZÁLEZ	III
CIMO-02	Estudio en fase III, aleatorizado, doble ciego y controlado con placebo de Debio 1143 en combinación con quimioterapia con un derivado del platino y radioterapia de intensidad modulada con fraccionamiento convencional en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado apto para quimiorradioterapia definitiva (TrilynX).	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III
CIMO-02	ARCHER 1050: Estudio en fase III, aleatorizado, abierto, sobre la eficacia y seguridad de Dacomitinib (PF-00299804) frente a Gefitinib, en el tratamiento de primera línea del cáncer de pulmón no microcítico localmente avanzado o metastásico en pacientes con mutacion(es) activadora(s) del receptor del factor de crecimiento epidérmico (EGFR)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio de fase II, sin enmascaramiento y con un solo grupo de DS-1062a en cáncer de pulmón no microcítico avanzado o metastásico con alteraciones genómicas accionales y que ha progresado durante o después del tratamiento con inhibidores de cinasas y quimioterapia basada en platino	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio de fase III aleatorizado de DS-1062a frente a docetaxel en cáncer de pulmón no microcítico avanzado o metastásico sin alteraciones genómicas accionales que ha recibido tratamiento previo. Estudio TROPION-LUNG01	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) / Estudio en fase III aleatorizado de datopotamab deruxtecán (Dato-DXd) y pembrolizumab, con o sin quimioterapia con platino, en sujetos sin tratamiento previo para cáncer de pulmón avanzado o metastásico con TPS PD-L1 <50 % no microcítico no epidermoide sin alteraciones genómicas susceptibles de ser dianas terapéuticas (TROPION-Lung07).	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	Ш
CIMO-02	Ensayo en fase III, aleatorizado, abierto de Dato-DXd más pembrolizumab frente a pembrolizumab en monoterapia en pacientes sin tratamiento previo con cáncer de pulmón no microcítico avanzado o metastásico con PD-L1 alto (PPT =50 %) sin alteraciones genómicas susceptibles de ser dianas terapéuticas (Tropion-Lung08)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio de fase II abierto, multicéntrico y aleatorizado de DS-7300a, un conjugado de anticuerpo y fármaco (CAF) B7-H3, en participantes con cáncer de pulmón microcítico en estadio avanzado (CPM-EA) pretratado	INDEPENDENT CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
CIMO-02	Estudio en fase I/II, abierto, multicéntrico para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia antitumoral de DZD9008 en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con mutación de EGFR o HER2	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio de fase III, abierto, aleatorizado, multicéntrico, de DZD9008 frente a quimioterapia basada en doblete con platino como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación de inserción del exón 20 del receptor del factor de crecimiento epidérmico	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	Ш
CIMO-02	Estudio abierto, multicéntrico, de fase 1b/2 con E7386 en combinación con Pembrolizumab en pacientes previamente tratados con tumores sólidos específicos	INDEPENDENT CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	П
CIMO-02	Proyecto basado en encuestas para evaluar la facilidad de uso y el nivel de satisfacción de los pacientes y sus profesionales sanitarios después de utilizar una herramienta de monitorización médica digital para pacientes con cáncer de pulmón	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MANUEL COBO DOLS	0

Group	Title	Subtype	LR Name	Phase
CIMO-02	Estudio fundamental, randomizado y abierto de campos eléctricos para el tratamiento de tumores (TTFields) de forma simultánea con tratamientos de referencia para el tratamiento del cáncer de pulmón no microcítico (NSCLC) en estadio 4 después del fracaso con tratamiento que contenga platino. LUNAR	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	MANUEL COBO DOLS	0
CIMO-02	Ensayo de fase 3 abierto, aleatorizado de SAR408701 versus Docetaxel en pacientes con cáncer de pulmón no microcítico no escamoso metastásico previamente tratados, con tumores positivos a CEACAM5 (CARMEN-LC03)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Ensayo de fase III, abierto y multicéntrico de avelumab (MSB0010718C) frente al doblete con base de platino como tratamiento de primera línea del cáncer de pulmón no microcítico PD-L1+ recurrente o en estadio IV.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio de fase III, abierto, aleatorizado, multicéntrico y global para investigar la eficacia y la seguridad de furmonertinib en comparación con quimioterapia basada en platino como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
CIMO-02	Registro de Tumores Torácicos.	NON-POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	NO
CIMO-02	Ensayo clínico fase II, exploratorio y multicéntrico, de quimioinmunoterapia neo-adyuvante para el tratamiento del cáncer de pulmón no microcítico estadío III operable	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Ensayo clínico Fase II randomizado de quimioinmunoterapia neo-adyuvante versus quimioterapia sola para el tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) localmente avanzado y potencialmente resecable. NADIM II	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Ensayo clínico Fase II abierto de Atezolizumab en combinación con bevacizumab como primera línea de tratamiento para pacientes con carcinoma de pulmón no microcítico no escamoso localmente avanzado o metastásico seleccionados según carga mutacional tumoral (TMB) alta-intermedia. TELMA	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Utilidad clínica de la biopsia líquida como herramienta para evaluar la evolución de pacientes tratados con brigatinib con cáncer de pulmón de células no pequeñas con translocación EML4-ALK: un estudio exploratorio	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Ensayo clínico Fase II de tratamiento neoadyuvante con Carboplatino-Pemetrexed-Bevacizumab más Atezolizumab para el tratamiento de pacientes con cáncer de pulmón localmente avanzado y potencialmente resecable y mutaciones de EGFR	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Ensayo clínico Fase II de combinación de pembrolizumab, lenvatinib y quimioterapia en primera línea para pacientes con cáncer de pulmón de células pequeñas con enfermedad avanzada (EA-CPNM)	INDEPENDENT CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	П
CIMO-02	Nivolumab e Ipilimumab más dos ciclos de quimioterapia basada en platino como tratamiento de primera línea para pacientes con cáncer de pulmón no microcítico (CPNM) estadio IV o recurrente con metástasis cerebrales sincrónicas. (NIVIPI-Brain)	INDEPENDENT CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	П
CIMO-02	"Ensayo clínico fase II de quimio-inmunoterapia neoadyuvante seguida de tratamiento adyuvante según el estado de resección para el tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) con diagnóstico de tumor de pancoast. Un estudio exploratorio multicéntrico". DUMAS	CLINICAL TRIALS WITH DRUGS	JOSÉ MIGUEL JURADO GARCÍA	Ш
CIMO-02	Ensayo clínico de fase II multicéntrico para evaluar la actividad del encorafenib y del binimetinib previo al tratamiento local en pacientes con melanoma BRAF mutado con metástasis cerebral.	INDEPENDENT CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
CIMO-02	Estudio fase II, abierto de la eficacia preliminar de Sitravatinib en combinación con Tislelizumab en pacientes con melanoma metastásico uveal con hepáticas metástasis.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	II
CIMO-02	Estudio Observacional descriptivo sobre las características del melanoma avanzado y metastásico en España. GEM -1801	INDEPENDENT POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL BERCIANO GUERRERO	SP

Group	Title	Subtype	LR Name	Phase
CIMO-02	Estudio de fase Ib/II, multicéntrico, abierto, para evaluar la seguridad/tolerabilidad, la farmacocinética y la eficacia de GFH925 en combinación con cetuximab en pacientes con CPNM con mutación KRAS G12C en estadio avanzado no tratado previamente	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	П
CIMO-02	ESTUDIO DE FASE III, DOBLE CIEGO, ALEATORIZADO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DEL TRATAMIENTO NEOADYUVANTE CON ATEZOLIZUMAB O PLACEBO EN COMBINACIÓN CON QUIMIOTERAPIA CON DERIVADOS DEL PLATINO, EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO RESECABLE EN ESTADIO II, IIIA O IIIB DE DETERMINADO TIPO.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	ESTUDIO FASE II, ALEATORIZADO, CIEGO Y CONTROLADO CON PLACEBO DE MTIG7192A, UN ANTICUERPO ANTI-TIGIT, EN COMBINACIÓN CON ATEZOLIZUMAB EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO LOCALMENTE AVANZADO O METASTÁSICO QUE NO HAN RECIBIDO QUIMIOTERAPIA PREVIA	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio fase III, aleatrorizado, doble ciego y controlado con placebo de Tiragolumab, un anticuerpo anti- Tigit, en combinación con Atezolizumab en pacientes con cáncer de pulmón no microcítico localmente avanzado irresecable o metastásico no tratado previamente seleccionados por PD-L1.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio fase III, abierto, aleatorizado de atezolizumab y tiragolumab en comparación con durvalumab en pacientes con cáncer de pulmón no microcítico localmente avanzado en estadio III irresecable que no han presentado progresión después de quimiorradioterapia con platino concomitante (skyscraper-03)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	ESTUDIO DE FASE III, ALEATORIZADO, ABIERTO Y MULTICÉNTRICO DE LURBINECTEDINA EN COMBINACIÓN CON ATEZOLIZUMAB, EN COMPARACIÓN CON ATEZOLIZUMAB, COMO TRATAMIENTO DE MANTENIMIENTO EN PACIENTES CON CÁNCER DE PULMÓN MICROCÍTICO EN ENFERMEDAD EXTENSA (CPM-EE) DESPUÉS DE TRATAMIENTO DE INDUCCIÓN DE PRIMERA LÍNEA CON CARBOPLATINO, ETOPÓSIDO Y ATEZOLIZUMAB	CLINICAL TRIALS WITH DRUGS	JOSE CARLOS BENÍTEZ MONTAÑÉS	III
CIMO-02	ESTUDIO DE FASE II, DE UN ÚNICO BRAZO Y ABIERTO PARA EVALUAR LA SEGURIDAD Y LA FARMACOCINÉTICA DE UNA COMBINACIÓN A DOSIS FIJA POR VÍA INTRAVENOSA (CDF IV) DE TIRAGOLUMAB Y ATEZOLIZUMAB EN PACIENTES CON TUMORES SÓLIDOS LOCALMENTE AVANZADOS, RECURRENTES O METASTÁSICOS	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
CIMO-02	Ensayo aleatorizado fase III de nivolumab en adyuvancia y quimioterapia concomitante en pacientes de alto riesgo con carcinoma de células escamosas de cabeza y cuello resecado (NIVO POST-OP)	INDEPENDENT CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	Ш
CIMO-02	Estudio de fase 2 de tratamiento combinado con magrolimab en pacientes con carcinoma de células escamosas de cabeza y cuello	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	II
CIMO-02	Estudio de fase 2 de multiples brazos de Magrolimab en pacientes con tumores solidos	INDEPENDENT CLINICAL TRIAL	ALEJANDRA CANTERO GONZÁLEZ	II
CIMO-02	Estudio en fase II, multicéntrico, abierto, de combinaciones de sacituzumab govitecán como primera línea de tratamiento en pacientes con cáncer de pulmón no microcítico (CPNM) metastásico o avanzado sin alteraciones genómicas de utilidad clínica	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio de fase III, abierto, aleatorizado, global y multicéntrico de sacituzumab govitecán frente a docetaxel en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado o metastásico con progresión durante o después de la quimioterapia a base de platino e inmunoterapia anti-PD-1/PD-L1	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio en fase III, aleatorizado y abierto para evaluar Zimberelimab y Domvanalimab en combinación con quimioterapia frente a pembrolizumab con quimioterapia, como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico metastásico sin aberraciones tumorales genómicas del receptor del factor de crecimiento epidérmico ni de la quinasa del linfoma anaplásico	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
CIMO-02	Estudio de fase III multicéntrico, aleatorizado y doble ciego de HBI-8000 combinado con nivolumab frente a placebo con nivolumab en pacientes con melanoma irresecable o metastásico no tratados previamente con inhibidores de PD-1 o PD-L1	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	Ш

Group	Title	Subtype	LR Name	Phase
CIMO-02	Estudio de fase 2, aleatorizado, doble ciego y controlado con placebo de acetato de abiraterona más prednisona con o sin abemaciclib en pacientes con cáncer de próstata metastásico resistente a la castración	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	П
CIMO-02	Estudio de fase 1, primero en el ser humano, de búsqueda de dosis/Estudio de fase 2, aleatorizado, de IMM60 y pembrolizumab en el melanoma avanzado y en el cáncer de pulmón no microcítico metastásico	CLINICAL TRIALS WITH DRUGS	JOSÉ MIGUEL JURADO GARCÍA	I
CIMO-02	Estudio en fase II, aleatorizado, doble ciego y multicéntrico de retifanlimab en combinación con INCAGN02385 (anti-LAG-3) e INCAGN02390 (anti-TIM-3) como tratamiento de primera línea en participantes con carcinoma escamoso de cabeza y cuello metastásico/recidivante positivo para PD-L1 (CPS =1).	COMMERCIAL CLINICAL TRIAL	ELISABETH PEREZ RUIZ	II
CIMO-02	Estudio Abierto de Fase 2, Multicéntrico, de un Solo Brazo Para Evaluar la Eficacia y la Seguridad del Pemigatinib en Sujetos con Tumores Sólidos Malignos, localmente avanzados/metastásicos o quirúrgicamente irresecables tratados previamente para las mutaciones o traslocaciones FGFR activadas (FIGHT-207)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio de fase II, abierto, de un solo grupo y multicéntrico para evaluar la eficacia y la seguridad de pemigatinib en participantes con cáncer pulmonar no microcítico avanzado con una alteración del receptor del factor de crecimiento fibroblástico que progresó en el tratamiento anterior (FIGHT-210)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	П
CIMO-02	Estudio de fase II para evaluar INCB099280 en participantes con carcinoma epidermoide avanzado	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	II
CIMO-02	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y seguridad de tafasitamab más lenalidomida además de rituximab frente a lenalidomida además de rituximab en pacientes con linfoma folicular recidivante/resistente (R/R) de grado 1 a 3a o linfoma de la zona marginal R/R	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III
CIMO-02	Ensayo clínico de fase III, abierto y aleatorizado de IO102-IO103 en combinación con pembrolizumab en comparación con pembrolizumab en monoterapia en pacientes con melanoma irresecable o metastásico (avanzado) no tratados anteriormente	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	Ш
CIMO-02	Ensayo clínico de fase I para evaluar la seguridad y eficacia de repotrectinib combinado con osimertinib en pacientes con Cáncer de pulmón no microcítico (CPCNP) avanzado o metastásico con mutación del EGFR (TOTEM).	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	I
CIMO-02	Estudio en fase 2, multicéntrico, de linfocitos infiltrantes de tumores autó³logos (LN-144 o LN-145) en pacientes con tumores sólidos.	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
CIMO-02	Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de cemiplimab en comparación con la combinación de cemiplimab más ISA101b en el tratamiento de sujetos con cáncer orofaríngeo (COF) VPH-16 positivo resistente al platino	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
CIMO-02	Ensayo de fase 3, abierto, aleatorizado y multicéntrico que compara selpercatinib con una terapia basada en platino y pemetrexed, con o sin pembrolizumab, como tratamiento inicial del cáncer de pulmón no microcítico avanzado o metastásico, positivo para fusión de RET (LIBRETTO-431)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se evalúa la administración adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusión en el gen RET (LIBRETTO-432)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio pivotal no comparativo de 2 cohortes para evaluar la eficacia de tipifarnib en pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) con mutaciones de HRAS (AIM-HN) y el impacto de las mutaciones de HRAS en la respuesta a las terapias sistémicas de primera línea para el CCECC (SEQ-HN). El estudio AIM-HN y SEQ-HN	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
CIMO-02	Estudio en fase III, abierto y aleatorizado, de LOXO-305 en comparación con un inhibidor de tirosina cinasa de Bruton (BTK, por sus siglas en inglés) a elegir por el investigador, en pacientes con linfoma de células del manto tratados previamente y sin tratamiento previo con inhibidores de BTK (BRUIN MCL-321).	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III

Group	Title	Subtype	LR Name	Phase
CIMO-02	Estudio de fase II abierto para evaluar la seguridad y la eficacia de telisotuzumab vedotina (ABBV-399) en pacientes con cáncer de pulmón no microcítico c-Met+ tratado previamente	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
CIMO-02	Estudio de fase III, aleatorizado, de pembrolizumab administrado de forma concomitante con quimiorradioterapia y como tratamiento de mantenimiento frente a la quimiorradioterapia sola en pacientes con carcinoma epidermoide de cabeza y cuello localmente avanzado. MK-3475-412	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	III
CIMO-02	Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo de pembrolizumab (MK-3475) en monoterapia para el tratamiento adyuvante del carcinoma renal tras una nefrectomía (KEYNOTE-564)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	Ш
CIMO-02	Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar pembrolizumab frente a un placebo como tratamiento adyuvante después de cirugía y radioterapia del carcinoma epidermoide cutáneo localmente avanzado (CEC LA) de alto riesgo, MK3475-630.	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	Ш
CIMO-02	Ensayo de fase 3, aleatorizado y doble ciego de pembrolizumab (MK-3475) más enzalutamida frente a un placebo más enzalutamida en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) (KEYNOTE-641)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	Ш
CIMO-02	Estudio de fase 3, aleatorizado y doble ciego de quimioterapia con pemetrexed + platino con o sin pembrolizumab (MK-3475) en pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide, metastásico, con mutación de EGFR y resistente a inhibidores de la tirosina cinasa (KEYNOTE-789).	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio de fase 3, abierto y aleatorizado para evaluar la eficacia y la seguridad de pembrolizumab (MK-3475) en combinación con belzutifán (MK-6482) y lenvatinib (MK-7902), o MK-1308A en combinación con lenvatinib, en comparación con pembrolizumab y lenvatinib, como tratamiento de primera línea en participantes con carcinoma renal de células claras (CRcc) avanzado	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	Ш
CIMO-02	Estudio de fase 3, multicéntrico, aleatorizado y doble ciego para comparar la eficacia y la seguridad de belzutifán (MK-6482) más pembrolizumab (MK-3475) frente a un placebo más pembrolizumab en el tratamiento adyuvante del carcinoma renal de células claras (CRcc) tras una nefrectomía (MK-6482-022).	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	Ш
CIMO-02	Estudio de fase 3 de pembrolizumab en combinación con carboplatino/taxano (paclitaxel o nab- paclitaxel), seguido de pembrolizumab con o sin mantenimiento con olaparib, en el tratamiento de primera línea del cáncer de pulmón no microcítico (CPNM) epidermoide metastásico	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio de fase 3, aleatorizado y abierto de pembrolizumab (MK-3475) más olaparib frente a acetato de abiraterona o enzalutamida en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) que no son seleccionados por defectos en la reparación por recombinación homóloga y que han mostrado fracaso con el tratamiento previo con un fármaco hormonal de última generación (FHUG) y quimioterapia (KEYLYNK-010)	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	Ш
CIMO-02	Estudio de fase 3 de pembrolizumab (MK-3475) en combinación con quimiorradioterapia concurrente, seguidos de pembrolizumab con o sin olaparib, frente a quimiorradioterapia concurrente seguida de durvalumab en participantes con cáncer de pulmón no microcítico (CPNM) en estadio III, localmente avanzado e irresecable.	COMMERCIAL CLINICAL TRIAL	JOSÉ MIGUEL JURADO GARCÍA	III
CIMO-02	Estudio de fase 3, aleatorizado, doble ciego y controlado con placebo de pembrolizumab (MK-3475) en combinación con quimiorradioterapia concomitante seguido de pembrolizumab con o sin olaparib (MK-7339) en comparación con la quimiorradioterapia concomitante sola en participantes con cáncer de pulmón microcítico en estadio limitado (CPM-EL) de diagnóstico reciente y sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	Ш
CIMO-02	Estudio de fase 3, aleatorizado y doble ciego de MK-7684A en combinación con etopósido y platino seguido de MK-7684A en comparación con atezolizumab en combinación con etopósido y platino seguido de atezolizumab para el tratamiento de primera línea de participantes con cáncer de pulmón microcítico en estadio extenso	COMMERCIAL CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	Ш

Group	Title	Subtype	LR Name	Phase
CIMO-02	Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con un comparador activo de MK-7684A (vibostolimab con pembrolizumab) adyuvante frente a pembrolizumab adyuvante en participantes con melanoma en estadio II-IV de alto riesgo (KEYVIBE-010)	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
CIMO-02	Ensayo de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de pembrolizumab (MK-3475) y lenvatinib (E7080/MK-7902) en comparación con pembrolizumab en monoterapia como intervención de primera línea en participantes con melanoma avanzado (LEAP-003).	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL BERCIANO GUERRERO	Ш
CIMO-02	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de pemetrexed + quimioterapia a base de platino + pembrolizumab (MK-3475) con o sin lenvatinib (E7080/MK-7902) como intervención de primera línea en participantes con cáncer de pulmón no microcítico, no epidermoide, metastásico (LEAP-006)	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio clínico de fase 2 aleatorizado abierto y de tres grupos, para evaluar la seguridad y la eficacia de lenvatinib (E7080/MK-7902) en combinación con pembrolizumab (MK-3475) frente a la quimioterapia de referencia y lenvatinib en monoterapia en participantes con carcinoma epidermoide de cabeza y cuello recurrente/metastásico (CECC R/M) que han progresado después del tratamiento con platino e inmunoterapia (inhibidores de PD-1/PD-L1) (LEAP-009)	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	II
CIMO-02	Estudio Fase IIIb, de un solo brazo de carboplatino o cisplatino más etopósido con Atezolizumab (anticuerpo anti-PD-L1) en pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	Ш
CIMO-02	Estudio Fase III multicéntrico, abierto, aleatorizado de Entrectinib comparado con Crizotinib en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico on reordenamientos del Gen ROS1, con o sin metástasis en el sistema nervioso central.	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	ESTUDIO INTERVENCIONAL TIPO PLATAFORMA PARA INVESTIGAR EL IMPACTO DE LAS SOLUCIONES DE SALUD DIGITAL EN LOS RESULTADOS EN LA SALUD Y LA UTILIZACIÓN DE RECURSOS SANITARIOS EN PARTICIPANTES QUE RECIBEN TRATAMIENTO SISTÉMICO EN LA PRÁCTICA CLÍNICA (ORIGAMA).	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	IV
CIMO-02	Estudio en fase II de dos grupos para investigar tepotinib en combinación con osimertinib en el cáncer de pulmón no microcítico (CPNM) con amplificación de MET avanzado o metastásico que alberga mutaciones activadoras del EGFR y que ha adquirido resistencia al tratamiento previo con osimertinib (estudio INSIGHT 2).	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Registro de enfermedades en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con alteraciones por omisión de METex14 MOMENT (Met nOn sMall cEll caNcer registry)	OBSERVATIONAL STUDY WITH DRUGS	MANUEL COBO DOLS	NA
CIMO-02	Estudio multicéntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparación con quimiorradioterapia concurrente más placebo seguida de durvalumab en participantes con cáncer de pulmón no microcítico irresecable en estadio III	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies (DDRiver NSCLC 322)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	III
CIMO-02	Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de dos grupos, para evaluar la eficacia y la seguridad de xevinapant y radioterapia en comparación con placebo y radioterapia para demostrar la mejora de la supervivencia sin enfermedad en participantes con carcinoma de células escamosas de cabeza y cuello resecado, que presentan un riesgo alto de recidiva y no son aptos para la administración de dosis altas de cisplatino.	CLINICAL TRIALS WITH DRUGS	ANTONIO RUEDA DOMÍNGUEZ	III
CIMO-02	Estudio observacional ambispectivo que describe los patrones de diagnóstico y de tratamiento en adultos con carcinomas pulmonares no microcíticos metastásicos con mutación del gen BRAF V600E en la práctica clínica, para evaluar la efectividad del tratamiento y la calidad de vida OCTOPUS	OBSERVATIONAL STUDY WITH DRUGS	MANUEL COBO DOLS	NA

Group	Title	Subtype	LR Name	Phase
CIMO-02	Describe III Revisión retrospectiva de las historias clínicas de la monoterapia con dabrafenib y/o la terapia de combinación con dabrafenib y trametinib en pacientes con melanoma metastásico con el objeto de caracterizar a los pacientes que han obtenido un beneficio a largo plazo en el programa individualizado de pacientes (PIP)	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL BERCIANO GUERRERO	OD
CIMO-02	Estudio de Fase IB multicéntrico, abierto de RO7082859 y Atezolizumab o Polatuzumab Vedoitna (más una dosis única de Obinutuzumab como pretratamiento) en pacientes adultos con linfoma no Hodgkin de células B recurrente/Refractario.	COMMERCIAL CLINICAL TRIAL	ANTONIO RUEDA DOMÍNGUEZ	I
CIMO-02	Estudio observacional para identificar pacientes con CPNM avanzado/metastásico y translocación de ALK y ROS1 y conocer su manejo terapéutico (IDEALK&ROS).	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	SP
CIMO-02	Estudio multicéntrico controlado, aleatorizado y abierto sobre la eficacia del tratamiento intratumoral neoadyuvante con Daromun (L19IL2 + L19TNF) seguido de cirugía y una terapia adyuvante frente a cirugía y una terapia adyuvante en pacientes con melanoma en estadio IIIB/C	INDEPENDENT CLINICAL TRIAL	ELISABETH PEREZ RUIZ	III
CIMO-02	Estudio de fase III aleatorizado, multicéntrico y abierto de Lurbinectedina como agente único o Lurbinectedina en combinación con Irinotecán frente a la elección del investigador (Topotecán o Irinotecán) en Pacientes con cáncer de pulmón de células pequeñas en recaída (CPCP) (Ensayo LAGOON)	CLINICAL TRIALS WITH DRUGS	MARIA VANESA GUTIERREZ CALDERON	III
CIMO-02	Estudio de fase III de fianlimab (REGN3767, anti-LAG-3) + cemiplimab en comparación con pembrolizumab en pacientes con melanoma metastásico o localmente avanzado inoperable no tratado previamente	CLINICAL TRIALS WITH DRUGS	ELISABETH PEREZ RUIZ	Ш
CIMO-02	Estudio de Fase 1b/2, multicéntrico, de un solo grupo de RBN 2397 en combinación con pembrolizumab en pacientes con carcinoma epidermoide pulmonar (CEP)	CLINICAL TRIALS WITH DRUGS	MANUEL COBO DOLS	II
CIMO-02	Estudio observacional para describir los patrones de tratamiento trás una secuenciación genómica exhaustiva en pacientes fallos de screening del estudio TELMA con cáncer de pulmón no microcítico no escamoso localmente avanzado o metastásico y carga mutacional tumoral baja o desconocida. Estudio TELMORE (ML41575)	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL COBO DOLS	SP
CIMO-02	Estudio en fase II multicéntrico, abierto en pacientes con cáncer de pulmón no microcítico (CPNM) irresecable o metastásico no tratado anteriormente, CPNM resistente a PD-X recurrente o cáncer epidermoide de cabeza y cuello (CECC) recurrente o metastásico que reciben la proteína de fusión LAG-3 soluble eftilagimod alfa (IMP321) en combinación con pembrolizumab (antagonista de PD-1). TACTI-002 (Dos inmunoterapias activas):	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	Estudio de fase 3 abierto, aleatorizado y multicéntrico para comparar la eficacia de TAK-788 como tratamiento de primera línea frente a quimioterapia a base de platino en pacientes con cáncer de pulmón no microcítico con mutaciones de EGFR por inserción en el exón 20	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	III
CIMO-02	Estudio multicéntrico, abierto, de fase I/II de EOS884448 en combinación con el tratamiento estándar y/o terapias experimentales en participantes con tumores sólidos avanzados	CLINICAL TRIALS WITH DRUGS	ALEJANDRA CANTERO GONZÁLEZ	II
CIMO-02	Ensayo clínico fase II multicéntrico aleatorizado para evaluar la eficacia y seguridad de la combinación de nivolumab y paclitaxel en primera línea de tratamiento en pacientes con carcinoma escamoso de cabeza y cuello recurrente o metastásico no candidatos a recibir quimioterapia basada en platino (NIVOTAX).	INDEPENDENT CLINICAL TRIAL	MARIA VANESA GUTIERREZ CALDERON	II
CIMO-02	Estudio de fase II, aleatorizado y sin enmascaramiento de patritumab deruxtecán (U3-1402) en sujetos con cáncer pulmonar de células no pequeñas (CPCNP) con mutación del EGFR metastásico o localmente avanzado que han recibido tratamiento previo. HERTHENA-Lung01	COMMERCIAL CLINICAL TRIAL	MANUEL COBO DOLS	II
CIMO-02	HERTHENA-Lung02: Estudio en fase III, aleatorizado, abierto de patritumab deruxtecán frente a quimioterapia basada en platino en el cáncer de pulmón no microcítico (CPNM) metastásico o localmente avanzado con mutación del receptor del factor de crecimiento epidérmico (EGFRm) tras el fracaso del tratamiento con inhibidores de la tirosina cinasa (ITC) del factor de crecimiento epidérmico (EGFR)	INDEPENDENT CLINICAL TRIAL	MANUEL COBO DOLS	III

Group	Title	Subtype	LR Name	Phase
CIMO-02	Estudio de fase III, aleatorizado, doble ciego, comparativo con placebo y con tratamiento activo de V940 (ARNm-4157) adyuvante más pembrolizumab frente a un placebo adyuvante más pembrolizumab en participantes con melanoma en estadio II-IV de alto riesgo	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
CIMO-02	Estudio de fase III, aleatorizado y triple ciego en colaboración con el Grupo de Melanoma de la Organización Europea para la Investigación y el Tratamiento del Cáncer (EORTC) de encorafenib y binimetinib como tratamiento complementario comparado con placebo en el melanoma en estadio IIB/C completamente resecado con mutación V600E/K de BRAF	CLINICAL TRIALS WITH DRUGS	MIGUEL ÁNGEL BERCIANO GUERRERO	III
CIMO-02	Estudio de fase III multicéntrico, aleatorizado, abierto para evaluar la eficacia y seguridad de Atezolizumab administrado en combinación con Cabozantinib frente a Cabozantinib en monoterapia en pacientes con carcinoma de células renales localmente avanzado o metastásico inoperable que han presentado progresión tumoral radiológica durante o después del tratamiento con un inhibidor de puntos de control inmunitario.	COMMERCIAL CLINICAL TRIAL	ALVARO MONTESA PINO	III
CIMO-02	Estudio de fase III aleatorizado y abierto de XL092 + nivolumab en comparación con sunitinib en participantes con carcinoma de células renales no claras metastásico o avanzado	CLINICAL TRIALS WITH DRUGS	ALVARO MONTESA PINO	III
D-01	Estudio de fase III, aleatorizado, multicéntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a dolutegravir más lamivudina en adultos infectados por el VIH 1 con supresión virológica	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	III
D-01	Estudio de fase IIIb, multicéntrico, no aleatorizado, de grupos paralelos, abierto, híbrido de tipo I que evalúa la eficacia, la seguridad, la efectividad de la implementación y los resultados comunicados por el paciente de dolutegravir/lamivudina por vía oral una vez al día como tratamiento de primera línea, seguido de un cambio opcional elegido por el participante a cabotegravir intramuscular de acción prolongada más rilpivirina cada dos meses para el mantenimiento de la supresión virológica en adultos con VIH-1 sin tratamiento antirretrovíricos	CLINICAL TRIALS WITH DRUGS	ROSARIO PALACIOS MUÑOZ	III
D-01	MULTICENTER, RANDOMIZED, PRAGMATIC, OPEN-LABEL, PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIFFERENT DURATIONS OF ANTIMICROBIAL TREATMENT OF OSTEOSYNTHESIS MATERIAL-ASSOCIATED INFECTIONS AFTER LONG BONE FRACTURE. DURATIOM	INDEPENDENT CLINICAL TRIAL	ENRIQUE NUÑO ÁLVAREZ	III
D-01	Estudio en fase III para evaluar el efecto de la pitavastatina para prevenir los acontecimientos vasculares en personas con infección por VIH-1. Estudio REPRIEVE	INDEPENDENT CLINICAL TRIAL	CRISTINA GOMEZ AYERBE	III
D-01	Ensayo clínico piloto, multicéntrico, para comparar la eficacia de RAL 1200 QD vs DRV-cb (800-150) QD ambos en combinación con TAF/FTC en pacientes con infección VIH y CD4<200 cel/microL	INDEPENDENT CLINICAL TRIAL	ROSARIO PALACIOS MUÑOZ	IV
D-01	FIS-PSE-2022-01 Estudio prospectivo de las infecciones del torrente sanguíneo por Pseudomonas aeruginosa en pacientes adultos: eficacia y seguridad de diferentes estrategias terapéuticas, en el contexto actual de resistencia a múltiples fármacos	COMMERCIAL POST-AUTHORIZATION STUDY	ANDREA PROLO ACOSTA	OD
D-01	Estudio de intervención quasi-experimental para la optimización del uso de nuevos antibióticos (Poyecto NEW_SAFE).	INDEPENDENT POST-AUTHORIZATION STUDY	GUILLERMO OJEDA BURGOS	SP
D-01	Estudio de fase IV, multicéntrico, abierto y aleatorizado, para evaluar el impacto del cambio de tratamiento antirretroviral de terapia dual a terapia triple sobre la inflamación en pacientes con infección por VIH tipo 1	INDEPENDENT CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	IV
D-01	Eficacia virológica de dolutegravir/lamivudina en personas virológicamente suprimidas con resistencia confirmada o sospechada a lamivudina. Estudio VOLVER	INDEPENDENT CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	II
D-01	Estudio observacional para evaluar la tasa de reinfección en personas que se inyectan drogas (PID) infectadas con el virus de la hepatitis C (VHC) que se han sometido con éxito a un tratamiento para el VHC en España. Estudio LIVERate. Sponsor Code: ID VEAP: 6375	COMMERCIAL POST-AUTHORIZATION STUDY	ROSARIO PALACIOS MUÑOZ	SP
D-01	Estudio clínico de fase 3, aleatorizado, doble ciego y controlado con producto activo para evaluar el cambio a doravirina/islatravir (DOR/ISL) una vez al día en participantes con supresión virológica del VIH-1 con bictegravir/emtricitabina/tenofovir alafenamida(BIC/FTC/TAF)	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	III

Group	Title	Subtype	LR Name	Phase
D-01	Estudio clínico de fase 3, aleatorizado, doble ciego y comparativo con tratamiento activo para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de doravirina/islatravir una vez al día en participantes infectados por el VIH-1 sin tratamiento previo	COMMERCIAL CLINICAL TRIAL	JESÚS SANTOS GONZÁLEZ	III
D-01	Estudio abierto, multicéntrico y aleatorizado para investigar el tratamiento antirretroviral con inhibidor de la integrasa frente al inhibidor de la proteasa potenciado para pacientes con enfermedad por el VIH avanzada. Estudio Late Presenter Treatment Optimisation (Optimización del tratamiento para pacientes con infección avanzada, LAPTOP).	INDEPENDENT CLINICAL TRIAL	CRISTINA GOMEZ AYERBE	Ш
D-01	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR	INDEPENDENT CLINICAL TRIAL	ROSARIO PALACIOS MUÑOZ	IV
D-03	Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos sobre la seguridad, tolerabilidad, farmacocinética y eficacia terapéutica de SAR441344 en pacientes adultos con síndrome de Sjögren primario (primary Sjögren's Syndrome, pSjS) phaethuSA	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio de fase 3, aleatorizado, en doble ciego, de grupos paralelos y controlado con principio activo, para comparar la eficacia, seguridad, farmacodinamia, farmacocinética e inmunogenia de denosumab de Enzene (ENZ215) y Prolia® en mujeres posmenopáusicas con osteoporosis (DANUBE)	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	Ш
D-03	Estudio fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de obinutuzumab en pacientes con nefritis lúpica de clase III o IV de la ISN/RPS de 2003	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio abierto y multicéntrico para pacientes que hayan completado un estudio previo con secukinumab patrocinado por Novartis y que, a criterio del investigador, se estén beneficiando del tratamiento continuado con secukinumab	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	IV
D-03	Estudio de tipo observacional no postautorización Evaluación del riesgo cardiovascular y de sus determinantes, en pacientes con artritis reumatoide, espondilitis anquilosante y artritis psoriásica-proyecto carma	NON-POST-AUTHORIZATION STUDY	ANGELINES BELMONTE LÓPEZ	NO
D-03	Estudio de extensión a largo plazo con dosis múltiples para demostrar la seguridad y la eficacia del tildrakizumab en sujetos con artritis psoriásica y espondilitis anquilosante o espondiloartritis axial no radiográfica que hayan completado previamente estudios con tildrakizumab	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	Ш
D-03	Estudio preliminar de eficacia en fase II, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar guselkumab para el tratamiento de pacientes con arteritis de células gigantes de nueva aparición o recidivante	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Ensayo clínico multicéntrico en fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de guselkumab administrado por vía subcutánea en pacientes con artritis psoriásica activa	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio de fase 3b, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de guselkumab administrado por vía subcutánea en la mejoría de los signos y síntomas clínicos y en la inhibición de la progresión radiográfica en participantes con artritis psoriásica activa.(APEX)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio de fase 3B, multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y seguridad de Guselkumab administrado por vía subcutánea en participantes con artritis psoriásica activa que tuvieron una respuesta inadecuada y/o intolerancia a un tratamiento anterior de inhibición del factor de necrosis tumoral a	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio de fase IV, multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y la seguridad de guselkumab administrado por vía subcutánea en pacientes que no han recibido tratamiento biológico previo con artritis psoriásica axial activa.	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	IV

Group	Title	Subtype	LR Name	Phase
D-03	Estudio observacional ambispectivo para describir la persistencia de la secuenciación de guselkumab o TNFi como terapia de segunda línea para el tratamiento de la artritis psoriásica activa MANHATTAN	OBSERVATIONAL STUDY WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	NA
D-03	Ensayo fase III, multicéntrico, aleatorizado, en grupos paralelos, doble ciego, de dos brazos, para evaluar la seguridad y eficacia de anifrolumab frente a placebo en pacientes entre 18 y 70 años con esclerosis sistémica (Estudio DAISY)	CLINICAL TRIALS WITH DRUGS	NATALIA MENA VAZQUEZ	III
D-03	Estudio de dosis-respuesta, aleatorizado, doble ciego, controlado con placebo de la eficacia y la seguridad de MEDI7352 en sujetos con artrosis dolorosa de rodilla	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de SAR441566 más metotrexato en adultos con artritis reumatoide de moderada a grave	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Tratamiento precoz con terapia biológica en espondiloartritis axial: Efectividad a 5 años. Estudio TBSPA	INDEPENDENT POST-AUTHORIZATION STUDY	SARA MANRIQUE ARIJA	OD
D-03	Registro español de acontecimientos adversos de terapias biológicas y biosimilares en enfermedades reumáticas. Estudio BIOBADASER III.	INDEPENDENT POST-AUTHORIZATION STUDY	SARA MANRIQUE ARIJA	AS
D-03	Registro de pacientes adultos jóvenes con diagnóstico de Artritis Idiopática Juvenil	INDEPENDENT POST-AUTHORIZATION STUDY	GISELA DÍAZ-CORDOVÉS REGO	SP
D-03	Prevalencia de enfermedad Inflamatoria Intestinal no diagnosticada en pacientes con Espondiloartritis. Estudio EISER	INDEPENDENT POST-AUTHORIZATION STUDY	SARA MANRIQUE ARIJA	OD
D-03	Estudio multicéntrico, aleatorizado, con doble enmascaramiento y de comparación con placebo para evaluar la eficacia, la seguridad, la tolerabilidad, la farmacocinética y la farmacodinámica de GLPG3667 administrado por vía oral en pacientes adultos con lupus eritematoso sistémico activo	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio de extensión a largo plazo, multicéntrico y doble ciego para evaluar la seguridad y la eficacia de Filgotinib en pacientes con artritis reumatoide	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	Estudio de fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de BMS-986165 con tratamiento de base en pacientes con nefritis lúpica	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio multicéntrico para caracterizar la seguridad y la eficacia a largo plazo de BMS-986165 en pacientes con lupus eritematoso sistémico	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad del tratamiento con branebrutinib en pacientes con lupus eritematoso sistémico activo o síndrome de Sjögrem primario, o el tratamiento con branebrutinib seguido de tratamiento abierto con abatecept en pacientes con artritis reumatoide activa	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio observacional de la persistencia del tratamiento en la artritis psoriásica (Estudio PRO-SPIRIT, I1F-MC-B009)	COMMERCIAL POST-AUTHORIZATION STUDY	ANTONIO FERNÁNDEZ NEBRO	SP
D-03	Estudio de extensión fase 2, multicéntrico, y abierto (EEA) en pacientes con artritis reumatoide que han completado el estudio controlado y aleatorizado (ECA) en fase 2 con ABT-494 precedente	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio de Fase 3, aleatorizado, doble ciego para comparar ABT-494 con placebo en tratamiento estable con fármacos antirreumáticos modificadores de la enfermedad sintéticos convencionales (FARMEsc) en sujetos con artritis reumatoide de actividad moderada a grave con respuesta insuficiente o intolerancia a los FARME biológicos (FARMEb). A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs).	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	111
D-03	Estudio de fase 3, aleatorizado, doble ciego comparando ABT-494 con placebo en sujetos con artritis reumatoide activa moderada a grave que reciben una dosis estable de fármacos antirreumáticos modificadores de la enfermedad sintéticos convencionales (FARMEsc) y que no han respondido de forma adecuada a FARMEsc	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III

Group	Title	Subtype	LR Name	Phase
D-03	Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ABBV-154 en sujetos con artritis reumatoide activa moderada a grave con respuesta insuficiente a fármacos antirreumáticos modificadores de la enfermedad biológicos o sintéticos dirigidos (FARMEb/sd)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio de fase II, doble ciego, de rango de dosis, con grupos paralelos y de extensión a largo plazo para evaluar la seguridad y la eficacia de Enpatoran en participantes con lupus eritematoso cutáneo subagudo, lupus eritematoso discoide y/o lupus eritematoso sistémico que han completado el tratamiento del estudio WILLOW (MS200569_0003)	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Estudio en fase II, aleatorizado, doble ciego, de búsqueda de dosis, controlado con placebo, de grupos paralelos y adaptativo para evaluar la eficacia y la seguridad de enpatoran en participantes con lupus eritematoso sistémico y con lupus eritematoso cutáneo (lupus eritematoso cutáneo subagudo o lupus eritematoso discoide) que toman el tratamiento de referencia.	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-03	Ensayo clínico en fase II, multicéntrico, aleatorizado, controlado con placebo, con doble enmascaramiento y con grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de MT-7117 en pacientes con esclerosis sistémica cutánea difusa	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	II
D-03	ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, EN DOBLE CIEGO, CONTROLADO CON PLACEBO Y CON FÁRMACO ACTIVO DE REFERENCIA (ADALIMUMAB), PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE BIMEKIZUMAB EN EL TRATAMIENTO DE SUJETOS CON ARTRITIS PSORIÁSICA ACTIVA	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	III
D-03	ESTUDIO DE EXTENSIÓN, ABIERTO Y MULTICÉNTRICO, PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD Y EFICACIA A LARGO PLAZO DE BIMEKIZUMAB EN EL TRATAMIENTO DE SUJETOS CON ARTRITIS PSORIÁSICA ACTIVA (BE VITAL)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	Ш
D-03	Análisis del impacto del coste en pacientes con Artritis Reumatoide moderada severa que no responden a fármaco modificador de la enfermedad biológico (FAMEb) o a fármaco modificador de la enfermedad sintético convencional (FAMEsc). Sponsor Code: A3921325. Estudio CIARA	COMMERCIAL POST-AUTHORIZATION STUDY	ANTONIO FERNÁNDEZ NEBRO	SP
D-03	Un estudio multinacional, no intervencionista de tofacitinib en pacientes tratados para la artritis psoriásica. Estudio TOPSATI. Sponsor protocol code: A3921332	OBSERVATIONAL STUDY WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	NA
D-03	Estudio doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de PRAO23 en sujetos con esclerosis sistémica asociada a enfermedad pulmonar intersticial (ES-EPI).	INDEPENDENT CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	П
D-03	Evolución del Lupus Eritematoso Sistémico en España	NON-POST-AUTHORIZATION STUDY	ANTONIO FERNÁNDEZ NEBRO	NO
D-03	Registro Multicéntrico de Vasculitis Asociadas a ANCA (granulomatosis con poliangeítis, granulomatosis eosinofílica con poliangeítis y poliangeítis microscópica)	OBSERVATIONAL STUDY WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	NA
D-03	Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de dapirolizumab pegol en participantes del estudio con lupus eritematoso sistémico de moderado a grave	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	Ш
D-03	Estudio de extensión, abierta y multicéntrico, para evaluar la seguridad y tolerabilidad a largo plazo del tratamiento con dapirolizumab pegol en participantes del estudio con lupus eritematoso sistémico	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	III
D-03	INSPIRE 2 Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia y la seguridad de tildrakizumab en sujetos con artritis psoriásica activa II que no habían recibido tratamiento previo con anti-TNF (INSPIRE 2).	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	Ш
D-03	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia y la seguridad de tildrakizumab en sujetos con artritis psoriásica activa I que habían recibido tratamiento previo con anti-TNF (INSPIRE 1)	COMMERCIAL CLINICAL TRIAL	ANTONIO FERNÁNDEZ NEBRO	Ш
D-03	Estudio de extensión abierto para evaluar la seguridad y la eficacia a largo plazo de tildrakizumab en pacientes con artritis psoriásica	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	I

Group	Title	Subtype	LR Name	Phase
D-03	Estudio de fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de VTX958 en pacientes con artritis psoriásica activa	CLINICAL TRIALS WITH DRUGS	ANTONIO FERNÁNDEZ NEBRO	II
D-04	Estudio de 52 semanas de duración, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad, para evaluar la tasa de exacerbación, las mediciones adicionales de control del asma y la seguridad en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico tratados con GSK3511294 en comparación con mepolizumab o benralizumab	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	Estudio de extensión, abierto, multicéntrico y de un solo grupo para evaluar la seguridad a largo plazo de GSK3511294 (depemokimab) en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico de los estudios 206713 o 213744	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	Estudio de 52 semanas, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y multicéntrico de la eficacia y la seguridad del tratamiento complementario con GSK3511294 en participantes adultos y adolescentes con asma grave no controlada con fenotipo eosinofílico	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	POLLINEX® GO: 600 SU/ml, 1.600 SU/ml, 4.000 SU/ml suspensión inyectable. Extracto alergénico modificado de pólenes: mezcla de gramíneas y olivo. Estudio GOL	COMMERCIAL POST-AUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAÉN	SP
D-04	BIOBADALER. Understanding similarities and differences of biological therapies for severe asthma	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAÉN	SP
D-04	Similarities and differences of biological therapies for allergic diseases	REST OF OBSERVATIONAL STUDIES WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	OD
D-04	Estudio de fase II de búsqueda de dosis, aleatorizado, doble ciego y controlado con un placebo, para evaluar la eficacia y la seguridad del CDX-0159 en pacientes con urticaria crónica espontánea	CLINICAL TRIALS WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	II
D-04	Estudio de fase II de búsqueda de dosis, aleatorizado, doble ciego y controlado con un placebo, para evaluar la eficacia y la seguridad del CDX-0159 en pacientes con urticaria crónica inducible	CLINICAL TRIALS WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	П
D-04	Estudio de extensión multicéntrico, abierto y doble ciego, controlado con placebo con retirada aleatorizada, seguido de ciclos de tratamiento abierto de larga duración para evaluar la eficacia, seguridad y tolerabilidad de remibrutinib (LOU064) en pacientes adultos con urticaria crónica espontánea que hayan completado los estudios anteriores de fase III de remibrutinib	CLINICAL TRIALS WITH DRUGS	ALMUDENA TESTERA MONTES	III
D-04	Estudio de fase III, multicéntrico y abierto: monitorización ambulatoria de la presión arterial en pacientes adultos con urticaria crónica espontánea inadecuadamente controlada con antihistamínicos H1 y tratados con remibrutinib hasta 12 semanas	CLINICAL TRIALS WITH DRUGS	ALMUDENA TESTERA MONTES	III
D-04	Estudio doble ciego para participante e investigador de un mes de duración en el que se evalúan la eficacia y la seguridad de remibrutinib (LOU064) en varios niveles de dosis en participantes adultos con alergia al cacahuete.	CLINICAL TRIALS WITH DRUGS	MARÍA JOSÉ TORRES JAÉN	II
D-04	Estudio multicéntrico, aleatorizado, doble ciego, con control activo y placebo para investigar la eficacia y seguridad de ligelizumab (QGE031) en el tratamiento de la urticaria crónica espontánea (UCE) en adolescentes y adultos inadecuadamente controlados con antihistamínicos H1	COMMERCIAL CLINICAL TRIAL	FRANCISCA GÓMEZ PÉREZ	III
D-04	Estudio de extensión multicéntrico, doble ciego y abierto para evaluar la eficacia y seguridad de ligelizumab como retratamiento, terapia autoadministrada y monoterapia en pacientes con urticaria crónica espontánea que han completado los estudios CQGE031C2302, CQGE031C2303, CQGE031C2202 o CQGE031C1301.	COMMERCIAL CLINICAL TRIAL	FRANCISCA GÓMEZ PÉREZ	III
D-04	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la seguridad de ligelizumab (QGE031) en el tratamiento de la urticaria crónica inducible (CINDU) en adolescentes y adultos inadecuadamente controlados con antihistamínicos H1.	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	Ш
D-04	Ensayo de fase 3 de 3 partes, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para demostrar la eficacia y seguridad de Benralizumab en pacientes con Gastritis y/o Gastroenteritis eosinofílica (ensayo HUDSON GI)	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III

Group	Title	Subtype	LR Name	Phase
D-04	Ensayo clínico fase III multicéntrico, doble ciego, aleatorizado y controlado con placebo, en grupos paralelos, que evalúa la eficacia clínica y seguridad de la inmunoterapia con el alérgeno mayor purificado Cup a 1, en pacientes con rinoconjuntivitis alérgica moderada/ grave con o sin asma controlado, sensibilizados a Cupresáceas	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III
D-04	Ensayo prospectivo multicéntrico aleatorizado, controlado con placebo y comparativo de la eficacia y la seguridad de la inmunoterapia subcutánea con mezcla de gramíneas y ácaros a dosis adecuadas frente a monoterapia, para el tratamiento de la alergia	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	Protocolo maestro de dos estudios aleatorizados, controlados con placebo, doble ciegos, multicéntricos, de grupos paralelos de dupilumab en pacientes con urticaria crónica espontánea (UCE) que siguen siendo sintomáticosa pesar del uso de tratamiento antihistamínico H1 en pacientes sin tratamiento previo con omalizumab y en pacientes intolerantes o con respuesta incompleta a omalizumab. (CUPID)	COMMERCIAL CLINICAL TRIAL	IBON EGUILUZ GRACIA	III
D-04	Estudio observacional, multicéntrico, prospectivo, para evaluar la efectividad y seguridad en vida real de Depigoid® DUO Gato-Dermatophagoides pteronyssinus (DPT) (100/100 DPP/ml) en pacientes con rinitis/ rinoconjuntivitis persistente moderada-grave con o sin asma alérgica controlada en España"	OBSERVATIONAL STUDY WITH DRUGS	CARMEN RONDÓN SEGOVIA	NA
D-04	Reacciones de hipersensibilidad cruzada a Ibuprofeno y otros derivados Arilpropiónicos: entidades clínicas y mecanismos implícitos. Papel de la atopia e interacción fenotipo-genotipo SEAIC2018	INDEPENDENT POST-AUTHORIZATION STUDY	MARÍA JOSÉ TORRES JAÉN	SP
D-04	Estudio aleatorizado doble ciego controlado por placebo para evaluar la eficacia y mecanismos implicados en la inmunoterapia sublingual especifica con Pru p 3 (Pru p 3-ITSL) en pacientes con alergia a nsLTP con síntomas graves en su respuesta frente a melocotón, cacahuete artemisia y olivo.	INDEPENDENT CLINICAL TRIAL	FRANCISCA GÓMEZ PÉREZ	III
D-04	Ensayo clínico de eficacia y seguridad, prospectivo, aleatorizado, doble ciego, de doble simulación, controlado con placebo, multicéntrico, con inmunoterapia en pacientes con asma de leve a moderada controlada y rinitis/rinoconjuntivitis, alérgicos a Dermatophagoides pteronyssinus y/o Dermatophagoides farinae	INDEPENDENT CLINICAL TRIAL	CARMEN RONDÓN SEGOVIA	III
D-04	Ensayo multicéntrico, prospectivo y no intervencionista que supervisa las vías terapéuticas de los pacientes con asma tratados con una triple terapia extrafina de un único inhalador con ICS/LABA/LAMA en condiciones reales y que caracteriza los efectos sobre los resultados relacionados con la salud	OBSERVATIONAL STUDY WITH DRUGS	GUILLERMO BENTABOL RAMOS	NA
D-04	Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea (Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del polvo en pacientes con rinitis/rinoconjuntivitis alérgica	COMMERCIAL CLINICAL TRIAL	MARÍA JOSÉ TORRES JAÉN	III
D-04	ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA SEGURIDAD DEL TRATAMIENTO CON "ALLERGOVAC® HIMENÓPTEROS" EN PACIENTES SENSIBILIZADOS A ESTE VENENO" HIPNOS	OBSERVATIONAL STUDY WITH DRUGS	MARINA LABELLA ALVAREZ	NA
D-04	Estudio de fase II para evaluar la tolerabilidad, seguridad y eficacia de la inmunoterapia sublingual en pacientes con alergia a los ácaros del polvo doméstico. (SULGEN Study)	COMMERCIAL CLINICAL TRIAL	CARMEN RONDÓN SEGOVIA	II
D-04	NUEVO estudio observacional, longitudinal en pacientes con un diagnóstico o sospecha de diagnóstico de asma y/o EPOC para describir las características de los pacientes, patrones de tratamiento y carga de la enfermedad con el paso del tiempo para identificar fenotipos y endotipos asociados a resultados diferenciales que pueden respaldar el desarrollo futuro de estrategias de tratamiento personalizadas. D2287R00103 (NOVELTY-227190)	COMMERCIAL POST-AUTHORIZATION STUDY	-	SP
D-04	Estudio en fase IIIb, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo, para evaluar la seguridad y la eficacia de 30 mg de benralizumab SC en pacientes con asma grave no controlada con tratamiento según la práctica clínica habitual (ANDHI Study)	COMMERCIAL CLINICAL TRIAL	-	III
D-05	Estudio Fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de la administración de bepirovirsen en pacientes con Hepatitis B crónica HBeAg negativos y en tratamiento con análogos de nucleós(t)idos (B-Well 1)	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III

Group	Title	Subtype	LR Name	Phase
D-05	Estudio prospectivo, multicéntrico (B-Sure) para evaluar la durabilidad a largo plazo de la respuesta virológica sostenida en participantes con hepatitis B crónica tratados y no tratados con nucleósidos/ nucleótidos, que recibieron GSK3228836 en un estudio de tratamiento previo y respondieron a dicho tratamiento	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio fase IIb, aleatorizado, multicéntrico, abierto para evaluar la eficacia y seguridad del tratamiento secuencial con GSK3228836 seguido de Interferon pegilado alfa-2a en sujetos con Hepatitis B crónica (B-Together)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Minimización de la 17b-hidroxiesteroide deshidrogenasa tipo 13 para el tratamiento de EHNA (HORIZON): Estudio Fase 2b, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de GSK4532990 en adultos con esteatohepatitis no alcohólica precirrótica.	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio de fase III, multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo, para evaluar la eficacia y seguridad de cenicriviroc para el tratamiento de la fibrosis hepática en pacientes adultos con esteatohepatitis no alcohólica	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase 3, multicéntrico, aleatorizado, con doble enmascaramiento, a largo plazo y controlado con placebo para evaluar la seguridad y la eficacia del ácido obeticólico en sujetos con esteatohepatitis no alcohólica.	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Registro no intervencionista de larga duración para evaluar la seguridad y la efectividad de HUMIRA® (adalimumab) en pacientes con colitis ulcerosa (CU) de actividad moderada a grave. P11-282, LEGACY	COMMERCIAL POST-AUTHORIZATION STUDY	RAQUEL CAMARGO CAMERO	LA
D-05	Estudio observacional de regorafenib en carcinoma hepatocelular. REFINE	COMMERCIAL POST-AUTHORIZATION STUDY	RAÚL J. ANDRADE BELLIDO	LA
D-05	Estudio abierto a largo plazo para evaluar la seguridad y la tolerabilidad de seladelpar en sujetos con colangitis biliar primaria (CBP). ASSURE	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	IV
D-05	Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de Seladelpar en pacientes con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al ácido ursodesoxicólico (UDCA).RESPONSE	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Evaluación integrada mecanística, diagnóstica y pronóstica en hepatotoxicidad	INDEPENDENT POST-AUTHORIZATION STUDY	MERCEDES ROBLES DÍAZ	AS
D-05	ESTUDIO MULTICÉNTRICO DE FASE III ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DEL ETROLIZUMAB COMO TRATAMIENTO DE INDUCCIÓN Y MANTENIMIENTO EN PACIENTES CON ENFERMEDAD DE CROHN ACTIVA DE MODERADA A GRAVE	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	ESTUDIO ABIERTO DE EXTENSIÓN Y SUPERVISIÓN DE LA SEGURIDAD DE PACIENTES CON ENFERMEDAD DE CROHN CON ACTIVIDAD DE MODERADA A GRAVE PREVIAMENTE INSCRITOS EN EL PROTOCOLO DE FASE III CON ETROLIZUMAB, GA29144	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	Seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños. GIS-DUMBO-2018	INDEPENDENT POST-AUTHORIZATION STUDY	RAQUEL CAMARGO CAMERO	AS
D-05	Estudio Epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España.	NON-POST-AUTHORIZATION STUDY	RAQUEL CAMARGO CAMERO	NO
D-05	SUSPENSIÓN DEL TRATAMIENTO ANTI-TNF EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL: ENSAYO CLÍNICO MULTICÉNTRICO, PROSPECTIVO Y ALEATORIZADO	INDEPENDENT CLINICAL TRIAL	RAQUEL CAMARGO CAMERO	IV
D-05	TRANSFORM: Ensayo clínico de fase IIb/III, adaptativo, doble ciego, aleatorizado, controlado con placebo y de 52 semanas de duración de setanaxib con una fase de extensión de 52 semanas en pacientes con colangitis biliar primaria (CBP) y rigidez hepática elevada	CLINICAL TRIALS WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III

Group	Title	Subtype	LR Name	Phase
D-05	Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	III
D-05	ASCEND-NASH: Estudio de fase IIB, aleatorizado, multicéntrico, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de CRV431 en sujetos adultos con esteatohepatitis no alcohólica y fibrosis hepática avanzada	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio fase 2, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de múltiples dosis, para evaluar la eficacia y la seguridad de BMS-986263 en adultos con cirrosis compensada por esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio abierto para evaluar la seguridad, actividad antiviral y farmacocinética de IMC-I109V en pacientes positivos para HLA-A*02:01 con infección crónica por VHB, no cirróticos, negativos para el antígeno e de hepatitis B y con carga viral suprimida	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis	CLINICAL TRIAL WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II
D-05	Ensayo doble ciego, aleatorizado, controlado con placebo, fase IIb sobre la eficacia y seguridad de comprimidos de ácido norursodesoxicólico en pacientes con esteatohepatitis no alcohólica (EHNA)	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	П
D-05	Estudio doble ciego, aleatorizado, controlado con placebo y en fase II de búsqueda de dosis en el que se comparan distintas dosis de RhuDex gránulos con placebo en el tratamiento de la colangitis biliar primaria	COMMERCIAL CLINICAL TRIAL	RAÚL J. ANDRADE BELLIDO	II
D-05	Registro español de alteraciones hematológicas durante el tratamiento con siponimod. Estudio REALhES.	OBSERVATIONAL STUDY WITH DRUGS	JUDITH ADRIANA SANABRIA CABRERA	
D-05	Estudio Multicéntrico, Aleatorizado, Doble Ciego y Controlado con Placebo para evaluar la eficacia y la seguridad de la rifaximina en comprimidos de Dispersión Sólida Soluble (SSD) para el retraso de la Descompensación de la Encefalopatía en la Cirrosis (Red-C)	CLINICAL TRIAL WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	Estudio de fase 2b/3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del saroglitazar magnésico en sujetos con colangitis biliar primaria.	CLINICAL TRIAL WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
D-05	FLUID DAY. HTF-FLU-2018-01	INDEPENDENT POST-AUTHORIZATION STUDY	JOSE AURELIO GÓMEZ LUQUE	OD
D-05	Estudio de fase II, aleatorizado, doble ciego, comparativo con placebo y de búsqueda de dosis para evaluar la eficacia y la seguridad de TAK-062 para el tratamiento de la celiaquía activa en participantes que siguen una dieta sin gluten	CLINICAL TRIAL WITH DRUGS	RAÚL J. ANDRADE BELLIDO	II
D-05	Estudio de fase III aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de fazirsiran en el tratamiento de la enfermedad hepática asociada a la deficiencia de alfa-1 antitripsina con fibrosis en estadio F2 a F4 de METAVIR	CLINICAL TRIAL WITH DRUGS	RAÚL J. ANDRADE BELLIDO	III
DA-06	Pautas de tratamiento con upadacitinib, consecución de los objetivos terapéuticos y mantenimiento de la respuesta en pacientes con artritis reumatoide de moderada a grave en la práctica real (Estudio UPHOLD, P20-095)	COMMERCIAL POST-AUTHORIZATION STUDY	ROSA MARIA GARCIA PORTALES	SP
DA-06	Estudio de prevalencia y adecuación del uso hospitalario de antimicrobianos en España.	INDEPENDENT POST-AUTHORIZATION STUDY	ELENA SANCHEZ YAÑEZ	OD
DA-06	Estudio observacional para evaluar la adherencia a TREMFYA (Guselkumab) en la práctica clínica en pacientes con psoriasis moderada a grave. ADHERENCE	OBSERVATIONAL STUDY WITH DRUGS	ELENA SANCHEZ YAÑEZ	NA
DA-06	Factores asociados al descenso de densidad mineral ósea y a la incidencia de fracturas durante el periodo de descanso terapéutico con Bifosfonatos Sponsor Code: Vacaciones Terapéuticas	INDEPENDENT POST-AUTHORIZATION STUDY	BLANCA PANERO LAMOTHE	OD

Group	Title	Subtype	LR Name	Phase
DE-02	Estudio Fase III aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapiaantirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intramuscular de acción prolongada con cabotegravir y rilpivirina en pacientes adultos infectados por el VIH-1 con supresión virológica.	COMMERCIAL CLINICAL TRIAL	MANUEL CASTAÑO CARRACEDO	III
DE-02	Estudio Salutem: uso de hidroxicloroquina en profilaxis pre-exposición a la COVID-19 en trabajadores sanitarios	INDEPENDENT CLINICAL TRIAL	JUAN DIEGO RUIZ MESA	Ш
DE-02	Estudio Fase IIIb, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia, seguridad y tolerabilidad de cabotegravir de acción prolongada más rilpivirina de acción prolongada administrados cada 8 semanas o cada 4 semanas en adultos infectados por VIH-1 que presentan supresión virológica	COMMERCIAL CLINICAL TRIAL	MANUEL CASTAÑO CARRACEDO	III
DE-02	Temocilina vs Meropenem para el Tratamiento de la Bacteriemia por Enterobacteriales Resistentes a Cefalosporinas de Tercera Generación: Ensayo Aleatorizado y Pragmático.	INDEPENDENT CLINICAL TRIAL	LUCÍA VALIENTE DE SANTIS	Ш
DE-02	Estudio clínico traslacional en fase II multicéntrico, abierto, aleatorizado, controlado, en canasta y pragmático para determinar la eficacia y seguridad de la plitidepsina frente al control en pacientes adultos inmunodeprimidos con COVID-19 sintomática que necesitan asistencia hospitalaria (NEREIDA)	CLINICAL TRIAL WITH DRUGS	MARCIAL DELGADO FERNÁNDEZ	II
DE-02	Estudio comparativo en fase III, prospectivo, aleatorizado, multicéntrico, abierto pero enmascarado para el evaluador principal y de grupos paralelos para determinar la eficacia, seguridad y tolerabilidad de Aztreonam-Avibactam (ATM-AVI) ± Metronidazol (MTZ) en comparación con Meropenem ± Colistina (MER ± COL) en el tratamiento de infecciones graves por Bacterias Gramnegativas, incluidos los patógenos multirresistentes que producen Metalo-?-Lactamasa (MBL), para las que hay pocas o ninguna opción de tratamiento (REVISIT)	COMMERCIAL CLINICAL TRIAL	JOSÉ MARÍA REGUERA IGLESIAS	III
DE-02	Prevención y tratamiento con Calcifediol del síndrome respiratorio agudo (SARS) inducido por Coronavirus COVID-19 (COVID-19)	INDEPENDENT CLINICAL TRIAL	ANTONIO PLATA CIEZAR	П
DE-02	ENSAYO ABIERTO MULTICÉNTRICO ALEATORIZADO Y PRAGMÁTICO DE FASE IV PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DIFERENTES DURACIONES DE TRATAMIENTO ANTIMICROBIANO DE INFECCIONES ASOCIADAS AL MATERIAL DE OSTEOSÍNTESIS TRAS FRACTURA DE HUESO LARGO.	INDEPENDENT CLINICAL TRIAL	BEATRIZ SOBRINO DIAZ	III
DE-02	CABO-CHANCE: Estudio en vida real sobre el uso de Cabotegravir/Rilpivirina de acción prolongada (CAB/RPV AP) en pacientes pretratados que viven con el VIH (PVVIH).	OBSERVATIONAL STUDY WITH DRUGS	INES PEREZ CAMACHO	NA
DE-02	Estudio de la función tubular renal y marcadores de remodelado óseo durante el tratamiento prolongado con entecavir y tenofovir en pacientes con infección crónica por el virus de la hepatitis B. Estudio MENTE	OBSERVATIONAL STUDY WITH DRUGS	JOSÉ MARÍA REGUERA IGLESIAS	NA
DE-02	Eficacia de fosfomicina intravenosa en la infección urinaria complicada con condiciones de vida real. Impacto de la CMI y de las mutaciones basales. Proyecto FOSFO-MIC	INDEPENDENT POST-AUTHORIZATION STUDY	JOSÉ MARÍA REGUERA IGLESIAS	SP
DE-02	FIS-PSE-2022-01 Estudio prospectivo de las infecciones del torrente sanguíneo por Pseudomonas aeruginosa en pacientes adultos: eficacia y seguridad de diferentes estrategias terapéuticas, en el contexto actual de resistencia a múltiples fármac	COMMERCIAL POST-AUTHORIZATION STUDY	LUCÍA VALIENTE DE SANTIS	OD
DE-02	Estudio de intervención quasi-experimental para la optimización del uso de nuevos antibióticos (Poyecto NEW_SAFE).	INDEPENDENT POST-AUTHORIZATION STUDY	LUCÍA VALIENTE DE SANTIS	SP
DE-02	Clínica y Epidemiología del brote de infección por Monkeypox en España en el año 2022 ESTUDIO CEME 22	OBSERVATIONAL STUDY WITH DRUGS	INES PEREZ CAMACHO	NA
DE-02	Estudio de cohortes, no intervencionista, en múltiples países, de la efectividad, seguridad, adherencia y calidad de vida relacionada con la salud en pacientes adultos infectados con el VIH-1 que reciben bictegravir/emtricitabina/tenofovir alafenamida (B/F/TAF). GS-EU-380-4472	COMMERCIAL POST-AUTHORIZATION STUDY	MANUEL CASTAÑO CARRACEDO	SP
DE-02	Ensayo clínico aleatorizado de no inferioridad para evaluar la eficacia y seguridad del tratamiento corto de la bacteriemia enterocócica no complicada. INTENSE	INDEPENDENT CLINICAL TRIAL	ANTONIO PLATA CIEZAR	IV

Group	Title	Subtype	LR Name	Phase
DE-02	Estudio Clínico, Farmacológico y Microbiológico del Tratamiento Optimizado con beta-lactámicos en combinación con colistina de la infección osteoarticular con y sin material ortopédico por bacilos gramnegativos resistentes a fluoroquinolonas. Estudio COLBETA-17	INDEPENDENT POST-AUTHORIZATION STUDY	BEATRIZ SOBRINO DIAZ	SP
DE-02	Ensayo clínico aleatorizado, de superioridad, doble ciego, controlado con placebo, en fase ii, para demostrar la eficacia del trasplante de microbiota fecal en la descolonización intestinal selectiva de los pacientes colonizados por Enterobacterias productoras de carbapenemasa tipo KPC u OXA-48	INDEPENDENT CLINICAL TRIAL	JUAN DIEGO RUIZ MESA	II
DE-02	Multicentre EuRopean study of MAjor Infectious Disease Syndromes (MERMAIDS). Acute Respiratory Infections (MERMAIDS ARI) 2.0. Estudio RECoVER.	NON-POST-AUTHORIZATION STUDY	JOSÉ MARÍA REGUERA IGLESIAS	NO
DE-02	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR	INDEPENDENT CLINICAL TRIAL	JUAN DIEGO RUIZ MESA	IV
DE-02	Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el tratamiento de pacientes con bacteriemia por Enterobacteriaceae	INDEPENDENT CLINICAL TRIAL	ANTONIO PLATA CIEZAR	III
DE-07	"Retrospective Analysis of Real-World Use of Cefiderocol in the Management of Gram-Negative Infections as part of the Early Access Program (PERSEUS Study)." // "Análisis retrospectivo del uso en la práctica real de cefiderocol para el tratamiento de infecciones por gramnegativos como parte del programa de acceso precoz (estudio PERSEUS)."	OBSERVATIONAL STUDY WITH DRUGS	CESAR ARAGON GONZALEZ	NA
DE-07	Estudio exploratorio para evaluar la eficacia y seguridad de la administración en la nutrición de 1,5 g de proteína/kg/día frente a 1,0 g de proteína/kg/día en la fase catabólica del paciente crítico bajo ventilación mecánica.	INDEPENDENT CLINICAL TRIAL	JUAN FRANCISCO MARTINEZ CARMONA	IV
DE-07	Tratamiento antiagregante en el síndrome coronario agudo. Seguridad y eficacia del cruce entre antiagregantes.	INDEPENDENT POST-AUTHORIZATION STUDY	JOSE ANDRES ARBOLEDA SANCHEZ	SP
DE-07	Tratamiento antiplaquetario en síndromes coronarios agudos. Seguridad y eficacia del cambio de antiplaquetario. Seguridad y eficacia de Tricagrelor VS Clopidogrel en pacientes con síndrome coronario agudo. Antiplatelet treatment in acute coronary syndromes. safety and efficacy of antiplatelet switching. Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients with Acute Coronary Syndrome.	INDEPENDENT POST-AUTHORIZATION STUDY	JOSE ANDRES ARBOLEDA SANCHEZ	OD
DE-07	Randomized, Embedded, Multifactorial Adaptive Platform trial for Community- Acquired Pneumonia (REMAP-CAP)	CLINICAL TRIAL WITH DRUGS	MANUEL ENRIQUE HERRERA GUTIERREZ	IV
DE-07	Estudio retrospectivo de revisión de historias clínicas en el que se evalúa la práctica clínica, los patrones de tratamiento y los resultados relacionados con los concentrados de complejo de protrombina de 4 factores (4F-PCC) en pacientes tratados con inhibidores del factor Xa (FXa) antes de una cirugía o un procedimiento invasivo y en aquellos que precisan una neutralización a demanda por una hemorragia grave	OBSERVATIONAL STUDY WITH DRUGS	MªDOLORES ARIAS VERDU	NA
DE-08	Ensayo ABC-HCC: Ensayo en fase IIIb, aleatorizado, multicéntrico y abierto de atezolizumab más bevacizumab frente a quimioembolización transarterial (QETA) en carcinoma hepatocelular en estadio intermedio	CLINICAL TRIAL WITH DRUGS	MIGUEL JIMÉNEZ PÉREZ	III
DE-08	Un estudio prospectivo, aleatorizado, simple ciego y multicéntrico de fase III sobre la conservación de órganos con la solución Custodiol-N en comparación con la solución Custodiol en el trasplante de hígado (Custodiol-N-LTX-ESP)	INDEPENDENT CLINICAL TRIAL	JULIO SANTOYO SANTOYO	III
DE-08	Duodenopancreatectomía cefálica en tumores de páncreas y periampulares: abordaje inicial de la arteria mesentérica superior versus abordaje clásico. Estudio prospectivo, aleatorizado y multicéntrico.	NON-POST-AUTHORIZATION STUDY	JULIO SANTOYO SANTOYO	NO

Group	Title	Subtype	LR Name	Phase
DE-08	Estudio de fase 4, multicéntrico y observacional para evaluar la seguridad y la tolerabilidad de lenvatinib en pacientes con carcinoma hepatocelular avanzado o irresecable (STELLAR) E7080-M000-508	COMMERCIAL POST-AUTHORIZATION STUDY	MIGUEL JIMÉNEZ PÉREZ	LA
DE-08	Eficacia del cambio de diana terapéutica en práctica clínica tras el fracaso del tratamiento con un primer fármaco antiTNF en la enfermedad de Crohn	INDEPENDENT POST-AUTHORIZATION STUDY	RAUL VICENTE OLMEDO MARTIN	OD
DE-08	Efectividad y seguridad de Ustekinumab en pacientes Bionaive con enfermedad de Chron moderadagrave refractaria a tratamiento convencional: un estudio retrospectivo observacional multicéntrico	INDEPENDENT POST-AUTHORIZATION STUDY	RAUL VICENTE OLMEDO MARTIN	OD
DE-08	Estudio Epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España.	NON-POST-AUTHORIZATION STUDY	RAUL VICENTE OLMEDO MARTIN	NO
DE-08	DICE INCIDENCE CAPTURE: Determinantes, Incidencia y Consecuencias del Exceso de corticoesteroides en EII	COMMERCIAL POST-AUTHORIZATION STUDY	PATRICIA ROMERO CARA	0
DE-08	Registro informatizado de pacientes con Patologías Pancreáticas	NON-POST-AUTHORIZATION STUDY	LETICIA MONGIL PONCE	NO
DE-10	Evaluación de una pauta de tratamiento extendida y proactiva en pacientes con degeneración macular asociada a la edad húmeda (DMAEh) sin tratamiento previo [Evaluation of an eXtended and proacTive dosing regimEn in treatment-Naïve patients with wet age-related macular Degeneration (wAMD)]	COMMERCIAL POST-AUTHORIZATION STUDY	ISABEL BAQUERO ARANDA	SP
DE-10	Evaluación prospectiva de la eficacia y la seguridad del tratamiento tópico con hidrocortisona en los signos y síntomas clínicos de la xeroftalmia asociada a una disfunción moderada de las glándulas de Meibomio	COMMERCIAL CLINICAL TRIAL	YOLANDA FERNANDEZ BARRIENTOS	IV
FA-07	Estudio de fase IIb, multicéntrico, aleatorizado, con doble enmascaramiento y comparativo con placebo, para evaluar la eficacia y la seguridad de un único implante de osteoblastos alogénicos (ALLOB®) en la fractura de tibia	COMMERCIAL CLINICAL TRIAL	ANTONIO LEIVA GEA	П
FA-07	Estudio de extensión de fase III, abierto, para evaluar la seguridad y la eficacia a largo plazo de BMN 111 en pacientes pediátricos con acondroplasia	COMMERCIAL CLINICAL TRIAL	ANTONIO LEIVA GEA	III
FA-07	Estudio clínico multicéntrico y multinacional de evaluación sobre pacientes pediátricos con acondroplasia	NON-POST-AUTHORIZATION STUDY	FRANCISCO DE BORJA DELGADO RUFINO	NO
FA-07	Estudio de fase III, multicéntrico, aleatorizado, doble ciego, de ARN-509 controlado con placebo en hombres con cáncer de próstata no metastásico (M0) y resistente a la castración.	COMMERCIAL CLINICAL TRIAL	JUAN MIGUEL GOMEZ PALOMO	III
FA-07	Estudio de fase II, abierto, de escalada y expansión de dosis de Infigratinib, un inhibidor selectivo de la tirosina quinasa de los receptores del factor de crecimiento fibroblástico 1-3 (fgfr 1-3), en niños con acondroplasia: Propel 2.	COMMERCIAL CLINICAL TRIAL	FRANCISCO DE BORJA DELGADO RUFINO	Ш
FA-07	Estudio de extensión de fase II, abierto, a largo plazo de infigratinib, un inhibidor selectivo de la tirosina quinasa de los receptores del factor de crecimiento fibroblástico 1-3 (FGFR 1-3), en niños con acondroplasia: PROPEL OLE	COMMERCIAL CLINICAL TRIAL	FRANCISCO DE BORJA DELGADO RUFINO	II
FA-07	Ensayo clínico fase III, multicéntrico, aleatorizado, abierto, de comparación del tratamiento con células mesenquimales alogénicas frente a células mesenquimales autólogas y frente a control activo con ácido hialurónico en pacientes con artrosis de rodilla.	INDEPENDENT CLINICAL TRIAL	-	Ш
FE-18	Eficacia de un programa de rehabilitación cardiaca domiciliario de supervisión mixta mediante chaleco de monitorización modelo NUUBO en pacientes con cardiopatía isquémica de riesgo moderado	COMMERCIAL HEALTH PRODUCT CLINICAL RESEARCH	RAQUEL BRAVO ESCOBAR	0

ASSOCIATED GROUPS. CLINICAL STUDIES ACTIVE IN 2023

Group	Title	Subtype	LR Name	Phase
AA-24	Estudio ALCALOTIC: La ALCALOsis MeTabólica en la Insuficiencia Cardiaca descompensada: prevalencia e influencia en el pronóstico	NON-POST-AUTHORIZATION STUDY	JESUS OLMEDO LLANES	NO
AA-24	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisirán en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1)	CLINICAL TRIAL WITH DRUGS	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	III
AA-24	Estudio de resultados cardiovasculares con semaglutida en pacientes con diabetes tipo 2	COMMERCIAL CLINICAL TRIAL	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	III
AA-24	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	OBSERVATIONAL STUDY WITH DRUGS	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	NA
AA-24	Influencia en práctica clínica real de dabigatrán y acenocumorol en la función renal de pacientes diabéticos de edad avanzada con fibrilación auricular no valvular y enfermedad renal crónica levemoderada. Estudio Dadifarec.	INDEPENDENT POST-AUTHORIZATION STUDY	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	SP
AA-24	Estudio de fase 3, aleatorizado, enmascarado para el observador y comparado con producto activo, para evaluar la seguridad y la eficacia de mRNA-1010, una vacuna experimental frente a la gripe estacional en adultos de 50 o más años.	CLINICAL TRIAL WITH DRUGS	MIGUEL ÁNGEL GARCÍA ORDÓÑEZ	III
BA-14	Estudio Fase II, aleatorizado, para evaluar la incidencia de discontinuación debida a Diarrea en los 3 primeros ciclos de tratamiento en pacientes con Cáncer de Mama Precoz HER2 positivo (HER2+), Receptor Hormonal positivo (RH+), tratados con Neratinib más Loperamida versus Neratinib con escalada inicial de dosis más Loperamida (según necesidad) versus Neratinib más Loperamida más Colesevelam. "Estudio DIANER"	CLINICAL TRIAL WITH DRUGS	IRENE ZARCOS PEDRINACI	II
BA-14	Estudio fase II de un solo brazo la eficacia y la seguirdad de la combinación de trastuzumab, TUCAtinib y viNorelbina en pacientes con cáncer de mama localmente avanzado no resecable o metastásico HER2-psoitivo. Estudio TrasTUCAN	CLINICAL TRIAL WITH DRUGS	IRENE ZARCOS PEDRINACI	II
CA-14	Estudio FaseIIb, aleatorizado, con grupo control activo, parcialmente cegado, de búsqueda de dosis de GSK3640254 en comparación con un brazo control de dolutegravir, cada uno en combinación con inhibidores de la transcriptasa inversa análogos de nucleósidos, en adultos infectados con VIH-1 que no han recibido tratamiento antirretroviral previo.	CLINICAL TRIAL WITH DRUGS	JULIAN OLALLA SIERRA	II
CA-14	Estudio en fase IIIb, abierto, hibrido tipo III que evalúa las estrategias de implementación de cabotegravir de acción prolongada más rilpivirina de acción prolongada cada dos meses en adultos con infección por VIH-1 y supresión virológica en entornos sanitarios europeos seleccionados.	CLINICAL TRIAL WITH DRUGS	JULIAN OLALLA SIERRA	Ш
CA-14	Estudio descriptivo, prospectivo, multinacional y multicéntrico para evaluar las variables relacionadas con la enfermedad genital causada por el virus herpes simple tipo 2 (VHS-2) según los resultados obtenidos a partir de cuestionarios de salud y muestras anogenitales realizados por pacientes = 18 años de edad en Estados Unidos y Europa mediante un proceso descentralizado	OBSERVATIONAL STUDY WITH DRUGS	JULIAN OLALLA SIERRA	NA
CA-14	Estudio Fase I/II observador ciego, aleatorizado, internacional y controlado con placebo para evaluar la reactogenicidad, seguridad, respuesta inmune y eficacia de la vacuna frente al virus Herpes simplex (VHS) en sujetos sanos de 18 a 40 años o en pacientes de 18 a 60 años con herpes genital recurrente por VHS tipo 2.	INDEPENDENT CLINICAL TRIAL	JULIAN OLALLA SIERRA	II
CA-14	: "Estudio de fase IIIb, abierto, multicéntrico, aleatorizado, de grupos paralelos y de no inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad de la combinación de dolutegravir/lamivudina administrada por vía oral una vez al día como tratamiento de primera línea, en comparación con la combinación de bictegravir/emtricitabina/tenofovir alafenamida administrada por vía oral una vez al día, para la inhibición y el mantenimiento virológico en adultos con VIH sin tratamiento antirretroviral previo"	CLINICAL TRIAL WITH DRUGS	JULIAN OLALLA SIERRA	III

Group	Title	Subtype	LR Name	Phase
CA-14	Estudio de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de bemnifosbuvir en pacientes ambulatorios de alto riesgo con COVID-19	CLINICAL TRIAL WITH DRUGS	JULIAN OLALLA SIERRA	III
CA-14	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de inclisirán en la prevención de acontecimientos cardiovasculares adversos mayores en pacientes de alto riesgo en prevención primaria (VICTORION-1 PREVENT)	CLINICAL TRIAL WITH DRUGS	JULIAN OLALLA SIERRA	III
CA-14	ENSAYO ABIERTO MULTICÉNTRICO ALEATORIZADO Y PRAGMÁTICO DE FASE III PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DIFERENTES DURACIONES DE TRATAMIENTO ANTIMICROBIANO DE INFECCIONES ASOCIADAS AL MATERIAL DE OSTEOSÍNTESIS TRAS FRACTURA DE HUESO LARGO (DURATIOM).	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	III
CA-14	"Estudio de fase 2b, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de EDP-938 en adultos no hospitalizados con infección aguda por el virus respiratorio sincitial que tienen un riesgo alto de complicaciones"	CLINICAL TRIAL WITH DRUGS	JULIAN OLALLA SIERRA	II
CA-14	CABO-CHANCE: Estudio en vida real sobre el uso de Cabotegravir/Rilpivirina de acción prolongada (CAB/RPV AP) en pacientes pretratados que viven con el VIH (PVVIH).	OBSERVATIONAL STUDY WITH DRUGS	JULIAN OLALLA SIERRA	NA
CA-14	Sustitución de Dolutegravir por Raltegravir 1200 mg QD en pacientes infectados con VIH que desarrollan síntomas neuropsiquiátricos tras iniciar triple terapia. Estudio clínico piloto.	INDEPENDENT CLINICAL TRIAL	XAVIER PEREZ STACHOWSKI	IV
CA-14	Ensayo clínico piloto, multicéntrico, para comparar la eficacia de RAL 1200 QD vs DRV-cb (800-150) QD ambos en combinación con TAF/FTC en pacientes con infección VIH y CD4<200 cel/microL	INDEPENDENT CLINICAL TRIAL	XAVIER PEREZ STACHOWSKI	IV
CA-14	Estudio ambispectivo y multicéntrico a largo plazo en práctica clínica habitual con semaglutida en pacientes con diabetes tipo 2 en España. Estudio SEMA-RWE	OBSERVATIONAL STUDY WITH DRUGS	MARIA DOLORES GARCIA DE LUCAS	NA
CA-14	DTG / 3TC frente a BIC / FTC / TAF como terapia de mantenimiento en personas que viven con VIH: ensayo clínico abierto y aleatorizado	CLINICAL TRIAL WITH DRUGS	XAVIER PEREZ STACHOWSKI	IV
CA-14	Ensayo clínico fase IV, aleatorizado, multicéntrico y doble ciego diseñado para evaluar la seguridad y la conveniencia del cambio de Dolutegravir/Lamivudina por Bictegravir/Emtricitabina/Tenofovir alafenamida en personas con VIH, buen control virológico y vulnerabilidades neuropsiquiátricas: Estudio MIND	INDEPENDENT CLINICAL TRIAL	JULIAN OLALLA SIERRA	IV
CA-14	Estudio de fase III, aleatrorizado, doble ciego y controlado con placebo para evaluar la efecacia y la seguridad de GS-5245 para el tratamiento de la COVID-19 en participantes con alto riesgo de progresión de la enfermedad	CLINICAL TRIAL WITH DRUGS	JULIAN OLALLA SIERRA	III
CA-14	Ensayo clínico aleatorizado de no inferioridad para evaluar la eficacia y seguridad del tratamiento corto de la bacteriemia enterocócica no complicada. INTENSE	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	IV
CA-14	Implementation of Out-of-HOspital administration of the Long-Acting combination cabotegravir+rilpivirine as an optional therapy in HIV-Infected patients from Spain. Acceptability, appropriateness, feasibility and satisfaction The HOLA Study	CLINICAL TRIAL WITH DRUGS	JULIAN OLALLA SIERRA	
CA-14	Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR.	INDEPENDENT CLINICAL TRIAL	ALFONSO DEL ARCO JIMENEZ	IV
CA-19	Fibrilación Auricular No Tratada en Andalucía: Screening Tras el Ictus (FANTASTIC)	OBSERVATIONAL STUDY WITH DRUGS	JULIO OSUNA SÁNCHEZ	NA
CA-19	Registro informatizado de la enfermedad tromboembólica (RIETE)	NON-POST-AUTHORIZATION STUDY	MONICA LORING CAFFARENA	NO

PATENTS:

APPLICATIONS FOR PRIORITY PATENTS/UTILITY MODELS, INDUSTRIAL DESIGNS, AND INTELLECTUAL PROPERTY REGISTRATIONS					
TITLE	REFERENCE	APPLICATION DATE	IBIMA GROUP		
KLRB1 COMO BIOMARCADOR DE PRONÓSTICO EN PACIENTES CON COVID-19	P202331044	12/15/2023	BA-14		

INTERNATIONAL PATENT APPLICATIONS (PCT)					
TITLE	REFERENCE	APPLICATION DATE	IBIMA GROUP		
DISPOSITIVO, SISTEMA Y PROCEDIMIENTO DE ACTIVACIÓN PARA LA DESINFECCIÓN INTRAOPERATORIA DE PRÓTESIS ÓSEAS MEDIANTE EFECTO BIOELÉCTRICO	PCT/ES2023/070371	06/02/2023	FA-16		



